<SEC-DOCUMENT>0001193125-18-216210.txt : 20180711
<SEC-HEADER>0001193125-18-216210.hdr.sgml : 20180711
<ACCEPTANCE-DATETIME>20180711173037
ACCESSION NUMBER:		0001193125-18-216210
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		18
FILED AS OF DATE:		20180711
DATE AS OF CHANGE:		20180711

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Spero Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001701108
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-226093
		FILM NUMBER:		18949280

	BUSINESS ADDRESS:	
		STREET 1:		675 MASSACHUSETTS AVENUE
		STREET 2:		14TH FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		857-242-1600

	MAIL ADDRESS:	
		STREET 1:		675 MASSACHUSETTS AVENUE
		STREET 2:		14TH FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Spero Therapeutics, LLC
		DATE OF NAME CHANGE:	20170316
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>d521849ds1a.htm
<DESCRIPTION>S-1/A
<TEXT>
<HTML><HEAD>
<TITLE>S-1/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on July 11, 2018. </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-226093</FONT> </B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:3.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:13.5pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13.5pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13.5pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:13.5pt; font-family:Times New Roman" ALIGN="center"><B>Amendment
No. 1 </B></P>   <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13.5pt; font-family:Times New Roman" ALIGN="center"><B>to </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13.5pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">S-1</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>UNDER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>THE SECURITIES ACT
OF&nbsp;1933 </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:13.5pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">(Exact name of registrant as specified in its charter) </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">46-4590683</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center">(State or other jurisdiction of</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center">incorporation or</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center">organization)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center">(Primary Standard Industrial</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center">Classification Code Number)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center">(I.R.S. Employer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center">Identification Number)</P></TD></TR>
</TABLE> <center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>675 Massachusetts Avenue, 14<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Cambridge, Massachusetts 02139 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(857) <FONT STYLE="white-space:nowrap">242-1600</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center">(Address, including zip code, and telephone number, including area code, of registrant&#146;s principal executive offices) </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Ankit Mahadevia, M.D. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>President and Chief Executive Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Spero Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>675 Massachusetts Avenue, 14<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Cambridge, Massachusetts 02139 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(857) <FONT STYLE="white-space:nowrap">242-1600</FONT> </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center">(Name, address, including zip code, and telephone number, including area code, of agent for service) </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-size:8.5pt"><B>Copies to:</B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Matthew J. Gardella, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Lewis J. Geffen, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Mintz, Levin, Cohn, Ferris, Glovsky&nbsp;&amp; Popeo, P.C.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>One Financial Center</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Boston, Massachusetts 02111</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(617) <FONT STYLE="white-space:nowrap">542-6000</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Peter N. Handrinos, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Nathan Ajiashvili, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Latham&nbsp;&amp; Watkins LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>200 Clarendon Street</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Boston, Massachusetts 02116</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(617) <FONT STYLE="white-space:nowrap">948-6000</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Approximate date of commencement of proposed sale to the public: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center">As soon as practicable after the effective date of this registration statement. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:7%; font-size:8.5pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the
Securities Act of 1933 check the following box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:7%; font-size:8.5pt; font-family:Times New Roman">If this Form is filed to register additional securities for an
offering pursuant to Rule&nbsp;462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:7%; font-size:8.5pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:7%; font-size:8.5pt; font-family:Times New Roman">If
this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(d) under the Securities Act, check the following box and list the Securities Act registration number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:7%; font-size:8.5pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT
STYLE="white-space:nowrap">non-accelerated</FONT> filer, smaller reporting company or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company&#148; and
&#147;emerging growth company&#148; in <FONT STYLE="white-space:nowrap">Rule&nbsp;12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;&nbsp;(Do not check if a smaller reporting company)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
</TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:7%; font-size:8.5pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9746; </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Title of Each Class of Securities To be Registered </B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Maximum</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Aggregate<BR>Offering&nbsp;Price(1)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Amount of<BR>Registration&nbsp;Fee</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Common stock, par value $0.001 per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Series A Preferred Stock, par value $0.001 per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$86,263,340(2)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$10,739.79(3)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Includes shares that the underwriters have the option to purchase to cover overallotments. </TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Previously paid. </TD></TR></TABLE>    <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:7%; font-size:8.5pt; font-family:Times New Roman"><B>The registrant
hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become
effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until this registration statement shall become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:3.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P></center>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#c21128">The information in this prospectus is not complete and may be changed. We may not sell
these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction
where the offer or sale is not permitted. </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#c21128"><B>Subject to Completion </B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#c21128"><B>Preliminary Prospectus dated July&nbsp;11, 2018 </B></FONT></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B><U>PROSPECTUS </U></B></P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>3,250,000 Shares
of Common Stock </B></P>   <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2,166 Shares of Series A Convertible Preferred Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2,166,000 Shares of Common Stock Issuable upon Conversion of Series A Convertible Preferred Stock </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g521849g48n25.jpg" ALT="LOGO">
 </P>   <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:8pt; font-family:Times New Roman">We are offering 3,250,000 shares of our common stock and 2,166 shares of our Series A Convertible Preferred Stock, which we refer to as Series A
Preferred Stock. This prospectus also relates to the offering of our shares of common stock issuable upon the conversion of the Series A Preferred Stock offered hereby. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:8pt; font-family:Times New Roman">Our common stock is listed on The Nasdaq Global Select Market under the symbol &#147;SPRO.&#148; The last reported sale price of our common
stock on The Nasdaq Global Select Market on July&nbsp;10, 2018 was $13.85 per share. We do not intend to list our Series A Preferred Stock on any securities exchange or trading system. The final public offering price of our common stock and Series A
Preferred Stock will be determined through negotiation between us and the lead underwriters in the offering and the recent market price of our common stock used throughout this prospectus may not be indicative of the final offering price. </P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:8pt; font-family:Times New Roman">Each share of Series A Preferred Stock is convertible into 1,000 shares of our common stock at any time at the option of the holder,
provided that the holder will be prohibited from converting the Series A Preferred Stock into shares of our common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 9.99% of the total number of
shares of our common stock then issued and outstanding. In the event of our liquidation, dissolution, or winding up, holders of our Series A Preferred Stock will receive a payment equal to $0.001 per share of Series A Preferred Stock before any
proceeds are distributed to the holders of our common stock. The Series A Preferred Stock has no voting rights, except as required by law and except that the consent of the Series A Preferred Stock holders will be required to amend the terms of the
Series A Preferred Stock. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:8pt; font-family:Times New Roman"><B>We are an &#147;emerging growth company&#148; under the federal securities laws and are subject to
reduced public company disclosure standards. See &#147;Prospectus Summary&#151;Implications of Being an Emerging Growth Company.&#148; </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B>Investing in our common stock and our Series A Preferred Stock involves risks. See &#147;<A HREF="#toc521849_2">Risk Factors</A>&#148;
beginning on page 15 of this prospectus. </B></P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:34.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Per&nbsp;Share</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:50.20pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Public offering price of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Underwriting discounts and commissions for common stock(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Public offering price of Series A Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Underwriting discounts and commissions for Series A Preferred Stock(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">We refer you to &#147;Underwriting&#148; beginning on page 169 of this prospectus for additional information regarding underwriting compensation. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:8pt; font-family:Times New Roman">We have granted the underwriters an option for a period of 30 days after the date of this prospectus to purchase up to an additional 487,500
shares of common stock. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:8pt; font-family:Times New Roman">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved
of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:8pt; font-family:Times New Roman">The underwriters expect to deliver the shares to investors on or
about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018. </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:14pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"><FONT STYLE="font-size:8pt"><B><I>Joint Book-running Managers</I></B></FONT></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:14pt">
<TD VALIGN="bottom"><B>Cowen</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Stifel&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>Cantor</B></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Lead Manager </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Oppenheimer&nbsp;&amp; Co. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="98%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B><I><FONT STYLE="white-space:nowrap">Co-Manager</FONT></I></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:14pt">
<TD VALIGN="top" ALIGN="center"><B>H.C. Wainwright&nbsp;&amp; Co.</B></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">The date of this prospectus is
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc521849_1">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc521849_2">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc521849_3">Special Note Regarding Forward-Looking Statements </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc521849_4">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc521849_22">Market Price of our Common Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc521849_5">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc521849_6">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc521849_7">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc521849_8">Selected Consolidated Financial Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc521849_9">Management&#146;s Discussion and Analysis of Financial Condition and Results of
 Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc521849_10">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc521849_11">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc521849_12">Executive and Director Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc521849_13">Certain Relationships and Related Party Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc521849_14">Principal Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc521849_15">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc521849_16">Material U.S. Federal Income and Estate Tax Consequences to <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc521849_17">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc521849_18">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc521849_19">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc521849_20">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc521849_21">Index to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B>You should rely only on the information contained in this prospectus and any free writing prospectus prepared by or on behalf of us or to
which we have referred you. Neither we nor the underwriters have authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses we may authorize to be
delivered or made available to you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares of
common stock and Series A Preferred Stock offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date, or other earlier date stated in
this prospectus, regardless of the time of delivery of this prospectus or any sale of shares of our common stock or Series A Preferred Stock. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For investors outside of the United States: We have not, and the underwriters have not, done anything that would permit this offering or
possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about,
and observe any restrictions relating to, this offering of shares of our common stock and Series A Preferred Stock and the distribution of this prospectus outside of the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Certain industry data and market data included in this prospectus were obtained from
independent third-party surveys, market research, publicly available information, reports of governmental agencies and industry publications and surveys. All of management&#146;s estimates presented herein are based upon management&#146;s review of
independent third-party surveys and industry publications prepared by a number of sources and other publicly available information. All of the market data used in this prospectus involves a number of assumptions and limitations, and you are
cautioned not to give undue weight to such estimates. We believe that the information from these industry publications and surveys included in this prospectus is reliable. The industry in which we operate is subject to a high degree of uncertainty
and risk due to a variety of factors, including those described in the section titled &#147;Risk Factors.&#148; These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties
and by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc521849_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information contained elsewhere in this prospectus and does not contain all of the information that you
should consider in making your investment decision. Before investing in our securities, you should carefully read this entire prospectus, including our consolidated financial statements and the related notes thereto and the information set forth
under the sections of this prospectus titled &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; Unless the context otherwise requires or as otherwise noted, we use the
terms &#147;Spero Therapeutics,&#148; &#147;company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; in this prospectus to refer to Spero Therapeutics, Inc. and its subsidiaries taken as a whole. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are a multi-asset,
clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. Our most advanced product candidate, SPR994, is designed to be the first
broad-spectrum oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. Treatment with effective orally administrable antibiotics may prevent hospitalizations for serious infections and enable earlier, more
convenient and cost-effective treatment of patients after hospitalization. We also have a platform technology known as our Potentiator Platform that we believe will enable us to develop drugs that will expand the spectrum and potency of existing
antibiotics, including formerly inactive antibiotics, against Gram-negative bacteria. Our lead product candidates generated from our Potentiator Platform are two intravenous, or IV,-administered agents, SPR741 and SPR206, designed to treat MDR
Gram-negative infections in the hospital setting. In addition, we are developing SPR720, an oral antibiotic designed for the treatment of a disease called pulmonary <FONT STYLE="white-space:nowrap">non-tuberculous</FONT> mycobacterial infections, or
NTM. We believe that our novel product candidates, if successfully developed and approved, would have a meaningful patient impact and significant commercial applications for the treatment of MDR infections in both the community and hospital
settings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Antibiotic-resistant bacteria are one of the largest threats to global health, and their prevalence is increasing. While the
majority of life-threatening infections historically resulting from antibiotic-resistant bacteria are acquired in the hospital setting, there is an increasing incidence of MDR pathogens in the community setting. Antibiotics used currently for
first-line empiric treatment of MDR bacterial infections suffer from significant limitations and risks, including narrow spectrums of coverage and safety and tolerability concerns, and they can be associated with serious adverse effects. In
addition, there are no oral antibiotics commercially available that can reliably be used in adults with MDR Gram-negative bacterial infections. This limits the ability of physicians to prevent hospitalizations and transition patients home from the
hospital after receiving <FONT STYLE="white-space:nowrap">IV-administered</FONT> therapy. The increasing prevalence of drug resistance and MDR Gram-negative bacteria, as well as the limitations of existing therapies and traditional drug development
approaches, highlights the critical need for novel therapies, and in particular orally administrable agents, that are capable of overcoming these obstacles to effective patient treatment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Developments </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>SPR994 Dose Selection Data
Supporting Planned Pivotal Phase 3 Clinical Trial </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In July 2018, we announced positive interim data from our Phase 1
dose-selection clinical trial of SPR994 in complicated urinary tract infection, or cUTI. Based on those data, we have identified a proposed dose for our planned pivotal Phase 3 clinical trial of SPR994 in cUTI. Based on the data received to date,
administration of 300 mg (immediate-release formulation) of SPR994 three times per day (i)&nbsp;has been well tolerated and free drug exposures in plasma and urine have been comparable to available data for the FDA-approved dose of IV-administered
ertapenem, the most commonly used carbapenem for cUTI, (ii) has shown dose linearity of drug levels, (iii) suggested that SPR994 can be administered without regard to food and (iv) has not been associated with serious adverse events. At this dosing
level, SPR994 has shown exposure levels that </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
were observed in preclinical studies to be potent against pathogens that are commonly encountered in drug-resistant cUTI, such as <I>E. coli</I> and <I>K. pneumoniae</I>. Additionally, based on
the interim data from the Phase 1 trial, the administration of SPR994 in an immediate-release formulation produced plasma exposure comparable to that observed with extended-release formulations. The multiple-ascending dose, or MAD, component of the
Phase 1 trial is continuing to evaluate the maximum tolerated dose for SPR994 and we expect to receive data from the MAD portion of the trial in the third quarter of 2018. We believe these interim data provide us with a sufficient basis to advance
SPR994 into a pivotal Phase 3 clinical trial in cUTI at a dosage of 300 mg of SPR994 administered three times per day. Following completion of the Phase 1 trial, we intend to request a pre-Phase 3 meeting with the U.S. Food and Drug Administration,
or FDA, in the second half of 2018. Subject to our discussions with the FDA, we expect to submit an investigational new drug application, or IND, and initiate a pivotal Phase 3 clinical trial of SPR994 for the treatment of cUTI around year-end 2018.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Potentiator Platform Positive Top-Line Data for Two Product Candidates </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In May 2018, we announced data from our completed Phase 1b drug-drug interaction clinical trial of SPR741. The Phase 1b trial was designed to
assess the impact, if any, on the pharmacokinetics or tolerability of either SPR741 or the beta-lactam drug when the two are dosed together. The single-dose data indicated that the administration of beta-lactam antibiotics had no impact on the
pharmacokinetics or tolerability of SPR741. Such results provide support for the further development of SPR741 as a combination agent for the treatment of MDR infection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In May 2018, we announced results from IND-enabling studies of SPR206. SPR206 was assessed in a suite of preclinical, IND-enabling studies,
including 14-day, two species, GLP toxicology experiments, and <I>in vitro </I>and <I>in vivo</I> GLP safety pharmacology, and absorption, distribution, metabolism and excretion studies. The data, combined with earlier microbiological and <I>in
vivo</I> efficacy testing of SPR206, support SPR206&#146;s advancement as a clinical candidate for the treatment of MDR and extensively drug-resistant, or XDR, bacterial strains, including carbapenem-resistant <I>Pseudomonas aeruginosa</I>,
<I>Acinetobacter baumannii</I> and Enterobacteriaceae. We believe the composite data suggest that SPR206 has the potential for wide therapeutic margins in the setting of serious hospital Gram-negative infections. Moreover, data from these studies
suggest a potency and safety profile for SPR206 that may be superior to SPR741, and we believe SPR206 may have a potentially faster path to pivotal clinical trials when compared with SPR741, because SPR206 is being developed as a single agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Based on these positive results from the Phase 1b clinical trial of SPR741 and positive preclinical toxicology results for SPR206, we intend
to prioritize one of our IV Potentiator product candidates for further clinical development internally and seek partnering opportunities or other non-dilutive funding for the other candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Update </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of June 30, 2018,
we had cash, cash equivalents and marketable securities of approximately $66.6&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The estimated cash, cash equivalents and
marketable securities as of June 30, 2018 are preliminary and may change, are based on information available to management as of the date of this prospectus, and are subject to completion by management of the financial statements as of and for the
quarter ended June 30, 2018. There can be no assurance that our cash, cash equivalents and marketable securities as of June 30, 2018 will not differ from these estimates and any such changes could be material. The preliminary financial data included
in this prospectus has been prepared by, and is the responsibility of, our management. PricewaterhouseCoopers LLP has not audited, reviewed, compiled, or applied agreed-upon procedures with respect to the preliminary financial data. Accordingly,
PricewaterhouseCoopers LLP does not express an opinion or any other form of assurance with respect thereto. Complete quarterly results will be included in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2018. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Product Candidates </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are developing a portfolio of novel product candidates, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I><U>Oral SPR994</U></I></B><B><I>: Novel Antibiotic with Potential to be the First Broad-Spectrum Oral Carbapenem for Use in Adults</I></B>. SPR994 is our novel oral formulation of tebipenem, a carbapenem-class
antibiotic marketed by Meiji Seika Pharma Co. Ltd., or Meiji, in Japan as Orapenem since 2009 for common pediatric infections. Carbapenems are an important class of antibiotics because they are safe and effective against drug-resistant Gram-negative
bacterial infections. Carbapenem use has increased dramatically as a result of the rising resistance to commonly used agents such as fluoroquinolones and cephalosporin antibiotics. Carbapenems are now considered as the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> for treating these resistant bacteria, but they are currently only available intravenously for such indications. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Based on discussion from our <FONT STYLE="white-space:nowrap">pre-IND</FONT> meeting with the FDA and subject to our receiving favorable
results from our Phase 1 clinical trial of SPR994, we believe we will be able to progress directly to a pivotal Phase 3 clinical trial of SPR994 for the treatment of cUTI. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Under a Clinical Trial Notification, or CTN, we initiated a Phase 1 dose-selection clinical trial of SPR994 in Australia in October 2017. A
CTN, which is similar to an IND in the United States, enables conduct of a clinical trial in Australia. We have received positive interim data from the Phase 1 clinical trial that we believe are supportive of advancing an immediate-release
formulation of SPR994 into a pivotal Phase 3 clinical trial in cUTI. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">During the second half of 2018, we intend to request a pre-Phase 3
meeting with the FDA to discuss the appropriate dose and protocol for a pivotal Phase 3 clinical trial. Pending our discussions with the FDA, we expect to submit an IND and initiate a pivotal Phase 3 clinical trial of SPR994 for the treatment of
cUTI around <FONT STYLE="white-space:nowrap">year-end</FONT> 2018 in support of a new drug application, or NDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman"><B><I>Prior Safety and
Efficacy Experience with Tebipenem in Japan</I></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Our clinical strategy is supported by extensive safety data underlying
tebipenem&#146;s regulatory approval in Japan and long-standing use in Japan for common pediatric infections. Approximately 1,100 subjects, including approximately 741 adults, have been dosed with tebipenem at a range of doses in clinical and
pharmacologic studies. In addition, Meiji has completed a post-market study including 3,540 patients following the safety and tolerability of tebipenem at the approved dose. In addition, two exploratory Phase 2 trials were conducted in Japan in
patients with urinary tract infections, or UTI, the first indication in which we intend to study for SPR994. We have the rights to all the registration and post-marketing studies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">In addition, we received Qualified Infectious Disease Product, or QIDP, designation from the FDA for SPR994 for the treatment of cUTI,
community-acquired bacterial pneumonia, or CABP, and moderate to severe diabetic foot infections, or DFI. QIDP designation entitles us to priority review of SPR994 for regulatory approval by the FDA. The QIDP designation for SPR994, however, does
not guarantee a faster development process or ensure FDA approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">We have global commercialization rights to SPR994, except in certain
contractually specified Asian countries. We believe that our intellectual property portfolio will provide us global protection for SPR994, including in the United States and Europe, through 2038. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I><U>IV Potentiator Platform (SPR741 and SPR206)</U></I></B><B><I>: Our Technology Designed to Treat
Infections Caused by MDR Gram-Negative Bacteria in the Hospital Setting. </I></B>Our Potentiator Platform is our novel and proprietary technology that we believe will enable us to develop drugs against
Gram-</P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
negative bacteria, a subset of bacterial organisms distinguished by the presence of an outer cell membrane. Our IV Potentiator Platform molecules are designed to treat Gram-negative bacterial
infections through interactions with the bacteria&#146;s outer cell membrane either as a monotherapy or by <FONT STYLE="white-space:nowrap">co-administering</FONT> our potentiator molecules with currently approved antibiotics, potentially making the
existing antibiotics more effective by clearing a path for them to enter and kill the bacteria. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">We have two IV
Potentiator Platform product candidates, SPR741 and SPR206. SPR741 is an <FONT STYLE="white-space:nowrap">IV-administered</FONT> agent that has demonstrated <I>in vitro</I> the ability to expand the spectrum and increase the potency of a <FONT
STYLE="white-space:nowrap">co-administered</FONT> antibiotic. SPR206 is a direct acting <FONT STYLE="white-space:nowrap">IV-administered</FONT> agent that has demonstrated <I>in vitro</I> activity alone in preclinical studies. Both have demonstrated
potency against Gram-negative bacteria, including organisms identified by the Centers for Disease Control and Prevention, or the CDC, and the World Health Organization, or the WHO, as urgent and serious threats to human health. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman"><B><I>SPR741 </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">The
first clinical trial of SPR741 was a double-blind, placebo-controlled, ascending dose, multi-cohort trial. The trial was conducted in two parts, a SAD and a MAD. The SAD part of the trial was a single ascending dose design, with subjects receiving
one dose of SPR741. The MAD part was a multiple ascending dose design, with subjects receiving repeat dosing over a period of 14 days. In both study parts, sequential cohorts were exposed to increasing doses of SPR741. Generally, there were no
dose-related or treatment-related trends in any of the safety and tolerability endpoints for SPR741 when administered as single doses up to and including 800 mg or multiple doses up to and including 600 mg every 8 hours for 14 days. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Following the completion of our first clinical trial, in late November 2017, we initiated our Phase 1b drug-drug interaction clinical trial
of SPR741 in the United Kingdom. The Phase 1b trial enrolled 27 healthy volunteers to evaluate the tolerability and pharmacokinetics of SPR741 as a single dose in combination with some commonly used beta-lactam antibiotics, including cephalosporins
(ceftazidime), monobactams (aztreonam) and beta-lactams/beta-lactamase inhibitors (piperacillin/tazobactam). In this Phase 1b drug-drug interaction study, we observed no impact on the tolerability or standalone pharmacokinetics of SPR741 or the
beta-lactam drug when the two are dosed together as a single dose, supporting further development of SPR741 as a combination agent for the treatment of MDR infections. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman"><B><I>SPR206 </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">In
addition, we continue to advance the development of our direct acting Potentiator Platform molecules, exemplified by our product candidate SPR206. In preclinical studies, SPR206 showed activity as a single agent against MDR and extremely drug
resistant, or XDR, bacterial strains, including isolates of <I>Pseudomonas aeruginosa</I>, <I>Acinetobacter baumannii</I> and carbapenem-resistant Enterobacteriaceae both in <I>in vitro</I> and in <I>in vivo</I> models of infection. We have
completed a preclinical toxicology study of SPR206 in accordance with good laboratory practice, or GLP, requirements. Data from recent preclinical studies of SPR206 suggest a potency and safety profile for SPR206 that may be superior to SPR741, and
we believe SPR206 may have a potentially faster path to pivotal clinical trials when compared with SPR741 because SPR206 is being developed as a single agent. In May 2018, we announced preclinical toxicology and efficacy data that we believe are
sufficient for the advancement of SPR206 into clinical development. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I><U>Oral SPR720</U></I></B><B><I>: Novel Oral Antibiotic Designed for Treatment of Pulmonary <FONT
STYLE="white-space:nowrap">Non-tuberculous</FONT> Mycobacterial Infections</I></B>. SPR720 is our novel orally available product candidate designed for the treatment of NTM infection.&nbsp;Lung infections caused by NTM are rare, and occur most
frequently in </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
patients with compromised immune systems or abnormal pulmonary anatomy. Such conditions include human immunodeficiency virus, or HIV, or respiratory conditions, such as cystic fibrosis, chronic
obstructive pulmonary disease, asthma and bronchiectasis. The annual prevalence of NTM infection is increasing at an estimated rate of 8% per year. The current treatment for NTM infection is lengthy and involves combination therapy, often including
three or more antibiotics, including some, such as aminoglycosides, that are parenterally administered. None of these treatments are approved for use in NTM infection. Treatment failure is common and is often due to poor compliance or patients&#146;
inability to tolerate the regimen. Many patients experience progressive lung disease and mortality is high. We believe SPR720, if successfully developed, has the potential to become the first oral antibiotic specifically approved for the treatment
of this debilitating rare disease. <I>In vitro</I> and <I>in vivo </I>studies have demonstrated the potency of SPR720 against a range of bacteria causing NTM infection, including both <I>Mycobacterium avium</I> complex and <I>Mycobacterium
abscessus</I>, a highly resistant strain causing infections with high mortality. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">SPR720 is currently in preclinical
development. We are conducting <FONT STYLE="white-space:nowrap">28-day</FONT> and <FONT STYLE="white-space:nowrap">31-day</FONT> toxicity studies in rats and <FONT STYLE="white-space:nowrap">non-human</FONT> primates in accordance with GLP
requirements. We have also observed activity as good as or better than positive controls in <I>in vitro</I> and <I>in vivo</I> studies, including in an acute murine pneumonia model of infection caused by <I>Mycobacterium abscessus</I>. We are
currently testing SPR720 in animal studies to assess activity across other pathogens of interest including <I>Mycobacterium avium</I> and <I>M. kansasii</I>. We anticipate reporting data in the second half of 2018. Pending positive results from our
ongoing preclinical studies and discussions with the appropriate regulatory agencies, we plan to initiate a Phase 1 clinical trial of SPR720 in the first half of 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Pipeline </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table sets
forth our product candidates, their status and anticipated milestones. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g521849g25i47.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">We intend to progress SPR994 to a pivotal Phase 3 cUTI clinical trial after we have a pre-Phase 3 meeting with the FDA to confirm that no additional clinical trials or nonclinical studies are required prior to
initiating a Phase 3 clinical trial. </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our goal is to identify, develop and commercialize novel treatments for MDR bacterial infections, focusing on areas of high unmet medical need
for safe and effective antibiotic treatments. Key elements of our strategy are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Advance our lead product candidate SPR994 through clinical development and regulatory approval</I></B>. We initiated a Phase 1 dose-selection clinical trial of SPR994 in Australia in October 2017. In July 2018, we
announced positive interim data from our Phase 1 dose-selection clinical trial of SPR994 in cUTI. Based on those data, we have identified a proposed dose for our planned pivotal Phase 3 clinical trial of SPR994 in cUTI. Following completion of this
trial, and leveraging data and <FONT STYLE="white-space:nowrap">know-how</FONT> we have licensed from Meiji, we intend to request a <FONT STYLE="white-space:nowrap">pre-Phase</FONT> 3 meeting with the FDA in the second half of 2018. Subject to our
discussions with the FDA, we expect to submit an IND and initiate a pivotal Phase 3 clinical trial of SPR994 for the treatment of cUTI around <FONT STYLE="white-space:nowrap">year-end</FONT> 2018. In addition to cUTI, we believe that SPR994 has the
potential to treat other serious and life-threatening infections. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Diversify into rare infectious disease markets such as NTM infection. </I></B>We believe there is a significant opportunity to develop products for underserved &#147;orphan&#148; infectious disease areas, such as
NTM infection. These markets offer the attributes of fewer branded or generic competitors as well as chronic therapy. We believe our drug candidate SPR720 has the potential to be the first oral antibiotic approved for the treatment of pulmonary <FONT
STYLE="white-space:nowrap">non-tuberculous</FONT> mycobacterial infections. We may seek to acquire other product candidates for other underserved, debilitating rare infectious diseases. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Advance a product candidate from our IV Potentiator Platform through clinical development and regulatory approval, either through a collaboration or with <FONT STYLE="white-space:nowrap">non-dilutive</FONT>
funding (or both), and advance our other product candidates</I></B>. Both product candidates within our IV Potentiator Platform are advancing, and we expect to bring forward one of our Potentiator Platform product candidates for further clinical
testing in 2018. Data from recent preclinical studies of SPR206 suggest a potency and safety profile that may be superior to SPR741, and we believe SPR206 may have a potentially faster path to pivotal clinical trials compared with SPR741 because
SPR206 is being developed as a single agent. We expect to decide which of these product candidates we will bring forward as our lead clinical Potentiator product candidate based on these data for SPR206 and data from our recently completed Phase 1
clinical trial of SPR741. We may seek partnering opportunities or other non-dilutive funding for further clinical development of the Potentiator candidate we elect to deprioritize. We intend to continue to advance our other product candidates,
including SPR720, through preclinical and clinical development. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Maximize the value of our IV Potentiator Platform through collaborations with other pharmaceutical companies</I></B>. We may elect to pursue strategic collaborations with other pharmaceutical companies to leverage
our Potentiator Platform. We believe it may be beneficial to develop and commercialize one or more of our Potentiator product candidates through partnering opportunities. These may include global collaborations to advance the entire Potentiator
Platform, or product-specific deals pairing our product candidates with collaborators&#146; antibiotics, whether generic or novel, with the intention of enhancing those antibiotics&#146; performance and efficacy. We believe this approach will
facilitate the capital-efficient development and commercialization of our Potentiator Platform. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Continue to pursue collaborations with <FONT STYLE="white-space:nowrap">non-commercial</FONT> organizations
for scientific expertise and funding support</I></B>. We have received funding support from the U.S. National Institute of Allergy and Infectious Diseases, or NIAID, the U.S. Department of Defense, or DoD, and the Combating Antibiotic Resistant
Bacteria Biopharmaceutical Accelerator, or <FONT STYLE="white-space:nowrap">CARB-X,</FONT> a public-private </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
partnership funded by the Biomedical Advanced Research and Development Authority, or BARDA, within the U.S. Department of Health and Human Services. We intend to continue to collaborate with
government agencies and <FONT STYLE="white-space:nowrap">non-profit</FONT> foundations to support the development of our product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Expand our portfolio of product candidates for the treatment of MDR infections</I></B>.<B><I> </I></B>Since our inception, we have focused on identifying and developing antibiotics to treat MDR infections, and we
are using our expertise to aggressively build and expand a portfolio of product candidates for the treatment of such infections. Our management team has deep-rooted relationships in the academic, medical and corporate infectious disease community,
which provide us visibility into new and innovative therapies under development. We believe the greatest unmet medical needs for safe and effective antibiotic treatments lie among infections due to MDR bacteria, as patients with these infections
often have limited or inadequate therapeutic options, leading to high rates of mortality. The increasing prevalence of drug resistance and MDR bacteria, and the limitations of existing therapies and traditional drug development approaches, highlight
the critical need for novel therapies capable of overcoming resistance, particularly orally administrable agents. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Establish global commercialization and marketing capabilities</I></B><I>. </I>We have global commercialization rights to all of our product candidates, with the exception of SPR994 in certain contractually
specified Asian countries. Our management team has significant expertise in the commercialization of infectious disease treatments. Prior to joining us, members of our management team have collectively played leading roles in the approval and launch
of 11 infectious disease products. We intend to build a targeted sales force and directly commercialize our product candidates in the United States in both hospital and community settings. Outside the United States, we intend to enter into
collaborations with third parties to develop and market our product candidates in targeted geographical markets. By collaborating with companies that have an existing commercial presence and experience in such markets, we believe we can efficiently
maximize the commercial potential of our product candidates. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Problem: Growing Antibiotic Resistance in the Hospital and Community
Setting </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Antibiotics are drugs used to treat infections that are caused by bacteria. Prior to the introduction of the first
antibiotics in the 1930s and 1940s, bacterial infections were often fatal. Today, antibiotics are used routinely to treat and prevent infections. There are two main varieties of bacteria, Gram-negative bacteria and Gram-positive bacteria, which are
distinguished by structural differences in their cell envelope. Gram-positive bacteria are surrounded by a single lipid membrane and a thick cell wall, while Gram-negative bacteria are encircled by two lipid membranes, an inner membrane and an outer
membrane, with a thinner cell wall in between. Antibiotics that target Gram-negative bacteria must be specifically designed to cross both the inner and outer membranes to enter the bacteria. The outer membrane, with its <FONT
STYLE="white-space:nowrap">LPS-containing</FONT> outer leaflet, represents a significant barrier to the entry into the bacteria by antibiotics and is a significant contributor toward reduced potency of many agents in treating Gram-negative bacterial
infections. A study of 13,796 patients in intensive care units around the world reported in 2009 that 51% of patients experienced bacterial infections, and of these patients 62% were infected by Gram-negative organisms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Antibiotic resistance is one of the largest threats to global health, and resistance rates are increasing. Antibiotic resistance can affect
anyone, of any age and in any country. According to the CDC, each year in the United States at least 2&nbsp;million people become infected with bacteria that are resistant to antibiotics, and at least 23,000 people die each year as a direct result
of these infections. Approximately 70% of the pathogens that cause these infections are resistant to at least one drug, meaning the incidence rate of serious infections is increasing and the proportion of the infections caused by MDR pathogens is
increasingly seen as an emerging threat to world health. The CDC estimates that the excess annual cost resulting from these infections in the United States is as high as $20&nbsp;billion. According to the CDC, among all of the bacterial resistance
problems, Gram-negative pathogens, which cause a majority of all bacterial infections, are particularly worrisome because they are </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
becoming resistant to nearly all drugs that would be considered for treatment. In February 2017, the WHO published a list of Gram-negative bacteria based on the urgency of need for new
antibiotics and highlighted a critical group of MDR Gram-negative bacteria that pose a particular threat to human health, including <I>Acinetobacter</I>, <I>Pseudomonas</I> and various Enterobacteriaceae (including <I>Klebsiella sp.</I>, <I>E.
coli,</I> <I>Serratia</I> and <I>Proteus</I>). These pathogens are associated with significant mortality because the increased incidence of antibiotic resistance has limited the number of effective treatment options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">There is an acute need for new antibiotics to treat MDR bacterial infections, as few new antibiotics capable of addressing such infections
have been approved recently for commercialization or are in clinical development. Further, the majority of MDR bacterial infections historically have been acquired in the hospital setting, where they have been treated using <FONT
STYLE="white-space:nowrap">IV-administered</FONT> antibiotics. However, increasingly such infections are being acquired in the community setting, emphasizing the need for orally administrable antibiotics that can effectively treat such infections.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Solution </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Antibiotics currently
used for first-line empiric treatment of MDR bacterial infections and NTM infection suffer from significant limitations. We believe that our product candidates will overcome these limitations, as described below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>SPR994 is designed to address the lack of orally administrable antibiotics to prevent hospitalization and permit <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">IV-to-oral</FONT></FONT> switch
therapy in resistant Gram-negative infections</I></B>. Resistance to most commonly used classes of oral antibiotics, such as cephalosporins and fluoroquinolones, has increased significantly. Many of the most commonly used antibiotics for MDR
Gram-negative infections are only available in an <FONT STYLE="white-space:nowrap">IV-administered</FONT> formulation. Treatment with effective orally administrable antibiotics may prevent hospitalizations for serious infections and enable earlier,
more convenient and cost-effective treatment of patients following hospitalization. SPR994 is an orally administrable tablet that we believe has the potential to treat such infections in both the community and hospital settings, thereby preventing
certain hospitalizations and enabling patients to transition to oral treatment. In the community setting, SPR994, if successfully developed and approved, may allow patients who develop an infection with a resistant pathogen, but are stable enough to
be treated in the community, to avoid the need for an IV catheter and even hospitalization. In the hospital setting, the lack of effective oral stepdown options results in the potential for lengthy hospital stays or the insertion of a peripherally
inserted central catheter (PICC) to facilitate administration of IV antibiotics, SPR994 may enable faster discharges, providing cost-saving advantages for the hospital and mitigating the risk of catheter-related infection for patients.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>SPR741 and SPR206 are designed to address the decline of novel and effective <FONT STYLE="white-space:nowrap">IV-administered</FONT> antibiotics to treat MDR Gram-negative infections in the hospital
setting</I></B>. First-line IV empiric antibiotics, such as levofloxacin, ceftazidime and <FONT STYLE="white-space:nowrap">piperacillin-tazobactam,</FONT> have experienced diminished utility as the number of bacterial strains resistant to these
antibiotics in the hospital has increased. Due to gaps in the spectrum of coverage of antibiotics currently on the market, physicians are often confronted with the need to design complicated multi-drug cocktails for patients with serious infections.
We believe that SPR741 has the potential to address the need for more effective treatments against MDR Gram-negative bacterial infections by expanding the spectrum and potency of existing antibiotics, including formerly inactive antibiotics. Based
on results from preclinical studies, we believe that SPR206 has the potential to address this need as a single agent. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>SPR720 is designed to be the first oral treatment for NTM infection where treatment failure is common and
no approved therapies exist</I></B>. The current treatment for NTM infection is lengthy and involves combination therapy, often including three or more antibiotics, including injectables. None
</P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
of these combination treatments are currently approved for use in NTM infection. Treatment failure is common and is often due to poor compliance or patients&#146; inability to tolerate the
regimen. Many patients experience progressive lung disease as a result of NTM infection, and mortality rates are high, ranging from 29% to 69% within five years of diagnosis. We believe SPR720, if successfully developed, has the potential to become
the first approved oral agent for NTM infection, and it has demonstrated activity <I>in vitro</I> and <I>in vivo</I> against a range of pathogens, including <I>Mycobacterium abscessus</I>, a highly resistant organism causing NTM infection with a
high rate of mortality. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Associated with Our Business </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our business is subject to a number of risks of which you should be aware before making an investment decision. These risks are discussed more
fully in the &#147;Risk Factors&#148; section of this prospectus immediately following this prospectus summary. These risks include, among others, the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have a limited operating history, have incurred net losses in each year since our inception and anticipate that we will continue to incur significant losses for the foreseeable future. We do not expect to generate
any product revenue for the foreseeable future. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We expect that we will need substantial additional funding. If we are unable to raise capital when needed, we may be forced to delay, reduce or eliminate our product development programs or commercialization efforts.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We are heavily dependent on the success of our lead product candidate, SPR994, which is still under development. Our ability to generate product revenue is substantially dependent on our ability to further develop,
obtain marketing approval for and successfully commercialize SPR994. Even if we receive regulatory approval to market product candidates, the market may not be receptive to our product candidates upon their commercial introduction, which will
prevent us from becoming profitable. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our clinical program for SPR994 is subject to a number of specific risks, including our use of a new formulation of the active pharmaceutical ingredient of SPR994 and our reliance, in part, on clinical data from two
exploratory Phase 2 clinical trials conducted by Meiji in Japan, which were not conducted in accordance with FDA guidance for clinical trials in patients with UTI, as support for our plan to proceed from a Phase 1 dose-selection clinical trial
directly to a pivotal Phase 3 clinical trial. If the FDA were to discount significantly the value of the Meiji clinical data, our clinical path for SPR994 could be materially delayed and we could incur material costs associated with conducting
additional clinical trials. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">If our planned clinical trials of SPR994 or any other product candidate that we advance to clinical trials fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise
produce favorable results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of such product candidates. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We rely on third parties to conduct our preclinical studies and clinical trials and to manufacture preclinical and clinical supplies of SPR994 and SPR741. If the third parties do not perform satisfactorily, we may not
be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our success depends in large part on our ability to obtain and maintain patent protection, trade secret protection and regulatory exclusivity, both in the United States and internationally, with respect to our
proprietary chemistry technology and our product candidates. If we are unable to protect the confidentiality of our trade secrets, our business and competitive position will be harmed. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our ability to continue as a going concern requires that we obtain sufficient funding to finance our operations. </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We were formed as Spero Therapeutics, LLC in December 2013 under the laws of the State of Delaware. On June&nbsp;30, 2017, through a series of
transactions, Spero Therapeutics, LLC merged with and into Spero Therapeutics, Inc. (formerly known as Spero OpCo, Inc.), a Delaware corporation. Our principal executive offices are located at 675 Massachusetts Avenue, Cambridge, Massachusetts
02139, and our telephone number is (857) <FONT STYLE="white-space:nowrap">242-1600.</FONT> Our website address is <I>www.sperotherapeutics.com</I>. The information contained on, or that can be accessed through, our website is not part of this
prospectus. Investors should not rely on any such information in deciding whether to purchase our securities. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The mark &#147;Spero
Therapeutics&#148; is our common law trademark. All other service marks, trademarks and trade names appearing in this prospectus are the property of their respective owners. We do not intend our use or display of other companies&#146; trade names,
trademarks or service marks to imply a relationship with, or an endorsement or sponsorship of us by, these other companies. Solely for convenience, trademarks and tradenames referred to in this prospectus may appear without the <SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> or <SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable
law, our rights, or that the applicable owner will not assert its rights, to these trademarks and tradenames. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth
Company </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act.
We will remain an emerging growth company until the earlier of (i)&nbsp;the last day of the fiscal year following the fifth anniversary of the completion of our initial public offering, (ii)&nbsp;the last day of the fiscal year in which we have
total annual gross revenue of at least $1.07&nbsp;billion, (iii)&nbsp;the last day of the fiscal year in which we are deemed to be a &#147;large accelerated filer&#148; as defined in <FONT STYLE="white-space:nowrap">Rule&nbsp;12b-2</FONT> under the
Securities Exchange Act of 1934, as amended, or the Exchange Act, which would occur if the market value of our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeded $700.0&nbsp;million as of the last business day of
the second fiscal quarter of such fiscal year, or (iv)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities during the prior three-year period. An emerging
growth company may take advantage of specified reduced reporting requirements and is relieved of certain other significant requirements that are otherwise generally applicable to public companies. As an emerging growth company: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may present in this prospectus only two years of audited financial statements, in addition to any required unaudited financial statements, with correspondingly reduced Management&#146;s Discussion and Analysis of
Financial Condition and Results of Operations disclosure; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may avail ourselves of the exemption from the requirement to obtain an attestation and report from our auditors on the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of
2002, or the Sarbanes-Oxley Act; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may provide reduced disclosure about our executive compensation arrangements; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may not require stockholder <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory votes on executive compensation or golden parachute arrangements. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have chosen to opt out of the extended transition periods available to emerging growth companies under the JOBS Act for complying with new
or revised accounting standards. Section&nbsp;107 of the JOBS Act provides that our decision to opt out of the extended transition periods for complying with new or revised accounting standards is irrevocable. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Offering </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock</B> </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock offered by us </P></TD>
<TD>3,250,000 shares </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding after this offering </P></TD>
<TD>17,619,182 shares </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Option to purchase additional shares </P></TD>
<TD>The underwriters have an option within 30 days of the date of this prospectus to purchase up to 487,500 additional shares of our common stock in this offering. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Dividend policy </P></TD>
<TD>We have not paid or declared any dividends on our common stock. For more information, see the section titled &#147;Dividend policy.&#148; </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq Global Select Market symbol </P></TD>
<TD>&#147;SPRO&#148; </TD></TR></TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Series A Convertible Preferred Stock </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Series A Preferred Stock offered by us </P></TD>
<TD>2,166 shares(1) </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Conversion </P></TD>
<TD>Each share of our Series A Preferred Stock is convertible into 1,000 shares of our common stock at any time at the option of the holder, provided that the holder will be prohibited from converting Series A Preferred Stock into shares of our
common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 9.99% of the total number of shares of our common stock then issued and outstanding. The holder of such shares of Series A Preferred Stock
can change this requirement, upon 61 days&#146; notice to us. </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Liquidation preference </P></TD>
<TD>In the event of our liquidation, dissolution, or winding up, holders of our Series A Preferred Stock will receive a payment equal to $0.001 per share of Series A Preferred Stock before any proceeds are distributed to the holders of our common
stock. </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Voting rights </P></TD>
<TD>Shares of Series A Preferred Stock will generally have no voting rights, except as required by law and except that the consent of the holders of the outstanding Series A Preferred Stock will be required to amend the terms of the Series A
Preferred Stock. </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Dividend policy </P></TD>
<TD>Shares of Series A Preferred Stock will not be entitled to receive any dividends, unless and until specifically declared by our board of directors. </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Listing </P></TD>
<TD>We are not listing our Series A Preferred Stock on any securities exchange or trading system and we do not expect that a trading market for our Series A Preferred Stock will develop. </TD></TR></TABLE>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Based on an assumed offering price of $13,850 per share (which is equal to $13.85, the last reported sales price of our common stock on July 10, 2018, multiplied by 1,000). </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We estimate the net proceeds from this offering will be approximately $69.9&nbsp;million (or $76.3&nbsp;million if the underwriters exercise their option to purchase additional shares in full), based on an assumed public offering price of $13.85
per share of common stock, the last reported sale price of our common stock on The Nasdaq Global Select Market on July&nbsp;10, 2018, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.
</TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We intend to use the net proceeds from this offering of common shares and Series A Preferred Stock, together with our existing cash and cash equivalents, to fund&nbsp;the planned pivotal Phase 3 clinical trial of SPR994
through the top-line data readout and the remainder for working capital and other general corporate purposes. See &#147;Use of Proceeds.&#148; </TD></TR></TABLE>    <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>You should read the section titled &#147;Risk Factors&#148; beginning on page&nbsp;15 of this prospectus and other information included in this prospectus for a discussion of factors to consider carefully before deciding to invest in our
securities. </TD></TR></TABLE>    <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering is based on
14,369,182 shares of our common stock outstanding as of March&nbsp;31, 2018, and excludes: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2,166,000 shares of common stock issuable upon the conversion of the 2,166 shares of Series A Preferred Stock offered hereby; </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2,129,082 shares of common stock issuable upon the exercise of outstanding stock options as of March&nbsp;31, 2018, having a weighted average exercise price of $7.60 per share; and </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">567,319 shares of common stock available for future issuance as of March&nbsp;31, 2018 under our 2017 Stock Incentive Plan, as amended, or the 2017 Plan, as well as any automatic increases in the number of shares of our
common stock reserved for issuance under the 2017 Plan. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Except as otherwise indicated, all information in this prospectus
assumes or gives effect to: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no exercise of the outstanding options described above after&nbsp;March 31, 2018; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no exercise by the underwriters of their option to purchase up to an additional 487,500 shares of our common stock in this offering. </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Summary Consolidated Financial Data </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">You should read the following summary consolidated financial data together with our consolidated financial statements and the related notes
appearing elsewhere in this prospectus and the &#147;Selected Consolidated Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; sections of this prospectus. We have derived
the consolidated statement of operations data for the years ended December&nbsp;31, 2017, 2016 and 2015 from our audited consolidated financial statements appearing elsewhere in this prospectus. The consolidated statement of operations data for the
three months ended March&nbsp;31, 2017 and 2018 and the consolidated balance sheet data as of March&nbsp;31, 2018 have been derived from our unaudited consolidated financial statements appearing elsewhere in this prospectus and have been prepared on
the same basis as the audited consolidated financial statements. Our historical results are not necessarily indicative of the results that may be expected in the future, and our results for any interim period are not necessarily indicative of
results that may be expected for any full year. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Year Ended</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:46.65pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:72.90pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Three Months
Ended<BR>March&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:16.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:16.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:16.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:16.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:16.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(In thousands, except per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statement of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,327</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,221</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41,730</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,599</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,816</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income and other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,153</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,641</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,886</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,411</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,644</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Net loss attributable to <FONT STYLE="white-space:nowrap">non-controlling</FONT>
interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,999</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,143</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(535</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to Spero Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,154</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,491</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,743</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,876</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,644</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued return on preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(932</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,146</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,236</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of redeemable bridge units and redeemable convertible preferred shares to redemption
value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(996</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,208</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders of Spero Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,427</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(29,928</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(46,097</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,130</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,644</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders of Spero Therapeutics, Inc. per share,
basic and diluted(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(53.11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(95.87</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17.82</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(21.60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.74</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding, basic and diluted(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">See Note 15 to our consolidated financial statements for the year ended December&nbsp;31, 2017 and Note 12 to our
consolidated financial statements for the three months ended March&nbsp;31, 2018 appearing elsewhere in </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
this prospectus for further details on the calculation of basic and diluted net loss per share attributable to common stockholders of Spero Therapeutics, Inc. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of March&nbsp;31, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">151,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">We define working capital as current assets less current liabilities. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">The as adjusted balance sheet data give effect to our issuance and sale of 3,250,000 shares of common stock in this offering at an assumed public offering price of $13.85 per share, which is the last reported sale price
of our common stock on July&nbsp;10, 2018, and our issuance and sale of 2,166 shares of Series A Preferred Stock at an assumed public offering price of $13,850 per share, after deducting estimated underwriting discounts and commissions and estimated
offering expenses payable by us. The as adjusted information is illustrative only and will change based on the actual public offering price and other terms of this offering determined at pricing. A $1.00 increase (decrease) in the assumed public
offering price of $13.85 per share of common stock, which was the last reported sale price of our common stock on July&nbsp;10, 2018, would increase (decrease) the as adjusted amount of each of cash, cash equivalents and marketable securities,
working capital, total assets and total stockholders&#146; equity by $3.1&nbsp;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting
discounts and commissions and estimated offering expenses payable by us. An increase (decrease) of 1,000,000 shares in the number of shares of common stock offered by us, as set forth on the cover page of this prospectus, would increase (decrease)
the as adjusted amount of each of cash, cash equivalents and marketable securities, working capital, total assets and total stockholders&#146; equity by $13.0&nbsp;million, assuming no change in the assumed public offering price per share and after
deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. <A NAME="cov521849_1"></A> </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc521849_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Careful consideration should be given to the following risk factors, in addition to the other information set forth in this prospectus,
including the section of this prospectus entitled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operation&#148; and our consolidated financial statements and related notes, and in other documents that we file
with the SEC, in evaluating our company and business. Investing in our securities involves a high degree of risk. If any of the following risks actually occur, our business, financial condition, results of operations and future growth prospects
could be materially and adversely affected and the trading price of our securities could decline. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of factors that are described below and
elsewhere in this prospectus. </I></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Financial Position and Need for Additional Capital </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred net losses in each year since our inception and anticipate that we will continue to incur significant losses for the foreseeable
future, and if we are unable to achieve and sustain profitability, the market value of our securities will likely decline. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company with a limited operating history. We have not generated any revenue from the sale of
products and have incurred losses in each year since our inception in 2013. Our net loss was $10.6&nbsp;million for the three months ended March&nbsp;31, 2018, and $39.9&nbsp;million and $32.6&nbsp;million for the years ended December&nbsp;31, 2017
and 2016, respectively. All of our product candidates are in development, none have been approved for sale and we may never have a product candidate approved for commercialization. We have financed our operations primarily through sales of our
equity securities, collaborations and government funding for research and development. We have devoted substantially all of our financial resources and efforts to research and development, including preclinical and clinical development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future as we continue to advance our
product candidates through preclinical and clinical development and seek marketing approval for such candidates if clinical trials are successful. Our expenses will also increase substantially if and as we: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">conduct additional clinical trials and studies of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">continue to discover and develop additional product candidates; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish a sales, marketing and distribution infrastructure to commercialize any product candidates for which we may obtain marketing approval; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish manufacturing and supply chain capacity sufficient to provide commercial quantities of any product candidates for which we may obtain marketing approval; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintain, expand and protect our intellectual property portfolio; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">hire additional clinical, scientific and commercial personnel; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts, as well as to support our transition to a
public reporting company;&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acquire <FONT STYLE="white-space:nowrap">or&nbsp;in-license&nbsp;other</FONT> product candidates and technologies. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If our product candidates fail to demonstrate safety and efficacy in clinical trials, do not gain regulatory approval, or do not achieve
market acceptance following regulatory approval and commercialization, we may never become profitable. Even if we achieve profitability in the future, we may not be able to sustain profitability </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in subsequent periods. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders&#146; equity and working capital. If we are
unable to achieve and sustain profitability, the market value of our common stock will likely decline. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Because of the numerous risks
and uncertainties associated with developing biopharmaceutical products, we are unable to predict the extent of any future losses or when, if ever, we will become profitable. Our expenses could increase if we are required by the FDA, or any
comparable foreign regulatory authority to perform studies in addition to those currently expected, or if there are any delays in completing our clinical trials or the development of any of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect that we will need substantial additional funding. If we are unable to raise capital when needed, or do not receive payment under our
government awards, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is a time-consuming, expensive and uncertain
process that takes years to complete. We expect that our expenses will increase substantially as we commence and advance our planned clinical trials and other studies of SPR994, seek marketing approval for SPR994 if clinical trials are successful,
and evaluate the advancement of our other product candidates, including SPR741, SPR206 and SPR720. If we obtain marketing approval for SPR994 or any other product candidate, we expect to incur significant commercialization expenses related to
product sales, marketing, distribution and manufacturing. Some of these expenses may be incurred in advance of marketing approval, and could be substantial. Accordingly, we will be required to obtain further funding through public or private equity
offerings, debt financings, collaborations, licensing arrangements, government funding or other sources. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would
have a negative effect on our financial condition and our ability to pursue our business strategy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We believe that the proceeds from this
offering, together with our existing cash and cash equivalents, will enable us to fund our operating expenses and capital expenditure requirements into the second half of 2020, including through top-line data readout of our planned pivotal Phase 3
clinical trial of SPR994. Our cash forecasts are based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Changing circumstances could cause us to consume capital
significantly faster than we currently anticipate, and we may need to spend more than currently expected because of circumstances beyond our control. Our future funding requirements, both short-term and long-term, will depend on many factors,
including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing and costs of our ongoing and planned clinical trials of SPR994; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing and costs of our ongoing clinical trials of SPR741; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the initiation, progress, timing, costs and results of preclinical studies and clinical trials of our other product candidates and potential product candidates; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the amount of funding that we receive under government awards that we have applied for; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number and characteristics of product candidates that we pursue; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the outcome, timing and costs of seeking regulatory approvals; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of commercialization activities for SPR994 and other product candidates if we receive marketing approval, including the costs and timing of establishing product sales, marketing, distribution and manufacturing
capabilities; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the receipt of marketing approval and revenue received from any potential commercial sales of SPR994; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms and timing of any future collaborations, licensing or other arrangements that we may establish; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property
rights, including milestone and royalty payments and patent prosecution fees that we are obligated to pay pursuant to our license agreements; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and defending against any intellectual property related claims; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of operating as a public company;&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which <FONT STYLE="white-space:nowrap">we&nbsp;in-license&nbsp;or</FONT> acquire other products and technologies. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause dilution to our stockholders, including purchasers of our securities in this offering, restrict our operations or
require us to relinquish rights to our technologies or product candidates. </I></B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Unless and until we can generate a substantial
amount of revenue from our product candidates, we expect to finance our future cash needs through public or private equity offerings, debt financings or collaborations, licensing arrangements and government funding arrangements. In addition, we may
seek additional capital due to favorable market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">To the extent that we raise additional capital through the sale of common stock, convertible securities or other equity securities, your
ownership interest may be materially diluted, and the terms of these securities could include liquidation or other preferences and anti-dilution protections that could adversely affect your rights as a stockholder. In addition, debt financing, if
available, would result in increased fixed payment obligations and may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring
dividends, which could adversely affect our ability to conduct our business. In addition, securing additional financing would require a substantial amount of time and attention from our management and may divert a disproportionate amount of their
attention away <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">from&nbsp;day-to-day&nbsp;activities,</FONT></FONT> which may adversely affect our management&#146;s ability to oversee the development of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third
parties, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to continue as a going concern requires that we obtain sufficient funding to finance our operations. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our ability to continue as a going concern requires that we obtain sufficient funding to finance our operations. If we are unable to obtain
sufficient funding, our business, prospects, financial condition and results of operations will be materially and adversely affected and we may be unable to continue as a going concern. If we are unable to continue as a going concern, we may have to
liquidate our assets and may receive less than the value at which those assets are carried on our audited financial statements, and it is likely that investors will lose all or a part of their investment. If we seek additional financing to fund our
business activities in the future and there remains substantial doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding to us on commercially reasonable terms or at
all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to use our net operating loss carryforwards may be limited. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017, we had U.S. federal, state and foreign net operating loss carryforwards, or NOLs, of $76.4&nbsp;million,
$76.0&nbsp;million and $4.3&nbsp;million, respectively. Our NOLs begin to expire in 2033. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Utilization of these NOLs depends on many factors, including our future income, which cannot be assured. These NOLs could expire unused and be unavailable to offset our future income tax
liabilities. In addition, under Section&nbsp;382 of the Internal Revenue Code of 1986, as amended, or the Code, and corresponding provisions of state law, if a corporation undergoes an &#147;ownership change,&#148; which is generally defined as a
greater than 50% change, by value, in its equity ownership by 5% stockholders over a three-year period, the corporation&#146;s ability to use <FONT STYLE="white-space:nowrap">its&nbsp;pre-change&nbsp;NOLs</FONT> and
<FONT STYLE="white-space:nowrap">other&nbsp;pre-change&nbsp;tax</FONT> attributes to offset its post-change income may be limited. We have not determined if we have experienced Section&nbsp;382 ownership changes in the past and if a portion of our
NOLs is subject to an annual limitation under Section&nbsp;382. In addition, we may experience ownership changes in the future as a result of subsequent changes in our stock ownership, including this offering, some of which may be outside of our
control. If we determine that an ownership change has occurred and our ability to use our historical NOLs is materially limited, it would harm our future operating results by effectively increasing our future tax obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under recently enacted U.S. federal tax legislation, although the treatment of net operating loss carryforwards arising in tax years beginning
on or before December&nbsp;31, 2017 has generally not changed, net operating loss carryforwards arising in tax years beginning after December&nbsp;31, 2017 may be used to offset only 80% of taxable income. In addition, net operating losses arising
in tax years beginning after December&nbsp;31, 2017 may be carried forward indefinitely, as opposed to the <FONT STYLE="white-space:nowrap">20-year</FONT> carryforward under prior law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have a limited operating history and no history of commercializing pharmaceutical products, which may make it difficult to evaluate the prospects for
our future viability. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We were established in 2013 and began operations in 2014. Our operations to date have been limited to
financing and staffing our company, developing our technology and developing SPR994 and our other product candidates. We have not yet demonstrated an ability to successfully complete a large-scale, pivotal clinical trial, obtain marketing approval,
manufacture a commercial scale product, or arrange for a third party to do so on our behalf, commercialize a product or conduct sales and marketing activities necessary for successful product commercialization. Consequently, predictions about our
future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing pharmaceutical products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will need to transition from a development-focused company to a company with commercial activities, and we may experience difficulties in managing
this transition, which could disrupt our operations. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We may encounter unforeseen expenses, difficulties, complications, delays
and other known or unknown factors in achieving our business objectives. We will eventually need to transition from a company with a development focus to a company capable of supporting commercial activities. We may not be successful in such a
transition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We expect our financial condition and operating results to continue to fluctuate significantly from quarter to quarter and
year to year due to a variety of factors, many of which are beyond our control. Accordingly, stockholders should not rely upon the results of any quarterly or annual periods as indications of future operating performance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Product Development and Commercialization </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are heavily dependent on the success of SPR994, which is still under development, and our ability to develop, obtain marketing approval for and
successfully commercialize SPR994. If we are unable to develop, obtain marketing approval for and successfully commercialize SPR994, or if we experience significant delays in doing so, our business could be materially harmed. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We currently have no products approved for sale and have invested a significant portion of our efforts and financial resources in the
development of SPR994 as a product candidate for the treatment of MDR bacterial infections. Our near-term prospects are substantially dependent on our ability to develop, obtain marketing approval for and successfully commercialize SPR994. The
success of SPR994 will depend on several factors, including the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">successful completion of clinical trials with safety, tolerability and efficacy profiles that are satisfactory to the FDA or any comparable foreign regulatory authority; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">receipt of marketing approvals from applicable regulatory authorities; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishment of arrangements with third-party manufacturers to obtain manufacturing supply; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtainment and maintenance of patent, trade secret protection and regulatory exclusivity, both in the United States and internationally, including our ability to maintain our license agreement with Meiji with respect to
SPR994; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">protection of our rights in our intellectual property portfolio; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">launch of commercial sales of SPR994, if approved, whether alone or in collaboration with others; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acceptance of SPR994, if approved, by patients, the medical community and third-party payors; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">competition with other therapies;&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a continued acceptable safety profile of SPR994 following approval. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Successful development of
SPR994 for any additional indications would be subject to these same risks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Many of these factors are beyond our control, including
clinical development, the regulatory submission process, potential threats to our intellectual property rights and the manufacturing, marketing and sales efforts of any future collaborator. If we are unable to develop, receive marketing approval
for, or successfully commercialize SPR994, or if we experience delays as a result of any of these factors or otherwise, our business could be materially harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have no experience as a company in obtaining regulatory approval for a drug. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As a company, we have never obtained regulatory approval for, or commercialized, a drug. It is possible that the FDA may refuse to accept any
or all of our planned new drug applications, or NDAs, for substantive review or may conclude after review of our data that our application is insufficient to obtain regulatory approval for any current or future product candidates. If the FDA does
not approve any of our planned NDAs, it may require that we conduct additional costly clinical, nonclinical or manufacturing validation studies before it will reconsider our applications. Depending on the extent of these or any <FONT
STYLE="white-space:nowrap">other&nbsp;FDA-required&nbsp;studies,</FONT> approval of any NDA or other application that we submit may be significantly delayed, possibly for several years, or may require us to expend more resources than we have
available. Any failure or delay in obtaining regulatory approvals would prevent us from commercializing SPR994 or any of our other product candidates for which we may seek regulatory approval, generating revenues and achieving and sustaining
profitability. It is also possible that additional studies, if performed and completed, may not be considered sufficient by the FDA to approve any NDA or other application that we submit. If any of these outcomes occur, we may be forced to abandon
the development of our product candidates, which would materially adversely affect our business and could potentially cause us to cease operations. We face similar risks for our applications in foreign jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If clinical trials of SPR994 or any other product candidate that we may advance to clinical trials fail to demonstrate safety and efficacy to the
satisfaction of the FDA or comparable foreign regulatory authorities or do not otherwise produce favorable results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and
commercialization of SPR994 or any other product candidate. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We cannot commercialize, market, promote, or sell any product
candidate in the United States without obtaining marketing approval from the FDA or in other countries without obtaining approvals from comparable foreign regulatory authorities, such as the European Medicines Agency, or EMA, and we may never
receive such approvals. We must complete extensive preclinical studies and clinical trials to demonstrate the safety and efficacy of our product candidates in humans before we will be able to obtain these approvals. Clinical testing is expensive,
difficult to design and implement, can take many years to complete and is inherently uncertain as to outcome. We have not previously submitted an NDA to the FDA or similar applications to comparable foreign regulatory authorities for any of our
product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The clinical development of SPR994 and any of our other product candidates is susceptible to
the risk of failure inherent at any stage of drug development, including failure to demonstrate efficacy in a trial or across a broad population of patients, the occurrence of severe adverse events, failure to comply with protocols or applicable
regulatory requirements, and determination by the FDA or any comparable foreign regulatory authority that a drug product is not approvable. A number of companies in the pharmaceutical industry, including biotechnology companies, have suffered
significant setbacks in clinical trials, even after promising results in earlier nonclinical studies or clinical trials. The results of preclinical and other nonclinical studies and/or early clinical trials of our product candidates may not be
predictive of the results of later-stage clinical trials. Notwithstanding any promising results in early nonclinical studies or clinical trials, we cannot be certain that we will not face similar setbacks. For example, although SPR994 is a new
formulation of the active pharmaceutical ingredient tebipenem that exhibited a favorable safety and efficacy profile during Phase&nbsp;2 clinical trials conducted by Meiji and a global pharmaceutical company, which we refer to as Global Pharma, in
Japan, we may nonetheless fail to achieve success in our clinical trials. Even if our clinical trials are completed, the results may not be sufficient to obtain regulatory approval for our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, preclinical and clinical data are often susceptible to varying interpretations and analyses. Many companies that believed their
product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval for the product candidates. Even if we believe that the results of our clinical trials warrant marketing
approval, the FDA or comparable foreign regulatory authorities may disagree and may not grant marketing approval of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In some instances, there can be significant variability in safety and/or efficacy results between different trials of the same product
candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, adherence to the dosing regimen and other trial protocols and the rate of dropout among
clinical trial participants, among others. It is possible that even if one or more of our product candidates has a beneficial effect, that effect will not be detected during clinical evaluation as a result of one of the factors listed or otherwise.
Conversely, as a result of the same factors, our clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any. Similarly, in our clinical trials, we may fail to detect
toxicity of or intolerability of our product candidates or may determine that our product candidates are toxic or not well tolerated when that is not in fact the case. In the case of our clinical trials, results may differ on the basis of the type
of bacteria with which patients are infected. We cannot make assurances that any Phase&nbsp;2, Phase&nbsp;3 or other clinical trials that we may conduct will demonstrate consistent or adequate efficacy and safety to obtain regulatory approval to
market our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We may encounter unforeseen events prior to, during, or as a result of, clinical trials that could delay
or prevent us from obtaining regulatory approval for SPR994 or any of our other product candidates, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA or other comparable foreign regulatory authorities may disagree as to the design or implementation of our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may not reach agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">clinical trials of our product candidates may produce unfavorable or inconclusive results; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate participants may drop out of these
clinical trials at a higher rate than we anticipate or we may fail to recruit suitable patients to participate in a trial; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our third-party contractors, including those manufacturing our product candidates or conducting clinical trials on our behalf, may fail to comply with regulatory requirements or meet their contractual obligations to us
in a timely manner, or at all; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA or institutional review boards may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may have to suspend or terminate clinical trials of our product candidates for various reasons, including a finding that the participants are being exposed to unacceptable health risks, undesirable side effects or
other unexpected characteristics of the product candidate; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulators or institutional review boards may require that we or our investigators suspend or terminate clinical trials of our product candidates for various reasons, including noncompliance with regulatory requirements
or a finding that the participants are being exposed to unacceptable health risks, undesirable side effects or other unexpected characteristics of the product candidate; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we enter into agreement for clinical and commercial supplies;
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate;&nbsp;and </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We could also encounter delays if a clinical trial is suspended or terminated by us, by the institutional review boards, or IRBs, of the
institutions in which such trials are being conducted, by the Data Safety Monitoring Board, or DSMB, if any, for such trial or by the FDA or other regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of
factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the
imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, or changes in governmental regulations or administrative actions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If we are required to conduct additional clinical trials or other testing of SPR994 or any other product candidate beyond the trials and
testing that we contemplate, if we are unable to successfully complete clinical trials or other testing of our product candidates, if the results of these trials or tests are unfavorable or are only modestly favorable or if there are safety concerns
associated with SPR994 or any other product candidate, we may: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">incur additional unplanned costs; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">be delayed in obtaining marketing approval for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">not obtain marketing approval at all; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain approval for indications or patient populations that are not as broad as intended or desired; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain approval with labeling that includes significant use or distribution restrictions or significant safety warnings, including boxed warnings; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">be subject to additional post-marketing testing or other requirements;&nbsp;or </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">be required to remove the product from the market after obtaining marketing approval. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our failure to successfully initiate and complete clinical trials of our product candidates
and to demonstrate the efficacy and safety necessary to obtain regulatory approval to market any of our product candidates would significantly harm our business. Our product candidate development costs will also increase if we experience delays in
testing or marketing approvals and we may be required to obtain additional funds to complete clinical trials. We cannot make assurances that our clinical trials will begin as planned or be completed on schedule, if at all, or that we will not need
to restructure our trials after they have begun. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to
market before we do and impair our ability to successfully commercialize our product candidates, which may harm our business and results of operations. In addition, many of the factors that cause, or lead to, delays of clinical trials may ultimately
lead to the denial of regulatory approval of SPR994 or any other product candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we experience delays or difficulties in the enrollment of
patients in clinical trials, clinical development activities could be delayed or otherwise adversely affected. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The timely
completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. We may not be able to initiate, continue or complete
clinical trials of SPR994 or any other product candidate that we develop if we are unable to locate and enroll a sufficient number of eligible patients to participate in clinical trials as required by the FDA or comparable foreign regulatory
authorities, such as the EMA. Patient enrollment is a significant factor in the timing of clinical trials, and is affected by many factors, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the size and nature of the patient population; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the severity of the disease under investigation; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the proximity of patients to clinical sites; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the eligibility criteria for participation in the clinical trial; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the design of the clinical trial; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to recruit clinical trial investigators with appropriate experience; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">competing clinical trials and clinicians&#146; and patients&#146; perceptions as to the potential advantages and risks of the product candidate being studied in relation to other available therapies, including any new
drugs that may be approved for the indications that we are investigating; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain and maintain patient consents; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the risk that patients enrolled in clinical trials will drop out of the trials before completion. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The inclusion and exclusion criteria for our contemplated Phase 3 clinical trials of SPR994 may adversely affect our enrollment rates for
patients in these trials. In addition, many of our competitors also have ongoing clinical trials for product candidates that would treat the same indications as we contemplate for SPR994 or our other product candidates, and patients who would
otherwise be eligible for any clinical trials we may conduct for such product candidates may instead enroll in clinical trials of our competitors&#146; product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or might require us to
abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, slow down or halt our product candidate development and approval process and jeopardize
our ability to seek and obtain the marketing approval required to commence product sales and generate revenue, which would cause the value of our company to decline and limit our ability to obtain additional financing if needed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future legislation, and/or regulations and policies adopted by the FDA, the EMA or similar regulatory
authorities may increase the time and cost required for us to conduct and complete clinical trials of SPR994 and our other product candidates and potential product candidates. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The FDA has established regulations to govern the drug development and approval process, as have foreign regulatory authorities. The policies
of the FDA and other regulatory authorities may change and additional laws may be enacted or government regulations may be promulgated that could prevent, limit, delay but also accelerate regulatory review of our product candidates. For example, in
December 2016, the 21st Century Cures Act, or Cures Act, was signed into law. The Cures Act, among other things, is intended to modernize the regulation of drugs and spur innovation, but all of its provisions have not yet been implemented. Among
other things, the Cures Act provides a new &#147;limited population&#148; pathway for certain antibacterial and antifungal drugs, or LPAD, but the FDA has not yet issued guidance regarding the LPAD. Additionally, in August 2017, FDA issued final
guidance setting forth its current thinking with respect to development programs and clinical trial designs for antibacterial drugs to treat serious bacterial diseases in patients with an unmet medical need. We cannot predict what if any effect the
Cures Act or any existing or future guidance from FDA will have on the development of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our clinical program for SPR994 is
subject to a number of specific risks that may affect the outcome of the trial, including the use of a new formulation of the active pharmaceutical ingredient, tebipenem. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our planned pivotal Phase 3 clinical trial of SPR994 is subject to a number of specific risks arising from our clinical program and the design
of the trial. We have not conducted a clinical trial of SPR994 in patients with cUTI, who will be the subjects of the clinical trial, and we have no direct clinical evidence that SPR994 is effective in treating cUTIs in humans. Although we believe
that SPR994 has the potential to treat cUTI in humans based on the results of our nonclinical<I>&nbsp;in vitro</I>&nbsp;and<I>&nbsp;in vivo</I>&nbsp;animal model studies, together with Meiji&#146;s and Global Pharma&#146;s Phase 2 clinical trial
results, these results are not necessarily predictive of the results of our planned clinical trials and we cannot guarantee that SPR994 will demonstrate the expected efficacy in our planned pivotal Phase 3 clinical trial patients. We also cannot
guarantee that the projections made from the pharmacokinetic and pharmacodynamic models that we developed from our nonclinical and clinical SPR994 studies will be validated in our planned pivotal Phase 3 clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, we may face competition in enrolling suitable patients as a result of other companies conducting clinical trials for antibiotic
product candidates that are intended to treat similar infections, resulting in slower than anticipated enrollment in our trials. Enrollment delays in the trial may result in increased development costs for SPR994, or slow down or halt our product
development for SPR994. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>To support our accelerated clinical development strategy for SPR994, we are relying, in part, on clinical data from two
exploratory Phase 2 clinical trials conducted by Meiji (ME1211) and Global <FONT STYLE="white-space:nowrap">Pharma&nbsp;(L-084&nbsp;04)</FONT> in Japan, which were not conducted in accordance with FDA guidance for clinical trials in patients with
cUTI. To the extent that these clinical trial design differences limit our use of the clinical data, our proposed clinical trial plan for SPR994 with the FDA could be materially delayed and we may incur material additional costs. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">There are significant differences in the trial design for the two exploratory Phase 2 clinical trials conducted by Meiji and Global Pharma in
Japan compared to the clinical trial design described by the FDA in its guidance for clinical trials in patients with cUTI, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The studies were not randomized and were open-label and had no comparator arm. Treatment assignments were made by the investigators. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The inclusion criteria specified complicated UTI as an entry criterion, but other than retained residual volume (100 ml) there were no other criteria defining &#147;complicated&#148; UTI. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">While&nbsp;L-084&nbsp;04</FONT> excluded patients who received prior antibiotics and who had no clinical response, there were no parameters or limits for inclusion (e.g., less than 24
hours of a potentially effective antibiotic or number of doses). ME1211 did not specifically mention prior antibiotic use. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">While urine cultures were obtained at baseline, these were not quantitative, and there was no minimum requirement for bacterial load for entry. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">While microbiological outcome was assessed, the definitions did not include a minimum reduction in bacterial counts (i.e., a reduction to less than 10<SUP STYLE="font-size:85%; vertical-align:top">4</SUP>&nbsp;cfu/ml).
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Clinical outcomes were global assessments by the investigators and did not specifically mention the resolution of baseline signs and symptoms. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The primary endpoint was not a composite of both clinical and microbiological outcomes. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If
the FDA were to discount significantly the value of these clinical data as support for our clinical plan to proceed from a Phase 1 dose-selection clinical trial directly to a pivotal Phase 3 clinical trial of SPR994, then our clinical pathway for
SPR994 could be materially delayed and we could incur material costs associated with conducting additional clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preliminary or interim
data from our clinical studies that we announce or publish from time to time, including preliminary data from our Phase 1 clinical trial of SPR994 in cUTI and our dose-selection findings, may change as more patient data become available and are
subject to audit and verification procedures that could result in material changes in the final data. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Preliminary or interim data
from our clinical studies are not necessarily predictive of final data. Preliminary and interim data are subject to the risk that one or more of the clinical outcomes may materially change, as more patient data become available and we issue our
final clinical study report. Preliminary or interim data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim
and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could affect our planned clinical path for SPR994, including potentially increasing cost
and/or causing delay in such development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A Phase 2 clinical trial of SPR741 would be subject to a number of specific risks that may affect the
outcome of the trials, including the need <FONT STYLE="white-space:nowrap">to&nbsp;co-administer&nbsp;SPR741</FONT> with a companion antibiotic and identifying available development funding. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">A Phase 2 clinical trial of SPR741 would be subject to a number of specific risks arising from our clinical program and the design of the
trial. We have not conducted a clinical trial of SPR741 in patients with cUTI, who would be the subjects of any such clinical trial, and we have no direct clinical evidence that SPR741 as a potentiator in combination with a partner antibiotic has
the potential to treat cUTI in humans. Although we believe that SPR741 as a potentiator in combination with a partner antibiotic has the potential to treat cUTI in humans based upon our nonclinical<I></I><I>&nbsp;in
vitro</I>&nbsp;and<I></I><I>&nbsp;in vivo</I>&nbsp;animal model study results, these results are not necessarily predictive of the results in humans. We cannot guarantee that SPR741 as a potentiator in combination with a partner antibiotic will
demonstrate the efficacy we expect to observe in patients in a Phase&nbsp;2 clinical trial of SPR741. We also cannot guarantee that the projections made from the pharmacokinetic and pharmacodynamic models that we developed from our nonclinical and
clinical SPR741 studies would be validated in a Phase&nbsp;2 clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, we may face competition in enrolling suitable
patients in any such trial as a result of other companies conducting clinical trials for antibiotic product candidates that are intended to treat similar infections, resulting in slower than anticipated enrollment in our trials. Enrollment delays in
any such trial may result in increased development costs for SPR741, or slow down or halt our product development and approval process for SPR741. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Serious adverse events or undesirable side effects or other unexpected properties of SPR994 or any
other product candidate may be identified during development or after approval that could delay, prevent or cause the withdrawal of regulatory approval, limit the commercial potential, or result in significant negative consequences following
marketing approval. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Serious adverse events or undesirable side effects caused by, or other unexpected properties of, our product
candidates could cause us, an institutional review board, or regulatory authorities to interrupt, delay or halt our clinical trials and could result in a more restrictive label, the imposition of distribution or use restrictions or the delay or
denial of regulatory approval by the FDA or comparable foreign regulatory authorities. If SPR994 or any of our other product candidates is associated with serious or unexpected adverse events or undesirable side effects, the FDA, the IRBs at the
institutions in which our studies are conducted, or a DSMB, could suspend or terminate our clinical trials or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for
any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our
business, financial condition and prospects significantly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">While the active pharmaceutical ingredient in SPR994, tebipenem, is approved
in Japan, our formulation of tebipenem, SPR994, has not yet been tested extensively in patients. There may be unforeseen serious adverse events or side effects that differ from those seen in the Japanese studies. To date, patients treated with the
active ingredient in SPR994 have experienced drug-related side effects including diarrhea, temporary increases in hepatic enzymes, allergic reactions, rash, and convulsions. To date, SPR741 has generally been well tolerated in clinical trials
conducted in healthy subjects and there have been no reports of serious adverse events related to SPR741, but additional adverse events may emerge in any subsequent clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If unexpected adverse events occur in any of our planned clinical trials, we may need to abandon development of our product candidates, or
limit development to lower doses or to certain uses or subpopulations in which the undesirable side effects or other unfavorable characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Many compounds that
initially showed promise in clinical or earlier stage testing are later found to cause undesirable or unexpected side effects that prevented further development of the compound. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Undesirable side effects or other unexpected adverse events or properties of SPR994 or any of our other product candidates could arise or
become known either during clinical development or, if approved, after the approved product has been marketed. If such an event occurs during development, our trials could be suspended or terminated and the FDA or comparable foreign regulatory
authorities could order us to cease further development of, or could deny approval of, SPR994 or our other product candidates. If such an event occurs after such product candidates are approved, a number of potentially significant negative
consequences may result, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may withdraw the approval of such product; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be required to recall a product or change the way such product is administered to patients; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may require additional warnings on the label or impose distribution or use restrictions; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may require one or more post-market studies; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may require the addition of a &#147;black box&#148; warning; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be required to implement a REMS including the creation of a medication guide outlining the risks of such side effects for distribution to patients; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we could be sued and held liable for harm caused to patients; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our product may become less competitive; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our reputation may suffer. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us from achieving or maintaining market acceptance of the
affected product candidate, if approved, or could substantially increase commercialization costs and expenses, which could delay or prevent us from generating revenue from the sale of our products and harm our business and results of operations.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if a product candidate does obtain regulatory approval, it may never achieve the market acceptance by physicians, patients, hospitals,
third-party payors and others in the medical community that is necessary for commercial success and the market opportunity may be smaller than we estimate. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Even if we obtain FDA or other regulatory approvals and are able to launch SPR994 or any other product candidate commercially, the product
candidate may not achieve market acceptance among physicians, patients, hospitals (including pharmacy directors) and third-party payors and, ultimately, may not be commercially successful. For example, physicians are often reluctant to switch their
patients from existing therapies even when new and potentially more effective or convenient treatments enter the market. Further, patients often acclimate to the therapy that they are currently taking and do not want to switch unless their
physicians recommend switching products or they are required to switch therapies due to lack of coverage and reimbursement for existing therapies. Market acceptance of any product candidate for which we receive approval depends on a number of
factors, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the efficacy and safety of the product candidate as demonstrated in clinical trials; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">relative convenience and ease of administration; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the clinical indications for which the product candidate is approved; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential and perceived advantages and disadvantages of the product candidates, including cost and clinical benefit relative to alternative treatments; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the willingness of physicians to prescribe the product; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the willingness of hospital pharmacy directors to purchase the product for their formularies; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acceptance by physicians, patients, operators of hospitals and treatment facilities and parties responsible for coverage and reimbursement of the product; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the availability of coverage and adequate reimbursement by third-party payors and government authorities; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effectiveness of our sales and marketing efforts; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the strength of marketing and distribution support; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limitations or warnings, including distribution or use restrictions, contained in the product&#146;s approved labeling or an approved risk evaluation and mitigation strategy; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the product is designated under physician treatment guidelines as a first-line therapy or as a second- or third-line therapy for particular infections; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the approval of other new products for the same indications; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of market introduction of the approved product as well as competitive products; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adverse publicity about the product or favorable publicity about competitive products; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the emergence of bacterial resistance to the product;&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the rate at which resistance to other drugs in the target infections grows. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Any failure by SPR994 or any other product candidate that obtains regulatory approval to
achieve market acceptance or commercial success would adversely affect our business prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may expend our limited resources to pursue a
particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Because we have limited financial and managerial resources, we intend to focus on developing product candidates for specific indications that
we identify as most likely to succeed, in terms of both their potential for marketing approval and commercialization. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that may prove
to have greater commercial potential. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our resource allocation decisions may cause us to fail to capitalize on viable commercial products
or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable product candidates. If we do not accurately evaluate the
commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more
advantageous for us to retain sole development and commercialization rights to the product candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to establish sales,
marketing and distribution capabilities or enter into sales, marketing and distribution agreements with third parties, we may not be successful in commercializing SPR994 or any other product candidate if such product candidate is approved.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We do not have a sales, marketing or distribution infrastructure and we have no experience in the sale, marketing or distribution
of pharmaceutical products. To achieve commercial success for any approved product, we must either develop a sales and marketing organization or outsource those functions to third parties. We intend to build a commercial organization in the United
States and recruit experienced sales, marketing and distribution professionals. The development of sales, marketing and distribution capabilities will require substantial resources, will be time-consuming and could delay any product launch. If the
commercial launch of a product candidate for which we recruit a sales force and establish marketing and distribution capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these
commercialization costs. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. In addition, we may not be able to hire a sales force in the United States that is sufficient in size
or has adequate expertise in the medical markets that we intend to target. If we are unable to establish a sales force and marketing and distribution capabilities, our operating results may be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Factors that may inhibit our efforts to commercialize our products on our own include: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to recruit and retain adequate numbers of effective sales and marketing personnel; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability of sales personnel to obtain access to or persuade adequate numbers of physicians to prescribe any future products; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines;&nbsp;and </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unforeseen costs and expenses associated with creating an independent sales and marketing organization. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We intend to use collaborators to assist with the commercialization of SPR994 and any other product candidate outside the United States. As a
result of entering into arrangements with third parties to perform sales, marketing and distribution services, our product revenues or the profitability of these product revenues to us would likely be lower than if we were to directly market and
sell products in those markets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Furthermore, we may be unsuccessful in entering into the necessary arrangements with third
parties or may be unable to do so on terms that are favorable to us. In addition, we likely would have little control over such third parties, and any of them might fail to devote the necessary resources and attention to sell and market our products
effectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third
parties, we will not be successful in commercializing our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face substantial competition from other pharmaceutical and
biotechnology companies and our operating results may suffer if we fail to compete effectively. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The development and
commercialization of new drug products is highly competitive. We face competition from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide with respect to SPR994 and our other product candidates
that we may seek to develop and commercialize in the future. There are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of product candidates for the treatment of
drug resistant infections. Potential competitors also include academic institutions, government agencies and other public and private research organizations. Our competitors may succeed in developing, acquiring or licensing technologies and drug
products that are more effective or less costly than SPR994 or any other product candidates that we are currently developing or that we may develop, which could render our product candidates obsolete and noncompetitive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">There are a variety of available oral therapies marketed for the treatment urinary tract infections that we would expect would compete with
SPR994, such as Levaquin, Cipro and Bactrim. Many of the available therapies are well established and widely accepted by physicians, patients and third-party payors. Insurers and other third-party payors may also encourage the use of generic
products, for example in the fluoroquinolone class. However, the susceptibility of urinary tract pathogens to the existing treatment alternatives is waning. If SPR994 is approved, the pricing may be at a significant premium over other competitive
products. This may make it difficult for SPR994 to compete with these products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">There are also a number of oral product candidates in
clinical development by third parties that are intended to treat UTIs. <FONT STYLE="white-space:nowrap">Some&nbsp;mid-&nbsp;to</FONT> late-stage product candidates include&nbsp;ceftibuten/clavulanate
<FONT STYLE="white-space:nowrap">(&#147;C-Scape&#148;)&nbsp;from</FONT> Achaogen, Inc., sulopenem from Iterum Therapeutics Limited, eravacycline from Tetraphase Pharmaceuticals, Inc. and omadacycline from Paratek Pharmaceuticals, Inc. If our
competitors obtain marketing approval from the FDA or comparable foreign regulatory authorities for their product candidates more rapidly than us, it could result in our competitors establishing a strong market position before we are able to enter
the market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">There are several <FONT STYLE="white-space:nowrap">IV-administered</FONT> products marketed for the treatment of infections
resistant to first-line therapy for Gram-negative infections, including ceftazidime-avibactam (&#147;Avycaz&#148;) from Allergan plc and Pfizer Inc., ceftolozane-tazobactam (&#147;Zerbaxa&#148;) from Merck and Co., and plazomicin
(&#147;Zemdri&#148;) from Achaogen, Inc. There are also a number of <FONT STYLE="white-space:nowrap">IV-administered</FONT> product candidates in late-stage clinical development that are intended to treat resistant Gram-negative infections,
including Vabomere from Melinta Therapeutics, Inc., cefiderocol from Shionogi&nbsp;&amp; Co. Ltd., eravacycline IV from Tetraphase Pharmaceuticals, Inc. and imipenem-relebactam from Merck&nbsp;&amp; Co. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical
testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a
smaller number of our competitors. Smaller and other early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in
recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient recruitment for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In July 2012, the Food and Drug Administration Safety and Innovation Act was passed, which
included the Generating Antibiotics Incentives Now Act, or the GAIN Act. The GAIN Act is intended to provide incentives for the development of new, qualified infectious disease products. In December 2016, the Cures Act was passed, providing
additional support for the development of new infectious disease products. These incentives may result in more competition in the market for new antibiotics, and may cause pharmaceutical and biotechnology companies with more resources than we have
to shift their efforts towards the development of product candidates that could be competitive with SPR994 and our other product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even
if we are able to commercialize SPR994 or any other product candidate, the product may become subject to unfavorable pricing regulations, or third-party payor coverage and reimbursement policies that could harm our business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Marketing approvals, pricing, coverage and reimbursement for new drug products vary widely from country to country. Some countries require
approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains
subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of
the product, possibly for lengthy time periods, which may negatively affect the revenues that we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or
more product candidates, even if our product candidates obtain marketing approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We currently expect that some of our product
candidates, if approved, will be administered in a hospital inpatient setting. In the United States, governmental and other third-party payors generally reimburse hospitals a single bundled payment established on a prospective basis intended to
cover all items and services provided to the patient during a single hospitalization. Hospitals bill third-party payors for all or a portion of the fees associated with the patient&#146;s hospitalization and bill patients for any deductibles <FONT
STYLE="white-space:nowrap">or&nbsp;co-payments.&nbsp;Because</FONT> there is typically no separate reimbursement for drugs administered in a hospital inpatient setting, some of our target customers may be unwilling to adopt our product candidates in
light of the additional associated cost. If we are forced to lower the price we charge for our product candidates, if approved, our gross margins may decrease, which would adversely affect our ability to invest in and grow our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">To the extent SPR994 or any other product candidate we develop is used in an outpatient setting, the commercial success of our product
candidates will depend substantially, both domestically and abroad, on the extent to which coverage and reimbursement for these products and related treatments are available from government health programs and third-party payors. If coverage is not
available, or reimbursement is limited, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing
sufficient to realize a sufficient return on our investments. Government authorities and third-party payors, such as health insurers and managed care organizations, publish formularies that identify the medications they will cover and the related
payment levels. The healthcare industry is focused on cost containment, both in the United States and elsewhere. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for
particular medications, which could affect our ability to sell our product candidates profitably. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Increasingly, third-party payors are
requiring higher levels of evidence of the benefits and clinical outcomes of new technologies and are challenging the prices charged. We cannot be sure that coverage will be available for SPR994 or any other product candidate that we commercialize
and, if available, that the reimbursement rates will be adequate. Further, the net reimbursement for outpatient drug products may be subject to additional reductions if there are changes to laws that presently restrict imports of drugs from
countries where they may be sold at lower prices than in the United States. An inability to promptly obtain coverage and adequate payment rates from both government-funded and private payors for any approved products used on an outpatient basis that
we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We cannot predict whether bacteria may develop resistance to SPR994 or our other product candidates,
which could affect their revenue potential. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are developing SPR994 and certain of our other product candidates to treat
drug-resistant bacterial infections. The bacteria responsible for these infections evolve quickly and readily transfer their resistance mechanisms within and between species. We cannot predict whether or when bacterial resistance to SPR994 or any of
such other product candidates may develop. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Specifically, neither SPR994 nor SPR741 (as a potentiator in combination with a partner
antibiotic) are highly active against infections caused by&nbsp;<I>Pseudomonas aeruginosa</I>. As with some commercially available carbapenems, SPR994 is not active against organisms expressing a resistance mechanism mediated by enzymes known as
carbapenemases. Although occurrence of this resistance mechanism is currently rare, we cannot predict whether carbapenemase-mediated resistance will become widespread in regions where we intend to market SPR994 if it is approved. The growth of drug
resistant infections in community settings or in countries with poor public health infrastructures, or the potential use of SPR994 or any of our other product candidates outside of controlled hospital settings, could contribute to the rise of
resistance. If resistance to SPR994 or any of our other product candidates becomes prevalent, our ability to generate revenue from SPR994 or such product candidates could suffer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B><I>If we are not successful in discovering, developing and commercializing additional product candidates, our ability to expand our
business and achieve our strategic objectives would be impaired. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Although a substantial amount of our efforts will focus on
planned clinical trials and potential approval of our lead product candidate, SPR994, our lead Potentiator Platform product candidates, SPR741 and SPR206, and SPR 720, a key element of our strategy is to discover, develop and commercialize a
portfolio of therapeutics to treat drug resistant bacterial infections. We are seeking to do so through our internal research programs and are exploring, and intend to explore in the future, strategic partnerships for the development of new product
candidates. Other than SPR994 and SPR741, all of our potential product candidates remain in the discovery and preclinical stages. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Research programs to identify product candidates require substantial technical, financial and human resources, whether or not any product
candidates are ultimately identified. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for many reasons, including the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the research methodology used may not be successful in identifying potential product candidates; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be unable to successfully modify candidate compounds to be active in Gram-negative bacteria or defeat bacterial resistance mechanisms or identify viable product candidates in our screening campaigns;
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">competitors may develop alternatives that render our product candidates obsolete; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product candidates that we develop may nevertheless be covered by third parties&#146; patents or other exclusive rights; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a product candidate may, on further study, be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria;
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors;&nbsp;and </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the development of bacterial resistance to potential product candidates may render them ineffective against target infections. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If we are unsuccessful in identifying and developing additional product candidates, our potential for growth may be impaired. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Product liability lawsuits against us could divert our resources, cause us to incur substantial liabilities and limit commercialization of any products
that we may develop. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We face an inherent risk of product liability claims as a result of the clinical testing of our product
candidates despite obtaining appropriate informed consents from our clinical trial participants. We will face an even greater risk if we obtain marketing approval for and commercially sell SPR994 or any other product candidate. For example, we may
be sued if any product that we develop allegedly causes injury or is found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing,
defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against
product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Regardless of the merits or eventual outcome, liability claims may result in: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduced resources for our management to pursue our business strategy; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">decreased demand for our product candidates or products that we may develop; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injury to our reputation and significant negative media attention; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">withdrawal of clinical trial participants; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">initiation of investigations by regulators; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product recalls, withdrawals or labeling, marketing or promotional restrictions; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">significant costs to defend resulting litigation; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">substantial monetary awards to trial participants or patients; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">loss of revenue;&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability to commercialize any products that we may develop. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Although we maintain general
liability insurance and clinical trial liability insurance, this insurance may not fully cover potential liabilities that we may incur. The cost of any product liability litigation or other proceeding, even if resolved in our favor, could be
substantial. We will need to increase our insurance coverage if and when we receive marketing approval for and begin selling SPR994 or any other product candidate. In addition, insurance coverage is becoming increasingly expensive. If we are unable
to obtain or maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product liability claims, it could prevent or inhibit the development and commercial production and sale of our product candidates,
which could adversely affect our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with environmental,
health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the
handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
materials, including chemicals and biological materials, and may also produce hazardous waste products. Even if we contract with third parties for the disposal of these materials and wastes, we
cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any
liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We maintain workers&#146; compensation insurance to cover us for costs and expenses that we may incur due to injuries to our employees
resulting from the use of hazardous materials, but this insurance may not provide adequate coverage against potential liabilities. Moreover, we do not currently maintain insurance for environmental liability or toxic tort claims that may be asserted
against us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws
and regulations. Current or future environmental laws and regulations may impair our research, development or production efforts, which could adversely affect our business, financial condition, results of operations or prospects. In addition,
failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our internal computer systems, or
those of our contract research organizations or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We utilize information technology systems and networks to process, transmit and store electronic information in connection with our business
activities. As the use of digital technologies has increased, cyber incidents, including deliberate attacks and attempts to gain unauthorized access to computer systems and networks, have increased in frequency and sophistication. These threats pose
a risk to the security of our systems and networks and the confidentiality, availability and integrity of our data. There can be no assurance that we will be successful in preventing cyber-attacks or successfully mitigating their effects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Despite the implementation of security measures, our internal computer systems and those of our contract research organizations and other
contractors and consultants are vulnerable to damage or disruption from hacking, computer viruses, software bugs, unauthorized access, natural disasters, terrorism, war, and telecommunication, equipment and electrical failures. While we have not, to
our knowledge, experienced any significant system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our programs. For example, the loss
of clinical trial data from completed or ongoing clinical trials for any of our product candidates could result in delays in our development and regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To
the extent that any disruption or security breach results in a loss of or damage to our data or applications, or inappropriate disclosure or theft of confidential or proprietary information, we could incur liability, the further development of our
product candidates could be delayed or our competitive position could be compromised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Dependence on Third Parties </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect to depend on collaborations with third parties for the development and commercialization of some of our product candidates. Our prospects with
respect to those product candidates will depend in part on the success of those collaborations. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Although we expect to
commercialize SPR994 ourselves in the United States, we intend to commercialize it outside the United States through collaboration arrangements. If we develop SPR741 to <FONT STYLE="white-space:nowrap">be&nbsp;co-administered&nbsp;in</FONT>
combination with branded and not generic antibiotic compounds, then we will be required to obtain and maintain rights from third-party collaborators for the development and commercialization of
<FONT STYLE="white-space:nowrap">SPR741&nbsp;co-administered&nbsp;with</FONT> such other branded antibiotic compounds. In addition, we may seek third-party collaborators for development and commercialization of certain of our product candidates. Our
likely collaborators for any marketing, distribution, development, licensing or broader collaboration arrangements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
include large <FONT STYLE="white-space:nowrap">and&nbsp;mid-size&nbsp;pharmaceutical</FONT> companies, regional and national pharmaceutical companies and biotechnology companies. We are not
currently party to any such arrangements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We may derive revenue from research and development fees, license fees, milestone payments and
royalties under any collaborative arrangement into which we enter. Our ability to generate revenue from these arrangements will depend on our collaborators&#146; abilities to successfully perform the functions assigned to them in these arrangements.
In addition, our collaborators may have the right to abandon research or development projects and terminate applicable agreements, including funding obligations, prior to or upon the expiration of the agreed upon terms. As a result, we can expect to
relinquish some or all of the control over the future success of a product candidate that we license to a third party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We face
significant competition in seeking and obtaining appropriate collaborators. Collaborations involving our product candidates may pose a number of risks, including the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may not perform their obligations as expected; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the
collaborators&#146; strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new
formulation of a product candidate for clinical testing; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the
commercialization of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of such product or products; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or
commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual
property or proprietary information or expose us to potential litigation; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;&nbsp;and </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If a
collaborator of ours is involved in a business combination, it could decide to delay, diminish or terminate the development or commercialization of any product candidate licensed to it by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may have to alter our development and commercialization plans if we are not able to establish
collaborations. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We will require additional funds to complete the development and potential commercialization of SPR994 and our
other product candidates. For some of our product candidates, we may decide to collaborate with pharmaceutical and biotechnology companies for the development and potential commercialization of those product candidates. For SPR741, if we develop
such product candidate to <FONT STYLE="white-space:nowrap">be&nbsp;co-administered&nbsp;in</FONT> combination with branded and not generic antibiotic compounds, we will be required to obtain and maintain rights from third-party collaborators for
such development and commercialization of <FONT STYLE="white-space:nowrap">SPR741&nbsp;co-administered&nbsp;with</FONT> such collaborator&#146;s branded antibiotic compound. Moreover, we intend to utilize a variety of types of collaboration
arrangements for the potential commercialization of our product candidates outside the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We face significant competition in
seeking and obtaining appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#146;s resources and expertise, the terms and conditions of the
proposed collaboration and the proposed collaborator&#146;s evaluation of a number of factors. Those factors may include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the design or results of clinical trials; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the likelihood of approval by the FDA or comparable foreign regulatory authorities; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential market for the subject product candidate; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs and complexities of manufacturing and delivering such product candidate to patients; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential for competing products; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our patent position protecting the product candidate, including any uncertainty with respect to our ownership of our technology or our licensor&#146;s ownership of technology we license from them, which can exist if
there is a challenge to such ownership without regard to the merits of the challenge; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the need to seek licenses <FONT STYLE="white-space:nowrap">or&nbsp;sub-licenses&nbsp;to</FONT> third-party intellectual property;&nbsp;and </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">industry and market conditions generally. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The collaborator may also consider alternative
product candidates or technologies for similar indications that may be available for collaboration and whether such a collaboration could be more attractive than the one with us for our product candidate. We may also be restricted under future
license agreements from entering into agreements on certain terms with potential collaborators. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced
number of potential future collaborators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If we are unable to reach agreements with suitable collaborators on a timely basis, on
acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any
sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain
additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and
commercialization activities, we may not be able to further develop our product candidates or bring them to market and our business may be materially and adversely affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on third parties to conduct some of our preclinical studies and all of our clinical trials. If
these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for or commercialize any of our product candidates. If they do not perform satisfactorily, our
business may be materially harmed. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We do not independently conduct nonclinical studies that comply with good laboratory practice,
or GLP, requirements. We also do not have the ability to independently conduct clinical trials of any of our product candidates. We rely on third parties, such as contract research organizations, clinical data management organizations, medical
institutions, and clinical investigators, to conduct our clinical trials of SPR994 and SPR741 and expect to rely on these third parties to conduct clinical trials of our other product candidates and potential product candidates. Any of these third
parties may terminate their engagements with us at any time. If we need to enter into alternative arrangements, it would delay our product development activities and increase our costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our reliance on these third parties for clinical development activities limits our control over these activities but we remain responsible for
ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards. For example, notwithstanding the obligations of a contract research organization for a trial of one of our product
candidates, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial and applicable regulatory requirements. While we will have agreements
governing their activities, we control only certain aspects of their activities and have limited influence over their actual performance. The third parties with whom we contract for execution of our GLP studies and our clinical trials play a
significant role in the conduct of these studies and trials and the subsequent collection and analysis of data. Although we rely on these third parties to conduct <FONT STYLE="white-space:nowrap">our&nbsp;GLP-compliant&nbsp;nonclinical</FONT>
studies and clinical trials, we remain responsible for ensuring that each of our nonclinical studies and clinical trials are conducted in accordance with applicable laws and regulations, and our reliance on the CROs does not relieve us of our
regulatory responsibilities. The FDA and regulatory authorities in other jurisdictions also require us to comply with standards, commonly referred to as good clinical practice, or GCP, for conducting, monitoring, recording and reporting the results
of clinical trials to assure that data and reported results are accurate and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. The FDA enforces GCP compliance through periodic inspections of
trial sponsors, principal investigators, clinical trial sites and institutional review boards. If we or our third-party contractors fail to comply with applicable GCP standards, the clinical data generated in our clinical trials may be deemed
unreliable and the FDA may require us to perform additional clinical trials before approving our product candidates, which would delay the regulatory approval process. We cannot make assurances that, upon inspection, the FDA will determine that any
of our clinical trials comply with GCP. We are also required to register clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result
in fines, adverse publicity and civil and criminal sanctions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Furthermore, the third parties conducting clinical trials on our behalf are
not our employees, and except for remedies available to us under our agreements with such contractors, we cannot control whether or not they devote sufficient time and resources to our ongoing development programs. These contractors may also have
relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities, which could impede their ability to devote appropriate time to our clinical programs.
If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we may not be able to obtain, or may be delayed
in obtaining, marketing approvals for our product candidates. If that occurs, we may not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. In such an event, our financial results and the commercial
prospects for SPR994 or our other product candidates could be harmed, our costs could increase and our ability to generate revenue could be delayed, impaired or foreclosed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We also rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our
distributors could delay clinical development or marketing approval of our product candidates or commercialization of any resulting products, producing additional losses and depriving us of potential product revenue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We contract with third parties for the manufacture of preclinical and clinical supplies of SPR994 and
SPR741 and expect to continue to do so in connection with any future commercialization and for any future clinical trials and commercialization of our other product candidates and potential product candidates. This reliance on third parties
increases the risk that we will not have sufficient quantities of our product candidates or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We do not currently have nor do we plan to build the internal infrastructure or capability to manufacture SPR994 or our other product
candidates for use in the conduct of our preclinical research, our clinical trials or for commercial supply. We currently rely on and expect to continue to rely on third-party contract manufacturers to manufacture supplies of SPR994 and our other
product candidates, and we expect to rely on third-party contract manufacturers to manufacture commercial quantities of any product candidate that we commercialize following approval for marketing by applicable regulatory authorities, if any.
Reliance on third-party manufacturers entails risks, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">manufacturing delays if our third-party manufacturers give greater priority to the supply of other products over our product candidates or otherwise do not satisfactorily perform according to the terms of the agreement
between us; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possible breach of the manufacturing agreement by the third party; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the failure of the third-party manufacturer to comply with applicable regulatory requirements;&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possible misappropriation of our proprietary information, including our trade secrets <FONT STYLE="white-space:nowrap">and&nbsp;know-how.</FONT> </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We currently rely on a small number of third-party contract manufacturers for all of our required raw materials, drug substance and finished
product for our preclinical research and clinical trials. We do not have long-term agreements with any of these third parties. We also do not have any current contractual relationships for the manufacture of commercial supplies of any of our product
candidates. If any of our existing manufacturers should become unavailable to us for any reason, we may incur delays in identifying or qualifying replacements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If any of our product candidates are approved by any regulatory agency, we intend to enter into agreements with third-party contract
manufacturers for the commercial production of those products. This process is difficult and time consuming and we may face competition for access to manufacturing facilities as there are a limited number of contract manufacturers operating under
cGMPs that are capable of manufacturing our product candidates. Consequently, we may not be able to reach agreement with third-party manufacturers on satisfactory terms, which could delay our commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Third-party manufacturers are required to comply with cGMPs and similar regulatory requirements outside the United States. Facilities used by
our third-party manufacturers must be in substantial compliance with cGMP to the satisfaction of the FDA before potential approval of the product candidate. Similar regulations apply to manufacturers of our product candidates for use or sale in
foreign countries. We do not control the manufacturing process and are completely dependent on our third-party manufacturers for compliance with the applicable regulatory requirements for the manufacture of our product candidates. The inability or
failure of our manufacturers to successfully manufacture material that conforms to the strict regulatory requirements of the FDA and any applicable foreign regulatory authority, may require us to find alternative manufacturing facilities, which
could result in delays in obtaining approval for the applicable product candidate. In addition, our manufacturers are subject to ongoing periodic unannounced inspections by the FDA and corresponding state and foreign agencies for compliance with
cGMPs and similar regulatory requirements. Failure by any of our manufacturers to comply with applicable cGMPs or other regulatory requirements could result in sanctions being </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
imposed on us, including fines, injunctions, civil penalties, delays, suspensions or withdrawals of approvals, operating restrictions, interruptions in supply and criminal prosecutions, any of
which could significantly and adversely affect supplies of our product candidates and have a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our current and anticipated future dependence upon others for the manufacture of SPR994 and our other product candidates and potential product
candidates may adversely affect our future profit margins and our ability to commercialize any products for which we receive marketing approval on a timely and competitive basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with our obligations in the agreements under which <FONT STYLE="white-space:nowrap">we&nbsp;in-license&nbsp;or</FONT> acquire
development or commercialization rights to products, technology or data from third parties, including those for SPR994, we could lose such rights that are important to our business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are a party to agreements with Meiji for SPR994, Northern for SPR741, Vertex Pharmaceuticals for SPR720 and PBB Distributions Limited for
SPR206, and we may enter into additional agreements, including license agreements, with other parties in the future that impose diligence, development and commercialization timelines, milestone payments, royalties, insurance and other obligations on
us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For example, we have an <FONT STYLE="white-space:nowrap">exclusive&nbsp;know-how&nbsp;license</FONT> with Meiji, or the Meiji
License, that gives us rights outside of specified countries in Asia to develop, manufacture, and commercialize SPR994 as well as the right to use, cross-reference, file or incorporate by reference any information and relevant Meiji regulatory
documentation to support any regulatory filings outside of Asia. In addition, we have the right to develop, manufacture and have manufactured SPR994 in Asia solely for the purpose of furthering development, manufacturing and commercialization of
SPR994 outside of Asia. In exchange for those rights, we are obligated to satisfy diligence requirements, including using commercially reasonable efforts to develop and commercialize SPR994 and to implement a specified development plan, meeting
specified development milestones and providing an update on progress on an annual basis. The Meiji License requires us to pay milestone payments of up to $3.0&nbsp;million upon the achievement of specified clinical and regulatory milestones and
royalties of a low single-digit percentage on net sales on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;country-by-country&nbsp;basis.</FONT></FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If we fail to comply with our obligations to Meiji or any of our other partners, our counterparties may have the right to terminate these
agreements, in which event we might not be able to develop, manufacture or market any product candidate that is covered by these agreements, which could materially adversely affect the value of the product candidate being developed under any such
agreement. Termination of these agreements or reduction or elimination of our rights under these agreements may result in our having to negotiate new or reinstated agreements with less favorable terms, or cause us to lose our rights under these
agreements, including our rights to important intellectual property or technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our U.S. Government Contracts and to Certain Grant
Agreements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our use of government funding for certain of our programs adds complexity to our research and commercialization efforts with respect
to those programs and may impose requirements that increase the costs of commercialization and production of product candidates developed under those government-funded programs. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have received non-dilutive financing from various government agencies for the further development of our product candidates. Such funding
sources may pose risks to us not encountered in other commercial contracts, including significant regulatory compliance risks. Contracts funded by the U.S. government and its agencies include provisions that reflect the government&#146;s substantial
public policy and compliance requirements, and substantial rights and remedies, many of which are not typically found in commercial contracts, including powers of the government to: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">terminate agreements, in whole or in part, for any reason or no reason; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduce or modify the government&#146;s obligations under such agreements without the consent of the contractor; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">claim rights, including intellectual property rights, in products and data developed under such agreements; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">audit contract-related costs and fees, including allocated indirect costs; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspend the contractor from receiving new contracts pending resolution of alleged violations of procurement laws or regulations; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">impose U.S. manufacturing requirements for products that embody inventions conceived or first reduced to practice under such agreements; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspend or debar the contractor from doing future business with the government; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">control and potentially prohibit the export of products; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pursue criminal or civil remedies under the False Claims Act, or the FCA, the False Statements Act and similar remedy provisions specific to government agreements. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We may not have the right to prohibit the U.S. government from using or allowing others to use certain technologies developed by us, and we
may not be able to prohibit third-party companies, including our competitors, from using those technologies in providing products and services to the U.S. government. The U.S. government generally obtains the right to royalty-free use of data,
results and technologies that are developed under U.S. government grants and contracts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, government contracts normally
contain additional compliance requirements that may increase our costs of doing business, reduce our profits, and expose us to liability for failure to comply with these terms and conditions. These requirements include, for example: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">specialized accounting systems unique to government contracts; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">mandatory financial audits and potential liability for price adjustments or recoupment of government funds after such funds have been spent; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">public disclosures of certain contract information, which may enable competitors to gain insights into our research program; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">mandatory socioeconomic or public policy compliance requirements, including labor standards, anti-human-trafficking, non-discrimination, and affirmative action programs, energy efficiency and environmental compliance
requirements. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If we fail to maintain compliance with these requirements, we may be subject to potential contract or FCA
liability and to termination of our contracts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. government agencies have special contracting requirements that give them the ability to
unilaterally control our contracts. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">U.S. government contracts typically contain unfavorable termination provisions and are
subject to audit and modification by the government at its sole discretion, which will subject us to additional risks. These risks include the ability of the U.S. government to unilaterally: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspend or prevent us for a set period of time from receiving new contracts or extending our existing contracts based on violations or suspected violations of laws or regulations; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">cancel, terminate or suspend our contracts based on violations or suspected violations of laws or regulations; </TD></TR></TABLE> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">terminate our contracts if in the government&#146;s interest, including if funds become unavailable to the applicable governmental agency; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduce the scope and value of our contract; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">change certain terms and conditions in our contract. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The U.S. government will be able to
terminate any of its contracts with us, either for convenience or if we default by failing to perform in accordance with or to achieve the milestones set forth in the contract schedules and terms. Termination-for-convenience provisions generally
enable us to recover only our costs incurred or committed and settlement expenses on the work completed prior to termination. Except for the amount of services received by the government, termination-for-default provisions do not permit these
recoveries and would make us liable for excess costs incurred by the U.S. government in procuring undelivered items from another source. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our
business is subject to audit by the U.S. government and other potential sources for grant funding, including under our contracts with NIAID, DoD, and CARB-X, and a negative outcome in an audit could adversely affect our business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">U.S. government agencies such as the Department of Health and Human Services, or the DHHS, and the Defense Contract Audit Agency, or the DCAA,
routinely audit and investigate government contractors. These agencies review a contractor&#146;s performance under its contracts, cost structure and compliance with applicable laws, regulations and standards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The DHHS and the DCAA also review the adequacy of, and a contractor&#146;s compliance with, its internal control systems and policies,
including the contractor&#146;s purchasing, property, estimating, compensation and management information systems. Any costs found to be improperly allocated to a specific contract will not be paid, while such costs already paid must be refunded. If
an audit uncovers improper or illegal activities, we may be subject to civil and criminal penalties and administrative sanctions, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">termination of contracts; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">forfeiture of profits; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspension of payments; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fines; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspension or prohibition from conducting business with the U.S. government. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, we
could suffer serious reputational harm if allegations of impropriety were made against us, which could cause our stock price to decrease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Laws and
regulations affecting government contracts make it more expensive and difficult for us to successfully conduct our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We
must comply with numerous laws and regulations relating to the formation, administration and performance of government contracts, which can make it more difficult for us to retain our rights under our government contracts. These laws and regulations
affect how we conduct business with government agencies. Among the most significant government contracting regulations that affect our business are: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Federal Acquisition Regulations, or the FAR, and agency-specific regulations supplemental to the FAR, which comprehensively regulate the procurement, formation, administration and performance of government
contracts; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">business ethics and public integrity obligations, which govern conflicts of interest and the hiring of former government employees, restrict the granting of gratuities and funding of lobbying activities and include
other requirements such as the Anti-Kickback Statute and the Foreign Corrupt Practices Act; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">export and import control laws and regulations; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">laws, regulations and executive orders restricting the use and dissemination of information classified for national security purposes and the exportation of certain products and technical data. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">These requirements change frequently, such as through appropriations bills or executive orders. Any changes in applicable laws and regulations
could restrict our ability to maintain our existing government contracts and obtain new contracts, which could limit our ability to conduct our business and materially adversely affect our results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provisions in our U.S. government contracts may affect our intellectual property rights. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Certain of our activities have been funded, and may in the future be funded, by the U.S. government. When new technologies are developed with
U.S. government funding, the government obtains certain rights in any resulting patents, including the right to a nonexclusive license authorizing the government to use the invention and rights that may permit the government to disclose our
confidential information to third parties and to exercise &#147;march-in&#148; rights. The government can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the U.S.
government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, U.S. government-funded inventions must be reported to
the government, U.S. government funding must be disclosed in any resulting patent applications, and our rights in such inventions may be subject to certain requirements to manufacture products in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Intellectual Property </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we
are unable to obtain and maintain sufficient patent protection for our technology or our product candidates, or if the scope of the patent protection is not sufficiently broad, our competitors could develop and commercialize technology and products
similar or identical to ours, and our ability to successfully commercialize our technology and product candidates may be adversely affected. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with
respect to our proprietary chemistry technology and product candidates. If we do not adequately protect our intellectual property, competitors may be able to use our technologies and erode or negate any competitive advantage that we may have, which
could harm our business and ability to achieve profitability. To protect our proprietary position, we file patent applications in the United States and abroad related to our novel technologies and product candidates that are important to our
business. The patent application and approval process are expensive and time-consuming. We may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. We may also fail to identify
patentable aspects of our research and development before it is too late to obtain patent protection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The patent position of
biotechnology and pharmaceutical companies generally is highly uncertain. No consistent policy regarding the breadth of claims allowed in biotechnology and pharmaceutical patents has emerged to date in the United States or in many foreign
jurisdictions. In addition, the determination of patent rights with respect to pharmaceutical compounds and technologies commonly involves complex legal and factual questions, which has in recent years been the subject of much litigation. As a
result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Furthermore, recent changes in patent laws in the United States, including the America Invents Act of 2011, may affect the scope,
strength and enforceability of our patent rights or the nature of proceedings which may be brought by us related to our patent rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our pending and future patent applications may not result in patents being issued which
protect our technology or product candidates, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United
States and other countries may diminish the value of our patents or narrow the scope of our patent protection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The laws of foreign
countries may not protect our rights to the same extent or in the same manner as the laws of the United States. For example, even assuming the other requirements for patentability are met, currently, in the United States, the first to make the
claimed invention is entitled to the patent, while outside the United States, the first to file a patent application is entitled to the patent. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and
patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our
patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result of the America Invents Act of 2011, the United States transitioned to <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">a&nbsp;first-inventor-to-file&nbsp;system</FONT></FONT> in March 2013, under which, assuming the other requirements for patentability are met, the first inventor to file a patent application is entitled to the patent.
However, as a result of the lag in the publication of patent applications following filing in the United States, we are still not able to be certain upon filing that we are the first to file for patent protection for any invention. Moreover, we may
be subject to a third-party preissuance submission of prior art to the U.S. Patent and Trademark Office, or become involved in opposition, derivation, reexamination,<I></I><I>&nbsp;inter partes</I>&nbsp;review or interference proceedings, in the
United States or elsewhere, challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to
commercialize our technology or product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent
competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in <FONT
STYLE="white-space:nowrap">a&nbsp;non-infringing&nbsp;manner.</FONT> Our competitors may seek to market generic versions of any approved products by submitting Abbreviated New Drug Applications to the FDA in which they claim that patents owned or
licensed by us are invalid, unenforceable and/or not infringed. Alternatively, our competitors may seek approval to market their own products similar to or otherwise competitive with our products. In these circumstances, we may need to defend and/or
assert our patents, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or other agency with jurisdiction may find our patents invalid and/or unenforceable. Even if we have valid and enforceable
patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may
be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which
could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. In addition, given the amount of time required for the
development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and
unsuccessful. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Competitors may infringe our patents, trademarks, copyrights or other intellectual property, or those of our
licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming and divert the time and attention of our management and scientific personnel. Any claims we assert
against perceived infringers could provoke these parties to assert counterclaims </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
against us alleging that we infringe their patents. In addition, in a patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable,
in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#146;s claims narrowly or
decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patents do not cover the invention. An adverse outcome in a litigation or proceeding involving our patents could limit our ability
to assert our patents against those parties or other competitors, and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Any of these occurrences could adversely affect our
competitive business position, business prospects and financial condition. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we
have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In any infringement litigation, any award of monetary damages we receive may not be commercially valuable. Furthermore, because of the
substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. Moreover, there can be no assurance that we
will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the
diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we
are sued for infringing intellectual property rights of third parties, or otherwise become involved in disputes regarding our intellectual property rights, such litigation could be costly and time consuming and could prevent or delay us from
developing or commercializing our product candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our commercial success depends, in part, on our ability to develop,
manufacture, market and sell our product candidates and use our proprietary chemistry technology without infringing the intellectual property and other proprietary rights of third parties. Numerous third-party U.S.
<FONT STYLE="white-space:nowrap">and&nbsp;non-U.S.&nbsp;issued</FONT> patents and pending applications exist in the area of antibacterial treatment, including compounds, formulations, treatment methods and synthetic processes that may be applied
towards the synthesis of antibiotics. If any of their patents or patent applications cover our product candidates or technologies, we may not be free to manufacture or market our product candidates as planned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">There is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party
to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our technology or product candidates, including interference proceedings before the U.S. Patent and Trademark Office.
Intellectual property disputes arise in a number of areas including with respect to patents, use of other proprietary rights and the contractual terms of license arrangements. Third parties may assert claims against us based on existing or future
intellectual property rights. The outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance. With respect to our Meiji License of certain <FONT STYLE="white-space:nowrap">know-how</FONT>
used in SPR994, we are neither a party to, nor an express third-party beneficiary of, the letter agreement between Meiji and Global Pharma consenting to Meiji&#146;s arrangement with us. As such, if any dispute among the parties were to occur, our
direct enforcement rights with respect to the letter agreement may be limited or uncertain. A termination or early expiration of the head license between Meiji and Global Pharma (which currently by its terms is set to expire in January 2022) or any
restriction on our ability to use the Global Pharma <FONT STYLE="white-space:nowrap">know-how</FONT> could have a negative impact on our development of SPR994 and adversely affect our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If we are found to infringe a third party&#146;s intellectual property rights, we could be forced, including by court order, to cease
developing, manufacturing or commercializing the infringing product candidate or product. Alternatively, we may be required to obtain a license from such third party in order to use the infringing technology and continue developing, manufacturing or
marketing the infringing product candidate. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could
<FONT STYLE="white-space:nowrap">be&nbsp;non-exclusive,&nbsp;thereby</FONT> giving our competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary damages, including treble damages and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
attorneys&#146; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our
business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims that we or our employees have misappropriated the intellectual property of a third party, or claiming ownership of what we
regard as our own intellectual property. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Many of our employees were previously employed at universities or other biotechnology or
pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees do not use the intellectual property and other proprietary information
<FONT STYLE="white-space:nowrap">or&nbsp;know-how&nbsp;of</FONT> others in their work for us, we may be subject to claims that we or these employees have used or disclosed such intellectual property or other proprietary information. Litigation may
be necessary to defend against these claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, while we typically require our employees, consultants and contractors who may
be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard
as our own. To the extent that we fail to obtain such assignments or such assignments are breached, we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as
our intellectual property. If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in prosecuting or defending against
such claims, litigation could result in substantial costs and be a distraction to our management and scientific personnel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to
protect the confidentiality of our trade secrets, the value of our technology could be materially adversely affected and our business would be harmed. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition to seeking patents for some of our technology and products, we also rely on trade secrets, including <FONT
STYLE="white-space:nowrap">unpatented&nbsp;know-how,&nbsp;technology</FONT> and other proprietary information, in seeking to develop and maintain a competitive position. We seek to protect these trade secrets, in part, by entering <FONT
STYLE="white-space:nowrap">into&nbsp;non-disclosure&nbsp;and</FONT> confidentiality agreements with parties who have access to them, such as our consultants, independent contractors, advisors, corporate collaborators, outside scientific
collaborators, contract manufacturers, suppliers and other third parties. We, as well as our licensors, also enter into confidentiality and invention or patent assignment agreements with employees and certain consultants. Any party with whom we have
executed such an agreement may breach that agreement and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or
misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, if any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to
prevent such third party, or those to whom they communicate such technology or information, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor,
our business and competitive position could be harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have not yet registered our trademarks. Failure to secure those registrations could
adversely affect our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have not yet registered our trademarks in the United States or other countries. If we do not
secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would, which could adversely affect our business. We have also not yet registered trademarks for any of our product
candidates in any jurisdiction. When we file trademark applications for our product candidates those applications may not be allowed for registration, and registered trademarks may not be obtained, maintained or enforced. During trademark
registration proceedings in the United States and foreign jurisdictions, we may receive rejections. We are given an opportunity to respond to those rejections, but we may not be able to overcome such rejections. In addition, in the United States
Patent and Trademark Office and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, any proprietary name we propose to use with SPR994 or any other product candidate in the United States must be approved by the
FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA
objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable proprietary product name that would qualify under applicable trademark laws, not infringe the
existing rights of third parties and be acceptable to the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Regulatory Approval and Other Legal Compliance Matters </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize SPR994 or our
other product candidates, and our ability to generate revenue will be materially impaired. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our product candidates and the
activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to
comprehensive regulation by the FDA and other regulatory agencies in the United States and by comparable foreign regulatory authorities, with regulations differing from country to country. Failure to obtain marketing approval for a product candidate
will prevent us from commercializing the product candidate. We currently do not have any products approved for sale in any jurisdiction. We have only limited experience in filing and supporting the applications necessary to gain marketing approvals
and expect to rely on third-party contract research organizations to assist us in this process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The time required to obtain approval, if
any, by the FDA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities.
In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#146;s clinical development and may vary among jurisdictions. We have not obtained
regulatory approval for any product candidate and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval. Neither we nor any future collaborator
is permitted to market any of our product candidates in the United States until we or they receive regulatory approval of an NDA from the FDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In order to obtain approval to commercialize a product candidate in the United States or abroad, we or our collaborators must demonstrate to
the satisfaction of the FDA or foreign regulatory agencies, that such product candidates are safe and effective for their intended uses. Results from nonclinical studies and clinical trials can be interpreted in different ways. Even if we believe
that the nonclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. The FDA may also require us to conduct additional nonclinical studies or
clinical trials for our product candidates either prior to or post-approval, and it may otherwise object to elements of our clinical development program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have not submitted an NDA for any of our product candidates. An NDA must include extensive preclinical and clinical data and supporting
information to establish the product candidate&#146;s safety and efficacy for each desired indication. The NDA must also include significant information regarding the chemistry, manufacturing and controls for the product candidate. Obtaining
approval of an NDA is a lengthy, expensive and uncertain process. The FDA has substantial discretion in the review and approval process and may refuse to accept for filing any application or may decide that our data are insufficient for approval and
require additional nonclinical, clinical or other studies. Foreign regulatory authorities have differing requirements for approval of drugs with which we must comply prior to marketing. Obtaining marketing approval for marketing of a product
candidate in one country does not ensure that we will be able to obtain marketing approval in other countries, but the failure to obtain marketing approval in one jurisdiction could negatively affect our ability to obtain marketing
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approval in other jurisdictions. The FDA or any foreign regulatory bodies can delay, limit or deny approval of our product candidates or require us to conduct additional nonclinical or clinical
testing or abandon a program for many reasons, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA or the applicable foreign regulatory agency&#146;s disagreement with the design or implementation of our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">negative or ambiguous results from our clinical trials or results that may not meet the level of statistical significance required by the FDA or comparable foreign regulatory agencies for approval; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">serious and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to demonstrate to the satisfaction of the FDA or the applicable foreign regulatory body that our product candidates are safe and effective for the proposed indication; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s or the applicable foreign regulatory agency&#146;s disagreement with the interpretation of data from nonclinical studies or clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to demonstrate the clinical and other benefits of our product candidates outweigh any safety or other perceived risks; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s or the applicable foreign regulatory agency&#146;s requirement for additional nonclinical studies or clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s or the applicable foreign regulatory agency&#146;s disagreement regarding the formulation, labeling and/or the specifications for our product candidates; or </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential for approval policies or regulations of the FDA or the applicable foreign regulatory agencies to significantly change in a manner rendering our clinical data insufficient for approval. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Of the large number of drugs in development, only a small percentage complete the FDA or foreign regulatory approval processes and are
successfully commercialized. The lengthy review process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval, which would significantly harm our business, financial condition,
results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Even if we eventually receive approval of an NDA or foreign marketing application for our product
candidates, the FDA or the applicable foreign regulatory agency may grant approval contingent on the performance of costly additional clinical trials, often referred to as Phase 4 clinical trials, and the FDA may require the implementation of a Risk
Evaluation and Mitigation Strategy, or REMS, which may be required to ensure safe use of the drug after approval. The FDA or the applicable foreign regulatory agency also may approve a product candidate for a more limited indication or patient
population than we originally requested, and the FDA or applicable foreign regulatory agency may not approve the labeling that we believe is necessary or desirable for the successful commercialization of a product candidate. Any delay in obtaining,
or inability to obtain, applicable regulatory approval would delay or prevent commercialization of that product candidate and would materially adversely impact our business and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may seek fast track designation for SPR994 or one or more of our other product candidates, but we might not receive such designation, and in any
case, such designation may not actually lead to a faster development or regulatory review or approval process. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If a drug is
intended for the treatment of a serious condition and nonclinical or clinical data demonstrate the potential to address unmet medical need for this condition, a drug sponsor may apply for fast track designation by the FDA for the particular
indication under study. If fast track designation is obtained, the FDA may initiate review of sections of an NDA before the application is complete. This &#147;rolling review&#148; is available if </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the applicant provides and the FDA approves a schedule for the remaining information. If we seek fast track designation for a product candidate, we may not receive it from the FDA. However, even
if we receive fast track designation, fast track designation does not ensure that we will receive marketing approval or that approval will be granted within any particular timeframe. We may not experience a faster development or regulatory review or
approval process with fast track designation compared to conventional FDA procedures. In addition, the FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program.
Fast track designation alone does not guarantee qualification for the FDA&#146;s priority review procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may seek orphan drug designation
for certain of our product candidates. We may not be able to obtain or maintain orphan drug designations for any of our product candidates, and we may be unable to take advantage of the benefits associated with orphan drug designation, including the
potential for market exclusivity. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Regulatory authorities in some jurisdictions, including the United States, may designate drugs
for relatively small patient populations as orphan drugs. Under the Orphan Drug Act of 1983, the FDA may designate a product as an orphan product if it is intended to treat a rare disease or condition, which is generally defined as a patient
population of fewer than 200,000 individuals in the United States, or a patient population of greater than 200,000 individuals in the United States, but for which there is no reasonable expectation that the cost of developing the drug will be
recovered from sales in the United States. There can be no assurance that the FDA will grant orphan designation for any indication for which we apply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In the United States, orphan designation entitles a party to financial incentives such as opportunities for grant funding towards clinical
trial costs, tax advantages and <FONT STYLE="white-space:nowrap">user-fee</FONT> waivers. In addition, if a product candidate that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such
designation, it is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications, including an NDA, to market the same drug for the same indication for seven years, except in limited circumstances, such as a
showing of clinical superiority to the product with orphan drug exclusivity or where the manufacturer is unable to assure sufficient product quantity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because
different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA or comparable foreign regulatory authority can subsequently approve the same drug for the same condition if such regulatory authority concludes
that the later drug is clinically superior if it is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug
any advantage in the regulatory review or approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to obtain marketing approval in international jurisdictions, we will
not be able to market our product candidates abroad. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In order to market and sell SPR994 or our other product candidates in the
European Union and many other jurisdictions, we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. Approval by the FDA does not ensure approval by regulatory authorities in other countries or
jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. The approval procedure varies among countries and can involve
additional testing. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The
regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement
before the product can be approved for sale in that country. We may not obtain approvals from regulatory authorities outside the United States on a timely basis or at all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we receive regulatory approval for any product candidate, we will be subject to ongoing obligations
and continuing regulatory review, which may result in significant additional expense. Our product candidates, if approved, could be subject to restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with
regulatory requirements or if we experience unanticipated problems with our product candidates, when and if approved. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Any product
candidate for which we obtain marketing approval will also be subject to ongoing regulatory requirements for labeling, packaging, storage, distribution, advertising, promotion, record keeping and submission of safety and other post-market
information. For example, approved products, manufacturers and manufacturers&#146; facilities are required to comply with extensive FDA requirements, including ensuring that quality control and manufacturing procedures conform to cGMPs. As such, we
and our contract manufacturers will be subject to continual review and periodic inspections to assess compliance with cGMPs. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory
compliance, including manufacturing, production and quality control. We will also be required to report certain adverse reactions and production problems, if any, to the FDA and to comply with requirements concerning advertising and promotion for
our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, even if marketing approval of a product candidate is granted, the approval may be subject to limitations on
the indicated uses for which the product may be marketed, may be subject to significant conditions of approval or may impose requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the product. The FDA
may also require a REMS as a condition of approval of our product candidates, which could include requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods,
patient registries and other risk minimization tools. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure that drugs are marketed only for the approved indications and in accordance with the provisions of the
approved labeling and regulatory requirements. The FDA also imposes stringent restrictions on manufacturers&#146; communications <FONT STYLE="white-space:nowrap">regarding&nbsp;off-label&nbsp;use</FONT> and if we do not restrict the marketing of our
products only to their approved indications, we may be subject to enforcement action <FONT STYLE="white-space:nowrap">for&nbsp;off-label&nbsp;marketing.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or
problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, it may impose restrictions on that product or us. In addition, if any product fails to comply with applicable
regulatory requirements, a regulatory agency may: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issue fines, warning letters, untitled letters or impose holds on clinical trials if any are <FONT STYLE="white-space:nowrap">still&nbsp;on-going;</FONT> </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">mandate modifications to promotional materials or require provision of corrective information to healthcare practitioners; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">impose restrictions on the product or its manufacturers or manufacturing processes; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">impose restrictions on the labeling or marketing of the product; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">impose restrictions on product distribution or use; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require post-marketing clinical trials; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require withdrawal of the product from the market; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refuse to approve pending applications or supplements to approved applications that we submit; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require recall of the product; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require entry into a consent decree, which can include imposition of various fines (including restitution or disgorgement of profits or revenue), reimbursements for inspection costs, required due dates for specific
actions and penalties for noncompliance; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspend or withdraw marketing approvals; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refuse to permit the import or export of the product; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">seize or detain supplies of the product;&nbsp;or </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issue injunctions or impose civil or criminal penalties. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our relationships with customers and
third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits
and future earnings. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and
prescription of any product candidates for which we may obtain marketing approval. Our future arrangements with third-party payors and customers will expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may
constrain the business or financial arrangements and relationships through which we market, sell and distribute any products for which we obtain marketing approval and reimbursement. These laws and regulations include, for example, the False Claims
Act and Anti-Kickback Statute and regulations. At such time as we market, sell and distribute any products for which we obtain marketing approval and reimbursement, it is possible that our business activities could be subject to challenge under one
or more of these laws and regulations. Restrictions under applicable federal and state healthcare laws and regulations include the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal healthcare Anti-Kickback Statute, among other things, prohibits persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to
induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federally funded healthcare programs such as Medicare and Medicaid. A person or entity
does not need to have actual knowledge of the statute or specific intent to violate the statute in order to have committed a violation. In addition, the government may assert that a claim that includes items or services resulting from a violation of
the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal False Claims Act imposes criminal and civil penalties, which can be enforced by private citizens through civil whistleblower and qui tam actions, against individuals or entities for knowingly presenting, or
causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal ban on physician self-referrals, which prohibits, subject to certain exceptions, physician referrals of Medicare or Medicaid patients to an entity providing certain &#147;designated health services&#148; if
the physician or an immediate family member of the physician has any financial relationship with the entity; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or for making any false statements
relating to healthcare matters; as in the case of the federal healthcare Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate the statute in order to have committed a
violation; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, also imposes obligations on certain covered entities as well as their business associates that perform certain services
involving the use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information, and requires
notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for
healthcare benefits, items or services; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal transparency or &#147;sunshine&#148; requirements under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively, the ACA,
requires manufacturers of marketed drugs, devices, biologics and medical supplies to report to the U.S. Department of Health and Human Services information related to physician payments and other transfers of value and physician ownership and
investment interests;&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">analogous state laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed <FONT
STYLE="white-space:nowrap">by&nbsp;non-governmental&nbsp;third-party</FONT> payors, including private insurers, and some state laws require pharmaceutical companies to implement compliance programs and to track and report gifts, compensation and
other remuneration provided to physicians, in addition to requiring drug manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures and pricing information. State laws also govern
the privacy and security of health information in some circumstances, and many such state laws differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We will be required to spend substantial time and money to ensure that our business arrangements with third parties, and our business
generally, comply with applicable healthcare laws and regulations. Even then, governmental authorities may conclude that our business practices, including arrangements we may have with physicians and other healthcare providers, some of whom may
receive stock options as compensation for services provided, do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If governmental authorities find that
our operations violate any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, imprisonment, fines, exclusion from government funded
healthcare programs, such as Medicare and Medicaid, and we may be required to curtail or restructure our operations. Moreover, we expect that there will continue to be federal and state laws and regulations, proposed and implemented, that could
affect our operations and business. The extent to which future legislation or regulations, if any, relating to healthcare fraud and abuse laws or enforcement, may be enacted or what effect such legislation or regulation would have on our business
remains uncertain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently enacted and future policies and legislation may increase the difficulty and cost for us to obtain marketing approval of
and commercialize our product candidates and may affect the reimbursement made for any product candidate for which we receive marketing approval. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The pricing and reimbursement environment may become more challenging due to, among other reasons, policies advanced by the new presidential
administration, federal agencies, new healthcare legislation passed by the U.S. Congress or fiscal challenges faced by all levels of government health administration authorities. Among policy makers and payors in the United States and foreign
countries, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and expanding access to healthcare. In the United States, the pharmaceutical industry has
been a particular focus of these efforts and has been significantly affected by major legislative initiatives. We expect to experience pricing pressures in connection with the sale of any products for which we obtain marketing approval, due to the
trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative proposals. Resulting legislative, administrative, or policy changes from payors may reduce payments for any products for which
we obtain marketing approval and could affect future revenues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The ACA became law in the United States in March 2010 with the goals of
broadening access to health insurance, reducing or constraining the growth of healthcare spending, enhancing remedies against fraud and abuse, adding new transparency requirements for the health care and health insurance industries and imposing
additional health policy reforms. Provisions of ACA may negatively affect our future revenues. For example, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ACA requires, among other things, that annual fees be paid by manufacturers for certain branded prescription drugs, that manufacturers participate in a discount program for certain outpatient
drugs under Medicare Part D, and that manufacturers provide increased rebates under the Medicaid Drug Rebate Program for outpatient drugs dispensed to Medicaid recipients. The ACA also addresses a new methodology by which rebates owed by
manufacturers under the Medicaid Drug Rebate Program are calculated for line extensions and expands oversight and support for the federal government&#146;s comparative effectiveness research of services and products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA. As a result, there have been delays
in the implementation of certain aspects of the ACA. Both Congress and President Trump have expressed their intention to repeal or repeal and replace the ACA, and as a result certain sections of the ACA have not been fully implemented or effectively
repealed. The uncertainty around the future of the ACA, and in particular the impact to reimbursement levels, may lead to uncertainty or delay in the purchasing decisions of our customers, which may in turn negatively impact our product sales. If
there are not adequate reimbursement levels, our business and results of operations could be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Beginning on
April&nbsp;1, 2013, Medicare payments for all items and services under Part&nbsp;A and&nbsp;B, including drugs and biologicals, and most payments to plans under Medicare Part&nbsp;D were reduced by 2%, or automatic spending reductions, required by
the Budget Control Act of 2011, or BCA, as amended by the American Taxpayer Relief Act of 2012. The BCA requires sequestration for most federal programs, excluding Medicaid, Social Security, and certain other programs. The BCA caps the cuts to
Medicare payments for items and services and payments to Part&nbsp;D plans at 2%. Subsequent legislation extended the 2% reduction, on average, to 2027. As long as these cuts remain in effect, they could adversely affect payment for our product
candidates. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could
result in reduced demand for our product candidates or additional pricing pressures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Moreover, there has been heightened governmental
scrutiny over the manner in which manufacturers set prices for their marketed products. There have been several U.S. Congressional inquiries and proposed bills designed to, among other things, bring more transparency to drug pricing, reduce the cost
of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. Individual states in the United States have also become
increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost
disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for
pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the effect of such changes on the marketing approvals of our
product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#146;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and
post-marketing testing and other requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we successfully commercialize one of our product candidates, failure to comply with our reporting
and payment obligations under U.S. governmental pricing programs could have a material adverse effect on our business, financial condition and results of operations. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If we participate in the Medicaid Drug Rebate Program if and when we successfully commercialize a product candidate, we will be required to
report certain pricing information for our product to the Centers for Medicare&nbsp;&amp; Medicaid Services, the federal agency that administers the Medicaid and Medicare programs. We may also be required to report pricing information to the U.S.
Department of Veterans Affairs. If we become subject to these reporting requirements, we will be liable for errors associated with our submission of pricing data, for failure to report pricing data in a timely manner, and for overcharging government
payers, which can result in civil monetary penalties under the Medicaid statute, the federal civil False Claims Act, and other laws and regulations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees, independent contractors, principal investigators, contract research organizations,
consultants or vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk that our employees, independent contractors, principal investigators, contract research organizations, consultants
or vendors may engage in fraudulent or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violates: FDA regulations, including those
laws requiring the reporting of true, complete and accurate information to the FDA; manufacturing standards; federal and state healthcare fraud and abuse laws and regulations; or laws that require the true, complete and accurate reporting of
financial information or data. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These
laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements that may be common and even advisable in every day commerce
but are illegal in the healthcare industry. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials or creating fraudulent data in our preclinical studies or
clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by our employees and other third parties, and the precautions we take to detect and prevent
this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations.
Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those
actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare
programs, contractual damages, reputational harm, diminished potential profits and future earnings, and curtailment of our operations, any of which could adversely affect our business, financial condition, results of operations or prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The recently passed comprehensive tax reform bill could adversely affect our business and financial condition. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On December&nbsp;22, 2017, President Trump signed into law the &#147;Tax Cuts and Jobs Act,&#148; or TCJA, which significantly reforms the
Code. The TCJA, among other things, includes changes to U.S. federal tax rates, imposes significant additional limitations on the deductibility of interest and net operating loss carryforwards, allows for the expensing of capital expenditures, and
puts into effect the migration from a &#147;worldwide&#148; system of taxation to a territorial system. As a result of the TCJA, our net deferred tax assets and liabilities existing as of December&nbsp;31, 2017 were revalued at the newly enacted
U.S. corporate rate. The impact of this tax reform is uncertain and could be adverse. We urge our investors to consult with their legal and tax advisors with respect to such legislation and the potential tax consequences of investing in our
securities. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Employee Matters and Managing Growth </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future success depends on our ability to retain our chief executive officer and other key executives and to attract, retain and motivate qualified
personnel. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our industry has experienced a high rate of turnover of management personnel in recent years. We are highly dependent
on the development, regulatory, commercialization and business development expertise of Ankit Mahadevia, M.D., our President and Chief Executive Officer, as well as the other principal members of our management, scientific and clinical team.
Although we have formal employment agreements with our executive officers, these agreements do not prevent them from terminating their employment with us at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If we lose one or more of our executive officers or key employees, our ability to implement our business strategy successfully could be
seriously harmed. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to
develop, gain regulatory approval of and commercialize product candidates successfully. Competition to hire from this limited pool is intense, and we may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be unable to hire, train, retain or motivate these additional key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar
personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in
formulating our research and development and commercialization strategy. Our consultants and advisors may be engaged by entities other than us and may have commitments under consulting or advisory contracts with other entities that may limit their
availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to develop and commercialize product candidates will be limited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect to grow our organization, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the
areas of product candidate development, regulatory affairs and sales, marketing and distribution. Our management may need to divert a disproportionate amount of its attention away from
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">our&nbsp;day-to-day&nbsp;activities</FONT></FONT> to devote time to managing these growth activities. To manage these growth activities, we must continue to implement and improve our
managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company
with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. Our inability to effectively manage the expansion of our operations may result in weaknesses
in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert
financial resources from other projects, such as the development of additional product candidates. If our management is unable to effectively manage our expected growth, our expenses may increase more than expected, our potential ability to generate
revenue could be reduced and we may not be able to implement our business strategy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If foreign approvals are obtained, we will be subject to
additional risks in conducting business in international markets. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Even if we are able to obtain approval for commercialization of
a product candidate in a foreign country, we will be subject to additional risks related to international business operations, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">potentially reduced protection for intellectual property rights; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential <FONT STYLE="white-space:nowrap">for&nbsp;so-called&nbsp;parallel</FONT> importing, which is what happens when a local seller, faced with high or higher local prices, opts to import goods from a foreign
market (with low or lower prices) rather than buying them locally; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unexpected changes in tariffs, trade barriers and regulatory requirements; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">economic weakness, including inflation, or political instability in particular foreign economies and markets; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">workforce uncertainty in countries where labor unrest is more common than in the United States; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">production shortages resulting from any events affecting a product candidate and/or finished drug product supply or manufacturing capabilities abroad; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">business interruptions resulting <FONT STYLE="white-space:nowrap">from&nbsp;geo-political&nbsp;actions,</FONT> including war and terrorism, or natural disasters, including earthquakes, hurricanes, typhoons, floods and
fires;&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to comply with Office of Foreign Asset Control rules and regulations and the Foreign Corrupt Practices Act. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These and other risks may materially adversely affect our ability to attain or sustain revenue from
international markets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may engage in acquisitions that could disrupt our business, cause dilution to our stockholders or reduce our financial
resources. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In the future, we may enter into transactions to acquire other businesses, products or technologies. If we do identify
suitable candidates, we may not be able to make such acquisitions on favorable terms, or at all. Any acquisitions we make may not strengthen our competitive position, and these transactions may be viewed negatively by customers or investors. We may
decide to incur debt in connection with an acquisition or issue our common stock or other equity securities to the stockholders of the acquired company, which would reduce the percentage ownership of our existing stockholders. We could incur losses
resulting from undiscovered liabilities of the acquired business that are not covered by the indemnification we may obtain from the seller. In addition, we may not be able to successfully integrate the acquired personnel, technologies and operations
into our existing business in an effective, timely and nondisruptive manner. Acquisitions may also divert management attention
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">from&nbsp;day-to-day&nbsp;responsibilities,</FONT></FONT> increase our expenses and reduce our cash available for operations and other uses. We cannot predict the number, timing or
size of future acquisitions or the effect that any such transactions might have on our operating results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Common Stock and this
Offering </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for the purchasers
of our common stock in this offering. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If you purchase shares in this offering, you may not be able to resell those shares at or
above the public offering price. The trading price of the shares has fluctuated, and is likely to continue to fluctuate substantially. The trading price of our securities depends on a number of factors, including those described in this &#147;Risk
Factors&#148; section, many of which are beyond our control and may not be related to our operating performance. In addition, although the shares are listed on The Nasdaq Global Select Market, we cannot assure you that a trading market for those
shares will be maintained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Since the shares were sold at our initial public offering in November 2017 at a price of $14.00 per share, the
price per share has ranged as low as $9.66 and as high as $19.00 through July&nbsp;6, 2018. The market price for our common stock may be influenced by many factors, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the success of existing or new competitive products or technologies; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of clinical trials of SPR994 and any other product candidate; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">results of clinical trials of SPR994 and any other product candidate; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure or discontinuation of any of our development programs; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">results of clinical trials of product candidates of our competitors; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory or legal developments in the United States and other countries; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developments or disputes concerning patent applications, issued patents or other proprietary rights; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the recruitment or departure of key personnel; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the level of expenses related to any of our product candidates or clinical development programs; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the results of our efforts to <FONT STYLE="white-space:nowrap">develop,&nbsp;in-license&nbsp;or</FONT> acquire additional product candidates or products; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcement or expectation of additional financing efforts; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sales of our common stock by us, our insiders or other stockholders; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">variations in our financial results or those of companies that are perceived to be similar to us; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in estimates or recommendations by securities analysts, if any, that cover our stock; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in the structure of healthcare payment systems; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">market conditions in the pharmaceutical and biotechnology sectors; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">general economic, industry and market conditions;&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the other factors described in this &#147;Risk Factors&#148; section. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, the stock
market has experienced significant volatility, particularly with respect to pharmaceutical, biotechnology and other life sciences company stocks. The volatility of pharmaceutical, biotechnology and other life sciences company stocks often does not
relate to the operating performance of the companies represented by the stock. In the past, securities class action litigation has often been initiated against companies following periods of volatility in their stock price. This type of litigation
could result in substantial costs and divert our management&#146;s attention and resources, and could also require us to make substantial payments to satisfy judgments or to settle litigation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts do not or do not continue to publish research or publish inaccurate or unfavorable research about our business, our
share price and trading volume could decline. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The trading market for our common stock relies in part on the research and reports
that securities or industry analysts publish about us or our business. If few analysts commence coverage of us, the trading price of our stock would likely decrease. If one or more of the analysts covering our business downgrade our stock or change
their opinion of our stock, our share price would likely decline. In addition, if one or more of these analysts cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could
cause our share price or trading volume to decline. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If you purchase securities in this offering, you will suffer substantial and immediate
dilution of your investment. </I></B></P>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">You will suffer immediate and substantial dilution in the net tangible book value of the
common stock you purchase in this offering or issuable upon conversion of the Series A Preferred Stock. The public offering price of our common stock is substantially higher than the net tangible book value per share of our common stock. Therefore,
if you purchase securities in this offering, you will pay a price per share (on an as-converted basis) that substantially exceeds the net tangible book value per share of common stock after this offering. Based on a public offering price of $13.85
per share of common stock, which is the last reported sale price of our common stock on July&nbsp;10, 2018, you will experience immediate dilution of $6.53 per share of common stock, representing the difference between our net tangible book value
per share of common stock, after giving effect to this offering, and the public offering price. See the &#147;Dilution&#148; section for a more detailed description of the dilution to new investors in the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have broad discretion in the use of our cash reserves, including the net proceeds from this offering, and may not use them effectively. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion in the application of our cash reserves, including the proceeds from our IPO and from this offering,
and could spend these funds in ways that do not improve our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
results of operations or enhance the value of our common stock. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse
effect on our business, cause the price of our common stock to decline and delay the development of our product candidates. Pending their use, we may invest our cash reserves in a manner that does not produce income or that loses value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an &#147;emerging growth company,&#148; and the reduced disclosure requirements applicable to emerging growth companies may make our common stock
less attractive to investors. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company,&#148; as defined in the JOBS Act and may remain an
emerging growth company for up to five years. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not
emerging growth companies. These exemptions include not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation and exemptions
from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. We cannot predict whether investors will find our common stock less attractive
if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new
or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of
this exemption and we will therefore be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred and will continue to incur increased costs as a result of operating as a public company, and our management devotes substantial time to
new compliance initiatives and corporate governance practices. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As a public company, and particularly after we are no longer an
&#147;emerging growth company,&#148; we will incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing
requirements of The Nasdaq Global Select Market and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and
corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and
will make some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance, which could make it more
difficult for us to attract and retain qualified members of our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are evaluating these rules and regulations, and
cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their
application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure
and governance practices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act, we will be required to furnish a report by our
management on our internal control over financial reporting beginning with our second filing of an Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;with</FONT> the SEC after we become a public company. However, while we remain
an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section&nbsp;404 within the
prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to
improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is
a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section&nbsp;404. If we identify one or more material weaknesses, it could result
in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A significant portion
of our total outstanding shares may be sold into the market in the near future, which could cause the market price of our common stock to decline significantly, even if our business is doing well. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in
the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock. All <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements entered into in connection with our
initial public offering expired on April&nbsp;30, 2018. Our outstanding shares of common stock may be freely sold in the public market at any time to the extent permitted by Rules 144 and 701 under the Securities Act of 1933, as amended (the
&#147;Securities Act&#148;), or to the extent that such shares have already been registered under the Securities Act and are held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> of ours. Moreover, holders of a substantial number of shares
of our common stock have rights, subject to conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We also have
registered all shares of common stock that we may issue under our equity compensation plans or that are issuable upon exercise of outstanding options. These shares can be freely sold in the public market upon issuance and once vested, subject to
volume limitations applicable to affiliates. If any of these additional shares are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Series A Preferred Stock has never been publicly traded and an active trading market for such stock is not expected to develop. </I></B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been no public market for our Series A Preferred Stock. We are not listing our Series A Preferred Stock
on any exchange or trading system and we do not expect that a trading market for our Series A Preferred Stock will develop. </P>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Series A
Preferred Stock will rank junior to all our liabilities to third party creditors, and to any class or series of our capital stock created after this offering specifically ranking by its terms senior to the Series A Preferred Stock, in the event of a
bankruptcy, liquidation or winding up of our assets. </I></B></P>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In the event of bankruptcy, liquidation or winding up, our assets
will be available to pay obligations on our Series A Preferred Stock only after all our liabilities have been paid. Our Series A Preferred Stock will effectively rank junior to all existing and future liabilities held by third party creditors. The
terms of our Series A Preferred Stock do not restrict our ability to raise additional capital in the future through the issuance of debt. Our Series A Preferred Stock will also rank junior to any class or series of our capital stock created after
this offering specifically ranking by its terms senior to the Series A Preferred Stock. In the event of bankruptcy, liquidation or winding up, there may not be sufficient assets remaining, after paying our liabilities, to pay amounts due on any or
all of our Series A Preferred Stock then outstanding. </P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We do not anticipate paying any cash dividends on our capital stock in the foreseeable
future. Accordingly, stockholders must rely on capital appreciation, if any, for any return on their investment. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have never
declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the operation, development and growth of our business. To the extent that we enter into any future debt agreements,
the terms of such agreements may also preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be our stockholders&#146; sole source of gain for the foreseeable future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our executive officers, directors and principal stockholders and their affiliates, if they choose to
act together, continue to have the ability to exercise significant influence over all matters submitted to stockholders for approval. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2018, our executive officers and directors, combined with our stockholders who as of such date owned more than 5% of our
outstanding common stock, in the aggregate, beneficially own shares representing approximately 76% of our capital stock, or 62% after giving effect to the offering. As a result, if these stockholders were to choose to act together, they would be
able to control all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control the election of directors and approval of any merger,
consolidation or sale of all or substantially all of our assets. This concentration of ownership control may: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delay, defer or prevent a change in control; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">entrench our management and/or our board of directors;&nbsp;or </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">impede a merger, consolidation, takeover or other business combination involving us that other stockholders may desire. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">See the &#147;Principal Stockholders&#148; section of this prospectus for more information regarding the ownership of our outstanding common
stock by our executive officers, directors, principal stockholders and their affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provisions in our corporate charter documents and under
Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Provisions in our amended and restated certificate of incorporation and amended and
<FONT STYLE="white-space:nowrap">restated&nbsp;by-laws&nbsp;may</FONT> discourage, delay or prevent a merger, acquisition or other change in control of us that our stockholders may consider favorable, including transactions in which our stockholders
might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In
addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more
difficult for stockholders to replace members of our board of directors. Among other things, these provisions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish a classified board of directors such that all members of the board are not elected at one time; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">allow the authorized number of our directors to be changed only by resolution of our board of directors; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limit the manner in which stockholders can remove directors from our board of directors; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish advance notice requirements for nominations for election to our board of directors or for proposing matters that can be acted on at stockholder meetings; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limit who may call a special meeting of stockholders; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#147;poison pill&#148; that would work to dilute the stock ownership of a potential hostile
acquirer, effectively preventing acquisitions that have not been approved by our board of directors;&nbsp;and </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require the approval of the holders of at least 75% of the votes that all of our stockholders would be entitled to cast to amend or repeal certain provisions of our certificate of incorporation <FONT
STYLE="white-space:nowrap">or&nbsp;by-laws.</FONT> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Moreover, because we are incorporated in Delaware, we are governed by
the provisions of Section&nbsp;203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the
transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. This could discourage, delay or prevent someone from acquiring us or merging with us,
whether or not it is desired by, or beneficial to, our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc521849_3"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This prospectus contains forward-looking statements that involve risks and uncertainties. All statements other than statements of historical
facts contained in this prospectus are forward-looking statements. In some cases, you can identify forward-looking statements by words such as &#147;anticipate,&#148; &#147;believe,&#148; &#147;contemplate,&#148; &#147;continue,&#148;
&#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;seek,&#148; &#147;should,&#148; &#147;target,&#148;
&#147;will,&#148; &#147;would,&#148; or the negative of these words or other comparable terminology. These forward-looking statements include, but are not limited to, statements about: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our use of the net proceeds from this offering; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the initiation, timing, progress and results of, including interim data from, our preclinical studies and clinical trials, and our research and development programs; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified professionals; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to advance product candidates into, and successfully complete, clinical trials; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing or likelihood of regulatory filings and approvals; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the commercialization of our product candidates, if approved; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the pricing, coverage and reimbursement of our product candidates, if approved; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the implementation of our business model, strategic plans for our business and product candidates and our Potentiator Platform; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our Potentiator Platform; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to enter into strategic arrangements and/or collaborations and the potential benefits of such arrangements; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our estimates regarding expenses, capital requirements and needs for additional financing; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our financial performance; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developments relating to our competitors and our industry. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">These forward-looking statements
are subject to a number of risks, uncertainties and assumptions, including those described in &#147;Risk Factors&#148; and elsewhere in this prospectus. Moreover, we operate in a very competitive and rapidly changing environment, and new risks
emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ
materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this prospectus may not occur and actual results could
differ materially and adversely from those anticipated or implied in the forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">You should not rely upon
forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events
and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
statements for any reason after the date of this prospectus to conform these statements to new information, actual results or to changes in our expectations, except as required by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">You should read this prospectus and the documents that we reference in this prospectus and have filed with the SEC as exhibits to the
registration statement of which this prospectus is a part with the understanding that our actual future results, levels of activity, performance, and events and circumstances may be materially different from what we expect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc521849_4"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We estimate that we will receive net proceeds of approximately $69.9&nbsp;million from our sale of securities in this offering, or
approximately $76.3&nbsp;million if the underwriters exercise their option to purchase additional shares in full, based on an assumed public offering price of $13.85 per share of common stock, which is the last reported sale price of our common
stock on The Nasdaq Global Select Market on July&nbsp;10, 2018, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from this offering to fund the planned pivotal Phase 3 clinical trial of SPR994 through the top-line data
readout and the remainder for working capital and other general corporate purposes. We believe opportunities may exist from time to time to expand our current business through acquisitions or <FONT STYLE="white-space:nowrap">in-licensing</FONT> of
complementary companies, medicines or technologies. While we have no current agreements, commitments or understandings for any specific acquisitions or <FONT STYLE="white-space:nowrap">in-licensing</FONT> at this time, we may use a portion of the
net proceeds for these purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This expected use of the net proceeds to us from this offering represents our intentions based upon our
current plans and business conditions. The amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including the progress of our research and development efforts, the status of and results from clinical
trials, any collaborations that we may enter into with third parties for our programs, any unforeseen cash needs and the factors described in &#147;Risk Factors&#148;. Accordingly, our management will have broad discretion in applying the net
proceeds from this offering. An investor will not have the opportunity to evaluate the economic, financial or other information on which we base our decisions on how to use the proceeds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Based on our current plans, we believe that our existing cash, cash equivalents and marketable securities, together with the net proceeds from
this offering, will be sufficient to enable us to fund our operating expenses and capital expenditure requirements into the second half of 2020, including through top-line data readout of our planned pivotal Phase 3 clinical trial of SPR994. We have
based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. We do not expect the net proceeds from this offering and our existing cash and cash equivalents to be
sufficient to fund the development of our product candidates through regulatory approval and commercialization. In particular, we anticipate that those funds will not be sufficient to enable us to complete our planned pivotal Phase&nbsp;3 clinical
trial of SPR994. We will need to raise substantial additional funds before we can expect to commercialize any products, if approved. We may satisfy our future cash needs through the sale of equity securities, debt financings, working capital lines
of credit, corporate collaborations or license agreements, grant funding, interest income earned on invested cash balances or a combination of one or more of these sources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Pending their use as described above, we plan to invest the net proceeds from this offering in short-term, interest-bearing obligations,
investment-grade instruments, and certificates of deposit or guaranteed obligations of the U.S. government. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc521849_22"></A>MARKET PRICE OF OUR COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our common stock has been listed on The Nasdaq Global Select Market under the symbol &#147;SPRO&#148; since November&nbsp;1, 2017. Prior to
that time, there was no public market for our common stock. The following table sets forth for the periods indicated the high and low sales prices per share of our common stock as reported on The Nasdaq Global Select Market: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2017:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fourth quarter (beginning November&nbsp;1, 2017 through December&nbsp;31, 2017)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2018:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third quarter (beginning July 1, 2018 through July&nbsp;10, 2018)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On July&nbsp;10, 2018, the closing price of our common stock as reported on The Nasdaq Global Select
Market was $13.85 per share. As of June&nbsp;30, 2018, we had approximately 24&nbsp;stockholders of record. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc521849_5"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all available funds and future earnings, if
any, for use in the operation of our business and do not anticipate paying any cash dividends on our securities in the foreseeable future. Any future determination to declare and pay dividends will be made at the discretion of our board of directors
and will depend on various factors, including applicable laws, our results of operations, our financial condition, our capital requirements, general business conditions, our future prospects and other factors that our board of directors may deem
relevant. Additionally, our ability to pay dividends on our capital stock could be limited by terms and covenants of any future indebtedness. Investors should not purchase our securities with the expectation of receiving cash dividends. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc521849_6"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash, cash equivalents, marketable securities and our capitalization as of March&nbsp;31, 2018: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on an actual basis; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on an as adjusted basis to give further effect to our issuance and sale of 3,250,000 shares of our common stock in this offering at an assumed public offering price of $13.85 per share, which is the last reported sale
price of our common stock on The Nasdaq Global Select Market on July&nbsp;10, 2018, and our issuance and sale of 2,166 shares of our Series A Preferred Stock in this offering at an assumed public offering price of $13,850 per share, after deducting
estimated underwriting discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The as adjusted
information below is illustrative only, and our capitalization following the completion of this offering will be adjusted based on the actual public offering price and other terms of this offering determined at pricing. For the purposes of this
Capitalization discussion, we have assumed that none of the shares of Series A Preferred Stock have converted into common stock. You should read this table together with our consolidated financial statements and the related notes appearing elsewhere
in this prospectus and &#147;Selected Consolidated Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; sections of this prospectus. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of March&nbsp;31, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:48.10pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>As&nbsp;Adjusted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(dollars in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">145,904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value; 60,000,000 shares authorized, 14,369,182 shares issued and
outstanding, actual, 60,000,000&nbsp;shares authorized, 17,619,182 issued and outstanding, as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.001 par value; 10,000,000 shares authorized, zero shares issued and
outstanding, actual, 10,000,000 shares authorized, 2,166 shares issued and outstanding, as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">251,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(107,484</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(107,484</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Spero Therapeutics, Inc. stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-controlling</FONT> interests</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">74,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">144,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The as adjusted information is illustrative only and will change based on the actual public offering price and other terms of this offering determined at pricing. A $1.00 increase (decrease) in the assumed public
offering price of $13.85 per share of common stock, which is the last reported sale price of our common stock on July&nbsp;10, 2018, would increase (decrease) the as adjusted amount of each of cash, cash equivalents and marketable securities,
working capital, total assets and total stockholders&#146; equity by $3.1&nbsp;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting
discounts and commissions and estimated offering expenses payable by us. An increase (decrease) of 1,000,000 shares in the number of shares of common stock offered by us, as set forth on the cover page of this prospectus, would increase (decrease)
the as adjusted amount of each of cash, cash equivalents, working capital, total assets and total stockholders&#146; equity by $13.0 million, assuming no change in the assumed public offering price per share of our common stock and after deducting
estimated underwriting discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering is based on
14,369,182 shares of our common stock outstanding as of March&nbsp;31, 2018, and excludes: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2,166,000 shares of common stock issuable upon the conversion of the 2,166 shares of Series A Preferred Stock offered hereby; </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2,129,082 shares of common stock issuable upon the exercise of outstanding stock options as of March&nbsp;31, 2018, having a weighted average exercise price of $7.60 per share; and </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">567,319 shares of common stock available for future issuance as of March&nbsp;31, 2018 under our 2017 Stock Incentive Plan, as amended, or the 2017 Plan, as well as any automatic increases in the number of shares of our
common stock reserved for issuance under the 2017 Plan. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc521849_7"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If you invest in our securities in this offering, your ownership interest will be diluted immediately to the extent of the difference between
the public offering price per share of common stock and the as adjusted net tangible book value per share of common stock immediately after this offering. This discussion assumes that all purchasers in this offering elect to purchase common stock or
to convert their shares of Series A Preferred Stock into common stock. </P>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2018, our historical net tangible
book value was $74.9&nbsp;million, or $5.21 per share. Our historical net tangible book value per share is equal to our total tangible assets, less total liabilities, divided by the number of outstanding shares. After giving effect to the sale of
3,250,000 shares of common stock and 2,166 shares of Series A Preferred Stock in this offering, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, at the public offering price of $13.85
per share of common stock and $13,850 per share of Series A Preferred Stock, our as adjusted net tangible book value as of March&nbsp;31, 2018 would have been approximately $144.8 million, or approximately $7.32 per share of common stock. This
represents an immediate increase in as adjusted net tangible book value of $2.11 per share to our existing stockholders and an immediate dilution of $6.53 per share of common stock to investors participating in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table illustrates this dilution on a per share basis: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed public offering price per share of preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed public offering price per share of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value (deficit) per share of common stock as of March&nbsp;31,
2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase per share of common stock attributable to new investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As adjusted net tangible book value per share of common stock after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share of common stock to new investors purchasing common stock in this
offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">A $1.00 increase (decrease) in the assumed public offering price of $13.85 per share of common stock,
which is the last reported sale price of our common stock on July&nbsp;10, 2018, would increase (decrease) the as adjusted amount of each of cash, cash equivalents and marketable securities, working capital, total assets and total stockholders&#146;
equity by $3.1 million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses
payable by us. An increase (decrease) of 1,000,000 shares in the number of shares of common stock offered by us, as set forth on the cover page of this prospectus, would increase (decrease) the as adjusted amount of each of cash, cash equivalents
and marketable securities, working capital, total assets and total stockholders&#146; equity by $13.0 million, assuming no change in the assumed public offering price per share of common stock and after deducting estimated underwriting discounts and
commissions and estimated offering expenses payable by us. </P>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If the underwriters exercise their option to purchase additional
shares in full, the as adjusted net tangible book value per share of common stock after this offering would be $157.5, representing an immediate increase in as adjusted net tangible book value per share of $2.56 to existing stockholders and
immediate dilution in as adjusted net tangible book value per share of $6.08 to new investors purchasing common stock in this offering, assuming a public offering price of $13.85 per share of common stock, which is the last reported sale price of
our common stock on The Nasdaq Global Select Market on July&nbsp;10, 2018. </P>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table summarizes, as of March&nbsp;31,
2018, on the as adjusted basis described above, the total number of shares of common stock purchased from us on an as converted to common stock basis, the total consideration paid or to be paid, and the average price per share paid or to be paid by
existing stockholders and by new investors in this offering at an assumed public offering price of $13.85 per share, which is the last reported sale price of our common stock on The Nasdaq Global Select Market on July&nbsp;10, 2018, before deducting
estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:61.10pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Shares
Purchased</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:68.60pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Total
Consideration</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Average</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Price</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:34.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Per&nbsp;Share</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:28.45pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:37.75pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Percentage</B></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:28.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Amount</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:37.75pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Percentage</B></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,369,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">179,938,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,416,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,011,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,785,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">254,950,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The table above assumes no exercise of the underwriters&#146; option to purchase additional shares in
this offering. If the underwriters exercise their option to purchase additional shares in full, the number of shares of our common stock held by existing stockholders would be reduced to 70.9% of the total number of shares of our common stock
outstanding after this offering, and the number of shares of common stock held by new investors participating in this offering would be increased to 29.1% of the total number of shares of our common stock outstanding after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering is based on 14,369,182 shares of our common stock outstanding
as of March&nbsp;31, 2018, and excludes: </P>   <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2,129,082 shares of common stock issuable upon the exercise of outstanding stock options as of March&nbsp;31, 2018, having a weighted average exercise price of $7.60 per share; and </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">567,319 shares of common stock available for future issuance as of March&nbsp;31, 2018 under our 2017 Stock Incentive Plan, as amended, or the 2017 Plan, as well as any automatic increases in the number of shares of our
common stock reserved for issuance under the 2017 Plan. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc521849_8"></A>SELECTED CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">You should read the following selected consolidated financial data together with our consolidated financial statements and the related notes
appearing elsewhere in this prospectus and the &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; section of this prospectus. The selected consolidated financial data contained in this section are
not intended to replace our consolidated financial statements and the related notes. We have derived the consolidated statement of operations data for the years ended December&nbsp;31, 2015, 2016 and 2017 and the consolidated balance sheet data as
of December&nbsp;31, 2016 and 2017 from our audited consolidated financial statements appearing elsewhere in this prospectus. The consolidated statement of operations data for the three months ended March&nbsp;31, 2017 and 2018 and the consolidated
balance sheet data as of March&nbsp;31, 2018 have been derived from our unaudited consolidated financial statements appearing elsewhere in this prospectus and have been prepared on the same basis as the audited consolidated financial statements. In
the opinion of management, the unaudited data reflects all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the financial information in those statements. Our historical results are not necessarily
indicative of the results that may be expected in the future, and our results for any interim period are not necessarily indicative of results that may be expected for any full year. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:110.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(In thousands, except per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statement of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,327</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,221</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41,730</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,599</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,816</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income and other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,153</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,641</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,886</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,411</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,644</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Net loss attributable to <FONT STYLE="white-space:nowrap">non-controlling</FONT>
interest</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,999</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,143</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(535</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to Spero Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,154</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,491</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,743</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,876</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,644</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued return on preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(932</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,146</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,236</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of redeemable bridge units and redeemable convertible preferred shares to redemption
value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(996</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,208</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders of Spero Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,427</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(29,928</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(46,097</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,130</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,644</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders of Spero Therapeutics, Inc. per share,
basic and diluted(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(53.11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(95.87</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17.82</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(21.60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.74</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding, basic and diluted(1):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">See Note 15 to our consolidated financial statements for the year ended December&nbsp;31, 2017 and Note 12 to our
consolidated financial statements for the three months ended March&nbsp;31, 2018 appearing elsewhere in </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
this prospectus for further details on the calculation of basic and diluted net loss per share attributable to common stockholders of Spero Therapeutics, Inc. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:66.20pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>As of
December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:53.10pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>March&nbsp;31,&nbsp;2018</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">87,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">52,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bridge units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49,248</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">We define working capital as current assets less current liabilities.<B> </B> </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc521849_9"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion and analysis of our financial condition and results of operations together with the &#147;Selected
Consolidated Financial Data&#148; section of this prospectus and our consolidated financial statements and related notes appearing elsewhere in this prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere
in this prospectus, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors
set forth in the &#147;Risk Factors&#148; section of this prospectus, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are a multi-asset,
clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. Our most advanced product candidate, SPR994, is designed to be the first broad-spectrum oral
carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. Treatment with effective orally administrable antibiotics may prevent hospitalizations for serious infections and enable earlier, more convenient and cost-effective
treatment of patients after hospitalization. We also have a platform technology known as our Potentiator Platform that we believe will enable us to develop drugs that will expand the spectrum and potency of existing antibiotics, including formerly
inactive antibiotics, against Gram-negative bacteria. Our lead product candidates generated from our Potentiator Platform are two IV-administered agents, SPR741 and SPR206, designed to treat MDR Gram-negative infections in the hospital setting. In
addition, we are developing SPR720, an oral antibiotic designed for the treatment of pulmonary <FONT STYLE="white-space:nowrap">non-tuberculous</FONT> mycobacterial infections. We believe that our novel product candidates, if successfully developed
and approved, would have a meaningful patient impact and significant commercial applications for the treatment of MDR infections in both the community and hospital settings. Since our inception in 2013, we have focused substantially all of our
efforts and financial resources on organizing and staffing our company, business planning, raising capital, acquiring and developing product and technology rights, building our intellectual property portfolio and conducting research and development
activities for our product candidates. We do not have any products approved for sale and have not generated any revenue from product sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On November&nbsp;6, 2017, we completed an initial public offering, or IPO, of our common stock, and issued and sold 5,500,000 shares of common
stock at a public offering price of $14.00 per share, resulting in net proceeds of $71.6&nbsp;million after deducting underwriting discounts and commissions but before deducting offering costs. On November&nbsp;14, 2017, we issued and sold an
additional 471,498 shares of our common stock at the IPO price of $14.00 per share pursuant to the underwriters&#146; partial exercise of their option to purchase additional shares of common stock, resulting in additional net proceeds of
$6.1&nbsp;million after deducting underwriting discounts. Aggregate net proceeds from the IPO totaled $74.2&nbsp;million after deducting underwriting discounts, commissions and offering costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Prior to the IPO, we funded our operations with proceeds from the sale of preferred units and bridge units and payments received under a
concluded collaboration agreement and funding from government contracts. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of
our product candidates. As of March&nbsp;31, 2018, we had an accumulated deficit of $107.5&nbsp;million. We expect to continue to incur significant expenses and increasing operating losses for at least the next several years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval
for our product candidates. If we obtain regulatory approval for any of our product candidates and do not enter into a commercialization partnership, we expect to incur significant expenses related to developing our internal commercialization
capability to support product sales, marketing and distribution. Further, we expect to incur additional costs associated with operating as a public company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As a result, we will need substantial additional funding to support our continuing
operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of equity offerings, debt financings, government funding
arrangements, collaborations, strategic alliances and marketing, distribution or licensing arrangements. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we
fail to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the
timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain
profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2018, we had cash, cash equivalents and marketable securities of $75.4&nbsp;million. We believe that our existing cash,
cash equivalents and marketable securities, together with the proceeds of this offering, will enable us to fund our operating expenses and capital expenditure requirements into the second half of 2020, including through top-line data readout of our
planned pivotal Phase 3 clinical trial of SPR994. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of Our Results of Operations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Grant Revenue </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">To date, we have
not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval, we
may generate revenue in the future from product sales. We cannot predict if, when, or to what extent we will generate revenue from the commercialization and sale of our product candidates. We may never succeed in obtaining regulatory approval for
any of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">To date, all of our revenue has been derived from government awards. We expect that our revenue for the
next several years will be derived primarily from payments under our government awards that we may enter into in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>U.S.
Department of Defense </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In September 2016, we were awarded a cooperative agreement with the U.S. Department of Defense to further
develop anti-infective agents to combat Gram-negative bacteria. The agreement is structured as a single, <FONT STYLE="white-space:nowrap">two-year</FONT> $1.5&nbsp;million award. We are eligible for the full funding from DoD and there are no options
to be exercised at a later date. The DoD funding supports next-generation potentiator discovery and screening of SPR741 partner antibiotics. We receive funding under the DoD award as we incur qualifying expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>NIAID </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In February 2017,
we received an award from the U.S. National Institute of Allergy and Infectious Diseases to conduct additional preclinical studies of SPR720. The award is structured as a <FONT STYLE="white-space:nowrap">12-month</FONT> $0.6&nbsp;million base
period, which has already been committed, and a $0.4&nbsp;million option period. In February 2018 NIAID exercised the $0.4&nbsp;million <FONT STYLE="white-space:nowrap">12-month</FONT> option period. We receive funding under the NIAID award as we
incur qualifying expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In June 2016, we entered into agreements with Pro Bono Bio PLC, a corporation organized under the laws of
England, and certain of its affiliates, including PBB Distributions Limited and Cantab Anti-Infectives Limited, in order to acquire certain intellectual property and government funding arrangements relating to SPR206. Under these agreements, CAI
agreed to submit a request to NIAID to assign the <FONT STYLE="white-space:nowrap">CAI-held</FONT> NIAID contract to us. The NIAID contract provides for total development funding of up to $6.0&nbsp;million over a base period and three option
periods. To date, funding for the base period and the first two option periods totaling </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
$5.4&nbsp;million have been committed. Novation of the NIAID contract was finalized in December 2017. We will pay PBB a percentage of funds received from NIAID up to a maximum of
$1.3&nbsp;million, of which $0.3&nbsp;million was paid upfront to PBB as part of this agreement. During the three months ended March&nbsp;31, 2018, we recorded approximately $0.1&nbsp;million in amounts payable to PBB under this agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">CARB-X</FONT> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In April 2017, we received an award from the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, a public-private
partnership funded by the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services, to be used to screen, identify and complete Phase&nbsp;1 clinical trials with at least one partner compound for
SPR741, one of our lead potentiator product candidates. The award committed funding of $1.5&nbsp;million over a <FONT STYLE="white-space:nowrap">12-month</FONT> period. In March 2018, <FONT STYLE="white-space:nowrap">CARB-X</FONT> committed an
additional $0.4&nbsp;million related to the first option for a period from December&nbsp;1, 2017 to March&nbsp;31, 2018. There will be no additional options exercised under the <FONT STYLE="white-space:nowrap">CARB-X</FONT> award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Expenses </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Research
and Development Expenses </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Research and development expenses consist primarily of costs incurred for our research activities, including
our drug discovery efforts, and the development of our product candidates, which include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">employee-related expenses, including salaries, related benefits, travel and share-based compensation expense for employees engaged in research and development functions; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expenses incurred in connection with the preclinical and clinical development of our product candidates, including under agreements with contract research organizations, or CROs; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of consultants and contract manufacturing organizations, or CMOs, that manufacture drug products for use in our preclinical studies and clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance and supplies;&nbsp;and </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">payments made under third-party licensing agreements. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Prior to novation of the NIAID contract
to us, under our agreements with PBB and certain of its affiliates, CAI continued to perform research and development at our direction. We paid CAI for such research and development services at an agreed-upon rate that took into consideration costs
incurred by CAI, net of amounts reimbursed to CAI by NIAID. Thus, prior to novation of the NIAID contract to us, the amount we record as research and development expenses is net of the NIAID reimbursement amount that CAI received. We also paid CAI a
portion of the NIAID reimbursement received at rates specified in the agreement, which we also recorded as research and development expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Since the fourth quarter of 2016, we have recorded research and development expenses for our SPR741 program conducted by our Australian
subsidiary net of a 43.5% research and development tax incentive we expect to receive for qualified expenses from the Australian government. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We expense research and development costs as incurred. Nonrefundable advance payments we make for goods or services to be received in the
future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our direct research and development expenses are tracked on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis and consist primarily of external costs, such as fees paid to consultants, contractors, CMOs and CROs in connection with our preclinical and
clinical development activities. License fees and other costs incurred after a product candidate has been designated and that are directly related to the product candidate are included in direct research and development expenses for that program.
License fees and other costs incurred prior to designating a product candidate are included in early stage research programs. We do not allocate employee costs, costs associated with our preclinical programs or facility expenses, including
depreciation or other indirect costs, to specific product development programs because these costs are deployed across multiple product development programs and, as such, are not separately classified. The table below summarizes our research and
development expenses incurred by development program: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Three Months<BR>Ended March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Direct research and development expenses by program:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPR994</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPR741</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPR720</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPR206</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preclinical programs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unallocated expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel related (including share-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facility related and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Product candidates in later stages of clinical development generally have higher development costs than those
in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will increase substantially in connection with our planned clinical and
preclinical development activities in the near term and in the future as we initiate additional clinical trials and other studies of SPR994 and our other product candidates, continue to discover and develop additional product candidates, hire
additional clinical, scientific and commercial personnel and acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates and technologies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the
preclinical and clinical development of any of our product candidates. The successful development and commercialization of our product candidates is highly uncertain. This is due to the numerous risks and uncertainties, including the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">successful completion of clinical trials with safety, tolerability and efficacy profiles that are satisfactory to the FDA or any comparable foreign regulatory authority; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">receipt of marketing approvals from applicable regulatory authorities; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishment of arrangements with third-party manufacturers to obtain manufacturing supply; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtainment and maintenance of patent, trade secret protection and regulatory exclusivity, both in the United States and internationally, including our ability to maintain our license agreement with Meiji with respect to
SPR994; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">protection of our rights in our intellectual property portfolio; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">launch of commercial sales of SPR994 and our other product candidates, if approved, whether alone or in collaboration with others; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acceptance of SPR994 and our other product candidates, if approved, by patients, the medical community and third-party payors; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">competition with other therapies;&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a continued acceptable safety profile of SPR994 and our other product candidates, if approved. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">A change in the outcome of any of these variables with respect to the development of any of our product candidates would significantly change
the costs and timing associated with the development of that product candidate. We may never succeed in obtaining regulatory approval for any of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist primarily of salaries and related costs, including share-based compensation, for personnel in
executive, finance and administrative functions. General and administrative expenses also include direct and allocated facility-related costs as well as professional fees for legal, patent, consulting, investor and public relations, accounting and
audit services. We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued research activities and development of our product candidates. We also anticipate that we
will incur increased accounting, audit, legal, regulatory, compliance, and director and officer insurance costs as well as investor and public relations expenses associated with operating as a public company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income (Expense) </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Change
in Fair Value of Derivative Liabilities </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Contingent Prepayment Options. </I>Bridge units issued to our investors in 2016 were
automatically convertible into equity units sold in a subsequent round of qualified financing at a discounted rate. We refer to these automatic conversion features as contingent prepayment options. We classified the contingent prepayment options as
a derivative liability on our consolidated balance sheet that we remeasured to fair value at each reporting date, and we recognized changes in the fair value of the derivative liability associated with the contingent prepayment options as a
component of other income (expense) in our consolidated statement of operations and comprehensive loss. The contingent prepayment options were settled in the first quarter of 2017 upon the issuance of Class&nbsp;C preferred units. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Anti-Dilution Rights. </I>In connection with the issuance of <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests in certain
of our subsidiaries, specifically Spero Potentiator, Inc., Spero Europe, Ltd. and Spero Gyrase, Inc., we granted the minority investors the right to maintain ownership interests at no additional cost, subject to a maximum ownership percentage, which
rights we refer to collectively as anti-dilution rights. We classified the anti-dilution rights as derivative liabilities on our consolidated balance sheet that we remeasured to fair value at each reporting date, and we recognized changes in the
fair value of the derivative liabilities associated with the anti-dilution rights as a component of other income (expense) in our consolidated statement of operations and comprehensive loss. As of December&nbsp;31, 2016, anti-dilution rights related
to Spero Potentiator, Inc. were fully settled as the maximum number of shares to be issued to the minority investor had been reached in August 2016. In May 2017, we repurchased 100% of the minority investor&#146;s outstanding shares in Spero Europe,
Ltd. and settled the anti-dilution rights associated with the shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2018 and December&nbsp;31, 2017, the
derivative liability of $0.2&nbsp;million recorded on our consolidated balance sheet relates only to the anti-dilution rights held by the minority investor in Spero Gyrase, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Interest Income and Other Income (Expense), Net </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Interest income consists of interest earned on our cash equivalents, which are invested in money market accounts. Our interest income has not
been significant due to nominal investment balances and low interest earned on those balances. Other income (expense), net, consists of insignificant amounts of miscellaneous income and expenses unrelated to our core operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Since our inception, we have not recorded any income tax benefits for the net losses we have incurred in each year or for our earned research
and development tax credits, as we believe, based upon the weight of available evidence, that it is more likely than not that all of our net operating loss carryforwards and tax credits will not be realized. As of December&nbsp;31, 2017, we had
federal and state net operating loss carryforwards of $76.4&nbsp;million and $76.0&nbsp;million, respectively, which may be available to offset future income tax liabilities and begin to expire in 2033. In addition, as of December&nbsp;31, 2017, we
had foreign net operating loss carryforwards of $4.3&nbsp;million, which may be available to offset future income tax liabilities and do not expire. As of December&nbsp;31, 2017, we also had federal and state research and development tax credit
carryforwards of $1.7&nbsp;million and $0.4&nbsp;million, respectively, which begin to expire in 2033 and 2028, respectively. We have recorded a full valuation allowance against our net deferred tax assets at each balance sheet date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On June&nbsp;30, 2017, we completed a series of transactions, or the Reorganization, pursuant to which Spero Therapeutics, LLC merged with and
into Spero Therapeutics, Inc., a Delaware corporation (formerly known as Spero OpCo, Inc.), with Spero Therapeutics, Inc. continuing as the surviving corporation. Prior to the Reorganization, our former parent company, Spero Therapeutics, LLC, was
treated as a partnership for federal income tax purposes and, therefore, its owners, and not itself, were subject to U.S. federal or state income taxation on the income of Spero Therapeutics, LLC. Prior to the Reorganization, all of Spero
Therapeutics, LLC&#146;s directly held subsidiaries (including Spero Therapeutics, Inc.) were treated as corporations for U.S. federal income tax purposes and were subject to taxation in the United States or in other countries. Upon the
Reorganization, Spero Therapeutics, Inc., whose consolidated financial statements are presented in this prospectus, became the parent company for Spero Therapeutics, LLC&#146;s former subsidiaries and these entities continue to be subject to
taxation in the United States or in other countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Income (Loss) Attributable to <FONT STYLE="white-space:nowrap">Non-Controlling</FONT>
Interests </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Net income (loss) attributable to <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests in our consolidated
statement of operations and comprehensive loss is a result of minority investments in our subsidiaries, Spero Europe, Ltd., Spero Potentiator, Inc., Spero Cantab, Inc. and Spero Gyrase, Inc., and consists of the portion of the net income or loss of
these subsidiaries that is not allocated to us. Changes in the amount of net income (loss) attributable to <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests are directly impacted by changes in the net income or loss of our
consolidated subsidiaries and by the ownership percentage of the minority investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In May 2017, we repurchased 100% of the issued and
outstanding shares of Spero Europe, Ltd. held by the minority investor. In June 2017, we repurchased 100% of the issued and outstanding shares of Spero Potentiator, Inc. held by the minority investor. In July 2017, we repurchased 100% of the issued
and outstanding shares of Spero Cantab, Inc. held by the minority investor. As a result of these repurchases of the <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests, for periods subsequent to each repurchase, we no longer attribute
net income (loss) to the <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest. As of March&nbsp;31, 2018, the remaining <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest relates only to Spero Gyrase, Inc. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the three months ended March&nbsp;31, 2018 and 2017 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations for the three months ended March&nbsp;31, 2018 and 2017: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Three Months Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:32.25pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>$&nbsp;Change</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,816</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,599</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,199</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income and other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,016</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,644</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,411</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,233</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Net loss attributable to <FONT STYLE="white-space:nowrap">non-controlling</FONT>
interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(535</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to Spero Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,644</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,876</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,768</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Grant Revenue </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Grant revenue recognized during the three months ended March&nbsp;31, 2018 consisted of the reimbursement of qualifying expenses incurred in
connection with our various government awards, including $0.5&nbsp;million under our awards with NIAID related to our SPR720 program, $0.1&nbsp;million under our award from the DoD related to our SPR741 program, and $0.5&nbsp;million under our <FONT
STYLE="white-space:nowrap">CARB-X</FONT> award related to our SPR741 program. Grant revenue recognized during the three months ended March&nbsp;31, 2017, was primarily related to $0.1&nbsp;million under our award from the DoD related to our SPR741
program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Three&nbsp;Months&nbsp;Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>$&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Direct research and development expenses by program:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPR994</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPR741</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(974</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPR720</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPR206</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preclinical programs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(419</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unallocated expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel related (including share-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facility related and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Direct costs related to our related to our SPR994 program increased during the three months ended
March&nbsp;31, 2018 compared to the three months ended March&nbsp;31, 2017 primarily due to expenses related to our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Phase 1 clinical trial, which commenced in October 2017, as well as formulation development, manufacturing process and manufacturing of clinical trial material. These increases were partly offset
by a decrease in preclinical costs for SPR994 during the three months ended March&nbsp;31, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Direct costs related to our SPR741
program decreased in the three months ended March&nbsp;31, 2018 primarily due to higher costs during the three months ended March&nbsp;31, 2017 in connection with preparing for our Phase 1b drug-drug interaction clinical trial of SPR741 in the
United Kingdom, which was initiated in November 2017. Research and development expenses for our SPR741 program conducted by our Australian subsidiary were recorded net of a 43.5% research and development tax incentive for qualified expenses from the
Australian government of less than $0.1&nbsp;million in the three months ended March&nbsp;31, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Direct costs related to our SPR720
program decreased during the three months ended March&nbsp;31, 2018 as compared to the three months ended March&nbsp;31, 2017, primarily due to higher preclinical and manufacturing costs related
<FONT STYLE="white-space:nowrap">to&nbsp;IND-enabling&nbsp;toxicology</FONT> studies during the three months ended March&nbsp;31, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We designated SPR206 as a product candidate in July 2017. Direct costs related to our SPR206 program during the three months ended
March&nbsp;31, 2018 were primarily due to preclinical costs related to <FONT STYLE="white-space:nowrap">IND-enabling</FONT> toxicology studies and manufacturing efforts to support <FONT STYLE="white-space:nowrap">IND-enabling</FONT> efforts and a
potential Phase 1 study. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Direct costs related to our preclinical programs decreased by $0.4&nbsp;million during the three months ended
March&nbsp;31, 2018 compared to the three months ended March&nbsp;31, 2017 due primarily to lower spending on preclinical programs as we focused development efforts on our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The increase in personnel-related costs included in unallocated expenses was due to an increase in headcount in our research and development
function. Personnel-related costs for the three months ended March&nbsp;31, 2018 and 2017 included share-based compensation expense of $0.3&nbsp;million and less than $0.1&nbsp;million, respectively. The increase in facility-related and other costs
was primarily due to the increased costs of supporting a larger group of research and development personnel and their research efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Three&nbsp;Months&nbsp;Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>$&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel related (including share-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional and consultant fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facility related and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The increase in personnel-related costs was primarily a result of an increase in headcount in our general and
administrative function and an increase in stock-based compensation expense related to additional employee stock options granted at a higher fair value of our common stock. Personnel-related costs for the three months ended March&nbsp;31, 2018 and
2017 included share-based compensation expense of $0.4&nbsp;million and less than $0.1&nbsp;million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The increase in
professional and consultant fees primarily consisted of an increase in expenses related to activities to support our operating as a public company, including accounting, audit, and legal fees, as well as costs associated with ongoing business
development activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Other Income (Expense), Net </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Other income, net was $0.2&nbsp;million for the three months ended March&nbsp;31, 2018, compared to $1.2&nbsp;million for the three months
ended March&nbsp;31, 2017. Other income for the three months ended March&nbsp;31, 2018 primarily consisted of $0.2&nbsp;million of interest income related to interest earned on our invested cash </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
balances. Other income for the three months ended March&nbsp;31, 2017 was primarily due to a decrease of $1.2&nbsp;million in the fair value of the derivative liability for anti-dilution rights
granted to minority investors in Spero Gyrase Inc. and Spero Europe Ltd. resulting from our discontinuation of the underlying development programs of these subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Years Ended December&nbsp;31, 2017 and 2016 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations for the years ended December&nbsp;31, 2017 and 2016: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>$ Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41,730</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,221</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,509</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income and other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,886</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,641</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,245</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Net loss attributable to <FONT STYLE="white-space:nowrap">non-controlling</FONT>
interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,143</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to Spero Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(38,743</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25,491</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,252</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Grant Revenue </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Grant revenue recognized during 2017 was primarily due to the reimbursement of qualifying expenses incurred in connection with our <FONT
STYLE="white-space:nowrap">CARB-X</FONT> award related to our SPR741 program of $0.9&nbsp;million as well as $0.7&nbsp;million under our award from the DoD, also related to our SPR741 program. We also recognized $0.4&nbsp;million under our award
from NIAID related to our SPR720 program. During the year ended December&nbsp;31, 2016, all recognized revenue related to the reimbursement of qualifying expenses incurred in connection with our SPR741 program under our research and development
award from the DoD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>$&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Direct research and development expenses by program:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPR994</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,814</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPR741</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,347</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPR720</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPR206</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preclinical programs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,173</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unallocated expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel related (including share-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facility related and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We designated SPR994 as a product candidate in the fourth quarter of 2016. Direct costs
related to our SPR994 program during 2017 were primarily due to preclinical manufacturing and preclinical costs as we focused efforts on formulation development, manufacturing process and manufacturing of clinical trial material in anticipation of a
Phase 1 clinical trial, which commenced in October 2017. We also incurred $1.6&nbsp;million of research and development expense related to a payment of $1.0&nbsp;million to Meiji Seika Pharma Co. Ltd. that became due and was paid in October 2017
under our <FONT STYLE="white-space:nowrap">know-how</FONT> license with Meiji upon the enrollment of the first patient in clinical trials and $0.6&nbsp;million for an upfront license fee paid to Meiji. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Direct costs related to our SPR741 program decreased primarily due to a decrease in preclinical costs resulting from costs incurred in the
prior year to support our CTN filing in Australia in the fourth quarter of 2016, partially offset by an increase in clinical trial costs and manufacturing costs as well as expense related to a total payment to Northern Antibiotics OY Ltd. of
$2.6&nbsp;million which became due and was paid under our agreements with Northern upon the completion of our IPO in November 2017. The increase in clinical trial costs and manufacturing costs was due to our Phase 1 clinical trial of SPR741, which
was initiated in the fourth quarter of 2016, as well as manufacturing of clinical trial materials for our Phase 1b drug-drug interaction clinical trial of SPR741 in the United Kingdom, which was initiated in November 2017, and a possible Phase 2
clinical trial. Research and development expenses for our SPR741 program conducted by our Australian subsidiary were recorded net of a 43.5% research and development tax incentive for qualified expenses from the Australian government of
$1.8&nbsp;million in the year ended December&nbsp;31, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We designated SPR720 as a product candidate in the second half of 2016.
Direct costs related to our SPR720 program during the year ended December&nbsp;31, 2017 were primarily due to preclinical and manufacturing costs related <FONT STYLE="white-space:nowrap">to&nbsp;IND-enabling&nbsp;toxicology</FONT> studies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We designated SPR206 as a product candidate in July 2017. Direct costs related to our SPR206 program during the year ended December&nbsp;31,
2017 were primarily due to preclinical and manufacturing costs related <FONT STYLE="white-space:nowrap">to&nbsp;IND-enabling&nbsp;toxicology</FONT> studies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Direct costs related to our preclinical programs decreased by $5.2&nbsp;million during the year ended December&nbsp;31, 2017 compared to the
prior year due primarily to the cost <FONT STYLE="white-space:nowrap">of&nbsp;in-licensing&nbsp;technology</FONT> incurred in 2016 of $5.1&nbsp;million and to decreased spending on preclinical programs in 2017. The cost of <FONT
STYLE="white-space:nowrap">in-licensing</FONT> technology incurred in 2016 of $5.1&nbsp;million was a result of the issuance of equity and anti-dilution rights to Promiliad Biopharma Inc., or Promiliad, Biota Pharmaceuticals, Inc. (now Aviragen
Therapeutics, Inc.), or Aviragen, and PBB, and a license fee payment of $0.5&nbsp;million we made to Vertex Pharmaceuticals Inc., or Vertex. Our research and development expenses related to our preclinical programs decreased in 2017 as compared to
2016 as we focused development efforts on our product candidates. Direct costs related to our preclinical programs were recorded net of the recognition of funding received from a concluded collaboration agreement of $0.9&nbsp;million during the year
ended December&nbsp;31, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The increase in personnel-related costs included in unallocated expenses was due to an increase in
headcount in our research and development function. Personnel-related costs for the years ended December&nbsp;31, 2017 and 2016 included share-based compensation expense of $0.4&nbsp;million and $0.1&nbsp;million, respectively. The increase in
facility-related and other costs was primarily due to new laboratory space and the increased costs of supporting a larger group of research and development personnel and their research efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>$&nbsp;Change</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel related (including share-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,087</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional and consultant fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facility related and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(154</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The increase in personnel-related costs was primarily a result of an increase in headcount
in our general and administrative function and an increase in stock-based compensation expense related to additional employee stock options granted at a higher fair value of our common stock. Personnel-related costs for the years ended
December&nbsp;31, 2017 and 2016 included share-based compensation expense of $1.1&nbsp;million and $0.1&nbsp;million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The
increase in professional and consultant fees primarily consisted of an increase in professional fees, including accounting, audit, business development and legal fees, as well as costs associated with ongoing business activities and our preparations
to operate as a public company. We also incurred increased legal fees in connection with the Reorganization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Other Income (Expense),
Net </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Other income, net was $1.8&nbsp;million for the year ended December&nbsp;31, 2017, compared to $0.6&nbsp;million for the year
ended December&nbsp;31, 2016. The increase in other income was primarily due to a decrease of $1.5&nbsp;million in the fair value of the derivative liability for anti-dilution rights granted to minority investors in Spero Gyrase Inc. and Spero
Europe Ltd. resulting from our discontinuation of the underlying development programs of these subsidiaries. We also had interest income of $0.3&nbsp;million in the twelve months ended December&nbsp;31, 2017 as a result of interest earned on
invested cash balances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Years Ended December&nbsp;31, 2016 and 2015 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations for the years ended December&nbsp;31, 2016 and 2015: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>$ Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,221</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,327</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,894</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,641</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,153</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,488</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Net loss attributable to <FONT STYLE="white-space:nowrap">non-controlling</FONT>
interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,999</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,151</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to Spero Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25,491</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,154</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Grant Revenue </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2016, all recognized grant revenue related to the reimbursement of qualifying expenses incurred in
connection with our SPR741 program under our research and development award from the DoD. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>$ Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Direct research and development expenses by program:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPR994</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPR741</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPR720</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPR206 and other preclinical programs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unallocated expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel related (including share-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facility related and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We designated SPR994 as a product candidate in the second half of 2016. Direct costs related to our SPR994
program during the year ended December&nbsp;31, 2016 were primarily due to preclinical and manufacturing costs as we focused efforts on formulation development, manufacturing process and manufacturing of clinical trial material in anticipation of a
Phase 1 clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Direct costs related to our SPR741 program increased by $5.6&nbsp;million, primarily due to an increase of
$8.4&nbsp;million in preclinical costs, partially offset by the cost of <FONT STYLE="white-space:nowrap">in-licensing</FONT> technology under the program incurred in 2015 of $3.5&nbsp;million. The increase in preclinical costs was primarily due to
costs incurred to support our CTN filing in Australia in the fourth quarter of 2016. The cost of <FONT STYLE="white-space:nowrap">in-licensing</FONT> technology under the SPR741 program incurred in 2015 of $3.5&nbsp;million was a result of the
issuance of equity and anti-dilution rights to Northern Antibiotics Oy Ltd., or Northern. Research and development expenses for our SPR741 program conducted by our Australian subsidiary were recorded net of a 43.5% research and development tax
incentive from the Australian government of $0.1&nbsp;million in the year ended December&nbsp;31, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We designated SPR720 as a product
candidate in the second half of 2016. Direct costs related to our SPR720 program during the year ended December&nbsp;31, 2016 were primarily due to preclinical costs related to <FONT STYLE="white-space:nowrap">IND-enabling</FONT> toxicology studies
and other preclinical studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Direct costs related to our SPR206 program and other preclinical programs increased by $4.0&nbsp;million
primarily due to the cost of <FONT STYLE="white-space:nowrap">in-licensing</FONT> technology of $5.1&nbsp;million, partially offset by a decrease in preclinical costs as we increased our focus on our more advanced programs, including SPR994 and
SPR720, which we designated as product candidates in the second half of 2016. The cost of <FONT STYLE="white-space:nowrap">in-licensing</FONT> technology incurred in 2016 of $5.1&nbsp;million was a result of the issuance of equity and anti-dilution
rights to Promiliad, Aviragen and PBB and a license fee payment of $0.5&nbsp;million we made to Vertex in the first half of 2016. Our preclinical programs expense was recorded net of the recognition of funding received from a concluded collaboration
agreement of $1.5&nbsp;million and $0.9&nbsp;million in the years ended December&nbsp;31, 2015 and 2016, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The increase in
personnel-related costs included in unallocated expenses of $1.9&nbsp;million was due to an increase in headcount in our research and development function. Personnel-related costs for the years ended December&nbsp;31, 2015 and 2016 included
share-based compensation expense of less than $0.1&nbsp;million and $0.1&nbsp;million, respectively. The increase in facility-related and other costs was primarily due to new laboratory space and the increased costs of supporting a larger group of
research and development personnel and their research efforts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>$&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel related (including share-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional and consultant fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facility related and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The increase in professional and consultant fees of $3.0&nbsp;million was primarily due to increases in legal
fees relating to business development, regulatory and patent costs, accounting and audit fees and public and investor relations fees due to ongoing business activities. Personnel-related costs increased by $1.3&nbsp;million as a result of an
increase in headcount in our general and administrative function. Personnel-related costs for the years ended December&nbsp;31, 2015 and 2016 included share-based compensation expense of less than $0.1&nbsp;million and $0.1&nbsp;million,
respectively. The increase in facility-related and other costs of $0.6&nbsp;million was primarily due to the lease of office space that we entered into at the end of 2015, software costs and general support costs for the increase in headcount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Other Income (Expense), Net </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Other income, net was $0.6&nbsp;million for the year ended December&nbsp;31, 2016, compared to $0.2&nbsp;million for the year ended
December&nbsp;31, 2015. The increase of $0.4&nbsp;million was primarily due to a decrease of $0.6&nbsp;million in the fair value of the derivative liability associated with the Class&nbsp;B tranche rights resulting from a decrease in the fair value
of our Class&nbsp;B preferred units over the same period, partially offset by an increase of $0.2&nbsp;million in the fair value of the derivative liability associated with the investment option held by our former collaboration partner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Since
our inception, we have incurred significant operating losses. We have generated limited revenue to date from funding arrangements with the DoD, NIAID and <FONT STYLE="white-space:nowrap">CARB-X.</FONT> We have not yet commercialized any of our
product candidates and we do not expect to generate revenue from sales of any product candidates for several years, if at all. To date, we have funded our operations with proceeds from the sales of preferred units and bridge units, payments received
under a concluded collaboration agreement and funding from government contracts and, in November 2017, with proceeds from the IPO of our common stock. As of March&nbsp;31, 2018, we had cash, cash equivalents and marketable securities of
$75.4&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table summarizes our sources and uses of cash for each of the periods presented: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Three Months Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,608</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,959</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(39,111</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,979</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,961</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(232</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(830</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,825</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">76,973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(34,786</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Operating Activities </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities for the three months ended March&nbsp;31, 2018 was $12.0&nbsp;million, primarily resulting from our net
loss of $10.6&nbsp;million, adjusted for net <FONT STYLE="white-space:nowrap">non-cash</FONT> items of $0.7&nbsp;million (primarily </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stock-based compensation). Net cash used by changes in our operating assets and liabilities was $2.0&nbsp;million and consisted primarily of a decrease of $2.3&nbsp;million in accounts payable
and accrued expenses, partially offset by an increase of $0.3&nbsp;million in other receivables. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities
for the three months ended March&nbsp;31, 2017 was $7.0&nbsp;million, primarily resulting from our net loss of $5.9&nbsp;million, adjusted for net <FONT STYLE="white-space:nowrap">non-cash</FONT> items of $1.1&nbsp;million, primarily related to the
change in fair value of our derivative liabilities of $1.2&nbsp;million. Net cash provided by our operating assets and liabilities was $0.5&nbsp;million, primarily related to the timing of vendor invoicing, payments and accruals, as well as a
$0.5&nbsp;million advance payment from our collaborators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities for the year ended December&nbsp;31, 2017
was $39.1&nbsp;million, primarily resulting from our net loss of $39.9&nbsp;million, adjusted for net <FONT STYLE="white-space:nowrap">non-cash</FONT> items of $0.3&nbsp;million. Net cash used by changes in our operating assets and liabilities was
$0.4&nbsp;million and consisted primarily of a $2.5&nbsp;million increase in receivables related to the Australian research and development tax incentive and to our government contracts, partially offset by an increase in accounts payable and
accrued expenses and other current liabilities of $3.7&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2016, operating activities
used $29.0&nbsp;million of cash, primarily resulting from our net loss of $32.6&nbsp;million and cash used by changes in our operating assets and liabilities of $0.8&nbsp;million, partially offset by net
<FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $4.5&nbsp;million. Net cash used by changes in our operating assets and liabilities for the year ended December&nbsp;31, 2016 consisted primarily of a $1.0&nbsp;million increase in prepaid
expenses and other current assets, a $0.9&nbsp;million decrease in advance payments from collaborator, a $0.6&nbsp;million decrease in accounts payable, a $0.4&nbsp;million increase in receivables related to our government awards and the Australian
research and development tax incentive, partially offset by a $2.3&nbsp;million increase in accrued expenses and other current liabilities. The decrease in advance payments from collaborator was primarily a result of the recognition of research
funding received in prior periods as an offset to research and development expense as well as the termination of our collaboration agreement in August 2016, at which time we recognized the remaining portion of the liability that had been recorded in
a prior year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2015, operating activities used $9.6&nbsp;million of cash, primarily resulting from
our net loss of $13.2&nbsp;million, partially offset by net <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $3.4&nbsp;million and cash provided by changes in our operating assets and liabilities of $0.2&nbsp;million. Net cash provided by
changes in our operating assets and liabilities for the year ended December&nbsp;31, 2015 consisted primarily of a $0.7&nbsp;million increase in accounts payable and a $0.4&nbsp;million increase in accrued expenses and other current liabilities,
partially offset by a decrease in advance payments from collaborator of $0.5&nbsp;million as a result of the recognition of payments received in 2014 as an offset to research and development expenses, an increase in prepaid expenses and other
current assets of $0.3&nbsp;million and an increase in deposits of $0.2&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Changes in accounts payable, accrued expenses and
other current liabilities, and prepaid expenses and other current assets in all periods were generally due to growth in our business, the advancement of our development programs and the timing of vendor invoicing and payments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Investing Activities </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Cash used in investing activities during the three months ended March&nbsp;31, 2018 was $22.8&nbsp;million related to the purchase of
marketable securities. We did not use any cash for investing activities during the three months ended March&nbsp;31, 2017. We did not use any significant cash for investing activities during the year ended December&nbsp;31, 2017. During the years
ended December&nbsp;31, 2016 and 2015, net cash used in investing activities was $0.8&nbsp;million and $0.2&nbsp;million, respectively, consisting of purchases of property and equipment, primarily for our new office and laboratory spaces. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Financing Activities </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Cash provided by financing activities three months ended March&nbsp;31, 2017 of $43.1&nbsp;million related to the sale of our Class&nbsp;C
preferred units. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2017, net cash provided by financing activities was
$116.1&nbsp;million, consisting primarily of net proceeds of $74.2&nbsp;million from the completion of our IPO in November 2017, as well as $43.1&nbsp;million from the sale of our Class&nbsp;C preferred units, partially offset by $1.2&nbsp;million
of cash used to purchase outstanding shares of Spero Potentiator, Inc. and Spero Cantab, Inc. from the minority interest holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">During
the year ended December&nbsp;31, 2016, net cash provided by financing activities was $34.4&nbsp;million, consisting of net proceeds of $25.9&nbsp;million from the sale of our Class&nbsp;B preferred units and proceeds of $8.5&nbsp;million the sale of
our 2016 bridge units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2015, net cash provided by financing activities was $15.3&nbsp;million,
consisting primarily of proceeds of $8.0&nbsp;million from the sale of our 2015 bridge units and net proceeds of $7.3&nbsp;million from the sale of our Class&nbsp;A preferred units. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Funding Requirements </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We expect
our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the preclinical activities and clinical trials for our product candidates in development. In addition, we expect to incur additional costs
associated with operating as a public company. The timing and amount of our operating expenditures will depend largely on: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing and costs of our planned clinical trials of SPR994; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the initiation, progress, timing, costs and results of preclinical studies and clinical trials of our other product candidates and potential new product candidates; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the amount of funding that we receive under government contracts that we have applied for; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number and characteristics of product candidates that we pursue; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the outcome, timing and costs of seeking regulatory approvals; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of commercialization activities for SPR994 and other product candidates if we receive marketing approval, including the costs and timing of establishing product sales, marketing, distribution and manufacturing
capabilities; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the receipt of marketing approval and revenue received from any potential commercial sales of SPR994; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms and timing of any future collaborations, licensing or other arrangements that we may establish; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property
rights, including milestone and royalty payments and patent prosecution fees that we are obligated to pay pursuant to our license agreements; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and defending against any intellectual property related claims; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of operating as a public company;&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which we <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire other products and technologies. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Based on our current plans, we believe that the net proceeds from this offering, together with our existing cash and cash equivalents will
enable us to fund our operating expenses and capital expenditure </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
requirements into the second half of 2020, including through top-line data readout of our planned pivotal Phase 3 clinical trial of SPR994. However, we do not expect that these funds will be
sufficient to fund the development of our product candidates through regulatory approval and commercialization. In particular, we anticipate that these funds will not be sufficient to enable us to complete our pivotal Phase 3 clinical trial of
SPR994. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Without giving effect to the anticipated net proceeds from this offering, (i) we expect that our existing cash and cash
equivalents will be sufficient to fund our operating expenses and capital requirements through late in the second quarter of 2019 and (ii) for the balance of 2018, our internal operational plans and budget and our estimate of our cash runway are
based on us funding the development of SPR994 and SPR720 and either SPR206 or SPR741 during that period. We may seek partnering opportunities or other <FONT STYLE="white-space:nowrap">non-dilutive</FONT> funding for further clinical development of
the Potentiator candidate we elect to deprioritize. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have based these estimates on assumptions that may prove to be wrong, and we could
utilize our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical product candidates, we are unable to estimate the exact
amount of our working capital requirements. Our future funding requirements will depend on and could increase significantly as a result of many factors, including those listed above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations through a combination of equity
offerings, debt financings, government funding, collaborations, strategic alliances and marketing, distribution or licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our
stockholders&#146; ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if
available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. If we raise additional
funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates
or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our research, product
development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations and Commitments </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table summarizes our contractual obligations as of December&nbsp;31, 2017 and the effects that such obligations are expected to
have on our liquidity and cash flows in future periods:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Payments Due by Period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Less&nbsp;Than</B><br><B>1 Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>1&nbsp;to&nbsp;3</B><br><B>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>4&nbsp;to&nbsp;5</B><br><B>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>More&nbsp;Than</B><br><B>5 Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease commitments(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Reflects payments due for our leases of office and laboratory space under operating lease agreements that expire in 2019 and 2020. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition to the lease obligations above, on January&nbsp;17, 2018, we entered into an amendment, or the Amendment, to our operating lease
agreement for our corporate headquarters located at 675 Massachusetts Avenue, Cambridge, Massachusetts, to add approximately 7,800 square feet of office space. The Amendment also extends the expiration date of the original lease from 2020 to 2025.
The Amendment requires additional annual payments of $0.5&nbsp;million beginning in December 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As further described below, under various licensing and related agreements with third
parties, we have agreed to make milestone payments and pay royalties to third parties. We have not included any contingent payment obligations, such as milestones or royalties, in the table above as the amount, timing and likelihood of such payments
are not known. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under our license agreement with Meiji, we are obligated (i)&nbsp;to make milestone payments of up to $3.0&nbsp;million
upon the achievement of specified clinical and regulatory milestones, (ii)&nbsp;to pay royalties, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, of a low single-digit percentage based on net sales of products licensed under the agreement and (iii)&nbsp;to pay to Meiji a low double-digit percentage of any sublicense fees
received by us up to $7.5&nbsp;million. In October 2017, we paid a $1.0&nbsp;million milestone payment to Meiji upon the enrollment of the first patient in our Phase 1 clinical trial of SPR994. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under our license agreement with Northern, we are obligated to make milestone payments of up to an aggregate of $7.0&nbsp;million upon the
achievement of specified clinical, commercial and other milestones. Upon the closing of our IPO in November 2017, we paid Northern $2.6&nbsp;million in connection with this license agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under an agreement we entered into with PBB, we are obligated to make milestone payments of up to $5.8&nbsp;million upon the achievement of
specified clinical milestones and a payment of &pound;5.0&nbsp;million ($6.7&nbsp;million as of December&nbsp;31, 2017) upon the achievement of a specified commercial milestone. In addition, we have agreed to pay to PBB royalties, on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, of a low single-digit percentage based on net
sales of products licensed under the agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under our agreement with Vertex, we are obligated to make milestone payments of up to
$81.1&nbsp;million upon the achievement of specified clinical, regulatory and commercial milestones and to pay to Vertex tiered royalties, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, of a mid single-digit to low double-digit percentage based on net sales of products licensed under the agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under our agreement with Aviragen, we are obligated to make milestone payments of up to an aggregate of $12.0&nbsp;million upon the
achievement of specified clinical, regulatory and commercial milestones and to pay royalties of low single-digit percentages based on net sales of products we acquired under the agreement. We are no longer pursuing development of the technology
acquired under the agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We enter into contracts in the normal course of business with CROs, CMOs and other third parties for
clinical trials, preclinical research studies and testing, manufacturing and other services. These contracts are cancelable by us upon prior notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred,
including <FONT STYLE="white-space:nowrap">non-cancellable</FONT> obligations of our service providers, up to the date of cancellation. These payments are not included in the table of contractual obligations and commitments above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Significant Judgments and Estimates </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States, or GAAP.
The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, costs and expenses, and the disclosure of contingent
assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for
making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different
assumptions or conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">While our significant accounting policies are described in more detail in Note 2 to our consolidated financial
statements appearing elsewhere in this prospectus, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Funding Received from Government Contracts, Tax Incentives and Collaborations </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Since our inception, we have been able to obtain partial funding for our research and development activities from government contracts,
government tax incentives and a collaboration arrangement. The classification within our statement of operations and comprehensive loss of the funding received under these arrangements is subject to management judgment based on the nature of the
arrangements we enter into, the source of the funding and whether the funding is considered central to our business operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Government Contracts </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We
generate revenue from government contracts that reimburse us for certain allowable costs for funded projects. For contracts with government agencies, when we have concluded that we are the principal in conducting the research and development
expenses and where the funding arrangement is considered central to our ongoing operations, we classify the recognized funding received as revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have concluded to recognize funding received from the DoD, NIAID and <FONT STYLE="white-space:nowrap">CARB-X</FONT> as revenue, rather than
as a reduction of research and development expenses, because we are the principal in conducting the research and development activities and these contracts are central to our ongoing operations. Revenue is recognized as the qualifying expenses
related to the contracts are incurred. Revenue recognition commences only once persuasive evidence of a contract exists, services have been rendered, the reimbursement amounts under the contract are fixed or determinable, and collectibility is
reasonably assured. Revenue recognized upon incurring qualifying expenses in advance of receipt of funding is recorded in our consolidated balance sheet as other receivables. The related costs incurred by us are included in research and development
expenses in our consolidated statements of operations and comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Government Tax Incentives </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For available government tax incentives that we may earn without regard to the existence of taxable income and that require us to forego tax
deductions or the use of future tax credits and net operating loss carryforwards, we classify the funding recognized as a reduction of the related qualifying research and development expenses incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Since the fourth quarter of 2016, our operating subsidiary in Australia has met the eligibility requirements to receive a 43.5% tax incentive
for qualifying research and development activities. We recognize these incentives as a reduction of research and development expenses in our consolidated statements of operations in the same period that the related qualifying expenses are incurred.
Reductions of research and development expense recognized upon incurring qualifying expenses in advance of receipt of tax incentive payments are recorded in our consolidated balance sheet as tax incentive receivables. Related to these incentives, we
recognized reductions of research and development expense of $1.8&nbsp;million and $0.1&nbsp;million during the years ended December&nbsp;31, 2017 and 2016, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Collaboration Agreements </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For collaboration agreements with a third party, to determine the appropriate statement of operations classification of the recognized
funding, we first assess whether the collaboration arrangement is within the scope of the accounting guidance for collaboration arrangements. If it is, we evaluate the collaborative arrangement for proper classification in the statement of
operations based on the nature of the underlying activity and we assess the payments to and from the collaborative partner. If the payments to and from the collaborative partner are not within the scope of other authoritative accounting guidance, we
base the statement of operations classification for the payments received on a reasonable, rational analogy to authoritative accounting guidance, applied in a consistent manner. Conversely, if the collaboration arrangement is not within the scope of
accounting guidance for collaboration arrangements, we assess whether the collaboration arrangement represents a vendor/customer relationship. If the collaborative arrangement does not represent a vendor/customer relationship, we then classify the
funding payments received in our statement of operations and comprehensive loss as a reduction of the related expense that is incurred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For example, in 2014, we entered into a research and development services and support
agreement with Roche and concluded that the agreements were not within the scope of the accounting guidance for collaboration arrangements. Due to the <FONT STYLE="white-space:nowrap">co-funded</FONT> nature of the payments and our assessment that
we did not have a vendor/customer relationship with Roche, we recognized the nonrefundable payments received under the agreement as a reduction to the research and development expenses incurred. We terminated our agreement with Roche in August 2016.
Related to payments received under this concluded collaboration, we recognized reductions of research and development expense of $0.9&nbsp;million and $1.5&nbsp;million during the years ended December&nbsp;31, 2016 and 2015, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Research and Development Expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development
expenses. This process involves reviewing open contracts and purchase orders, communicating with our applicable personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated
cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for services performed, on a <FONT STYLE="white-space:nowrap">pre-determined</FONT>
schedule or when contractual milestones are met; however, some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to us at
that time. We periodically confirm the accuracy of the estimates with the service providers and make adjustments if necessary. Examples of estimated accrued research and development expenses include fees paid to: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">vendors in connection with the preclinical development activities; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">CMOs in connection with the production of preclinical and clinical trial materials; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">CROs in connection with preclinical and clinical studies;&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">investigative sites in connection with clinical trials. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We base our expenses related to
preclinical studies and clinical trials on our estimates of the services received and efforts expended pursuant to quotes and contracts with multiple research institutions and CROs that conduct and manage preclinical studies and clinical trials on
our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services
provided and result in a prepayment of the expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of
services or the level of effort varies from the estimate, we adjust the accrual or prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and
timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to
our prior estimates of accrued research and development expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share-Based Compensation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Prior to the Reorganization, our former parent company, Spero Therapeutics, LLC, had granted incentive units, which we accounted for as
equity-classified awards. Subsequent to the Reorganization on June&nbsp;30, 2017, we began granting common stock options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We measure all
share-based awards granted to employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model, and we recognize compensation expense of those awards over the requisite service period, which is
generally the vesting period of the respective award. Generally, we issue awards with only service-based vesting conditions and record the expense for these awards using the straight-line method. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For share-based awards granted to <FONT STYLE="white-space:nowrap">non-employee</FONT>
consultants, we recognize compensation expense over the period during which services are rendered by such consultants until completed. At the end of each financial reporting period prior to completion of the service, the fair value of these awards
is remeasured using the then-current fair value of our common stock or common units and updated assumption inputs in the Black-Scholes option-pricing model. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Black-Scholes option-pricing model uses as inputs the fair value of our common stock or common units and assumptions we make for the
volatility of our common stock or common units, the expected term of our common stock options and incentive units, the risk-free interest rate for a period that approximates the expected term of our common stock options and incentive units, and our
expected dividend yield. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Determination of the Fair Value of Common Units and Common Stock </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As there was no public market for our common units and common stock prior to our IPO, the estimated fair value of our common units and common
stock was determined by our board of directors as of the date of each award grant, with input from management, considering our most recently available third-party valuations and our board of directors&#146; assessment of additional objective and
subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the
American Institute of Certified Public Accountants&#146; Accounting and Valuation Guide,<I>&nbsp;Valuation of Privately-Held-Company Equity Securities Issued as Compensation</I>. Our common unit and common stock valuations were prepared using the
option pricing method, or OPM, which used a market approach to estimate our enterprise value. The OPM treats the company&#146;s securities as call options on the total equity value of a company, with exercise prices based on the value thresholds at
which the allocation among the various holders of a company&#146;s securities changes. Under this method, the common stock and, prior to the Reorganization, the common units, have value only if the funds available for distribution to stockholders
exceeded the value of the preferred share liquidation preferences at the time of the liquidity event, such as a strategic sale or a merger. A discount for lack of marketability of the common units or common stock is then applied to arrive at an
indication of value for the common units or common stock. These third-party valuations were performed at various dates, which resulted in valuations of our common units of $4.08 per unit as of February&nbsp;26, 2016 and $1.95 per unit as of
March&nbsp;10, 2017, and a valuation of our common stock of $5.90 per share as of June&nbsp;30, 2017. In addition to considering the results of these third-party valuations, our board of directors considered various objective and subjective factors
to determine the fair value of our common units and common stock as of each grant date, which may be a date later than the most recent third-party valuation date, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the prices at which we sold preferred units and the superior rights and preferences of the preferred stock and preferred units relative to our common stock and common units at the time of each grant; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the progress of our research and development programs, including the status of preclinical studies and clinical trials for our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our stage of development and commercialization and our business strategy; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">external market conditions affecting the biotechnology industry, and trends within the biotechnology industry; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our financial position, including cash on hand, and our historical and forecasted performance and operating results; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the lack of an active public market for our common and preferred stock and our common units and preferred units; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the likelihood of achieving a liquidity event, such as an initial public offering or a sale of our company in light of prevailing market conditions;&nbsp;and </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the analysis of IPOs and the market performance of similar companies in the biopharmaceutical industry. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The assumptions underlying these valuations represent management&#146;s best estimates, which involve inherent uncertainties and the
application of management judgment. As a result, if factors or expected outcomes change and we use significantly different assumptions or estimates, our share-based compensation expense could be materially different. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Valuation of Derivative Liabilities </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Tranche Rights </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our
Class&nbsp;A preferred units and Class&nbsp;B preferred units provided our investors with tranche rights, which provided these investors the right to participate in subsequent offerings of Class&nbsp;A and Class&nbsp;B preferred units in the event
certain milestones were achieved. We classified each of the tranche rights as a derivative liability on our consolidated balance sheet because they met the definition of freestanding financial instruments that may require us to transfer assets upon
exercise. We remeasured to fair value of the derivative liabilities associated with the tranche rights at each reporting date, and we recognized changes in the fair value of the derivative liabilities as a component of other income (expense) in our
consolidated statement of operations and comprehensive loss. The tranche rights were settled in 2016, and we stopped recognizing changes in the fair value of the derivative liability related to the tranche rights at that time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The fair value of these derivative liabilities was determined using the probability-weighted expected return method, or PWERM, which
considered as inputs the probability and time that a milestone would be achieved, the potential fair value of our preferred stock upon the exercise of the tranche right and the risk-adjusted discount rate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Anti-Dilution Rights </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In
connection with the issuance of <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests in certain of our subsidiaries, specifically Spero Potentiator, Inc., Spero Europe, Ltd. and Spero Gyrase, Inc., we granted anti-dilution rights to the
minority investors. We classify the anti-dilution rights as derivative liabilities on our consolidated balance sheet because they are freestanding instruments that represent a conditional obligation to issue a variable number of shares. We remeasure
the derivative liabilities associated with the anti-dilution rights to fair value at each reporting date, and we recognize changes in the fair value of the derivative liabilities as a component of other income (expense) in our consolidated statement
of operations and comprehensive loss. As of December&nbsp;31, 2016, anti-dilution rights related to Spero Potentiator, Inc. were fully settled as the maximum number of shares to be issued to the minority investor had been reached in August 2016. In
May 2017, we repurchased 100% of the minority investor&#146;s outstanding shares in Spero Europe, Ltd., at which time the anti-dilution rights were settled. In periods subsequent to the settlement of any anti-dilution rights, we no longer recognize
changes in the fair value of the derivative liability related to the settled anti-dilution right. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The fair value of these derivative
liabilities was determined using a discounted cash flow model. The most significant assumption in the discounted cash flow model impacting the fair value of the anti-dilution rights is the probability that we would fund the maximum amount of
investment providing anti-dilution protection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Contingent Prepayment Option</I><B><I> </I></B><I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Bridge units issued to our investors in 2015 and 2016 contained contingent prepayment options, whereby such units were automatically
convertible into equity units sold in a subsequent round of qualified financing at a discounted rate. We classified the contingent prepayment options as derivative liabilities on our consolidated balance sheet because the bridge units were deemed to
be more akin to debt than equity and the embedded prepayment options were at a substantial discount, thus meeting the definition of derivative liabilities. We remeasured the fair value of the derivative liabilities at each reporting date, and we
recognized changes in the fair value of the derivative liabilities associated with the contingent prepayment options as a component of other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
income (expense) in our consolidated statement of operations and comprehensive loss. The contingent prepayment option associated with the bridge units issued in 2015 was settled in 2015 upon the
issuance of Class&nbsp;A preferred units. The contingent prepayment option associated with the bridge units issued in 2016 was settled in the first quarter of 2017 upon the issuance of Class&nbsp;C preferred units in March 2017.&nbsp;In periods
subsequent to the settlement of any contingent prepayment option, we no longer recognize changes in the fair value of the derivative liability related to the settled contingent prepayment option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The fair value of these derivative liabilities was determined using the PWERM, which considered as inputs the probability and time that a
subsequent round of preferred stock financing would occur and the risk-adjusted discount rate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investment Option</I><B><I> </I></B><I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our concluded collaboration agreement provided our collaboration partner with an investment option, whereby the collaboration partner could
participate in our next round of financing subsequent to April 2014 in an amount up to $2.0&nbsp;million at 90.0% of the per unit price of the related financing. We classified the investment option as a derivative liability on our consolidated
balance sheet because it met the definition of a freestanding financial instrument that may require us to transfer assets upon exercise. We remeasured the fair value of the derivative liability at each reporting date, and we recognized changes in
the fair value of the derivative liability associated with the investment option as a component of other income (expense) in our consolidated statement of operations and comprehensive loss. The subsequent financing occurred in June 2015 and our
collaboration partner elected not to exercise the investment option, which then expired. We stopped recognizing changes in the fair value of the derivative liability related to the investment option at that time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The fair value of this derivative liability was determined using the PWERM, which considered as inputs the probability and time that a
qualified round of preferred stock financing would occur and the risk-adjusted discount rate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT>
Sheet Arrangements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We did not have during the periods presented, and we do not currently have, any
<FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements, as defined in the rules and regulations of the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recently Issued and
Adopted Accounting Pronouncements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">A description of recently issued accounting pronouncements that may potentially impact our
financial position and results of operations is disclosed in Note 2 to our consolidated financial statements appearing elsewhere in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosures about Market Risks </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of March 31, 2018, we had cash, cash equivalents and marketable securities of $75.4 million, consisting of cash, corporate bonds,
commercial paper, money market accounts and U.S. government debt securities. The primary objectives of our investment activities are to preserve principal, provide liquidity and maximize income without significantly increasing risk. Our primary
exposure to market risk is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates. If market interest rates were to increase immediately and uniformly by 50 basis points, from levels as of March 31,
2018, the net fair value of our interest-sensitive marketable securities would hypothetically decline by less than $0.1 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Emerging Growth
Company Status </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Jumpstart Our Business Startups Act of 2012, or the JOBS Act, permits an &#147;emerging growth company&#148; such
as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have irrevocably elected to &#147;opt
out&#148; of this provision and, as a result, we will comply with new or revised accounting standards when they are required to be adopted by public companies that are not emerging growth companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For so long as we are an emerging growth company we expect that: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we will present in this prospectus only two years of audited financial statements, in addition to any required unaudited financial statements, with correspondingly reduced Management&#146;s Discussion and Analysis of
Financial Condition and Results of Operations disclosure; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we will avail ourselves of the exemption from the requirement to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding a supplement to the auditor&#146;s report
providing additional information about the audit and the financial statements; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we will avail ourselves of the exemption from the requirement to obtain an attestation and report from our auditors on the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley
Act;&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we will provide less extensive disclosure about our executive compensation arrangements. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We
will remain an emerging growth company for up to five years, although we will cease to be an &#147;emerging growth company&#148; upon the earliest of: (i)&nbsp;the last day of the fiscal year following the fifth anniversary of our initial public
offering, (ii)&nbsp;the last day of the first fiscal year in which our annual revenues are $1.07&nbsp;billion or more, (iii)&nbsp;the date on which we have, during the previous rolling three-year period, issued more than $1.0&nbsp;billion in <FONT
STYLE="white-space:nowrap">non-convertible</FONT> debt securities or (iv)&nbsp;the date on which we are deemed to be a &#147;large accelerated filer&#148; as defined in the Exchange Act.<B> </B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc521849_10"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are a multi-asset,
clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. Our most advanced product candidate, SPR994, is designed to be the first broad-spectrum oral
carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. Treatment with effective orally administrable antibiotics may prevent hospitalizations for serious infections and enable earlier, more convenient and cost-effective
treatment of patients after hospitalization. We also have a platform technology known as our Potentiator Platform that we believe will enable us to develop drugs that will expand the spectrum and potency of existing antibiotics, including formerly
inactive antibiotics, against Gram-negative bacteria. Our lead product candidates generated from our Potentiator Platform are two intravenous, or IV,-administered agents, SPR741 and SPR206, designed to treat MDR Gram-negative infections in the
hospital setting. In addition, we are developing SPR720, an oral antibiotic designed for the treatment of a disease called pulmonary <FONT STYLE="white-space:nowrap">non-tuberculous</FONT> mycobacterial infections, or NTM. We believe that our novel
product candidates, if successfully developed and approved, would have a meaningful patient impact and significant commercial applications for the treatment of MDR infections in both the community and hospital settings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Antibiotic-resistant bacteria are one of the largest threats to global health, and their prevalence is increasing. While the majority of
life-threatening infections historically resulting from antibiotic-resistant bacteria are acquired in the hospital setting, there is an increasing incidence of MDR pathogens in the community setting. Antibiotics used currently for first-line empiric
treatment of MDR bacterial infections suffer from significant limitations and risks, including narrow spectrums of coverage and safety and tolerability concerns, and they can be associated with serious adverse effects. In addition, there are no oral
antibiotics commercially available that can reliably be used in adults with MDR Gram-negative bacterial infections. This limits the ability of physicians to prevent hospitalizations and transition patients home from the hospital after receiving <FONT
STYLE="white-space:nowrap">IV-administered</FONT> therapy. The increasing prevalence of drug resistance and MDR Gram-negative bacteria, as well as the limitations of existing therapies and traditional drug development approaches, highlights the
critical need for novel therapies, and in particular orally administrable agents, that are capable of overcoming these obstacles to effective patient treatment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">To address the foregoing, we are developing a portfolio of novel product candidates, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I><U>Oral SPR994</U></I></B><B><I>: Novel Antibiotic with Potential to be the First Broad-Spectrum Oral Carbapenem for Use in Adults</I></B>. SPR994 is our novel oral formulation of tebipenem, a carbapenem-class
antibiotic marketed by Meiji Seika Pharma Co. Ltd., or Meiji, in Japan as Orapenem since 2009 for common pediatric infections. Carbapenems are an important class of antibiotics because they are safe and effective against drug-resistant Gram-negative
bacterial infections. Carbapenem use has increased dramatically as a result of the rising resistance to commonly used agents such as fluoroquinolones and cephalosporin antibiotics. Carbapenems are now considered as the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> for treating these resistant bacteria, but they are currently only available intravenously for such indications. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">Based on discussion from our <FONT STYLE="white-space:nowrap">pre-IND</FONT> meeting with the FDA and subject to our receiving favorable
results from our Phase 1 clinical trial of SPR994, we believe we will be able to progress directly to a pivotal Phase 3 clinical trial of SPR994 for the treatment of cUTI. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">Under a CTN, we initiated a Phase 1 dose-selection clinical trial of SPR994 in Australia in October 2017. A CTN, which is similar to an IND
in the United States, enables conduct of a clinical trial in Australia. We have received positive interim data from the Phase 1 clinical trial that we believe are supportive of advancing an immediate-release formulation of SPR994 into a pivotal
Phase 3 clinical trial in cUTI. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">During the second half of 2018, we intend to request a pre-Phase 3 meeting with the FDA to discuss the
appropriate dose and protocol for a pivotal Phase 3 clinical trial. Pending our discussions with the FDA, we expect to submit an IND and initiate a pivotal Phase 3 clinical trial of SPR994 for the treatment of cUTI around <FONT
STYLE="white-space:nowrap">year-end</FONT> 2018 in support an NDA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman"><B><I>Prior Safety and Efficacy Experience with Tebipenem in Japan </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">Our clinical strategy is supported by extensive safety data underlying tebipenem&#146;s regulatory approval in Japan and long-standing use in
Japan for common pediatric infections. Approximately 1,100 subjects, including approximately 741 adults, have been dosed with tebipenem at a range of doses in clinical and pharmacologic studies. In addition, Meiji has completed a post-market study
including 3,540 patients following the safety and tolerability of tebipenem at the approved dose. In addition, two exploratory Phase 2 trials were conducted in Japan in patients with cUTI, the first indication in which we intend to study for SPR994.
We have the rights to all the registration and post-marketing studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">In addition, we received QIDP designation from the FDA for SPR994
for the treatment of cUTI, CABP, and DFI. QIDP designation entitles us to priority review of SPR994 for regulatory approval by the FDA. The QIDP designation for SPR994, however, does not guarantee a faster development process or ensure FDA approval.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">We have global commercialization rights to SPR994, except in certain contractually specified Asian countries. We believe that our
intellectual property portfolio will provide us global protection for SPR994, including in the United States and Europe, through 2038. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I><U>Intravenous, or IV, Potentiator Platform (SPR741 and SPR206)</U></I></B><B><I>: Our Technology Designed to Treat Infections Caused by MDR Gram-Negative Bacteria in the Hospital Setting. </I></B>Our Potentiator
Platform is our novel and proprietary technology that we believe will enable us to develop drugs against Gram-negative bacteria, a subset of bacterial organisms distinguished by the presence of an outer cell membrane. Our IV Potentiator Platform
molecules are designed to treat Gram-negative bacterial infections through interactions with the bacteria&#146;s outer cell membrane either as a monotherapy or by <FONT STYLE="white-space:nowrap">co-administering</FONT> our potentiator molecules
with currently approved antibiotics, potentially making the existing antibiotics more effective by clearing a path for them to enter and kill the bacteria. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">We have two IV Potentiator Platform product candidates, SPR741 and SPR206. SPR741 is an
<FONT STYLE="white-space:nowrap">IV-administered</FONT> agent to be used in combination that has demonstrated <I>in vitro </I>the ability to expand the spectrum and increase the potency of a <FONT STYLE="white-space:nowrap">co-administered</FONT>
antibiotic. SPR206 is a direct acting <FONT STYLE="white-space:nowrap">IV-administered</FONT> agent that has demonstrated intrinsic antibacterial activity in preclinical studies. Both have demonstrated potency against Gram-negative bacteria,
including organisms identified by the CDC and the WHO as urgent and serious threats to human health. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman"><B><I>SPR741 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">The first clinical trial of SPR741 was a double-blind, placebo-controlled, ascending dose, multi-cohort trial. The trial was conducted in two
parts, a SAD and a MAD. The SAD part of the trial was a single ascending dose design, with subjects receiving one dose of SPR741. The MAD part was a multiple ascending dose design, with subjects receiving repeat dosing over a period of 14 days. In
both study parts, sequential cohorts were exposed to increasing doses of SPR741. Generally, there were no dose-related or treatment-related trends in any of the safety and tolerability endpoints for SPR741 when administered as single doses up to and
including 800 mg or multiple doses up to and including 600 mg every 8 hours for 14 days. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">Following the completion of our first clinical
trial, in late November 2017, we initiated our Phase 1b drug-drug interaction clinical trial of SPR741 in the United Kingdom. The Phase 1b trial enrolled 27 healthy volunteers to evaluate the tolerability and pharmacokinetics of SPR741 as a single
dose in combination with some commonly used beta-lactam antibiotics, including cephalosporins (ceftazidime), monobactams (aztreonam) and beta-lactams/beta-lactamase inhibitors (piperacillin/tazobactam). In this Phase 1b drug-drug interaction study,
we observed no impact on the tolerability or standalone pharmacokinetics of SPR741 or the beta-lactam drug when the two are dosed together as a single dose, supporting further development of SPR741 as a combination agent for the treatment of MDR
infections. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">We believe that our intellectual property portfolio for SPR741 will provide SPR741
protection globally, including in the United States and Europe, through 2038. Additionally, we have multiple patent applications pending for SPR206 that we believe will provide SPR206 protection globally, including in the United States and Europe,
through 2035. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman"><B><I>SPR206 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">In addition, we continue to progress the development of our direct acting Potentiator Platform molecules, exemplified by our product
candidate SPR206. In preclinical studies, SPR206 showed activity as a single agent against MDR and XDR bacterial strains, including isolates of <I>Pseudomonas aeruginosa</I>, <I>Acinetobacter baumannii</I> and carbapenem-resistant Enterobacteriaceae
in both <I>in vitro</I> and <I>in vivo</I> models of infection. We have completed a preclinical toxicology study of SPR206 in accordance with GLP requirements. Data from recent preclinical studies of SPR206 suggest a potency and safety profile for
SPR206 that may be superior to SPR741, and we believe SPR206 may have a potentially faster path to pivotal clinical trials when compared with SPR741 because SPR206 is being developed as a single agent. In May 2018, we announced preclinical
toxicology and efficacy data that we believe are sufficient for the advancement of SPR206 into clinical development. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I><U>Oral SPR720</U></I></B><B><I>: Novel Oral Antibiotic Designed for Treatment of Pulmonary <FONT STYLE="white-space:nowrap">Non-tuberculous</FONT> Mycobacterial Infections</I></B>. SPR720 is our novel orally
available product candidate designed for the treatment for NTM infection.&nbsp;Lung infections caused by NTM are rare, and occur most frequently in patients with compromised immune systems or abnormal pulmonary anatomy. Such conditions include human
immunodeficiency virus, or HIV, or respiratory conditions, such as cystic fibrosis, chronic obstructive pulmonary disease, asthma and bronchiectasis. The annual prevalence of NTM infection is increasing at an estimated rate of 8% per year. The
current treatment for NTM infection is lengthy and involves combination therapy, often including three or more antibiotics, including some, such as aminoglycosides, that are parenterally administered. None of these treatments are approved for use in
NTM infection. Treatment failure is common and is often due to poor compliance or patients&#146; inability to tolerate the regimen. Many patients experience progressive lung disease and mortality is high. We believe SPR720, if successfully
developed, has the potential to be the first oral antibiotic specifically approved for the treatment of this debilitating rare disease. <I>In vitro</I> and <I>in vivo</I> studies have demonstrated the potency of SPR720 against a range of bacteria
causing NTM infection, including both <I>Mycobacterium avium</I> complex and <I>Mycobacterium abscessus</I>, a highly resistant strain causing infections with high mortality. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">SPR720 is currently in preclinical development. We are conducting <FONT STYLE="white-space:nowrap">28-day</FONT> and <FONT
STYLE="white-space:nowrap">31-day</FONT> toxicity studies in rats and <FONT STYLE="white-space:nowrap">non-human</FONT> primates in accordance with GLP requirements. We have also observed activity as good as or better than positive controls in <I>in
vitro</I> and <I>in vivo</I> studies, including in an acute murine pneumonia model of infection caused by <I>Mycobacterium abscessus</I>. We are currently testing SPR720 in animal studies to assess activity across other pathogens of interest
including <I>Mycobacterium avium</I> and <I>M.</I> <I>kansasii</I>. We anticipate reporting data in the second half of 2018. Pending positive results, anticipated in the second half of 2018, from our ongoing preclinical studies and discussions with
the appropriate regulatory agencies, we plan to initiate a Phase 1 clinical trial of SPR720 in the first half of 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">We believe that
our intellectual property portfolio for SPR720 will provide protection globally, including in the United States and Europe, through 2033. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent
Developments </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>SPR994 Dose Selection Data Supporting Planned Pivotal Phase 3 Clinical Trial </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In July 2018, we announced positive interim data from our Phase 1 dose-selection clinical trial of SPR994 in cUTI. Based on those data, we
have identified a proposed dose for our planned pivotal Phase 3 clinical trial of SPR994 in cUTI. Based on the data received to date, administration of 300 mg (immediate-release formulation) of SPR994 three times per day (i) has been well tolerated
and free drug exposures </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in plasma and urine that have been comparable to available data for the FDA-approved dose of IV-administered ertapenem, the most commonly used carbapenem for cUTI, (ii) has shown dose linearity
of drug levels, (iii)&nbsp;suggested that SPR994 can be administered without regard to food and (iv) has not been associated with serious adverse events. At this dosing level, SPR994 has shown exposure levels that were observed in preclinical
studies to be potent against pathogens that are commonly encountered in drug-resistant cUTI, such as <I>E. coli</I> and <I>K.&nbsp;pneumoniae</I>. Additionally, based on the interim data from the Phase 1 trial, the administration of SPR994 in an
immediate-release formulation produced plasma exposure comparable to that observed with extended-release formulations. The MAD component of the Phase 1 trial is continuing to evaluate the maximum tolerated dose for SPR994 and we expect to receive
data from the MAD portion of the trial in the third quarter of 2018. We believe these interim data provide us with a sufficient basis to advance SPR994 into a pivotal Phase 3 clinical trial in cUTI at a dosage of 300 mg of SPR994 administered three
times per day. Following completion of the Phase 1 trial, we intend to request a pre-Phase 3 meeting with the FDA in the second half of 2018. Subject to our discussions with the FDA, we expect to submit an IND and initiate a pivotal Phase 3 clinical
trial of SPR994 for the treatment of cUTI around year-end 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Potentiator Platform Positive Top-Line Data for Two Product Candidates </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In May 2018, we announced data from our completed Phase 1b drug-drug interaction clinical trial of SPR741. The Phase 1b trial was designed to
assess the impact, if any, on the pharmacokinetics or tolerability of either SPR741 or the beta-lactam drug when the two are dosed together. The single-dose data indicated that the administration of beta-lactam antibiotics had no impact on the
pharmacokinetics or tolerability of SPR741. Such results provide support for the further development of SPR741 as a combination agent for the treatment of MDR infection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In May 2018, we announced results from IND-enabling studies of SPR206. SPR206 was assessed in a suite of preclinical, IND-enabling studies,
including 14-day, two species, GLP toxicology experiments, and <I>in vitro</I> and <I>in vivo</I> GLP safety pharmacology, and absorption, distribution, metabolism and excretion studies. The data, combined with earlier microbiological and <I>in
vivo</I> efficacy testing of SPR206, support SPR206&#146;s advancement as a clinical candidate for the treatment of MDR and extensively drug-resistant, or XDR, bacterial strains, including carbapenem-resistant Pseudomonas aeruginosa,
<I>Acinetobacter baumannii</I> and Enterobacteriaceae. We believe the composite data suggest that SPR206 has the potential for wide therapeutic margins in the setting of serious hospital Gram-negative infections. Moreover, data from these studies
suggest a potency and safety profile for SPR206 that may be superior to SPR741, and we believe SPR206 may have a potentially faster path to pivotal clinical trials when compared with SPR741, because SPR206 is being developed as a single agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Based on these positive results from the Phase 1b clinical trial of SPR741 and positive preclinical toxicology results for SPR206, we intend
to prioritize one of our IV Potentiator product candidates for further clinical development internally and seek partnering opportunities or other non-dilutive funding for the other candidate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Pipeline </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table sets forth our product candidates, their status and anticipated milestones. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g521849g25i47.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">We intend to progress SPR994 to a pivotal Phase 3 cUTI clinical trial after we have a <FONT STYLE="white-space:nowrap">pre-Phase</FONT> 3 meeting with the FDA to confirm that no additional clinical trials or nonclinical
studies are required prior to initiating a Phase 3 clinical trial. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our goal is to identify, develop and commercialize novel treatments for MDR bacterial infections, focusing on areas of high unmet medical need
for safe and effective antibiotic treatments. Key elements of our strategy are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Advance our lead product candidate SPR994 through clinical development and regulatory approval</I></B>. We initiated a Phase 1 dose-selection clinical trial of SPR994 in Australia in October 2017. In July 2018, we
announced positive interim data from our Phase 1 dose-selection clinical trial of SPR994 in cUTI. Based on those data, we have identified a proposed dose for our planned pivotal Phase 3 clinical trial of SPR994 in cUTI. Following completion of this
trial, and leveraging data and <FONT STYLE="white-space:nowrap">know-how</FONT> we have licensed from Meiji, we intend to request a <FONT STYLE="white-space:nowrap">pre-Phase</FONT> 3 meeting with the FDA in the second half of 2018. Subject to our
discussions with the FDA, we expect to submit an IND and initiate a pivotal Phase 3 clinical trial of SPR994 for the treatment of cUTI around <FONT STYLE="white-space:nowrap">year-end</FONT> 2018. In addition to cUTI, we believe that SPR994 has the
potential to treat other serious and life-threatening infections. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Diversify into rare orphan infectious disease markets such as NTM infection. </I></B>We believe there is a significant opportunity to develop products for underserved &#147;orphan&#148; infectious disease areas,
such as NTM infection. These markets offer the attributes of fewer branded or generic competitors as well as chronic therapy. We believe our drug candidate SPR720 has the potential to be the first oral antibiotic approved for the treatment of
pulmonary <FONT STYLE="white-space:nowrap">non-tuberculous</FONT> mycobacterial infections. We may seek to acquire other product candidates for other underserved, debilitating orphan infectious diseases. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Advance a product candidate from our IV Potentiator Platform through clinical development and regulatory
approval, either through a collaboration or with <FONT STYLE="white-space:nowrap">non-dilutive</FONT> funding (or both), and advance our other product candidates</I></B>. Both product candidates within our IV Potentiator Platform are advancing, and
we expect to bring forward one of our Potentiator Platform product candidates </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
for further clinical testing in 2018. Data from recent preclinical studies of SPR206 suggest a potency and safety profile that may be superior to SPR741, and we believe SPR206 may have a
potentially faster path to pivotal clinical trials compared with SPR741 because SPR206 is being developed as a single agent. We expect to decide which of these product candidates we will bring forward as our lead clinical Potentiator product
candidate based on these data for SPR206 and data from our recently completed Phase 1 clinical trial of SPR741. We may seek partnering opportunities or other non-dilutive funding for further clinical development of the Potentiator candidate we elect
to deprioritize. We intend to continue to advance our other product candidates, including SPR720, through preclinical and clinical development. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Maximize the value of our IV Potentiator Platform through collaborations with other pharmaceutical companies</I></B>. We may elect to pursue strategic collaborations with other pharmaceutical companies to leverage
our Potentiator Platform. We believe it may be beneficial to develop and commercialize one or more of our Potentiator product candidates through partnering opportunities. These may include global collaborations to advance the entire Potentiator
Platform, or product-specific deals pairing our product candidates with collaborators&#146; antibiotics, whether generic or novel, with the intention of enhancing those antibiotics&#146; performance and efficacy. We believe this approach will
facilitate the capital-efficient development and commercialization of our Potentiator Platform. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Continue to pursue collaborations with <FONT STYLE="white-space:nowrap">non-commercial</FONT> organizations for scientific expertise and funding support</I></B>. We have received funding support from the U.S.
National Institute of Allergy and Infectious Diseases, or NIAID, the U.S. Department of Defense, or DoD, and the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, or <FONT STYLE="white-space:nowrap">CARB-X,</FONT> a
public-private partnership funded by the Biomedical Advanced Research and Development Authority, or BARDA, within the U.S. Department of Health and Human Services. We intend to continue to collaborate with government agencies and <FONT
STYLE="white-space:nowrap">non-profit</FONT> foundations to support the development of our product candidates. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Expand our portfolio of product candidates for the treatment of MDR infections</I></B>.<B><I> </I></B>Since our inception, we have focused on identifying and developing antibiotics to treat MDR infections, and we
are using our expertise to aggressively build and expand a portfolio of product candidates for the treatment of such infections. Our management team has deep-rooted relationships in the academic, medical and corporate infectious disease community,
which provide us visibility into new and innovative therapies under development. We believe the greatest unmet medical needs for safe and effective antibiotic treatments lie among infections due to MDR bacteria, as patients with these infections
often have limited or inadequate therapeutic options, leading to high rates of mortality. The increasing prevalence of drug resistance and MDR bacteria, and the limitations of existing therapies and traditional drug development approaches, highlight
the critical need for novel therapies capable of overcoming resistance, particularly orally administrable agents. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><B></B><B><I>Establish global commercialization and marketing capabilities</I></B><B></B><I>.</I><B></B><I> </I>We have global commercialization rights to all of our product candidates, with the exception of
SPR994 in certain contractually specified Asian countries. Our management team has significant expertise in the commercialization of infectious disease treatments. Prior to joining us, members of our management team have collectively played leading
roles in the approval and launch of 11 infectious disease products. We intend to build a targeted sales force and directly commercialize our product candidates in the United States in both hospital and community settings. Outside the United States,
we intend to enter into collaborations with third parties to develop and market our product candidates in targeted geographical markets. By collaborating with companies that have an existing commercial presence and experience in such markets, we
believe we can efficiently maximize the commercial potential of our product candidates. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Problem: Antibiotics and Drug Resistance </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Antibiotic Background </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Antibiotics are drugs used to treat infections that are caused by bacteria. Prior to the introduction of the first antibiotics in the 1930s
and 1940s, bacterial infections were often fatal. Today, antibiotics are used routinely to treat and prevent infections. There are two main varieties of bacteria, Gram-negative bacteria and Gram-positive bacteria, which are distinguished by
structural differences in their cell envelope. Gram-positive bacteria are surrounded by a single lipid membrane and a thick cell wall, while Gram-negative bacteria are encircled by two lipid membranes, an inner membrane and an outer membrane, with a
thinner cell wall in between, as shown in the illustration below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g521849g86o64.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Antibiotics that target Gram-negative bacteria must be specifically designed to cross both the inner and
outer membranes to enter the bacteria. The outer membrane, with its <FONT STYLE="white-space:nowrap">LPS-containing</FONT> outer leaflet, represents a significant barrier to the entry into the bacteria by antibiotics and is a significant contributor
toward reduced potency of many agents in treating Gram-negative bacterial infections. A study of 13,796 patients in intensive care units around the world reported in 2009 that 51% of patients experienced bacterial infections, and of these patients
62% were infected by Gram-negative organisms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Antibiotics are evaluated according to several criteria, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Spectrum</I></B>. Antibiotics that are effective against a wide variety of bacteria are considered to be broad-spectrum, while those that act upon only a limited number of bacteria are considered to be
narrow-spectrum. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Potency</I></B>. Potency is the measure of the microbiological ability of an antibiotic to kill or inhibit growth of bacteria <I>in vitro</I>. Potency is commonly expressed as the minimum inhibitory concentration,
or MIC, in &micro;g/mL, which is the lowest concentration at which the drug inhibits growth of the bacteria. Antibiotics with lower MICs are considered to be more potent. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Resistance</I></B>. Antibiotic resistance refers to the inability of an antibiotic to effectively control bacterial growth. Some bacteria are naturally resistant to certain types of antibiotics. Antibiotic
resistance can also occur due to genetic mutations or changes in gene expression. There are numerous mechanisms responsible for antibiotic resistance, and resistance mechanisms are often found together and can be transferred between different
bacteria, leading to multi-drug resistance. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Growing Antibiotic Resistance in the Hospital and Community Settings </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Antibiotic resistance is one of the largest threats to global health, and resistance rates are increasing. Antibiotic resistance can affect
anyone, of any age and in any country. According to the CDC, each year in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
United States at least 2&nbsp;million people become infected with bacteria that are resistant to antibiotics, and at least 23,000 people die each year as a direct result of these infections.
Approximately 70% of the pathogens that cause these infections are resistant to at least one drug, meaning the incidence rate of serious infections is increasing and the proportion of the infections caused by MDR pathogens is increasingly seen as an
emerging threat to world health. The CDC estimates that the excess annual cost resulting from these infections in the United States is as high as $20&nbsp;billion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">According to the CDC, among all of the bacterial resistance problems, Gram-negative pathogens, which cause a majority of all bacterial
infections, are particularly worrisome because they are becoming resistant to nearly all drugs that would be considered for treatment. In February 2017, the WHO published a list of Gram-negative bacteria based on the urgency of need for new
antibiotics and highlighted a critical group of MDR Gram-negative bacteria that pose a particular threat to human health, including <I>Acinetobacter</I>, <I>Pseudomonas</I> and various Enterobacteriaceae (including <I>Klebsiella sp</I>., <I>E. coli,
Serratia and Proteus</I>). These pathogens are associated with significant mortality because the increased incidence of antibiotic resistance has limited the number of effective treatment options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">There is an acute need for new antibiotics to treat MDR bacterial infections, as few new antibiotics capable of addressing such infections
have been approved recently for commercialization or are in clinical development. Further, the majority of MDR bacterial infections historically have been acquired in the hospital setting, where they have been treated using <FONT
STYLE="white-space:nowrap">IV-administered</FONT> antibiotics. However, increasingly such infections are being acquired in the community setting, emphasizing the need for orally administrable antibiotics that can effectively treat such infections.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Solution </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Antibiotics currently
used for first-line empiric treatment of MDR bacterial infections and NTM infection suffer from significant limitations. We believe that our product candidates will overcome these limitations, as described below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>SPR994 is designed to address the lack of orally administrable antibiotics to prevent hospitalization and permit <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">IV-to-oral</FONT></FONT> switch
therapy in resistant Gram-negative infections</I></B>. Resistance to most commonly used classes of oral antibiotics, such as cephalosporins and fluoroquinolones, has increased significantly. Many of the most commonly used antibiotics for MDR
Gram-negative infections are only available in an <FONT STYLE="white-space:nowrap">IV-administered</FONT> formulation. Treatment with effective orally administrable antibiotics may prevent hospitalizations for serious infections and enable earlier,
more convenient and cost-effective treatment of patients following hospitalization. SPR994 is an orally administrable tablet that we believe has the potential, if approved, to treat such infections in both the community and hospital settings,
thereby preventing certain hospitalizations and enabling patients to transition to oral treatment. In the community setting, SPR994, if successfully developed and approved, may allow patients who develop an infection with a resistant pathogen, but
are stable enough to be treated in the community, to avoid the need for an IV catheter and even hospitalization. In the hospital setting, the lack of effective oral stepdown options results in the potential for lengthy hospital stays or the
insertion of a peripherally inserted central catheter (PICC) to facilitate administration of IV antibiotics. SPR994 may enable faster discharges, providing cost-saving advantages for the hospital and mitigating the risk of catheter-related infection
for patients. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>SPR741 and SPR206 are designed to address the decline of novel and effective
<FONT STYLE="white-space:nowrap">IV-administered</FONT> antibiotics to treat MDR Gram-negative infections in the hospital setting</I></B>. First-line IV empiric antibiotics, such as levofloxacin, ceftazidime and
<FONT STYLE="white-space:nowrap">piperacillin-tazobactam,</FONT> have experienced diminished utility as the number of bacterial strains resistant to these antibiotics in the hospital has increased. Due to gaps in the spectrum of coverage of
antibiotics currently on the market, physicians are often confronted with the need to design complicated multi-drug cocktails for patients with serious infections. We believe that SPR741 has the potential to address the need for more effective
treatments against MDR Gram-negative bacterial infections by expanding the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
spectrum and potency of existing antibiotics, including formerly inactive antibiotics. Based on results from preclinical studies to date, we believe that SPR206 has the potential to address this
need as a single agent. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>SPR720 is designed to be the first oral treatment for NTM infection where treatment failure is common and no approved therapies exist</I></B>. The current treatment for NTM infection is lengthy and involves
combination therapy, often including three or more antibiotics, including injectables. None of these combination treatments are currently approved for use in NTM infection. Treatment failure is common and is often due to poor compliance or
patients&#146; inability to tolerate the regimen. Many patients experience progressive lung disease as a result of NTM infection, and mortality rates are high, ranging from 29% to 69% within five years of diagnosis. We believe SPR720, if
successfully developed, has the potential to be the first approved oral agent for NTM infection, and it has demonstrated activity <I>in vitro</I> and <I>in vivo</I> against a range of pathogens, including <I>Mycobacterium abscessus</I>, a highly
resistant organism causing NTM infection with a high rate of mortality. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Product Candidates </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Oral SPR994 (Tebipenem Pivoxil) </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our lead product candidate, SPR994, is a broad-spectrum oral carbapenem intended for use in adults to treat MDR Gram-negative infections.
Carbapenems have been utilized for over 30 years and are considered the standard of care for many serious MDR Gram-negative bacterial infections, but to date they have only been available as <FONT STYLE="white-space:nowrap">IV-administered</FONT>
formulations. Currently, there are no commercially available oral carbapenems for use in adults, and we believe SPR994 has the potential to address this unmet need. SPR994 is an oral tablet formulation of tebipenem. Tebipenem was approved in 2009 in
Japan for sale under the name Orapenem for pediatric use in common infections. To accelerate our clinical development of SPR994, in June 2017 we signed an exclusive license to certain data and <FONT STYLE="white-space:nowrap">know-how</FONT> from
Meiji and a global pharmaceutical company, to which we refer as Global Pharma, which we intend to use to support our clinical development of SPR994. We have global commercialization rights to SPR994, except in certain contractually specified Asian
countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The FDA has designated SPR994 as a QIDP for the treatment of cUTI, CABP and DFI under the Generating Antibiotics Incentives
Now Act, or the GAIN Act, which enables priority review for regulatory approval by the FDA. If SPR994 is approved for treatment of cUTI, CABP or DFI, the QIDP designation for SPR994 will extend by an additional five years any <FONT
STYLE="white-space:nowrap">non-patent</FONT> exclusivity period awarded for SPR994 in the United States, such as a five-year New Chemical Entity, or NCE, exclusivity granted under the Drug Price Competition and Patent Term Restoration Act of 1984,
or the Hatch-Waxman Act, for a total of 10 years. In Europe, exclusivity for NCEs is 10 years (eight years for data exclusivity and an additional two years for market exclusivity), with the possibility of a
<FONT STYLE="white-space:nowrap">one-year</FONT> extension if the chemical entity is approved for use in an additional indication. Additionally, we believe that our intellectual property portfolio for SPR994, which includes multiple patent
applications pending, will provide SPR994 protection globally, including in the United States and Europe, through 2038. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B><I>Potential
Advantages of SPR994 </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We believe that the following key attributes differentiate SPR994 from other antibiotics targeting MDR
Gram-negative infections. We believe these attributes have the potential to make SPR994 a safe and effective treatment for cUTI and other serious and life-threatening infections for which we may develop SPR994. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Potential to be the first oral carbapenem in adults, if approved</I></B>. SPR994 is designed to be the first broad-spectrum oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections.
Unlike other carbapenems, which are only available as <FONT STYLE="white-space:nowrap">IV-administered</FONT> infusions, SPR994 is an orally administered tablet. Oral administration may potentially allow physicians to avoid <FONT
STYLE="white-space:nowrap">IV-administered</FONT> antibiotics for otherwise healthy or stable patients and/or allow for a reduction in costs associated with avoiding or shortening hospitalization. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Safety, antimicrobial potency, and exposure profile observed in clinical trials to date has been comparable to IV carbapenems supported by Spero clinical and preclinical studies with SPR994.</I></B> Interim data
from our Phase 1 clinical trial of SPR994 studying a dosage of 300 mg three times per day have suggested a tolerability profile and exposures in plasma and urine for SPR994 that are comparable to available data for IV-administered ertapenem given
once daily. We believe these interim data provide a strong basis for advancing this dose into a Phase 3 clinical trial. In <I>in vitro</I> studies, SPR994 displayed potent antibiotic activity against the most difficult to treat Gram-negative
bacteria, including those resistant to fluoroquinolone antibiotics, and cephalosporin-resistant bacteria producing extended spectrum beta lactamases, or ESBLs. These antibiotic-resistant bacteria are associated with poor clinical outcomes in severe
infections. Further, the potency of SPR994 against Enterobacteriaceae was observed to be similar to IV-administered ertapenem and imipenem in preclinical studies. As a result, we believe that SPR994 has the potential to be used for the treatment of
cUTI and other serious and life-threatening infections caused by resistant Gram-negative pathogens. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Targeted pharmacokinetic profile observed in Spero clinical trials and Meiji data.</I></B> A favorable pharmacokinetic profile, or ability for the drug to reach infected tissues, is an important component of
clinical viability. Meiji demonstrated oral bioavailability, or the ability of the oral therapy to reach the bloodstream, and high concentrations in relevant tissues including the urinary tract without the aid of food or any pharmacologic agent
needed to enhance these levels. Our review of interim pharmacokinetic data from our Phase 1 trial of SPR994 suggests that the data are, to date, consistent with Meiji&#146;s findings, with dose linear exposures and high oral bioavailability. These
data also indicate that SPR994 can be administered without regard to meals. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Favorable safety, efficacy and tolerability profile suggested by clinical trials of tebipenem in Japanese populations</I></B>. A granule formulation of tebipenem has been approved for use in Japan in pediatric
patients since 2009, where it has demonstrated a favorable safety and efficacy profile. Approximately 1,100 subjects have been dosed with the active pharmaceutical ingredient of SPR994, tebipenem, in clinical and pharmacologic studies during
development of this drug by Meiji and Global Pharma in Japan. This data set includes 741 adults, including 88 patients with cUTIs, the initial indication for which we plan to develop SPR994. In each case tebipenem has demonstrated a favorable
safety, pharmacokinetic and tolerability profile. In addition, Meiji has conducted a 3,540 patient post-marketing study supporting the safety and tolerability profile of tebipenem, specifically demonstrating a safety profile that aligns well with
that observed across the clinical trial program and tolerability in line with other broad spectrum oral antibiotics. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Potential to enable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">IV-to-oral</FONT></FONT> transition of antibiotic treatment to assist with reduction in hospital stays and/or eliminate the
need for hospitalization</I></B>. We believe the unique oral formulation of SPR994 may enable patients who begin <FONT STYLE="white-space:nowrap">IV-administered</FONT> treatment for ESBLs in the hospital setting to transition to oral dosing of
SPR994 either in the hospital or upon discharge for convenient home-based care. We believe that the availability and use of an oral carbapenem as a transition therapy may eliminate hospitalization or reduce the length of a patient&#146;s hospital
stay and the overall cost of care. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We believe the foregoing advantages of SPR994 also significantly differentiate SPR994
from fluoroquinolones. Fluoroquinolones are the most widely used antibiotic class in treating community and hospital Gram-negative infections, but they have encountered increasing resistance among MDR Gram-negative bacteria and are associated with
significant adverse effects. The table below reflects resistance rates in the United States in the community and hospital settings. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="30%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="30%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:89.70pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>cUTIs in the United States</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2013-2014&nbsp;</FONT></B><B><I>E.&nbsp;coli</I></B><B>&nbsp;Resistance</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:95.90pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Rates to Fluoroquinolones</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2000-2004&nbsp;</FONT></B><B><I>E.&nbsp;coli</I></B><B>&nbsp;Resistance</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:95.90pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Rates to Fluoroquinolones</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Community Setting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hospital Setting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Currently, fluoroquinolones are the most frequently selected antibiotic for empirical
urinary tract infection, or UTI, treatment in the community and hospital settings. Current UTI treatment guidelines published by the Infectious Diseases Society of America identify fluoroquinolones as an appropriate empirical therapy option. This
recommendation, however, is contingent on local resistance rates being less than 10%. The endemicity (high rates) of fluoroquinolone-resistant <I>E. coli</I> found in the United States today in the community and hospital settings based on the table
above would suggest that fluoroquinolones should not be used empirically for cUTI patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table highlights the observed
<I>in vitro</I> potency differences between SPR994 and levofloxacin, the most widely used fluoroquinolone. As shown below, SPR994 has a MIC90 value of 0.03 &micro;g/mL, which compares favorably (i.e., at or below) to the potency value obtained by
levofloxacin. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="38%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:38.25pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Compound</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B></B><I></I><B><I>E. coli</I></B><I></I><B></B><br><B>MIC<SUB STYLE="font-size:85%; vertical-align:bottom">90</SUB></B><br><B>(&micro;g&nbsp;/mL)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SPR994</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Levofloxacin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&gt;4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, the FDA has issued several warnings against the use of fluoroquinolones in certain patients. In
particular, an FDA Advisory Committee stated in November 2015 that the risk of serious side effects caused by fluoroquinolones generally outweighs the benefits for patients with acute bacterial sinusitis, acute exacerbation of chronic bronchitis and
uncomplicated UTIs. The FDA has determined that fluoroquinolones should be reserved for use in patients with these conditions who have no alternative treatment options. We believe SPR994 could become a potential alternative to oral fluoroquinolones
based on its safety and efficacy profile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Significant Market Opportunity for SPR994 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Given the observed activity of SPR994 against different bacteria, we view the market opportunity for SPR994, if approved, to be substantial,
including for the following uses: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Community setting: Treating urinary tract infections acquired in the community setting without the need for patient hospitalization. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Hospital setting: Transitioning patients hospitalized for UTIs or cUTIs to an oral therapy as they are discharged from the hospital. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">UTIs are among the most common bacterial diseases worldwide, with significant clinical and economic burden. QuintilesIMS estimates that
between 33 and 34&nbsp;million patients either visit their physician or are hospitalized for a UTI or otherwise suspected of experiencing a UTI in the United States annually. While drugs such as trimethoprim/sulfamethoxazole (Bactrim/Septra) and
fluoroquinolones (levofloxacin, ciprofloxacin) have been the primary oral options for treatment of UTIs caused by Gram-negative organisms, nearly 30% to 35% of UTIs are resistant, which has led to increased use of
<FONT STYLE="white-space:nowrap">IV-administered</FONT> therapeutics such as carbapenems. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">QuintilesIMS completed a market assessment in
August 2017 in the community and hospital settings in which it estimated that there were 11 to 12&nbsp;million patients annually who presented in the community physician&#146;s office with a UTI and 3.5 to 4.5&nbsp;million patients annually in the
hospital with a UTI in the United States alone. Of these UTIs, 10 to 11&nbsp;million are suspected to be caused by Gram-negative bacteria, and 4 to 5&nbsp;million of these patients had an infection that is resistant to or failed first-line therapy,
such as the fluoroquinolone class, or require IV therapy due to the severity of infection. Physicians in the survey reported high concern with growing fluoroquinolone resistance and lack of oral options for MDR Gram-negative infections. We believe
SPR994 is well positioned to meet the unmet need for an oral therapy for community-acquired UTI and may offer physicians an option for treating MDR UTIs while avoiding patient hospitalization. In addition, we believe SPR994 has the potential to
accelerate hospital discharge and obviate the need for continued <FONT STYLE="white-space:nowrap">IV-administered</FONT> therapy at home by transitioning discharged patients to an <FONT STYLE="white-space:nowrap">at-home</FONT> oral therapy. Our
planned pivotal Phase 3 clinical trial for SPR994 will focus on patients who suffer from a subset of UTIs called cUTIs, which affect </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approximately 4.9&nbsp;million patients in the United States annually. A significant majority of UTIs, including cUTIs, are caused by a group of MDR Gram-negative bacteria called
Enterobacteriaceae. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>SPR994 Clinical Development Program </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Based on our <FONT STYLE="white-space:nowrap">pre-IND</FONT> meeting with the FDA, we initiated a Phase 1 pharmacokinetics and safety clinical
trial of SPR994 in Australia in October 2017. We have reported positive interim data from the trial, as described below, and expect to report top-line data from the MAD portion of the trial in the third quarter of 2018. Following completion of this
trial, we intend to request a <FONT STYLE="white-space:nowrap">pre-Phase</FONT> 3 meeting with the FDA to confirm that no additional clinical trials or nonclinical studies are required prior to initiating a Phase 3 clinical trial. Subject to
feedback from the FDA, and using <FONT STYLE="white-space:nowrap">know-how</FONT> we have licensed from Meiji, we hope to obtain agreement on the clinical trial protocol in late 2018 and expect to submit an IND and initiate the pivotal Phase 3
clinical trial of SPR994 for the treatment of cUTI around <FONT STYLE="white-space:nowrap">year-end</FONT> 2018. We believe that the data from this Phase 3 trial will form the basis for the clinical trial data package that we may submit to the FDA
in support of an NDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The FDA has designated SPR994 as a QIDP for the treatment of cUTI, CABP and DFI under the GAIN Act, which enables
priority review for regulatory approval by the FDA. The QIDP designation for SPR994, however, does not guarantee a faster development process or ensure FDA approval. Further, if SPR994 is successfully developed and approved for the treatment of
cUTI, CABP or DFI, the FDA&#146;s QIDP designation for SPR994 should extend any <FONT STYLE="white-space:nowrap">non-patent</FONT> exclusivity period awarded to SPR994 in the United States for five years, such as a five-year New Chemical Entity data
exclusivity granted under the Hatch-Waxman Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our ongoing Phase 1 clinical trial of SPR994 is assessing the safety, tolerability and
pharmacokinetics of orally administered SPR994, including the impact of utilizing immediate and sustained release formulations to optimize the pharmacokinetic profile of the drug. In addition, the impact of administration in the fed and fasted state
has been evaluated. We expect to use data from the trial to refine a pharmacokinetic/pharmacodynamic model to establish an <I>in vitro/in vivo</I> relationship to support dose and schedule administration for our planned pivotal Phase 3 clinical
trial based on drug concentration and inter-patient variability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">To date, the trial has enrolled 115 healthy adult volunteers into 14 SAD
cohorts and one MAD cohort </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">evaluating an immediate-release and various extended-release formulations of SPR994 at single oral doses ranging from 100 mg to
900 mg in the SAD cohorts and repeated doses of 300 mg orally three times daily for 14 days in the MAD cohort. Interim results from the Phase 1 clinical trial have demonstrated that, to date: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Oral administration of SPR994 has been well-tolerated at all doses tested. There has been a linear increase in plasma concentration following oral administration of doses ranging from 100 mg to 900 mg of SPR994.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Administration of SPR994 following a high fat meal has not substantially altered the plasma exposure as compared with administration to volunteers in a fasted state. We believe these data indicate that SPR994 can be
administered without regard to meals. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Administration of SPR994 in an immediate-release formulation produced plasma exposure (AUC) comparable to that observed with extended-release formulations, supporting our decision to utilize an immediate-release
formulation of SPR994 in our planned pivotal Phase 3 clinical trial of SPR994. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The mean plasma free drug concentrations versus time observed following administration of SPR994 300 mg (immediate-release formulation) to healthy adult volunteers (fasted and fed) are presented in the figure below. The
mean plasma concentrations of tebipenem remain above the MIC<SUB STYLE="font-size:85%; vertical-align:bottom">90</SUB> for the relevant bacterial pathogens for &gt;50% of an 8-hour dosing interval (three-times daily administration). This exposure is
predicted to be effective as a treatment for cUTI based on preclinical pharmacodynamic models. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Tebipenem Pharmacokinetic Profile Following Administration of 300 mg of SPR994 (IR)
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>to Healthy Volunteers in the Fasted or Fed State (Mean +/- SD) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g521849g32e47.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Furthermore, the tebipenem plasma exposure (AUC<SUP STYLE="font-size:85%; vertical-align:top">0-24</SUP>) following the administration of SPR994 300 mg orally three times daily was comparable to the exposure level which
reduced infections in the Phase 2 UTI trials conducted by Meiji. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Renal elimination of tebipenem has resulted in urine concentrations that are approximately 100-fold higher than the maximum plasma free drug concentrations following the administration of 300 mg of SPR994 and in excess
of the MICs of the most prevalent urinary pathogens for greater than the 8-hour dosing interval, as presented in the figure below. We believe that this provides an added margin of exposure for the treatment of cUTI with SPR994 300 mg administered
orally three times per day. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g521849g51q40.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The tebipenem plasma free drug exposure predicted following the administration of SPR994 300 mg orally three times daily (expressed as a function of the dosing interval, tau) was comparable to that observed following
the administration of ertapenem (1g) administered intravenously every 24 hours. Since both ertapenem and tebipenem exhibit time and concentration-dependent antibacterial activity, we believe that the similar plasma free drug exposures over time
mitigate the risk of comparing the efficacy of oral tebipenem with IV-administered ertapenem in our planned pivotal Phase 3 clinical trial of SPR994. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The most common adverse event in the Phase 1 study has been diarrhea, occurring in 9/107 (8.4%) of Phase 1 subjects dosed to date with SPR994 or placebo (3:1 randomization; data remain blinded). These events have been
mild in severity and self-limited and the frequency is consistent with prior experience with Orapenem (9.5%) and other carbapenem antibiotics, including ertapenem <FONT STYLE="white-space:nowrap">(9.2-10.3%</FONT> of patients in clinical trials,
Invanz USPI). </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2/107 (1.9%) subjects dosed to date with SPR994 or placebo (3:1 randomization; data remain blinded) have
experienced a clinically significant increase in transaminase levels to 4-8 times the upper limit of normal (ULN). There have been no Hy&#146;s law cases or other evidence of drug-induced liver injury. Alanine transaminase (ALT) elevations in these
patients returned toward normal after dosing in one subject (SAD) and despite continued dosing in the other subject (MAD). As these </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
events were considered to be monitorable and reversible, no change in the Phase 1 dose escalation for SPR994 was made by the Safety Monitoring Group. Transaminase elevation is a known class
effect of carbapenem antibiotics, including Orapenem, reported as &lt;1% in clinical trials and the post-marketing surveillance study, and the data received to date for SPR994 suggest that its effect on transaminase levels is comparable to that
observed with other carbapenems in independent studies. In third-party clinical studies that did not involve a comparison of such drugs with SPR994, transaminase elevations were reported for ertapenem (8%), ceftaroline (2%) and aztreonam (10-38%)
(as reported in the LiverTox database maintained by the National Institute of Diabetes and Digestive and Kidney Diseases), as well as for doripenem (4.0%) and ceftazidime-avibactam (4.6%) (as reported in the FDA summary basis for approval of
ceftazidime-avibactam (Avycaz)). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The MAD portion of the Phase 1 clinical trial is designed to assess the safety,
tolerability and pharmacokinetics of SPR994 administered orally for 14 days to healthy volunteers (8 subjects per cohort). The initial cohort MAD received 300 mg (immediate-release formulation) orally three times per day. This dose was chosen
because, in clinical trials to date, 300 mg of SPR994 was well tolerated as a single dose, the plasma drug exposure observed with such dose was consistent with that predicted for microbial efficacy based on preclinical infection models, and such
dose was previously demonstrated to reduce infections in a Phase 2 UTI trial utilizing Orapenem tablets. Dosing of this cohort has been completed with tolerability consistent with Orapenem clinical trials and the post-marketing surveillance data
including a 3,540 patient Japanese post-marketing study. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>In vitro Activity Against MDR Enterobacteriaceae </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Results from multiple susceptibility testing studies against MDR Enterobacteriaceae demonstrate that SPR994 remained potent against strains
resistant to multiple antibiotics. In these studies, we measured the potency, or MIC, of each drug by determining the concentration of drug required to inhibit the growth of 50% and 90% of the isolate set (i.e., the MIC50 or MIC90). The graph below
depicts the <I>in vitro</I> activity of SPR994 compared to two commercially available intravenously delivered antibiotics commonly used to treat cUTI against a large number of clinical isolates, namely Invanz (ertapenem, or ETP) from Merck and
generically available imipenem, or IMI. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPR994 Activity Against Contemporary Isolates of</B><B><I> E. coli</I></B><B> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g521849g81r65.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">SPR994 has demonstrated MIC50 and MIC90 values of less than or equal to 0.015 &micro;g/mL and 0.03
&micro;g/mL, which compare favorably (i.e., at or below) to the values obtained by competitive agents ertapenem and imipenem. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Regarding a more resistant set of <I>E. coli</I> isolates, including
fluoroquinolone-resistant strains, SPR994 again showed <I>in vitro</I> activity similar to commercially available intravenously delivered drugs such as Merrem (meropenem, or MEM), and better than levofloxacin, or LVX, as shown in the graph below.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPR994 is Active Against </B><B><I>E. coli</I></B><B>, Including Fluoroquinolone-Resistant Isolates </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g521849g92g41.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">SPR994 has also shown activity in preclinical <I>in vitro</I> studies against a wide variety of
ESBL-producing <I>E. coli</I> and ESBL-producing <I>K. pneumoniae</I> strains, as highlighted in the table below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPR994 Has Potent
Activity Against A Variety of ESBL Enzymes </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B><B><I>In vitro</I></B><B> Activity of SPR994 and Comparator Antibiotics against
Clinical Isolates </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g521849g65v09.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We believe these data show the ability of orally available SPR994 to deliver similar activity to
comparative <FONT STYLE="white-space:nowrap">IV-administered</FONT> agents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Approximately 1,100 subjects have been dosed with tebipenem in clinical and pharmacologic
studies during the development of this drug by Meiji in Japan. The data set from these studies includes 741 adults, including 88 patients with cUTIs, the initial indication for which we plan to develop SPR994. In addition, there are post-marketing
outcomes data reporting the safety and efficacy of tebipenem in 3,540 pediatric patients with pneumonia, otitis media, or sinusitis. These data are consistent with the safety profile of tebipenem as established in the clinical trial. We have also
tested SPR994 <I>in vitro </I>and in animal models. We believe that nonclinical assays are generally predictive of clinical efficacy for antibiotics, particularly in the case of a well-understood class such as carbapenems. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Meiji Phase 2 Clinical Trial Data of Tebipenem in UTI </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Meiji and Global Pharma conducted two exploratory, dose-ranging Phase 2 clinical trials of tebipenem in patients with cUTI including patients
with acute pyelonephritis. These trials were conducted in Japan between 2001 and 2004. Study <FONT STYLE="white-space:nowrap">L-084</FONT> 04 (report date 2003), a multicenter open-label study to evaluate the efficacy (clinical and microbiological)
and safety (adverse events and laboratory tests) of tebipenem at doses of 100 mg administered three times daily, or TID, (Group A), 150 mg administered BID (Group B), and 150 mg administered TID (Group C), for seven days in patients with cUTI. There
were 51 adult patients, aged <FONT STYLE="white-space:nowrap">20-74</FONT> years inclusive, enrolled with 40 being evaluable for efficacy (14 in Group A; 17 in Group B; 9 in Group C). Study ME1211 (report date 2004), a multicenter, open-label study
to evaluate efficacy (early and late assessments) and safety (adverse events and laboratory tests) of tebipenem at doses of 250 mg administered BID (500 mg Group) and 300 mg administered TID (900 mg Group) for seven days in patients with UTI. There
were 37 adult patients, aged 20 to 74 years inclusive, enrolled with all being evaluable for efficacy (19 in <FONT STYLE="white-space:nowrap">500-mg</FONT> Group; 18 in <FONT STYLE="white-space:nowrap">900-mg</FONT> Group). In these studies, dosing
three times per day showed the greatest effect as compared with other dosing regimens, consistent with the interim results from our Phase&nbsp;1 clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Although the design of the Phase 2 clinical trials in Japan was different from what is recommended in FDA guidance for clinical trials in
patients with cUTI, including acute pyelonephritis, we believe these results are consistent with our plan to advance SPR994 into a pivotal Phase 3 clinical trial at a dose of 300 mg TID for the treatment of cUTI. With respect to these results, which
are summarized in the chart below, the efficacy rate refers to the proportion of subjects judged to have experienced a &#147;markedly effective&#148; or &#147;effective&#148; tebipenem dosage versus the total number of subjects tested, and the
negative conversion rate refers to the proportion of subjects with negative urine cultures versus the total number of subjects tested. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Observed Efficacy of Tebipenem in Meiji Phase 2 Trials in UTI </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="12" ALIGN="center"><B>Study <FONT STYLE="white-space:nowrap">L-084</FONT> 04</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:28.85pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Subjects</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Efficacy</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:27.95pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Rate*</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Negative</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Conversion</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:39.10pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Rate</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">300-mg</FONT> group A</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(100 mg administered TID)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">92.9</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">92.9</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">300-mg</FONT> group B</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(150 mg administered BID)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">94.1</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">94.1</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">450-mg</FONT> group C</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(150 mg administered TID)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Based on overall clinical outcome. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="12" ALIGN="center"><B>Study ME1211</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Subjects</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Early</B><br><B>Efficacy</B><br><B>Assessment*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Negative</B><br><B>Conversion</B><br><B>Rate**</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">500-mg</FONT> group A</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(250 mg administered BID)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">93.8</TD>
<TD NOWRAP VALIGN="top">%***&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">87.5</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>900 mg group B</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(300 mg administered TID)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">93.8</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">93.8</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Based on overall clinical effect at the end of therapy. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top">Early assessment, at end of therapy. For the purpose of this assessment, negative conversion rate is defined as the rate of subjects with negative urine cultures. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">&#147;Markedly effective&#148; or &#147;effective.&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Japanese Data Supporting Safety
of Tebipenem </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Tebipenem pivoxil is a prodrug that is metabolized to tebipenem, its therapeutically active form. We view the clinical
safety profile of tebipenem pivoxil established by Meiji as relevant and supportive of SPR994 because both metabolize to the active metabolite, tebipenem, in plasma. Our formulation development efforts are designed to improve target concentration
while maintaining the exposure per dose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Tebipenem pivoxil is an orally administered carbapenem, which is a <FONT
STYLE="white-space:nowrap">sub-group</FONT> of the beta-lactam class of antibiotics. The safety of tebipenem pivoxil was evaluated in approximately 1,100 subjects supporting the application for approval in Japan. In this safety data set, there are
741 adult subjects across 17 trials and 440 pediatric subjects across six trials. These 23 trials in total, included one double-blind, comparator-controlled trial in children, five open-label trials in children, five trials enrolling adult patients
(including two open-label cUTI trials), and 12 Phase 1 clinical pharmacology trials. Among the pharmacology trials, tebipenem pivoxil was studied for an effect on QT interval, and for the known effect of the pivoxil prodrug on plasma carnitine
concentrations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In these studies, tebipenem pivoxil was generally well tolerated, with an adverse event, or AE, profile comparable to
common, approved oral beta lactam antibiotics and <FONT STYLE="white-space:nowrap">IV-administered</FONT> carbapenems. The most common AEs were gastrointestinal (e.g., diarrhea, loose stools) in both children and adults, and in the Phase 3 clinical
trial of otitis media, the incidence was similar to that reported for the comparator, cefditoren (also a pivoxil prodrug), an oral cephalosporin antibiotic. No effect of the administration of tebipenem pivoxil on the prolongation of the QT interval
was observed, and the effect on plasma carnitine concentrations was reversed post treatment and not associated with AEs. A side effect seen with beta-lactam antibiotics is seizures; however, there have been no reports of inducement of seizures due
to the administration of tebipenem pivoxil in clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Meiji has reported post-marketing outcomes data reporting the safety and
efficacy of Orapenem Fine Granules 10% for Pediatric Use (tebipenem pivoxil) in pediatric patients with pneumonia, otitis media, or sinusitis. A total of 3,547 cases were enrolled into the observational study, and the analysis was conducted using
3,540 cases for which it was possible to recover the questionnaires. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">A total of 348 instances of adverse drug reactions were observed in
334 cases amongst the 3,337 cases (including 6 adult cases) used in the safety analyses, and the incidence of adverse drug reactions was 10.01% (334 cases/3,337 cases). The adverse drug reaction that occurred most frequently was &#147;diarrhea&#148;
(9.5%, 318 instances/3,337 cases). One serious drug reaction was observed of &#147;multi-organ failure&#148;. These data are consistent with the safety profile of tebipenem as established in the pediatric clinical trials and reflected in the
Orapenem product labeling in Japan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">A clinical trial evaluating the effect of tebipenem pivoxil dosing over one week on intestinal flora
was also performed. Total aerobic and anaerobic bacterial counts were evaluated. Total bacterial count was reduced by day 7 of the study in both the 100 and 200 mg TID groups. However, no additional change in bacterial count was observed on
subsequent examination days. Neither fecal <I>C. difficile</I> nor its toxin was detected in any of the subjects during or following completion of the <FONT STYLE="white-space:nowrap">7-day</FONT> dosing period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Planned Pivotal SPR994 Phase 3 Clinical Trial </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Based on our <FONT STYLE="white-space:nowrap">pre-IND</FONT> meeting with the FDA, we believe that results from our Phase 1 clinical trial of
SPR994, if favorable, together with nonclinical studies, PK/PD, and other supporting data, will be acceptable to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the FDA to allow us to commence a pivotal Phase 3 clinical trial of SPR994 under a U.S. IND. After we complete our Phase 1 clinical trial, we plan to request a
<FONT STYLE="white-space:nowrap">pre-Phase</FONT> 3 meeting with the FDA. Subject to feedback from the FDA, we expect to initiate our planned pivotal Phase 3 clinical trial of SPR994 for the treatment of cUTI around
<FONT STYLE="white-space:nowrap">year-end</FONT> 2018. Clinical trial applications will also be submitted in Europe and other regions, as needed, to support study enrollment. Our planned pivotal Phase 3 clinical trial evaluating the efficacy and
safety of SPR994 is currently designed as a double-blind, double-dummy trial to compare SPR994 with an existing standard of care antibiotic IV ertapenem in approximately 1,200 patients randomized 1:1 in each arm. In the United States, the primary
endpoint of the trial will be the combined clinical and microbiological response at the test cure with a 10% <FONT STYLE="white-space:nowrap">non-inferiority</FONT> margin versus a standard of care IV antibiotic. We intend to commence our planned
pivotal Phase 3 clinical trial with a <FONT STYLE="white-space:nowrap">lead-in</FONT> cohort with intensive pharmacokinetics sampling in order to analyze exposure prior to enrolling the majority of the Phase 3 clinical trial cohort. In this Phase 3
trial, the primary efficacy endpoint is clinical cure and microbiological eradication in the microbiological <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">intent-to-treat</FONT></FONT> population per U.S. FDA guidance for cUTI
trials. We will also assess the trial for the primary efficacy endpoint of microbiological eradiation in the microbiologically evaluable population per the European regulatory requirements, under a separate statistical analysis plan of the same
datasets. We believe this Phase 3 design also supports the key value proposition for SPR994 of demonstrating clinical equivalency of an oral versus intravenous regimen. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Following receipt of <FONT STYLE="white-space:nowrap">top-line</FONT> data from this pivotal Phase 3 clinical trial, if favorable, together
with requisite safety data, drug-drug interaction studies and other studies, we intend to submit to the FDA an NDA for SPR994 to treat cUTI, including acute pyelonephritis. These data, if positive, may also support marketing applications in other
global regions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our IV Potentiator Platform (SPR741 and SPR206) </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have two product candidates in our IV Potentiator Platform, SPR741 and SPR206 to treat Gram-negative infections in the hospital. Both have
shown <I>in vitro</I> activity against Gram-negative bacteria, including organisms identified by the CDC and the WHO as urgent and serious threats to human health. SPR741 has minimal observed antibacterial activity as a single agent and has required
combination therapy with a companion antibiotic to demonstrate antimicrobial potency. SPR741 also has demonstrated activity primarily against MDR Gram Negative organisms such as <I>Enterbacteriaceae</I> and against some strains of <I>Acinetobacter
baumannii</I> depending on its combination partner. SPR206 has shown activity as a single agent and exerted potency with and without a partner. SPR206 has also shown broad spectrum of activity including all the strains SPR741 covers, as well as
expanded coverage of carbapenem-resistant <I>Pseudomonas aeruginosa</I>, carbapenem-resistant <I>Acinetobacter baumannii</I> and carbapenem-resistant Enterobacteriaceae. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have completed a Phase 1, two part, randomized, double-blind, placebo-controlled, dose-escalation trial of SPR741. The safety and
pharmacokinetics data from this study were recently reported at the European Congress of Clinical Microbiology and Infectious Diseases congress in Madrid, Spain. The data indicated that SPR741 was generally well tolerated at single doses up to and
including 800 mg and at doses up to and including 600 mg every 8 hours for 14 days. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We initiated our Phase 1b drug-drug interaction
clinical trial of SPR741 in the United Kingdom during the fourth quarter of 2017. The Phase 1b trial enrolled 27 healthy volunteers to evaluate SPR741 as a single dose in combination with compounds from the beta-lactam class of antibiotics,
including cephalosporins (ceftazidime), monobactams (aztreonam) and beta-lactam/beta-lactamase inhibitors (piperacillin/tazobactam). The trial was designed to assess the impact, if any, on the standalone pharmacokinetics of SPR741 or the standalone
pharmacokinetics of the beta-lactam combination drug when the two are dosed together as a single dose. In this study, we observed no impact on the tolerability or standalone pharmacokinetics of SPR741 or the beta-lactam drug when the two are dosed
together as a single dose, supporting further development of SPR741 as a combination agent for the treatment of MDR infections. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We
believe that our intellectual property portfolio for SPR741, which includes multiple issued patents and patent applications pending, will provide SPR741 protection globally, including in the United States and Europe, through 2038. Additionally, we
have multiple patent applications pending for SPR206 that we believe will provide SPR206 protection globally, including in the United States and Europe, through 2035. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Advantages of our Potentiator Platform </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We believe that the following key attributes of our Potentiator Platform generally have the potential to support the clinical utility and
commercial value of our Potentiator Platform for the safe and effective treatment of serious infections: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Potential to Expand the Potency of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Standard-of-Care</FONT></FONT> Antibiotics</I></B>. We believe SPR741 and SPR206 have the potential to expand
the potency of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> antibiotics by restoring and expanding their Gram-negative activity, thereby improving therapeutic outcomes, decreasing physicians&#146;
reliance on drugs of last resort and encouraging improved antibiotic stewardship. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>SPR741 was generally well tolerated in Phase 1 and Phase 1b studies</I></B>. Data from our Phase 1 SAD and MAD clinical trial of SPR741 demonstrate SPR741 was generally well tolerated at single doses up to and
including 800 mg and at doses up to and including 600 mg every 8 hours for 14 days, as well as in combination with beta lactam antibiotics. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>SPR206 may potentially be a potent <FONT STYLE="white-space:nowrap">IV-administered</FONT> direct-acting agent</I></B>. Like SPR741, our Potentiator Platform candidate SPR206 is designed to interact with LPS to
disrupt the outer membrane. However, SPR206 is also designed to have direct antibiotic activity, while retaining potentiator activity, including activity against <I>Pseudomonas</I> and <I>Acinetobacter</I>. Data from <I>in vitro</I> and <I>in
vivo</I> GLP safety pharmacology and ADME studies and a 14-day, two-species GLP toxicology study provide evidence that SPR206 may be well-tolerated. We are developing SPR206 as a treatment for high-risk patients with suspected or known Gram-negative
infections such as carbapenem-resistant Enterobacteriaceae, or CRE, carbapenem resistant <I>Acinetobacter baumannii</I>, or CRAB, and MDR <I>Pseudomonas aeruginosa</I>, or MDR PA, to prevent mortality and reduce the length of stay in the hospital
setting. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Significant Market Opportunity for SPR741 and SPR206, including Gram-Negative IV Market </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The need for new antibiotics to treat CRE, CRAB and MDR PA is particularly acute, as together these represent among the top global threats in
infectious disease and can cause severe and often deadly infections. As such, there is an acute need for new drugs to treat MDR Gram-negative bacteria. Currently approved products are increasingly ineffective against Gram-negative bacteria due to
increasing resistance, resulting in limited treatment options for patients with MDR infections. Few new therapeutic agents have been approved or are in clinical development to treat infections caused by Gram-negative bacteria. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Acinetobacter baumannii</I> is an opportunistic bacterial pathogen primarily associated with hospital-acquired infections with between
50,000 to 80,000 infections annually in the United States and approximately 63% of isolates are MDR. Mortality rates for patients with <I>Acinetobacter baumannii</I> have been reported as high as 43%. Currently the only drugs to treat these
resistant organisms are polymyxins such as colistin, polymixyn B, or PMB, and tigecycline, or TIG, both of which have significant safety and tolerability issues. SPR206 would provide a much needed addition to the treatment of these very serious
infections. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Pseudomonas is one of the most common Gram-negative organisms in the hospital setting. Incidence ranges from 13% in UTIs and
as high as 25% in respiratory tract infections. Resistance to commonly used agents such as cephalosporins, piperacillin/tazobactam and quinolones ranges from 10% in the <FONT STYLE="white-space:nowrap">non-ICU</FONT> setting to upwards of 35% in the
ICU. In preclinical studies to date, SPR206 has demonstrated potent activity across a broad range of resistant strains of <I>Pseudomonas aeruginosa</I>. There are limited treatment options available today to treat these resistant organisms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>SPR741&#151;Phase 1 Clinical Trial and Clinical Development </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Data from our Phase 1 SAD and MAD clinical trial show SPR741 administered intravenously in single doses up to and including 800 mg and
multiple daily doses up to and including 600 mg every 8 hours for 14 days was generally well tolerated in healthy adult subjects. There were no deaths or serious adverse events. All subjects completed the study. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We initiated our Phase 1b drug-drug interaction clinical trial of SPR741 in the United
Kingdom during the fourth quarter of 2017. The Phase 1b trial enrolled 27 healthy volunteers to evaluate SPR741 as a single dose in combination with compounds from the beta-lactam class of antibiotics, including cephalosporins (ceftazidime),
monobactams (aztreonam) and beta-lactams/beta-lactamase inhibitors (piperacillin/tazobactam). The trial was designed to assess the impact, if any, on the standalone pharmacokinetics of SPR741 or the standalone pharmacokinetics of the beta-lactam
combination drug when the two are dosed together as a single dose. In this study, we observed no impact on the tolerability or standalone pharmacokinetics of SPR741 or the beta-lactam drug when the two are dosed together as a single dose, supporting
further development of SPR741 as a combination agent for the treatment of MDR infections. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our Potentiator Platform is funded in part with
<FONT STYLE="white-space:nowrap">non-dilutive</FONT> funding from the DoD and <FONT STYLE="white-space:nowrap">CARB-X,</FONT> consisting of $3.4&nbsp;million through March&nbsp;31, 2018. We have global commercialization rights to SPR741, which has
global patent protection extending through 2038. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>In Vitro Activity of SPR741 Against MDR Gram-Negative Bacteria </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Results from multiple susceptibility testing studies against suggest that SPR741 is capable of potentiating the activity of several classes of
antibiotics, including some beta-lactams and macrolides. We ascertained the potential clinical profile of combinations of SPR741 against MDR Enterobacteriaceae encountered in the hospital setting by testing the combinations against a large number of
clinical isolates collected from unique patients with different types of infections from hospitals around the world. In one such study, we measured the ability of SPR741 to enhance the activity of ceftazidime, or CAZ, or <FONT
STYLE="white-space:nowrap">piperacillin-tazobactam</FONT> (Zosyn, or TZP) against a large collection of clinical isolates expressing the drug-resistant phenotype ESBL. In each case, as shown in the graph and summarized in the table below, SPR741
potentiated the activity of the antibiotics resulting in an MIC90 shift from 256 to 8 for CAZ and from 256 to 1 for TZP. We believe that these data demonstrate SPR741&#146;s ability to restore the combined antibiotic&#146;s therapeutic activity
against a resistant strain of bacteria. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Potency of <FONT STYLE="white-space:nowrap">Piperacillin-Tazobactam</FONT> and Ceftazidime with
and without SPR741 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>in Global Set of Clinical Isolates Classified as ESBL Producers </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g521849g41w64.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MIC90 and % of Bacteria Susceptible to <FONT STYLE="white-space:nowrap">Piperacillin-Tazobactam</FONT>
and Ceftazidime </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>with and without SPR741 in Global Set of Clinical Isolates Classified as ESBL Producers </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="55.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="57%"></TD>
<TD VALIGN="bottom" WIDTH="18%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="18%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>MIC90</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:30.15pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>(mg/mL)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>%</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:47.90pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Susceptible(1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CAZ</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CAZ+SPR741</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>88</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TZP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TZP+SPR741</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>98</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Breakpoints for CAZ+SPR741 and TZP+SPR741 are defined by regulatory bodies only upon approval of NDA(s) and as such none exist today. As a surrogate, we have used the clinically approved breakpoints for CAZ and TZP to
define anticipated susceptibility for our combinations. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>SPR206&#151;Development Plan </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>In Vitro Activity of SPR206 Against MDR Gram-Negative Bacteria </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">SPR206 was assessed in a suite of non-clinical, IND-enabling studies, including 14-day, two species, GLP toxicology experiments and <I>in
vitro</I> and <I>in vivo</I> GLP safety pharmacology and ADME studies. The data suggest the potential for an acceptable safety profile and add context to earlier microbiological and <I>in vivo</I> efficacy testing of SPR206 that demonstrated potent
activity as a single agent against MDR and extensively drug-resistant (XDR) bacterial strains, including carbapenem-resistant <I>Pseudomonas aeruginosa, Acinetobacter baumannii</I>, and Enterobacteriaceae. The composite data suggest SPR206 has the
potential for wide therapeutic margins in the setting of serious hospital Gram-negative infections. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Results from multiple susceptibility
testing studies against MDR Enterobacteriaceae suggests that SPR206 is capable potent activity against MDR Enterobacteriaceae, carbapenem resistant <I>Pseudomonas aeruginosa</I> and carbapenem resistant <I>Acinetobacter baumannii</I>. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g521849g14h50.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>In vivo Activity of SPR206 against Carbapenem-Resistant Acinetobacter baumannii </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The activity of SPR206 against a carbapenem resistant strain of <I>Acinetobacter baumannii</I> exceeded the activity of polymyxin B (PMB) and
tigecycline (TIG) in a mouse lung infection model as shown below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Activity of SPR206 vs. Comparators in a Mouse Lung Infection Model </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g521849g78m75.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>SPR720 Pulmonary <FONT STYLE="white-space:nowrap">Non-Tuberculous</FONT> Mycobacterial Infection
Program </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">A third area of our focus is anti-infective disease. We are developing SPR720, a therapeutic candidate with a novel
mechanism of action for the treatment of NTM infection. SPR720 is designed to be the first novel, oral candidate to treat NTM infection. SPR720 is an orally available gyrase inhibitor. SPR720 has shown potent activity against most common NTM
infection species, such as <I>M. avium</I>, <I>M. abscessus</I> and <I>M. kansasii</I>. As shown in the exhibit below, SPR720 showed dose responsive activity against difficult to treat, multidrug resistant pathogens, with better activity as compared
to amikacin, or AMK, considered one of the positive control in this experiment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Lung Infections in Multidrug Resistant Abscessus
Strains </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g521849g40c11.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-tuberculous</FONT> mycobacteria are typically found in
water and soil. NTM cause a rare infection of the lung that is acquired through inhalation of this microbe. There are approximately 150 types of mycobacteria, with <I>Mycobacterium avium</I> complex, or MAC, and <I>Mycobacterium abscessus</I> the
most common cause of NTM infections, together comprising almost 90% of all NTM infections. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">NTM infections occur in many different types
of patients. NTM infections often occur in people with compromised immune systems, such as those with HIV, or those with respiratory conditions such as cystic fibrosis, chronic obstructive pulmonary disease, asthma or bronchiectasis. According to
Strollo et al. and Adjemian et al., the diagnosed patient population is approximately 86,000 in the United States. The annual prevalence of NTM infection is increasing at an estimated rate of 8% per year. While people of any age can be infected by
NTM, it mostly affects middle-aged to elderly adults, and is increasing among patients over 65, a population expected to nearly double by 2030. While relatively rare compared to other infectious diseases, the prevalence of NTM infection has more
than doubled since 1997. By comparison, the prevalence of tuberculosis in North America has declined. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">There are currently no <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> therapeutics indicated for NTM infections. Given the unmet medical need, there are regulatory incentives available to encourage drug development to address NTM infection. These include orphan drug
designation, potential for breakthrough therapy status and QIDP designation. The current treatment for NTM infection is lengthy and involves combination therapy, often including three or more drugs including an injectable. Treatment failure is
common and is often due to poor compliance or inability to tolerate the regimen. Many patients experience progressive lung disease and mortality is high. We believe there is a need for new, potent, orally available therapies for NTM infection. While
there are competitive compounds in late-stage development for NTM infection, these therapies are not effective in all patients and are not orally available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We believe that our intellectual property portfolio for SPR720, which includes multiple issued patents and patent applications pending, will
provide SPR720 protection globally, including in the United States and Europe, through 2033. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Our SPR720 Development Plan
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our strategy is to develop SPR720 to become the first oral treatment <FONT STYLE="white-space:nowrap">FDA-indicated</FONT> for
NTM infection, and to enable refractory patients to regain a better quality of life. SPR720 is currently in preclinical development. We have conducted <FONT STYLE="white-space:nowrap">28-day</FONT> GLP toxicity studies in rats and <FONT
STYLE="white-space:nowrap">non-human</FONT> primates, and we are waiting for the final results of these studies. We have also observed activity as good as or better than positive controls in <I>in vitro</I> and <I>in vivo</I> testing, including in
an infection model caused by <I>Mycobacterium abscessus and Mycobacterium avium</I>. Pending further evidence of <I>in vivo</I> activity and positive results from our additional toxicity studies in the second half of 2018 as well as discussions with
the appropriate regulatory agencies, we plan to initiate a Phase 1 SAD/MAD clinical trial in healthy volunteers during the first half of 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Collaboration and License Agreements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In
addition to our own patents and patent applications, we have acquired or licensed patents, patent applications and <FONT STYLE="white-space:nowrap">know-how</FONT> from various third parties to access intellectual property covering product
candidates that we are exploring and developing. We have certain obligations under these acquisition or licensing agreements, including diligence obligations and payments, that are contingent upon achieving various development, regulatory and
commercial milestones. Also, pursuant to the terms of some of these license agreements, when and if commercial sales of a product commence, we may be obligated to pay royalties to such third parties on net sales of the respective products. Some of
our license agreements include sublicenses of rights owned by third-party head licensors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Meiji Agreements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">To support our development of SPR994, in June 2017 we entered into an exclusive License Agreement with Meiji Seika Pharma Co., Ltd., or the
Meiji License. Pursuant to the Meiji License, we obtained <FONT STYLE="white-space:nowrap">know-how,</FONT> data and regulatory documents that will support the development of SPR994. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We retain exclusive rights to commercialize SPR994 throughout the world, except in Japan,
Bangladesh, Brunei, Cambodia, China, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam, where Meiji will have exclusive rights to commercialize SPR994. With Meiji, we have established a joint
development committee for the management of the development of SPR994, including any joint, cross-territory studies that may be undertaken by the parties, if any. In addition, the parties will establish a joint commercialization committee to
coordinate information sharing relative to commercialization of the new formulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Meiji and we have granted each other exclusive cross
licenses to our respective tebipenem intellectual property, including <FONT STYLE="white-space:nowrap">know-how</FONT> and regulatory documentation. The license granted to us by Meiji includes certain <FONT STYLE="white-space:nowrap">know-how</FONT>
that Meiji received from Global Pharma, as described below. As such, our rights to the Global Pharma <FONT STYLE="white-space:nowrap">know-how</FONT> component are <FONT STYLE="white-space:nowrap">non-exclusive.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under the Meiji License, we have paid Meiji a <FONT STYLE="white-space:nowrap">one-time</FONT> nonrefundable upfront fee of $0.6&nbsp;million
and are obligated to pay Meiji future clinical and regulatory milestone payments up to an aggregate of $3.0&nbsp;million and royalties of a low single-digit percentage based on net sales of SPR994. In October 2017, we paid a $1.0&nbsp;million
milestone payment to Meiji upon the enrollment of the first patient in the Company&#146;s Phase 1 clinical trial of SPR994. Additionally, we are obligated to pay Meiji a percentage of certain amounts received from any sublicensees, up to an
aggregate of $7.5&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Some of the <FONT STYLE="white-space:nowrap">know-how</FONT> that we received under the Meiji License to
support SPR994 development was originally obtained by Meiji through a license from Global Pharma, which we refer to as the head license. Prior to entering into the Meiji License with us, Meiji received written approval from Global Pharma permitting
Meiji to enter into the Meiji License with us. Specifically, in a letter agreement between Global Pharma and Meiji entered into in January 2017, Global Pharma consented to Meiji assisting us with the transfer or license of the Global Pharma <FONT
STYLE="white-space:nowrap">know-how</FONT> and Meiji <FONT STYLE="white-space:nowrap">know-how</FONT> on a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> basis outside of those Asian countries identified above, as well as certain related
matters. This letter agreement does not contemplate us having any right to sublicense the Global Pharma <FONT STYLE="white-space:nowrap">know-how.</FONT> Global Pharma retains rights to its <FONT STYLE="white-space:nowrap">know-how</FONT> outside of
those Asian countries identified above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Meiji License continues in effect until the expiration of all payment obligations thereunder
(including royalty payments and licensee revenue) on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, unless earlier terminated by the parties. Pursuant to the terms of the Meiji License, in addition to each party&#146;s right to terminate the
agreement upon the other party&#146;s material breach (if not cured within a specified period after receipt of notice) or insolvency, we also have unilateral termination rights (i)&nbsp;in the event that we abandon the development and
commercialization of SPR994 for efficacy, safety, legal or business factors, and (ii)&nbsp;under certain circumstances arising out of the head license with Global Pharma. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Potentiator Platform Agreements </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Northern
License Agreement </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In February 2015, our subsidiary, Spero Potentiator, Inc., or Spero Potentiator, entered into a license agreement,
or the 2015 Northern License Agreement, with Northern Antibiotics Oy (Ltd.) of Finland pursuant to which Northern granted to Spero Potentiator an exclusive, worldwide, perpetual and irrevocable license to develop and commercialize certain licensed
compounds under certain patents, patent applications and <FONT STYLE="white-space:nowrap">know-how</FONT> of Northern. In exchange for such exclusive license, Spero Potentiator issued an equity interest in Spero Potentiator and entered into a
subscription agreement and shareholders agreement with Northern. In June 2017, we repurchased Northern&#146;s minority equity interest in Spero Potentiator in exchange for a <FONT STYLE="white-space:nowrap">one-time</FONT> nonrefundable upfront fee
of $1.0&nbsp;million immediately and agreed to pay Northern $0.1&nbsp;million within five days of the consummation of our initial public offering, or IPO, which event occurred and which amount was paid in November 2017. We also amended and restated
the 2015 Northern License Agreement, which, as amended, we refer to as the 2017 Northern License Agreement, to include certain contingent cash payments as described below. The 2017 Northern License Agreement has a perpetual term and no express
termination rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under the 2017 Northern License Agreement, Northern granted to Spero Potentiator an
exclusive, perpetual, irrevocable, worldwide license to develop and commercialize certain licensed compounds under certain Northern patents, patent applications and <FONT STYLE="white-space:nowrap">know-how</FONT> in consideration for one or more
near-term milestone payments up to an aggregate of $2.5&nbsp;million based on either clinical milestones or the completion of our IPO, which event occurred and which amount was paid in November 2017, and in consideration for up to an aggregate of
$4.5&nbsp;million upon receipt of marketing approval of SPR741 or other compounds licensed from Northern which, in either case, is approved to be <FONT STYLE="white-space:nowrap">co-administered</FONT> with a different antibiotic agent. With
Northern, we have established a joint development committee for the exchange of information and ideas regarding development of the licensed compounds, to monitor conduct of activities and to provide and receive updates regarding new inventions. In
addition, we provide periodic reports to Northern describing the development and commercialization of the licensed compounds, including SPR741. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cantab
Agreements </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In June 2016, we entered into a stock purchase agreement, or the Cantab Agreement, with Pro Bono Bio PLC, a corporation
organized under the laws of England, and its affiliates, including PBB Distributions Limited, or PBB, Cantab Anti-Infectives Ltd., or CAI and New Pharma License Holdings Limited, or NPLH, in order to acquire NPLH and its intellectual property rights
and assets relating to our Potentiator Platform, and our next-generation potentiating agents in particular. The intellectual property portfolio we acquired includes patents which cover SPR206 as well as other novel potentiating agents, polymyxin
derivatives and other LPS or outer-membrane bacterial disrupting agents. In exchange for the acquisition of NPLH, we paid PBB upfront consideration in the amount of $0.3&nbsp;million and also agreed to pay a total of up to $5.8&nbsp;million upon the
achievement of specified clinical and regulatory milestones and to pay &pound;5.0&nbsp;million ($6.7&nbsp;million as of December&nbsp;31, 2017) upon the achievement of a specified commercial milestone. We also agreed to pay royalties of a low
single-digit percentage based on net sales of products licensed under the agreement. In addition, Spero Cantab issued an equity interest in Spero Cantab and entered into a subscription agreement and shareholders agreement with PBB. In July 2017, we
repurchased PBB&#146;s minority equity interest in Spero Cantab in exchange for a <FONT STYLE="white-space:nowrap">one-time</FONT> nonrefundable upfront fee of approximately $0.2&nbsp;million and we also amended the Cantab Agreement to increase the
contingent milestone payments to PBB by an aggregate of $0.1&nbsp;million. The Cantab Agreement continues indefinitely, with royalty payment obligations thereunder continuing on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis until the later of ten years after the
first commercial sale of such product in such country or the expiration in such country of the last to expire valid claim of any of the applicable patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, Spero holds a NIAID contract that partially funds the next-generation potentiating agent development program. That contract was
novated from CAI to Spero in December 2017. If NIAID exercises future contract options and we receive further funding from NIAID, then we will pay a portion of the proceeds to PBB pursuant to the Cantab Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Vertex Assignment and License Agreement </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In May 2016, we entered into an agreement with Vertex Pharmaceuticals Incorporated, or Vertex, pursuant to which Vertex assigned to us rights
to patents relating to SPR720 and SPR719 (an active metabolite). The acquired patent portfolio includes protection for composition of matter, method of use, and specific key intermediates used in the manufacture of SPR719 and SPR720. We also
obtained certain <FONT STYLE="white-space:nowrap">know-how</FONT> and a license to research, develop, manufacture and sell products for a proprietary compound, as well as a transfer of materials as part of the transaction. In return, we granted
Vertex an exclusive license to the assigned patents and <FONT STYLE="white-space:nowrap">know-how</FONT> for use outside of the diagnosis, treatment or prevention of bacterial infections. In exchange for the assigned patents, we paid Vertex an
upfront, <FONT STYLE="white-space:nowrap">one-time,</FONT> <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable</FONT> fee of $0.5&nbsp;million, which was recognized as research and development
expense, and we also agreed to pay Vertex future clinical, regulatory and commercial milestones up to $81.1&nbsp;million in the aggregate and a royalty on the net sales of licensed products ranging from
<FONT STYLE="white-space:nowrap">mid-single</FONT> digits to low double digits. The agreement continues in effect until the expiration of all payment obligations thereunder, with royalty payment obligations continuing on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis until the later of ten years after the first
commercial sale of such product in such country or the date of expiration in such country of the last to expire applicable patent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Further, Vertex has the right to terminate the agreement if provided with notification from us of our intent to cease all development or if no material development or commercialization efforts
occur for a period of 12 consecutive months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Awards</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As described below, we currently receive funding support of up to an aggregate of $10.4 million in non-dilutive funding from NIAID, the DoD
and CARB-X. Our Potentiator Platform program is partially funded by a $1.5 million award from the DoD and an award of $1.9 million from CARB-X. The DoD funding supports next-generation Potentiator Platform discovery and screening of SPR741 partner
antibiotics. The CARB-X award supports screening and selection of SPR741 partner antibiotics (with the exception of azithromycin) with the goal of taking one SPR741/partner combination through IND-enabling studies, culminating in the completion of a
Phase 1 clinical trial. Our NIAID award provides up to $1.0 million of support for our SPR720 program. The scope of the program includes in vitro and in vivo assessments of SPR720 against tuberculous as well as nonclinical and manufacturing
activities in support of both tuberculous and NTM indications. Finally, NIAID is providing up to $6.0 million of funding for our next-generation Potentiator Platform molecules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">These awards are structured in the following manner. Our DoD cooperative agreement is structured as a single, two-year $1.5 million award. We
are eligible for the full funding from the DoD and there are no options to be exercised at a later date. The NIAID award is structured as a base period followed by a single option. For the base period of March 1, 2017 through February 28, 2018,
NIAID committed funding of approximately $0.6 million for the SPR720 program. In February 2018 NIAID exercised the approximately $0.4 million option, which will have a period of performance from March 1, 2018 through February 28, 2019. The CARB-X
award is structured as a base period followed by two sequential options. In March 2017, CARB-X committed funds of $1.5 million to support SPR741 development efforts for the period from April 1, 2017 to March 31, 2018. On March 12, 2018, CARB-X
committed an additional $0.4 million related to the first option for a period from December 1, 2017 to March 31, 2018. There will be no additional options exercised under the CARB-X award. The NIAID and CARB-X awards are subject to termination for
convenience at any time by NIAID and CARB-X. Neither organization is obligated to provide funding to us beyond the base period amounts from Congressionally approved annual appropriations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We strive to
protect the proprietary technology that we believe is important to our business, including seeking and maintaining patents intended to cover our product candidates and compositions, their methods of use and processes for their manufacture and any
other inventions that are commercially important to the development of our business. We also rely on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our success will significantly depend on our ability to obtain and maintain patent and other proprietary protection for commercially important
technology and inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> related to our business, defend and enforce our patents, preserve the confidentiality of our trade secrets and operate without infringing the valid and enforceable
patents and proprietary rights of third parties. We also rely on <FONT STYLE="white-space:nowrap">know-how</FONT> and continuing technological innovation to develop and maintain our proprietary position. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Spero-Owned Intellectual Property Relating to SPR994 and Other Compounds Under Development </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have patent applications directed to the composition of matter, formulation and/or use of SPR994, SPR741, SPR206 and SPR720 pending in the
United States, Europe, Japan and other countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Oral Carbapenem (SPR994) </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our SPR994 program contains two pending U.S. provisional applications and one patent cooperation treaty, or PCT, application covering novel
preparations of tebipenem pivoxil as of December&nbsp;31, 2017, all wholly owned by us. The provisional patent applications will be converted to Patent Cooperation Treaty, or PCT, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applications within one year of their filing dates. U.S. and foreign patents issuing from our tebipenem pivoxil patent applications will have statutory expiration dates of December 2037 and
February 2038. Patent term adjustments or patent term extensions could result in later expiration dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Potentiator Platform (Including SPR741)
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The intellectual property portfolio for our Potentiator Platform contains patent applications and issued patents directed to
composition of matter for SPR741 and analogs thereof, composition of matter with different structural features, combinations of SPR741 or other potentiators with other anti-bacterial compounds, and methods of use for these novel compounds and
compositions. As of December&nbsp;31, 2017, we owned or were exclusively licensed eight U.S. patents and one U.S. provisional application; 94 foreign patents and nine pending foreign patent applications in a number of jurisdictions, including
Australia, Brazil, Canada, China, the European Union member states, Israel, India, Indonesia, Japan, South Korea, Mexico, New Zealand, Russia, Singapore, South Africa, and Taiwan; four pending PCT applications; and two pending U.S. provisional
patent applications directed to our Potentiator Platform. Issued U.S. or foreign patents and any patents issuing any pending U.S., foreign or PCT applications covering SPR741 will have a statutory expiration date of August 2027, February 2029, April
2037, May 2037, May 2038 and July 2038. Patent term adjustments or patent term extensions could result in later expiration dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Next-Generation
Potentiator Platform Program (Including SPR206) </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The intellectual property portfolio for our next-generation polymyxin program
contains patent applications and issued patents directed to composition of matter for polymyxin-like compounds with different structural features, pharmaceutical compositions comprising the same, and methods of use for these novel compounds and
compositions. As of December&nbsp;31, 2017, we owned one U.S. patent, three pending U.S. applications, five foreign patents and 41 pending foreign patent applications in a number of jurisdictions including Argentina, Australia, Brazil, Canada,
China, Colombia, Eurasia, the European Union, Hong Kong, Israel, Indonesia, Japan, South Korea, Mexico, Russia, Singapore, South Africa, Taiwan and Vietnam. Issued U.S. or foreign patents and any patents issuing any pending U.S., foreign or PCT
applications covering our next-generation polymyxin program will have a statutory expiration date of November 2032, May 2034, March 2035 and November 2035. Patent term adjustments or patent term extensions could result in later expiration dates.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Orphan NTM Infection Program (SPR720) </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our intellectual property portfolio for our DNA Gyrase Inhibitor program includes issued patents and pending patent applications directed to
composition of matter for SPR720, and its close analogs and prodrugs, novel solid forms of SPR720 and its prodrugs, methods of manufacture, and methods of treatment using SPR720 alone and in combination with other antibiotic compounds. All patents
and patent applications in the portfolio are wholly owned by us. As of December&nbsp;31, 2017, we owned ten issued U.S. patents, one pending U.S. patent application, 62 issued foreign patents, and 27 pending foreign patent applications. The issued
and foreign patents are in a number of jurisdictions including the European Union and its member states, Argentina, Australia, Brazil, Canada, China, Hong Kong, Indonesia, Israel, Japan, South Korea, Mexico, New Zealand, the Philippines, Russia,
Singapore, South Africa, and Taiwan. Issued U.S. and foreign patents, and patents issuing from pending U.S. and foreign applications will have statutory expiration dates of January 2032, June 2032 and July 2033. Patent term adjustments or patent
term extensions could result in later expiration dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent Term and Patent Term Extensions </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The term of individual patents depends upon the legal term for patents in the countries in which they are obtained. In most countries,
including the United States, the patent term is 20 years from the earliest filing date of a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application. In the United States, a patent&#146;s term may be lengthened by patent term
adjustment, which compensates a patentee for administrative delays by the U.S. Patent and Trademark Office in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier filed patent. The term of a
patent that covers a drug, biological product or medical device approved pursuant to a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">pre-market</FONT> approval may also be eligible for patent term extension when FDA approval is granted, provided statutory and regulatory requirements are met.
The length of the patent term extension is related to the length of time the drug is under regulatory review while the patent is in force. The Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, permits a patent
term extension of up to five years beyond the expiration date set for the patent. Patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent applicable to each
regulatory review period may be granted an extension and only those claims reading on the approved drug are extended. Similar provisions are available in Europe and other foreign jurisdictions to extend the term of a patent that covers an approved
drug. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Trade Secrets </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We
rely, in some circumstances, on trade secrets to protect our unpatented technology. However, trade secrets can be difficult to protect. We seek to protect our trade secrets and proprietary technology and processes, in part, by confidentiality
agreements with our employees, consultants, scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic
security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached. We may not have adequate remedies for any breach and could lose our trade
secrets through such a breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our consultants, contractors or collaborators use intellectual property owned by others in
their work for us, disputes may arise as to the rights in related or resulting trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> and inventions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The biopharmaceutical
industry is characterized by intense competition and rapid innovation. Our potential competitors include large pharmaceutical and biotechnology companies, specialty pharmaceutical companies and generic drug companies. Many of our potential
competitors have greater financial, technical human resources than we do, as well as greater experience in the discovery and development of product candidates, obtaining FDA and other regulatory approvals of products and the commercialization of
those products. Accordingly, our potential competitors may be more successful than us in obtaining FDA approval drugs and achieving widespread market acceptance. We anticipate that we will face intense and increasing competition as new drugs enter
the market and advanced technologies become available. Finally, the development of new treatment methods for the diseases we are targeting could render our product candidates <FONT STYLE="white-space:nowrap">non-competitive</FONT> or obsolete. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We believe the key competitive factors that will affect the development and commercial success of most advanced product candidate, SPR994, if
approved, will be efficacy, coverage of drug-resistant strains bacteria, safety and tolerability profile, reliability, convenience of oral dosing, price, availability of reimbursement from governmental and other third-party payers and susceptibility
to drug resistance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are developing SPR994 as an oral antibiotic for use as a monotherapy for the treatment of resistant and MDR
infections. If approved, SPR994 would compete with several antibiotics currently in clinical development, including <FONT STYLE="white-space:nowrap">C-Scape</FONT> from Achaogen, Inc., sulopenem from Iterum Therapeutics Limited, eravacycline from
Tetraphase Pharmaceuticals, Inc. and omadacycline from Paratek Pharmaceuticals, Inc. We also expect that SPR994, if approved, would compete with future and current generic versions of marketed antibiotics. If approved, we believe that SPR994 would
compete effectively against these compounds on the basis of SPR994&#146;s potential: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">broad range of activity against a wide variety of resistant and MDR Gram-negative bacteria; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">low probability of drug resistance; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a favorable safety and tolerability profile; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a convenient oral dosing regimen and opportunity to step-down from <FONT STYLE="white-space:nowrap">IV-administered</FONT> therapy; and </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as a monotherapy treatment for MDR Gram-negative infections. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are also developing our
Potentiator Platform, SPR741 and SPR206, as <FONT STYLE="white-space:nowrap">IV-administered</FONT> agents for Gram-negative infections in the hospital. If approved, SPR741 or our single-agent candidate SPR206 would compete with several <FONT
STYLE="white-space:nowrap">IV-administered</FONT> product candidates marketed for the treatment of Gram-negative infections, including Avycaz from Allergan plc and Pfizer Inc., Zerbaxa from Merck&nbsp;&amp; Co. and Zemdri from Achaogen, Inc. There
are also a number of <FONT STYLE="white-space:nowrap">IV-administered</FONT> product candidates in late-stage clinical development that are intended to treat Gram-negative infections, including Vabomere from Melinta Therapeutics, Inc., cefiderocol
from Shionogi&nbsp;&amp; Co. Ltd., eravacycline IV from Tetraphase Pharmaceuticals Inc. and relabactam from Merck&nbsp;&amp; Co. Each of these products and product candidates employs a mechanism of action that differs from the mechanism of action
employed by SPR741. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are developing SPR720 to be the first approved oral treatment for NTM infection. There are currently no approved
agents to treat NTM infection. Current SOC is a combination of generically available options. There is one drug in late-stage development, Arikayce from Insmed. It is an inhaled version of a commonly used drug in the hospital setting called
amikacin. If approved, it would potentially compete with SPR720. It should be noted that combination therapy is recommended for treating this condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation and Product Approval </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Government authorities in the United States, at the federal, state and local level, and in other countries, extensively regulate, among other
things, the research, development, clinical trials, testing, manufacture, including any manufacturing changes, authorization, pharmacovigilance, adverse event reporting, recalls, packaging, storage, recordkeeping, labeling, advertising, promotion,
distribution, marketing, import and export of pharmaceutical products and product candidates such as those we are developing. The processes for obtaining regulatory approvals in the United States and in foreign countries, along with subsequent
compliance with applicable statutes and regulations, require the expenditure of substantial time and financial resources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent Changes in the
Regulatory Landscape </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The FDA&#146;s Division of Anti-Infective Products, or DAIP, has undergone evolution in recent years,
primarily driven by concerns that increasingly less effective antibiotics may have been approved in the last 10 to 15 years and a desire to bring what DAIP perceives to be greater statistical rigor to their analyses. The impact of this was a
rethinking of how antibiotic efficacy is measured in clinical trials, and a review of the statistical tools used to analyze the data. In February 2015, the FDA published guidance documents for industry entitled &#147;Complicated Urinary Tract
Infections: Developing Drugs for Treatment&#148; and guidance entitled &#147;Complicated Intra-Abdominal Infections: Developing Drugs for Treatment.&#148; The purpose of these guidance documents is to address considerations surrounding the clinical
development of drugs for cUTI and cIAI indications, including clinical trial design and efficacy. Additionally, in August 2017, the FDA published a guidance document entitled &#147;Antibacterial Therapies for Patients With an Unmet Medical Need for
the Treatment of Serious Bacterial Diseases,&#148; setting forth its current thinking with respect to development programs and clinical trial designs for antibacterial drugs to treat serious bacterial diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On December&nbsp;13, 2016, President Obama signed into law the Cures Act, which is intended to accelerate medical product development.
Section&nbsp;3042 of the Cures Act establishes the limited population pathway for certain antibacterial or antifungal drugs intended to treat targeted groups of patients suffering from serious or life-threatening infections where unmet need exists.
Approvals of these limited population drugs are expected to rely on data from smaller clinical trials than would ordinarily be required by the FDA. To date, the FDA has not approved any drugs utilizing the limited population pathway. For drugs
approved through this pathway, the statement &#147;Limited Population&#148; will appear prominently next to the drug&#146;s name in labeling, which is intended to provide notice to healthcare providers that the drug is indicated for use in a limited
and specific population of patients. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Government Regulation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and implementing regulations. The
process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the
applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#146;s refusal to approve pending
NDAs, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts,
restitution, disgorgement or civil and/or criminal penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The process required by the FDA before a drug may be marketed in the United
States generally involves the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">completion of preclinical laboratory tests, animal studies and formulation studies in compliance with GLP regulations; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">submission to the FDA of an IND which must become effective before human clinical trials may begin; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approval by an independent institutional review board, or IRB, at each clinical site before each trial may be initiated; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">performance of adequate and well-controlled human clinical trials in accordance with GCP to establish the safety and efficacy of the proposed drug product for each indication; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">submission to the FDA of an NDA; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">satisfactory completion of an FDA advisory committee review, if applicable; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">satisfactory completion of an FDA <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with current good
manufacturing practices, or cGMP, and to assure that the facilities, methods and controls are adequate to preserve the drug&#146;s identity, strength, quality and purity; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">satisfactory completion of audits of clinical trial sites conducted by FDA to assure compliance with GCPs and the integrity of clinical data; and </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">payment of user fees and securing FDA review and approval of the NDA. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preclinical Studies </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Preclinical studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as animal studies to assess
potential safety and efficacy. Preclinical tests intended for submission to the FDA to support the safety of a product candidate must be conducted in compliance with GLP regulations and the United States Department of Agriculture&#146;s Animal
Welfare Act. A drug sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data and any available clinical data or literature, among other things, to the FDA as part of an IND. Some nonclinical
testing may continue even after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places
the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to
commence. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical Trials </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators
in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial along with the requirement to ensure that the data and results
reported from the clinical trials are credible and accurate. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the criteria for determining subject eligibility, the dosing plan, the parameters
to be used in monitoring safety, the procedure for timely reporting of adverse events, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of
the IND. In addition, an IRB at each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution. Information about certain clinical trials must be submitted within
specific timeframes to the NIH for public dissemination on its <I>www.clinicaltrials.gov </I>website. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Human clinical trials are typically
conducted in three sequential phases, which may overlap or be combined: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Phase 1</I></B>: The drug is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution,
excretion and, if possible, to gain an early indication of its effectiveness. During Phase 1 clinical trials, sufficient information about the investigational drug&#146;s or biological product&#146;s pharmacokinetics and pharmacological effects may
be obtained to permit the design of well-controlled and scientifically valid Phase 2 clinical trials. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Phase 2</I></B>: The drug is administered to a larger, but still limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific
targeted indications and to determine dosage tolerance and optimal dosage. Phase 2 clinical trials are typically well-controlled and closely monitored. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Phase 3</I></B>: The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically
evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product. Phase 3 clinical trials usually involve a larger number
of participants than a Phase 2 clinical trial. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Progress reports detailing the results of the clinical trials must be
submitted at least annually to the FDA and more frequently if serious adverse events occur. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. Results from one trial may not be
predictive of results from subsequent trials. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health
risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the drug has been associated with unexpected serious
harm to patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Marketing Approval </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Assuming successful completion of the required clinical testing, the results of the nonclinical studies and clinical trials, together with
detailed information relating to the product&#146;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. In most
cases, the submission of an NDA is subject to a substantial application user fee. Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#147;filing&#148; of a
standard NDA for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the NDA is submitted to FDA because the FDA has approximately two months to make a &#147;filing&#148; decision.
Furthermore, the FDA is not required to complete its review within the established <FONT STYLE="white-space:nowrap">ten-month</FONT> timeframe and may extend the review process by issuing requests for additional information or clarification. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The FDA conducts a preliminary review of all NDAs within the first 60 days after submission,
before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted
with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an <FONT STYLE="white-space:nowrap">in-depth</FONT> substantive
review. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the facilities in which it is manufactured, processed, packaged or held meet standards designed to assure the product&#146;s
continued safety, quality and purity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, under the Pediatric Research Equity Act of 2003, as amended and reauthorized, certain
NDAs or supplements to an NDA must contain data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric
subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults or
full or partial waivers from the pediatric data requirements. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The FDA also may require submission of a risk evaluation and mitigation strategy, or REMS, plan to mitigate any identified or suspected
serious risks. The REMS plan could include medication guides, physician communication plans, assessment plans, and elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including
clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it
considers such recommendations carefully when making decisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Before approving an NDA, the FDA typically will inspect the facility or
facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the
product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical trial sites to assure compliance with GCP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The FDA generally accepts data from foreign clinical trials in support of an NDA if the trials were conducted under an IND. If a foreign
clinical trial is not conducted under an IND, the FDA nevertheless may accept the data in support of an NDA if the study was conducted in accordance with GCPs and the FDA is able to validate the data through an
<FONT STYLE="white-space:nowrap">on-site</FONT> inspection, if deemed necessary. Although the FDA generally requests that marketing applications be supported by some data from domestic clinical trials, the FDA may accept foreign data as the sole
basis for marketing approval if (1)&nbsp;the foreign data are applicable to the U.S. population and U.S. medical practice, (2)&nbsp;the studies were performed by clinical investigators with recognized competence, and (3)&nbsp;the data may be
considered valid without the need for an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection or, if the FDA considers the inspection to be necessary, the FDA is able to validate the data through an
<FONT STYLE="white-space:nowrap">on-site</FONT> inspection or other appropriate means. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The testing and approval process for an NDA
requires substantial time, effort and financial resources, and each may take several years to complete. Data obtained from preclinical and clinical testing are not always conclusive and may be susceptible to varying interpretations, which could
delay, limit or prevent regulatory approval. The FDA may not grant approval on a timely basis, or at all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">After evaluating the NDA and all related information, including the advisory committee
recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter generally contains a
statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical or preclinical testing in order for FDA to reconsider the application. Even with submission of this additional
information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#146;s satisfaction, the FDA will typically issue an approval letter. An
approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Even if the
FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling , require that post-approval studies, including Phase 4 clinical
trials, be conducted to further assess a drug&#146;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other
risk management mechanisms under a REMS which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance
programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Special FDA Expedited Review and Approval Programs </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The FDA has various programs, including fast track designation, accelerated approval and priority review, that are intended to expedite or
simplify the process for the development and FDA review of drugs that are intended for the treatment of serious or life-threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these programs is
to provide important new drugs to patients earlier than under standard FDA review procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">To be eligible for a fast track
designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need, or if the drug qualifies
as a QIDP under the GAIN Act. The FDA will determine that a product will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy that may be potentially superior to existing therapy based on efficacy or safety
factors. Fast track designation provides additional opportunities for interaction with the FDA&#146;s review team and may allow for rolling review of NDA components before the completed application is submitted, if the sponsor provides a schedule
for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. The FDA may
decide to rescind the fast track designation if it determines that the qualifying criteria no longer apply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The FDA may give a priority
review designation to drugs that offer major advances in treatment for a serious condition, or provide a treatment where no adequate therapy exists. Most products that are eligible for fast track designation are also likely to be considered
appropriate to receive a priority review. A priority review means that the goal for the FDA to review an application is six months, rather than the standard review of ten months under current PDUFA guidelines. Under the current PDUFA agreement,
these six and ten-month review periods are measured from the &#147;filing&#148; date rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two months to the timeline for review and decision from the
date of submission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, products studied for their safety and effectiveness in treating serious or life-threatening illnesses
and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval, meaning that it may be approved on (i)&nbsp;the basis of adequate and well-controlled clinical trials establishing that the drug product has
an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or (ii)&nbsp;on an intermediate clinical endpoint that can be measured earlier than irreversible morbidity or </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
mortality and that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the
condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require a sponsor of a drug receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on
irreversible morbidity or mortality or other clinical endpoint, and the drug may be subject to accelerated withdrawal procedures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Moreover, under the provisions of the Food and Drug Administration Safety and Innovation Act, or FDASIA, enacted in 2012, a sponsor can
request designation of a product candidate as a &#147;breakthrough therapy.&#148; A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or
condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical
development. Drugs designated as breakthrough therapies are also eligible for accelerated approval. The FDA must take certain actions, such as holding timely meetings and providing advice, intended to expedite the development and review of an
application for approval of a breakthrough therapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Even if a product qualifies for one or more of these programs, the FDA may later
decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Post-Approval Requirements </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Drugs
manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution,
advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also
are continuing, annual program user fee requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The FDA may impose a number of post-approval requirements as a condition of
approval of an NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#146;s safety and effectiveness after commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register
their establishments with the FDA and some state agencies, and are subject to periodic unannounced inspections by the FDA for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA
approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers. Accordingly,
manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The FDA strictly regulates the marketing, labeling, advertising and promotion of drug products that are placed on the market. A product cannot
be commercially promoted before it is approved, and approved drugs may generally be promoted only for their approved indications. Promotional claims must also be consistent with the product&#146;s <FONT STYLE="white-space:nowrap">FDA-approved</FONT>
label, including claims related to safety and effectiveness. The FDA and other federal agencies also closely regulate the promotion of drugs in specific contexts such as
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising, industry-sponsored scientific and education activities, and promotional activities involving the Internet and social media. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or
if problems occur after the product reaches the market. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Later discovery of previously unknown problems with a product, including adverse events of
unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or
clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences of regulatory <FONT STYLE="white-space:nowrap">non-compliance</FONT> include, among other things: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on, or suspensions of, the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">interruption of production processes, including the shutdown of manufacturing facilities or production lines or the imposition of new manufacturing requirements; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fines, warning letters or other enforcement letters or holds on post-approval clinical trials; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product seizure or detention, or refusal to permit the import or export of products; or </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injunctions or the imposition of civil or criminal penalties. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, the distribution
of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of
drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Exclusivity and Approval of Competing Products </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Hatch-Waxman Exclusivity </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Market and data exclusivity provisions under the FDCA can delay the submission or the approval of certain applications for competing products.
The FDCA provides a five-year period of <FONT STYLE="white-space:nowrap">non-patent</FONT> data exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the
FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the activity of the drug substance. We believe that our product candidates are new chemical entities. During the
exclusivity period, the FDA may not accept for review an abbreviated new drug application, or ANDA, or a 505(b)(2) NDA submitted by another company that references the previously approved drug. However, an ANDA or 505(b)(2) NDA may be submitted
after four years if it contains a certification of patent invalidity or <FONT STYLE="white-space:nowrap">non-infringement.</FONT> The FDCA also provides three years of marketing exclusivity for an NDA, 505(b)(2) NDA, or supplement to an existing NDA
or 505(b)(2) NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant, are deemed by the FDA to be essential to the approval of the application or supplement. Three-year exclusivity
may be awarded for changes to a previously approved drug product, such as new indications, dosages, strengths or dosage forms of an existing drug. This three-year exclusivity covers only the conditions of use associated with the new clinical
investigations and, as a general matter, does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for generic versions of the original, unmodified drug product. Five-year and three-year exclusivity will not delay the submission or approval
of a full NDA; however, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and
effectiveness. For drug products that contain an &#147;antibiotic&#148; ingredient approved prior to 1997, the statute imposes certain limitations on the award of <FONT STYLE="white-space:nowrap">non-patent</FONT> exclusivity. However, we do not
believe these limitations would apply to SPR994 or any of our other investigational antibiotics. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Qualified Infectious Disease Product Exclusivity </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under the GAIN Act provisions of FDASIA, which was signed into law in July 2012, the FDA may designate a product as a qualified infectious
disease product, or QIDP. In order to receive this designation, a drug must qualify as an antibiotic or antifungal drug for human use intended to treat serious or life-threatening infections, including those caused by either (i)&nbsp;an antibiotic
or antifungal resistant pathogen, including novel or emerging infectious pathogens, or (ii)&nbsp;a <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;qualifying pathogen&#148; found on a list of potentially dangerous, drug-resistant organisms
to be established and maintained by the FDA under the new law. A sponsor must request such designation before submitting a marketing application. We obtained a QIDP designation for the oral formulation of SPR994 for cUTI in November 2016 and CABP
and DFI in April 2017, and expect to request QIDP designations for our other product candidates prior to submitting a marketing application for such product candidates, as appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Upon approving an application for a qualified infectious disease product, the FDA will extend by an additional five years any <FONT
STYLE="white-space:nowrap">non-patent</FONT> marketing exclusivity period awarded, such as a five-year exclusivity period awarded for a new molecular entity. This extension is in addition to any pediatric exclusivity extension awarded, and the
extension will be awarded only to a drug first approved on or after the date of enactment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The GAIN Act provisions prohibit the grant of
an exclusivity extension where the application is a supplement to an application for which an extension is in effect or has expired, is a subsequent application for a specified change to an approved product, or is an application for a product that
does not meet the definition of qualified infectious disease product based on the uses for which it is ultimately approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Regulation
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials
and commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we must obtain approval by the comparable regulatory authorities of foreign countries or economic areas, such as the European Union and
Australia, before we may commence clinical trials or market products in those countries or areas. The approval process and requirements governing the conduct of clinical trials, product authorization, pricing and reimbursement vary greatly from
place to place, and the time may be longer or shorter than that required for FDA approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Before clinical trials may be conducted in any
EU Member State, a sponsor must submit a clinical trial authorization application, or CTA, which must be approved in each country in which the sponsor intends to perform a clinical trial. The procedure for submitting a CTA was set forth in an
existing EU Clinical Trial Directive. However, the way clinical trials are conducted in the EU will undergo a major change when the Clinical Trial Regulation becomes effective in 2019. The Regulation harmonizes the assessment and supervision
processes for clinical trials throughout the EU, via an EU portal and database. The European Medicines Agency, or the EMA, will set up and maintain the portal and database, in collaboration with the Member States and the European Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The goal of Clinical Trial Regulation is to create an environment that is favorable to conducting clinical trials in the EU, with the highest
standards of safety for participants and increased transparency of trial information. The Regulation will require consistent rules for conducting clinical trials throughout the EU and information on the authorization, conduct and results of each
clinical trial carried out in the EU to be publicly available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">When the Regulation becomes applicable, it will replace the existing EU
Clinical Trial Directive and national legislation that was put in place to implement the Directive. It will also apply to trials authorized under the previous legislation if they are still ongoing three years after the Regulation becomes effective.
The authorization and oversight of clinical trials will remain the responsibility of Member States, with EMA managing the database and supervising content publication on the public website. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under European Union regulatory systems, a company may submit marketing authorization
applications either under a centralized or decentralized procedure. The centralized procedure is compulsory for medicinal products produced by biotechnology or those medicinal products containing new active substances for specific indications such
as the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, viral diseases and designated orphan medicines, and optional for other medicines which are highly innovative. Under the centralized procedure, a marketing application is
submitted to the European Medicines Agency where it will be evaluated by the Committee for Medicinal Products for Human Use and a favorable opinion typically results in the grant by the European Commission of a single marketing authorization that is
valid for all European Union member states within 67 days of receipt of the opinion. The initial marketing authorization is valid for five years, but once renewed is usually valid for an unlimited period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The decentralized procedure provides for approval by one or more &#147;concerned&#148; member states based on an assessment of an application
performed by one member state, known as the &#147;reference&#148; member state. Under the decentralized approval procedure, an applicant submits an application, or dossier, and related materials to the reference member state and concerned member
states. The reference member state prepares a draft assessment and drafts of the related materials within 120 days after receipt of a valid application. Within 90 days of receiving the reference member state&#146;s assessment report, each concerned
member state must decide whether to approve the assessment report and related materials. If a member state does not recognize the marketing authorization, the disputed points are eventually referred to the European Commission, whose decision is
binding on all member states. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pharmaceutical Coverage and Reimbursement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Sales of our products will depend, in part, on the availability and extent of coverage and reimbursement by third-party payors, such as
government health programs, including Medicare and Medicaid, commercial insurance and managed healthcare organizations. These third-party payors are increasingly challenging the price and limiting the coverage and reimbursement amounts for medical
products and services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The containment of healthcare costs has become a priority for federal and state governments, and the prices of
drugs have been a focus in this effort. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement,
and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and
results. Decreases in third-party reimbursement for our product candidates or a decision by a third-party payor to not cover our product candidates could reduce physician usage of the product candidate and have a material adverse effect on our
sales, results of operations and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In the United States, the federal government provides health insurance for people
who are 65 or older, and certain people with disabilities or certain conditions irrespective of their age, through the Medicare program, which is administered by the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS. Coverage and
reimbursement for products and services under Medicare are determined in accordance with the Social Security Act and pursuant to regulations promulgated by CMS, as well as the agency&#146;s coverage and reimbursement guidance and determinations.
Drugs and other products that are utilized within the hospital <FONT STYLE="white-space:nowrap">in-patient</FONT> setting are typically reimbursed under a prospective payment system, or a predetermined payment amount that is based on diagnosis
related groups, or DRGs for Medicare patients and under a bundled payment for commercially insured patients. These payment amounts differ by type of diagnoses, procedures performed and the severity of the patient&#146;s condition, among other
things. A drug that is used in a treatment or procedure under a specific DRG or bundled payment is generally not eligible for any separate payment. For catastrophic cases where costs greatly exceed the bundled payment amount, the hospital may be
eligible for an outlier payment that is intended to cover part of the expense above the standard payment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Medicaid is a health insurance program for
<FONT STYLE="white-space:nowrap">low-income</FONT> children, families, pregnant women, and people with disabilities that is jointly funded by the federal and state governments, but administered by the states. In general, state Medicaid programs are
required to cover drugs and biologicals of manufacturers that have entered into a Medicaid Drug Rebate Agreement, although such drugs and biologicals may be subject to prior authorization or other utilization controls. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The U.S. Congress and state legislatures from time to time propose and adopt initiatives aimed at cost containment, which could impact our
ability to sell our products profitably. For example, the federal Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, known collectively as the ACA, among other things, contains
provisions that may reduce the profitability of drug products through increased rebates for drugs reimbursed by Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D
beneficiaries and annual fees based on pharmaceutical companies&#146; share of sales to federal health care programs. Adoption of general controls and measures, coupled with the tightening of restrictive policies in jurisdictions with existing
controls and measures, could limit payments for pharmaceutical drugs. The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary of the Department of Health
and Human Services as a condition for states to receive federal matching funds for manufacturers&#146; outpatient drugs furnished to Medicaid patients. The ACA also expanded the universe of Medicaid utilization subject to drug rebates by requiring
pharmaceutical manufacturers to pay rebates on Medicaid managed care utilization and by enlarging the population potentially eligible for Medicaid drug benefits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA. Both Congress and President Trump
have expressed their intention to repeal or repeal and replace the ACA, and as a result certain sections of the ACA have not been fully implemented or effectively repealed. The uncertainty around the future of the ACA, and in particular the impact
to reimbursement levels, may lead to uncertainty or delay in the purchasing decisions of our customers, which may in turn negatively impact our product sales. If there are not adequate reimbursement levels, our business and results of operations
could be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be
lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, in the EU, the sole legal instrument at the EU level governing the pricing and reimbursement of medicinal products is Council Directive
89/105/EEC, or the Price Transparency Directive. The aim of this Directive is to ensure that pricing and reimbursement mechanisms established in the EU Member States are transparent and objective, do not hinder the free movement of and trade in
medicinal products in the EU, and do not hinder, prevent or distort competition on the market. The Price Transparency Directive does not provide any guidance concerning the specific criteria on the basis of which pricing and reimbursement decisions
are to be made in individual EU Member States, nor does it have any direct consequence for pricing or reimbursement levels in individual EU Member States. The EU Member States are free to restrict the range of medicinal products for which their
national health insurance systems provide reimbursement, and to control the prices and/or reimbursement levels of medicinal products for human use. An EU Member State may approve a specific price or level of reimbursement for the medicinal product,
or alternatively adopt a system of direct or indirect controls on the profitability of the company responsible for placing the medicinal product on the market, including volume-based arrangements, caps and reference pricing mechanisms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Health Technology Assessment, or HTA, of medicinal products is becoming an increasingly common part of the pricing and reimbursement
procedures in some EU Member States, including the United Kingdom, France, Germany, Ireland, Italy and Sweden. The HTA process in the EU Member States is governed by the national laws of these countries. HTA is the procedure according to which the
assessment of the public health impact, therapeutic impact, and the economic and societal impact of use of a given medicinal product in the national healthcare systems of the individual country is conducted. HTA generally focuses on the clinical
efficacy and effectiveness, safety, cost, and cost-effectiveness of individual medicinal products as well as their potential implications for the healthcare system. Those elements of medicinal products are compared with other treatment options
available on the market. The outcome of HTA regarding specific medicinal products will often </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
influence the pricing and reimbursement status granted to these medicinal products by the competent authorities of individual EU Member States. The extent to which pricing and reimbursement
decisions are influenced by the HTA of the specific medicinal product vary between EU Member States. A negative HTA of one of our products by a leading and recognized HTA body, such as the National Institute for Health and Care Excellence in the
United Kingdom, could not only undermine our ability to obtain reimbursement for such product in the EU Member State in which such negative assessment was issued, but also in other EU Member States. For example, EU Member States that have not yet
developed HTA mechanisms could rely to some extent on the HTA performed in countries with a developed HTA framework, such as the United Kingdom, when adopting decisions concerning the pricing and reimbursement of a specific medicinal product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Healthcare Laws </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Although we
currently do not have any products on the market, if our product candidates are approved and we begin commercialization, we may be subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states
and foreign jurisdictions in which we conduct our business. Such laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, privacy and security and physician sunshine laws and regulations. If our operations
are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to penalties, including, without limitation, civil and criminal penalties, damages, fines, the curtailment or restructuring of
our operations, exclusion from participation in federal and state healthcare programs and imprisonment, any of which could adversely affect our ability to operate our business and our financial results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We do not own or operate
manufacturing facilities for the production of any of our product candidates, nor do we have plans to develop our own manufacturing operations in the foreseeable future. We currently rely on a limited number of third-party contract manufacturers for
all of our required raw materials, drug substance, and finished drug product for our preclinical research and clinical trials. We currently employ internal resources to manage our manufacturing. We intend to have two suppliers for SPR994&#146;s
active pharmaceutical ingredient. Each supplier would be capable of producing kilogram quantities for commercial scale and would be able to produce over 10kg of active pharmaceutical ingredient under cGMP conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are not party to
any material legal proceedings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our headquarters are located in Cambridge, Massachusetts, where we lease approximately 7,800 square feet of office space. In January 2018, we
entered into an amendment to our Cambridge, Massachusetts facility lease. Pursuant to the amendment, we leased an additional approximately 7,800 square feet of office space in the same building. The term for the new office space is seven years from
the delivery of the expansion premises to us, which we estimate to be December&nbsp;1, 2018. In addition, the term of our existing office space lease has been extended so that it is coterminous with the new office space lease. We also sublease
approximately 7,000 square feet of laboratory space in Watertown, Massachusetts. Our sublease extends through November 2019. We believe that our existing facilities will be sufficient to meet our current needs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of June 30, 2018, we had
44 full-time employees, including a total of 13 employees with M.D. or Ph.D. degrees. 29 employees were primarily engaged in research and development activities, with the rest providing administrative, business and operations support. None of our
employees are represented by labor unions or covered by collective bargaining agreements. We consider our employee relations to be good. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc521849_11"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers, Key Employees and Directors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table provides information regarding our executive officers and directors as of the date of this prospectus: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="58%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:13.35pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Age</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:27.50pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Position</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Executive Officers:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ankit Mahadevia, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer, President and Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joel Sendek</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cristina Larkin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Operating Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Melnick, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Medical Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas Parr Jr., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Scientific Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Casper Breum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Milind Deshpande, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chairman of the Board of Directors</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jean-Fran&ccedil;ois Formela, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Southwell</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Frank Thomas</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick Vink, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B><I>Ankit Mahadevia, M.D.</I></B> has served as our Chief Executive Officer and President since March 2015 and has been a member of our
board of directors since September 2013. He <FONT STYLE="white-space:nowrap">co-founded</FONT> the Company in 2013. Prior to joining us, Dr.&nbsp;Mahadevia was a Venture Partner in the life sciences group at Atlas Venture in Cambridge,
Massachusetts, where he supported the formation of eight companies focused on novel drug discovery platforms and therapeutic products, including Synlogic Therapeutics and Translate Bio. He has led three of these companies as acting or full-time CEO.
Prior to joining Atlas Venture in 2008, Dr.&nbsp;Mahadevia worked on product and business development with the founding team at Arcion Therapeutics, Inc. He has also held positions in business development both at Genentech, Inc. and at Vanda
Pharmaceuticals Inc. Previously, he worked in the health care groups of McKinsey&nbsp;&amp; Company and Monitor Group. Dr.&nbsp;Mahadevia began his career in health care policy, with roles in the U.S. Senate Health, Education, Labor, and Pensions
committees, the U.S. Government Accountability Office and the Mexican Institute of Social Security. Dr.&nbsp;Mahadevia holds an M.D. from the Johns Hopkins School of Medicine, an M.B.A. from the Wharton School at the University of Pennsylvania and a
B.A. in Economics and Biology from Northwestern University. We believe that Dr.&nbsp;Mahadevia is qualified to serve on our board of directors due to his experience serving as our Chief Executive Officer and President and his extensive experience in
the life sciences industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B><I>Joel Sendek</I></B> has served as our Chief Financial Officer since May 2017. Mr.&nbsp;Sendek has more
than 25 years of experience in the life sciences sector, including 18 years as a senior sell-side research analyst covering biotechnology. Prior to joining us, Mr.&nbsp;Sendek was the Chief Financial Officer at Forward Pharma A/S since August 2014.
As an analyst, he served as a Managing Director at Stifel Financial Corp. from January 2012 to July 2014, where he led the firm&#146;s healthcare equity research group, and previously he was a Managing Director at Lazard Ltd. since January 2000,
where he established the firm&#146;s healthcare equity research effort. Prior to his career in equity research, Mr.&nbsp;Sendek worked as Senior Director of Corporate Development at Progenics Pharmaceuticals, Inc. and as an investment banking
analyst at Goldman, Sachs&nbsp;&amp; Co. Mr.&nbsp;Sendek holds a B.A. in Biochemistry from Rice University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B><I>Cristina Larkin</I></B>
was promoted to Chief Operating Officer as of September 2017 and had served as our Chief Commercial Officer since March 2016. Ms.&nbsp;Larkin has over 24 years of experience developing strategic commercial insights for biopharmaceutical companies
and their infectious disease products such as Avycaz, Dalvance, Teflaro, Levaquin and Floxin. Prior to joining us, Ms.&nbsp;Larkin founded CLC Insights, LLC. Prior to that, since 2004, she worked at Actavis, plc, formerly Forest Laboratories, Inc.,
where she served in various </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
positions, including Assistant Vice President from 2014 to 2015. During that time, Ms.&nbsp;Larkin led the commercial hospital antibiotic franchise team and was responsible for the U.S. launch
and execution strategy for several antibiotics. Additionally, she was a member of the business assessments and business development team and played an integral role in several strategic ventures, including the
<FONT STYLE="white-space:nowrap">out-licensing</FONT> of ceftaroline to AstraZeneca plc and the acquisition of Durata. From 1996 to 2002, Ms.&nbsp;Larkin served in various roles at Ortho-McNeil Pharmaceutical, LLC. Ms.&nbsp;Larkin received a
bachelor&#146;s degree from Florida State University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B><I>David Melnick, M.D.</I></B><I>,</I> has served as our Chief Medical Officer
since January 2018. Prior to joining us, Dr.&nbsp;Melnick served as Vice President of Clinical Development for Anti-Infectives at Allergan since 2015. In that capacity, he oversaw the development and regulatory approval of Teflaro, Avycaz, and
Dalvance in the United States. Prior to Allergan, Dr.&nbsp;Melnick served fifteen years at AstraZeneca in various levels of increasing responsibility, most recently as Vice President of Clinical Development for Anti-Infectives. In that capacity, he
oversaw the late stage clinical development of Merrem, Teflaro, and Avycaz. In addition, he served as the acting Vice President for early development at AstraZeneca. He received his medical training at Columbia University, followed by a Residency in
Internal Medicine at The New York Hospital-Cornell Medical Center. Following a Fellowship in Infectious Disease at Yale University, he held faculty positions at the Boston University School of Medicine and the National Institute of Allergy and
Infectious Diseases. He subsequently joined Kaiser-Permanente as a practicing Infectious Diseases specialist and as the Director of HIV Clinical Research at Kaiser Permanente <FONT STYLE="white-space:nowrap">Mid-Atlantic,</FONT> with a faculty
appointment at Georgetown University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B><I>Thomas Parr Jr., Ph.D.</I></B><I>,</I> has served as our Chief Scientific Officer since April
2014. He has more than 30 years of drug discovery experience across both large pharmaceutical and small biotechnology companies. Prior to joining us, from 2012 to 2014, Dr.&nbsp;Parr was the Chief Scientific Officer at Fedora Pharmaceuticals, Inc.
where the company moved novel diazabicyclooctane beta-lactramase inhibitors toward development partnerships. Prior to Fedora, he was the Chief Scientific Officer at Targanta Therapeutics, now part of The Medicines Company. Dr.&nbsp;Parr earned his
Ph.D. from the University of Calgary and conducted a postdoctoral fellowship at the University of British Columbia. He was an Assistant Professor in the Department of Microbiology and Biochemistry at the University of Ottawa before beginning his
drug discovery and development career. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B><I>Casper Breum</I></B> has served on our board of directors since June 2015. Mr.&nbsp;Breum is a Senior Partner at Lundbeckfond Ventures,
where he has been since 2009. Previously, Mr.&nbsp;Breum was Chief Executive Officer of Ilochip A/S, a venture-backed company focused on the development of diagnostic biochips. Prior to Ilochip, Mr.&nbsp;Breum held different positions at H. Lundbeck
A/S, most recently in corporate business development and strategy. While working at H. Lundbeck A/S, he was a member of the board of directors of Lundbeckfond and Lundbeckfond Invest A/S, the main shareholder of H. Lundbeck A/S and <FONT
STYLE="white-space:nowrap">ALK-Abello</FONT> A/S, as an employee representative. Mr.&nbsp;Breum is currently a member of the board of directors of Atox Bio Inc., Aura Biosciences, Inc., Dysis Medical Ltd., and Laboratoris Sanifit, S.L.
Mr.&nbsp;Breum obtained an MSc in Organic Chemistry and an M.B.A. in Management of Technology, both from the Technical University of Denmark. We believe Mr.&nbsp;Breum is qualified to serve on our board of directors because of his extensive
operational experience within the pharmaceutical industry, his experience as a chief executive officer and his experience as a venture capitalist serving on other boards of directors in the life sciences industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B><I>Milind Deshpande, Ph.D.</I></B><I>,</I> has served on our board of directors since January 2014 and currently serves as chairman of our
board of directors. Dr.&nbsp;Deshpande joined Achillion Pharmaceuticals, Inc. in September 2001 as Vice President of Chemistry, was named Head of Drug Discovery in April 2002, Senior Vice President of Drug Discovery in December 2002, Senior Vice
President and Chief Scientific Officer in December 2004 and Executive Vice President of Research and Chief Scientific Officer in June 2007. He was promoted to President of Research and Development in October 2010. In May 2013, Dr.&nbsp;Deshpande was
appointed President and Chief Executive Officer of Achillion and joined its board of directors, and continued to serve in such capacity until he stepped down in May 2018. Prior to joining Achillion, Dr.&nbsp;Deshpande was Associate Director of Lead
Discovery and Early Discovery Chemistry at the Pharmaceutical Research Institute at Bristol-Myers Squibb Co. from 1991 to 2001, where he managed the identification of new clinical candidates to treat infectious and neurological
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
diseases. From 1988 to 1991, he held a faculty position at Boston University Medical School. Dr.&nbsp;Deshpande received his Ph.D. in Organic Chemistry from Ohio University, following his
undergraduate education in India. We believe that Dr.&nbsp;Deshpande is qualified to serve on our board of directors due to his extensive experience in the life sciences industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B><I>Jean-Fran&ccedil;ois Formela, M.D.</I></B>, has served on our board of directors since March 2013. Dr.&nbsp;Formela is currently a
partner at Atlas Venture and focuses on new advances in biology and drug discovery technologies as well as novel therapeutics. Dr.&nbsp;Formela joined Atlas Venture in 1993 to build its U.S. life sciences franchise. Prior to joining Atlas, he worked
at Schering-Plough Corporation, where he directed U.S. Phase 4 clinical trials in all therapeutic areas. Before that, he was responsible for the marketing of Intron A, Schering-Plough&#146;s alpha-interferon. Dr.&nbsp;Formela began his career as a
medical doctor and practiced emergency medicine at Necker University Hospital in Paris. Dr.&nbsp;Formela serves as chair of the board of directors of IFM Therapeutics, and serves on the boards of directors of Intellia Therapeutics, <FONT
STYLE="white-space:nowrap">F-Star</FONT> Biotechnology Ltd., Kyn Therapeutics, Inc. and Translate Bio, which he <FONT STYLE="white-space:nowrap">co-founded.</FONT> Dr.&nbsp;Formela received his M.D. from Paris University School of Medicine and his
M.B.A. from Columbia University. We believe Dr.&nbsp;Formela&#146;s experience in the life sciences industry, as well as his practice of medicine, provides him with the qualifications and skills to serve as a director of our company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B><I>David Southwell </I></B>served as President and Chief Executive Officer and member of the board of directors of Inotek Pharmaceuticals
from July 2014 until its merger with Rocket Pharmaceuticals in January 2018. From March 2010 to October 2012, Mr.&nbsp;Southwell served as Executive Vice President, Chief Financial Officer of Human Genome Sciences until its merger with
GlaxoSmithKline plc. Prior to Human Genome Sciences, Mr.&nbsp;Southwell served as Executive Vice President and Chief Financial Officer of Sepracor from 1994-2008, and as an investment banker at Lehman Brothers from 1984-1986 and 1988-1994.
Mr.&nbsp;Southwell currently serves on the board of directors of PTC Therapeutics, since December 2005, and Rocket Pharmaceuticals since January 2018. He previously served on the Boards of Directors of Human Genome Sciences (2008-2010), THL Credit
(2007-2016), inVentiv Health (2016), and Biosphere Medical (1998-2010). Mr.&nbsp;Southwell received a B.A. from Rice University and an M.B.A. from the Tuck School at Dartmouth College, where he has served as head of the MBA Advisory Board and
currently serves on the Board of Overseers. We believe that Mr.&nbsp;Southwell&#146;s extensive experience building, growing and financing clinical and commercial stage organizations and his financial expertise qualifies him to serve on our board of
directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B><I>Frank Thomas</I></B> has served on our board of directors since July 2017. Mr.&nbsp;Thomas has served as Chief Financial
Officer and Chief Business Officer of Orchard Therapeutics Limited since January 2018, a development-stage biotechnology company based in the United Kingdom. Prior to Orchard, Mr.&nbsp;Thomas served as the President and Chief Operating Officer of
AMAG Pharmaceuticals, Inc., a publicly traded commercial-stage pharmaceutical company, from April 2015 to April 2017, as AMAG&#146;s Executive Vice President and Chief Operating Officer from May 2012 through April 2015 and as Executive Vice
President, Chief Financial Officer and Treasurer from August 2011 through May 2012. Prior to AMAG, he served as Senior Vice President, Chief Operating Officer and Chief Financial Officer for Molecular Biometrics, Inc., a commercial-stage medical
diagnostics company, from October 2008 to July 2011. Prior to Molecular Biometrics, Mr.&nbsp;Thomas spent four years at Critical Therapeutics, Inc., a public biopharmaceutical company, from April 2004 to March 2008, where he was promoted to
President in June 2006 and Chief Executive Officer in December 2006 from the position of Senior Vice President and Chief Financial Officer. He also served on the board of directors of Critical Therapeutics from 2006 to 2008. Prior to 2004,
Mr.&nbsp;Thomas served as the Chief Financial Officer and Vice President of Finance and Investor Relations at Esperion Therapeutics, Inc., a public biopharmaceutical company. Mr.&nbsp;Thomas was a member of the board of directors of the
Massachusetts Biotechnology Council from 2007 to 2015 and currently serves as a member of the board of directors of Zafgen, Inc., a public biopharmaceutical company, which he joined in June 2014. Mr.&nbsp;Thomas holds a B.B.A. from the University of
Michigan, Ann Arbor. We believe that Mr.&nbsp;Thomas&#146; extensive commercial and operational management experience at biopharmaceutical companies and with financial matters qualifies him to serve on our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B><I>Patrick Vink, M.D.</I></B>, has served on our board of directors since September 2015. Dr.&nbsp;Vink has been an advisor to the
pharmaceutical industry since 2015 and <FONT STYLE="white-space:nowrap">non-executive</FONT> board member of several companies. Previously, Dr.&nbsp;Vink was employed at Cubist Pharmaceuticals, Inc. Most recently he served as Executive
Vice-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
President and Chief Operating Officer, overseeing all worldwide commercial and technical operations as well as global alliance management and managing the company&#146;s profit and loss. He
joined Cubist in 2012 as Senior Vice-president and Head of all International Business Operations. In this role he was responsible for the all business activities in International markets outside USA. Prior to joining Cubist, Dr.&nbsp;Vink served as
Senior Vice President, Global Head of Hospital Business and Global Head of Biologics for Mylan Inc. In this role, Dr.&nbsp;Vink managed the global hospital business of the company. He joined Mylan in 2008 and established a number of global functions
for the company in Switzerland. Before joining Mylan, Dr.&nbsp;Vink held several leadership positions across the industry, including Head of Global Business Franchise Biopharmaceuticals for Novartis Sandoz; Vice-President International Business for
Biogen, Inc.; and Head of Worldwide Marketing, Cardiovascular and Thrombosis for Sanofi-Synth&eacute;labo SA. Dr.&nbsp;Vink served as a member of the Executive Committee of the European Federation of Pharmaceutical Industries and Associations
(EFPIA) between 2013 and 2015. Dr.&nbsp;Vink graduated as a medical doctor from the University of Leiden, Netherlands in 1988 and obtained his M.B.A. in 1992 from the University of Rochester. Dr.&nbsp;Vink serves on the boards of directors of
Concordia International Corp., Santhera Pharmaceuticals Ag., and Arch Biopartners and is Chairman of the board of directors of Targovax Oy. We believe that Dr.&nbsp;Vink is qualified to serve on our board of directors because of his extensive
operational business experience, significant knowledge of the activities of our company, and diverse background serving on the board of directors of various public and private life science companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Composition </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our board of
directors currently consists of seven members. Our nominating and corporate governance committee and our board of directors may therefore consider a broad range of factors relating to the qualifications and background of nominees, which may include
diversity, which is not only limited to race, gender or national origin. We have no formal policy regarding board diversity. Our nominating and corporate governance committee&#146;s and our board of directors&#146; priority in selecting board
members is identification of persons who will further the interests of our stockholders through his or her established record of professional accomplishment, the ability to contribute positively to the collaborative culture among board members,
knowledge of our business, understanding of the competitive landscape and professional and personal experiences and expertise relevant to our growth strategy. Our directors hold office until their successors have been elected and qualified or until
the earlier of their death, resignation or removal. Our amended and restated certificate of incorporation and amended and restated <FONT STYLE="white-space:nowrap">by-laws</FONT> also provide that our directors may be removed only for cause by the
affirmative vote of the holders of at least 75% of the votes that all our stockholders would be entitled to cast in an annual election of directors, and that any vacancy on our board of directors, including a vacancy resulting from an enlargement of
our board of directors, may be filled only by vote of a majority of our directors then in office. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Director Independence
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Rule 5605 of the Nasdaq Listing Rules requires a majority of a listed company&#146;s board of directors to be comprised of
independent directors within one year of listing. In addition, the Nasdaq Listing Rules require that, subject to specified exceptions, each member of a listed company&#146;s audit, compensation and nominating and corporate governance committees be
independent and that audit committee members also satisfy independence criteria set forth in Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Securities Exchange Act of 1934, as amended, or the Exchange Act. Under Rule 5605(a)(2), a
director will only qualify as an &#147;independent director&#148; if, in the opinion of our board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the
responsibilities of a director. In order to be considered independent for purposes of Rule <FONT STYLE="white-space:nowrap">10A-3,</FONT> a member of an audit committee of a listed company may not, other than in his or her capacity as a member of
the audit committee, the board of directors, or any other board committee, accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries or otherwise be an affiliated person of
the listed company or any of its subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our board of directors has determined that all members of our board of directors, except
Ankit Mahadevia, M.D., are independent directors, including for purposes of the rules of The Nasdaq Stock Market and relevant federal securities<B> </B>laws and regulations. There are no family relationships among any of our directors or executive
officers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Staggered Board </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In accordance with the terms of our amended and restated certificate of incorporation and amended and restated
<FONT STYLE="white-space:nowrap">by-laws,</FONT> our board of directors is divided into three staggered classes of directors of the same or nearly the same number and each director is assigned to one of the three classes. At each annual meeting of
the stockholders, a class of directors is elected for a three-year term to succeed the directors of the same class whose terms are then expiring. The terms of the directors expire upon the election and qualification of successor directors at the
annual meeting of stockholders to be held during the years 2019 for Class&nbsp;II directors, 2020 for Class&nbsp;III directors and 2021 for Class I directors: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Class&nbsp;I directors are Casper Breum and David Southwell; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Class&nbsp;II directors are Frank Thomas and Patrick Vink, M.D.; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Class&nbsp;III directors are Ankit Mahadevia, M.D., Jean-Fran&ccedil;ois Formela, M.D. and Milind Deshpande, Ph.D. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and amended and restated <FONT STYLE="white-space:nowrap">by-laws</FONT> provide that
the number of our directors shall be fixed from time to time by a resolution of the majority of our board of directors. Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so
that, as nearly as possible, each class shall consist of one third of our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The division of our board of directors into
three classes with staggered three-year terms may delay or prevent stockholder efforts to effect a change of our management or a change in control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Committees of the Board of Directors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our board of directors has an audit committee, a compensation committee and a nominating and corporate governance committee, which have the
composition and responsibilities described below. Each of the below committees has a written charter approved by our board of directors. Each of the committees reports to our board of directors as such committee deems appropriate and as our board of
directors may request. Copies of each charter are posted on the investor relations section of our website. Members serve on these committees until their resignation or until otherwise determined by our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our Audit
Committee currently has three members, Frank Thomas (Chairman), David Southwell, and Patrick Vink. Our Audit Committee&#146;s role and responsibilities are set forth in the Audit Committee&#146;s written charter and include the authority to retain
and terminate the services of our independent registered public accounting firm. In addition, the Audit Committee reviews annual financial statements, considers matters relating to accounting policy and internal controls and reviews the scope of
annual audits. All members of the Audit Committee satisfy the current independence standards promulgated by the SEC and by The Nasdaq Stock Market, as such standards apply specifically to members of audit committees. The Board has determined that
Mr.&nbsp;Thomas is an &#147;audit committee financial expert,&#148; as the Securities and Exchange Commission has defined that term in Item 407 of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> Please also see the report of the Audit
Committee set forth elsewhere in this proxy statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our Compensation Committee currently has three members, Patrick Vink (Chairman), Casper Breum, and Jean-Fran&ccedil;ois Formela. Our
Compensation Committee&#146;s role and responsibilities are set forth in the Compensation Committee&#146;s written charter and includes reviewing, approving and making recommendations regarding our compensation policies, practices and procedures to
ensure that legal and fiduciary responsibilities </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the board of directors are carried out and that such policies, practices and procedures contribute to our success. Our Compensation Committee met four times during fiscal 2017. Our
Compensation Committee also administers our Spero Therapeutics, Inc. 2017 Stock Incentive Plan, as amended, or the 2017 Plan. The Compensation Committee is responsible for the determination of the compensation of our chief executive officer, and
shall conduct its decision making process with respect to that issue without the chief executive officer present. All members of the Compensation Committee qualify as independent under the definition promulgated by The Nasdaq Stock Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and Governance Committee </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our Nominating and Corporate Governance Committee (&#147;Nominating Committee&#148;) did not meet during fiscal 2017 and has three members,
Milind Deshpande (Chairman), Jean-Fran&ccedil;ois Formela, and Frank Thomas. Our board of directors has determined that all members of the Nominating Committee qualify as independent under the definition promulgated by The Nasdaq Stock Market. The
Nominating Committee&#146;s responsibilities are set forth in the Nominating Committee&#146;s written charter and include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">identifying and recommending candidates for membership on our board of directors; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recommending directors to serve on board committees; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and recommending our corporate governance guidelines and policies; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing proposed waivers of the code of conduct for directors and executive officers; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">evaluating, and overseeing the process of evaluating, the performance of our board of directors and individual directors; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">assisting our board of directors on corporate governance matters. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Generally, our Nominating
Committee considers candidates recommended by stockholders as well as from other sources such as other directors or officers, third party search firms or other appropriate sources. Once identified, the Nominating Committee will evaluate a
candidate&#146;s qualifications in accordance with the criteria set forth in our Corporate Governance Guidelines. Our Nominating Committee has not adopted a formal diversity policy in connection with the consideration of director nominations or the
selection of nominees. However, the Nominating Committee will consider issues of diversity among its members in identifying and considering nominees for director, and strive where appropriate to achieve a diverse balance of backgrounds,
perspectives, experience, age, gender, ethnicity and country of citizenship on the board and its committees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Leadership Structure and Risk
Oversight </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company&#146;s Board of Directors is currently chaired by Milind Deshpande, Ph.D. As a general policy, our board of
directors believes that separation of the positions of chairman and chief executive officer reinforces the independence of our board of directors from management, creates an environment that encourages objective oversight of management&#146;s
performance and enhances the effectiveness of our board of directors as a whole. As such, Dr.&nbsp;Mahadevia serves as our Chief Executive Officer while Dr.&nbsp;Deshpande serves as the chairman of our board of directors but is not an officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our board of directors oversees the management of risks inherent in the operation of our business and the implementation of our business
strategies. Our board of directors performs this oversight role by using several different levels of review. In connection with its reviews of the operations and corporate functions of our company, our board of directors addresses the primary risks
associated with those operations and corporate functions. In addition, our board of directors reviews the risks associated with the Company&#146;s business strategies periodically throughout the year as part of its consideration of undertaking any
such business strategies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Each of our board committees also oversees the management of the Company&#146;s risk that falls within the
committee&#146;s areas of responsibility. In performing this function, each committee has full access to management, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
as well as the ability to engage advisors. Our Chief Executive Officer reports to the Audit Committee and is responsible for identifying, evaluating and implementing risk management controls and
methodologies to address any identified risks. In connection with its risk management role, our Audit Committee meets privately with representatives from our independent registered public accounting firm and our Chief Executive Officer. The Audit
Committee oversees the operation of our risk management program, including the identification of the primary risks associated with our business and periodic updates to such risks, and reports to our board of directors regarding these activities.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee Interlocks and Insider Participation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">None of the members of our Compensation Committee has at any time during the prior three years been one of our officers or employees. None of
our executive officers currently serves, or in the past fiscal year has served, as a member of our board of directors or compensation committee of any entity that has one or more executive officers serving on our board of directors or compensation
committee. For a description of transactions between us and members of our compensation committee and affiliates of such members, see &#147;Certain Relationships and Related Person Transactions.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct and Ethics </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We
have adopted a Code of Business Conduct and Ethics that applies to all of our employees, including our chief executive officer and chief financial and accounting officers. The text of the Code of Business Conduct and Ethics is posted on our website
at <I>www.sperotherapeutics.com</I> and will be made available to stockholders without charge, upon request, in writing to the Secretary of the Company at Spero Therapeutics, Inc., 675 Massachusetts Avenue, 14th Floor, Cambridge, Massachusetts
02139. Disclosure regarding any amendments to, or waivers from, provisions of the Code of Business Conduct and Ethics that apply to our directors, principal executive and financial officers will be included in a Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> within four business days following the date of the amendment or waiver, unless website posting or the issuance of a press release of such amendments or waivers is then permitted by the rules of The Nasdaq Stock
Market.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc521849_12"></A>EXECUTIVE AND DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Compensation Table </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The
following table shows the total compensation paid or accrued during the last two fiscal years ended December&nbsp;31, 2017 and 2016 to our President and Chief Executive Officer and our two next most highly compensated executive officers who earned
more than $100,000 during the fiscal year ended December&nbsp;31, 2017 and were serving as executive officers as of such date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:97.90pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:16.90pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Year</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Salary</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:22.20pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Bonus</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:21.35pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>($)(1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Option</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Awards</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:26.70pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>($)(2)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>All other</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Compensation</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:49.30pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>($)(3)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:29.50pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Total
($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ankit Mahadevia, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">389,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,679,616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,087</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,184,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">360,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">345,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">814,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joel Sendek,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">236,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">905,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,225,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Financial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christina Larkin,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">330,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">796,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,226,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Operating Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">234,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">409,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Amounts represent cash bonuses earned for the applicable fiscal year. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">These amounts represent the aggregate grant date fair value for stock and option awards computed in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, or ASC 718. A
discussion of the assumptions used in determining grant date fair value may be found in Note 8 to our consolidated financial statements for the year ended December&nbsp;31, 2017. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Consists of the dollar value of life insurance premiums the Company paid with respect to term life insurance for the benefit of the executive officers named in the table above. With respect to Mr. Sendek, this amount
includes reimbursement for legal fees and expenses incurred in connection with the preparation of his employment agreement. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Narrative
Disclosure to Summary Compensation Table </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our employment arrangements with our named executive officers are described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ankit Mahadevia, M.D. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On
March&nbsp;2, 2015, Dr.&nbsp;Mahadevia executed an offer letter with respect to his employment as our Chief Executive Officer beginning on the same date. Under the terms of the offer letter, Dr.&nbsp;Mahadevia&#146;s annual base salary was $360,500
in 2016 and $400,000 effective on May&nbsp;19, 2017. Under the offer letter, he was eligible to receive an annual incentive bonus determined at the discretion of our board of directors or compensation committee, with a target bonus opportunity of
30% of his then-current base salary. Dr.&nbsp;Mahadevia&#146;s bonus was $114,000 in 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Mahadevia entered into a new
employment agreement on October&nbsp;20, 2017. This agreement provides for the following increased severance payments upon termination by us without Cause (as defined below) or by Dr.&nbsp;Mahadevia for Good Reason (as defined below): (i) payment of
his then-current base salary for a period of 12 months following termination; (ii)&nbsp;a <FONT STYLE="white-space:nowrap">pro-rated</FONT> target bonus for the period during which Dr.&nbsp;Mahadevia was employed in the year of termination; and
(iii)&nbsp;continued coverage under our group health insurance plan until the earlier of 12 months from termination or the date Dr.&nbsp;Mahadevia becomes eligible for medical benefits with another employer. Further, the new agreement provides that
upon termination by us without Cause or by Dr.&nbsp;Mahadevia for Good Reason within 90 days prior to the earlier to occur of a Change of Control (as defined below) or the execution of a definitive agreement the consummation of which would result in
a Change of Control or one year following a Change of Control, Dr.&nbsp;Mahadevia will be entitled to receive (i)&nbsp;a lump sum payment equal to 12 months of his then-current base salary; (ii)&nbsp;a
<FONT STYLE="white-space:nowrap">pro-rated</FONT> target bonus for the period during which Dr.&nbsp;Mahadevia was employed in the year of termination; (iii)&nbsp;acceleration of all unvested equity awards as of the date of termination; and
(iv)&nbsp;continued coverage under our group health insurance plan until the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
earlier of 12 months from termination or the date Dr.&nbsp;Mahadevia becomes eligible for medical benefits with another employer. Payment in each case is subject to Dr.&nbsp;Mahadevia&#146;s
execution of a release satisfactory to us following such termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, if Dr.&nbsp;Mahadevia&#146;s employment terminates as
a result of disability or death, he shall be entitled to receive a <FONT STYLE="white-space:nowrap">pro-rated</FONT> target bonus for the period during which Dr.&nbsp;Mahadevia was employed in the year of termination. The new agreement also provides
that Dr.&nbsp;Mahadevia shall serve as a member of our board of directors during his employment with us until the term of his directorship expires and he is not <FONT STYLE="white-space:nowrap">re-elected</FONT> or his earlier resignation or removal
from our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Joel Sendek </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On April&nbsp;21, 2017, Joel Sendek executed an offer letter with respect to his employment as our Chief Financial Officer beginning in May
2017. The terms of Mr.&nbsp;Sendek&#146;s offer letter provided for an annual base salary of $355,000, prorated for fiscal year 2017, and eligibility for an annual incentive bonus, with a target bonus opportunity of 30% of his then-current base
salary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In October 2017, we entered into a new employment agreement with Mr.&nbsp;Sendek, which provides for a base salary of $355,000
and eligibility for an annual incentive bonus, with a target bonus opportunity of 30% of his then-current base salary. This arrangement is an employment &#147;at will.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The agreement also provides for the following severance payments upon termination by us without Cause or by Mr.&nbsp;Sendek for Good Reason:
(i)&nbsp;payment of his then-current base salary for a period of nine months following termination; (ii)&nbsp;a <FONT STYLE="white-space:nowrap">pro-rated</FONT> target bonus for the period during which Mr.&nbsp;Sendek was employed in the year of
termination; and (iii)&nbsp;continued coverage under our group health insurance plan until the earlier of 12 months from termination or the date Mr.&nbsp;Sendek becomes eligible for medical benefits with another employer. Further, the agreement
provides that upon termination by us without Cause or by Mr.&nbsp;Sendek for Good Reason within 90 days prior to the earlier to occur of a Change of Control or the execution of a definitive agreement the consummation of which would result in a
Change of Control or one year following a Change of Control, Mr.&nbsp;Sendek will be entitled to receive: (i)&nbsp;a lump sum payment equal to 12 months of his then-current base salary; (ii)&nbsp;a <FONT STYLE="white-space:nowrap">pro-rated</FONT>
target bonus for the period during which Mr.&nbsp;Sendek was employed in the year of termination; (iii)&nbsp;acceleration of (A)&nbsp;all unvested equity awards as of the date of termination if Mr.&nbsp;Sendek&#146;s employment commenced at least 24
months prior to a Change of Control (B) 50% of all unvested equity awards as of the date of termination if Mr.&nbsp;Sendek&#146;s employment commenced fewer than 24 months but at least 12 months prior to a Change of Control or (C) 25% of all
unvested equity awards as of the date of termination if Mr.&nbsp;Sendek&#146;s employment commenced fewer than 12 months prior to a Change of Control; and (iv)&nbsp;continued coverage under our group health insurance plan until the earlier of 12
months from termination or the date Mr.&nbsp;Sendek becomes eligible for medical benefits with another employer. Payment in each case is subject to Mr.&nbsp;Sendek&#146;s execution of a release satisfactory to us following such termination. In
addition, if Mr.&nbsp;Sendek&#146;s employment terminates as a result of disability or death, he shall be entitled to receive a <FONT STYLE="white-space:nowrap">pro-rated</FONT> target bonus for the period during which Mr.&nbsp;Sendek was employed
in the year of termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cristina Larkin </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In February 2016, Cristina Larkin, our then Chief Commercial Officer, executed an offer letter with respect to her employment beginning on
March&nbsp;7, 2016. Under the terms of the offer letter, Ms.&nbsp;Larkin&#146;s annual base salary was $305,000, prorated for fiscal year 2016, and she was eligible for an annual incentive bonus, with a target bonus opportunity of 25% of her
then-current base salary. In September 2017 Ms.&nbsp;Larkin was promoted to Chief Operating Officer, in connection with which her bonus target was increased to 30% of her then-current base salary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In October 2017, we entered into a new employment agreement with Ms.&nbsp;Larkin, which provides for a base salary of $345,000 and eligibility
for an annual incentive bonus, with a target bonus opportunity of 30% of her then-current base salary. This arrangement is an employment &#147;at will.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The agreement also provides for the following severance payments upon termination by us
without Cause or by Ms.&nbsp;Larkin for Good Reason: (i)&nbsp;payment of her then-current base salary for a period of nine months following termination; (ii)&nbsp;a <FONT STYLE="white-space:nowrap">pro-rated</FONT> target bonus for the period during
which Ms.&nbsp;Larkin was employed in the year of termination; and (iii)&nbsp;continued coverage under our group health insurance plan until the earlier of 12 months from termination or the date Ms.&nbsp;Larkin becomes eligible for medical benefits
with another employer. Further, the agreement provides that upon termination by us without Cause or by Ms.&nbsp;Larkin for Good Reason within 90 days prior to the earlier to occur of a Change of Control or the execution of a definitive agreement the
consummation of which would result in a Change of Control or one year following a Change of Control, Ms.&nbsp;Larkin will be entitled to receive: (i)&nbsp;a lump sum payment equal to 12 months of her then-current base salary; (ii)&nbsp;a <FONT
STYLE="white-space:nowrap">pro-rated</FONT> target bonus for the period during which Ms.&nbsp;Larkin was employed in the year of termination; (iii)&nbsp;acceleration of (A)&nbsp;all unvested equity awards as of the date of termination if
Ms.&nbsp;Larkin&#146;s employment commenced at least 24 months prior to a Change of Control (B) 50% of all unvested equity awards as of the date of termination if Ms.&nbsp;Larkin&#146;s employment commenced fewer than 24 months but at least 12
months prior to a Change of Control or (C) 25% of all unvested equity awards as of the date of termination if Ms.&nbsp;Larkin&#146;s employment commenced fewer than 12 months prior to a Change of Control; and (iv)&nbsp;continued coverage under our
group health insurance plan until the earlier of 12 months from termination or the date Ms.&nbsp;Larkin becomes eligible for medical benefits with another employer. Payment in each case is subject to Ms.&nbsp;Larkin&#146;s execution of a release
satisfactory to us following such termination. In addition, if Ms.&nbsp;Larkin&#146;s employment terminates as a result of disability or death, she shall be entitled to receive a <FONT STYLE="white-space:nowrap">pro-rated</FONT> target bonus for the
period during which Ms.&nbsp;Larkin was employed in the year of termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under each of the employment agreements, Cause means
(i)&nbsp;the executive&#146;s conviction of (A)&nbsp;a felony or (B)&nbsp;any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (ii)&nbsp;the executive&#146;s willful failure or refusal to comply with lawful directions of our board
of directors, with respect to Dr.&nbsp;Mahadevia, or of our Chief Executive Officer, with respect to Mr.&nbsp;Sendek and Ms.&nbsp;Larkin, which failure or refusal continues for more than thirty days after written notice is given to the executive by
our board of directors, with respect to Dr.&nbsp;Mahadevia, or by our Chief Executive Officer, with respect to Mr.&nbsp;Sendek and Ms.&nbsp;Larkin, which notice sets forth in reasonable detail the nature of such failure or refusal;
(iii)&nbsp;willful and material breach by the executive of a written company policy applicable to the executive or the executive&#146;s covenants and/or obligations under his or her employment agreement or the material breach of the executive&#146;s
proprietary information and inventions assignment agreement; and/or (iv)&nbsp;material misconduct by the executive that seriously discredits or damages us or any of our affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under each of the employment agreements, Good Reason means (i)&nbsp;relocation of the executive&#146;s principal business location to a
location more than thirty (30)&nbsp;miles from the executive&#146;s then-current business location; (ii)&nbsp;a material diminution in the executive&#146;s duties, authority or responsibilities; (iii)&nbsp;a material reduction in the
executive&#146;s base salary; (iv)&nbsp;willful and material breach by us of our covenants and/or obligations under the executive&#146;s employment agreement; or (v)&nbsp;within one year following a Change of Control, the executive is not an
executive of the parent company, provided that the executive&#146;s roles responsibilities and scope of authority within the subsidiary is not comparable to the executive&#146;s roles, responsibilities and scope of authority with us prior to the
Change of Control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under each of the employment agreements, Change of Control means (i)&nbsp;any person (as such term is used in Sections
13(d) and 14(d) of the Exchange Act) becomes the beneficial owner, directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company&#146;s then outstanding voting
securities (excluding for this purpose any such voting securities held by the Company, or any affiliate, parent or subsidiary of the Company, or by any employee benefit plan of the Company) pursuant to a transaction or a series of related
transactions; (ii)&nbsp;a merger or consolidation of the Company other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining
outstanding or by being converted into voting securities of the surviving entity or the parent of such corporation) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity
or parent of such corporation, as the case may be, outstanding immediately after such merger or consolidation; (iii)&nbsp;our stockholders approve an agreement for the sale or disposition by the Company of all or substantially all of our assets; or
(iv)&nbsp;a change in the composition of our board of directors, as a result of which fewer than a majority of the directors are incumbent directors </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">All of our executive officers have entered into our standard proprietary information and
inventions assignment agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at 2017 Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As part of the Reorganization, each of the capital units of Spero Therapeutics, LLC issued and outstanding prior to the Reorganization was
cancelled and converted into and exchanged for one share of Spero Therapeutics, Inc. capital stock of the same class and/or series, and each of the incentive units of Spero Therapeutics, LLC was terminated and cancelled. Promptly after the
Reorganization, previous holders of incentive units who were still employed by us at the time of the Reorganization received stock options under the 2017 Plan. Such stock options were granted for the same number of shares of our common stock as the
number of incentive units cancelled, and the stock options were granted with continued vesting on the same terms and with similar rights and restrictions as the incentive units. All such stock options have an exercise price of $5.90. Further, in
addition to the stock options granted in connection with the Reorganization, we granted additional stock options to our named executive officers under the 2017 Plan in July and December 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table shows grants of stock options outstanding on the last day of the fiscal year ended December&nbsp;31, 2017 to each of the
executive officers named in the Summary Compensation Table. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number of</B><br><B>Securities<BR>Underlying</B><br><B>Unexercised</B><br><B>Options (#)</B><br><B>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Option</B><br><B>Exercise&nbsp;Price<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ankit Mahadevia, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,957</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/5/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,285</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/5/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123,564</TD>
<TD NOWRAP VALIGN="bottom">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/5/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">297,220</TD>
<TD NOWRAP VALIGN="bottom">(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/5/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125,079</TD>
<TD NOWRAP VALIGN="bottom">(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/12/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joel Sendek</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,833</TD>
<TD NOWRAP VALIGN="bottom">(6)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/5/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,795</TD>
<TD NOWRAP VALIGN="bottom">(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/12/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cristina Larkin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,690</TD>
<TD NOWRAP VALIGN="bottom">(7)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/5/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,704</TD>
<TD NOWRAP VALIGN="bottom">(8)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/5/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,779</TD>
<TD NOWRAP VALIGN="bottom">(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/5/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,540</TD>
<TD NOWRAP VALIGN="bottom">(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/12/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">As part of the Reorganization, Dr.&nbsp;Mahadevia was granted options to replace his previously awarded incentive units in Spero Therapeutics, LLC. The options vest in accordance with the vesting terms of
Dr.&nbsp;Mahadevia&#146;s previously held incentive units: 25% of the underlying shares were deemed vested August&nbsp;24, 2016, the first anniversary of the vesting commencement date, with an additional 1/36<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> of the remaining shares vesting monthly thereafter until the option is fully vested. In addition, if Dr.&nbsp;Mahadevia&#146;s employment is terminated by us without cause within one year following
a change of control, the vesting of these options will accelerate in accordance with the terms of the option. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">As part of the Reorganization, Dr. Mahadevia was granted options to replace his previously awarded incentive units in Spero Therapeutics, LLC. The options vest in accordance with the vesting terms of Dr.
Mahadevia&#146;s previously held incentive units: 25% of the underlying shares were deemed vested April 28, 2017, the first anniversary of the vesting commencement date, with an additional 1/36th of the remaining shares vesting monthly thereafter
until the option is fully vested. In addition, if Dr. Mahadevia&#146;s employment is terminated by us without cause within one year following a change of control, the vesting of these options will accelerate in accordance with the terms of the
option and his employment agreement. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">100% of these options vested on July&nbsp;6, 2017. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">25% of the options vested on July&nbsp;6, 2018 and an additional 1/36th of the remaining shares vest monthly until the option is fully vested. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">25% of the options will vest on December&nbsp;13, 2018 and an additional 1/36th of the remaining shares vest monthly until the option is fully vested. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">25% of the options will vested on May&nbsp;1, 2018 and an additional 1/36th of the remaining shares vesting monthly thereafter until the option is fully vested. In addition, if Mr.&nbsp;Sendek&#146;s employment is
terminated by us without cause within one year following a change of control, the vesting of these options will accelerate in accordance with the terms of the option and his employment agreement. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">As part of the Reorganization, Ms.&nbsp;Larkin was granted options to replace her previously awarded incentive units in Spero Therapeutics, LLC. The options vest in accordance with the vesting terms of
Ms.&nbsp;Larkin&#146;s previously held incentive units: 25% of the underlying shares were deemed vested on March&nbsp;7, 2017, the first anniversary of the vesting commencement date, with an additional 1/36th of the remaining shares vesting monthly
thereafter until the option is fully vested. In addition, if Ms.&nbsp;Larkin&#146;s employment is terminated by us without cause within one year following a change of control, the vesting of these options will accelerate in accordance with the terms
of the option and her employment agreement. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top">As part of the Reorganization, Ms. Larkin was granted options to replace her previously awarded incentive units in Spero Therapeutics, LLC. The options vest in accordance with the vesting terms of Ms. Larkin&#146;s
previously held incentive units: 25% of the underlying shares were deemed vested April 28, 2017, the first anniversary of the vesting commencement date, with an additional 1/36th of the remaining shares vesting monthly thereafter until the option is
fully vested. In addition, if Ms. Larkin&#146;s employment is terminated by us without cause within one year following a change of control, the vesting of these options will accelerate in accordance with the terms of the option and her employment
agreement. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Compensation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table shows the total compensation paid or accrued during the fiscal year ended December&nbsp;31, 2017 to each of our current
and former <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. Directors who are employed by us are not compensated for their service on our board of directors. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended December&nbsp;31, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Fees&nbsp;Earned&nbsp;or</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:54.85pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Paid&nbsp;in&nbsp;Cash&nbsp;($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Option&nbsp;Awards</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:52.65pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>($)(3)(7)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:29.50pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Total ($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jean Fran&ccedil;ois Formela</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vikas Goyal(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Milind Deshpande</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187,197</TD>
<TD NOWRAP VALIGN="bottom">(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Casper Breum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick Vink</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108,330</TD>
<TD NOWRAP VALIGN="bottom">(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reza Halse(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Frank Thomas</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123,171</TD>
<TD NOWRAP VALIGN="bottom">(6)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Southwell</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Halse resigned from our board of directors in connection with our initial public offering in November 2017, and Mr.&nbsp;Goyal resigned from our board of directors in February 2018. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Goyal and Mr.&nbsp;Breum agreed to waive their retainer fees for 2017 of $7,083 and $6,667, respectively. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">These amounts represent the aggregate grant date fair value of options granted to each director in the fiscal year ended December&nbsp;31, 2017, computed in accordance with FASB ASC Topic 718. A discussion of the
assumptions used in determining grant date fair value may be found in Note 8 to our consolidated financial statements for the year ended December&nbsp;31, 2017. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On July&nbsp;6, 2017, Mr.&nbsp;Deshpande was granted options under the 2017 Plan to purchase 45,191 shares of our
common stock at an exercise price of $5.90 per share, which vest over four years with 25% of the options vesting on the first anniversary of the grant date, with an additional 1/36th of the remaining shares vesting monthly thereafter until the
option is fully vested. As part of the Reorganization, Mr.&nbsp;Deshpande was also granted options to replace his previously awarded incentive units in Spero Therapeutics, LLC, which
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
represented 3,290 shares of underlying common stock. The replacement options vest in accordance with the vesting terms of Dr.&nbsp;Deshpande&#146;s previously held incentive units: 25% of the
underlying shares were deemed vested on August&nbsp;24, 2016, the first anniversary of the original vesting commencement date, with an additional 1/36th of the remaining shares vesting monthly thereafter until the option is fully vested.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">On July&nbsp;6, 2017, Mr.&nbsp;Vink was granted options under the 2017 Plan to purchase 21,236 shares of our common stock at an exercise price of $5.90 per share, which vest over four years with 25% of the options
vesting on the first anniversary of the grant date, with an additional 1/36th of the remaining shares vesting monthly thereafter until the option is fully vested. As part of the Reorganization, Mr.&nbsp;Vink was also granted options to replace his
previously awarded incentive units in Spero Therapeutics, LLC, which represented 9,278 shares of underlying common stock. The replacement options vest in accordance with the vesting terms of Mr.&nbsp;Vink&#146;s previously held incentive units: 25%
of the underlying shares were deemed vested on August&nbsp;24, 2016, the first anniversary of the vesting commencement date, with an additional 1/36th of the remaining shares vesting monthly thereafter until the option is fully vested.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">25% of the options will vest on July&nbsp;17, 2018 and an additional 1/36th of the remaining shares vest monthly until the option is fully vested. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">As of December&nbsp;31, 2017, the aggregate number of options held by each of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors was as follows (representing both exercisable and unexercisable option
awards, none of which have been exercised): </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Shares</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Underlying</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Outstanding</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:48.15pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Stock&nbsp;Options</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Milind Deshpande, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick Vink, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Frank Thomas</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under our <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy, each
<FONT STYLE="white-space:nowrap">non-employee</FONT> director is eligible to receive compensation for his or her service consisting of annual cash retainers and equity awards. Our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors
receive the following annual retainers for their service:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:27.50pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Retainer</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Board Member</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Board Chairperson (additional retainer)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Committee Chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation Committee Chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nominating and Governance Committee Chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Committee Member</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation Committee Member</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nominating and Governance Committee Member</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Equity awards for <FONT STYLE="white-space:nowrap">non-employee</FONT> directors consist of (i)&nbsp;an
initial equity award consisting of a <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock option to purchase 12,146 shares of our common stock upon first appointment to our board of directors and vesting in equal monthly installments until
the third anniversary of the grant date, subject to the <FONT STYLE="white-space:nowrap">non-employee</FONT> director&#146;s continued service on our board of directors, and (ii)&nbsp;annual equity awards commencing in 2018 consisting of a <FONT
STYLE="white-space:nowrap">non-qualified</FONT> stock option to purchase 6,073 shares of our common stock vesting on the first anniversary of the grant date, subject to the <FONT STYLE="white-space:nowrap">non-employee</FONT> director&#146;s
continued service on our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Directors may be reimbursed for travel, food, lodging and other expenses directly related to
their service as directors. Directors are also entitled to the protection provided by their indemnification agreements and the indemnification provisions in our amended and restated certificate of incorporation and amended and restated <FONT
STYLE="white-space:nowrap">By-Laws.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Compensation Plans and Other Benefit Plans </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table provides certain aggregate information with respect to all of the Company&#146;s equity compensation plans in effect as of
December&nbsp;31, 2017. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(a)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(b)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(c)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:46.85pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Plan category</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number&nbsp;of&nbsp;securities</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>to be issued upon</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>exercise
of</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>outstanding options,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:71.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>warrants and rights</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Weighted-average</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>exercise price of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>outstanding&nbsp;options,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:69.25pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>warrants and rights</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number&nbsp;of&nbsp;securities&nbsp;remaining</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>for&nbsp;future&nbsp;issuance&nbsp;under&nbsp;equity</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>compensation&nbsp;plans&nbsp;(excluding</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:113.50pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>securities&nbsp;reflected&nbsp;in&nbsp;column&nbsp;(a))</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans approved by stockholders(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,011,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">685,105</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans not approved by stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,011,296</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7.24</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>685,105</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">This plan category consists of our 2017 Stock Incentive Plan under which, in addition to options, we may award restricted and unrestricted stock awards and other stock-based awards. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Under our 2017 Stock Incentive Plan, the number of shares of common stock that may be issued automatically increases on an annual basis on the first day of each fiscal year, beginning with the fiscal year ending
December 31, 2019 and continuing for each fiscal year until, and including, the fiscal year ending December 31, 2027, by an amount equal to the lesser of (i) 607,324 shares of common stock, (ii) 4% of the number of outstanding shares of our common
stock on such date, or (iii) an amount determined by our Board of Directors or Compensation Committee. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Benefits Programs </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Each named executive employee is eligible to participate in our benefits programs, which include health, life, disability and dental insurance
and a 401(k) retirement savings plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Spero Therapeutics, Inc. 2017 Stock Incentive Plan </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We adopted the Spero Therapeutics, Inc. 2017 Stock Incentive Plan on June&nbsp;30, 2017. The 2017 Plan will expire on June&nbsp;30, 2027.
Under the 2017 Plan, we may grant incentive stock options, <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options, restricted and unrestricted stock awards and other stock-based awards. There are 2,696,401 shares of our common stock
authorized for issuance under the 2017 Plan. Additionally, the number of shares of common stock that may be issued under the 2017 Plan will automatically increase on each January&nbsp;1, beginning with the fiscal year ending December&nbsp;31, 2019
and continuing for each fiscal year until, and including, the fiscal year ending December&nbsp;31, 2027, by an amount equal to the lowest of: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">607,324 shares of our common stock; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">4% of the number of shares of our common stock outstanding as of such date; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an amount determined by our board of directors or compensation committee. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our board of
directors is authorized to administer the 2017 Plan. In accordance with the provisions of the 2017 Plan, our board of directors determines the terms of the options and other awards issued pursuant thereto, including the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">which employees, directors and consultants shall be granted awards; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of shares of common stock subject to options and other awards; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the exercise price of each option, which generally shall not be less than fair market value of the common stock on the date of grant; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the termination or cancellation provisions applicable to the options; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms and conditions of other awards, including conditions for repurchase, termination or cancellation, issue price and repurchase price; and </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all other terms and conditions upon which each award may be granted in accordance with the 2017 Plan. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">No participant may receive awards for more than 1,000,000 shares of our common stock in any fiscal year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, our board of directors or any committee to which our board of directors delegates authority may, with the consent of the affected
plan participants, amend outstanding awards consistent with the terms of the 2017 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Upon a merger, consolidation, or sale of all or
substantially all of our assets, our board of directors or any committee to which our board of directors delegates authority, or the board of directors of any corporation assuming the our obligations, may, in its sole discretion, take any one or
more of the following actions pursuant to the 2017 Plan, as to some or all outstanding awards, to the extent not otherwise agreed under any individual agreement: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that outstanding options will be assumed or substituted for options of the successor corporation; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that the outstanding options must be exercised within a certain number of days, either to the extent the options are then exercisable, or at our board of directors&#146; discretion, any such options being made
partially or fully exercisable; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">terminate outstanding options in exchange for a cash payment of an amount equal to the difference between (a)&nbsp;the consideration payable upon consummation of the corporate transaction to a holder of the number of
shares into which such option would have been exercisable to the extent then exercisable, or in our board of directors&#146; discretion, any such options being made partially or fully exercisable, and (b)&nbsp;the aggregate exercise price of those
options; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that outstanding stock grants will be substituted for shares of the successor corporation or consideration payable with respect to our outstanding stock in connection with the corporate transaction; and
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">terminate outstanding stock grants in exchange for payment of an amount equal to the consideration payable upon consummation of the corporate transaction to a holder of the same number of shares comprising the stock
grant, to the extent the stock grant is no longer subject to any forfeiture or repurchase rights, or at our board of directors&#146; discretion, all forfeiture and repurchase rights being waived upon the corporate transaction. For purposes of
determining such payments, in the case of a corporate transaction the consideration for which, in whole or in part, is other than cash, the consideration other than cash shall be valued at the fair market value thereof as determined in good faith by
our board of directors. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In connection with the Reorganization, all outstanding incentive units issued under Spero
Therapeutics, LLC&#146;s operating agreement were cancelled. Any incentive unit holders who were employees, directors or consultants of the Company at the time of the Reorganization were issued options under the 2017 Plan with continued vesting on
the same schedule and the same terms as such person&#146;s incentive units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> Sales Plans
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Some of our directors and executive officers have adopted written plans, known as Rule
<FONT STYLE="white-space:nowrap">10b5-1</FONT> plans, in which they will have contracted with a broker to buy or sell shares of our common stock on a periodic basis. Under a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan, a broker executes
trades pursuant to parameters established by the director or officer when entering into the plan, without further direction from the director or officer. The director or officer may amend or terminate the plan in limited circumstances. Our directors
and executive officers may also buy or sell additional shares of our common stock outside of a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan when they are not in possession of material, nonpublic information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc521849_13"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following is a description of transactions, since January&nbsp;1, 2015, to which we have been a party, in which the amount involved
exceeds $120,000, and in which any of our directors, executive officers or holders of more than 5% of our capital stock, or an affiliate or immediate family member thereof, had or will have a direct or indirect material interest. We refer to such
transactions as &#147;related party transactions&#148; and such persons as &#147;related parties.&#148; With the approval of our board of directors, we have engaged in the related party transactions described below. We believe the terms obtained or
consideration that we paid or received, as applicable, in connection with the transactions described below were comparable to terms available or the amounts that would be paid or received, as applicable, from unaffiliated third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Other than as described below, there have not been, nor are there any currently proposed, transactions or series of similar transactions to
which we have been or will be a party other than compensation arrangements, which are described where required under &#147;Executive and Director Compensation.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Financings </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2014 Bridge Unit Financing
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In January 2014, we issued and sold 1,531,148 bridge units to investors upon the conversion of convertible notes in a total
amount of $1,531,148. The following table sets forth the number of bridge units purchased by our directors, executive officers and 5% stockholders and their affiliates at the time of or as a result of such issuance and the aggregate purchase price
paid for such units. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Bridge</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:56.20pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Units&nbsp;Purchased</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:51.30pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Purchase&nbsp;Price</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Atlas Venture Fund IX, L.P.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">665,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">665,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S.R. One, Limited(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">658,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">658,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Partners Innovation Fund, LLC(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">206,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">206,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Atlas Venture Fund IX, L.P. beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the bridge unit financing. Jean-Fran&ccedil;ois Formela, M.D., a member of
our board of directors, is a Partner at Atlas Venture. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">S.R. One, Limited beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the bridge unit financing. Vikas Goyal, a former member of our board of directors,
is a Principal at S.R. One, Limited. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Partners Innovation Fund, LLC beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the bridge unit financing. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Junior Preferred Stock Financing </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In April 2014, we issued an aggregate of 3,438,318 junior preferred units, consisting of (i) 1,500,000 junior preferred units issued and sold
at a price per unit of $1.00 for an aggregate purchase price of $1.5&nbsp;million, and (ii) 1,938,318 junior preferred units issued upon the conversion of the 2014 bridge units. The following table sets forth the number of junior preferred units
issued to our directors, executive officers and 5% stockholders and their affiliates at the time of or as a result of such issuance and the aggregate purchase price paid for such units. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Bridge</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Units</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:37.80pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exchanged</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Junior&nbsp;Preferred</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Units&nbsp;Received&nbsp;in</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exchange&nbsp;for</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:59.50pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Bridge&nbsp;Units</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Junior&nbsp;Preferred</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:57.95pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Units Purchased</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:51.30pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Purchase&nbsp;Price</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Atlas Venture Fund IX, L.P.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">665,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">842,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">650,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">650,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S.R. One, Limited(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">658,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">833,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">650,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">650,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Partners Innovation Fund, LLC(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">206,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">261,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Atlas Venture Fund IX, L.P. beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the junior preferred financing. Jean-Fran&ccedil;ois Formela, M.D., a
member of our board of directors, is a Partner at Atlas Venture. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">S.R. One, Limited beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the junior preferred financing. Vikas Goyal, a former member of our board of
directors, is a Principal at S.R. One, Limited. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Partners Innovation Fund, LLC beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the junior preferred financing. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2015 Bridge Unit Financing </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In
January 2015, we issued and sold 8,000 bridge units to existing investors at a price per unit of $1,000 for an aggregate purchase price of $8.0&nbsp;million. The following table sets forth the number of bridge units purchased by our directors,
executive officers and 5% stockholders and their affiliates at the time of or as a result of such issuance and the aggregate purchase price paid for such units. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Bridge</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:56.20pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Units&nbsp;Purchased</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:51.30pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Purchase&nbsp;Price</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Atlas Venture Fund IX, L.P.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,450,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S.R. One, Limited(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,450,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Partners Innovation Fund, LLC(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Atlas Venture Fund IX, L.P. beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the bridge unit financing. Jean-Fran&ccedil;ois Formela, M.D., a member of
our board of directors, is a Partner at Atlas Venture. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">S.R. One, Limited beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the bridge unit financing. Vikas Goyal, a former member of our board of directors,
is a Principal at S.R. One, Limited. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Partners Innovation Fund, LLC beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the bridge unit financing. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Class&nbsp;A Preferred Unit Financing </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In June 2015, we issued an aggregate of 4,202,278 <FONT STYLE="white-space:nowrap">Class&nbsp;A-1</FONT> preferred units, consisting of (i)
2,279,202 <FONT STYLE="white-space:nowrap">Class&nbsp;A-1</FONT> preferred units issued to existing investors in exchange for 8,000 bridge units, and (ii) 1,923,076 <FONT STYLE="white-space:nowrap">Class&nbsp;A-1</FONT> preferred units issued and
sold at a price per unit of $3.90 for an aggregate purchase price of approximately $7.5&nbsp;million. The <FONT STYLE="white-space:nowrap">Class&nbsp;A-1</FONT> preferred units were subsequently reclassified as Class&nbsp;A preferred units. The
following table sets forth the number of Class&nbsp;A preferred units purchased by our directors, executive officers and 5% stockholders and their affiliates at the time of or as a result of such issuance and the aggregate purchase price paid for
such units. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Bridge</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Units</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:37.80pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exchanged</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Class&nbsp;A&nbsp;Preferred</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Units&nbsp;Received&nbsp;in&nbsp;Exchange</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:94.85pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>for Bridge Units</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Class&nbsp;A&nbsp;Preferred</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:61.30pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Units Purchased</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:51.30pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Purchase&nbsp;Price</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Atlas Venture Fund IX, L.P.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">982,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S.R. One, Limited(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">982,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Partners Innovation Fund, LLC(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">313,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lundbeckfond Invest A/S(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,153,846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MRL Ventures Fund, LLC(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">384,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">KPC Venture Capital LLC(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">384,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Atlas Venture Fund IX, L.P. beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the Class&nbsp;A preferred unit financing. Jean-Fran&ccedil;ois Formela,
M.D., a member of our board of directors, is a Partner at Atlas Venture. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">S.R. One, Limited beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the Class&nbsp;A preferred unit financing. Vikas Goyal, a former member of our board
of directors, is a Principal at S.R. One, Limited. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Partners Innovation Fund, LLC beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the Class&nbsp;A preferred unit financing. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Lundbeckfond Invest A/S beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the Class&nbsp;A preferred unit financing. Casper Breum, a member of our board
of directors, is a Senior Partner at Lundbeckfond Ventures, an affiliate of Lundbeckfond Invest A/S. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">MRL Ventures Fund, LLC beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the Class&nbsp;A preferred unit financing. Reza Halse, a former member of our
board of directors, serves as President of MRL Ventures Fund, LLC. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">KPC Venture Capital LLC beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the Class&nbsp;A preferred unit financing. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Class&nbsp;B Preferred Unit Financing </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In February 2016, we issued and sold 5,909,089 <FONT STYLE="white-space:nowrap">Class&nbsp;B-1</FONT> preferred units at a price per unit of
$4.40, for an aggregate purchase price of approximately $26.0&nbsp;million. The <FONT STYLE="white-space:nowrap">Class&nbsp;B-1</FONT> preferred units were subsequently reclassified as Class&nbsp;B preferred units. The following table sets forth the
number of Class&nbsp;B preferred units purchased by our directors, executive officers and 5% stockholders and their affiliates at the time of or as a result of such issuance and the aggregate purchase price paid for such units. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Class&nbsp;B&nbsp;Preferred</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:60.85pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Units Purchased</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:51.30pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Purchase&nbsp;Price</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Atlas Venture Fund IX, L.P.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S.R. One, Limited(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Partners Innovation Fund, LLC(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lundbeckfond Invest A/S(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">681,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MRL Ventures Fund, LLC(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">KPC Venture Capital LLC(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">511,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Osage University Partners II, L.P.(7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">852,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Atlas Venture Fund IX, L.P. beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the Class&nbsp;B preferred unit financing. Jean-Fran&ccedil;ois Formela,
M.D., a member of our board of directors, is a Partner at Atlas Venture. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">S.R. One, Limited beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the Class&nbsp;B preferred unit financing. Vikas Goyal, a former member of our board
of directors, is a Principal at S.R. One, Limited. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Partners Innovation Fund, LLC beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the Class&nbsp;B preferred unit financing. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Lundbeckfond Invest A/S beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the Class&nbsp;B preferred unit financing. Casper Breum, a member of our board
of directors, is a Senior Partner at Lundbeckfonden Ventures, an affiliate of Lundbeckfond Invest&nbsp;A/S. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">MRL Ventures Fund, LLC beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the Class&nbsp;B preferred unit financing. Reza Halse, a former member of our
board of directors, serves as President of MRL Ventures Fund, LLC. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">KPC Venture Capital LLC beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the Class&nbsp;B preferred unit financing. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">Osage University Partners II, L.P. beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the Class&nbsp;B preferred unit financing. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2016 Bridge Unit Financing </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In
December 2016, we issued and sold 8,500 bridge units at a price per unit of $1,000 for an aggregate purchase price of approximately $8.5&nbsp;million. The following table sets forth the number of bridge units purchased by our directors, executive
officers and 5% stockholders and their affiliates at the time of or as a result of such issuance and the aggregate purchase price paid for such units. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Bridge</B><br><B>Units&nbsp;Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate</B><br><B>Purchase&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Atlas Venture Fund IX, L.P.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,833,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S.R. One, Limited(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,833,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lundbeckfond Invest A/S(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MRL Ventures Fund, LLC(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,833,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">KPC Venture Capital LLC(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Osage University Partners II, L.P.(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Atlas Venture Fund IX, L.P. beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the bridge unit financing. Jean-Fran&ccedil;ois Formela, M.D., a member of
our board of directors, is a Partner at Atlas Venture. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">S.R. One, Limited beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the bridge unit financing. Vikas Goyal, a former member of our board of directors,
is a Principal at S.R. One, Limited. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Lundbeckfond Invest A/S beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the bridge unit financing. Casper Breum, a member of our board of directors,
is a Senior Partner at Lundbeckfond Ventures, an affiliate of Lundbeckfond Invest A/S. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">MRL Ventures Fund, LLC beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the bridge unit financing. Reza Halse, a former member of our board of
directors, serves as President of MRL Ventures Fund, LLC. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">KPC Venture Capital LLC beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the bridge unit financing. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Osage University Partners II, L.P. beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the bridge unit financing. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Class&nbsp;C Preferred Unit Financing </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In March 2017, we issued an aggregate of 29,647,582 Class&nbsp;C preferred units, consisting of (i) 5,321,112 Class&nbsp;C preferred units in
exchange for 8,500 bridge units and (ii) 24,326,470 Class&nbsp;C preferred units at a price per unit of $1.7749 for an aggregate purchase price of approximately $43,177,052. The following table sets forth the number of Class&nbsp;C preferred units
purchased by our directors, executive officers and 5% stockholders and their affiliates at the time of or as a result of such issuance and the aggregate purchase price paid for such units </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Bridge</B><br><B>Units</B><br><B>Exchanged</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Class&nbsp;C&nbsp;Preferred</B><br><B>Units Received in</B><br><B>Exchange&nbsp;for&nbsp;Bridge</B><br><B>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Class&nbsp;C&nbsp;Preferred</B><br><B>Units Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate</B><br><B>Purchase&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GV 2015, L.P.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,760,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RA Capital Healthcare Fund, L.P.(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,673,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,519,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Atlas Venture Fund IX, L.P.(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,147,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,971,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S.R. One, Limited(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,147,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,535,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lundbeckfond Invest A/S(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">626,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,859,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,299,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MRL Ventures Fund, LLC(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,147,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">783,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,390,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">KPC Venture Capital LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">469,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">429,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">762,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Osage University Partners II, L.P.(7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">782,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">408,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">724,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Atlas Venture Fund X, L.P.(8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,662,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">GV 2015, L.P. beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the Class&nbsp;C preferred unit financing. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">RA Capital Healthcare Fund, L.P. beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the Class&nbsp;C preferred unit financing. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Atlas Venture Fund IX, L.P. beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the Class&nbsp;C preferred unit financing. Jean-Fran&ccedil;ois Formela,
M.D., a member of our board of directors, is a Partner at Atlas Venture. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">S.R. One, Limited beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the Class&nbsp;C preferred unit financing. Vikas Goyal, a member of our board of
directors, is a Principal at S.R. One, Limited. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Lundbeckfond Invest A/S beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the Class&nbsp;C preferred unit financing. Casper Breum, a member of our board
of directors, is a Senior Partner at Lundbeckfond Ventures, an affiliate of Lundbeckfond Invest A/S. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">MRL Ventures Fund, LLC beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the Class&nbsp;C preferred unit financing. Reza Halse, a member of our board of
directors, serves as President of MRL Ventures Fund, LLC. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">Osage University Partners II, L.P. beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the Class&nbsp;C preferred unit financing. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top">Atlas Venture Fund X, L.P. beneficially owned, in the aggregate, more than 5% of our outstanding capital stock at the time of or as a result of the Class&nbsp;C preferred unit financing. Jean-Fran&ccedil;ois Formela,
M.D., a member of our board of directors, is a Partner at Atlas Venture. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reorganization </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On June&nbsp;30, 2017, as part of the Reorganization, each of the capital units of Spero Therapeutics, LLC issued and outstanding prior to the
Reorganization was cancelled and converted into and exchanged for one share of Spero Therapeutics, Inc. capital stock of the same class and/or series. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series C Preferred Stock </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In July 2017, after the consummation of the Reorganization, we sold to Joel Sendek, our Chief Financial Officer, 61,880 shares of Series C
preferred stock of Spero Therapeutics, Inc., at a purchase price of $1.7749 per share, for an aggregate purchase price of $109,831. Such purchase and sale was made in accordance with the terms of Mr.&nbsp;Sendek&#146;s offer letter. In October 2017,
Mr.&nbsp;Sendek transferred his 61,880 shares to a retained annuity trust that he established and of which he is a beneficiary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Agreements with
Stockholders </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Investors&#146; Rights Agreement </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We entered into an investors&#146; rights agreement with the purchasers of our outstanding preferred stock, including entities with which
certain of our directors are affiliated. The investors&#146; rights agreement provides these holders the right, after April&nbsp;30, 2018, to demand that we file a registration statement or request that their shares be covered by a registration
statement that we are otherwise filing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Right of First Refusal and <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We entered into a right of first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT> agreement with certain holders of our common
stock and preferred stock, including entities with which certain of our directors are affiliated. This agreement provided for rights of first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT> relating to the shares of our common stock held
by the parties to the agreement. The right of first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT> agreement has terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting
Agreement </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We entered into a voting agreement with certain holders of our common stock and preferred stock, including entities
with which certain of our directors are affiliated. Under this agreement, our stockholders that were party to the agreement agreed to vote their shares to elect to our board of directors: (i)&nbsp;one director designated by Atlas Venture Fund IX,
L.P. and Atlas Venture Fund X, L.P., (ii) one director designated by S.R. One, Limited, (iii)&nbsp;one director designated by Lundbeckfond Invest A/S, (iv)&nbsp;one director designated by MRL Ventures Fund, LLC, (v)&nbsp;after delivery of written
notice from GV 2015, L.P. to the Company informing the Company that GV 2015, L.P. would designate a member of our board of directors, one director designated by GV 2015, L.P., (vi) the person who was the company&#146;s then-serving Chief Executive
Officer, (vii)&nbsp;one director with relevant industry experience who was reasonably acceptable to a majority of the other directors then serving on our board of directors and (viii)&nbsp;two directors designated by the stockholders holding a
majority of shares voting together as a single class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to common stock basis. The voting agreement has terminated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Participation in our Initial Public Offering </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In November 2017, in our initial public offering, we issued an aggregate of 5,971,498 shares of our common stock at a purchase price of $14.00
per share, which included 471,498 shares of common stock issued upon exercise by the underwriters of their option to purchase additional shares. Gross proceeds from the offering were approximately $83.6&nbsp;million, prior to deducting
$9.4&nbsp;million of underwriting discounts and commissions, and offering expenses paid by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Certain of our existing stockholders and their affiliated entities, including affiliates of
our directors, purchased an aggregate of approximately $30.0&nbsp;million of our shares in our initial public offering at the initial public offering price. The table below sets forth the aggregate number of common shares issued to our directors,
executive officers or holders of more than 5% of our capital stock, or an affiliate or immediate family member thereof, at the time of the transaction: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:23.10pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:51.30pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Purchase&nbsp;Price</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RA Capital Healthcare Fund, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">484,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,776,000</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Atlas Venture Fund X, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">428,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,999,994</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S.R. One, Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">428,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,999,994</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rock Spring Capital Management, LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,500,000</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lundbeckfond Invest A/S</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214,285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,999,990</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MRL Ventures Fund, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,699,998</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Osage University Partners II, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89,285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,249,990</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director and Executive Officer Compensation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">See &#147;Executive and Director Compensation&#148; for a discussion of payments and options granted to our named executive officers and <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Agreements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have entered into employment agreements with our executive officers. For more information regarding these agreements, see &#147;Executive
and Director Compensation&#151;Narrative Disclosure to Summary Compensation Table.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements with Officers and Directors and
Directors&#146; and Officers&#146; Liability Insurance </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with each of our executive
officers and directors. The indemnification agreements, our amended and restated certificate of incorporation and our amended and restated <FONT STYLE="white-space:nowrap">By-Laws</FONT> require us to indemnify our directors to the fullest extent
not prohibited by Delaware law. Subject to certain limitations, our amended and restated certificate of incorporation also requires us to advance expenses incurred by our directors and officers, subject to limited exceptions. We also maintain a
general liability insurance policy which covers certain liabilities of directors and officers of the Company arising out of claims based on acts or omissions in their capacities as directors or officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policies and Procedures for Related Party Transactions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have adopted a written policy that requires all future transactions between us and any director, executive officer, holder of 5% or more of
any class of our capital stock or any member of the immediate family of, or entities affiliated with, any of them, or any other related persons, as defined in Item 404 of Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> or their affiliates,
in which the amount involved is equal to or greater than $120,000, be approved in advance by our Audit Committee. Any request for such a transaction must first be presented to our Audit Committee for review, consideration and approval. In approving
or rejecting any such proposal, our Audit Committee is to consider the relevant facts and circumstances available and deemed relevant to the Audit Committee, including, but not limited to, the extent of the related party&#146;s interest in the
transaction, and whether the transaction is on terms no less favorable to us than terms we could have generally obtained from an unaffiliated third party under the same or similar circumstances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc521849_14"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information with respect to the beneficial ownership of our common stock at June 30, 2018 by: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of our directors; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of our named executive officers; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all of our current directors and executive officers as a group; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each person, or group of affiliated persons, who beneficially owned more than 5% of our common stock. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The column titled &#147;Percentage of Shares of Common Stock Beneficially Owned&#151;Before Offering&#148; is based on a total of 14,377,753
shares of our common stock outstanding as of June 30, 2018. The column titled &#147;Percentage of Shares of Common Stock Beneficially Owned&#151;After Offering&#148; is based on 17,627,753 shares of our common stock to be outstanding after this
offering, including the 3,250,000 shares of our common stock that we are selling in this offering, but not including any additional shares of common stock issuable upon exercise of outstanding options, any exercise by the underwriters of their
option to purchase additional shares of common stock or Series A Preferred Stock or the conversion of the 2,166 shares of Series A Preferred Stock offered hereby into 2,166,000 shares of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with the rules and regulations of the SEC and includes voting or investment power with
respect to our common stock. Shares of our common stock subject to options that are currently exercisable or exercisable within 60 days after June 30, 2018 are considered outstanding and beneficially owned by the person holding the options for the
purpose of calculating the percentage ownership of that person but not for the purpose of calculating the percentage ownership of any other person. Except as otherwise noted, the persons and entities in this table have sole voting and investment
power with respect to all of the shares of our common stock beneficially owned by them, subject to community property laws, where applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Except as otherwise set forth below, the address of the beneficial owner is c/o Spero Therapeutics, Inc., 675 Massachusetts Avenue, Cambridge,
Massachusetts 02139. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares of</B><br><B>Common Stock</B><br><B>Beneficially&nbsp;Owned</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Percentage&nbsp;of&nbsp;Shares</B><br><B>of Common Stock<BR>Beneficially Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:89.90pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Before</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:29.25pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Offering</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>After</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:29.25pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Offering</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Principal Stockholders</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S.R. One, Limited(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,854,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Atlas Venture Fund IX, L.P.(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,376,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RA Capital Healthcare Fund, L.P.(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,225,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GV 2015, L.P.(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,112,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lundbeckfond Invest A/S(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,091,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Atlas Venture Fund X, LLC(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,031,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with BVF Inc.(7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,029,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MRL Ventures Fund, LLC(8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">935,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Fidelity Investments(9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Named Executive Officers and Directors</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ankit Mahadevia, M.D.(10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">345,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joel Sendek(11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cristina Larkin(12)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Casper Breum(13)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,091,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Milind Deshpande, Ph.D.(14)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jean-Fran&ccedil;ois Formela, M.D.(2)(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,408,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Frank Thomas(15)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick Vink, M.D.(16)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David P. Southwell(17)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All current executive officers and directors as a group (11 persons)(18)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,077,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Indicates beneficial ownership of less than 1%. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 1,854,006 shares of common stock owned by S.R. One, Limited, or S.R. One, an indirect wholly owned subsidiary of GlaxoSmithKline plc. The address for S.R. One is 161 Washington Street, Suite 500, Eight Tower
Bridge, Conshohocken, Pennsylvania 19428. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">All shares are held directly by Atlas Venture Fund IX. Atlas Venture Associates IX, L.P., or AVA IX LP, is the general partner of Atlas Venture Fund IX, and Atlas Venture Associates IX, LLC, or AVA IX LLC, is the
general partner of AVA IX LP. Peter Barrett, Bruce Booth, Jean-Fran&ccedil;ois Formela, Jeff Fagnan, and Ryan Moore are the members of AVA IX LLC and collectively make investment decisions on behalf of Atlas Venture Fund IX. Dr.&nbsp;Formela is also
a member of our board of directors, Dr.&nbsp;Formela disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The address for Atlas Venture Fund IX, is 25 First Street, Suite 303, Cambridge,
Massachusetts 02141. This information is based solely on a Schedule 13G filed by Atlas Venture Fund IX, L.P. with the SEC on February&nbsp;13, 2018, which reported ownership as of December&nbsp;31, 2017. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">RA Capital Management, LLC is the investment advisor and sole general partner of RA Capital Healthcare Fund, L.P. The address of RA Capital Management, LLC is 20 Park Plaza, Suite 1200, Boston, Massachusetts 02116. This
information is based solely on a Schedule 13G filed by RA Capital Healthcare Fund, L.P. with the SEC on February&nbsp;14, 2018, which reported ownership as of December&nbsp;31, 2017. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">GV 2015 GP, L.L.C., the general partner of GV 2015, L.P., Alphabet Holdings LLC, the sole member of GV 2015 GP, L.L.C., Google LLC, the sole member of Alphabet Holdings LLC, XXVI Holdings Inc., the managing member of
Google LLC, and Alphabet Inc., the sole stockholder of XXVI Holdings Inc., may be deemed to have sole power to vote or dispose of the shares held by GV 2015, L.P. The address for GV 2015, L.P., GV 2015 GP, L.L.C., Alphabet Holdings LLC, Google LLC,
XXVI Holdings Inc. and Alphabet Inc. is 1600 Amphitheatre Parkway, Mountain View, California 94043. This information is based solely on a Schedule 13G filed by GV 2015, L.P. with the SEC on February&nbsp;14, 2018, which reported ownership as of
December&nbsp;31, 2017. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">The board of directors of Lundbeckfond Invest A/S consists of J&oslash;rgen Huno Rasmussen, Steffen Kragh, Lars Holmqvist, Susanne Kr&uuml;ger Kj&aelig;r, Michael Kj&aelig;r, Peter Sch&uuml;tze, Gunhild Waldemar, Vagn
Flink M&oslash;ller Pedersen, Henrik Sindal Jensen, and Peter Adler W&uuml;rtzen, who have shared investment and voting control with respect to the shares held by Lundbeckfond Invest A/S and may exercise such control only with the support of a
majority of the members of the Lundbeckfond Invest Ventures A/S board of directors. No individual member of the Lundbeckfond Invest A/S board of directors is deemed to hold any beneficial ownership or reportable pecuniary interest in the shares held
by Lundbeckfond Invest A/S. Casper Breum, one of our directors, is a partner of Lundbeckfond Ventures, a division within Lundbeckfond Invest A/S, and is not deemed to beneficially own the shares held by Lundbeckfond Invest A/S. The address for
Lundbeckfond Invest A/S is Scherfigsvej 7, 2100 Copenhagen &Oslash;, Denmark. This information is based solely on a Schedule 13G filed by Lundbeckfond Invest A/S with the SEC on February&nbsp;14, 2018, which reported ownership as of
December&nbsp;31, 2017. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">All shares are held directly by Atlas Venture Fund X, LLC, or Atlas Fund X. Atlas Venture Associates X, L.P., or AVA X LP, is the general partner of Atlas Venture Fund X, and Atlas Venture Associates X, LLC, or AVA X
LLC, is the general partner of AVA X LP. Peter Barrett, Bruce Booth, Jean-Fran&ccedil;ois Formela, David Gragzel and Jason Rhodes are the members of AVA X LLC and collectively make investment decisions on behalf of Atlas Venture Fund X.
Dr.&nbsp;Formela is also a member of our board of directors. Dr.&nbsp;Formela disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The address for Atlas Venture Fund X, is 400 Technology
Square, 10th&nbsp;Floor, Cambridge, Massachusetts 02139. This information is based solely on a Schedule 13D filed by Atlas Venture Fund X, L.P. with the SEC on March&nbsp;14, 2018, which reported ownership as of December&nbsp;31, 2017.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Includes (i) 510,846 shares of common stock held by Biotechnology Value Fund, L.P., or BVF, (ii) 326,647 shares
of common stock held by Biotechnology Value Fund II, L.P., or BVF II, and (iii) 87,695 shares of </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
common stock held by Biotechnology Value Trading Fund OS LP, or Trading Fund OS. BVF Partners OS Ltd, or Partners OS, as general partner of Trading Fund OS, may be deemed to beneficially own
87,695 shares of common stock beneficially owned by Trading Fund OS. BVF Partners L.P., or Partners, as general partner of BVF, BVF II, the investment manager of Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own
the 1,029,185 shares of common stock beneficially owned in the aggregate by BVF, BVF II, Trading Fund OS, and certain managed accounts of Partners, or the Partners Managed Accounts, including 103,997 shares of common stock held in the Partners
Managed Accounts. BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 1,029,185 shares of common stock owned by Partners. Mark N. Lampert is a director and officer of BVF Inc., and may be deemed to beneficially own
the 1,029,185 shares of common stock beneficially owned by BVF Inc. Partners OS disclaims beneficial ownership of the shares of common stock beneficially owned by Trading Fund OS. Each of Partners, BVF Inc. and Mr.&nbsp;Lampert disclaims beneficial
ownership of the shares of common stock beneficially owned by BVF, BVF II, Trading Fund OS, and the Partners Management Accounts. The address of the principal business and office of BVF Inc. and certain of its affiliates is 1 Sansome Street, 30th
Floor, San Francisco, California, 94194. This information is based solely on a Schedule 13G filed with the SEC on November&nbsp;9, 2017, which reported ownership as of such date. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top">All shares are held directly by MRL Ventures Fund, LLC, or MRL Ventures Fund, which is a subsidiary of Merck Sharp&nbsp;&amp; Dohme Corp. Reza Halse is the President of MRL Ventures. Dr.&nbsp;Halse was also a member of
our board of directors until his resignation immediately prior to the effectiveness of the registration statement filed in connection with our initial public offering. Dr.&nbsp;Halse disclaims beneficial ownership of such shares, except to the
extent of his pecuniary interest therein, if any. The address for MRL Ventures Fund, LLC is 320 Bent Street, Cambridge, Massachusetts 02141. This information is based solely on a Schedule 13G filed by Merck&nbsp;&amp; Co., Inc., Merck
Sharp&nbsp;&amp; Dohme Corp., and MRL Ventures Fund LLC with the SEC on November&nbsp;15, 2017, which reported ownership as of such date. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top">Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B
voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders&#146; voting agreement under which all Series B voting common shares will
be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders&#146; voting agreement, members of the Johnson family may be deemed,
under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. Neither FMR LLC nor Abigail P. Johnson has the sole power to vote or direct the voting of the shares owned directly by the various investment companies
registered under the Investment Company Act (&#147;Fidelity Funds&#148;) advised by Fidelity Management&nbsp;&amp; Research Company (&#147;FMR Co&#148;), a wholly owned subsidiary of FMR LLC, which power resides with the Fidelity Funds&#146; Boards
of Trustees. Fidelity Management&nbsp;&amp; Research Company carries out the voting of the shares under written guidelines established by the Fidelity Funds&#146; Boards of Trustees. The address for FMR LLC is 245 Summer Street, Boston, MA 02210.
This information is based solely on a Schedule 13G filed by FMR LLC and its affiliates with the SEC on February&nbsp;13, 2018, which reported ownership as of December&nbsp;31, 2017. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 65,817 shares of common stock held by Mahadevia-Mehta Family Trust, of which Dr.&nbsp;Mahadevia is the trustee, and (ii) 279,923 shares of common stock underlying options that are exercisable as of June
30, 2018 or will become exercisable within 60 days after such date held by Dr.&nbsp;Mahadevia. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 5,000 shares of common stock held by Mr.&nbsp;Sendek, (ii) 10,181 shares of common stock held by the Joel D. Sendek Retained Annuity Trust No.&nbsp;1, and (iii) 52,448 shares of common stock underlying
options that are exercisable as of June 30, 2018 or will become exercisable within 60 days after such date held by Mr. Sendek. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 1,500 shares of common stock and (ii) 37,717 shares of common stock underlying options that are exercisable as of June 30, 2018 or will become exercisable within 60 days after such date held by
Ms.&nbsp;Larkin. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Breum is a partner at Lundbeckfond Ventures, a division within Lundbeckfond Invest A/S, but has no voting or investment power with respect to the shares described in footnote 5. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 16,454 shares of common stock and (ii) 14,706 shares of common stock underlying options that are exercisable as of June 30, 2018 or will become exercisable within 60 days after such date held by
Mr.&nbsp;Deshpande. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 8,264 shares of common stock underlying options that are exercisable as of June 30, 2018 or will become exercisable within 60 days after such date held by Mr. Thomas. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(16)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 11,808 shares of common stock underlying options that are exercisable as of June 30, 2018 or will become exercisable within 60 days after such date held by Mr.&nbsp;Vink. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(17)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Southwell is a member of our board of directors and holds no voting or investment power with respect to our securities. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(18)</TD>
<TD ALIGN="left" VALIGN="top">See notes 2, 5, 6 and 10 through 17 above; also includes Thomas Parr Jr., Ph.D. and David Melnick, M.D., who are executive officers but not named executive officers. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc521849_15"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our authorized capital
stock consists of&nbsp;60,000,000 shares of common stock, par value $0.001 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share, 2,491 of which are designated as Series A Preferred Stock, and as of June&nbsp;30, 2018,
there were 14,377,753 shares of common stock outstanding and no shares of preferred stock outstanding. As of March 31, 2018, we had approximately 24 record holders of our capital stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following description of our capital stock and provisions of our amended and restated certificate of incorporation, the form of our
certificate of designation with respect to our Series A Preferred Stock and our amended and restated <FONT STYLE="white-space:nowrap">by-laws</FONT> are summaries of material terms and provisions and are qualified by reference to our amended and
restated certificate of incorporation, certificate of designation with respect to our Series A Preferred Stock and our amended and restated <FONT STYLE="white-space:nowrap">by-laws,</FONT> copies of which have been filed with the SEC as exhibits to
the registration statement of which this prospectus is a part. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are authorized to issue one class of common stock. Holders of our common stock are entitled to one vote for each share of common stock held
of record for the election of directors and on all matters submitted to a vote of stockholders. Holders of our common stock are entitled to receive dividends ratably, if any, as may be declared by our board of directors out of legally available
funds, subject to any preferential dividend rights of any preferred stock then outstanding. Upon our dissolution, liquidation or winding up, holders of our common stock are entitled to share ratably in our net assets legally available after the
payment of all our debts and other liabilities, subject to the preferential rights of any preferred stock then outstanding. Holders of our common stock have no preemptive, subscription, redemption or conversion rights. The rights, preferences and
privileges of holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future. Except as described under
&#147;&#151;Anti-takeover Effects of Delaware Law and Provisions of our Amended and Restated Certificate of Incorporation and our Amended and Restated <FONT STYLE="white-space:nowrap">By-Laws&#148;</FONT> below, a majority vote of the holders of
common stock is generally required to take action under our amended and restated certificate of incorporation and amended and restated <FONT STYLE="white-space:nowrap">by-laws.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our board of directors
is authorized, without action by the stockholders, to designate and issue up to an aggregate of&nbsp;10,000,000 shares of preferred stock in one or more series. Our board of directors can designate the rights, preferences and privileges of the
shares of each series and any of its qualifications, limitations or restrictions. Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of
the holders of common stock. The issuance of preferred stock, while providing flexibility in connection with possible future financings and acquisitions and other corporate purposes could, under certain circumstances, have the effect of restricting
dividends on our common stock, diluting the voting power of our common stock, impairing the liquidation rights of our common stock, or delaying, deferring or preventing a change in control of our company, which might harm the market price of our
common stock. See also &#147;Anti-takeover Effects of Delaware Law and Provisions of our Amended and Restated Certificate of Incorporation and our Amended and Restated <FONT STYLE="white-space:nowrap">By-Laws&#148;.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our board of directors will make any determination to issue such shares based on its judgment as to our company&#146;s best interests and the
best interests of our stockholders. We have no shares of preferred stock outstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series A Preferred Stock </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>General</I>. Our amended and restated certificate of incorporation authorizes our board of directors to issue up to 10,000,000 shares of
our preferred stock, par value $0.001 per share, none of which are issued and outstanding. Subject to the limitations prescribed by our amended and restated certificate of incorporation, our board of directors is authorized to establish the number
of shares constituting each series of preferred stock and to fix the designations, powers, preferences and rights of the shares of each of those series and the qualifications, limitations and restrictions of each of those series, all without any
further vote or action by our stockholders. In connection with this offering, our board of directors has designated 2,491 of the 10,000,000 authorized shares of preferred stock as Series A Preferred Stock. When issued, the shares of Series A
Preferred Stock will be validly issued, fully paid and non-assessable. </P>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Rank</I>. The shares of Series A Preferred Stock will
rank: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">senior to all of our common stock; </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">senior to any class or series of our capital stock hereafter created specifically ranking by its terms junior to the Series A Preferred Stock; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on parity to all our shares of Series A Preferred Stock; </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on parity to any class or series of our capital stock hereafter created specifically ranking by its terms on parity with the Series A Preferred Stock; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">junior to any class or series of our capital stock hereafter created specifically ranking by its terms senior to the Series A Preferred Stock; </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in each case, as to distributions of assets upon our liquidation, dissolution or winding up whether voluntarily or involuntarily and/or the right to receive
dividends. </P>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Conversion</I>. Each share of the Series A Preferred Stock is convertible into 1,000 shares of our common stock
(subject to adjustment as provided in the certificate of designation for our Series A Preferred Stock) at any time at the option of the holder, provided that the holder will be prohibited from converting Series A Preferred Stock into shares of our
common stock if, as a result of such conversion, the holder, together with its affiliates and Attribution Parties, would own more than 9.99% of the total number of shares of our common stock then issued and outstanding. The holder of such share of
Series A Preferred Stock can change this requirement upon 61 days&#146; notice to us. </P>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Liquidation preference</I>. Each holder
of shares of Series A Preferred Stock shall be entitled to receive, in preference to any distributions of any of the assets or surplus funds of the company to the holders of our common stock and any of our securities that by their terms are junior
to the Series A Preferred Stock, or Junior Securities, and <I>pari passu</I> with any distribution to the holders of any securities having (by their terms) parity with the Series A Preferred Stock, or Parity Securities, an amount equal to $0.001 per
share of Series A Preferred Stock, plus an additional amount equal to any dividends declared but unpaid on such shares, before any payments shall be made or any assets distributed to holders of any class of common stock or Junior Securities. If,
upon any such liquidation, dissolution or winding up of the company, the assets of the company shall be insufficient to pay the holders of shares of the Series A Preferred Stock the amount required under the preceding sentence, then all remaining
assets of the company shall be distributed ratably to holders of the shares of the Series A Preferred Stock and Parity Securities. After such preferential payment, each holder of shares of Series A Preferred Stock shall be entitled to participate
<I>pari passu</I> with the holders of common stock (on an as-converted basis, without regard to the 9.99% beneficial ownership limitation) and Parity Securities in the remaining distribution of the net assets of the company available for
distribution. </P>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Voting Rights</I>. Shares of Series A Preferred Stock will generally have no voting rights, except as required
by law and except that the consent of the holders of the outstanding Series A Preferred Stock will be required to amend the terms of the Series A Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Dividends</I>. Shares of Series A Preferred Stock will not be entitled to receive any dividends, unless and until specifically declared by
our board of directors. </P>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Redemption</I>. We are not obligated to redeem or repurchase any shares of Series A Preferred Stock.
Shares of Series A Preferred Stock are not entitled to any redemption rights or mandatory sinking fund or analogous fund provisions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Listing</I>. We do not intend to list the Series A Preferred Stock on any securities
exchange or other trading system. We expect the common stock issuable upon conversion of the Series&nbsp;A Preferred Stock to be listed on The Nasdaq Global Select Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Options </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of March 31, 2018,
options to purchase 2,129,082&nbsp;shares of our common stock at a weighted average exercise price of $7.60 were outstanding, of which options to purchase 382,759&nbsp;shares of our common stock were exercisable at a weighted average exercise price
of $5.90 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We entered into an Investors&#146; Rights Agreement dated as of June&nbsp;30, 2017, or the Investors&#146; Rights Agreement, with certain
holders of our capital stock. These shares represent approximately&nbsp;58.6% of our outstanding common stock. These shares also may be sold under Rule&nbsp;144 under the Securities Act of 1933, as amended, or the Securities Act, depending on their
holding period and subject to restrictions in the case of shares held by persons deemed to be our affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under the Investors&#146;
Rights Agreement holders of registrable shares can demand that we file&nbsp;a registration statement or request that their shares be included on a registration statement that we are otherwise filing, in either case, registering the resale of their
shares of common stock. These registration rights are subject to conditions and limitations, including the right, in certain circumstances, of the underwriters of an offering to limit the number of shares included in such registration and our right,
in certain circumstances, not to effect a requested <FONT STYLE="white-space:nowrap">S-1</FONT> registration within 60&nbsp;days before or 180&nbsp;days following any offering of our securities, including this offering, or a requested <FONT
STYLE="white-space:nowrap">S-3</FONT> registration within 30&nbsp;days before or 90&nbsp;days following any offering of our securities, including this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Demand Registration Rights </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The
holders of at least 60% of the registrable securities then outstanding under the Investors&#146; Rights Agreement may require us to file a registration statement under the Securities Act on a Form <FONT STYLE="white-space:nowrap">S-1</FONT> at our
expense, subject to certain exceptions, with respect to the resale of their registrable shares, and we are required to use commercially reasonable efforts to effect the registration. At any time after we are eligible to use a registration statement
under the Securities Act on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3,</FONT> the holders of at least 25% of the registrable securities then outstanding under the Investors&#146; Rights Agreement may require us to file a registration statement
on Form <FONT STYLE="white-space:nowrap">S-3</FONT> at our expense, subject to certain exceptions, with respect to the resale of their registrable shares, and we are required to use commercially reasonable efforts to effect the registration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Piggyback Registration Rights </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If
we propose to register any of our securities under the Securities Act for our own account or the account of any other holder, the holders of registrable shares are entitled to notice of such registration and to request that we include registrable
shares for resale on such registration statement, subject to the right of any underwriter to limit the number of shares included in such registration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expenses of Registration </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We will
pay all registration expenses, other than underwriting discounts and commissions, related to any demand or piggyback registration. The Investors&#146; Rights Agreement contains customary cross-indemnification provisions, pursuant to which we are
obligated to indemnify the selling stockholders, in the event of misstatements or omissions in the registration statement attributable to us except in the event of fraud, and they are obligated to indemnify us for misstatements or omissions
attributable to them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expiration of Registration Rights </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The registration rights will terminate upon the later of the date on which all registrable shares have been sold, the closing of certain
liquidation events, and November&nbsp;6, 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-takeover Effects of Delaware Law and Provisions of our Amended and Restated Certificate of
Incorporation and our Amended and Restated <FONT STYLE="white-space:nowrap">By-Laws</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of
incorporation and amended and restated <FONT STYLE="white-space:nowrap">by-laws</FONT> include a number of provisions that may have the effect of encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to
negotiate with our board of directors rather than pursue <FONT STYLE="white-space:nowrap">non-negotiated</FONT> takeover attempts. These provisions include the items described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Board Composition and Filling Vacancies </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In accordance with our amended and restated certificate of incorporation, our board is divided into three classes serving three-year terms,
with one class being elected each year. Our amended and restated certificate of incorporation also provides that directors may be removed only for cause and then only by the affirmative vote of the holders of 75% or more of the shares then entitled
to vote at an election of directors. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of our board, may only be filled by the affirmative vote of a majority of our
directors then in office, even if less than a quorum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>No Written Consent of Stockholders </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation provides that all stockholder actions are required to be taken by a vote of the
stockholders at an annual or special meeting, and that stockholders may not take any action by written consent in lieu of a meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Meetings of
Stockholders </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our amended and restated <FONT STYLE="white-space:nowrap">by-laws</FONT> provide that only a majority of the members
of our board of directors then in office may call special meetings of stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders. Our amended and restated <FONT
STYLE="white-space:nowrap">by-laws</FONT> limit the business that may be conducted at an annual meeting of stockholders to those matters properly brought before the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Advance Notice Requirements </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our
amended and restated <FONT STYLE="white-space:nowrap">by-laws</FONT> establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election as directors or new business to be brought before
meetings of our stockholders. These procedures provide that notice of stockholder proposals must be timely given in writing to our corporate secretary prior to the meeting at which the action is to be taken. Generally, to be timely, notice must be
received at our principal executive offices not less than 90&nbsp;days or more than 120&nbsp;days prior to the first anniversary date of the annual meeting for the preceding year. The notice must contain certain information specified in the amended
and restated <FONT STYLE="white-space:nowrap">by-laws.</FONT> These provisions may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed. These provisions may also discourage or deter a
potential acquirer from conducting a solicitation of proxies to elect the acquirer&#146;s own slate of directors or otherwise attempting to obtain control of our company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendment to <FONT STYLE="white-space:nowrap">By-laws</FONT> and Certificate of Incorporation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As required by the Delaware General Corporation Law, any amendment of our amended and restated certificate of incorporation must first be
approved by a majority of our board of directors and, if required by law or our amended and restated certificate of incorporation, thereafter be approved by a majority of the outstanding shares entitled to vote on the amendment, and a majority of
the outstanding shares of each class entitled to vote thereon as a class, except that the amendment of the provisions relating to stockholder action, directors, limitation of liability, exclusive jurisdiction of Delaware Courts and the amendment of
our amended and restated <FONT STYLE="white-space:nowrap">by-laws</FONT> and amended and restated certificate of incorporation must be approved by not less than 75% of the outstanding shares entitled to vote on the amendment, and not less than 75%
of the outstanding shares of each </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
class entitled to vote thereon as a class. Our amended and restated <FONT STYLE="white-space:nowrap">by-laws</FONT> may be amended by the affirmative vote of a majority of the directors then in
office, subject to any limitations set forth in the amended and restated <FONT STYLE="white-space:nowrap">by-laws;</FONT> and may also be amended by the affirmative vote of at least 75% of the outstanding shares entitled to vote on the amendment,
or, if our board of directors recommends that the stockholders approve the amendment, by the affirmative vote of the majority of the outstanding shares entitled to vote on the amendment, in each case voting together as a single class. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Blank Check Preferred Stock </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our
amended and restated certificate of incorporation provides for 10,000,000 authorized shares of preferred stock. The existence of authorized but unissued shares of preferred stock may enable our board of directors to render more difficult or to
discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not
in the best interests of us or our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other
rights of the proposed acquirer or insurgent stockholder or stockholder group. In this regard, our amended and restated certificate of incorporation grants our board of directors broad power to establish the rights and preferences of authorized and
unissued shares of preferred stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and
powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;203 of the Delaware General Corporation Law </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are subject to the provisions of Section&nbsp;203 of the Delaware General Corporation Law. In general, Section&nbsp;203 prohibits a
publicly-held Delaware corporation from engaging in a &#147;business combination&#148; with an &#147;interested stockholder&#148; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business
combination is approved in a prescribed manner. A &#147;business combination&#148; includes, among other things, a merger, asset or stock sale or other transaction resulting in a financial benefit to the interested stockholder. An &#147;interested
stockholder&#148; is a person who, together with affiliates and associates, owns, or did own within three years prior to the determination of interested stockholder status, 15% or more of the corporation&#146;s voting stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under Section&nbsp;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of
the following conditions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">before the stockholder became interested, the board of directors approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the
transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances; or </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at or after the time the stockholder became interested, the business combination was approved by the board of directors of the corporation and authorized at an annual or special meeting of the stockholders by the
affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding voting stock that is not owned by the interested stockholder. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">A Delaware corporation may &#147;opt out&#148; of these provisions with an express provision in its original certificate of incorporation or
an express provision in its amended and restated certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws</FONT> resulting from a stockholders&#146; amendment approved by at least a majority of the outstanding voting shares. We have
not opted out of these provisions. As a result, mergers or other takeover or change in control attempts of us may be discouraged or prevented. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exclusive Jurisdiction of Certain Actions </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation requires, to the fullest extent permitted by law, that derivative actions brought in our
name, actions against our directors, officers and employees for breach of fiduciary duty and other similar actions may be brought only in the Court of Chancery in the State of Delaware, unless we otherwise consent. Although we believe this provision
benefits us by providing increased consistency in the application of Delaware law in the types of lawsuits to which it applies, the provision may have the effect of discouraging lawsuits against our directors and officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Global Select Market Listing </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our
common stock is listed on The Nasdaq Global Select Market under the symbol &#147;SPRO.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc521849_16"></A>MATERIAL U.S. FEDERAL INCOME AND </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ESTATE TAX CONSEQUENCES TO <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following is a summary of the material U.S. federal income tax consequences of the ownership and disposition of our common stock or Series
A Preferred Stock to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders (defined below), but does not purport to be a complete analysis of all the potential tax considerations relating thereto. This summary is based upon the provisions of the
Internal Revenue Code of 1986, as amended, or the Code, Treasury regulations promulgated thereunder, administrative rulings and judicial decisions, all as of the date hereof. These authorities may be changed or subject to differing interpretations,
possibly with retroactive effect, so as to result in U.S. federal income tax consequences different from those set forth below. We have not sought and will not seek any ruling from the Internal Revenue Service, or the IRS, with respect to the
statements made and the conclusions reached in the following summary, and there can be no assurance that the IRS or a court will agree with such statements and conclusions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This summary also does not address the tax considerations arising under the laws of any U.S. state or local or any <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> jurisdiction, the 3.8% Medicare tax on net investment income or any alternative minimum tax consequences. In addition, this discussion does not address tax considerations applicable to a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s particular circumstances or to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that may be subject to special tax rules, including, without limitation: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">banks, insurance companies or other financial institutions; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> or government organizations; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">brokers of or dealers in securities or currencies; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">traders in securities that elect to use a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> method of accounting for their securities holdings; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons that own, or are deemed to own, more than five percent of our capital stock; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">certain U.S. expatriates, citizens or former long-term residents of the United States; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons who hold our common stock as a position in a hedging transaction, &#147;straddle,&#148; &#147;conversion transaction,&#148; synthetic security, other integrated investment, or other risk reduction transaction;
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons who do not hold our common stock as a capital asset within the meaning of Section&nbsp;1221 of the Code (generally, for investment purposes); </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons deemed to sell our common stock under the constructive sale provisions of the Code; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">real estate investment trusts or regulated investment companies; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pension plans; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (or investors in any such entities); </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons for whom our stock constitutes &#147;qualified small business stock&#148; within the meaning of Section&nbsp;1202 of the Code; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">integral parts or controlled entities of foreign sovereigns; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">controlled foreign corporations; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons subject to special tax accounting rules as a result of any item of gross income with respect to our common stock being taken into account in an &#147;applicable financial statement,&#148; as defined in the Code;
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">passive foreign investment companies and corporations that accumulate earnings to avoid U.S. federal income tax; or </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons that acquire our common stock or Series A Preferred Stock as compensation for services. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, if a partnership, including any entity or arrangement classified as a partnership for U.S. federal income tax purposes, holds our
common stock or Series A Preferred Stock, the tax treatment of a partner generally will depend on the status of the partner, the activities of the partnership, and certain determinations made at the partner level. Accordingly, partnerships that hold
our common stock or Series A Preferred Stock, and partners in such partnerships, should consult their tax advisors regarding the U.S. federal income tax consequences to them of the purchase, ownership, and disposition of our common stock or Series A
Preferred Stock. </P>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">You are urged to consult your tax advisor with respect to the application of the U.S. federal income tax laws
to your particular situation, as well as any tax consequences of the purchase, ownership and disposition of our common stock or Series A Preferred Stock arising under the U.S. federal estate or gift tax rules or under the laws of any U.S. state or
local or any <FONT STYLE="white-space:nowrap">non-U.S.</FONT> or other taxing jurisdiction or under any applicable tax treaty. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Definition of a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For purposes of this summary, a
<FONT STYLE="white-space:nowrap">&#147;Non-U.S.</FONT> Holder&#148; is any beneficial owner of our common stock that is not a &#147;U.S. person,&#148; and is not a partnership, or an entity disregarded from its owner, in each case for U.S. federal
income tax purposes. A U.S. person is any person that, for U.S. federal income tax purposes, is or is treated as any of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an individual who is a citizen or resident of the United States; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a corporation (or other entity taxable as a corporation for U.S. federal income tax purposes) created or organized under the laws of the United States, any state thereof, or the District of Columbia; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a trust that (1)&nbsp;is subject to the primary supervision of a U.S. court and the control of one or more U.S. persons (within the meaning of Section&nbsp;7701(a)(30) of the Code), or (2)&nbsp;has a valid election in
effect to be treated as a U.S. person for U.S. federal income tax purposes. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As discussed under &#147;Dividend Policy,&#148; above, we do not anticipate paying any dividends on our common stock or Series A Preferred
Stock in the foreseeable future. If we make distributions on our common stock or Series&nbsp;A Preferred Stock, those payments will constitute dividends for U.S. income tax purposes to the extent paid from our current or accumulated earnings and
profits, as determined under U.S. federal income tax principles. To the extent those distributions exceed both our current and our accumulated earnings and profits, they will constitute a return of capital and will first reduce a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s basis in our common stock or Series A Preferred Stock, but not below zero. Any excess will be treated as capital gain and will be treated as described below under &#147;Gain on Sale or Other
Disposition of Common Stock or Series A Preferred Stock.&#148; Any such distributions would be subject to the discussions below regarding backup withholding and FATCA (defined below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Subject to the discussion below on effectively connected income, any dividend paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
Holder generally will be subject to U.S. withholding tax either at a rate of 30% of the gross amount of the dividend or such lower rate as may be specified by an applicable income tax treaty. In order to receive a reduced treaty rate, a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder must provide us or our agent with an IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN,</FONT> IRS
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN-E</FONT></FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or another appropriate version of IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8</FONT> (or a successor form), which must be updated periodically, and which, in each case, must certify
qualification for the reduced rate. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding their entitlement to benefits under any applicable income tax treaty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that are effectively connected with the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, are attributable to a permanent establishment maintained by the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder in the United States) generally are exempt from the withholding tax described above. In order to obtain this exemption, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder must provide the
applicable withholding agent with an IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8ECI</FONT> or successor form or other applicable IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8</FONT> certifying that the dividends are effectively connected
with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States. Such effectively connected dividends, although not subject to withholding tax, are taxed at the same graduated rates
applicable to U.S. persons, net of certain deductions and credits, subject to an applicable income tax treaty providing otherwise. In addition, if you are <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation, dividends you
receive that are effectively connected with your conduct of a U.S. trade or business (and, if an income tax treaty applies, are attributable to a permanent establishment maintained by the you in the United States) may also be subject to a branch
profits tax at a rate of 30% (or such lower rate as may be specified by an applicable income tax treaty) on such effectively connected dividends, as adjusted for certain items. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If you are eligible for a reduced rate of withholding tax pursuant to a tax treaty, you may be able to obtain a refund of any excess amounts
currently withheld if you timely file an appropriate claim for refund with the IRS. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gain on Sale or Other Disposition of Common Stock or Series A
Preferred Stock </B></P>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Subject to the discussion below regarding backup withholding and FATCA, a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder generally will not be subject to U.S. federal income tax on any gain realized upon the sale or other disposition of our common stock or Series A Preferred Stock unless: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States (and, if an income tax treaty applies, the gain is
attributable to a permanent establishment maintained by the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder in the United States), in which case the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be subject to U.S. federal
income tax on the net gain derived from the sale under regular graduated U.S. federal income tax rates, and for a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation, such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
Holder may also be subject to the branch profits tax at a 30% rate (or such lower rate as may be specified by an applicable income tax treaty) on such effectively connected dividends, as adjusted for certain items; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is an individual who is present in the United States for a period or periods aggregating 183&nbsp;days or more during the calendar year in which the sale or
disposition occurs and certain other conditions are met, in which case the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be subject to U.S. federal income tax at a flat 30% rate on the gain derived from the sale, which tax may be
offset by U.S. source capital losses (even though the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is not considered a resident of the United States) (subject to applicable income tax or other treaties); or </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our common stock or Series A Preferred Stock constitutes a U.S. real property interest by reason of our status as
a &#147;U.S. real property holding corporation,&#148; or a USRPHC, for U.S. federal income tax purposes, at any time within the shorter of the five-year period preceding the disposition or the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
Holder&#146;s holding period for our common stock. We believe we are not currently and do not anticipate becoming a USRPHC. However, because the determination of whether we are a USRPHC depends on the fair market value of our U.S. real property
interests relative to the fair market value of our other business assets, there can be no assurance that we will not become a USRPHC in the future. Even if we become a USRPHC, however, gain arising from the sale or other taxable disposition by a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of our common stock or Series A Preferred Stock will not be subject to U.S. federal income tax as long as our common stock is &#147;regularly traded&#148;, as defined by applicable Treasury
Regulations, on an established securities market and such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
does not, actually or constructively, hold more than five percent of our common stock at any time during the applicable period that is specified in the Code. If the foregoing exception does not
apply, then if we are or were to become a USRPHC a purchaser may be required to withhold 15% of the proceeds payable to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder from a sale of our common stock and such
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder generally will be subject to U.S. federal income tax on its net gain derived from the disposition at the graduated U.S. federal income tax rates applicable to United States persons (as defined
in the Code). </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Conversion of Series A Preferred Stock in Exchange for Common Stock </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Non-U.S. Holders will not recognize any gain or loss by reason of receiving our common stock in exchange for our Series A Preferred Stock upon
conversion of the Series A Preferred Stock, except gain or loss will be recognized with respect to the fair market value of any shares of our common stock attributable to dividend arrearages and generally will be treated as a constructive
distribution, and will be taxable, as described above under &#147;&#151;Distributions,&#148; to the extent of our earnings and profits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Constructive Dividends </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The conversion rate of our Series A Preferred Stock is subject to adjustment in certain circumstances. Adjustments that have the effect of
increasing the proportionate interest of holders of our Series A Preferred Stock in our assets or earnings can give rise to deemed dividend income to such holders. Similarly, a failure to adjust the conversion price to reflect a stock dividend or
other events increasing the proportionate interest of the holders of our common stock can, in some circumstances, give rise to deemed dividend income to such common stock holders. Such deemed dividend income is taxable to such holders in the taxable
year of the adjustment (or failure to adjust). Any such deemed dividend with respect to our common stock or Series A Preferred Stock would be subject to U.S. federal withholding tax on dividend income to the same extent as an actual distribution, as
described above under &#147;&#151; Distributions.&#148; Because deemed distributions would not give rise to any cash from which any applicable withholding tax could be satisfied, we may withhold the U.S. federal tax on such dividend from any cash,
shares of common stock or Series A Preferred Stock, or sales proceeds otherwise payable to a Non-U.S. Holder. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Backup Withholding and Information
Reporting </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Generally, we must file information returns annually to the IRS in connection with any dividends on our common stock paid
to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder, regardless of whether any tax was actually withheld. A similar report will be sent to the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder. Pursuant to applicable income tax
treaties or other agreements, the IRS may make these reports available to tax authorities in the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s country of residence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Payments of dividends or of proceeds on the disposition of stock made to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder may be
subject to additional information reporting and backup withholding at a current rate of 28% unless such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder establishes an exemption, for example by properly certifying its <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> status on an IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN,</FONT> IRS <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN-E,</FONT></FONT> IRS <FONT
STYLE="white-space:nowrap">Form&nbsp;W-8ECI,</FONT> or another appropriate version of IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8</FONT> (or a successor form). Notwithstanding the foregoing, backup withholding and information reporting may
apply if either we or our paying agent has actual knowledge, or reason to know, that a holder is a U.S. person. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Backup withholding
is not an additional tax; rather, the U.S. income tax liability of persons subject to backup withholding will be reduced by the amount of tax withheld. If withholding results in an overpayment of taxes, a refund or credit may generally be obtained
from the IRS, provided that the required information is furnished to the IRS in a timely manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Foreign Account Tax Compliance Act </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Foreign Account Tax Compliance Act, or FATCA, imposes withholding tax on certain types of payments made to foreign financial institutions
and certain other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entities. The legislation imposes a 30% withholding tax on dividends on, and, on or after January&nbsp;1, 2019, gross proceeds from the sale or other disposition of, our common stock
or Series A Preferred Stock paid to a &#147;foreign financial institution&#148; or to certain <FONT STYLE="white-space:nowrap">&#147;non-financial</FONT> foreign entities&#148; (each as defined in the Code), unless (i)&nbsp;the foreign financial
institution undertakes certain diligence and reporting obligations, (ii)&nbsp;the <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity either certifies it does </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
not have any &#147;substantial United States owners&#148; (as defined in the Code) or furnishes identifying information regarding each substantial United States owner, or (iii)&nbsp;the foreign
financial institution or <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity otherwise qualifies for an exemption from these rules. If the payee is a foreign financial institution and is subject to the diligence and reporting
requirements in (i)&nbsp;above, it must enter into an agreement with the U.S. Department of the Treasury, or U.S. Treasury, requiring, among other things, that it undertake to identify accounts held by &#147;specified United States persons&#148; or
&#147;United States owned foreign entities&#148; (each as defined in the Code), annually report certain information about such accounts, and withhold 30% on payments to account holders whose actions prevent it from complying with these reporting and
other requirements. If the country in which a payee is resident has entered into an &#147;intergovernmental agreement&#148; with the United States regarding FATCA, that agreement may permit the payee to report to that country rather than to the U.S.
Treasury. Prospective investors should consult their own tax advisors regarding the possible impact of these rules on their investment in our common stock, and the possible impact of these rules on the entities through which they hold our common
stock, including, without limitation, the process and deadlines for meeting the applicable requirements to prevent the imposition of this 30% withholding tax under FATCA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Federal Estate Tax </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Common stock owned
(or treated as owned) by an individual who is not a citizen or a resident of the United States (as defined for U.S. federal estate tax purposes) at the time of death will be included in the individual&#146;s gross estate for U.S. federal estate tax
purposes unless an applicable estate or other tax treaty provides otherwise, and therefore may be subject to U.S. federal estate tax. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B>The preceding discussion of U.S. federal tax considerations is for general information only. It is not tax advice. Each prospective
investor should consult its tax advisor regarding the particular U.S. federal, state and local and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences of purchasing, holding and disposing of our common stock or Series A Preferred
Stock, including the consequences of any proposed change in applicable laws. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc521849_17"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Cowen and Company, LLC and Stifel, Nicolaus&nbsp;&amp; Company, Incorporated are acting as representatives of each of the underwriters named
below. Subject to the terms and conditions set forth in an underwriting agreement among us and the underwriters, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not jointly, to purchase from us, the
number of shares of common stock and Series A Preferred Stock set forth opposite its name below. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Underwriter</U></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:40.20pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>of&nbsp;Shares<BR>of&nbsp;Common<BR>Stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of&nbsp;Shares</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:36.85pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>of&nbsp;Series&nbsp;A<BR>Preferred<BR>Stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.15em; text-indent:-5.15em; font-size:10pt; font-family:Times New Roman">Cowen and Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5.15em; text-indent:-5.15em; font-size:10pt; font-family:Times New Roman">Stifel, Nicolaus&nbsp;&amp; Company,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:5.15em; text-indent:-5.15em; font-size:10pt; font-family:Times New Roman">Incorporated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cantor Fitzgerald&nbsp;&amp; Co.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oppenheimer&nbsp;&amp; Co. Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">H.C. Wainwright&nbsp;&amp; Co., LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions set forth in the underwriting agreement, the underwriters have
agreed, severally and not jointly, to purchase all of the shares sold under the underwriting agreement if any of these shares are purchased. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the
nondefaulting underwriters may be increased or the underwriting agreement may be terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the underwriters
against certain liabilities, including liabilities under the Securities Act, or to contribute to payments the underwriters may be required to make in respect of those liabilities and liabilities incurred in connection with the reserved share program
described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The underwriters are offering the shares, subject to prior sale, when, as and if issued to and accepted by them, subject
to approval of legal matters by their counsel, including the validity of the shares, and other conditions contained in the underwriting agreement, such as the receipt by the underwriters of officer&#146;s certificates and legal opinions. The
underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commissions and Discounts
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The representatives have advised us that the underwriters propose initially to offer the shares to the public at the public offering
price set forth on the cover page of this prospectus and to dealers at that price less a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. After the offering, the public offering price, concession or any other
term of this offering may be changed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table shows the public offering price, underwriting discount and proceeds before
expenses to us. The information assumes either no exercise or full exercise by the underwriters of their option to purchase additional shares. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Without&nbsp;Option</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>With&nbsp;Option</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price of Series A Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discount for common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discount for Series A Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The expenses of this offering, not including the underwriting discount, are estimated at $0.6 million and
are payable by us. We have agreed to reimburse the underwriters for certain of their expenses in an amount up to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
$25,000 incurred in connection with the review and clearance by the Financial Industry Regulatory Authority, Inc. of the terms of this offering, as set forth in the underwriting agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Option to Purchase Additional Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have granted an option to the underwriters, exercisable for 30 days after the date of this prospectus, to purchase up to 487,500 additional
shares of common stock at the public offering price, less the underwriting discount. If the underwriters exercise this option, each will be obligated, subject to conditions contained in the underwriting agreement, to purchase a number of additional
shares proportionate to that underwriter&#146;s initial amount reflected in the above table. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Sales of Similar Securities </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We, our executive officers and directors and our other existing security holders have agreed not to sell or transfer any common stock or
securities convertible into, exchangeable for, exercisable for, or repayable with common stock, including the Series A Preferred Stock, for 90 days after the date of this prospectus without first obtaining the written consent of Cowen and Company,
LLC and Stifel, Nicolaus&nbsp;&amp; Company, Incorporated. Specifically, we and these other persons have agreed, with certain limited exceptions, not to directly or indirectly: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">offer, pledge, sell or contract to sell any common stock, </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sell any option or contract to purchase any common stock, </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">purchase any option or contract to sell any common stock, </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">grant any option, right or warrant for the sale of any common stock, </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">lend or otherwise dispose of or transfer any common stock, </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">request or demand that we file a registration statement related to the common stock, or </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">enter into any swap or other agreement that transfers, in whole or in part, the economic consequence of ownership of any common stock whether any such swap or transaction is to be settled by delivery of shares or other
securities, in cash or otherwise. </TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This <FONT STYLE="white-space:nowrap">lock-up</FONT> provision applies to common
stock and to securities convertible into or exchangeable or exercisable for or repayable with common stock, including the Series A Preferred Stock. It also applies to common stock and Series A Preferred Stock owned now or acquired later by the
person executing the agreement or for which the person executing the agreement later acquires the power of disposition. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Global Select
Market Listing </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The Nasdaq Global Select Market under the symbol &#147;SPRO.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Price Stabilization, Short Positions and Penalty Bids </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In connection with this offering, the underwriters may engage in stabilizing transactions, which involves making bids for, purchasing and
selling shares of common stock in the open market for the purpose of preventing or retarding a decline in the market price of the common stock while this offering is in progress. These stabilizing transactions may include making short sales of the
common stock, which involves the sale by the underwriters of a greater number of shares of common stock than they are required to purchase in this offering, and purchasing shares of common stock on the open market to cover positions created by short
sales. Short sales may be &#147;covered&#148; shorts, which are short positions in an amount not greater than the underwriters&#146; option to purchase additional shares referred to above, or may be &#147;naked&#148; shorts, which are short
positions in excess of that amount. The underwriters may close out any covered short position either by exercising their option to purchase additional shares, in whole or in part, or by purchasing shares in the open market. In making this
determination, the underwriters will consider, among other things, the price of shares available for purchase in the open market compared to the price at which the underwriters may purchase shares through the option to purchase additional
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shares. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock in the open market that could
adversely affect investors who purchase in this offering. To the extent that the underwriters create a naked short position, they will purchase shares in the open market to cover the position. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The underwriters have advised us that, pursuant to Regulation M of the Securities Act, they may also engage in other activities that
stabilize, maintain or otherwise affect the price of the common stock, including the imposition of penalty bids. This means that if the representatives of the underwriters purchase common stock in the open market in stabilizing transactions or to
cover short sales, the representatives can require the underwriters that sold those shares as part of this offering to repay the underwriting discount received by them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, in connection with this offering, the underwriters may engage in passive market making transactions in our common stock on The
Nasdaq Global Select Market prior to the pricing and completion of this offering. Passive market making consists of displaying bids on The Nasdaq Global Select Market no higher than the bid prices of independent market makers and making purchases at
prices no higher than these independent bids and effected in response to order flow. Net purchases by a passive market maker on each day are generally limited to a specified percentage of the passive market maker&#146;s average daily trading volume
in the common stock during a specified period and must be discontinued when such limit is reached. Passive market making may cause the price of our common stock to be higher than the price that otherwise would exist in the open market in the absence
of these transactions. If passive market making is commenced, it may be discontinued at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">These activities may have the effect of
raising or maintaining the market price of the common stock or preventing or retarding a decline in the market price of the common stock, and, as a result, the price of the common stock may be higher than the price that otherwise might exist in the
open market. If the underwriters commence these activities, they may discontinue them at any time. The underwriters may carry out these transactions on The Nasdaq Global Select Market, in the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Neither we nor any of the underwriters make any
representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our common stock. In addition, neither we nor any of the underwriters make any representation that the
representatives will engage in these transactions or that these transactions, once commenced, will not be discontinued without notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic
Distribution </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In connection with this offering, certain of the underwriters or securities dealers may distribute prospectuses by
electronic means, such as emails. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Relationships </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Some of the underwriters and their affiliates have engaged in, and may in the future engage in, investment banking and other commercial
dealings in the ordinary course of business with us or our affiliates. They have received, or may in the future receive, customary fees and commissions for these transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, in the ordinary course of their business activities, the underwriters and their affiliates may make or hold a broad array of
investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers. Such investments and securities activities
may involve securities and/or instruments of ours or our affiliates. The underwriters and their affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or financial
instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>European Economic Area </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In relation to each member state of the European Economic Area, no offer of shares which are the subject of this offering has been, or will be
made to the public in that Member State, other than under the following exemptions under the Prospectus Directive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">to any legal entity which is a qualified investor as defined in the Prospectus Directive; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Directive), subject to obtaining the prior consent of the representative for any such offer; or </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">in any other circumstances falling within Article 3(2) of the Prospectus Directive, </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>provided</I> that no such offer of shares referred to in (a)&nbsp;to (c) above shall result in a requirement for the Company or the
representative to publish a prospectus pursuant to Article 3 of the Prospectus Directive, or supplement a prospectus pursuant to Article 16 of the Prospectus Directive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Each person located in a Member State to whom any offer of shares is made or who receives any communication in respect of an offer of shares,
or who initially acquires any shares will be deemed to have represented, warranted, acknowledged and agreed to and with the representative and the company that (1)&nbsp;it is a &#147;qualified investor&#148; within the meaning of the law in that
Member State implementing Article 2(1)(e) of the Prospectus Directive; and (2)&nbsp;in the case of any shares acquired by it as a financial intermediary as that term is used in Article 3(2) of the Prospectus Directive, the shares acquired by it in
the offer have not been acquired on behalf of, nor have they been acquired with a view to their offer or resale to, persons in any Member State other than qualified investors, as that term is defined in the Prospectus Directive, or in circumstances
in which the prior consent of the representatives has been given to the offer or resale; or where shares have been acquired by it on behalf of persons in any Member State other than qualified investors, the offer of those shares to it is not treated
under the Prospectus Directive as having been made to such persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The company, the representatives and their respective affiliates will
rely upon the truth and accuracy of the foregoing representations, acknowledgments and agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This prospectus has been prepared on
the basis that any offer of shares in any Member State will be made pursuant to an exemption under the Prospectus Directive from the requirement to publish a prospectus for offers of shares. Accordingly, any person making or intending to make an
offer in that Member State of shares which are the subject of this offering contemplated in this prospectus may only do so in circumstances in which no obligation arises for the company or the representatives to publish a prospectus pursuant to
Article 3 of the Prospectus Directive in relation to such offer. Neither the company nor either of the representatives has authorized, nor do they authorize, the making of any offer of shares in circumstances in which an obligation arises for the
company or the representatives to publish a prospectus for such offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an &#147;offer
of shares to the public&#148; in relation to any shares in any Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the shares to be offered so as to enable an investor to decide
to purchase or subscribe the shares, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State, the expression &#147;Prospectus Directive&#148; means Directive 2003/71/EC (as amended)
and includes any relevant implementing measure in each Member State. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The above selling restriction is in addition to any other selling
restrictions set out below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the United Kingdom </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may
only be directed at persons who are &#147;qualified investors&#148; (as defined in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Prospectus Directive)&nbsp;(i) who have professional experience in matters relating to investments falling within Article 19 (5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005, as amended, or the Order, and/or (ii)&nbsp;who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (d)&nbsp;of the Order (all such persons together
being referred to as &#147;relevant persons&#148;). This document must not be acted on or relied on in the United Kingdom by persons who are not relevant persons. In the United Kingdom, any investment or investment activity to which this document
relates is only available to, and will be engaged in with, relevant persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Switzerland </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any other stock exchange
or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing
prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating to our common stock or
this offering may be publicly distributed or otherwise made publicly available in Switzerland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Neither this document nor any other
offering or marketing material relating to this offering, the company or our shares of common stock have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of
shares will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA, or FINMA, and the offer of shares has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. The investor
protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to
Prospective Investors in the Dubai International Financial Centre </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This prospectus relates to an Exempt Offer in accordance with the
Offered Securities Rules of the Dubai Financial Services Authority, or the DFSA. This prospectus is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on
by, any other person. The DFSA has no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no
responsibility for this prospectus. The shares to which this prospectus relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the shares offered should conduct their own due diligence on the shares. If you
do not understand the contents of this prospectus you should consult an authorized financial advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Australia
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian
Securities and Investments Commission in relation to this offering. This prospectus does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001, or the Corporations Act, and does not
purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Any offer in Australia of the shares may only be made to persons (the &#147;Exempt Investors&#148;) who are &#147;sophisticated
investors&#148; (within the meaning of section 708(8) of the Corporations Act), &#147;professional investors&#148; (within the meaning of section 708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in section
708 of the Corporations Act so that it is lawful to offer the shares without disclosure to investors under Chapter 6D of the Corporations Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The shares applied for by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12 months after the date of
allotment under this offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to an exemption under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
section 708 of the Corporations Act or otherwise or where the offer is pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring shares must
observe such Australian <FONT STYLE="white-space:nowrap">on-sale</FONT> restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This prospectus contains general information only
and does not take account of the investment objectives, financial situation or particular needs of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors
need to consider whether the information in this prospectus is appropriate to their needs, objectives and circumstances, and, if necessary, seek expert advice on those matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Hong Kong </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to
&#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or (b)&nbsp;in other circumstances which do not result in the document being a
&#147;prospectus&#148; as defined in the Companies Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation or document relating to the shares has been or
may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if
permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the Securities and
Futures Ordinance and any rules made under that Ordinance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Japan </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The shares have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948, as
amended) and, accordingly, will not be offered or sold, directly or indirectly, in Japan, or for the benefit of any Japanese Person or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or
to any Japanese Person, except in compliance with all applicable laws, regulations and ministerial guidelines promulgated by relevant Japanese governmental or regulatory authorities in effect at the relevant time. For the purposes of this paragraph,
&#147;Japanese Person&#148; shall mean any person resident in Japan, including any corporation or other entity organized under the laws of Japan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Singapore </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other
document or material in connection with the offer or sale, or invitation for subscription or purchase, of shares may not be circulated or distributed, nor may the shares be offered or sold, or be made the subject of an invitation for subscription or
purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore, or the SFA, (ii)&nbsp;to a relevant person
pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions specified in Section&nbsp;275, of the SFA, or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any
other applicable provision of the SFA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Where the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant
person which is: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals,
each of whom is an accredited investor; or </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation or the beneficiaries&#146;
rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares pursuant to an offer made under Section&nbsp;275 of the SFA except: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person arising from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA;
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">where no consideration is or will be given for the transfer; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">where the transfer is by operation of law; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">as specified in Section&nbsp;276(7) of the SFA; or </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Canada </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in
National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument
<FONT STYLE="white-space:nowrap">31-103</FONT> Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus
requirements of applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a purchaser
with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the
securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with
a legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 (or, in the case of securities issued or guaranteed by the government of a <FONT
STYLE="white-space:nowrap">non-Canadian</FONT> jurisdiction, section 3A.4) of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (NI <FONT STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not
required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc521849_18"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The validity of the securities offered by this prospectus will be passed upon for us by Mintz, Levin, Cohn, Ferris, Glovsky&nbsp;&amp; Popeo,
P.C., Boston, Massachusetts. Certain legal matters in connection with this offering will be passed upon for the underwriters by Latham&nbsp;&amp; Watkins LLP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc521849_19"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The financial statements as of December&nbsp;31, 2017 and 2016 and for each of the three years in the period ended December&nbsp;31, 2017
included in this prospectus have been so included in reliance on the report (which contains an explanatory paragraph relating to the Company&#146;s requirement for additional financing to fund future operations as described in Note 1 to the
consolidated financial statements) of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc521849_20"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1,</FONT> including exhibits and
schedules, under the Securities Act that registers the securities to be sold in this offering. This prospectus, which constitutes a part of the registration statement, does not contain all the information contained in the registration statement and
the exhibits and schedules filed as part of the registration statement. For further information with respect to us and our securities, we refer you to the registration statement and the exhibits and schedules filed as part of the registration
statement. Statements contained in this prospectus as to the contents of any contract or other document are not necessarily complete. If a contract or document has been filed as an exhibit to the registration statement, we refer you to the copies of
the contract or document that has been filed. Each statement in this prospectus relating to a contract or document filed as an exhibit is qualified in all respects by the filed exhibit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We file our annual, quarterly and current reports, proxy statements and other information with the SEC under the Exchange Act. You can read
our SEC filings, including the registration statement, at the SEC&#146;s website at <I>www.sec.gov</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">You may read and copy this
information at the SEC&#146;s Public Reference Room at 100&nbsp;F Street, N.E., Washington D.C. 20549, at prescribed rates. You may obtain information regarding the operation of the public reference room by calling the SEC at <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-SEC-0330.</FONT></FONT></FONT> The SEC also maintains a website (<I>http://www.sec.gov</I>) that contains reports, proxy and information statements
and other information regarding issuers that file electronically with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our website address is <I>www.sperotherapeutics.com</I>.
The information contained in, and that can be accessed through, our website is not incorporated into and is not part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="index"></A><A NAME="toc521849_21"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin521849_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin521849_2">Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin521849_3">Consolidated Statements of Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin521849_4">Consolidated Statements of Bridge Units, Redeemable Convertible Preferred Shares
 and Stockholders&#146; Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin521849_5">Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-8</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin521849_6">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-10</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Interim Financial Statements (Unaudited)</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin521849_7">Consolidated Balance Sheets as of March&nbsp;31, 2018 and December&nbsp;
31, 2017</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin521849_8">Consolidated Statements of Operations and Comprehensive Loss for the three months
 ended March&nbsp;31, 2018 and 2017</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin521849_9">Consolidated Statements of Cash Flows for the three months ended March&nbsp;
31, 2018 and 2017</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin521849_10">Notes to Unaudited Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin521849_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Board of Directors and Stockholders of Spero Therapeutics, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Opinion on the Financial Statements </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have
audited the accompanying consolidated<B></B>&nbsp;balance sheets of Spero Therapeutics Inc. and its subsidiaries as of December&nbsp;31, 2017 and 2016 and the related consolidated statements of operations and comprehensive loss, of bridge units,
redeemable convertible preferred shares and stockholders&#146; equity (deficit) and of cash flows for each of the three years in the period ended December&nbsp;31, 2017, including the related notes (collectively referred to as the
&#147;consolidated<B></B>&nbsp;financial statements&#148;).&nbsp;In our opinion, the&nbsp;consolidated financial statements present fairly, in all material respects, the financial position of the Company<B></B>&nbsp;as of December&nbsp;31, 2017 and
2016, and the results of their operations and their cash flows for each of the three years in the period ended December&nbsp;31, 2017 in&nbsp;conformity with accounting principles generally accepted in the United States of America.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis for Opinion </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These&nbsp;consolidated<B></B>&nbsp;financial statements are the responsibility of the Company&#146;s management.&nbsp;Our responsibility is to express an
opinion on the Company&#146;s&nbsp;consolidated&nbsp;financial statements based on our audits.&nbsp;We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#147;PCAOB&#148;) and are required to
be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits of&nbsp;these consolidated financial statements in accordance with the standards of the PCAOB.&nbsp;Those standards require that we
plan and perform the audit to obtain reasonable assurance about whether the consolidated financial&nbsp;statements are free of material misstatement, whether due to error or fraud.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audits included performing procedures to assess the risks of material misstatement of the&nbsp;consolidated financial statements, whether due to error or
fraud, and performing procedures that respond to those risks.&nbsp;Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.&nbsp;Our audits also included evaluating
the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial&nbsp;statements.&nbsp;We believe that our audits provide a reasonable basis for our opinion.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Emphasis of Matter </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As discussed in Note 1
to the consolidated financial statements, the Company will require additional financing to fund future operations. Management&#146;s plans in regard to this matter are described in Note 1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ PricewaterhouseCoopers&nbsp;LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&nbsp;2, 2018 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s auditor
since 2016. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin521849_2"></A>CONSOLIDATED BALANCE SHEETS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except unit, share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">87,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax incentive receivables, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax incentive receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">93,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, Bridge Units, Redeemable Convertible Preferred Shares and Stockholders&#146;
Equity (Deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bridge units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred units (Class A, B, C and Junior); no units authorized, issued or
outstanding as of December&nbsp;31, 2017; 13,549,685 units issued and outstanding as of December&nbsp;31, 2016, aggregate liquidation preference of $50,326 as of December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity (deficit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common units, zero and 335,281 units issued and outstanding as of December&nbsp;31, 2017 and 2016,
respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.001 par value; 10,000,000 and zero shares authorized as of December&nbsp;31,
2017 and 2016, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value; 60,000,000 shares authorized as of December&nbsp;31, 2017;
14,369,182 shares issued and outstanding as of December&nbsp;31, 2017; no shares authorized, issued or outstanding as of December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">181,428</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(96,840</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45,440</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Spero Therapeutics, Inc. stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45,440</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-controlling</FONT> interests</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,808</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49,248</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, redeemable convertible preferred units, and stockholders&#146; equity
(deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">93,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin521849_3"></A>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41,730</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,221</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,327</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income and other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,886</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,641</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,153</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Net loss attributable to <FONT STYLE="white-space:nowrap">non-controlling</FONT>
interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,143</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,999</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to Spero Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,743</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,491</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,154</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cumulative dividends on redeemable convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,146</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(932</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of redeemable bridge units and redeemable convertible preferred shares to redemption
value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,208</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(996</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common shareholders of Spero Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(46,097</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(29,928</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,427</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common shareholders per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17.82</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(95.87</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(53.11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding, basic and diluted:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,586,865</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">312,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">252,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral
part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin521849_4"></A>CONSOLIDATED STATEMENTS OF BRIDGE UNITS, REDEEMABLE CONVERTIBLE PREFERRED SHARES AND </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCKHOLDERS&#146; EQUITY (DEFICIT) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except unit and share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="10" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">Paid-in</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Accumu-</B><br><B>lated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Spero<BR>Therapeutics,<BR>Inc.</B><br><B>Stockholders&#146;</B><br><B>Equity<BR>(Deficit)</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Non-</B><br><B>controlling</B><br><B>Interest</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B><br><B>Stockholders&#146;</B><br><B>Equity<BR>(Deficit)</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Bridge Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Preferred Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Preferred</B><br><B>Stock</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Common Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Par&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Par&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balances at December&nbsp;31, 2014</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,438,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">356,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,178</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,113</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,113</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of bridge units, net of derivative liability of $2,307</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Deemed contribution of capital for reduction in conversion discount</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Conversion of bridge units into Class&nbsp;A preferred units, net of tranche rights derivative
liability of $1,301</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,279,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Class&nbsp;A preferred units, net of tranche rights of $1,100 and offering costs of
$170</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,923,076</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cumulative dividends on redeemable convertible preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(932</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(932</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(932</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accretion of bridge units to redemption value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(539</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,768</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,307</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,307</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accretion of preferred units to redemption value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of 49.9% <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest in Spero
Potentiator in exchange for licensed technology</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,087</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,087</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of additional shares in Spero Potentiator to minority investor under anti-dilution
rights</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,154</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,154</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,999</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,153</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balances at December&nbsp;31, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,640,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">356,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(453</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,553</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF BRIDGE UNITS, REDEEMABLE CONVERTIBLE PREFERRED SHARES AND </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCKHOLDERS&#146; EQUITY (DEFICIT) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except unit and share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="10" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">Paid-in</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Accumu-</B><br><B>lated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Spero<BR>Therapeutics,<BR>Inc.</B><br><B>Stockholders&#146;</B><br><B>Equity<BR>(Deficit)</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Non-</B><br><B>controlling</B><br><B>Interest</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B><br><B>Stockholders&#146;</B><br><B>Equity<BR>(Deficit)</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Bridge Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Preferred Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Preferred</B><br><B>Stock</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Common Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Par&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Par&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Deemed contribution of capital for settlement of Class&nbsp;A preferred unit tranche
rights</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Class&nbsp;B preferred units, net of tranche rights derivative liability of $909 and
offering costs of $112</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,909,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of bridge units, net of contingent prepayment option derivative liability of $908</P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Repurchase of unvested common units</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,116</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cumulative dividends on redeemable convertible preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,503</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(938</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accretion of redeemable preferred units to redemption value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(911</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(969</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(969</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accretion of bridge units to redemption value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of 20% <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest in Spero Gyrase in
exchange for acquired technology</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of 5% <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest in Spero Europe in
exchange for licensed technology</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of 12.5% <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest in Spero Cantab
in exchange for licensed technology</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of additional shares in Spero Potentiator to minority investor under anti-dilution
rights</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,491</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,491</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,641</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balances at December&nbsp;31, 2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,549,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">335,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45,440</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45,440</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,808</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49,248</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF BRIDGE UNITS, REDEEMABLE CONVERTIBLE PREFERRED SHARES AND </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCKHOLDERS&#146; EQUITY (DEFICIT) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except unit and share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="10" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">Paid-in</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Accumu-</B><br><B>lated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Spero<BR>Therapeutics,<BR>Inc.</B><br><B>Stockholders&#146;</B><br><B>Equity<BR>(Deficit)</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Non-</B><br><B>controlling</B><br><B>Interest</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B><br><B>Stockholders&#146;</B><br><B>Equity<BR>(Deficit)</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Bridge Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Preferred Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Preferred</B><br><B>Stock</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Common Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Par&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Par&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Accretion of bridge units to redemption value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(123</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(453</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(576</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(576</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Conversion of bridge units into Class&nbsp;C preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,321,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Issuance of Class&nbsp;C preferred units, net of issuance costs of $176</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,326,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Purchase of <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest in Spero
Europe</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Purchase of <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest in Spero
Potentiator</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,395</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,395</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Purchase of <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest in Spero
Cantab</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,103</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(175</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Cumulative dividends on redeemable convertible preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,261</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,261</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,261</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Accretion of redeemable preferred units to redemption value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(369</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(369</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(369</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Exchange of units in Spero Therapeutics, LLC for shares in Spero Therapeutics, Inc. on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,197,267</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(103,760</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,197,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,760</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(335,281</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">335,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Issuance of Series C preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Cumulative dividends on redeemable convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,885</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,983</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(902</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,885</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,885</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Accretion of preferred stock to redemption value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">263</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(263</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(263</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(263</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Issuance of common stock, conversion of preferred stock to common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,259,147</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(107,018</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,062,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Issuance of common stock, initial public offering net of issuance costs of $3,574</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,971,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,743</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,743</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,143</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,886</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman"><B>Balances at December&nbsp;31, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,369,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">181,428</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(96,840</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">84,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">84,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin521849_5"></A>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(39,886</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,641</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,153</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,541</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(580</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(174</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized foreign currency transaction loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(707</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(294</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(575</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(966</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(280</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax incentive receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,811</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(144</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(644</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(128</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(84</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Advance payments from collaborator</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(929</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(470</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,111</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,959</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,608</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from investing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(830</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(232</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(830</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(232</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from financing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from initial public offering of common stock, net of commissions and underwriting
discounts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of initial public offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,574</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of Class&nbsp;A preferred units, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of bridge units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of offering costs related to 2016 issuance of Class&nbsp;B preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of Class&nbsp;B preferred units, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of Class&nbsp;C preferred units, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash payment for <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,175</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">87,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Supplemental disclosure of <FONT STYLE="white-space:nowrap">non-cash</FONT> investing and
financing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of bridge units into preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of preferred stock to common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">107,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Settlement of derivative liabilities upon issuance of preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of tranche rights with preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deemed contribution of capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Settlement of derivative liability upon issuance of bridge units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of contingent prepayment option with bridge units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cumulative dividends on redeemable convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of redeemable convertible preferred units and stock to redemption value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of bridge units to redemption value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of additional shares of common stock to minority investors under anti-dilution
rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment included in accounts payable, accrued expenses and deferred
rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering costs included in accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin521849_6"></A>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Nature of the Business and Basis of Presentation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Spero Therapeutics, Inc., together with its consolidated subsidiaries (the&nbsp;&#147;Company&#148;), is a multi-asset, clinical-stage
biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant (&#147;MDR&#148;) bacterial infections. The Company&#146;s most advanced product candidate, SPR994, is designed to be the
first broad-spectrum oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. Treatment with effective orally administrable antibiotics may prevent hospitalizations for serious infections and enable earlier, more
convenient and cost-effective treatment of patients after hospitalization. The Company also has a platform technology known as its Potentiator Platform that it believes will enable it to develop drugs that will expand the spectrum and potency of
existing antibiotics, including formerly inactive antibiotics, against Gram-negative bacteria. The Company&#146;s lead product candidates generated from its Potentiator Platform are two intravenous, or IV,-administered agents, SPR741 and SPR206,
designed to treat MDR Gram-negative infections in the hospital setting. In addition, the Company is developing SPR720, an oral antibiotic designed for the treatment of pulmonary <FONT STYLE="white-space:nowrap">non-tuberculous</FONT> mycobacterial
infections. The Company believes that its novel product candidates, if successfully developed and approved, would have a meaningful patient impact and significant commercial applications for the treatment of MDR infections in both the community and
hospital settings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company was formed as Spero Therapeutics, LLC in December 2013 under the laws of the State of Delaware. On
June&nbsp;30, 2017, through a series of transactions, Spero Therapeutics, LLC merged with and into Spero Therapeutics, Inc. (formerly known as Spero OpCo, Inc.), a Delaware corporation. As part of the transactions, holders of preferred units and
common units of Spero Therapeutics, LLC exchanged their units for shares of Spero Therapeutics, Inc. on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis. These transactions are collectively referred
to as the Reorganization. Upon completion of the Reorganization, the historical consolidated financial statements of Spero Therapeutics, LLC became the historical consolidated financial statements of Spero Therapeutics, Inc. because the
Reorganization was accounted for as a reorganization of entities under common control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company is subject to risks and uncertainties
common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government
regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and
regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#146;s product development
efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On
October&nbsp;20, 2017, the Company effected <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;one-for-6.0774&nbsp;reverse</FONT></FONT> stock split of its issued and outstanding shares of common stock and a proportional
adjustment to the existing conversion ratios for each series of the Company&#146;s Preferred Stock (see Note 5). Accordingly, all share and per share amounts for all periods presented in the accompanying consolidated financial statements and notes
thereto have been adjusted retroactively, where applicable, to reflect this reverse stock split and adjustment of the preferred stock conversion ratios. In addition, all common units and incentive units as well as the conversion ratios of preferred
units of Spero Therapeutics, LLC have been presented as if the reverse stock split of the common stock of Spero Therapeutics, Inc. had been applied to such units and ratios of Spero Therapeutics, LLC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On November&nbsp;6, 2017, Spero Therapeutics, Inc. completed an initial public offering (&#147;IPO&#148;) of its common stock, and issued and
sold 5,500,000 shares of common stock at a public offering price of $14.00 per share, resulting in net proceeds of $71.6&nbsp;million after deducting underwriting discounts and commissions but before deducting offering costs. On November&nbsp;14,
2017, Spero Therapeutics, Inc., issued and sold an additional 471,498 shares of its common stock at the IPO price of $14.00 per share pursuant to the underwriters&#146; partial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exercise of their option to purchase additional shares of common stock, resulting in additional net proceeds of $6.1&nbsp;million after deducting underwriting discounts and commissions. Upon the
closing of the IPO in November 2017, the Company&#146;s outstanding convertible preferred shares automatically converted into shares of common stock (see Note 6). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements of the Company have been prepared in conformity with accounting principles generally
accepted in the United States of America (&#147;GAAP&#148;) and include the accounts of the Company and its consolidated subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In accordance with Accounting Standards Update (&#147;ASU&#148;) <FONT STYLE="white-space:nowrap">2014-15,</FONT><I>&nbsp;Disclosure of
Uncertainties about an Entity&#146;s Ability to Continue as a Going Concern (Subtopic <FONT STYLE="white-space:nowrap">205-40)</FONT></I>, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise
substantial doubt about the Company&#146;s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. Since inception, the Company has funded its operations with proceeds from sales
of preferred units (including bridge units, which converted into preferred units), payments received in connection with a concluded collaboration agreement and funding from government contracts, and most recently, with proceeds from the IPO
completed in November 2017. The Company has incurred recurring losses since inception, including net losses attributable to Spero Therapeutics, Inc. of $38.7&nbsp;million, $25.5&nbsp;million and $10.2&nbsp;million for the years ended
December&nbsp;31, 2017, 2016 and 2015, respectively. In addition, as of December&nbsp;31, 2017, the Company had an accumulated deficit of $96.8&nbsp;million. The Company expects to continue to generate operating losses for the foreseeable future. As
of the issuance date of the annual consolidated financial statements, the Company expects that its cash and cash equivalents, would be sufficient to fund its operating expenses, capital expenditure requirements through at least 12 months from the
issuance date of these annual consolidated financial statements. However, the future viability of the Company beyond that point is dependent on its ability to raise additional capital to finance its future operations. The Company will seek
additional funding through public or private financings, debt financing, collaboration agreements or government grants. The inability to obtain funding, as and when needed, would have a negative impact on the Company&#146;s financial condition and
ability to pursue its business strategies. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization
efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. Although management intends to pursue plans to obtain additional funding to finance its operations, there is no assurance that the
Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Accordingly, the consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the
ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The preparation
of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for research and development
expenses, the valuation of common shares prior to the Company&#146;s IPO, the valuation of share-based awards and the valuation of derivative liabilities. The Company bases its estimates on historical experience, known trends and other
market-specific or other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience.
Actual results may differ from those estimates or assumptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Consolidation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company consolidates entities in which it has a controlling financial interest. The Company evaluates each of its subsidiaries to
determine whether the entity represents a variable interest entity (&#147;VIE&#148;), for which consolidation should be evaluated under the VIE model, or, alternatively, if the entity is a voting interest entity, for which consolidation should be
evaluated using the voting interest model. The Company has concluded that none of its subsidiaries is a VIE and has consolidated each subsidiary under the voting interest model because it has majority voting control of each subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Ownership interests in the Company&#146;s subsidiaries that are held by entities other than the Company are reported as <FONT
STYLE="white-space:nowrap">non-controlling</FONT> interests in the consolidated balance sheets. Losses attributed to <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests and to the Company are reported separately in the consolidated
statements of operations and comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016, the Company consolidated the following subsidiaries that
were not wholly owned: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Subsidiary</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Relationship</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Country</B><br><B>Domiciled</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year of</B><br><B>Inclusion</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Spero Potentiator, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Controlling interest</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">United&nbsp;States</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Spero Europe, Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Controlling&nbsp;interest</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">United&nbsp;Kingdom</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Spero Gyrase, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Controlling interest</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">United&nbsp;States</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Spero Cantab, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Controlling interest</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">United&nbsp;States</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">All of the <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests in Spero Europe, Ltd., Spero
Potentiator, Inc. and Spero Cantab, Inc. were repurchased by the Company during the year ended December&nbsp;31, 2017 (see Note&nbsp;9). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentrations of Credit Risk and of Significant Suppliers </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The
Company maintains most of its cash and cash equivalents at one accredited financial institution. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. In
particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be
adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Deferred Offering Costs
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with <FONT
STYLE="white-space:nowrap">in-process</FONT> equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders&#146; deficit as a reduction of
additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital generated as a result of the offering. Should the planned equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in
the consolidated statement of operations and comprehensive loss. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Equivalents </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash
equivalents. Cash equivalents consisted of money market funds at December&nbsp;31, 2017. The Company did not have any cash equivalents as of December&nbsp;31, 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Property
and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:130.10pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;Estimated Useful Life&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer software and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3 years</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office furniture and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">7 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Shorter&nbsp;of&nbsp;life&nbsp;of&nbsp;lease&nbsp;or&nbsp;5&nbsp;years</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Costs for capital assets not yet placed into service are capitalized as construction in progress and are
depreciated in accordance with the above guidelines once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or
loss is included in loss from operations. Expenditures for repairs and maintenance are charged to expense as incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of Long-Lived
Assets </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Long-lived assets consist of property and equipment. Long-lived assets to be held and used are tested for recoverability
whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant
underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset
group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized when estimated
undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined
based on discounted cash flows. The Company did not record any impairment losses on long-lived assets during the years ended December&nbsp;31, 2017, 2016 or 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Measurements </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Certain
assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset
or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and
liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level 1&#151;Quoted prices in active markets for identical assets or liabilities. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level 2&#151;Observable inputs (other than Level&nbsp;1 quoted prices), such as quoted prices in active markets
for similar assets or liabilities, quoted prices in markets that are not active for identical or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level 3&#151;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow
methodologies and similar techniques. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company&#146;s cash equivalents and derivative liabilities are carried at fair
value, determined according to the fair value hierarchy described above (see Note 3). The carrying values of the Company&#146;s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Derivative Liabilities </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In
connection with certain equity financings, licensing transactions and research collaborations, the Company has identified certain embedded and freestanding derivatives, which are recorded as liabilities on the Company&#146;s consolidated balance
sheet and are remeasured to fair value at each reporting date until the derivative is settled. Changes in the fair value of the derivative liabilities are recognized as other income (expense) in the consolidated statement of operations and
comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Classification and Accretion of Bridge Units and Redeemable Convertible Preferred Shares </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company has classified bridge units and redeemable convertible&nbsp;preferred shares outside of stockholders&#146; equity (deficit)
because the shares contain certain redemption features that are not solely within the control of the Company. The carrying values of these instruments are accreted to their respective redemption values from the date of issuance through the earliest
date of redemption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Segment Information </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The
Company&#146;s singular focus is on identifying, developing and commercializing novel treatments for MDR bacterial infections. All of the Company&#146;s tangible assets are held in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Government Contracts and Revenue Recognition </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company generates revenue from government contracts that reimburse the Company for certain allowable costs for funded projects. For
contracts with government agencies, when the Company has concluded that it is the principal in conducting the research and development expenses and where the funding arrangement is considered central to the Company&#146;s ongoing operations, the
Company classifies the recognized funding received as revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company has concluded to recognize funding received from the U.S.
Department of Defense (&#147;DoD&#148;), the National Institute of Allergy and Infectious Diseases (&#147;NIAID&#148;) of the National Institutes of Health (&#147;NIH&#148;) and Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator <FONT
STYLE="white-space:nowrap">(&#147;CARB-X&#148;)</FONT> as revenue, rather than as a reduction of research and development expenses, because the Company is the principal in conducting the research and development activities and these contracts are
central to its ongoing operations. Revenue is recognized as the qualifying expenses related to the contracts are incurred. Revenue recognition commences only once persuasive evidence of a contract exists, services have been rendered, the
reimbursement amounts under the contract are fixed or determinable, and collectibility is reasonably assured. Revenue recognized upon incurring qualifying expenses in advance of receipt of funding is recorded in the Company&#146;s consolidated
balance sheet as other receivables. The related costs incurred by the Company are included in research and development expense in the Company&#146;s consolidated statements of operations and comprehensive loss. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Government Tax Incentives </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For available government tax incentives that the Company may earn without regard to the existence of taxable income and that require the
Company to forego tax deductions or the use of future tax credits and net operating loss carryforwards, the Company classifies the funding recognized as a reduction of the related qualifying research and development expenses incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Since the fourth quarter of 2016, the Company&#146;s operating subsidiary in Australia has met the eligibility requirements to receive a 43.5%
tax incentive for qualifying research and development activities (see Note 14). The Company recognizes these incentives as a reduction of research and development expenses in the consolidated statements of operations and comprehensive loss in the
same period that the related qualifying expenses are incurred. Reductions of research and development expense recognized upon incurring qualifying expenses in advance of receipt of tax incentive payments are recorded in the consolidated balance
sheet as tax incentive receivables. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Collaboration Agreements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For collaboration agreements with a third party, to determine the appropriate statement of operations classification of the recognized
funding, the Company first assesses whether the collaboration arrangement is within the scope of the accounting guidance for collaboration arrangements. If it is, the Company evaluates the collaborative arrangement for proper classification in the
statement of operations based on the nature of the underlying activity and the Company assesses the payments to and from the collaborative partner. If the payments to and from the collaborative partner are not within the scope of other authoritative
accounting guidance, the Company bases the statement of operations classification for the payments received on a reasonable, rational analogy to authoritative accounting guidance, applied in a consistent manner. Conversely, if the collaboration
arrangement is not within the scope of accounting guidance for collaboration arrangements, the Company assesses whether the collaboration arrangement represents a vendor/customer relationship. If the collaborative arrangement does not represent a
vendor/customer relationship, the Company then classifies the funding payments received in the statement of operations and comprehensive loss as a reduction of the related expense that is incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In 2014, the Company entered into a research and development services and support agreement with
<FONT STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche Inc. and certain of its affiliates (&#147;Roche&#148;) and concluded that the agreements were not within the scope of the accounting guidance for collaboration arrangements (see Note 13). Due
to the <FONT STYLE="white-space:nowrap">co-funded</FONT> nature of the payments and the Company&#146;s assessment that it did not have a vendor/customer relationship with Roche, the Company recognized the nonrefundable payments received under the
agreement as a reduction to the research and development expenses incurred, based on a proportional methodology comparing the total expenses incurred in the period under the project to the total expenses expected to be incurred under the project.
The Company terminated the agreement with Roche in August 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Costs </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Research and development costs are expensed as incurred. Research and development expenses are comprised of costs incurred in performing
research and development activities, including salaries, share-based compensation and benefits, facilities costs, depreciation, manufacturing expenses and external costs of outside vendors engaged to conduct preclinical development activities and
trials as well as the cost of licensing technology. Upfront payments and milestone payments made for the licensing of technology are expensed as research and development in the period in which they are incurred. Nonrefundable advance payments for
goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research Contract Costs and Accruals </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company has entered into various research and development contracts with research institutions and other companies both inside and outside
of the United States. These agreements are generally cancelable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of
the accrued liabilities, the Company analyzes progress of the studies or trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at
the end of any reporting period. Actual results could differ from the Company&#146;s estimates. The Company&#146;s historical accrual estimates have not been materially different from the actual costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent Costs </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">All patent-related
costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share-Based Compensation </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The
Company measures all share-based awards granted to employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model. Compensation expense of those awards is recognized over the requisite service
period, which is generally the vesting period of the respective award. Generally, the Company issues awards with only service-based vesting conditions and records the expense for these awards using the straight-line method. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For share-based awards granted to <FONT STYLE="white-space:nowrap">non-employee</FONT> consultants, compensation expense is recognized over
the period during which services are rendered by such consultants until completed. At the end of each financial reporting period prior to completion of the service, the fair value of these awards is remeasured using the then-current fair value of
the Company&#146;s common shares and updated assumption inputs in the Black-Scholes option-pricing model. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company classifies
share-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#146;s payroll costs are classified or in which the award recipient&#146;s service payments are
classified. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive Loss </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Comprehensive loss includes net loss as well as other changes in stockholders&#146; equity (deficit) that result from transactions and
economic events other than those with shareholders. There was no difference between net loss and comprehensive loss for each of the periods presented in the accompanying consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Income (Loss) per Share Attributable to Spero Therapeutics, Inc. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company follows the <FONT STYLE="white-space:nowrap">two-class</FONT> method when computing net income (loss) per share, as the Company
has issued shares that meet the definition of participating securities. The <FONT STYLE="white-space:nowrap">two-class</FONT> method determines net income (loss) per share for each class of common and participating securities according to dividends
declared or accumulated and participation rights in undistributed earnings. The <FONT STYLE="white-space:nowrap">two-class</FONT> method requires income available to common stockholders for the period to be allocated between common and participating
securities based upon their respective rights to receive dividends as if all income for the period had been distributed. Net income (loss) per share attributable to common stockholders is calculated based on net income (loss) attributable to Spero
Therapeutics, Inc. and excludes net income (loss) attributable to <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Basic net income (loss) per share attributable to common stockholders is computed by dividing
the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) attributable to common stockholders is computed by adjusting net income (loss)
attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income
(loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company&#146;s preferred stock contractually entitles the holders of such shares to participate in dividends but does not contractually
require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a
net loss attributable to common stockholders of Spero Therapeutics, Inc., diluted net loss per share attributable to common stockholders of Spero Therapeutics, Inc. is the same as basic net loss per share attributable to common stockholders of Spero
Therapeutics, Inc., since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders of Spero Therapeutics, Inc. for the years ended
December&nbsp;31, 2017, 2016 and 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and
liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#146;s tax returns. Deferred tax assets and liabilities are determined on the basis of the
differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the
provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not
that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits
expected and considering prudent and feasible tax planning strategies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company accounts for uncertainty in income taxes recognized in
the consolidated financial statements by applying a <FONT STYLE="white-space:nowrap">two-step</FONT> process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will
be sustained upon external examination by the taxing authorities. If the tax position is deemed <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> to be sustained, the tax position is then assessed to determine the amount of benefit to
recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the
effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Adopted Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In August 2014, the Financial Accounting Standards Board (&#147;FASB&#148;) issued ASU
<FONT STYLE="white-space:nowrap">No.&nbsp;2014-15,</FONT> <I>Disclosure of Uncertainties about an Entity&#146;s Ability to Continue as a Going Concern</I> (&#147;ASU <FONT STYLE="white-space:nowrap">2014-15&#148;).</FONT> The amendments in this
update explicitly require a company&#146;s management to assess an entity&#146;s ability to continue as a going concern and to provide related footnote disclosures in certain circumstances. The new standard is effective for annual periods ending
after December&nbsp;15, 2016 and for interim periods thereafter. The Company adopted ASU <FONT STYLE="white-space:nowrap">2014-15</FONT> as of the required effective date of December&nbsp;31, 2016. This guidance relates to footnote disclosure only,
and its adoption had no impact on the Company&#146;s financial position, results of operations or cash flows. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In November 2014, the FASB issued ASU
<FONT STYLE="white-space:nowrap">No.&nbsp;2014-16,</FONT> <I>Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity</I> (&#147;ASU
<FONT STYLE="white-space:nowrap">2014-16&#148;).</FONT> The guidance requires an entity to determine the nature of the host contract by considering all stated and implied substantive terms and features of the hybrid financial instrument, weighing
each term and feature on the basis of the relevant facts and circumstances (commonly referred to as the whole-instrument approach). The Company adopted the standard retrospectively to all periods presented on the required effective date of
January&nbsp;1, 2016, and its adoption had no impact on the Company&#146;s financial position, results of operations or cash flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In
November 2015,&nbsp;the FASB&nbsp;issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2015-17,</FONT><I>&nbsp;Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes</I>&nbsp;(&#147;ASU
<FONT STYLE="white-space:nowrap">2015-17&#148;),</FONT> which requires deferred tax liabilities and assets to be classified as <FONT STYLE="white-space:nowrap">non-current</FONT> in the consolidated balance sheet.
<FONT STYLE="white-space:nowrap">ASU&nbsp;2015-17</FONT> is required to be adopted for annual periods beginning after December&nbsp;15, 2016, including interim periods within those fiscal years.&nbsp;The amendment may be applied either prospectively
to all deferred tax liabilities and assets or retrospectively to all periods presented.&nbsp;The Company elected to early adopt the standard on January&nbsp;1, 2016 and has reflected the adoption retrospectively to all periods presented. The
adoption of ASU <FONT STYLE="white-space:nowrap">2015-17</FONT> had no material impact on the Company&#146;s financial position, results of operations or cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In March 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-09,</FONT> <I>Compensation&#151;Stock Compensation (Topic
718): Improvements to Employee Share-Based Payment Accounting</I> (&#147;ASU <FONT STYLE="white-space:nowrap">2016-09&#148;).</FONT> ASU <FONT STYLE="white-space:nowrap">2016-09</FONT> involves several aspects of the accounting for share-based
transactions, including the income tax consequences, classification of awards as either equity or liabilities, an option to recognize gross share compensation expense with actual forfeitures recognized as they occur and certain classifications on
the statement of cash flows. Certain of these changes are required to be applied retrospectively, while other changes are required to be applied prospectively. The Company adopted ASU <FONT STYLE="white-space:nowrap">2016-09</FONT> as of the
required effective date of January&nbsp;1, 2017 and has elected to account for forfeitures as they occur rather than apply an estimated forfeiture rate to share-based compensation expense. The adoption of ASU
<FONT STYLE="white-space:nowrap">2016-09</FONT> had no material impact on the Company&#146;s financial position, results of operations or cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Issued Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In May 2014, the FASB issued <FONT STYLE="white-space:nowrap">ASU&nbsp;No.&nbsp;2014-09,</FONT><I>&nbsp;Revenue from Contracts with Customers
(Topic 606)</I><FONT STYLE="white-space:nowrap">&nbsp;(&#147;ASU&nbsp;2014-09&#148;),&nbsp;which</FONT> supersedes existing revenue recognition guidance under GAAP. The standard&#146;s core principle is that a company will recognize revenue when it
transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The standard outlines a five-step process to achieve this principle,
and will require companies to use more judgment and make more estimates than under the current guidance. The Company expects that these judgments and estimates will include identifying performance obligations in the customer contract, estimating the
amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. <FONT STYLE="white-space:nowrap">ASU&nbsp;2014-09&nbsp;also</FONT> requires additional disclosure
about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. In August 2015, the FASB issued <FONT STYLE="white-space:nowrap">ASU&nbsp;2015-14,</FONT><I>&nbsp;Revenue from Contracts with Customers
(Topic 606): Deferral of the Effective Date</I>, which delays the effective date of <FONT STYLE="white-space:nowrap">ASU&nbsp;2014-09&nbsp;such</FONT> that the standard is effective for public entities for annual periods beginning after
December&nbsp;15, 2017 and for interim periods within those fiscal years. In March 2016, the FASB issued <FONT STYLE="white-space:nowrap">ASU&nbsp;No.&nbsp;2016-08,</FONT><I>&nbsp;Revenue from Contracts with Customers (Topic 606): Principal versus
Agent Considerations</I><FONT STYLE="white-space:nowrap">&nbsp;(&#147;ASU&nbsp;2016-08&#148;),&nbsp;which</FONT> further clarifies the implementation guidance on principal versus agent considerations in
<FONT STYLE="white-space:nowrap">ASU&nbsp;2014-09.&nbsp;In</FONT> April 2016, the FASB issued <FONT STYLE="white-space:nowrap">ASU&nbsp;No.&nbsp;2016-10,</FONT><I> Revenue from Contracts with Customers (Topic 606): Identifying Performance
Obligations and Licensin</I>g, clarifying the implementation guidance on identifying performance obligations and licensing. Specifically, the amendments in this update reduce the cost and complexity of identifying promised goods or services and
improve the guidance for determining whether promises are separately identifiable. The amendments in this update also provide implementation guidance on determining whether an entity&#146;s promise to grant a license
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provides a customer with either a right to use the entity&#146;s intellectual property (which is satisfied at a point in time) or a right to access the entity&#146;s intellectual property (which
is satisfied over time). In May 2016, the FASB issued <FONT STYLE="white-space:nowrap">ASU&nbsp;No.&nbsp;2016-12,</FONT><I>&nbsp;Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients</I><FONT
STYLE="white-space:nowrap">&nbsp;(&#147;ASU&nbsp;2016-12&#148;),&nbsp;which</FONT> clarifies the objective of the collectability criterion, presentation of taxes collected from customers,
<FONT STYLE="white-space:nowrap">non-cash&nbsp;consideration,</FONT> contract modifications at transition, completed contracts at transition and how guidance in <FONT STYLE="white-space:nowrap">ASU&nbsp;2014-09&nbsp;is</FONT> retrospectively
applied. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ASU&nbsp;2016-08,&nbsp;ASU&nbsp;2016-10&nbsp;and</FONT></FONT> <FONT STYLE="white-space:nowrap">ASU&nbsp;2016-12&nbsp;have</FONT> the same effective dates and transition
requirements as <FONT STYLE="white-space:nowrap">ASU&nbsp;2014-09.&nbsp;The</FONT> Company plans to adopt this standard using the modified retrospective approach. The Company&#146;s preliminary assessment is that government grant revenue is outside
the scope of ASC 606. Therefore, the Company does not believe the adoption of ASC 606 will impact the Company&#146;s financial position, results of operations or cash flows as its only existing revenue source as of December&nbsp;31, 2017 is
government grants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-02,</FONT> <I>Leases (Topic
842</I>) (&#147;ASU <FONT STYLE="white-space:nowrap">2016-02&#148;),</FONT> which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e.,&nbsp;lessees and lessors). The
new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine
whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and a lease liability for all leases with a term of greater than 12&nbsp;months regardless of their classification. Leases with a term of
12&nbsp;months or less will be accounted for similar to existing guidance for operating leases today. The guidance is effective for public entities for annual reporting periods beginning after December&nbsp;15, 2018 and for interim periods within
those fiscal years, and early adoption is permitted. The Company is currently evaluating the impact the adoption of ASU <FONT STYLE="white-space:nowrap">2016-02</FONT> will have on its consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In August 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-15,</FONT> <I>Statement of Cash Flows: Classification of
Certain Cash Receipts and Cash Payments</I> (&#147;ASU <FONT STYLE="white-space:nowrap">2016-15&#148;),</FONT> to address diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash
flows. The standard is effective for annual periods beginning after December&nbsp;15, 2017, including interim periods within those fiscal years. The Company does not believe that the adoption of ASU <FONT STYLE="white-space:nowrap">2016-15</FONT>
will have a material impact on its consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In November 2016, the FASB issued ASU <FONT
STYLE="white-space:nowrap">2016-18</FONT> <I>Statement of Cash Flows (Topic 230) </I>(&#147;ASU <FONT STYLE="white-space:nowrap">2016-18&#148;),</FONT> which requires that amounts generally described as restricted cash and restricted cash
equivalents should be included with cash and cash equivalents when reconciling the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">beginning-of-period</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">end-of-period</FONT></FONT> total amounts shown on the statement of cash flows. ASU <FONT STYLE="white-space:nowrap">2016-18</FONT> is effective for fiscal years beginning after December&nbsp;15, 2017 and interim periods
within those fiscal years and should be applied using a retrospective transition method to each period presented. Early adoption is permitted. The Company does not believe the adoption of ASU <FONT STYLE="white-space:nowrap">2016-18</FONT> will have
a material impact on its consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In January 2017, FASB issued ASU
<FONT STYLE="white-space:nowrap">No.&nbsp;2017-01,</FONT> <I>Business Combinations (Topic 805): Clarifying the Definition of a Business</I> (&#147;ASU <FONT STYLE="white-space:nowrap">2017-01&#148;).</FONT> The amendments in this update clarify the
definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The definition of a business affects many areas of
accounting including acquisitions, disposals, goodwill and consolidation. The standard is effective for annual periods beginning after December&nbsp;15, 2017, including interim periods within those fiscal years. The Company does not believe the
adoption of ASU <FONT STYLE="white-space:nowrap">2017-01</FONT> will materially impact its consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In May
2017, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2017-09,</FONT> <I>Compensation&#151;Stock Compensation (Topic 718): Scope of Modification Accounting</I> (&#147;ASU <FONT STYLE="white-space:nowrap">2017-09&#148;),</FONT> which
clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. The standard is
effective for annual periods beginning after December&nbsp;15, 2017, including interim periods within those fiscal years. Early adoption is permitted. The Company does not believe the adoption of ASU <FONT STYLE="white-space:nowrap">2017-09</FONT>
will materially impact its consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In July 2017, the FASB issued ASU
<FONT STYLE="white-space:nowrap">2017-11,</FONT> <I>Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815) I. Accounting for Certain Financial Instruments with Down Round Features II.
Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception</I>. Part I applies to entities that issue
financial instruments such as warrants, convertible debt or convertible preferred stock that contain down-round features. Part II replaces the indefinite deferral for certain mandatorily redeemable noncontrolling interests and mandatorily redeemable
financial instruments of nonpublic entities contained within ASC Topic 480 with a scope exception and does not impact the accounting for these mandatorily redeemable instruments. ASU <FONT STYLE="white-space:nowrap">2017-11</FONT> is required to be
adopted for annual periods beginning after December&nbsp;15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact that the adoption of ASU <FONT STYLE="white-space:nowrap">2017-11</FONT> will have
on its consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Fair Value of Financial Assets and Liabilities </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following tables present information about the Company&#146;s assets and liabilities that are measured at fair value on a recurring basis
(in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;Fair&nbsp;Value&nbsp;Measurements&nbsp;at&nbsp;December&nbsp;31,&nbsp;2017&nbsp;Using:&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;1&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;2&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;3&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Total&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">83,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">83,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">83,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">83,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anti-dilution rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;Fair&nbsp;Value&nbsp;Measurements&nbsp;at&nbsp;December&nbsp;31,&nbsp;2016&nbsp;Using:&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anti-dilution rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contingent prepayment option</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">During the years ended December&nbsp;31, 2017 and 2016, there were no transfers between Level&nbsp;1,
Level&nbsp;2 and Level&nbsp;3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tranche Rights </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company&#146;s sales of <FONT STYLE="white-space:nowrap">Class&nbsp;A-1</FONT> preferred units (&#147;Class&nbsp;A preferred units&#148;)
and <FONT STYLE="white-space:nowrap">Class&nbsp;B-1</FONT> preferred units (&#147;Class&nbsp;B preferred units&#148;) (see Note 6) provided investors with the right to participate in subsequent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
offerings of Class&nbsp;A and Class&nbsp;B preferred units in the event specified development and regulatory milestones were achieved. The Company classified each of the tranche rights as a
derivative liability on its consolidated balance sheet because they met the definition of freestanding financial instruments that could have required the Company to transfer assets upon exercise. The Company remeasured the derivative liabilities
associated with tranche rights to fair value at each reporting date, and recognized changes in the fair value of the derivative liabilities as a component of other income (expense) in the consolidated statement of operations and comprehensive loss.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The fair value of these derivative liabilities was determined using the probability-weighted expected return method (&#147;PWERM&#148;),
which considered as inputs the probability and time that a milestone would be achieved, the potential fair value of preferred stock upon the exercise of the tranche right and the risk-adjusted discount rate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Class&nbsp;A Tranche Rights </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The fair value of the tranche right related to the Company&#146;s Class&nbsp;A preferred unit financing (see Note 6) upon issuance in June
2015 was $2.4&nbsp;million, which increased slightly as of December&nbsp;31, 2015. Upon the issuance of the Class&nbsp;B preferred units in February 2016, the tranche right was cancelled and the settlement of the fair value of the derivative
liability of $2.4&nbsp;million was recorded as an increase to additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital as a deemed capital contribution from the Class&nbsp;A preferred unit investors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Class&nbsp;B Tranche Rights </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The fair value of the tranche right related to the Company&#146;s Class&nbsp;B preferred unit financing upon issuance in February 2016 was
$0.9&nbsp;million. Upon the issuance of bridge units in December 2016, the tranche rights were cancelled and the fair value of the derivative liability, which had decreased by $0.6&nbsp;million to $0.3&nbsp;million as of the date of settlement due
to a decrease in the fair value of the Company&#146;s underlying units, was settled (see Note&nbsp;6). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anti-Dilution Rights </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In connection with the issuance of <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests in certain of the Company&#146;s
subsidiaries (see Note 9), specifically Spero Potentiator, Inc., Spero Europe, Ltd. and Spero Gyrase, Inc., the Company granted anti-dilution rights to the minority investors. The Company classifies the anti-dilution rights as a derivative liability
on its consolidated balance sheet because they are freestanding instruments that represent a conditional obligation to issue a variable number of shares. The Company remeasures the derivative liability associated with the anti-dilution rights to
fair value at each reporting date, and recognizes changes in the fair value of the derivative liability as a component of other income (expense) in the consolidated statement of operations and comprehensive loss.&nbsp;The fair value of these
derivative liabilities was determined using a discounted cash flow model. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Spero Potentiator </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In connection with the Company&#146;s issuance of a <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest in its subsidiary, Spero
Potentiator Inc. (&#147;Spero Potentiator&#148;), to Northern Antibiotics Oy Ltd. (&#147;Northern&#148;) in&nbsp;February 2015, the Company granted to Northern certain anti-dilution rights (see Note 9). The fair value of the derivative liability
related to the anti-dilution rights upon issuance in February 2015 was $2.4&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In November 2015, the Company issued an
additional 2,736 shares of Spero Potentiator&#146;s common shares for no additional cost to Northern as a result of the anti-dilution rights. Upon issuance, the fair value of the additional shares of Spero Potentiator issued to Northern of
$1.5&nbsp;million was recorded as a reduction of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
derivative liability and as an increase to the <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest. In January and August 2016, the Company issued an additional 2,160 shares of Spero
Potentiator&#146;s common shares for no additional cost to Northern as a result of the anti-dilution rights. Upon issuance, the fair value of the additional shares of Spero Potentiator issued to Northern of $1.0&nbsp;million was recorded as a
reduction of the derivative liability and as an increase to the <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest. At that time, the derivative liability related to the anti-dilution rights issued to Northern was fully settled as
Northern had received the maximum number of shares it was entitled to under the anti-dilution rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The most significant assumption
impacting the fair value of the anti-dilution rights was the probability that the Company would fund the maximum amount of investment providing anti-dilution protection. Upon issuance of the rights and through August 2016, the date the maximum
anti-dilution protection was reached, the Company&#146;s assumption for the probability of such funding was 100%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Spero Europe,
Ltd</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In January 2016, in connection with the issuance of a <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest in its
subsidiary, Spero Europe, Ltd. (&#147;Spero Europe&#148;), to Promiliad Biopharma Inc. (&#147;Promiliad&#148;), the Company granted to Promiliad certain anti-dilution rights (see Note 9). The fair value of the derivative liability related to the
anti-dilution rights upon issuance in January 2016 was $0.2&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The change in the fair value of the derivative liability
associated with the anti-dilution rights was insignificant during the year ended December&nbsp;31, 2016. During 2017, the fair value of the derivative liability decreased by $0.2&nbsp;million to $0 by May 2017. In May 2017, the <FONT
STYLE="white-space:nowrap">non-controlling</FONT> interest in Spero Europe, Ltd. was repurchased and the anti-dilution rights were settled. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The most significant assumption impacting the fair value of the anti-dilution rights was the probability that the Company would fund the
maximum amount of investment providing anti-dilution protection. Upon the issuance of the rights and through December&nbsp;31, 2016, the probability of such funding was determined to be 100%. During 2017, the probability of funding Spero Europe,
Ltd. was reduced to 0% due to the Company&#146;s decision to no longer pursue development of the licensed technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Spero Gyrase,
Inc. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In March 2016, in connection with the issuance of a <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest in its
subsidiary, Spero Gyrase, Inc. (&#147;Spero Gyrase&#148;), to Biota Pharmaceuticals, Inc. (now Aviragen Therapeutics, Inc.) (&#147;Aviragen&#148;), the Company granted to Aviragen certain anti-dilution rights (see Note 9). The fair value of the
derivative liability related to the anti-dilution rights upon issuance in March 2016 was $1.6&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The change in the fair value
of the derivative liability associated with the anti-dilution rights was insignificant during the year ended December&nbsp;31, 2016. During 2017, the fair value of the derivative liability decreased by $1.4&nbsp;million to $0.2&nbsp;million by
June&nbsp;30, 2017, and remained unchanged as of December&nbsp;31, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The most significant assumption impacting the fair value of the
anti-dilution rights was the probability that the Company would fund the maximum amount of investment providing anti-dilution protection. Upon issuance of the rights and through December&nbsp;31, 2016, the probability of such funding was determined
to be 100%. During 2017, the probability of such funding was reduced to 0% due to the Company&#146;s decision to no longer pursue development of the acquired technology. As of December&nbsp;31, 2017, the value of the derivative liability of
$0.2&nbsp;million represents amounts funded to the entity that could be settled by the issuance of equity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contingent Prepayment Options
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Bridge units issued to investors in January 2015 and December 2016 contained contingent prepayment options whereby such units
were automatically convertible into equity units sold in a subsequent round of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
qualified financing at a discounted rate. The Company classified the contingent prepayment options as derivative liabilities on its consolidated balance sheet because the bridge units were deemed
to be more akin to debt than equity and the embedded prepayment options were at a substantial discount, thus meeting the definition of derivative liabilities. The Company remeasured the derivative associated with the contingent prepayment options to
fair value at each reporting date, and recognized changes in the fair value of the derivative liabilities as a component of other income (expense) in its consolidated statement of operations and comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The fair value of these derivative liabilities was determined using the PWERM, which considered as inputs the probability and time that a
subsequent round of preferred stock financing would occur and the risk-adjusted discount rate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>January 2015 Bridge Units </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The fair value of the derivative liability related to the contingent prepayment option associated with bridge units issued in January 2015 was
$2.3&nbsp;million. The option was settled in June 2015 upon the issuance of Class&nbsp;A preferred units. As a condition to the June 2015 financing, the Company and the holders of the bridge units agreed to reduce the previously agreed-upon discount
to the per unit conversion price from 20% to 10% of the per unit price of $3.90 to be paid for the sale of the Class&nbsp;A preferred units. The reduction of the discount resulted in a decrease to the fair value of the derivative liability of
$1.4&nbsp;million, which was recorded as an increase to additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital as a deemed capital contribution by the holders of the bridge units. The remaining fair value of the derivative liability of
$0.9&nbsp;million was settled upon conversion of the bridge notes into Class&nbsp;A preferred units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>December 2016 Bridge Units
</I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The fair value of the derivative liability related to the contingent prepayment option associated with bridge units issued in
December 2016 was $0.9&nbsp;million. The change in the fair value of the derivative liability associated contingent prepayment option was not material during the year ended December&nbsp;31, 2016. The fair value of the derivative liability increased
by less than $0.1&nbsp;million as of March 2017, at which time the contingent prepayment option was settled upon the issuance of Class&nbsp;C preferred units. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Investment Option </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The
Company&#146;s concluded collaboration agreement provided its collaboration partner with an option to participate in the next round of financing subsequent to April 2014 in an amount up to $2.0&nbsp;million at 90.0% of the per unit price of the
related financing. The Company classified the investment option as a derivative liability on its consolidated balance sheet because it met the definition of a freestanding financial instrument that may require the Company to transfer assets upon
exercise. The Company remeasured the derivative liability to fair value at each reporting date, and recognized changes in the fair value of the derivative liability as a component of other income (expense) in the consolidated statement of operations
and comprehensive loss. The fair value of the derivative liability related to the investment option was $0.2&nbsp;million as of December&nbsp;31, 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The fair value of the derivative liability associated with investment option decreased by $0.1&nbsp;million as of June 2015, at which time the
subsequent financing occurred and the collaboration partner elected not to exercise the investment option, which then expired. Upon expiration, the Company recorded other income equal to the fair value of the derivative liability upon expiration of
$0.1&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The fair value of this derivative liability was determined using the PWERM, which considered as inputs the probability
and time that a qualified round of preferred stock financing would occur and the risk-adjusted discount rate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table provides a roll forward of the aggregate fair values of the
Company&#146;s derivative liabilities, for which fair value was determined by Level&nbsp;3 inputs (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Contingent<BR>Prepayment<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Tranche<BR>Rights</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Anti-<BR>Dilution<BR>Rights</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value at issuance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(600</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(580</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Settlement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,713</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(980</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,693</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,583</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,541</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Settlement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(944</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(944</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Property and Equipment, Net </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Property and equipment, net consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:62.65pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;December&nbsp;31,&nbsp;&nbsp;&nbsp;&nbsp;
</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:32.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:32.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer software and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office furniture and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(643</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(290</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Depreciation and amortization expense was $0.4&nbsp;million, $0.3&nbsp;million and less than $0.1&nbsp;million
for the years ended December&nbsp;31, 2017, 2016 and 2015, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Accrued Expenses and Other Current Liabilities </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:62.65pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;December&nbsp;31,&nbsp;&nbsp;&nbsp;&nbsp;
</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:32.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:32.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued external research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued payroll and related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Redeemable Convertible Preferred Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016, the operating agreement of Spero Therapeutics, LLC, as amended and restated, provided for the issuance of Junior
preferred units, Class&nbsp;A preferred units, Class&nbsp;B preferred units and bridge units, but did not specify an authorized number of each for issuance. Subsequent to the Reorganization (see Note 1), the Company&#146;s amended and restated
certificate of incorporation authorized the issuance of 43,297,267 shares of preferred stock, par value $0.001 per share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2015 Bridge Units </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In January 2015, the Company issued and sold 8,000 bridge units to existing investors at a price of $1,000 per unit for gross proceeds of
$8.0&nbsp;million (the &#147;2015 bridge units&#148;). The bridge units did not have any stated rate of return and were automatically convertible into the same type of units issuable upon a qualified financing at a discount of either 20.0% or 25.0%
to the per unit price paid by investors in a qualified financing, depending on the timing of such financing. The Company classified this contingent prepayment option as a derivative liability on its consolidated balance sheet on the date of issuance
(see Note 3), and the fair value of contingent prepayment option on the date of issuance of $2.3&nbsp;million was recorded as both a derivative liability and as a reduction to the carrying value of the bridge units. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Class&nbsp;A Preferred Unit Financing </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In June 2015, the Company issued and sold 1,923,076 Class&nbsp;A preferred units at a price of $3.90 per unit for proceeds of
$7.3&nbsp;million, net of issuance costs of $0.2&nbsp;million. The sale of Class&nbsp;A preferred units met the definition of a qualified financing under the 2015 bridge unit agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As a condition to the June 2015 Class&nbsp;A preferred unit financing, the Company and the holders of the 2015 bridge units agreed to reduce
the previously agreed-upon discount to the per unit conversion price from 20% to 10% of the price to be paid for the sale of Class&nbsp;A preferred units of $3.90 per unit. Accordingly, the Company issued 2,279,202 Class&nbsp;A preferred units upon
the conversion of the 2015 bridge units in the amount of $8.0&nbsp;million, at a conversion price of $3.51 per unit. The conversion was accounted for as an extinguishment for accounting purposes. Accordingly, the Company recorded the Class&nbsp;A
preferred units issued upon conversion of the 2015 bridge units at their aggregate fair value of $8.9&nbsp;million and recorded a corresponding adjustment to extinguish the then-current carrying value of the 2015 bridge units of $8.0&nbsp;million
and the then-current fair value of the derivative liability related to the contingent prepayment option associated with the 2015 bridge units of $0.9&nbsp;million (see Note 3). There was no gain or loss recognized upon the extinguishment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Class&nbsp;A preferred unit financing included a provision for the issuance of an additional 3,295,455 Class&nbsp;A preferred units at a
price of $4.40 per unit in exchange for gross proceeds of $14.5&nbsp;million in the event the Company achieved a regulatory milestone. The Company classified this tranche right as a derivative liability on its consolidated balance sheet on the date
of issuance, and the fair value of tranche right on the date of issuance of $2.4&nbsp;million was recorded as both a derivative liability and as a reduction to the carrying value of the Class&nbsp;A preferred units. Upon issuance of the Class&nbsp;B
preferred units in February 2016, the tranche right was cancelled (see Note 3). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Class&nbsp;B Preferred Unit Financing </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In February 2016, the Company issued and sold 5,909,089 Class&nbsp;B preferred units at a price of $4.40 per unit for proceeds of
$25.9&nbsp;million, net of issuance costs of $0.1&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Class&nbsp;B preferred unit financing included a provision for the
issuance of an additional 1,609,846 Class&nbsp;B preferred units at a price of $5.28 per unit in exchange for gross proceeds of $8.5&nbsp;million in the event the Company achieved a regulatory milestone. The Company classified this tranche right as
a derivative liability on its consolidated balance sheet on the date of issuance, and the fair value of the tranche right on the date of issuance of $0.9&nbsp;million was recorded as both a derivative liability and as a reduction to the carrying
value of the Class&nbsp;B preferred units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2016 Bridge Units </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The regulatory milestone related to the Class&nbsp;B tranche right was achieved in the fourth quarter of 2016; however, the Company and the
holders of the Class&nbsp;B preferred units agreed to replace the second closing of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Class&nbsp;B preferred units with the issuance of bridge units that would be convertible in the next qualified financing at a 10% discount. Accordingly, in December 2016, the Company issued and
sold 8,500 bridge units to existing investors at a price of $1,000 per unit for gross proceeds of $8.5&nbsp;million (the &#147;2016 bridge units&#148;). Upon issuance of the 2016 bridge units, the fair value of the derivative liability associated
with the Class&nbsp;B tranche right of $0.3&nbsp;million was settled, resulting in a decrease to the carrying value of the derivative liability and an increase to the carrying value of the 2016 bridge units (see Note 3). The bridge units did not
provide for any stated rate of return and were automatically convertible into the same type of units issuable upon a qualified financing at a 10% discount to the per unit price paid by investors in a qualified financing. The Company classified this
contingent prepayment option as a derivative liability on its consolidated balance sheet on the date of issuance, and the fair value of the contingent prepayment option on the date of issuance of $0.9&nbsp;million was recorded as both a derivative
liability and as a reduction to the carrying value of the bridge units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Class&nbsp;C Preferred Unit Financing </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In March 2017, the Company issued and sold 24,326,470 Class&nbsp;C preferred units at a price of $1.7749 per unit for proceeds of
$43.0&nbsp;million, net of issuance costs of $0.2&nbsp;million. The sale of Class&nbsp;C preferred units met the definition of a qualified financing under the 2016 bridge unit agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company issued 5,321,112 Class&nbsp;C preferred units upon the conversion of the 2016 bridge units in the amount of $8.5&nbsp;million, at
a conversion price of $1.60 per unit, which represented a discount of 10% to the price per unit paid by other investors in the Class&nbsp;C preferred unit financing. The conversion was accounted for as an extinguishment for accounting purposes.
Accordingly, the Company recorded the Class&nbsp;C preferred units issued upon conversion of the 2016 bridge units at their aggregate fair value of $9.4&nbsp;million and recorded a corresponding adjustment to extinguish the then-current carrying
value of the 2016 bridge units of $8.5&nbsp;million and the then-current fair value of the derivative liability related to the contingent prepayment option associated with the 2016 bridge units of $0.9&nbsp;million (see Note 3). There was no gain or
loss recognized upon the extinguishment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In July 2017 the Company sold to its Chief Financial Officer 61,880 shares of the Company&#146;s
Series C preferred stock at a price of $1.7749 per share, for proceeds of $0.1&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Shares of Preferred Stock of Spero Therapeutics, Inc.
Issued upon the Reorganization </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On June&nbsp;30, 2017, pursuant to the terms of the Reorganization (see Note 1), holders of
outstanding preferred units of Spero Therapeutics, LLC exchanged their units for preferred stock of Spero Therapeutics, Inc. on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis. The rights and
preferences of each class of stock (as described below) were the same both before and after the Reorganization. Upon the closing of the Company&#146;s IPO in November 2017, all of the then outstanding convertible preferred shares automatically
converted into shares of common stock (see Note 7). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Junior preferred stock, the Series A preferred stock, the Series B preferred
stock and the Series C preferred stock are collectively referred to as the &#147;Preferred Stock&#148;. The holders of the Preferred Stock have the following rights and preferences: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The holders of Preferred
Stock are entitled to vote, together with the holders of common stock, on all matters submitted to stockholders for a vote. The holders of Preferred Stock are entitled to the number of votes equal to the number of common shares into which each such
share of Preferred Stock could convert. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Conversion </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Each share of Preferred Stock is convertible at the option of the holder at any time after the date of issuance. Each share of Preferred Stock
would be automatically converted into shares of common stock at the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicable conversion ratio then in effect (i)&nbsp;upon the closing of a firm commitment public offering with at least $50.0&nbsp;million of proceeds to the Company or (ii)&nbsp;upon the written
consent of the holders of at least 60% of the then-outstanding shares of Series B and Series C preferred stock, voting together as a single class. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The conversion ratio of each series of Preferred Stock is determined by dividing the Original Issue Price of each series by the Conversion
Price of each series. The Original Issue Price is $1.00 per share for Junior preferred stock, $3.90 per share for Series A preferred stock, $4.40 per share for Series B preferred stock and $1.7749 per share for Series C preferred stock. The
Conversion Price at issuance was $6.0774 per share for Junior preferred stock, $23.7019 per share for Series A preferred stock, $26.7406 per share for Series B preferred stock and $10.7868 per share for Series C preferred stock, subject to
appropriate adjustment in the event of any stock split, stock dividend, combination or other similar recapitalization and other adjustments as set forth in the Company&#146;s certificate of incorporation, as amended and restated. In March and July
2017, as a result of the issuances of Series C preferred stock at a price per share less than the Series A and Series B preferred stock Conversion Price, the Conversion Price for each of Series A and Series B preferred stock was adjusted according
to their terms. Prior to the Company&#146;s Reorganization in June 2017, the Conversion Price of Series A and Series B preferred stock was $15.5715 per share and $16.7256 per share, respectively. The Conversion Price for Junior preferred stock was
not adjusted according to its terms. In July 2017, after the consummation of the Reorganization, the Company sold to its Chief Financial Officer 61,880 shares of the Company&#146;s Series C preferred stock at a price of $1.7749 per share, for
proceeds of $0.1&nbsp;million. Because the price per share of the Series C preferred stock in this transaction was lower than the Conversion Price of the Company&#146;s Series A and Series B preferred stock, in accordance with the Company&#146;s
certificate of incorporation, as amended and restated, the Conversion Price of Series A preferred stock was adjusted from $15.5715 to $15.5654 per share and the Conversion Price of Series B preferred stock was adjusted from $16.7256 to $16.7177 per
share. The Conversion Price for Junior preferred stock was not adjusted according to its terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On October&nbsp;20, 2017, the Company
effected a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-6.0774</FONT></FONT> reverse stock split of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion rations for
each series or the Company&#146;s Preferred Stock. Upon the closing of the Company&#146;s IPO in November 2017, the Company&#146;s outstanding preferred shares automatically converted into shares of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Holders of the Series
A, Series B and Series C preferred stock are entitled to receive, out of funds legally available, cumulative dividends at an annual rate of 8%, compounded annually, when and if declared by the board of directors. Holders of the Junior preferred
stock are entitled to receive, out of funds legally available, noncumulative dividends at an annual rate of 5%, when and if declared by the board of directors. The Company may not declare, pay or set aside any dividends on shares of any other series
of capital stock of the Company, other than dividends on common stock payable in common stock, unless the holders of the Series C preferred stock first receive, or simultaneously receive, a dividend on each outstanding share of Series C preferred
stock to which they are entitled. The Company may not declare, pay or set aside any dividends on shares of any other series of capital stock of the Company, other than dividends on shares of Series C preferred stock and dividends on common stock
payable in common stock, unless the holders of the Series B preferred stock first receive, or simultaneously receive, a dividend on each outstanding share of Series B preferred stock to which they are entitled. The Company may not declare, pay or
set aside any dividends on shares of any other series of capital stock of the Company, other than dividends on shares of Series B preferred stock or Series C preferred stock and dividends on common stock payable in common stock, unless the holders
of the Series A preferred stock first receive, or simultaneously receive, a dividend on each outstanding share of Series A preferred stock to which they are entitled. The Company may not declare, pay or set aside any dividends on shares of any other
series of capital stock of the Company, other than dividends on shares of Series A, Series B or Series C preferred stock and dividends on common stock payable in common stock, unless the holders of the Junior preferred stock first receive, or
simultaneously receive, a dividend on each outstanding share of Junior preferred stock to which they </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
are entitled. Through December&nbsp;31, 2017 and 2016, no cash dividends have been declared or paid by the Company&#146;s board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In the event of any
voluntary or involuntary liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company or Liquidating Event (as described below), the holders of shares of Preferred Stock will receive, in preference to the common
stockholders, an amount equal to the greater of (i)&nbsp;the Original Issue Price per share of the respective share of preferred stock, plus all dividends declared but unpaid on such shares or (ii)&nbsp;the amount the holders would receive if the
Preferred Stock were converted into common stock prior to such liquidation event. If, upon any such liquidation event, the assets of the Company available for distribution are insufficient to permit payment in full to the holders of Preferred Stock,
the holders of the Series C preferred stock are entitled to receive such amount prior to and in preference of the holders of the Series B, Series A, Junior preferred stock and common stock. After payment in full to holders of Series C preferred
stock, the holders of the Series B preferred stock are entitled to receive such amount prior to and in preference of the holders of the Series A, Junior preferred stock and common stock. After payment in full to holders of Series C and Series B
preferred stock, the holders of the Series A preferred stock are entitled to receive such amount prior to and in preference of the holders of the Junior preferred stock and common stock. After payment in full to holders of Series C, Series B and
Series A preferred stock, the holders of the Junior preferred stock are entitled to receive such amount prior to and in preference of the holders of the common stock. In the event that the assets available for distribution to the Company&#146;s
stockholders are not sufficient to permit payment to any class of holders in order of preference and in the full amount to which they are entitled, the assets available for distribution are distributed on a pro rata basis. In addition, solely if
(i)&nbsp;proceeds are received in connection with the sale or merger of Spero Potentiator, Inc. and (ii)&nbsp;contracted distribution thresholds in relation to anti-dilution clauses are satisfied, then distributions to the Series A holders shall be
made until their Adjusted Potentiator Shortfall Amount, as defined, is met, after payments to Series C and Series B preferred stock have been made in full but prior to and in preference of the holders of the Junior preferred stock and common stock.
After the payment of all preferential amounts to the holders of the Preferred Stock then, to the extent available, the remaining assets available for distribution shall be distributed among the holders of the Preferred Stock and common stock ratably
in proportion to the number of shares of stock held as converted to common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Unless the holders of 60% of the then-outstanding
shares of Series B and Series C preferred stock, voting together as a single class, and holders of 60% of the then-outstanding shares of Series C preferred stock elect otherwise, a Liquidating Event shall include a merger or consolidation (other
than one in which stockholders of the Company own a majority by voting power of the outstanding shares of the surviving or acquiring corporation) or a sale, lease, transfer, exclusive license or other disposition of all or substantially all of the
assets of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redemption </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">At any time on or after February&nbsp;1, 2021, shares of each of the Junior preferred stock, Series A, Series B and Series C preferred stock
are subject to mandatory redemption by the Company in three equal annual installments beginning 60 days after receipt of a notice of redemption from the holders of at least 60% of the combined voting power of the holders of the outstanding Series B
and Series C preferred stock, voting as a single class at the Original Issue Price, subject to appropriate adjustment for any stock splits, stock dividends, combinations or any other similar recapitalization affecting such shares, plus any dividends
declared but unpaid thereon plus cumulative dividends. If, upon any such redemption, the assets of the Company available for distribution are insufficient to permit payment in full to the holders of Preferred Stock, the holders of the Series C
preferred stock are entitled to receive such amount prior to and in preference of the holders of the Series B, Series A and Junior preferred stock. After payment in full to holders of Series C preferred stock, the holders of the Series B preferred
stock are entitled to receive such amount prior to and in preference of the holders of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Series A and Junior preferred stock. After payment in full to holders of Series C and Series B preferred stock, the holders of the Series A preferred stock are entitled to receive such amount
prior to and in preference of the holders of the Junior preferred stock. In the event that the assets are not sufficient to permit payment of the redemption amount to any class of holders in order of preference and in the full amount to which they
are entitled, the assets available for distribution are distributed on a pro rata basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016, the operating agreement of Spero Therapeutics, LLC, as amended and restated, provided for the issuance of common
units, but did not specify an authorized number for issuance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Subsequent to the Reorganization on June&nbsp;30, 2017 (see Note 1), the
Company&#146;s amended and restated certificate of incorporation authorized the issuance of 61,917,986 shares of common stock, par value $0.001 per share. Subsequent to the Company&#146;s IPO on November&nbsp;6, 2017 (See Note 1), the Company&#146;s
amended and restated certificate of incorporation authorized the issuance of 60,000,000 shares of common stock, par value $0.001 per share. Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the
Company&#146;s stockholders. Common stockholders are not entitled to receive dividends, unless declared by the board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In
2014, the Company issued and sold restricted common units, which were subject to vesting requirements. In 2016, the Company repurchased 21,116 unvested common units upon forfeiture at the original issuance price of $0.001 per unit. As of
December&nbsp;31, 2015 and 2016, there were 75,210 units and 7,062 units, respectively, of unvested restricted common units outstanding. There were no unvested common units outstanding as of December&nbsp;31, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On June&nbsp;30, 2017, pursuant to the terms of the Reorganization (see Note&nbsp;1), holders of common units of Spero Therapeutics, LLC
exchanged their units for common stock of Spero Therapeutics, Inc. on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis. On October&nbsp;20, 2017, the Company effected
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;one-for-6.0774&nbsp;reverse</FONT></FONT> stock split of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for
each series of the Company&#146;s Preferred Stock (see Note 6). Accordingly, all share and per share amounts for all periods presented in the accompanying consolidated financial statements and notes thereto have been adjusted retroactively, where
applicable, to reflect this reverse stock split and adjustment of the preferred stock conversion ratios. In addition, all common units and incentive units as well as the conversion ratios of preferred units of Spero Therapeutics, LLC have been
presented as if the reverse stock split of the common stock of Spero Therapeutics, Inc. had been applied to such units and ratios of Spero Therapeutics, LLC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Share-Based Compensation </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Prior to
the Reorganization, the Company&#146;s operating agreement, as amended and restated, provided for the granting of incentive units to officers, directors, employees, consultants and advisors. Under the terms of the incentive unit grant agreements,
such incentive units were subject to a vesting schedule, with 25% of the incentive units vesting following one year of continued employment or service and the balance vesting in equal monthly installments for 36 months beginning on the <FONT
STYLE="white-space:nowrap">one-year</FONT> anniversary of the holder&#146;s employment or service with the Company. Holders of incentive units were entitled to receive distributions in proportion to their ownership percent interest, when and if
distributed, that were in excess of the strike price of the award set by the board of directors on the date of grant. The Company determined that the underlying terms of the incentive units and the intended purpose of the awards were more akin to an
equity-based compensation award than a performance bonus or profit-sharing arrangement and, therefore, the incentive units were equity-classified awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The total number of incentive units that could have been issued under the Company&#146;s operating agreement was 573,156 as of
December&nbsp;31, 2016, of which 159,890 units remained available for future issuance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
as of December&nbsp;31, 2016. Upon the Reorganization on June&nbsp;30, 2017 (see Note 1), the Company could no longer issue incentive units. In addition, in June 2017, in connection with the
Reorganization, the Company cancelled the then-outstanding 402,857 incentive units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table summarizes the Company&#146;s
incentive unit activity since December&nbsp;31, 2016: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number<BR>of Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted<BR>Average<BR>Strike<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted<BR>Average<BR>Contractual<BR>Term</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate<BR>Intrinsic<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">413,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,541</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(402,857</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016, total unrecognized compensation cost related to the unvested share-based awards
was $0.8&nbsp;million, which was expected to be recognized over a weighted average period of 3.1 years. As of December&nbsp;31, 2017, all of the incentive units were cancelled; however, the Company will continue to recognize compensation costs
related to these awards (see below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2017 Stock Incentive Plan </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On June&nbsp;28, 2017, the Company&#146;s stockholders approved the 2017 Stock Incentive Plan (the &#147;2017 Plan&#148;). The 2017 Plan
provides for the grant of incentive stock options, nonstatutory stock options, stock grants and stock-based awards. The 2017 Plan is administered by the board of directors, or at the discretion of the board of directors, by a committee of the board.
The exercise prices, vesting and other restrictions are determined at the discretion of the board of directors, or their committee if so delegated, except that the exercise price per share of stock options may not be less than 100% of the fair
market value of the share of common stock on the date of grant and the term of stock option may not be greater than ten years. The number of shares initially reserved for issuance under the 2017 Plan was 1,785,416 shares of common stock. The shares
of common stock underlying any awards that are forfeited, cancelled, repurchased or are otherwise terminated by the Company under the 2017 Plan will be added back to the shares of common stock available for issuance under the 2017 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On October&nbsp;18, 2017, the Company&#146;s stockholders approved an amendment to the 2017 Plan, which became effective upon the completion
of the Company&#146;s IPO, to increase the total number of shares reserved for issuance under the 2017 Plan from 1,785,416 to 2,696,401. Additionally, the number of shares of common stock that may be issued under the 2017 Plan will automatically
increase on each January&nbsp;1, beginning with the fiscal year ending December&nbsp;31, 2019 and continuing for each fiscal year until, and including, the fiscal year ending December&nbsp;31, 2027, equal to the lowest of (i) 607,324 shares of
common stock, (ii) 4% of the outstanding shares of common stock on such date and (iii)&nbsp;an amount determined by the Company&#146;s board of directors or compensation committee. As of December&nbsp;31, 2017, there were 685,105 shares remaining
available to be issued under the 2017 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In July 2017, the Company additionally granted options for the purchase of 1,154,989 shares
of common stock at an exercise price of $5.90 per share under the 2017 Plan. The options vest over four years and the fair value of these option grants was $3.96 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In July 2017, previous holders of the cancelled incentive units who were still employed by the Company at the time of the Reorganization
received stock options under the 2017 Stock Incentive Plan (described below). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Such stock options were granted for the same number of shares of common stock as the number of incentive units cancelled, and the stock options were granted on the same vesting terms as the
incentive units. All such stock options have an exercise price of $5.90 per share. The Company accounted for the cancellation of the incentive units and the issuance of new awards as a modification of the awards for accounting purposes in the three
months ended September&nbsp;30, 2017. Unrecognized compensation expense related to the original award is being recognized over the remaining service period of the modified award. The incremental fair value of the replacement options, based on the
positive difference between the fair value of the modified award and the fair value of the original award immediately before it was modified was not material. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Incentive Unit and Stock Option Valuation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The fair value of each incentive unit award and stock options are estimated using the Black-Scholes option-pricing model. The Company does not
have sufficient company-specific historical and implied volatility information and it therefore estimates its expected share volatility based on the historical volatility of a set of publicly traded peer companies. The Company expects to continue to
do so until such time as it has adequate historical data regarding the volatility of its own traded share price. The Company has estimated the expected term of the Company&#146;s incentive units utilizing the &#147;simplified&#148; method for awards
that qualify as &#147;plain-vanilla.&#148; The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award.
Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The assumptions that the Company used in the Black-Scholes option-pricing model to determine the fair value of incentive unit and stock option
awards granted to employees and directors were as follows, presented on a weighted average basis: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table summarizes stock option activity during 2017: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted<BR>Average<BR>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted<BR>Average<BR>Contractual<BR>Term</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate<BR>Intrinsic<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>(in years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,012,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(810</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,011,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2017&#151;vested and expected to vest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,011,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable at December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">357,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The weighted average grant-date fair value of stock options granted during 2017 was $4.72 per share. No stock
options were exercised during 2017. The weighted average grant-date fair value of awards granted during the years ended December&nbsp;31, 2016 and 2015 was $3.40 per unit and $1.03 per unit, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017, total unrecognized compensation cost related to unvested stock
option grants was approximately $7.7&nbsp;million. This amount is expected to be recognized over a weighted average period of approximately 3.4 years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company recorded share-based compensation expense, for both incentive units and stock options in the following expense categories of its
consolidated statements of operations and comprehensive loss (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. <FONT STYLE="white-space:nowrap">Non-Controlling</FONT> Interests </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Spero Potentiator </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In
February&nbsp;2015, the Company&#146;s wholly owned subsidiary, Spero Potentiator, issued 996 shares of its common stock with an aggregate fair value of $1.1&nbsp;million to Northern in exchange for an exclusive license to develop and commercialize
certain licensed compounds and licensed products. The Company recognized research and development expense of $1.1&nbsp;million upon acquisition of the license and recorded a <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest in Spero
Potentiator in a corresponding amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In connection with the acquisition of the license, Northern obtained anti-dilution rights to
maintain its 49.9% ownership percentage in Spero Potentiator at no additional cost to Northern in the event that Spero Potentiator completed subsequent equity financings, subject to a maximum amount of such financings. The maximum amount of gross
proceeds from equity financings subject to the anti-dilution rights was $5.0&nbsp;million through the date the Company filed an investigational new drug application (&#147;IND&#148;) related to the licensed technology. Subsequent to the filing of an
IND, the maximum amount of gross proceeds from equity financings subject to the anti-dilution rights was $6.5&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company
accounted for the anti-dilution rights as a derivative liability on its consolidated balance sheet (see Note 3). The fair value of the derivative liability associated with the anti-dilution rights upon issuance in February 2015 of $2.4&nbsp;million
was recorded as research and development expenses as it was deemed to represent additional consideration for the license. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In November
2015, Northern was issued an additional 2,736 common shares of Spero Potentiator for no additional cost as a result of the anti-dilution rights. The Company valued these shares at $1.5&nbsp;million and recorded the amount as an increase in the <FONT
STYLE="white-space:nowrap">non-controlling</FONT> interest and a reduction in the carrying value of the derivative liability. In January and August 2016, Northern was issued an additional 2,160 common shares of Spero Potentiator for no additional
cost. The Company valued these shares at $1.0&nbsp;million and recorded the amount as an increase in the <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest and a reduction of the derivative liability. At that time, the anti-dilution
rights issued to Northern were fully settled as Northern had received the maximum number of shares it was entitled to under the anti-dilution rights (See Note&nbsp;3). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In June 2017, the Company repurchased all of the shares of Spero Potentiator held by Northern in exchange for a cash payment of
$1.0&nbsp;million and contingent consideration of $0.1&nbsp;million. As a condition of the repurchase of the shares from Northern, the Company amended the license agreement with Northern such that the Company will be obligated to make milestone
payments of up to $7.0&nbsp;million upon the achievement of specified clinical, commercial and other milestones, including a payment of $2.5&nbsp;million upon the closing of an IPO, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which occurred and was paid in November 2017. As a result of this transaction, during the six months ended June&nbsp;30, 2017, the Company reclassified the balance of the <FONT
STYLE="white-space:nowrap">non-controlling</FONT> interest of $6.4&nbsp;million as of the date of the transaction to accumulated deficit as an increase to that account. Additionally, the cash payment of $1.0&nbsp;million was recorded as an increase
to accumulated deficit. The Company will record the contingent payments as research and development expense when it becomes probable that the payments will be due. For periods subsequent to the acquisition, the Company no longer reports a <FONT
STYLE="white-space:nowrap">non-controlling</FONT> interest related to Spero Potentiator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Spero Europe </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In January&nbsp;2016, the Company entered into an agreement with Promiliad whereby Promiliad granted to Spero Europe certain <FONT
STYLE="white-space:nowrap">know-how</FONT> and a sublicense to research, develop, manufacture and sell certain compounds. In exchange for the <FONT STYLE="white-space:nowrap">know-how</FONT> and sublicense, Spero Europe provided Promiliad with a 5%
equity ownership interest in Spero Europe, with a fair value of $0.1&nbsp;million. In addition, Spero Europe agreed to make payments to Promiliad upon the achievement of future regulatory and commercial milestones of $4.1 million&nbsp;and to pay to
Promiliad royalties of a mid single-digit percentage on net sales of licensed products under the agreement. Spero had the right to terminate the agreement with thirty days&#146; notice. The Company recognized research and development expense of
$0.1&nbsp;million upon the acquisition of the license and recorded a <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest in Spero Europe in a corresponding amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In connection with the acquisition of the license, Promiliad obtained anti-dilution rights to maintain their 5% equity ownership in Spero
Europe at no additional cost to Promiliad in the event that Spero Europe completed subsequent funding events, subject to a maximum amount of such funding of $5.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company accounted for the anti-dilution rights as a derivative liability on its consolidated balance sheet (see Note 3). The fair value of
the derivative liability associated with the anti-dilution rights upon issuance in January 2016 of $0.2&nbsp;million was recorded as research and development expenses as it was deemed to represent additional consideration for the license. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In May 2017, the Company repurchased all of the shares of Spero Europe from Promiliad in exchange for the return of the license. As a result
of the transaction, the Company reclassified the balance of the <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest in Spero Europe of less than $0.1&nbsp;million as of the date of the transaction to accumulated deficit as an increase
to that account. For periods subsequent to the repurchase, the Company no longer reports a <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest related to Spero Europe. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Spero Gyrase </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In March 2016, the
Company entered into an agreement with Aviragen and its affiliates in order to acquire certain intellectual property and <FONT STYLE="white-space:nowrap">know-how</FONT> related to certain compounds.&nbsp;In connection with the transaction, the
Company established Spero Gyrase, a Delaware corporation, and issued to Aviragen 200 common shares of Spero Gyrase with a fair value of $1.1&nbsp;million, which represented a 20% equity ownership interest in Spero Gyrase. In addition, Spero Gyrase
agreed to make future milestone and royalty payments in exchange for the intellectual property. The Company accounted for the acquisition of technology as an&nbsp;asset acquisition&nbsp;because it did not&nbsp;meet the definition of a business. The
Company recorded the acquired technology as research and development expense in the consolidated statement of operations and comprehensive loss in the amount of $1.1&nbsp;million, because the acquired technology had not reached commercial
feasibility and had&nbsp;no alternative future use, and recorded a <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest in Spero Gyrase in a corresponding amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In connection with the agreement, Aviragen obtained anti-dilution rights to maintain their 20% equity ownership of Spero Gyrase at no
additional cost to Aviragen in the event that Spero Gyrase completed subsequent funding events, subject to a maximum amount of such funding of $8.0&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company accounted for the anti-dilution rights as a derivative liability on its
consolidated balance sheet (see Note 3). The fair value of the derivative liability associated with the anti-dilution rights upon issuance in March 2016 of $1.6&nbsp;million was recorded as research and development expenses as it was deemed to
represent additional consideration for the license. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Spero Cantab </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In June 2016, the Company entered into a stock purchase agreement and related agreements (the &#147;Cantab Agreements&#148;) with Pro Bono Bio
PLC, a corporation organized under the laws of England, and certain of its affiliates, including PBB Distributions Limited (&#147;PBB&#148;), Cantab Anti-Infectives Ltd. (&#147;CAI&#148;) and New Pharma License Holdings Limited (&#147;NPLH&#148;) in
order to acquire NPLH and its intellectual property rights and assets relating to the Company&#146;s Potentiator Platform. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under the
Cantab Agreements, CAI agreed to submit a request to NIAID to novate the <FONT STYLE="white-space:nowrap">CAI-held</FONT> NIAID contract to the Company. The NIAID contract provides for development funding of up to $5.7&nbsp;million over a base and
three option periods. As of December&nbsp;31, 2017, funding for the base period and the first two option periods totaling $5.1&nbsp;million had been committed to CAI. Novation of the NIAID contract to the Company was finalized in December 2017. The
Company shall pay PBB a percentage of funds received from NIAID up to a maximum of $1.3&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Consideration under Cantab
Agreements consisted of: (i)&nbsp;125 shares of Spero Cantab, the Company&#146;s subsidiary, which represented a 12.5% ownership interest in Spero Cantab, and anti-dilution rights (as described below) issued to PBB, with a combined fair value of
$1.6&nbsp;million, (ii)&nbsp;upfront consideration of $0.3&nbsp;million (to be credited against future payments payable to CAI), (iii)&nbsp;contingent milestone payments due upon the achievement of certain clinical, regulatory and commercial
milestones (see Note&nbsp;13), (iv)&nbsp;royalty payments of low single-digit percentages based on net sales of products from the licensed technology, and (v)&nbsp;a specified portion of funding payments made by NIAID. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company accounted for the acquisition of NPLH as an&nbsp;asset acquisition&nbsp;because NPLH did not&nbsp;meet the definition of a
business. The Company recognized research and development expense of $1.6&nbsp;million upon the acquisition of NPLH because the acquired technology had not reached commercial feasibility and had&nbsp;no alternative future use. Upon the issuance of
the shares and anti-dilution rights, the Company recorded a <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest in Spero Cantab of $1.6&nbsp;million. The $0.3&nbsp;million payment was recognized as research and development expenses as
the services were performed by CAI. The Company records the contingent payments outlined in (iii), (iv)&nbsp;and (v)&nbsp;as research and development expense when it becomes probable that the payments will be due. Novation of the NIAID contract to
Spero was finalized in December 2017. Prior to the contract novation, CAI performed research and development services at the Company&#146;s direction and applied for reimbursement from NIAID. The Company paid CAI for such research and development
services at an agreed-upon rate which took into consideration costs incurred by CAI, amounts reimbursed to CAI by NIAID and the portion of the NIAID reimbursement the Company paid to CAI. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In connection with the Cantab Agreements, PBB obtained anti-dilution rights to maintain a certain equity ownership, ranging from 5% to 12.5%,
of Spero Cantab at no additional cost to PBB in the event that Spero Cantab completed subsequent funding events, subject to maximum amount of such funding of $8.0&nbsp;million. These anti-dilution rights represent a conditional obligation to issue a
variable number of shares but are not freestanding and, therefore, do not require bifurcation for accounting purposes from the 125 shares issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In July 2017, the Company repurchased all of the outstanding shares of Spero Cantab owned by PBB in exchange for a cash payment of
$0.2&nbsp;million and an amendment to the licensing agreement to increase the first two contingent milestone payments by a total of $0.1&nbsp;million. For periods subsequent to the repurchase, the Company no longer reports a <FONT
STYLE="white-space:nowrap">non-controlling</FONT> interest related to Spero Cantab. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of each balance sheet date, <FONT STYLE="white-space:nowrap">non-controlling</FONT>
interests&#146; balances were as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:21.30pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Entity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Spero Potentiator</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,470</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Spero Europe</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Spero Gyrase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Spero Cantab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,808</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Income Taxes </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Prior to the Reorganization (see Note 1), the Company&#146;s former parent company, Spero Therapeutics, LLC, was treated as a partnership for
federal income tax purposes and, therefore, its owners, and not itself, were subject to U.S. federal or state income taxation on the income of Spero Therapeutics, LLC. Prior to the Reorganization, all of Spero Therapeutics, LLC&#146;s directly held
subsidiaries (including Spero Therapeutics, Inc.) were treated as corporations for U.S. federal income tax purposes and were subject to taxation in the United States or in other countries. Upon the Reorganization, Spero Therapeutics, Inc. became the
parent company for Spero Therapeutics, LLC&#146;s former subsidiaries and these entities continue to be subject to taxation in the United States or in other countries. In each reporting period, the Company&#146;s tax provision includes the effects
of consolidating the results of operations of its subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">During the years ended December&nbsp;31, 2017, 2016 and 2015, the Company
recorded no income tax benefits for the net operating losses incurred in each year or interim period due to its uncertainty of realizing a benefit from those items. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The domestic and foreign components of loss before income taxes were as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Domestic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(38,706</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(27,148</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,832</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,180</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,493</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(321</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(39,886</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,641</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,153</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">A reconciliation of the U.S. federal statutory income tax rate to the Company&#146;s effective income tax rate
is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal statutory income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34.0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34.0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34.0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal and state research and development tax credit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3.3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State taxes, net of federal benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5.3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4.4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign rate differential</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nondeductible items</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of US tax reform</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in deferred tax asset valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Net deferred tax assets as of December&nbsp;31, 2017 and 2016 consisted of the following (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development tax credit carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,519</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,152</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2017, the Company had U.S. federal and state net operating loss carryforwards of
$76.4&nbsp;million and $76.0&nbsp;million, respectively, which may be available to offset future income tax liabilities and begin to expire in 2033. In addition, as of December&nbsp;31, 2017, the Company had foreign net operating loss carryforwards
of $4.3&nbsp;million, which may be available to offset future income tax liabilities and do not expire. As of December&nbsp;31, 2017, the Company also had federal and state research and development tax credit carryforwards of $1.7&nbsp;million and
$0.4&nbsp;million, respectively, which may be available to offset future income tax liabilities and begin to expire in 2033 and 2028, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Utilization of the U.S. net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial
annual limitation under Section&nbsp;382 of the Internal Revenue Code of 1986 and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the
amount of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section&nbsp;382, results from transactions increasing the ownership of certain stockholders or public groups in
the stock of a corporation by more than 50% over a three-year period.&nbsp;The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the
significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined by Section&nbsp;382, at any time since inception, utilization of the net operating loss carryforwards or research and
development tax credit carryforwards would be subject to an annual limitation under Section&nbsp;382, which is determined by first multiplying the value of the Company&#146;s stock at the time of the ownership change by the applicable long-term <FONT
STYLE="white-space:nowrap">tax-exempt</FONT> rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit
carryforwards before utilization. Further, until a study is completed by the Company and any limitation is known, no amounts are being presented as an uncertain tax position. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets. Management has
considered the Company&#146;s history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception and has concluded that it is more likely than
not that the Company will not realize the benefits of the deferred tax assets. Accordingly, a full valuation allowance has been established against the deferred tax assets as of December&nbsp;31, 2017 and 2016. Management reevaluates the positive
and negative evidence at each reporting period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Changes in the valuation allowance for deferred tax assets during the years ended
December&nbsp;31, 2017 and 2016 related primarily to the increase in net operating loss carryforwards, capitalized research and development expenses and research and development tax credit carryforwards and were as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance as of beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,152</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decreases recorded as benefit to income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increases recorded to income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,367</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,995</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance as of end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(24,519</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,152</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company has not recorded any amounts for unrecognized tax benefits as of December&nbsp;31, 2017 or 2016.
The Company&#146;s policy is to record interest and penalties related to income taxes as part of its income tax provision. As of December&nbsp;31, 2017 and 2016, the Company had no accrued interest or penalties related to uncertain tax positions and
no amounts had been recognized in the Company&#146;s statement of operations and comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Prior to the Reorganization, the
Company filed separate U.S. income tax returns return for each of its subsidiaries. As a result of the Reorganization, the Company will file U.S. income tax returns as a U.S. consolidated group. In Massachusetts, the Company files income tax returns
as a combined group except for its Massachusetts Securities Corporation subsidiary, which is a separate income tax filing. The statute of limitations for assessment by the Internal Revenue Service and Massachusetts tax authorities remains open for
all years since 2013. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state authorities to the extent utilized in
a future period. No federal or state tax audits are currently in process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On December&nbsp;22, 2017, President Trump signed into law the
&#147;the Tax Cuts and Jobs Act&#148; ( &#147;TCJA&#148;). The TCJA includes a number of changes to existing tax law, including, among other things, a permanent reduction in the federal corporate income tax rate from a top marginal rate of 34% down
to a flat rate of 21%, effective as of January&nbsp;1, 2018, as well as limitation of the deduction for net operating losses to 80% of annual taxable income and elimination of net operating loss carrybacks, in each case, for losses arising in
taxable years beginning after December&nbsp;31, 2017 (though any such net operating losses may be carried forward indefinitely). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As a
result of the TCJA, the Company was required to revalue deferred tax assets and liabilities existing as of December&nbsp;31, 2017 from the 34% federal rate in effect through the end of 2017, to the new 21%. This revaluation resulted in a reduction
to the Company&#146;s deferred tax asset of $9.4&nbsp;million. This amount was offset by a corresponding reduction in the valuation allowance. There was no impact to the Company&#146;s consolidated statements of operations and comprehensive loss as
a result of the reduction in rates. The other provisions of the TCJA did not have a material impact on the Company&#146;s consolidated financial statements. The Company has recognized the provisional tax impacts related to the revaluation of
deferred tax assets and liabilities and included these amounts in its consolidated financial statements for the year ended December&nbsp;31, 2017. While the Company believes these estimates are reasonable, the ultimate impact may differ from these
provisional amounts due to further review of the enacted legislation, changes in interpretations and assumptions it has made, and additional accounting and regulatory guidance that may be issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Commitments and Contingencies </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>License
Agreements </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company has entered into license agreements with various parties under which it is obligated to make contingent
and <FONT STYLE="white-space:nowrap">non-contingent</FONT> payments (see Note&nbsp;13). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Leases </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In August 2015, the Company entered into an operating lease agreement for office space that commenced in January 2016 and expires in December
2020. The lease requires annual payments of $0.4&nbsp;million over the five-year term. The lease provides for a renewal option to extend the lease for an additional five years. Under the terms of the lease, the Company provided a security deposit of
$0.2&nbsp;million to the landlord, which is included in long-term assets in the accompanying consolidated balance sheets. The lease includes annual rent escalations as well as tenant incentives in the amount of $0.7&nbsp;million, of which
$0.3&nbsp;million is reimbursed to the landlord over the term of the lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In July 2016, the Company entered into an agreement to lease
laboratory space through November&nbsp;30, 2019 from a sublessor, which requires annual lease payments of $0.3&nbsp;million, subject to certain escalations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On January&nbsp;17, 2018, the Company entered into an amendment (the &#147;Amendment&#148;) to the lease agreement with respect to its
corporate headquarters located at 675 Massachusetts Avenue, Cambridge, Massachusetts. The Amendment makes certain changes to the original Lease Agreement, dated August&nbsp;24, 2015 (the &#147;Original Lease&#148;), by and between the Company and
U.S. REIF Central Plaza Massachusetts, LLC (the &#147;Landlord&#148;), including (i)&nbsp;the addition of approximately 7,800 square feet of office space in the same building (the &#147;Expansion Premises&#148;) and (ii)&nbsp;an extension of the
expiration date of the Original Lease to seven years following the delivery date of the Expansion Premises (the &#147;Lease Term&#148;), which is estimated to be December&nbsp;1, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under the Amendment, the Company has two consecutive options to extend the Lease Term for an additional period of five years (the &#147;Option
Terms&#148;), subject to certain conditions, upon notice to the Landlord. The Amendment provides for annual base rent for the Expansion Premises of approximately $0.5&nbsp;million in the first year of the Lease Term, which increases on an annual
basis to approximately $0.6&nbsp;million in the final year of the Lease Term, and annual base rent during the Option Terms to be calculated based on the Landlord&#146;s good faith determination of 100% of the fair market rate for such Option Terms.
The Company is also obligated to pay the Landlord certain costs, taxes and operating expenses, subject to certain exclusions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Rent
escalations and tenant incentives for operating leases are included in deferred rent in the consolidated balance sheet, and rent expense is recognized on a straight-line basis over the terms of occupancy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table summarizes the future minimum payments due under the operating leases as of December&nbsp;31, 2017 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="92%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:92.45pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Year Ending December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Rent expense for the years ended December&nbsp;31, 2017, 2016 and 2015 was $0.8&nbsp;million,
$0.4&nbsp;million and $0.1&nbsp;million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Indemnification Agreements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners
and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors that will require the Company, among other things, to indemnify
them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many
cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company does not believe that the outcome of any claims under indemnification arrangements will have a material effect on its
financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its consolidated financial statements as of December&nbsp;31, 2017, 2016 or 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legal Proceedings </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company is
not currently party to any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative
guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Government
Contracts </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Department of Defense </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In September 2016, the Company was awarded a cooperative agreement with the DoD to further develop anti-infective agents to combat
Gram-negative bacteria. The agreement is structured as a single, <FONT STYLE="white-space:nowrap">two-year</FONT> $1.5&nbsp;million award. The Company is eligible for the full funding from the DoD, and there are no options to be exercised at a later
date. The DoD funding supports next-generation potentiator discovery and screening of SPR741 partners. The Company recognizes revenue under this agreement as qualifying expenses are incurred. During the year ended December&nbsp;31, 2017, the Company
recognized $0.7&nbsp;million of revenue under this agreement, of which $0.1&nbsp;million was invoiced but unpaid and included in other receivables at December&nbsp;31, 2017. During the year ended December&nbsp;31, 2016, $0.3&nbsp;million of revenue
was recognized under this agreement, of which $0.3&nbsp;million was invoiced but unpaid and included in other receivables at December&nbsp;31, 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>NIAID </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In February 2017, the
Company was awarded a grant from NIAID to conduct additional preclinical studies of SPR720, the Company&#146;s novel oral bacterial gyrase inhibitor, for the treatment of <FONT STYLE="white-space:nowrap">non-tuberculous</FONT> mycobacterial
infections. The award is structured as a <FONT STYLE="white-space:nowrap">12-month</FONT> $0.6&nbsp;million base period and $0.4&nbsp;million option period. Through December&nbsp;31, 2017, only the base period funds had been committed. In February
2018 NIAID exercised the $0.4&nbsp;million <FONT STYLE="white-space:nowrap">12-month</FONT> option period. The Company recognized $0.4&nbsp;million of revenue in the year ended December&nbsp;31, 2017 under this agreement, of which less than
$0.1&nbsp;million was invoiced but unpaid and included in other receivables at December&nbsp;31, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In June 2016, the Company entered
into agreements with Pro Bono Bio PLC (&#147;PBB&#148;), a corporation organized under the laws of England, and certain of its affiliates, including PBB Distributions Limited and Cantab Anti-Infectives Limited (&#147;CAI&#148;), in order to acquire
certain intellectual property and government funding arrangements relating to SPR206. Under these agreements, CAI agreed to submit a request to NIAID to assign the <FONT STYLE="white-space:nowrap">CAI-held</FONT> NIAID contract to Spero. The NIAID
contract provides for development funding of up to $5.7&nbsp;million over a base period and three option periods. As of December&nbsp;31, 2017, funding for the base period and the first two option periods totaling $5.1&nbsp;million have been
committed. Novation of the NIAID contract to Spero was finalized in December 2017. Spero shall pay PBB a percentage of funds received from NIAID up to a maximum of $1.3&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">CARB-X</FONT> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In April 2017, the Company was awarded a grant from <FONT STYLE="white-space:nowrap">CARB-X,</FONT> a public-private partnership funded by the
Biomedical Advanced Research and Development Authority (&#147;BARDA&#148;) within the U.S. Department of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Health and Human Services to be used to screen, identify and complete Phase 1 trials with at least one partner compound for SPR741, the Company&#146;s lead Potentiator compound. The award
committed to funding of $1.5&nbsp;million over a <FONT STYLE="white-space:nowrap">12-month</FONT> period. On March&nbsp;12, 2018, <FONT STYLE="white-space:nowrap">CARB-X</FONT> committed an additional $0.4&nbsp;million related to the first option
for a period from December&nbsp;1, 2017 to March&nbsp;31, 2018. There will be no additional options exercised under the <FONT STYLE="white-space:nowrap">CARB-X</FONT> award. The Company recognized $0.9&nbsp;million of revenue in the year ended
December&nbsp;31, 2017 under this agreement, of which $0.7&nbsp;million was invoiced but unpaid and included in other receivables at December&nbsp;31, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Collaboration and License Agreements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company has certain obligations under license agreements with third parties that include annual maintenance fees and payments that are
contingent upon achieving various development, regulatory and commercial milestones. Pursuant to these license agreements, the Company is required to make milestone payments if certain development, regulatory and commercial milestones are achieved,
and may have certain additional research funding obligations. Also, pursuant to the terms of each of these license agreements, when and if commercial sales of a product commence, the Company will pay royalties to its licensors on net sales of the
respective products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Roche Collaboration Agreements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In April&nbsp;2014, the Company and Roche entered into a research and development services and support agreement (&#147;Research and
Development Agreement&#148;) and an option agreement (&#147;Option Agreement&#148;), whereby the Company was required to use its best efforts to research and develop a specified asset, while Roche would provide partial funding as well as participate
on a joint steering committee for the development of this asset. As part of these agreements, the Company provided Roche with the option to participate in the Company&#146;s next financing subsequent to April 2014 in an amount up to
$2.0&nbsp;million at 90.0% of the per unit price of the related financing (see Note 3). The subsequent financing occurred in June 2015 and, as Roche elected not to exercise its option, the option expired. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As consideration for the agreements, Roche made nonrefundable upfront payments aggregating to $2.0&nbsp;million in 2014 and paid annual
nonrefundable maintenance fees of $1.0&nbsp;million in 2015. Due to the cooperative nature of the development plans as driven by the joint steering committee and the partial defrayment of development costs, the nonrefundable payments were considered
reductions to research and development expense. Upon receipt, the payments the Company received in 2014 and 2015 from Roche were deferred and were recognized as reductions to research and development expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In June 2016, the Company provided notification to Roche that it intended to terminate its Research and Development Agreement with Roche based
on its rights under the agreement, effective August 2016, resulting in a recognition of the remaining deferred advance research and development payments. There was no termination fee required under the agreement. Related to payments received under
the concluded collaboration, the Company recognized reductions of research and development expense of $0.9&nbsp;million and $1.5&nbsp;million for the years ended December&nbsp;31, 2016 and 2015, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>MGH License Agreement </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In
March&nbsp;2014, the Company entered into a license agreement with The General Hospital Corporation, doing business as Massachusetts General Hospital, (&#147;MGH&#148;) to obtain an exclusive worldwide license to research, develop, manufacture and
sell products based on technology related to inhibitors of bacteria quorum sensing and technology pertaining to the methods for identifying compounds for treating, reducing or preventing pathogenic infections. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Upon signing of the license agreement, the Company issued to MGH 24,681 common units. The Company also agreed to reimburse MGH for all patent
costs related to the exclusive patent for the duration of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreement. In November 2016, the Company terminated its license agreement with MGH. There were no termination payments required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ascenion License Agreement </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In
September&nbsp;2014, the Company entered into a license agreement with Ascenion GmbH (formerly known as Helmholtz Zentrum fur Infektionsforschung GmbH) to obtain an exclusive worldwide license to research, develop, manufacture and sell products
based on Ascenion&#146;s PqsR modulator technology. Upon signing of the license agreement, the Company issued to Ascenion 9,625 common units. In November 2016, the Company terminated its license agreement with Ascenion. There were no termination
payments required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Aviragen Agreement </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under the Company&#146;s agreement with Aviragen (see Note 9) for certain intellectual property and
<FONT STYLE="white-space:nowrap">know-how</FONT> relating to developing a gyrase inhibitor to develop therapies for Gram-negative infections, the Company is obligated to make milestone payments of up to an aggregate of $12.0&nbsp;million upon the
achievement of specified clinical, regulatory and commercial milestones and to pay royalties of low single-digit percentages based on net sales of products the Company acquired under the agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cantab License Agreement </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under
the Cantab Agreements (see Note 9), the Company is obligated to make milestone payments of up to $5.8&nbsp;million upon the achievement of specified clinical and regulatory milestones and a payment of &pound;5.0&nbsp;million ($6.7&nbsp;million and
$6.2&nbsp;million as of December&nbsp;31, 2017 and 2016, respectively)) upon the achievement of a specified commercial milestone. In addition, the Company has agreed to pay to PBB royalties, on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, of a low single-digit percentage based on net sales of products licensed under
the agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Cantab Agreements continue indefinitely, with royalty payment obligations thereunder continuing on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis until the later of ten years after the first
commercial sale of such product in such country or the expiration in such country of the last to expire valid claim of any of the applicable patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Vertex License Agreement </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In May
2016, the Company entered into an agreement with Vertex Pharmaceuticals Incorporated (&#147;Vertex&#148;) whereby Vertex granted the Company certain <FONT STYLE="white-space:nowrap">know-how</FONT> and a sublicense to research, develop, manufacture
and sell products for a proprietary compound, as well as a transfer of materials. In exchange for the <FONT STYLE="white-space:nowrap">know-how,</FONT> sublicense and materials, Spero paid Vertex an upfront,
<FONT STYLE="white-space:nowrap">one-time,</FONT> nonrefundable, <FONT STYLE="white-space:nowrap">non-creditable</FONT> fee of $0.5&nbsp;million, which was recognized as research and development expense. As part of the agreement, the Company is
obligated to make future milestone payments of up to $81.1&nbsp;million upon the achievement of specified clinical, regulatory and commercial milestones and to pay Vertex tiered royalties, on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, of a mid single-digit to low double-digit percentage based on net sales of
products licensed under the agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The agreement continues in effect until the expiration of all payment obligations thereunder, with
royalty payment obligations continuing on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT>
basis until the later of ten years after the first commercial sale of such product in such country or the date of expiration in such country of the last to expire applicable patent. Further, Vertex has the right to terminate the agreement if
provided with notification from the Company of intent to cease all development or if no material development or commercialization efforts occur for one year. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Meiji License Agreement </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In June 2017, the Company entered into agreements with Meiji Seika Pharma Co. Ltd. (&#147;Meiji&#148;), a Japanese corporation, whereby Meiji
granted to the Company certain <FONT STYLE="white-space:nowrap">know-how</FONT> and a license to research, develop, manufacture and sell products for a proprietary compound in the licensed territory. In exchange for the <FONT
STYLE="white-space:nowrap">know-how</FONT> and license, the Company paid Meiji an upfront, <FONT STYLE="white-space:nowrap">one-time,</FONT> nonrefundable, <FONT STYLE="white-space:nowrap">non-creditable</FONT> fee of $0.6&nbsp;million, which was
recognized as research and development expense. As part of the agreement, the Company is obligated to make milestone payments of up to $3.0&nbsp;million upon the achievement of specified clinical and regulatory milestones, to pay royalties, on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, of a low single-digit percentage based on net
sales of products licensed under the agreement and to pay Meiji a low double-digit percentage of any sublicense fees received by the Company up to $7.5&nbsp;million. In October 2017, the Company paid a $1.0&nbsp;million milestone payment to Meiji
upon the enrollment of the first patient in the Company&#146;s Phase 1 clinical trial of SPR994. The payment was recorded as research and development expense in the statement of operations and comprehensive loss for the year ended December&nbsp;31,
2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The agreement continues in effect until the expiration of all payment obligations thereunder (including royalty payments and
licensee revenue) on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, unless earlier
terminated by the parties. Pursuant to the terms of the agreement, in addition to each party&#146;s right to terminate the agreement upon the other party&#146;s material breach (if not cured within a specified period after receipt of notice) or
insolvency, the Company also has unilateral termination rights (i)&nbsp;in the event that the Company abandons the development and commercialization of SPR994 for efficacy, safety, legal or business factors, and (ii)&nbsp;under certain circumstances
arising out of the head license with a global pharmaceutical company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Northern License Agreement </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In June 2017, in connection with the repurchase of all of the outstanding shares of Spero Potentiator (see Note&nbsp;9), the Company amended
its license agreement with Northern such that the Company agreed to pay Northern up to $7.0&nbsp;million upon the achievement of specified clinical, regulatory and other milestones, including a total payment of $2.5&nbsp;million upon the closing of
an initial public offering. In addition, under an exchange agreement the Company entered into with Northern, the Company is obligated to make a payment to Northern of $0.1&nbsp;million upon the closing of an initial public offering. The agreement
has a perpetual term and no express termination rights. Upon the closing of the Company&#146;s IPO in November 2017, the Company paid $2.6&nbsp;million to Northern in connection with both the license and exchange agreements. This payment was
recorded as research and development expense in the Company&#146;s statement of operations and comprehensive loss for the year ended December&nbsp;31, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Australia Research and Development Tax Incentive </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Australian government has established a research and development tax incentive to encourage industry investment in research and
development, which is available to companies incorporated under Australian law that have core research and development activities. In September 2016, the Company established Spero Potentiator Australia Pty Limited to carry out certain research and
development activities. As this subsidiary meets the eligibility requirements of the Australian tax law, it is eligible to receive a 43.5% tax incentive for qualified research and development activities. For the years ended December&nbsp;31, 2017
and 2016, $1.8&nbsp;million and $0.1&nbsp;million, respectively, was recorded as a reduction to research and development expenses in the consolidated statements of operations and comprehensive loss associated with this tax incentive, representing
43.5% of the Company&#146;s qualified research and development spending in Australia. The refund is denominated in Australian dollars and, therefore, the receivable is <FONT STYLE="white-space:nowrap">re-measured</FONT> to U.S. dollars as of each
reporting date. As of December&nbsp;31, 2017 and 2016, the Company&#146;s tax incentive receivables from the Australian government totaled $1.9&nbsp;million and $0.1&nbsp;million, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Net Loss per Share </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share attributable to common stockholders of Spero Therapeutics, Inc. was calculated as follows (in thousands,
except share and per share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(39,886</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,641</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,153</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Net loss attributable to <FONT STYLE="white-space:nowrap">non-controlling</FONT>
interests</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,143</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,999</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Plus: Cumulative dividends on redeemable convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,146</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(932</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Plus: Accretion of bridge units and redeemable convertible preferred shares to redemption
value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,208</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(996</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders of Spero Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(46,097</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(29,928</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,427</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,586,865</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">312,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">252,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders of Spero Therapeutics, Inc., basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17.82</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(95.87</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(53.11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company excluded potentially dilutive securities from the computation of diluted net loss per share as the
effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders of Spero Therapeutics, Inc. is the
same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because
including them would have had an anti-dilutive effect: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,011,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred shares (as converted to common shares)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,229,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,257,213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Incentive units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">413,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,011,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,642,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,428,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. Retirement Plan </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company has a defined-contribution plan under Section&nbsp;401(k) of the Internal Revenue Code (the &#147;401(k) Plan&#148;). The 401(k)
Plan covers all employees who meet defined minimum age and service requirements, and allows participants to defer a portion of their annual compensation on a <FONT STYLE="white-space:nowrap">pre-tax</FONT> basis. As currently established, the
Company is not required to make and to date has not made any contributions to the 401(k) Plan. The Company did not make any matching contributions during the years ended December&nbsp;31, 2017, 2016 and 2015. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. Quarterly Financial Data (unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="57%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>March&nbsp;31,</B><br><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>June&nbsp;30,</B><br><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>September&nbsp;30,</B><br><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B><br><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,411</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,763</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,844</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,868</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to Spero Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,876</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,169</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,836</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,862</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common shareholders of Spero Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,130</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,121</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,076</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,770</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common shareholders per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(21.60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(36.21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(36.02</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding, basic and diluted:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">330,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">334,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">335,285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,273,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>March&nbsp;31,</B><br><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>June&nbsp;30,</B><br><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>September&nbsp;30,</B><br><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B><br><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,430</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,096</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,918</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,197</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to Spero Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,905</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,059</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,316</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,211</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common shareholders of Spero Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,257</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,928</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,410</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,333</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common shareholders per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(21.51</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25.30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23.23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25.68</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding, basic and diluted:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">290,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">313,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">318,948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">324,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. Subsequent Events </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On January&nbsp;17, 2018, the Company entered into an amendment to the lease agreement with respect to its corporate headquarters located at
675 Massachusetts Avenue, Cambridge, Massachusetts. The Amendment makes certain changes to the original lease, by and between the Company and U.S. REIF Central Plaza Massachusetts, LLC (the &#147;Landlord&#148;), including (i)&nbsp;the addition of
approximately 7,800 square feet of office space in the same building (the &#147;Expansion Premises&#148;) and (ii)&nbsp;an extension of the expiration date of the Original Lease to seven years following the delivery date of the Expansion Premises
(the &#147;Lease Term&#148;), which is estimated to be December&nbsp;1, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under the Amendment, the Company has two consecutive
options to extend the Lease Term for an additional period of five years (the &#147;Option Terms&#148;), subject to certain conditions, upon notice to the Landlord. The Amendment provides for annual base rent for the Expansion Premises of
approximately $0.5&nbsp;million in the first year of the Lease Term, which increases on an annual basis to approximately $0.6&nbsp;million in the final year of the Lease Term, and annual base rent during the Option Terms to be calculated based on
the Landlord&#146;s good faith determination of 100% of the fair market rate for such Option Terms. The Company is also obligated to pay the Landlord certain costs, taxes and operating expenses, subject to certain exclusions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin521849_7"></A>CONSOLIDATED BALANCE SHEETS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share data) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>March&nbsp;31,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">52,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">87,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax incentive receivable, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax incentive receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">93,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities and Stockholders&#146; Equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.001 par value; 10,000,000 shares authorized as of March&nbsp;31, 2018 and
December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value; 60,000,000 shares authorized as of March&nbsp;31, 2018 and
December&nbsp;31, 2017; 14,369,182 shares issued and outstanding as of March&nbsp;31, 2018 and December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">181,428</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(107,484</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(96,840</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Spero Therapeutics, Inc. stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-controlling</FONT> interests</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">93,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:50pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin521849_8"></A>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share data) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,816</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,599</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income and other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,644</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,411</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Net loss attributable to <FONT STYLE="white-space:nowrap">non-controlling</FONT>
interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(535</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to Spero Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,644</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,876</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cumulative dividends on redeemable convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,236</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of redeemable bridge units and redeemable convertible preferred shares to redemption
value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders of Spero Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,644</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,130</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.74</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(21.60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares outstanding, basic and diluted:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,369,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">330,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,644</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,411</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive loss:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized gain (loss) on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,673</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,411</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:100pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:100pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral
part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin521849_9"></A>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:110.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:48.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:48.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,644</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,411</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,199</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized foreign currency transaction (gain) loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of discount on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(208</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax incentive receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(159</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,469</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(82</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(497</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Advance payments from collaborator</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,961</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,979</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from investing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,825</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,825</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from financing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of Class&nbsp;C preferred units, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,786</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">52,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Supplemental disclosure of <FONT STYLE="white-space:nowrap">non-cash</FONT> investing and
financing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of bridge units into preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Settlement of derivative liabilities upon issuance of preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cumulative dividends on redeemable convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of redeemable convertible preferred units to redemption value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of bridge units to redemption value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:96pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin521849_10"></A>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Nature of the Business
and Basis of Presentation </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Spero Therapeutics, Inc., together with its consolidated subsidiaries (the&nbsp;&#147;Company&#148;), is a
multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant (&#147;MDR&#148;) bacterial infections. The Company&#146;s most advanced product candidate,
SPR994, is designed to be the first broad-spectrum oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. Treatment with effective orally administrable antibiotics may prevent hospitalizations for serious
infections and enable earlier, more convenient and cost-effective treatment of patients after hospitalization. The Company also has a platform technology known as its Potentiator Platform that it believes will enable it to develop drugs that will
expand the spectrum and potency of existing antibiotics, including formerly inactive antibiotics, against Gram-negative bacteria. The Company&#146;s lead product candidates generated from its Potentiator Platform are two intravenous, or
IV,-administered agents, SPR741 and SPR206, designed to treat MDR Gram-negative infections in the hospital setting. In addition, the Company is developing SPR720, an oral antibiotic designed for the treatment of pulmonary <FONT
STYLE="white-space:nowrap">non-tuberculous</FONT> mycobacterial infections. The Company believes that its novel product candidates, if successfully developed and approved, would have a meaningful patient impact and significant commercial
applications for the treatment of MDR infections in both the community and hospital settings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company was formed as Spero
Therapeutics, LLC in December 2013 under the laws of the State of Delaware. On June&nbsp;30, 2017, through a series of transactions, Spero Therapeutics, LLC merged with and into Spero Therapeutics, Inc. (formerly known as Spero OpCo, Inc.), a
Delaware corporation. As part of the transactions, holders of preferred units and common units of Spero Therapeutics, LLC exchanged their units for shares of Spero Therapeutics, Inc. on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis. These transactions are collectively referred to as the Reorganization. Upon completion of the Reorganization, the historical consolidated financial statements of Spero Therapeutics, LLC
became the historical consolidated financial statements of Spero Therapeutics, Inc. because the Reorganization was accounted for as a reorganization of entities under common control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited
to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product
candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of
additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#146;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant
revenue from product sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On October&nbsp;20, 2017, the Company effected <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">a&nbsp;one-for-6.0774&nbsp;reverse</FONT></FONT> stock split of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each series of the Company&#146;s then
outstanding Preferred Stock. Accordingly, all share and per share amounts for all periods presented in the accompanying consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this reverse
stock split and adjustment of the preferred stock conversion ratios. In addition, all common units and incentive units as well as the conversion ratios of preferred units of Spero Therapeutics, LLC have been presented as if the reverse stock split
of the common stock of Spero Therapeutics, Inc. had been applied to such units and ratios of Spero Therapeutics, LLC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On November&nbsp;6,
2017, Spero Therapeutics, Inc. completed an initial public offering (&#147;IPO&#148;) of its common stock, and issued and sold 5,500,000 shares of common stock at a public offering price of $14.00 per share, resulting in net proceeds of
$71.6&nbsp;million after deducting underwriting discounts and commissions but before deducting offering costs. On November&nbsp;14, 2017, Spero Therapeutics, Inc., issued and sold an additional </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
471,498 shares of its common stock at the IPO price of $14.00 per share pursuant to the underwriters&#146; partial exercise of their option to purchase additional shares of common stock,
resulting in additional net proceeds of $6.1&nbsp;million after deducting underwriting discounts and commissions. Aggregate net proceeds from the IPO totaled $74.2&nbsp;million after deducting underwriting discounts, commissions and offering costs.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In accordance with Accounting Standards Update (&#147;ASU&#148;) <FONT STYLE="white-space:nowrap">2014-15,</FONT><I>&nbsp;Disclosure of
Uncertainties about an Entity&#146;s Ability to Continue as a Going Concern (Subtopic <FONT STYLE="white-space:nowrap">205-40)</FONT></I>, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise
substantial doubt about the Company&#146;s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. Since inception, the Company has funded its operations with proceeds from sales
of preferred units (including bridge units, which converted into preferred units), payments received in connection with a concluded collaboration agreement and funding from government contracts, and most recently, with proceeds from the IPO
completed in November 2017. The Company has incurred recurring losses since inception, including net losses attributable to Spero Therapeutics, Inc. of $10.6&nbsp;million for the three months ended March&nbsp;31, 2018, and $38.7&nbsp;million,
$25.5&nbsp;million and $10.2&nbsp;million for the years ended December&nbsp;31, 2017, 2016 and 2015, respectively. In addition, as of March&nbsp;31, 2018, the Company had an accumulated deficit of $107.5&nbsp;million. The Company expects to continue
to generate operating losses for the foreseeable future. As of the issuance date of the quarterly consolidated financial statements, the Company expects that its cash and cash equivalents, would be sufficient to fund its operating expenses, capital
expenditure requirements through at least 12 months from the issuance date of these quarterly consolidated financial statements. However, the future viability of the Company beyond that point is dependent on its ability to raise additional capital
to finance its future operations. The Company will seek additional funding through public or private financings, debt financing, collaboration agreements or government grants. The inability to obtain funding, as and when needed, would have a
negative impact on the Company&#146;s financial condition and ability to pursue its business strategies. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and
development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. Although management intends to pursue plans to obtain
additional funding to finance its operations, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Accordingly, the consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the
ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements of the Company have been prepared in conformity with
accounting principles generally accepted in the United States of America (&#147;GAAP&#148;) and include the accounts of the Company and its consolidated subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interim Financial Information </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The consolidated balance sheet at December&nbsp;31, 2017 was derived from audited financial statements, but does not include all disclosures
required by GAAP. The accompanying unaudited consolidated financial statements as of March&nbsp;31, 2018, and for three months ended March&nbsp;31, 2018 and 2017, have been prepared by the Company pursuant to the rules and regulations of the
Securities and Exchange Commission (&#147;SEC&#148;) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to
such rules and regulations. These consolidated financial statements should be read in conjunction with the Company&#146;s audited </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consolidated financial statements and the notes thereto for the year ended December&nbsp;31, 2017, included in the Company&#146;s Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017,&nbsp;on file with SEC. In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair statement of the
Company&#146;s financial position as of March&nbsp;31, 2018, and results of operations for the three months ended March&nbsp;31, 2018 and 2017, and cash flows for the three months ended March&nbsp;31, 2018 and 2017 have been made. The results of
operations for the three months ended March&nbsp;31, 2018 are not necessarily indicative of the results of operations that may be expected for the year ending December&nbsp;31, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Summary of Significant Accounting Policies </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use
of Estimates </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with GAAP requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant
estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition, the accrual for research and development expenses, the valuation of common shares prior to the Company&#146;s
completion of its IPO, the valuation of share-based awards and the valuation of derivative liabilities. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be
reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Actual results may differ from those estimates or assumptions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Equivalents </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company
considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Marketable
Securities </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Marketable securities consist of investments with original maturities greater than 90 days. The Company considers its
investment portfolio of investments to be <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale.</FONT></FONT> Accordingly, these investments are recorded at fair value, which is based on quoted market prices.
Investments with maturities beyond one year are generally classified as short term, based on their highly liquid nature and because such marketable securities represent the investment of cash that is available for current operations. Unrealized
gains and losses are reported as a component of accumulated other comprehensive income (loss) in stockholders&#146; equity. Realized gains and losses and declines in value judged to be other than temporary are included as a component of other income
(expense), net based on the specific identification method. When determining whether a decline in value is other than temporary,&nbsp;the Company&nbsp;considers various factors, including whether&nbsp;the Company has&nbsp;the intent to sell the
security, and whether it is more likely than not that&nbsp;the Company&nbsp;will be required to sell the security prior to recovery of its amortized cost basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Measurements </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Certain
assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset
or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and
liabilities carried at fair value are to be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level 1&#151;Quoted prices in active markets for identical assets or liabilities. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level 2&#151;Observable inputs (other than Level&nbsp;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar
assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level 3&#151;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow
methodologies and similar techniques. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company&#146;s cash equivalents and derivative liabilities are carried at fair
value, determined according to the fair value hierarchy described above (see Note 3). The carrying values of the Company&#146;s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Derivative Liabilities </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In
connection with certain equity financings, licensing transactions and research collaborations, the Company has identified certain embedded and freestanding derivatives, which are recorded as liabilities on the Company&#146;s consolidated balance
sheet and are remeasured to fair value at each reporting date until the derivative is settled. Changes in the fair value of the derivative liabilities are recognized as other income (expense) in the consolidated statement of operations and
comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Income (Loss) per Share Attributable to Spero Therapeutics, Inc. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company follows <FONT STYLE="white-space:nowrap">the&nbsp;two-class&nbsp;method</FONT> when computing net income (loss) per share, as the
Company has issued shares that meet the definition of participating securities. <FONT STYLE="white-space:nowrap">The&nbsp;two-class&nbsp;method</FONT> determines net income (loss) per share for each class of common and participating securities
according to dividends declared or accumulated and participation rights in undistributed earnings. <FONT STYLE="white-space:nowrap">The&nbsp;two-class&nbsp;method</FONT> requires income available to common stockholders for the period to be allocated
between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. Net income (loss) per share attributable to common stockholders is calculated based on net
income (loss) attributable to Spero Therapeutics, Inc. and excludes net income (loss) attributable <FONT STYLE="white-space:nowrap">to&nbsp;non-controlling&nbsp;interests.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Basic net income (loss) per share attributable to common stockholders is computed by dividing the net income (loss) attributable to common
stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) attributable to common stockholders is computed by adjusting net income (loss) attributable to common stockholders to
reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders
by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company&#146;s preferred stock contractually entitles the holders of such shares to participate in dividends but does not contractually
require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a
net loss attributable to common stockholders </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-51 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of Spero Therapeutics, Inc., diluted net loss per share attributable to common stockholders of Spero Therapeutics, Inc. is the same as basic net loss per share attributable to common stockholders
of Spero Therapeutics, Inc., since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders of Spero Therapeutics, Inc. for the three months
ended March&nbsp;31, 2018 and 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Issued and Adopted Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In May 2014, the FASB issued <FONT STYLE="white-space:nowrap">ASU&nbsp;No.&nbsp;2014-09,</FONT><I>&nbsp;Revenue from Contracts with Customers
(Topic 606)</I><FONT STYLE="white-space:nowrap">&nbsp;(&#147;ASU&nbsp;2014-09&#148;),&nbsp;which</FONT> supersedes existing revenue recognition guidance under GAAP. The standard&#146;s core principle is that a company will recognize revenue when it
transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The standard outlines a five-step process to achieve this principle,
and will require companies to use more judgment and make more estimates than under the current guidance. The Company expects that these judgments and estimates will include identifying performance obligations in the customer contract, estimating the
amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. <FONT STYLE="white-space:nowrap">ASU&nbsp;2014-09&nbsp;also</FONT> requires additional disclosure
about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. In August 2015, the FASB issued <FONT STYLE="white-space:nowrap">ASU&nbsp;2015-14,</FONT><I>&nbsp;Revenue from Contracts with Customers
(Topic 606): Deferral of the Effective Date</I>, which delays the effective date of <FONT STYLE="white-space:nowrap">ASU&nbsp;2014-09&nbsp;such</FONT> that the standard is effective for public entities for annual periods beginning after
December&nbsp;15, 2017 and for interim periods within those fiscal years. In March 2016, the FASB issued <FONT STYLE="white-space:nowrap">ASU&nbsp;No.&nbsp;2016-08,</FONT><I>&nbsp;Revenue from Contracts with Customers (Topic 606): Principal versus
Agent Considerations</I><FONT STYLE="white-space:nowrap">&nbsp;(&#147;ASU&nbsp;2016-08&#148;),&nbsp;which</FONT> further clarifies the implementation guidance on principal versus agent considerations in
<FONT STYLE="white-space:nowrap">ASU&nbsp;2014-09.&nbsp;In</FONT> April 2016, the FASB issued <FONT STYLE="white-space:nowrap">ASU&nbsp;No.&nbsp;2016-10,</FONT><I> Revenue from Contracts with Customers (Topic 606): Identifying Performance
Obligations and Licensin</I>g, clarifying the implementation guidance on identifying performance obligations and licensing. Specifically, the amendments in this update reduce the cost and complexity of identifying promised goods or services and
improve the guidance for determining whether promises are separately identifiable. The amendments in this update also provide implementation guidance on determining whether an entity&#146;s promise to grant a license provides a customer with either
a right to use the entity&#146;s intellectual property (which is satisfied at a point in time) or a right to access the entity&#146;s intellectual property (which is satisfied over time). In May 2016, the FASB issued
<FONT STYLE="white-space:nowrap">ASU&nbsp;No.&nbsp;2016-12,</FONT><I>&nbsp;Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical
Expedients</I><FONT STYLE="white-space:nowrap">&nbsp;(&#147;ASU&nbsp;2016-12&#148;),&nbsp;which</FONT> clarifies the objective of the collectability criterion, presentation of taxes collected from customers,
<FONT STYLE="white-space:nowrap">non-cash&nbsp;consideration,</FONT> contract modifications at transition, completed contracts at transition and how guidance in <FONT STYLE="white-space:nowrap">ASU&nbsp;2014-09&nbsp;is</FONT> retrospectively
applied. <FONT STYLE="white-space:nowrap">ASU&nbsp;2016-08,</FONT> <FONT STYLE="white-space:nowrap">ASU&nbsp;2016-10&nbsp;and</FONT> <FONT STYLE="white-space:nowrap">ASU&nbsp;2016-12&nbsp;have</FONT> the same effective dates and transition
requirements as <FONT STYLE="white-space:nowrap">ASU&nbsp;2014-09.</FONT> The Company adopted this standard using the modified retrospective approach, however the Company determined that government grant revenue is outside the scope of ASC 606.
Therefore, the adoption of ASC 606 did not impact the Company&#146;s financial position, results of operations or cash flows as its only existing revenue source as of March&nbsp;31, 2018 is government grants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-02,</FONT> <I>Leases (Topic 842</I>) (&#147;ASU <FONT
STYLE="white-space:nowrap">2016-02&#148;),</FONT> which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e.,&nbsp;lessees and lessors). The new standard requires
lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense
is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and a lease liability for all leases with a term of greater than 12&nbsp;months regardless of their classification. Leases with a term of
12&nbsp;months or less will be accounted for similar to existing guidance for operating leases today. The guidance is effective for public entities for annual reporting periods </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-52 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
beginning after December&nbsp;15, 2018 and for interim periods within those fiscal years, and early adoption is permitted. The Company is currently evaluating the impact the adoption of ASU <FONT
STYLE="white-space:nowrap">2016-02</FONT> will have on its consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In August 2016, the FASB issued ASU <FONT
STYLE="white-space:nowrap">No.&nbsp;2016-15,</FONT> <I>Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments</I> (&#147;ASU <FONT STYLE="white-space:nowrap">2016-15&#148;),</FONT> to address diversity in practice in how
certain cash receipts and cash payments are presented and classified in the statement of cash flows. The standard is effective for annual periods beginning after December&nbsp;15, 2017, including interim periods within those fiscal years. The
Company&#146;s adoption of ASU <FONT STYLE="white-space:nowrap">2016-15</FONT> did not have a material impact on the Company&#146;s consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In November 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-18</FONT> <I>Statement of Cash Flows (Topic 230) </I>(&#147;ASU <FONT
STYLE="white-space:nowrap">2016-18&#148;),</FONT> which requires that amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">beginning-of-period</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-period</FONT></FONT> total amounts shown on the statement of cash flows. ASU <FONT
STYLE="white-space:nowrap">2016-18</FONT> is effective for fiscal years beginning after December&nbsp;15, 2017 and interim periods within those fiscal years and should be applied using a retrospective transition method to each period presented. The
adoption of ASU <FONT STYLE="white-space:nowrap">2016-18</FONT> did not have a material impact on the Company&#146;s consolidated financial statements. The inclusion of restricted cash increased the beginning and ending balances of the unaudited
condensed consolidated statement of cash flows by $50,000 for the three months ended March&nbsp;31, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In January 2017, FASB issued
ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2017-01,</FONT> <I>Business Combinations (Topic 805): Clarifying the Definition of a Business</I> (&#147;ASU <FONT STYLE="white-space:nowrap">2017-01&#148;).</FONT> The amendments in this update clarify
the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The definition of a business affects many areas
of accounting including acquisitions, disposals, goodwill and consolidation. The standard is effective for annual periods beginning after December&nbsp;15, 2017, including interim periods within those fiscal years. The adoption of ASU <FONT
STYLE="white-space:nowrap">2017-01</FONT> did not materially impact the Company&#146;s consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In May 2017,
the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2017-09,</FONT> <I>Compensation&#151;Stock Compensation (Topic 718): Scope of Modification Accounting</I> (&#147;ASU <FONT STYLE="white-space:nowrap">2017-09&#148;),</FONT> which
clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of
the award (as equity or liability) changes as a result of the change in terms or conditions. The standard is effective for annual periods beginning after December&nbsp;15, 2017, including interim periods within those fiscal years. Early adoption is
permitted. The adoption of ASU <FONT STYLE="white-space:nowrap">2017-09</FONT> did not materially impact the Company&#146;s consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In July 2017, the FASB issued ASU <FONT STYLE="white-space:nowrap">2017-11,</FONT> <I>Earnings Per Share (Topic 260), Distinguishing
Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815) I. Accounting for Certain Financial Instruments with Down Round Features II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain
Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception</I>. Part I applies to entities that issue financial instruments such as warrants, convertible debt or convertible preferred stock that contain
down-round features. Part II replaces the indefinite deferral for certain mandatorily redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests and mandatorily redeemable financial instruments of nonpublic entities contained
within ASC Topic 480 with a scope exception and does not impact the accounting for these mandatorily redeemable instruments. ASU <FONT STYLE="white-space:nowrap">2017-11</FONT> is required to be adopted for annual periods beginning after
December&nbsp;15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact that the adoption of ASU <FONT STYLE="white-space:nowrap">2017-11</FONT> will have on its consolidated financial statements.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-53 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Fair Value Measurements and Marketable Securities </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following tables present information about the Company&#146;s assets and liabilities that are measured at fair value on a recurring basis
(in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Fair Value Measurements at March&nbsp;31, 2018 Using:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;1&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;2&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;3&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Total&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">44,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">44,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. corporate bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash equivalents and marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">70,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">70,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anti-dilution rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Fair&nbsp;Value&nbsp;Measurements&nbsp;at&nbsp;December&nbsp;31,&nbsp;2017&nbsp;Using:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;1&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;2&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;3&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Total&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">83,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">83,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">83,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">83,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anti-dilution rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">During the three months ended March&nbsp;31, 2018 and 2017, there were no transfers between Level&nbsp;1,
Level&nbsp;2 and Level&nbsp;3 categories. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Marketable Securities </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company&#146;s marketable securities are classified as Level&nbsp;2 assets under the fair value hierarchy as these assets were primarily
determined from independent pricing sources, which generally derive security prices from recently reported trades for identical or similar securities.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-54 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table summarizes the gross unrealized gains and losses of the Company&#146;s
marketable securities as of March&nbsp;31, 2018 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>March&nbsp;31, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;Amortized&nbsp;Cost&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Gross&nbsp;Unrealized<BR>Gains</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Gross&nbsp;Unrealized<BR>Losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. corporate bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2018, all of the Company&#146;s marketable securities had remaining contractual maturity
dates of one year or less from the consolidated balance sheet date. The Company did not own any marketable securities as of December&nbsp;31, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anti-Dilution Rights </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In
connection with the issuance of <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests in certain of the Company&#146;s subsidiaries (see Note 7), specifically Spero Potentiator, Inc., Spero Europe, Ltd. and Spero Gyrase, Inc., the
Company granted anti-dilution rights to the minority investors. The Company classifies the anti-dilution rights as a derivative liability on its consolidated balance sheet because they are freestanding instruments that represent a conditional
obligation to issue a variable number of shares. The Company remeasures the derivative liability associated with the anti-dilution rights to fair value at each reporting date, and recognizes changes in the fair value of the derivative liability as a
component of other income (expense) in the consolidated statement of operations and comprehensive loss.&nbsp;The fair value of these derivative liabilities was determined using a discounted cash flow model. As of March&nbsp;31, 2018 and
December&nbsp;31, 2017, the Company&#146;s fair value of the anti-dilution rights relates only to the anti-dilution rights held by the minority investor in Spero Gyrase, Inc., as detailed below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Spero Gyrase, Inc. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In March 2016, in
connection with the issuance of a <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest in its subsidiary, Spero Gyrase, Inc. (&#147;Spero Gyrase&#148;), to Biota Pharmaceuticals, Inc. (now Aviragen Therapeutics, Inc.)
(&#147;Aviragen&#148;), the Company granted to Aviragen certain anti-dilution rights (see Note 7). The fair value of the derivative liability related to the anti-dilution rights upon issuance in March 2016 was $1.6&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The most significant assumption impacting the fair value of the anti-dilution rights was the probability that the Company would fund the
maximum amount of investment providing anti-dilution protection. Upon issuance of the rights and through December&nbsp;31, 2016, the probability of such funding was determined to be 100%. During 2017, the probability of such funding was reduced to
0% due to the Company&#146;s decision to no longer pursue development of the acquired technology. The fair value of the derivative liability decreased accordingly by $1.4&nbsp;million to $0.2&nbsp;million by June&nbsp;30, 2017. As of March&nbsp;31,
2018 and December&nbsp;31, 2017, the value of the derivative liability of $0.2&nbsp;million represents amounts funded to the entity that could be settled by the issuance of equity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-55 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Accrued Expenses and Other Current Liabilities </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>March&nbsp;31,&nbsp;2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,&nbsp;2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued external research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued payroll and related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Redeemable Convertible Preferred Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Class&nbsp;C Preferred Unit Financing </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In March 2017, the Company issued and sold 24,326,470 Class&nbsp;C preferred units at a price of $1.7749 per unit for proceeds of
$43.0&nbsp;million, net of issuance costs of $0.2&nbsp;million. The sale of Class&nbsp;C preferred units met the definition of a qualified financing under the 2016 bridge unit agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company issued 5,321,112 Class&nbsp;C preferred units upon the conversion of the 2016 bridge units in the amount of $8.5&nbsp;million, at
a conversion price of $1.60 per unit, which represented a discount of 10% to the price per unit paid by other investors in the Class&nbsp;C preferred unit financing. The conversion was accounted for as an extinguishment for accounting purposes.
Accordingly, the Company recorded the Class&nbsp;C preferred units issued upon conversion of the 2016 bridge units at their aggregate fair value of $9.4&nbsp;million and recorded a corresponding adjustment to extinguish the then-current carrying
value of the 2016 bridge units of $8.5&nbsp;million and the then-current fair value of the derivative liability related to the contingent prepayment option associated with the 2016 bridge units of $0.9&nbsp;million (see Note 3). There was no gain or
loss recognized upon the extinguishment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In July 2017 the Company sold to its Chief Financial Officer 61,880 shares of the Company&#146;s
Series C preferred stock at a price of $1.7749 per share, for proceeds of $0.1&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Shares of Preferred Stock of Spero Therapeutics, Inc.
Issued upon the Reorganization </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Prior to the Reorganization, the operating agreement of Spero Therapeutics, LLC, as amended and
restated, provided for the issuance of Junior preferred units, Class&nbsp;A preferred units, Class&nbsp;B preferred units and bridge units, but did not specify an authorized number of each for issuance. Subsequent to the Company&#146;s
Reorganization on June&nbsp;30, 2017 (see Note 1), the Company&#146;s amended and restated certificate of incorporation authorized the issuance of 43,297,267 shares of preferred stock, par value $0.001 per share, and holders of outstanding preferred
units of Spero Therapeutics, LLC exchanged their units for preferred stock of Spero Therapeutics, Inc. on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis. The rights and preferences of each class
of stock were the same both before and after the Reorganization. On October&nbsp;20, 2017, the Company effected a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-6.0774</FONT></FONT> reverse stock split of its issued and
outstanding shares of common stock and a proportional adjustment to the existing conversion rations for each series or the Company&#146;s Preferred Stock. Upon the closing of the Company&#146;s IPO in November 2017, all of the then outstanding
convertible preferred shares automatically converted into shares of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Share-Based Compensation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On June&nbsp;28, 2017, the Company&#146;s stockholders approved the 2017 Stock Incentive Plan (the &#147;2017 Plan&#148;). The 2017 Plan
provides for the grant of incentive stock options, nonqualified stock options, stock grants and stock-based awards. The 2017 Plan is administered by the board of directors, or at the discretion of the board
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-56 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of directors, by a committee of the board. The exercise prices, vesting and other restrictions are determined at the discretion of the board of directors, or their committee if so delegated,
except that the exercise price per share of stock options may not be less than 100% of the fair market value of the share of common stock on the date of grant and the term of stock option may not be greater than ten years. The number of shares
initially reserved for issuance under the 2017 Plan was 1,785,416 shares of common stock. The shares of common stock underlying any awards that are forfeited, cancelled, repurchased or are otherwise terminated by the Company under the 2017 Plan will
be added back to the shares of common stock available for issuance under the 2017 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On October&nbsp;18, 2017, the Company&#146;s
stockholders approved an amendment to the 2017 Plan, which became effective upon the completion of the Company&#146;s IPO, to increase the total number of shares reserved for issuance under the 2017 Plan from 1,785,416 to 2,696,401. Additionally,
the number of shares of common stock that may be issued under the 2017 Plan will automatically increase on each January&nbsp;1, beginning with the fiscal year ending December&nbsp;31, 2019 and continuing for each fiscal year until, and including,
the fiscal year ending December&nbsp;31, 2027, equal to the lowest of (i) 607,324 shares of common stock, (ii) 4% of the outstanding shares of common stock on such date and (iii)&nbsp;an amount determined by the Company&#146;s board of directors or
compensation committee. There were 160,600 options granted during the three months ended March&nbsp;31, 2018. As of March&nbsp;31, 2018, there were 2,129,082 options outstanding under the 2017 Plan and 567,319 shares remaining available to be issued
under the 2017 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company recorded share-based compensation expense in the following expense categories of its consolidated
statements of operations and comprehensive loss (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. <FONT STYLE="white-space:nowrap">Non-Controlling</FONT> Interests </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Spero Potentiator </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In
February&nbsp;2015, the Company&#146;s wholly owned subsidiary, Spero Potentiator, issued 996 shares of its common stock with an aggregate fair value of $1.1&nbsp;million to Northern Antibiotics Oy Ltd. (&#147;Northern&#148;) in exchange for an
exclusive license to develop and commercialize certain licensed compounds and licensed products.&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In connection
with the acquisition of the license, Northern obtained anti-dilution rights to maintain its 49.9% ownership percentage in Spero Potentiator at no additional cost to Northern in the event that Spero Potentiator completed subsequent equity financings,
subject to a maximum amount of such financings. The Company accounted for the anti-dilution rights as a derivative liability on its consolidated balance sheet. The fair value of the derivative liability associated with the anti-dilution rights upon
issuance in February 2015 of $2.4&nbsp;million was recorded as research and development expenses as it was deemed to represent additional consideration for the license. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In November 2015, Northern was issued an additional 2,736 common shares of Spero Potentiator for no additional cost as a result of the
anti-dilution rights. The Company valued these shares at $1.5&nbsp;million and recorded the amount as an increase in the <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest and a reduction in the carrying value of the derivative
liability. In January and August 2016, Northern was issued an additional 2,160 common shares of Spero Potentiator for no additional cost. The Company valued these shares at $1.0&nbsp;million and recorded the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-57 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amount as an increase in the <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest and a reduction of the derivative liability. At that time, the anti-dilution rights issued to
Northern were fully settled as Northern had received the maximum number of shares it was entitled to under the anti-dilution rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In
June 2017, the Company repurchased all of the shares of Spero Potentiator held by Northern in exchange for a cash payment of $1.0&nbsp;million and contingent consideration of $0.1&nbsp;million. As a condition of the repurchase of the shares from
Northern, the Company amended the license agreement with Northern such that the Company will be obligated to make milestone payments of up to $7.0&nbsp;million upon the achievement of specified clinical, commercial and other milestones, including a
payment of $2.5&nbsp;million upon the closing of an IPO, which occurred and was paid in November 2017. As a result of this transaction, during the six months ended June&nbsp;30, 2017, the Company reclassified the balance of the <FONT
STYLE="white-space:nowrap">non-controlling</FONT> interest of $6.4&nbsp;million as of the date of the transaction to accumulated deficit as an increase to that account. Additionally, the cash payment of $1.0&nbsp;million was recorded as an increase
to accumulated deficit. The Company will record the contingent payments as research and development expense when it becomes probable that the payments will be due. For periods subsequent to the acquisition, the Company no longer reports a <FONT
STYLE="white-space:nowrap">non-controlling</FONT> interest related to Spero Potentiator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Spero Europe </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In January&nbsp;2016, the Company entered into an agreement with Promiliad Biopharma Inc. (&#147;Promiliad&#148;), whereby Promiliad granted
to Spero Europe certain <FONT STYLE="white-space:nowrap">know-how</FONT> and a sublicense to research, develop, manufacture and sell certain compounds. In exchange for the <FONT STYLE="white-space:nowrap">know-how</FONT> and sublicense, Spero Europe
provided Promiliad with a 5% equity ownership interest in Spero Europe, with a fair value of $0.1&nbsp;million. In addition, Spero Europe agreed to make payments to Promiliad upon the achievement of future regulatory and commercial milestones of
$4.1 million&nbsp;and to pay to Promiliad royalties of a mid single-digit percentage on net sales of licensed products under the agreement. Spero had the right to terminate the agreement with thirty days&#146; notice. The Company recognized research
and development expense of $0.1&nbsp;million upon the acquisition of the license and recorded a <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest in Spero Europe in a corresponding amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In connection with the acquisition of the license, Promiliad obtained anti-dilution rights to maintain their 5% equity ownership in Spero
Europe at no additional cost to Promiliad in the event that Spero Europe completed subsequent funding events, subject to a maximum amount of such funding of $5.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company accounted for the anti-dilution rights as a derivative liability on its consolidated balance sheet. The fair value of the
derivative liability associated with the anti-dilution rights upon issuance in January 2016 of $0.2&nbsp;million was recorded as research and development expenses as it was deemed to represent additional consideration for the license. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In May 2017, the Company repurchased all of the shares of Spero Europe from Promiliad in exchange for the return of the license. As a result
of the transaction, the Company reclassified the balance of the <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest in Spero Europe of less than $0.1&nbsp;million as of the date of the transaction to accumulated deficit as an increase
to that account. For periods subsequent to the repurchase, the Company no longer reports a <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest related to Spero Europe. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Spero Gyrase </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In March 2016, the
Company entered into an agreement with Aviragen and its affiliates in order to acquire certain intellectual property and <FONT STYLE="white-space:nowrap">know-how</FONT> related to certain compounds.&nbsp;In connection with the transaction, the
Company established Spero Gyrase, a Delaware corporation, and issued to Aviragen 200 common shares of Spero Gyrase with a fair value of $1.1&nbsp;million, which represented a 20% equity ownership </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-58 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
interest in Spero Gyrase. In addition, Spero Gyrase agreed to make future milestone and royalty payments in exchange for the intellectual property. The Company accounted for the acquisition of
technology as an&nbsp;asset acquisition&nbsp;because it did not&nbsp;meet the definition of a business. The Company recorded the acquired technology as research and development expense in the consolidated statement of operations and comprehensive
loss in the amount of $1.1&nbsp;million, because the acquired technology had not reached commercial feasibility and had&nbsp;no alternative future use, and recorded a <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest in Spero Gyrase
in a corresponding amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In connection with the agreement, Aviragen obtained anti-dilution rights to maintain their 20% equity
ownership of Spero Gyrase at no additional cost to Aviragen in the event that Spero Gyrase completed subsequent funding events, subject to a maximum amount of such funding of $8.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company accounted for the anti-dilution rights as a derivative liability on its consolidated balance sheet (see Note 3). The fair value of
the derivative liability associated with the anti-dilution rights upon issuance in March 2016 of $1.6&nbsp;million was recorded as research and development expenses as it was deemed to represent additional consideration for the license. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Spero Cantab </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In June 2016, the
Company entered into a stock purchase agreement and related agreements (the &#147;Cantab Agreements&#148;) with Pro Bono Bio PLC, a corporation organized under the laws of England, and certain of its affiliates, including PBB Distributions Limited
(&#147;PBB&#148;), Cantab Anti-Infectives Ltd. (&#147;CAI&#148;) and New Pharma License Holdings Limited (&#147;NPLH&#148;) in order to acquire NPLH and its intellectual property rights and assets relating to the Company&#146;s Potentiator Platform.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under the Cantab Agreements, CAI agreed to submit a request to NIAID to novate the <FONT STYLE="white-space:nowrap">CAI-held</FONT> NIAID
contract to the Company. The NIAID contract provides for development funding of up to $6.0&nbsp;million over a base and three option periods. To date, funding for the base period and the first two option periods totaling $5.4&nbsp;million had been
committed to CAI. Novation of the NIAID contract to the Company was finalized in December 2017. The Company shall pay PBB a percentage of funds received from NIAID up to a maximum of $1.3&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Consideration under Cantab Agreements consisted of: (i)&nbsp;125 shares of Spero Cantab, the Company&#146;s subsidiary, which represented a
12.5% ownership interest in Spero Cantab, and anti-dilution rights (as described below) issued to PBB, with a combined fair value of $1.6&nbsp;million, (ii)&nbsp;upfront consideration of $0.3&nbsp;million (to be credited against future payments
payable to CAI), (iii)&nbsp;contingent milestone payments due upon the achievement of certain clinical, regulatory and commercial milestones (see Note&nbsp;13), (iv)&nbsp;royalty payments of low single-digit percentages based on net sales of
products from the licensed technology, and (v)&nbsp;a specified portion of funding payments made by NIAID. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company accounted for the
acquisition of NPLH as an&nbsp;asset acquisition&nbsp;because NPLH did not&nbsp;meet the definition of a business. The Company recognized research and development expense of $1.6&nbsp;million upon the acquisition of NPLH because the acquired
technology had not reached commercial feasibility and had&nbsp;no alternative future use. Upon the issuance of the shares and anti-dilution rights, the Company recorded a <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest in Spero
Cantab of $1.6&nbsp;million. The $0.3&nbsp;million payment was recognized as research and development expenses as the services were performed by CAI. The Company records the contingent payments outlined in (iii), (iv)&nbsp;and (v)&nbsp;as research
and development expense when it becomes probable that the payments will be due. Novation of the NIAID contract to Spero was finalized in December 2017. Prior to the contract novation, CAI performed research and development services at the
Company&#146;s direction and applied for reimbursement from NIAID. The Company paid CAI for such research and development services at an agreed-upon rate which took into consideration costs incurred by CAI, amounts reimbursed to CAI by NIAID and the
portion of the NIAID reimbursement the Company paid to CAI. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-59 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In connection with the Cantab Agreements, PBB obtained anti-dilution rights to maintain a
certain equity ownership, ranging from 5% to 12.5%, of Spero Cantab at no additional cost to PBB in the event that Spero Cantab completed subsequent funding events, subject to maximum amount of such funding of $8.0&nbsp;million. These anti-dilution
rights represent a conditional obligation to issue a variable number of shares but are not freestanding and, therefore, do not require bifurcation for accounting purposes from the 125 shares issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In July 2017, the Company repurchased all of the outstanding shares of Spero Cantab owned by PBB in exchange for a cash payment of
$0.2&nbsp;million and an amendment to the licensing agreement to increase the first two contingent milestone payments by a total of $0.1&nbsp;million. For periods subsequent to the repurchase, the Company no longer reports a <FONT
STYLE="white-space:nowrap">non-controlling</FONT> interest related to Spero Cantab. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2018 and December&nbsp;31, 2017,
the Company&#146;s only remaining <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest relates to Spero Gyrase, Inc., which totaled $0.4&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Commitments and Contingencies </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>License
Agreements </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company has entered into license agreements with various parties under which it is obligated to make contingent
and <FONT STYLE="white-space:nowrap">non-contingent</FONT> payments (see Note&nbsp;10). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Leases </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In August 2015, the Company entered into an operating lease agreement with U.S. REIF Central Plaza Massachusetts, LLC (the
&#147;Landlord&#148;) with respect to its corporate headquarters located at 675 Massachusetts Avenue, Cambridge, Massachusetts (the &#147;Original Lease&#148;).The term of the Original Lease commenced in January 2016 and was scheduled to expire in
December 2020. The Original Lease required annual payments of $0.4&nbsp;million over the initial five-year term. The Original Lease provided for a renewal option to extend its term for an additional five years. Under the terms of the Original Lease,
the Company provided a security deposit of $0.2&nbsp;million to the Landlord, which is included in long-term assets in the accompanying consolidated balance sheets. The Original Lease provided for annual rent escalations as well as tenant incentives
in the amount of $0.7&nbsp;million, of which $0.3&nbsp;million would be reimbursed to the Landlord over the initial term of the Original Lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In July 2016, the Company entered into an agreement to lease laboratory space through November&nbsp;30, 2019 from a sublessor, which requires
annual lease payments of $0.3&nbsp;million, subject to certain escalations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On January&nbsp;17, 2018, the Company entered into an
amendment (the &#147;Amendment&#148;) to the Original Lease. The Amendment makes certain changes to the Original Lease, including (i)&nbsp;the addition of approximately 7,800 square feet of office space in the same building (the &#147;Expansion
Premises&#148;) and (ii)&nbsp;an extension of the expiration date of the Original Lease to seven years following the delivery date of the Expansion Premises (the &#147;Lease Term&#148;), which is estimated to be December&nbsp;1, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under the Amendment, the Company has two consecutive options to extend the Lease Term for an additional period of five years (the &#147;Option
Terms&#148;), subject to certain conditions, upon notice to the Landlord. The Amendment provides for annual base rent for the Expansion Premises of approximately $0.5&nbsp;million in the first year of the Lease Term, which increases on an annual
basis to approximately $0.6&nbsp;million in the final year of the Lease Term, and annual base rent during the Option Terms to be calculated based on the Landlord&#146;s good faith determination of 100% of the fair market rate for such Option Terms.
The Company is also obligated to pay the Landlord certain costs, taxes and operating expenses, subject to certain exclusions. The Amendment also includes a provision from the landlord of $0.4&nbsp;million for leasehold improvements on the Expansion
Premises. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Rent escalations and tenant incentives for operating leases are included in deferred rent in
the consolidated balance sheet, and rent expense is recognized on a straight-line basis over the terms of occupancy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table
summarizes the future minimum payments due under the operating leases as of March&nbsp;31, 2018 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="92%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:95.55pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Years Ending December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018 (remainder)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">658</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,076</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Rent expense for both the three months ended March&nbsp;31, 2018 and 2017 was $0.2&nbsp;million.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Indemnification Agreements </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In
the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach
of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors that will require the Company, among other
things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification
agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company does not believe that the outcome of any claims under indemnification arrangements will have a
material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its consolidated financial statements as of March&nbsp;31, 2018 or December&nbsp;31, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legal Proceedings </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company is
not currently party to any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative
guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Government
Contracts </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Department of Defense </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In September 2016, the Company was awarded a cooperative agreement with the DoD to further develop anti-infective agents to combat
Gram-negative bacteria. The agreement is structured as a single, <FONT STYLE="white-space:nowrap">two-year</FONT> $1.5&nbsp;million award. The Company is eligible for the full funding from the DoD, and there are no options to be exercised at a later
date. The DoD funding supports next-generation potentiator discovery and screening of SPR741 partners. The Company recognizes revenue under this agreement as qualifying expenses are incurred. The Company recognized $0.1&nbsp;million of revenue under
this agreement during the three months ended March&nbsp;31, 2018 and 2017. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-61 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>NIAID </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In February 2017, the Company was awarded a grant from NIAID under its Small Business Innovation Research program, to conduct additional
preclinical studies of SPR720, the Company&#146;s novel oral bacterial gyrase inhibitor, for the treatment of <FONT STYLE="white-space:nowrap">non-tuberculous</FONT> mycobacterial infections. The award is structured as a <FONT
STYLE="white-space:nowrap">12-month</FONT> $0.6&nbsp;million base period and a $0.4&nbsp;million option period. Through December&nbsp;31, 2017, only the base period funds had been committed. In February 2018, NIAID exercised the $0.4&nbsp;million <FONT
STYLE="white-space:nowrap">12-month</FONT> option period. The Company recognized $0.5&nbsp;million of revenue under this agreement during the three months ended March&nbsp;31, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In June 2016, the Company entered into agreements with Pro Bono Bio PLC (&#147;PBB&#148;), a corporation organized under the laws of England,
and certain of its affiliates, including PBB Distributions Limited and Cantab Anti-Infectives Limited (&#147;CAI&#148;), in order to acquire certain intellectual property and government funding arrangements relating to SPR206 (see Note 10). Under
these agreements, CAI agreed to submit a request to NIAID to assign the <FONT STYLE="white-space:nowrap">CAI-held</FONT> NIAID contract to Spero, which was finalized in December 2017. The NIAID contract provides for total development funding of up
to $6.0&nbsp;million, including a base period and three option periods. To date, funding for the base period and the first two option periods totaling $5.4&nbsp;million have been committed. Spero shall pay PBB a percentage of funds received from
NIAID up to a maximum of $1.3&nbsp;million, of which $0.3&nbsp;million was paid upfront to PBB as part of this agreement. During the three months ended March&nbsp;31, 2018, we recorded approximately $0.1&nbsp;million in amounts payable to PBB under
this agreement.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">CARB-X</FONT> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In April 2017, the Company was awarded a grant from <FONT STYLE="white-space:nowrap">CARB-X,</FONT> a public-private partnership funded by the
Biomedical Advanced Research and Development Authority (&#147;BARDA&#148;) within the U.S. Department of Health and Human Services to be used to screen, identify and complete Phase 1 trials with at least one partner compound for SPR741, the
Company&#146;s lead Potentiator compound. The award committed to funding of $1.5&nbsp;million over a <FONT STYLE="white-space:nowrap">12-month</FONT> period. On March&nbsp;12, 2018, <FONT STYLE="white-space:nowrap">CARB-X</FONT> committed an
additional $0.4&nbsp;million related to the first option for a period from December&nbsp;1, 2017 to March&nbsp;31, 2018. There will be no additional options exercised under the <FONT STYLE="white-space:nowrap">CARB-X</FONT> award. The Company
recognized $0.5&nbsp;million of revenue in the three months ended March&nbsp;31, 2018 under this agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Collaboration and License Agreements
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company has certain obligations under license agreements with third parties that include annual maintenance fees and payments
that are contingent upon achieving various development, regulatory and commercial milestones. Pursuant to these license agreements, the Company is required to make milestone payments if certain development, regulatory and commercial milestones are
achieved, and may have certain additional research funding obligations. Also, pursuant to the terms of each of these license agreements, when and if commercial sales of a product commence, the Company will pay royalties to its licensors on net sales
of the respective products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Aviragen Agreement </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under the Company&#146;s agreement with Aviragen (see Note 7) for certain intellectual property and
<FONT STYLE="white-space:nowrap">know-how</FONT> relating to developing a gyrase inhibitor to develop therapies for Gram-negative infections, the Company is obligated to make milestone payments of up to an aggregate of $12.0&nbsp;million upon the
achievement of specified clinical, regulatory and commercial milestones and to pay royalties of low single-digit percentages based on net sales of products the Company acquired under the agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-62 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cantab License Agreement </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under the Cantab Agreements (see Note 7), the Company is obligated to make milestone payments of up to $5.8&nbsp;million upon the achievement
of specified clinical and regulatory milestones and a payment of &pound;5.0&nbsp;million ($7.0&nbsp;million and $6.7&nbsp;million as of March&nbsp;31, 2018 and December&nbsp;31, 2017, respectively) upon the achievement of a specified commercial
milestone. In addition, the Company has agreed to pay to PBB royalties, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, of a low single-digit percentage based on net sales of products licensed under the agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Cantab Agreements continue indefinitely, with royalty payment obligations thereunder continuing on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis until the later of ten years after the first commercial sale of such product in
such country or the expiration in such country of the last to expire valid claim of any of the applicable patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Vertex License Agreement
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In May 2016, the Company entered into an agreement with Vertex Pharmaceuticals Incorporated (&#147;Vertex&#148;) whereby Vertex
granted the Company certain <FONT STYLE="white-space:nowrap">know-how</FONT> and a sublicense to research, develop, manufacture and sell products for a proprietary compound, as well as a transfer of materials. In exchange for the <FONT
STYLE="white-space:nowrap">know-how,</FONT> sublicense and materials, Spero paid Vertex an upfront, <FONT STYLE="white-space:nowrap">one-time,</FONT> nonrefundable, <FONT STYLE="white-space:nowrap">non-creditable</FONT> fee of $0.5&nbsp;million,
which was recognized as research and development expense. As part of the agreement, the Company is obligated to make future milestone payments of up to $81.1&nbsp;million upon the achievement of specified clinical, regulatory and commercial
milestones and to pay Vertex tiered royalties, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, of a mid single-digit to low double-digit percentage based on net sales of products licensed under the agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The agreement continues in effect until the expiration of all payment obligations thereunder, with royalty payment obligations continuing on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis until the later of ten years after the
first commercial sale of such product in such country or the date of expiration in such country of the last to expire applicable patent. Further, Vertex has the right to terminate the agreement if provided with notification from the Company of
intent to cease all development or if no material development or commercialization efforts occur for one year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Meiji License Agreement </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In June 2017, the Company entered into agreements with Meiji Seika Pharma Co. Ltd. (&#147;Meiji&#148;), a Japanese corporation, whereby Meiji
granted to the Company certain <FONT STYLE="white-space:nowrap">know-how</FONT> and a license to research, develop, manufacture and sell products for a proprietary compound in the licensed territory. In exchange for the <FONT
STYLE="white-space:nowrap">know-how</FONT> and license, the Company paid Meiji an upfront, <FONT STYLE="white-space:nowrap">one-time,</FONT> nonrefundable, <FONT STYLE="white-space:nowrap">non-creditable</FONT> fee of $0.6&nbsp;million, which was
recognized as research and development expense. As part of the agreement, the Company is obligated to make milestone payments of up to $3.0&nbsp;million upon the achievement of specified clinical and regulatory milestones, to pay royalties, on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, of a low single-digit percentage based on net
sales of products licensed under the agreement and to pay Meiji a low double-digit percentage of any sublicense fees received by the Company up to $7.5&nbsp;million. In October 2017, the Company paid a $1.0&nbsp;million milestone payment to Meiji
upon the enrollment of the first patient in the Company&#146;s Phase 1 clinical trial of SPR994. The payment was recorded as research and development expense in the statement of operations and comprehensive loss for the year ended December&nbsp;31,
2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The agreement continues in effect until the expiration of all payment obligations thereunder (including royalty payments and
licensee revenue) on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, unless earlier
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-63 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
terminated by the parties. Pursuant to the terms of the agreement, in addition to each party&#146;s right to terminate the agreement upon the other party&#146;s material breach (if not cured
within a specified period after receipt of notice) or insolvency, the Company also has unilateral termination rights (i)&nbsp;in the event that the Company abandons the development and commercialization of SPR994 for efficacy, safety, legal or
business factors, and (ii)&nbsp;under certain circumstances arising out of the head license with a global pharmaceutical company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Northern License
Agreement </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In June 2017, in connection with the repurchase of all of the outstanding shares of Spero Potentiator (see
Note&nbsp;6), the Company amended its license agreement with Northern such that the Company agreed to pay Northern up to $7.0&nbsp;million upon the achievement of specified clinical, regulatory and other milestones, including a total payment of
$2.5&nbsp;million upon the closing of an initial public offering. In addition, under an exchange agreement the Company entered into with Northern, the Company is obligated to make a payment to Northern of $0.1&nbsp;million upon the closing of an
initial public offering. The agreement has a perpetual term and no express termination rights. Upon the closing of the Company&#146;s IPO in November 2017, the Company paid $2.6&nbsp;million to Northern in connection with both the license and
exchange agreements. This payment was recorded as research and development expense in the Company&#146;s statement of operations and comprehensive loss for the year ended December&nbsp;31, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Australia Research and Development Tax Incentive </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Australian government has established a research and development tax incentive to encourage industry investment in research and
development, which is available to companies incorporated under Australian law that have core research and development activities. In September 2016, the Company established Spero Potentiator Australia Pty Limited to carry out certain research and
development activities. As this subsidiary meets the eligibility requirements of the Australian tax law, it is eligible to receive a 43.5% tax incentive for qualified research and development activities. The Company did not record any reduction to
research and development expenses in the consolidated statements of operations and comprehensive loss associated with this tax incentive during the three months ended March&nbsp;31, 2017. The Company recorded less than $0.1&nbsp;million as a
reduction to research and development expenses in the consolidated statements of operations and comprehensive loss during the three months ended March&nbsp;31, 2018, associated with this tax incentive, representing 43.5% of the Company&#146;s
qualified research and development spending in Australia. The tax incentive refund is denominated in Australian dollars and, therefore, the associated tax incentive receivable is <FONT STYLE="white-space:nowrap">re-measured</FONT> to U.S. dollars as
of each reporting date. The Company&#146;s tax incentive receivables from the Australian government totaled $1.9&nbsp;million as of March&nbsp;31, 2018 and December&nbsp;31, 2017. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-64 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Net Loss per Share </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share attributable to common stockholders of Spero Therapeutics, Inc. was calculated as follows (in thousands,
except share and per share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,644</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,411</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Net loss attributable to <FONT STYLE="white-space:nowrap">non-controlling</FONT>
interests</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(535</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Plus: Cumulative dividends on redeemable convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,236</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Plus: Accretion of bridge units and redeemable convertible preferred shares to redemption
value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders of Spero Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,644</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,130</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,369,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">330,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders of Spero Therapeutics, Inc., basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.74</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(21.60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company excluded potentially dilutive securities from the computation of diluted net loss per share as the
effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders of Spero Therapeutics, Inc. is the
same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because
including them would have had an anti-dilutive effect: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,129,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Incentive units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">422,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,129,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">422,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-65 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:50pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:30pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>3,250,000&nbsp;Shares of Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>2,166 Shares of Series A Convertible Preferred Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>2,166,000 Shares of Common Stock Issuable Upon Conversion of Series A Convertible Preferred Stock </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g521849g48n25.jpg" ALT="LOGO">
 </P>   <P STYLE="font-size:50pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS </B></P> <P STYLE="font-size:50pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:30pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Cowen </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Stifel </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Cantor </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Oppenheimer&nbsp;&amp; Co. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>H.C. Wainwright&nbsp;&amp; Co. </B></P> <P STYLE="font-size:50pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:30pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2018 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P><center>
<P STYLE="line-height:3.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P></center>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM 13. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table sets forth all costs and expenses, other than underwriting discounts and commissions, paid or payable by the Registrant in
connection with the sale of the securities being registered. All amounts shown are estimates except for the Securities and Exchange Commission, or SEC, registration fee and the Financial Industry Regulatory Authority, Inc., or FINRA, filing fee.
</P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accountants&#146; fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer agent and registrar fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">577,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&nbsp;14. INDEMNIFICATION OF DIRECTORS AND OFFICERS. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Section&nbsp;145(a) of the Delaware General Corporation Law provides, in general, that a corporation may indemnify any person who was or is a
party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation), because he or she is
or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against
expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding, if he or she acted in good faith and in a manner he or she
reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Section&nbsp;145(b) of the Delaware General Corporation Law provides, in general, that a corporation may indemnify any person who was or is a
party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor because the person is or was a director, officer, employee or agent of the
corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#146; fees) actually
and reasonably incurred by the person in connection with the defense or settlement of such action or suit if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the
corporation, except that no indemnification shall be made with respect to any claim, issue or matter as to which he or she shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other
adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, he or she is fairly and reasonably entitled to indemnity for such expenses that the Court of Chancery or other
adjudicating court shall deem proper. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Section&nbsp;145(g) of the Delaware General Corporation Law provides, in general, that a
corporation may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of
another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of his or her status as such, whether or not the
corporation would have the power to indemnify the person against such liability under Section&nbsp;145 of the Delaware General Corporation Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation provides that no director of our
company shall be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duty as a director, except for liability (1)&nbsp;for any breach of the director&#146;s duty of loyalty to us or our stockholders,
(2)&nbsp;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (3)&nbsp;in respect of unlawful dividend payments or stock redemptions or repurchases, or (4)&nbsp;for any transaction from which
the director derived an improper personal benefit. In addition, our amended and restated certificate of incorporation provides that if the Delaware General Corporation Law is amended to authorize the further elimination or limitation of the
liability of directors, then the liability of a director of our company shall be eliminated or limited to the fullest extent permitted by the Delaware General Corporation Law, as so amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The amended and restated certificate of incorporation further provides that any repeal or modification of such article by our stockholders or
amendment to the Delaware General Corporation Law will not adversely affect any right or protection existing at the time of such repeal or modification with respect to any acts or omissions occurring before such repeal or modification of a director
serving at the time of such repeal or modification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation provides that we will indemnify
each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding whether civil, criminal, administrative or investigative (other than an action by or in the right of us) by reason
of the fact that he or she is or was, or has agreed to become, our director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another
corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to as an &#147;Indemnitee&#148;), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including
attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she
reasonably believed to be in, or not opposed to, our best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful. Our amended and restated certificate of
incorporation also provides that we will advance expenses to Indemnitees in connection with a legal proceeding, subject to limited exceptions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with each of our directors and our executive officers. These agreements provide that we will
indemnify each of our directors and such officers to the fullest extent permitted by law and the amended and restated certificate of incorporation and amended and restated <FONT STYLE="white-space:nowrap">by-laws.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We also maintain a general liability insurance policy, which covers certain liabilities of directors and officers of our company arising out
of claims based on acts or omissions in their capacities as directors or officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In any underwriting agreement we enter into in
connection with the sale of common stock being registered hereby, the underwriters will agree to indemnify, under certain conditions, us, our directors, our officers and persons who control us within the meaning of the Securities Act of 1933, as
amended, against certain liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&nbsp;15. RECENT SALES OF UNREGISTERED SECURITIES. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In the three years preceding the filing of this registration statement, we have issued the following securities that were not registered under
the Securities Act of 1933, as amended, or the Securities Act: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In January 2015, we issued and sold 8,000 bridge units to existing
investors at a price per unit of $1,000 for an aggregate purchase price of $8.0&nbsp;million. Such bridge units were subsequently exchanged for <FONT STYLE="white-space:nowrap">Class&nbsp;A-1</FONT> preferred units. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In June 2015, we issued an aggregate of 4,202,278 <FONT STYLE="white-space:nowrap">Class&nbsp;A-1</FONT> preferred units, consisting of (i)
2,279,202 <FONT STYLE="white-space:nowrap">Class&nbsp;A-1</FONT> preferred units issued to existing investors in exchange for 8,000 bridge units, and (ii) 1,923,076 <FONT STYLE="white-space:nowrap">Class&nbsp;A-1</FONT> preferred units issued and
sold at a price per unit of $3.90 for an aggregate purchase price of approximately $7.5&nbsp;million. The <FONT STYLE="white-space:nowrap">Class&nbsp;A-1</FONT> preferred units were subsequently reclassified as Class&nbsp;A preferred units. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In February 2016, we issued and sold 5,909,089
<FONT STYLE="white-space:nowrap">Class&nbsp;B-1</FONT> preferred units at a price per unit of $4.40, for an aggregate purchase price of approximately $26.0&nbsp;million. The <FONT STYLE="white-space:nowrap">Class&nbsp;B-1</FONT> preferred units were
subsequently reclassified as Class&nbsp;B preferred units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In December 2016, we issued and sold 8,500 bridge units at a price per unit of
$1,000 for an aggregate purchase price of approximately $8.5&nbsp;million. Such bridge units were subsequently converted into Class&nbsp;C preferred units. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In March 2017, we issued an aggregate of 29,647,582 Class&nbsp;C preferred units, consisting of (i) 5,321,112 Class&nbsp;C preferred units in
exchange for 8,500 bridge units and (ii) 24,326,470 Class&nbsp;C preferred units at a price per unit of $1.7749 for an aggregate purchase price of approximately $43,177,052. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On June&nbsp;30, 2017, as part of the Reorganization, each of the capital units of Spero Therapeutics, LLC issued and outstanding prior to the
Reorganization was cancelled and converted into and exchanged for one share of Spero Therapeutics, Inc. capital stock of the same class and/or series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In July 2017, after the consummation of the Reorganization, we sold to Joel Sendek, our Chief Financial Officer, 61,880 shares of our Series C
preferred stock, at a purchase price of $1.7749 per share, for an aggregate purchase price of $109,831. Such purchase and sale was made in accordance with the terms of Mr.&nbsp;Sendek&#146;s offer letter. In October 2017, Mr.&nbsp;Sendek transferred
his 61,880 shares of Series C preferred stock to a retained annuity trust that he established and of which he is a beneficiary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Prior to
the Reorganization, we had granted a total of 431,375 incentive units to our employees, directors, and consultants, pursuant to the operating agreement of Spero Therapeutics, LLC, as amended, at threshold prices ranging between $1.28 and $5.84 per
incentive unit. In connection with the Reorganization, such incentive units were cancelled as they were deemed to be valueless based on a liquidation valuation basis for federal income tax purposes and pursuant to contractual rights under the
operating agreement of Spero Therapeutics, LLC. Promptly after the Reorganization, previous holders of incentive units who were still employed by us at the time of the Reorganization received stock options under the 2017 Plan. Such stock options
were granted for the same number of shares of our common stock as the number of incentive units cancelled, and the stock options were granted on the same vesting terms and with similar rights and restrictions as the incentive units. Effective on
July&nbsp;6, 2017, we granted stock options to purchase an aggregate of 1,511,770 shares of our common stock. All such stock options have an exercise price of $5.90. Further, on July&nbsp;17, 2017, we granted to Frank Thomas, a newly appointed
member of our board of directors, stock options to purchase 30,515 shares of our common stock, at an exercise price of $5.90 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">No underwriters were used in the foregoing transactions, and no discounts or commissions were paid. All sales of securities described above
were exempt from the registration requirements of the Securities Act in reliance on Section&nbsp;4(a)(2) of the Securities Act, Rule 701 promulgated under the Securities Act or Regulation D promulgated under the Securities Act, relating to
transactions by an issuer not involving a public offering. All of the foregoing securities are deemed restricted securities for purposes of the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">With respect to the foregoing transactions, the common units and incentive units, along with associated threshold prices, of Spero
Therapeutics, LLC have been presented as if the reverse stock split of the common stock of Spero Therapeutics, Inc. effected on October 20, 2017 in anticipation of our intial public offering had been applied to such units and prices. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&nbsp;16. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>(a) Exhibits. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT
INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:28.45pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:66.80pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Filed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:31.95pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Herewith</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Incorporated by</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Reference herein</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>from Form
or</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:57.95pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Schedule</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:37.95pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Filing Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>SEC File /<BR>Registration</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:42.15pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d521849dex11.htm">Form of Underwriting Agreement </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1701108/000119312517334318/d490191dex31.htm">Amended and Restated Certificate of Incorporation of the Registrant</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 8-K</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exhibit&nbsp;3.1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">11/6/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">001-38266</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1701108/000119312517334318/d490191dex32.htm">Amended and Restated Bylaws of the Registrant </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 8-K</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exhibit 3.2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">11/6/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">001-38266</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d521849dex33.htm">Form of Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1701108/000119312517305888/d431217dex41.htm">Form of Common Stock Certificate </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form S-1</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exhibit 4.1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10/6/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">333-220858</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1701108/000119312517305888/d431217dex42.htm">Investors&#146; Rights Agreement, dated as of June 30, 2017, by and between the Registrant and the other parties thereto</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form S-1</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exhibit 4.2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10/6/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">333-220858</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d521849dex51.htm">Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1701108/000119312517369457/d499419dex101.htm">2017 Stock Incentive Plan, as amended </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 10-Q</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exhibit&nbsp;10.1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">12/14/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">333-220858</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1701108/000119312517369457/d499419dex102.htm">Form of Stock Option Agreement under the 2017 Stock Incentive Plan, as amended </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 10-Q</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exhibit 10.2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">12/14/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">333-220858</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1701108/000119312517305888/d431217dex104.htm">Form of Director and Officer Indemnification Agreement. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form S-1</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exhibit 10.4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10/6/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">333-220858</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1701108/000119312517315961/d431217dex1020.htm">Non-Employee Director Compensation Policy </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form S-1/A</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exhibit&nbsp;10.20)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10/23/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">333-220858</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1701108/000119312517315961/d431217dex105.htm">Employment Agreement, dated October 20, 2017, by and between the Registrant and Ankit Mahadevia, M.D. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form S-1/A</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exhibit 10.5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10/23/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">333-220858</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1701108/000119312517315961/d431217dex106.htm">Employment Agreement, dated October 20, 2017, by and between the Registrant and Joel Sendek </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form S-1/A</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exhibit 10.6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10/23/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">333-220858</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1701108/000119312517315961/d431217dex107.htm">Employment Agreement, dated October 20, 2017, by and between the Registrant and Thomas Parr Jr., Ph.D. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form S-1/A</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exhibit 10.7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10/23/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">333-220858</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1701108/000119312517315961/d431217dex108.htm">Employment Agreement, dated October 20, 2017, by and between the Registrant and Cristina Larkin</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form S-1/A</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exhibit 10.8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10/23/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">333-220858</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1701108/000156459018007402/spro-ex109_1873.htm">Employment Agreement, dated December 13, 2017, by and between the Registrant and David Melnick, M.D. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Form 10-K (Exhibit 10.9)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">4/2/2018</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">001-38266</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1701108/000119312517305888/d431217dex109.htm">Letter Agreement, dated June 24, 2015, by and between the Registrant and John Tomayko, M.D. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form S-1</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exhibit 10.9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10/6/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">333-220858</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:28.45pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:66.80pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Filed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:31.95pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Herewith</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Incorporated by</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Reference herein</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>from Form
or</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:57.95pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Schedule</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:37.95pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Filing Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>SEC File /<BR>Registration</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:42.15pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1701108/000119312517305888/d431217dex1010.htm">Termination and Release, dated April 14, 2017, by and between the Registrant and John Tomayko, M.D. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form S-1</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exhibit 10.10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10/6/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">333-220858</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1701108/000119312517305888/d431217dex1011.htm">Lease Agreement, dated August 24, 2015, by and between the Registrant and U.S. REIF Central Plaza Massachusetts, LLC </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form S-1</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exhibit 10.11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10/6/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">333-220858</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1701108/000119312518016749/d527696dex991.htm">First Amendment to Lease Agreement, dated January 17, 2018, by and between the Registrant and U.S. REIF Central Plaza Massachusetts, LLC
</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Form 8-K (Exhibit 99.1)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">1/23/2018</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">001-38266</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1701108/000119312517305888/d431217dex1012.htm">Sublease, dated July 6, 2016, by and between the Registrant and Tetraphase Pharmaceuticals, Inc. with respect to 480 Arsenal Street
</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form S-1</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exhibit 10.12)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10/6/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">333-220858</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.15#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1701108/000119312517305888/d431217dex1013.htm">Stock Purchase Agreement, dated June 6, 2016, by and among Spero Cantab, Inc., the Registrant, Spero Cantab UK Limited, PBB Distributions Limited,
New Pharma License Holdings Limited, Cantab Anti-Infectives Ltd and Pro Bono Bio PLC, as amended by Amendment to Stock Purchase Agreement, dated July 18, 2017 </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form S-1</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exhibit 10.13)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10/6/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">333-220858</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.16#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1701108/000119312517315961/d431217dex1014.htm">Assignment and License Agreement, dated May 9, 2016, by and among Spero Trinem, Inc., the Registrant and Vertex Pharmaceuticals Incorporated.
 </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form S-1/A</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exhibit 10.14)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10/23/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">333-220858</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.17#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1701108/000119312517305888/d431217dex1015.htm">License Agreement, dated June 14, 2017, by and between the Registrant and Meiji Seika Pharma Co., Ltd., as supplemented by Addendum to License
 Agreement, dated June 14, 2017 </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form S-1</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exhibit 10.15)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10/6/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">333-220858</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.18#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1701108/000119312517315961/d431217dex1016.htm">Amended and Restated License Agreement, dated June 28, 2017, by and between Spero Potentiator, Inc. and Northern Antibiotics Oy (Ltd.)
</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form S-1/A</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exhibit 10.16)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10/23/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">333-220858</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.19</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1701108/000119312517315961/d431217dex1017.htm">Form of Proprietary Information and Inventions Assignment Agreement </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form S-1/A</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exhibit 10.17)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">10/23/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">333-220858</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1701108/000156459018007402/spro-ex211_429.htm">Subsidiaries of the Registrant </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Form 10-K (Exhibit 21.1)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">4/2/2018</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">001-38266</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d521849dex231.htm">Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d521849dex51.htm">Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit 5.1) </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#sig">Power of Attorney (included on signature page) </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">X</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top">Management contract or compensatory plan. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">#</TD>
<TD ALIGN="left" VALIGN="top">Confidential treatment received as to portions of the exhibit. Confidential materials omitted and filed separately with the SEC. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>(b) Financial Statement Schedules. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">No financial statement schedules are provided because the information called for is not required or is shown either in the financial
statements or notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&nbsp;17. UNDERTAKINGS. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement
certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of
the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In
the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit
or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to
a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby undertakes that: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of
prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities
offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="sig"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this Amendment No. 1 to Registration
Statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> to be signed on its behalf by the undersigned, thereunto duly authorized, in Cambridge, Massachusetts, on this 11th day of July, 2018. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SPERO THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ankit Mahadevia, M.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Ankit Mahadevia, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer and President</TD></TR>
</TABLE></DIV>    <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, this Amendment No.
1 to Registration Statement <FONT STYLE="white-space:nowrap">on&nbsp;Form&nbsp;S-1&nbsp;has</FONT> been signed by the following persons in the capacities and on the dates indicated. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="17%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:33.30pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:15.95pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:16.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Ankit Mahadevia, M.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Ankit Mahadevia, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Chief Executive Officer and President and Director</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(<I>Principal Executive Officer</I>)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">July 11, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Joel Sendek</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Joel Sendek</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Chief Financial Officer and Treasurer</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(<I>Principal Financial Officer and Principal</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Accounting Officer</I>)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">July 11, 2018</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Casper Breum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">July 11, 2018</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-bottom:0pt; margin-top:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Milind Deshpande, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">July 11, 2018</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-bottom:0pt; margin-top:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Jean-Fran&ccedil;ois Formela, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">July 11, 2018</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">David Southwell</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">July 11, 2018</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Frank E. Thomas</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">July 11, 2018</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-bottom:0pt; margin-top:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Patrick Vink, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">July 11, 2018</P></TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ankit Mahadevia, M.D. hereby signs this Amendment No. 1 to Registration Statement on Form S-1 on behalf of the
indicated persons for whom he is attorney-in-fact on July 11, 2018, pursuant to powers of attorney previously filed as Exhibit 24.1 to the Registration Statement on Form S-1 of Spero Therapeutics, Inc. filed with the Securities and Exchange
Commission on July 9, 2018. </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">*By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Ankit Mahadevia, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Ankit Mahadevia, M.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attorney-in-fact</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-7 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d521849dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Spero Therapeutics, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(a
Delaware corporation) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[&#149;] Shares of Common Stock </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[&#149;] Shares of Series A Convertible Preferred Stock </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>UNDERWRITING AGREEMENT </U></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: [&#149;],
2018 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Spero Therapeutics </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(a Delaware corporation) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[&#149;] Shares of Common Stock </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[&#149;] Shares of Series A Convertible Preferred Stock </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDERWRITING AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">[&#149;], 2018 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cowen and Company, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stifel, Nicolaus&nbsp;&amp; Company, Incorporated </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">as
Representatives of the several Underwriters </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Cowen and Company, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">599 Lexington Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Stifel, Nicolaus&nbsp;&amp; Company, Incorporated </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">787 7<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> Avenue, 11<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10019 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Spero Therapeutics, Inc.,
a Delaware corporation (the &#147;Company&#148;), confirms its agreement with Cowen and Company, LLC (&#147;Cowen&#148;) and Stifel, Nicolaus&nbsp;&amp; Company, Incorporated (&#147;Stifel&#148;) and each of the other Underwriters named in Schedule
A hereto (collectively, the &#147;Underwriters,&#148; which term shall also include any underwriter substituted as hereinafter provided in Section&nbsp;10 hereof), for whom Cowen and Stifel are acting as representatives (in such capacity, the
&#147;Representatives&#148;), with respect to (i)&nbsp;the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of shares of Common Stock, par value $0.001 per share, of the Company
(&#147;Common Stock&#148;) and Series A Convertible Preferred Stock, par value $0.001 per share, of the Company (&#147;Preferred Stock&#148;) set forth in Schedule&nbsp;A hereto and (ii)&nbsp;the grant by the Company to the Underwriters, acting
severally and not jointly, of the option described in Section&nbsp;2(b) hereof to purchase all or any part of [&#149;] additional shares of Common Stock. The aforesaid [&#149;] shares of Common Stock and [&#149;] shares of Preferred Stock (the
&#147;Initial Securities&#148;) to be purchased by the Underwriters, the Common Stock issuable upon the conversion of the Preferred Stock (the &#147;Conversion Shares&#148;), and all or any part of the [&#149;] shares of Common Stock subject to the
option described in Section&nbsp;2(b) hereof (the &#147;Option Securities&#148;) are herein called, collectively, the &#147;Securities.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company understands that the Underwriters propose to make a public offering of the Securities as soon as the Representatives deem
advisable after this Agreement has been executed and delivered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has filed with the Securities and Exchange Commission (the
&#147;Commission&#148;) a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> (No. <FONT STYLE="white-space:nowrap">333-226093),</FONT> including the related preliminary prospectus or prospectuses, covering the
registration of the sale of the Securities under the Securities Act of 1933, as amended (the &#147;1933 Act&#148;). Promptly after execution and delivery of this Agreement, the Company will prepare and file a prospectus in accordance with the
provisions of Rule 430A (&#147;Rule 430A&#148;) of the rules </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and regulations of the Commission under the 1933 Act (the &#147;1933 Act Regulations&#148;) and Rule 424(b) (&#147;Rule 424(b)&#148;) of the 1933 Act Regulations. The information included in such
prospectus that was omitted from such registration statement at the time it became effective but that is deemed to be part of such registration statement at the time it became effective pursuant to Rule 430A(b) is herein called the &#147;Rule 430A
Information.&#148; Such registration statement, including the amendments thereto, the exhibits thereto and any schedules thereto, at the time it became effective, and including the Rule 430A Information, is herein called the &#147;Registration
Statement.&#148; Any registration statement filed pursuant to Rule 462(b) of the 1933 Act Regulations is herein called the &#147;Rule 462(b) Registration Statement&#148; and, after such filing, the term &#147;Registration Statement&#148; shall
include the Rule 462(b) Registration Statement. Each prospectus used prior to the effectiveness of the Registration Statement, and each prospectus that omitted the Rule 430A Information that was used after such effectiveness and prior to the
execution and delivery of this Agreement, is herein called a &#147;preliminary prospectus.&#148; The final prospectus, in the form first furnished to the Underwriters for use in connection with the offering of the Securities, is herein called the
&#147;Prospectus.&#148; For purposes of this Agreement, all references to the Registration Statement, any preliminary prospectus, the Prospectus or any amendment or supplement to any of the foregoing shall be deemed to include the copy filed with
the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval system or any successor system (&#147;EDGAR&#148;). <B></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this Agreement: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Applicable Time&#148; means [&#149;] A./P.M., New York City time, on [&#149;], 2018 or such other time as agreed by the
Company and Cowen. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;General Disclosure Package&#148; means any Issuer General Use Free Writing Prospectuses issued at
or prior to the Applicable Time, the most recent preliminary prospectus that is distributed to investors prior to the Applicable Time and the information included on Schedule <FONT STYLE="white-space:nowrap">B-1</FONT> hereto, all considered
together. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Issuer Free Writing Prospectus&#148; means any &#147;issuer free writing prospectus,&#148; as defined in
Rule 433 of the 1933 Act Regulations (&#147;Rule 433&#148;), including without limitation any &#147;free writing prospectus&#148; (as defined in Rule 405 of the 1933 Act Regulations (&#147;Rule 405&#148;)) relating to the Securities that is
(i)&nbsp;required to be filed with the Commission by the Company, (ii)&nbsp;a &#147;road show that is a written communication&#148; within the meaning of Rule 433(d)(8)(i), whether or not required to be filed with the Commission, or
(iii)&nbsp;exempt from filing with the Commission pursuant to Rule 433(d)(5)(i) because it contains a description of the Securities or of the offering that does not reflect the final terms, in each case in the form filed or required to be filed with
the Commission or, if not required to be filed, in the form retained in the Company&#146;s records pursuant to Rule 433(g). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Issuer General Use Free Writing Prospectus&#148; means any Issuer Free Writing Prospectus that is intended for general
distribution to prospective investors (other than a &#147;<I>bona fide</I> electronic road show,&#148; as defined in Rule 433 (the &#147;Bona Fide Electronic Road Show&#148;)), as evidenced by its being specified in Schedule <FONT
STYLE="white-space:nowrap">B-2</FONT> hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Issuer Limited Use Free Writing Prospectus&#148; means any Issuer Free
Writing Prospectus that is not an Issuer General Use Free Writing Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">&#147;Testing-the-Waters</FONT></FONT> Communication&#148; means any oral or written communication with potential investors undertaken in reliance on Section&nbsp;5(d) of the 1933 Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication&#148; means any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication that is
a written communication within the meaning of Rule 405 under the 1933 Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1. <U>Representations and Warranties</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Representations and Warranties by the Company</I>. The Company represents and warrants to each Underwriter as of the date hereof, the
Applicable Time, the Closing Time (as defined below) and any Date of Delivery (as defined below), and agrees with each Underwriter, as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Registration Statement</U><U> and Prospectuses</U>. Each of the Registration Statement and any amendment thereto has
become effective under the 1933 Act. No stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto has been issued under the 1933 Act, no order preventing or suspending the use of any preliminary
prospectus or the Prospectus has been issued and no proceedings for any of those purposes have been instituted or are pending or, to the Company&#146;s knowledge, contemplated by the Commission. The Company has complied with each request (if any)
from the Commission for additional information. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the Registration Statement and any post-effective amendment
thereto, at the time it became effective, complied in all material respects with the requirements of the 1933 Act and the 1933 Act Regulations. Each preliminary prospectus, the Prospectus and any amendment or supplement thereto, at the time each was
filed with the Commission, complied in all material respects with the requirements of the 1933 Act and the 1933 Act Regulations. Each preliminary prospectus delivered to the Underwriters for use in connection with this offering and the Prospectus
was or will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation <FONT STYLE="white-space:nowrap">S-T.</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <U>Accurate Disclosure</U>. Neither the Registration Statement nor any amendment thereto, at its effective time, on the
date hereof, at the Closing Time or at any Date of Delivery, contained, contains or will contain an untrue statement of a material fact or omitted, omits or will omit to state a material fact required to be stated therein or necessary to make the
statements therein not misleading. At the Applicable Time, none of (A)&nbsp;the General Disclosure Package, (B)&nbsp;any individual Issuer Limited Use Free Writing Prospectus, when considered together with the General Disclosure Package or
(C)&nbsp;any individual Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, when considered together with the General Disclosure Package, included, includes or will include an
untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. Neither the Prospectus nor
any amendment or supplement thereto, as of its issue date, at the time of any filing with the Commission pursuant to Rule 424(b), at the Closing Time or at any Date of Delivery, included, includes or will include an untrue statement of a material
fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The representations and warranties in this subsection shall not apply to statements in or omissions from the Registration
Statement (or any amendment thereto), the General Disclosure Package or the Prospectus (or any amendment or supplement thereto) made in reliance upon and in conformity with written information furnished to the Company by any Underwriter through the
Representatives expressly for use therein. For purposes of this Agreement, the only information so furnished shall be the information in the [first paragraph under the heading &#147;Underwriting&#150;Commissions and Discounts,&#148; the information
in the second, third and fourth paragraphs under the heading &#147;Underwriting&#150;Price Stabilization, Short Positions and Penalty Bids&#148; and the information under the heading &#147;Underwriting&#150;Electronic Offer, Sale and Distribution of
Shares&#148; in each case contained in the Prospectus] (collectively, the &#147;Underwriter Information&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) <U>Issuer Free Writing Prospectuses</U>. No Issuer Free Writing Prospectus
conflicts or will conflict with the information contained in the Registration Statement or the Prospectus, and any preliminary or other prospectus deemed to be a part thereof that has not been superseded or modified. The Company has made available a
Bona Fide Electronic Road Show in compliance with Rule 433(d)(8)(ii) such that no filing of any &#147;road show&#148; (as defined in Rule 433(h)) is required in connection with the offering of the Securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) <U><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Materials</U>. The
Company (A)&nbsp;has not engaged in any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication other than
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications with the consent of the Representatives with entities that it has reasonable basis to believe are qualified institutional buyers within
the meaning of Rule 144A under the 1933 Act or institutions that are accredited investors within the meaning of Rule 501 under the 1933 Act and (B)&nbsp;has not authorized anyone other than the Representatives to engage in <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications. The Company reconfirms that the Representatives have been authorized to act on its behalf in undertaking <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications authorized by the Company. The Company has not distributed any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT>
Communications other than those listed on Schedule D hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <U>Company Not Ineligible Issuer</U>. At the time of
filing the Registration Statement and any post-effective amendment thereto, at the earliest time thereafter that the Company or another offering participant made a <I>bona fide</I> offer (within the meaning of Rule 164(h)(2) of the 1933 Act
Regulations) of the Securities and at the date hereof, the Company was not and is not an &#147;ineligible issuer,&#148; as defined in Rule 405, without taking account of any determination by the Commission pursuant to Rule 405 that it is not
necessary that the Company be considered an ineligible issuer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) <U>Emerging Growth Company Status.</U> From the time
of the initial confidential submission of the Registration Statement to the Commission (or, if earlier, the first date on which the Company engaged directly or through any Person authorized to act on its behalf in any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication) through the date hereof, the Company has been and is an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a) of the
1933 Act (an &#147;Emerging Growth Company&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) <U>Independent Accountants</U>. The accountants who certified the
financial statements and supporting schedules included in the Registration Statement, the General Disclosure Package and the Prospectus are independent public accountants with respect to the Company as required by the 1933 Act, the 1933 Act
Regulations, the Securities Exchange Act of 1934, as amended (the &#147;1934 Act&#148;), the Commission&#146;s rules and regulations under the 1934 Act (the &#147;1934 Act Regulations&#148;) and the Public Company Accounting Oversight Board. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) <U>Financial Statements</U>. The financial statements included in the Registration Statement, the General Disclosure
Package and the Prospectus, together with the related schedules and notes, present fairly, in all material respects, the financial position of the Company and its consolidated subsidiaries at the dates indicated and the statement of operations,
stockholders&#146; equity and cash flows of the Company and its consolidated subsidiaries for the periods specified; said financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#147;GAAP&#148;)
applied on a consistent basis throughout the periods involved, except in the case of unaudited financial statements, subject to normal <FONT STYLE="white-space:nowrap">year-end</FONT> audit adjustments and the exclusion of certain footnotes as
permitted by the applicable rules of the Commission. The supporting schedules, if any, present fairly, in all material respects, in accordance with GAAP the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
information required to be stated therein. The selected financial data and the summary financial information included in the Registration Statement, the General Disclosure Package and the
Prospectus present fairly, in all material respects, the information shown therein and have been compiled on a basis consistent with that of the audited financial statements included therein. Except as included therein, no historical or pro forma
financial statements or supporting schedules are required to be included or incorporated by reference in the Registration Statement, the General Disclosure Package or the Prospectus under the 1933 Act, the 1933 Act Regulations, the 1934 Act or the
1934 Act Regulations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) <U>No Material Adverse Change in Business</U>. Except as otherwise stated therein, since the
respective dates as of which information is given in the Registration Statement, the General Disclosure Package or the Prospectus, (A)&nbsp;there has been no material adverse change in the condition, financial or otherwise, or in the earnings,
business affairs or business prospects of the Company and its subsidiaries considered as one enterprise, whether or not arising in the ordinary course of business (a &#147;Material Adverse Effect&#148;), (B)&nbsp;there have been no transactions
entered into by the Company or any of its subsidiaries, other than those in the ordinary course of business, which are material with respect to the Company and its subsidiaries considered as one enterprise, and (C)&nbsp;there has been no dividend or
distribution of any kind declared, paid or made by the Company on any class of its capital stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) <U>Good Standing of
the Company</U>. The Company has been duly incorporated and is validly existing as a corporation in good standing under the laws of the State of Delaware and has corporate power and authority to own, lease and operate its properties and to conduct
its business as described in the Registration Statement, the General Disclosure Package and the Prospectus and to enter into and perform its obligations under this Agreement; and the Company is duly qualified as a foreign corporation to transact
business and is in good standing in each other jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure so to qualify or to be in good
standing would not result in a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi) <U>Good Standing of Subsidiaries</U>. Each &#147;significant
subsidiary&#148; of the Company (as such term is defined in Rule <FONT STYLE="white-space:nowrap">1-02</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X)</FONT> (each, a &#147;Subsidiary&#148; and, collectively, the &#147;Subsidiaries&#148;)
has been duly organized and is validly existing in good standing under the laws of the jurisdiction of its incorporation or organization, has corporate or similar power and authority to own, lease and operate its properties and to conduct its
business as described in the Registration Statement, the General Disclosure Package and the Prospectus and is duly qualified to transact business and is in good standing in each jurisdiction in which such qualification is required, whether by reason
of the ownership or leasing of property or the conduct of business, except where the failure to so qualify or to be in good standing would not result in a Material Adverse Effect. Except as otherwise disclosed in the Registration Statement, the
General Disclosure Package and the Prospectus, all of the issued and outstanding capital stock of each Subsidiary has been duly authorized and validly issued, is fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and is owned by
the Company, directly or through subsidiaries, free and clear of any security interest, mortgage, pledge, lien, encumbrance, claim or equity. None of the outstanding shares of capital stock of any Subsidiary were issued in violation of the
preemptive or similar rights of any securityholder of such Subsidiary. The only subsidiaries of the Company are the subsidiaries listed on Exhibit 21 to the Registration Statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xii) <U>Capitalization</U>. The authorized, issued and outstanding shares of
capital stock of the Company are as set forth in the Registration Statement, the General Disclosure Package and the Prospectus in the column entitled &#147;Actual&#148; under the caption &#147;Capitalization&#148; (except for subsequent issuances,
if any, pursuant to this Agreement, pursuant to reservations, agreements or employee benefit plans referred to in the Registration Statement, the General Disclosure Package and the Prospectus or pursuant to the exercise of convertible securities or
options referred to in the Registration Statement, the General Disclosure Package and the Prospectus). The outstanding shares of capital stock of the Company have been duly authorized and validly issued and are fully paid and <FONT
STYLE="white-space:nowrap">non-assessable.</FONT> None of the outstanding shares of capital stock of the Company were issued in violation of the preemptive or other similar rights of any securityholder of the Company. The Conversion Shares have been
duly authorized and reserved for issuance pursuant to the terms of the Preferred Stock, and upon valid conversion of the Preferred Stock, will be duly and validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and free
of any preemptive or similar rights, and will conform to the description thereof contained in the General Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiii) <U>Authorization of Agreement</U>. This Agreement has been duly authorized, executed and delivered by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiv) <U>Authorization and Description of Securities</U>. The Securities to be purchased by the Underwriters from the Company
have been duly authorized for issuance and sale to the Underwriters pursuant to this Agreement and, when issued and delivered by the Company pursuant to this Agreement against payment of the consideration set forth herein, will be validly issued and
fully paid and <FONT STYLE="white-space:nowrap">non-assessable;</FONT> and the issuance of the Securities is not subject to the preemptive or other similar rights of any securityholder of the Company that have not been duly and validly waived in
writing as of the date of this Agreement. The Common Stock and Preferred Stock conform, in all material respects, to all statements relating thereto contained in the Registration Statement, the General Disclosure Package and the Prospectus and such
description conforms, in all material respects, to the rights set forth in the instruments defining the same. No holder of Securities will be subject to personal liability solely by reason of being such a holder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xv) <U>Registration Rights</U>. There are no persons with registration rights or other similar rights to have any securities
registered for sale pursuant to the Registration Statement or otherwise registered for sale or sold by the Company under the 1933 Act pursuant to this Agreement, other than those rights that have been disclosed in the Registration Statement, the
General Disclosure Package and the Prospectus and have been waived. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xvi) <U>Absence of Violations, Defaults and
Conflicts</U>. Neither the Company nor any of its subsidiaries is (A)&nbsp;in violation of its charter, <FONT STYLE="white-space:nowrap">by-laws</FONT> or similar organizational document, (B)&nbsp;in default in the performance or observance of any
obligation, agreement, covenant or condition contained in any contract, indenture, mortgage, deed of trust, loan or credit agreement, note, lease or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which
it or any of them is bound or to which any of the properties or assets of the Company or any subsidiary is subject (collectively, &#147;Agreements and Instruments&#148;), except for such defaults that would not, singly or in the aggregate, result in
a Material Adverse Effect, or (C)&nbsp;in violation of any law, statute, rule, regulation, judgment, order, writ or decree of any arbitrator, court, governmental body, regulatory body, administrative agency or other authority, body or agency having
jurisdiction over the Company or any of its subsidiaries or any of their respective properties, assets or operations (each, a &#147;Governmental Entity&#148;), except for such violations that would not, singly or in the aggregate, result in a
Material Adverse Effect. The execution, delivery and performance of this Agreement and the consummation of the transactions contemplated herein and in the Registration Statement, the General Disclosure Package and the Prospectus (including the
issuance and sale of the Securities and the use of the proceeds from the sale of the Securities as described therein under the caption &#147;Use of Proceeds&#148;) and compliance by the Company with its obligations hereunder have been duly
authorized by all necessary corporate action and do not and will not, whether with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
or without the giving of notice or passage of time or both, conflict with or constitute a breach of, or default or Repayment Event (as defined below) under, or result in the creation or
imposition of any lien, charge or encumbrance upon any properties or assets of the Company or any subsidiary pursuant to, the Agreements and Instruments (except for such conflicts, breaches, defaults or Repayment Events or liens, charges or
encumbrances that would not, singly or in the aggregate, result in a Material Adverse Effect), nor will such action result in any violation of the provisions of the charter, <FONT STYLE="white-space:nowrap">by-laws</FONT> or similar organizational
document of the Company or any of its subsidiaries or any law, statute, rule, regulation, judgment, order, writ or decree of any Governmental Entity. As used herein, a &#147;Repayment Event&#148; means any event or condition which gives the holder
of any note, debenture or other evidence of indebtedness (or any person acting on such holder&#146;s behalf) the right to require the repurchase, redemption or repayment of all or a portion of such indebtedness by the Company or any of its
subsidiaries. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xvii) <U>Absence of Labor Dispute</U>. No labor dispute with the employees of the Company or any of its
subsidiaries exists or, to the knowledge of the Company, is imminent, and the Company is not aware of any existing or imminent labor disturbance by the employees of any of its or any subsidiary&#146;s principal suppliers, manufacturers, customers or
contractors, which, in either case, would result in a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xviii) <U>Absence of Proceedings</U>.
Except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, there is no action, suit, proceeding, inquiry or, to the knowledge of the Company, investigation before or brought by any Governmental Entity now
pending or, to the knowledge of the Company, threatened, against or affecting the Company or any of its subsidiaries, which would result in a Material Adverse Effect, or which would materially and adversely affect their respective properties or
assets or the consummation of the transactions contemplated in this Agreement or the performance by the Company of its obligations hereunder; and the aggregate of all pending legal or governmental proceedings to which the Company or any such
subsidiary is a party or of which any of their respective properties or assets is the subject which are not described in the Registration Statement, the General Disclosure Package and the Prospectus, including ordinary routine litigation incidental
to the business, would not result in a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xix) <U>Accuracy of Exhibits</U>. There are no contracts
or documents which are required to be described in the Registration Statement, the General Disclosure Package or the Prospectus or to be filed as exhibits to the Registration Statement which have not been so described and filed as required. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xx) <U>Absence of Further Requirements</U>. No filing with, or authorization, approval, consent, license, order, registration,
qualification or decree of, any Governmental Entity is necessary or required for the performance by the Company of its obligations hereunder, in connection with the offering, issuance or sale of the Securities hereunder or the consummation of the
transactions contemplated by this Agreement, except such as have been already obtained or as may be required under the 1933 Act, the 1933 Act Regulations, the rules of the Nasdaq Global Select Market, state securities laws or the rules of FINRA.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxi) <U>Possession of Licenses and Permits</U>. The Company and its subsidiaries possess such permits, certificates,
licenses, approvals, clearances, registrations, exemptions, consents and other authorizations issued by the appropriate Governmental Entities necessary to conduct the business now operated by them (collectively, &#147;Governmental Licenses&#148;),
including without limitation, all such Governmental Licenses required by the United States Food and Drug Administration (&#147;FDA&#148;) or any component thereof and/or by any other U.S., state, local or foreign
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
government or drug regulatory agency (collectively, the &#147;Regulatory Agencies&#148;) except where the failure so to possess would not, singly or in the aggregate, result in a Material Adverse
Effect. The Company and its subsidiaries are in compliance with the terms and conditions of all Governmental Licenses, except where the failure so to comply would not, singly or in the aggregate, result in a Material Adverse Effect. All of the
Governmental Licenses are valid and in full force and effect, except when the invalidity of such Governmental Licenses or the failure of such Governmental Licenses to be in full force and effect would not, singly or in the aggregate, result in a
Material Adverse Effect. Each of the Company and its subsidiaries has fulfilled and performed all of its material obligations with respect to the Licenses and, to the Company&#146;s knowledge, no event has occurred which allows, or after notice or
lapse of time would allow, revocation or termination thereof or results in any other material impairment of the rights of the holder of any License. Neither the Company nor any of its subsidiaries has received any notice of proceedings relating to
the revocation or modification of any Governmental Licenses which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would result in a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxii) <U>Title to Property</U>. The Company and its subsidiaries have good and marketable title to all real property owned by
them and good title to all other properties owned by them, in each case, free and clear of all mortgages, pledges, liens, security interests, claims, restrictions or encumbrances of any kind except such as (A)&nbsp;are described in the Registration
Statement, the General Disclosure Package and the Prospectus or (B)&nbsp;do not, singly or in the aggregate, materially adversely affect the value of such property and do not adversely interfere with the use made and proposed to be made of such
property by the Company or any of its subsidiaries; and all of the leases and subleases material to the business of the Company and its subsidiaries, considered as one enterprise, and under which the Company or any of its subsidiaries holds
properties described in the Registration Statement, the General Disclosure Package or the Prospectus, are in full force and effect, and neither the Company nor any such subsidiary has any notice of any material claim of any sort that has been
asserted by anyone adverse to the rights of the Company or any subsidiary under any of the leases or subleases mentioned above, or affecting or questioning the rights of the Company or such subsidiary to the continued possession of the leased or
subleased premises under any such lease or sublease. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxiii) <U>Possession of Intellectual Property</U>. The Company and
its subsidiaries own or possess, or can acquire on reasonable terms, adequate patents, patent rights, licenses, inventions, copyrights, <FONT STYLE="white-space:nowrap">know-how</FONT> (including trade secrets and other unpatented and/or
unpatentable proprietary or confidential information, systems or procedures), trademarks, service marks, trade names or other intellectual property (collectively, &#147;Intellectual Property&#148;) necessary for the conduct of their respective
businesses as currently conducted and as currently proposed to be conducted as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, now operated by them, and neither the Company nor any of its subsidiaries has
received any notice or is otherwise aware of any infringement of or conflict with asserted rights of others with respect to any Intellectual Property or of any facts or circumstances which would render any Intellectual Property invalid or inadequate
to protect the interest of the Company or any of its subsidiaries therein, and which infringement or conflict (if the subject of any unfavorable decision, ruling or finding) or invalidity or inadequacy, singly or in the aggregate, would result in a
Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxiv) <U>Regulatory Compliance</U>. Except as described in the Registration Statement, the
General Disclosure Package and the Prospectus, Company and its subsidiaries: (i)&nbsp;within the last five (5)&nbsp;years have not received any Form 483, notice of adverse finding, warning letter, untitled letter or other correspondence or written
notice from any Regulatory Agency or any other Governmental Entity alleging or asserting noncompliance with any Healthcare Laws (as defined </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
below) or the terms of any Government Licenses, except in each case as would not, individually or in the aggregate, have a Material Adverse Effect; (ii)&nbsp;have not received written notice of
any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any Governmental Entity or third party alleging that any product operation or activity is in violation of any Healthcare Laws or Governmental
Licenses and have no knowledge that any such Governmental Entity or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding, except in each case as would not, individually or in the aggregate,
have a Material Adverse Effect; (iii)&nbsp;(a) have filed, obtained, maintained or submitted all reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Healthcare Laws or
Governmental Licenses, (b)&nbsp;except as would not, individually or in the aggregate, have a Material Adverse Effect, all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were
complete and correct and not misleading on the date filed (or were corrected or supplemented by a subsequent submission), and (c)&nbsp;neither the Company nor its subsidiaries is aware of any reasonable basis for any material liability with respect
to such filings; and (iv)&nbsp;have not, and to the knowledge of the Company, the Company&#146;s officers, employees and agents have not, made any untrue statement of a material fact or fraudulent statement to any Governmental Entity or failed to
disclose a material fact required to be disclosed to any Governmental Entity. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxv) <U>Preclinical Studies and Clinical
Trials</U>. To the Company&#146;s knowledge, the descriptions of and information regarding the preclinical studies and clinical trials, and the data and results derived therefrom, contained in the Registration Statement, the General Disclosure
Package and the Prospectus are accurate and complete in all material respects and the Company and its subsidiaries, after due inquiry, are not aware of any nonclinical studies, clinical trials, or other information that would reasonably call into
question the validity, completeness, or accuracy of any study, trial, results or data described in the Registration Statement, the General Disclosure Package and the Prospectus when viewed in the context in which such studies, trials, results, or
data are described therein. The studies and trials conducted by or on behalf of or sponsored by the Company and its subsidiaries were and, if still pending, are being conducted in all material respect in accordance with standard medical and
scientific research procedures and all applicable Laws, including, but not limited to, the Federal Food, Drug and Cosmetic Act (the &#147;FDCA&#148;) and its applicable implementing regulations at 21 C.F.R. Parts 50, 54, 56, 58 and 312. Except to
the extent disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, no investigational new drug application submitted by or on behalf of the Company or its subsidiaries with the FDA has been terminated or suspended
by the FDA, and neither the FDA nor any applicable foreign regulatory agency has commenced, or, to the knowledge of the Company, threatened to initiate, any action to place a clinical hold order on, or otherwise terminate, delay or suspend, any
proposed or ongoing clinical investigation conducted or proposed to be conducted by or on behalf of the Company or its subsidiaries. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxvi) <U>Compliance with Healthcare Laws</U>. The Company and its subsidiaries have been in compliance in all material
respects with all applicable healthcare laws, rules and regulations, to the extent they apply to the Company and its current activities, including, without limitation, (i)&nbsp;the FDCA (21 U.S.C. &#167;&#167; 301 et seq.); (ii) all applicable
foreign, federal, state and local healthcare related fraud and abuse laws, including, without limitation, the federal Anti-kickback Statute (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b(b)),</FONT> the civil False Claims Act (31 U.S.C.
&#167;&#167; 3729 et seq.), the criminal False Claims Law (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b(a)),</FONT> the civil monetary penalties law (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7a),</FONT> the exclusion
laws (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7),</FONT> the Physician Payments Sunshine Act (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7h),</FONT> all criminal laws relating to healthcare fraud and abuse, including but
not limited to 18 U.S.C. Sections 286, 287, 1035, 1347 and 1349, the healthcare fraud criminal provisions under the U.S. Health Insurance Portability and Accountability Act of 1996 (&#147;HIPAA&#148;) (42 U.S.C. &#167;&#167;1320d
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
et seq.), the Medicare statute (Title XVIII of the Social Security Act), and the Medicaid statute (Title XIX of the Social Security Act); (iii) the patient privacy, data security and beach
notification provisions under HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (42 U.S.C. &#167;&#167;17921 et seq.); (iv) comparable state and local laws; and (v)&nbsp;the regulations promulgated
pursuant to such laws (collectively, the &#147;Healthcare Laws&#148;). Neither the Company nor any of its subsidiaries, nor to the Company&#146;s knowledge, their officers, directors, employees, agents, have engaged in activities which are, as
applicable, cause for false claims liability, civil penalties, or mandatory or permissive exclusion from Medicare, Medicaid, or any other state or federal healthcare program. Neither the Company nor any of its subsidiaries has received written
notice or other correspondence of any claim, action, suit, audit, survey, proceeding, hearing, enforcement, investigation, arbitration or other action (&#147;Action&#148;) from any court, arbitrator or Governmental Entity or third party alleging
that any product, operation or activity is in violation of any Healthcare Laws, and, to the Company&#146;s knowledge, no such Action is threatened. Neither the Company nor any of its subsidiaries is a party to or has any ongoing reporting
obligations pursuant to any corporate integrity agreement, deferred prosecution agreement, monitoring agreement, consent decree, settlement order, plan of correction or similar agreement with or imposed by any Governmental Entity. Additionally,
neither the Company nor any of its subsidiaries, nor any of their employees, officers or directors, or to the Company&#146;s knowledge, agents, is or has been excluded, suspended or debarred from participation in any U.S. state or federal healthcare
program or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxvii) <U>Environmental Laws</U>. Except as described in the Registration Statement, the General Disclosure Package and the
Prospectus or would not, singly or in the aggregate, result in a Material Adverse Effect, (A)&nbsp;neither the Company nor any of its subsidiaries is in violation of any federal, state, local or foreign statute, law, rule, regulation, ordinance,
code, policy or rule of common law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree or judgment, relating to pollution or protection of human health, the environment
(including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release or threatened release of chemicals, pollutants,
contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum products, asbestos-containing materials or mold (collectively, &#147;Hazardous Materials&#148;) or to the manufacture, processing, distribution, use, treatment,
storage, disposal, transport or handling of Hazardous Materials (collectively, &#147;Environmental Laws&#148;), (B) the Company and its subsidiaries have all permits, authorizations and approvals required for their operations under any applicable
Environmental Laws and are each in compliance with their requirements, (C)&nbsp;there are no pending or, to the knowledge of the Company, threatened administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens,
notices of noncompliance or violation, investigations or proceedings relating to any Environmental Law against the Company or any of its subsidiaries and (D)&nbsp;to the knowledge of the Company, there are no events or circumstances that would
reasonably be expected to form the basis of an order for <FONT STYLE="white-space:nowrap">clean-up</FONT> or remediation, or an action, suit or proceeding by any private party or Governmental Entity, against or affecting the Company or any of its
subsidiaries relating to Hazardous Materials or any Environmental Laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxviii) <U>Accounting Controls and Disclosure
Controls</U>. The Company and each of its subsidiaries maintain effective internal control over financial reporting (as defined under Rule <FONT STYLE="white-space:nowrap">13-a15</FONT> and <FONT STYLE="white-space:nowrap">15d-15</FONT> under the
1934 Act Regulations and a system of internal accounting controls sufficient to provide reasonable assurances that (A)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorization; (B)&nbsp;transactions are
recorded as necessary to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
permit preparation of financial statements in conformity with GAAP and to maintain accountability for assets; (C)&nbsp;access to assets is permitted only in accordance with management&#146;s
general or specific authorization; and (D)&nbsp;the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. Except as described in the
Registration Statement, the General Disclosure Package and the Prospectus, since the end of the Company&#146;s most recent audited fiscal year, there has been (1)&nbsp;no material weakness in the Company&#146;s internal control over financial
reporting (whether or not remediated) and (2)&nbsp;no change in the Company&#146;s internal control over financial reporting that has materially affected, or is reasonably likely to materially adversely affect, the Company&#146;s internal control
over financial reporting. The Company and each of its subsidiaries maintain an effective system of disclosure controls and procedures (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> and Rule
<FONT STYLE="white-space:nowrap">15d-15</FONT> under the 1934 Act Regulations) that are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the 1934 Act is recorded, processed,
summarized and reported, within the time periods specified in the Commission&#146;s rules and forms, and is accumulated and communicated to the Company&#146;s management, including its principal executive officer or officers and principal financial
officer or officers, as appropriate, to allow timely decisions regarding disclosure. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxix) <U>Compliance with the
Sarbanes-Oxley Act.</U> There is and has been no failure on the part of the Company or any of the Company&#146;s directors or officers, in their capacities as such, to comply in all material respects with any provision of the Sarbanes-Oxley Act of
2002 and the rules and regulations promulgated in connection therewith (the &#147;Sarbanes-Oxley Act&#148;), including Section&nbsp;402 related to loans and Sections 302 and 906 related to certifications.. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxx) <U>Payment of Taxes</U>. All United States federal income tax returns of the Company and its subsidiaries required by law
to be filed have been filed and all taxes shown by such returns or otherwise assessed, which are due and payable, have been paid, except assessments against which appeals have been or will be promptly taken and as to which adequate reserves have
been provided. The United States federal income tax returns of the Company through the fiscal year ended December&nbsp;31, 2017 have been settled and no assessment in connection therewith has been made against the Company. The Company and its
subsidiaries have filed all other tax returns that are required to have been filed by them pursuant to applicable foreign, state, local or other law except insofar as the failure to file such returns would not result in a Material Adverse Effect,
and has paid all taxes due pursuant to such returns or pursuant to any assessment received by the Company and its subsidiaries, except for such taxes, if any, as are being contested in good faith and as to which adequate reserves have been
established by the Company. The charges, accruals and reserves on the books of the Company in respect of any income and corporation tax liability for any years not finally determined are adequate to meet any assessments or <FONT
STYLE="white-space:nowrap">re-assessments</FONT> for additional income tax for any years not finally determined, except to the extent of any inadequacy that would not result in a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxi) <U>Insurance</U>. The Company and its subsidiaries carry or are entitled to the benefits of insurance, with financially
sound and reputable insurers, in such amounts and covering such risks as is generally maintained by companies of established repute and comparable size engaged in the same or similar business, and all such insurance is in full force and effect. The
Company has no reason to believe that it or any of its subsidiaries will not be able (A)&nbsp;to renew its existing insurance coverage as and when such policies expire or (B)&nbsp;to obtain comparable coverage from similar institutions as may be
necessary or appropriate to conduct its business as now conducted and at a cost that would not result in a Material Adverse Effect. Neither of the Company nor any of its subsidiaries has been denied any insurance coverage which it has sought or for
which it has applied. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxii) <U>Investment Company Act</U>. The Company is not required, and upon the
issuance and sale of the Securities as herein contemplated and the application of the net proceeds therefrom as described in the Registration Statement, the General Disclosure Package and the Prospectus will not be required, to register as an
&#147;investment company&#148; under the Investment Company Act of 1940, as amended (the &#147;1940 Act&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxiii)
<U>Absence of Manipulation</U>. Neither the Company nor, to the knowledge of the Company, any affiliate of the Company has taken, nor will the Company or any affiliate take, directly or indirectly, any action which is designed, or would reasonably
be expected, to cause or result in, or which constitutes, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Securities or to result in a violation of Regulation M under the 1934
Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxiv) <U>Foreign Corrupt Practices Act</U>. None of the Company, any of its subsidiaries or, to the knowledge of
the Company, any director, officer, agent, employee, affiliate or other person acting on behalf of the Company or any of its subsidiaries is aware of or has taken any action, directly or indirectly, that would result in a violation by such persons
of the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (the &#147;FCPA&#148;), including, without limitation, making use of the mails or any means or instrumentality of interstate commerce corruptly in
furtherance of an offer, payment, promise to pay or authorization of the payment of any money, or other property, gift, promise to give, or authorization of the giving of anything of value to any &#147;foreign official&#148; (as such term is defined
in the FCPA) or any foreign political party or official thereof or any candidate for foreign political office, in contravention of the FCPA and the Company and, to the knowledge of the Company, its affiliates have conducted their businesses in
compliance with the FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxv) <U>Money Laundering Laws</U>. The operations of the Company and its subsidiaries are and have been conducted at all
times in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all applicable jurisdictions, the rules and
regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any Governmental Entity (collectively, the &#147;Money Laundering Laws&#148;); and no action, suit or proceeding by or before any
Governmental Entity involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxvi) <U>OFAC</U>. None of the Company, any of its subsidiaries or, to the knowledge of the Company, any director, officer,
agent, employee, affiliate or representative of the Company or any of its subsidiaries is an individual or entity (&#147;Person&#148;) currently the subject or target of any sanctions administered or enforced by the United States Government,
including, without limitation, the U.S. Department of the Treasury&#146;s Office of Foreign Assets Control, the United Nations Security Council, the European Union, Her Majesty&#146;s Treasury, or other relevant sanctions authority (collectively,
&#147;Sanctions&#148;), nor is the Company located, organized or resident in a country or territory that is the subject of Sanctions; and the Company will not directly or indirectly use the proceeds of the sale of the Securities, or lend, contribute
or otherwise make available such proceeds to any subsidiaries, joint venture partners or other Person, to fund any activities of or business with any Person, or in any country or territory, that, at the time of such funding, is the subject of
Sanctions or in any other manner that will result in a violation by any Person (including any Person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxvii) <U>Lending Relationship</U><I>. </I>Except as disclosed in the
Registration Statement, the General Disclosure Package and the Prospectus, the Company (i)&nbsp;does not have any&nbsp;material lending or other relationship with any bank or lending affiliate of any Underwriter and (ii)&nbsp;does not intend to use
any of the proceeds from the sale of the Securities to repay any outstanding debt owed to any affiliate of any Underwriter. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxviii) <U>Statistical and Market-Related Data</U>. Any statistical and market-related data included in the Registration
Statement, the General Disclosure Package or the Prospectus are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable and accurate and, to the extent required, the Company has obtained the written
consent to the use of such data from such sources. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Officer&#146;s Certificates</I>. Any certificate signed by any officer of the
Company or any of its subsidiaries delivered to the Representatives or to counsel for the Underwriters shall be deemed a representation and warranty by the Company to each Underwriter as to the matters covered thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2. <U>Sale and Delivery to Underwriters; Closing</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Initial Securities</I>. On the basis of the representations and warranties herein contained and subject to the terms and conditions
herein set forth, the Company agrees to sell to each Underwriter, severally and not jointly, and each Underwriter, severally and not jointly, agrees to purchase from the Company, at the price per share set forth in Schedule A, that number of Initial
Securities set forth in Schedule A opposite the name of such Underwriter, plus any additional number of Initial Securities which such Underwriter may become obligated to purchase pursuant to the provisions of Section&nbsp;10 hereof, subject, in each
case, to such adjustments among the Underwriters as the Representatives in their sole discretion shall make to eliminate any sales or purchases of fractional shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Option Securities</I>. In addition, on the basis of the representations and warranties herein contained and subject to the terms and
conditions herein set forth, the Company hereby grants an option to the Underwriters, severally and not jointly, to purchase up to an additional [&#149;] shares of Common Stock, at the price per share set forth in Schedule A, less an amount per
share equal to any dividends or distributions declared by the Company and payable on the Initial Securities but not payable on the Option Securities. The option hereby granted may be exercised for 30&nbsp;days after the date hereof and may be
exercised in whole or in part at any time from time to time upon notice by the Representatives to the Company setting forth the number of Option Securities as to which the several Underwriters are then exercising the option and the time and date of
payment and delivery for such Option Securities. Any such time and date of delivery (a &#147;Date of Delivery&#148;) shall be determined by the Representatives, but shall not be later than seven full business days after the exercise of said option,
nor in any event prior to the Closing Time. If the option is exercised as to all or any portion of the Option Securities, each of the Underwriters, acting severally and not jointly, will purchase that proportion of the total number of Option
Securities then being purchased which the number of Initial Securities set forth in Schedule A opposite the name of such Underwriter bears to the total number of Initial Securities, subject, in each case, to such adjustments as the Representatives
in their sole discretion shall make to eliminate any sales or purchases of fractional shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Payment</I>. Payment of the purchase
price for, and delivery of certificates or security entitlements for, the Initial Securities shall be made at the offices of Latham&nbsp;&amp; Watkins LLP at 885 Third Avenue, New York, NY 10022, or at such other place as shall be agreed upon by the
Representatives and the Company, at 9:00&nbsp;A.M. (New York City time) on the second (third, if the pricing occurs after 4:30 P.M. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(New York City time) on any given day) business day after the date hereof (unless postponed in accordance with the provisions of Section&nbsp;10), or such other time not later than ten business
days after such date as shall be agreed upon by the Representatives and the Company (such time and date of payment and delivery being herein called &#147;Closing Time&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the event that any or all of the Option Securities are purchased by the Underwriters, payment of the purchase price for, and
delivery of certificates or security entitlements for, such Option Securities shall be made at the <FONT STYLE="white-space:nowrap">above-mentioned</FONT> offices, or at such other place as shall be agreed upon by the Representatives and the
Company, on each Date of Delivery as specified in the notice from the Representatives to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment shall be made to the
Company by wire transfer of immediately available funds to a bank account designated by the Company against delivery to the Representatives for the respective accounts of the Underwriters of certificates or security entitlements for the Securities
to be purchased by them. It is understood that each Underwriter has authorized the Representatives, for its account, to accept delivery of, receipt for, and make payment of the purchase price for, the Initial Securities and the Option Securities, if
any, which it has agreed to purchase. Cowen and Stifel, severally and not jointly, individually and not as a Representatives of the Underwriters, may (but shall not be obligated to) make payment of the purchase price for the Initial Securities or
the Option Securities, if any, to be purchased by any Underwriter whose funds have not been received by the Closing Time or the relevant Date of Delivery, as the case may be, but such payment shall not relieve such Underwriter from its obligations
hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3. <U>Covenants of the Company</U>. The Company covenants with each Underwriter as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Compliance with Securities Regulations and Commission Requests</I>. The Company, subject to Section&nbsp;3(b), will comply with the
requirements of Rule 430A, and will notify the Representatives immediately, and confirm the notice in writing, (i)&nbsp;when any post-effective amendment to the Registration Statement shall become effective or any amendment or supplement to the
Prospectus shall have been filed, (ii)&nbsp;of the receipt of any comments from the Commission, (iii)&nbsp;of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement to the Prospectus or for
additional information, (iv)&nbsp;of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment or of any order preventing or suspending the use of any preliminary
prospectus or the Prospectus, or of the suspension of the qualification of the Securities for offering or sale in any jurisdiction, or of the initiation or threatening of any proceedings for any of such purposes or of any examination pursuant to
Section&nbsp;8(d) or 8(e) of the 1933 Act concerning the Registration Statement and (v)&nbsp;if the Company becomes the subject of a proceeding under Section&nbsp;8A of the 1933 Act in connection with the offering of the Securities. The Company will
effect all filings required under Rule 424(b), in the manner and within the time period required by Rule 424(b) (without reliance on Rule 424(b)(8)), and will take such steps as it deems necessary to ascertain promptly whether the form of prospectus
transmitted for filing under Rule 424(b) was received for filing by the Commission and, in the event that it was not, it will promptly file such prospectus. The Company will make every reasonable effort to prevent the issuance of any stop order,
prevention or suspension and, if any such order is issued, to obtain the lifting thereof at the earliest possible moment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Continued
Compliance with Securities Laws</I>. The Company will comply with the 1933 Act and the 1933 Act Regulations so as to permit the completion of the distribution of the Securities as contemplated in this Agreement and in the Registration Statement, the
General Disclosure Package and the Prospectus. If at any time when a prospectus relating to the Securities is (or, but for the exception afforded by Rule 172 of the 1933 Act Regulations (&#147;Rule 172&#148;), would be) required by the 1933 Act to
be delivered in connection with sales of the Securities, any event shall occur or condition shall exist as a result of which </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
it is necessary, in the opinion of counsel for the Underwriters or for the Company, to (i)&nbsp;amend the Registration Statement in order that the Registration Statement will not include an
untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, (ii)&nbsp;amend or supplement the General Disclosure Package or the Prospectus in order
that the General Disclosure Package or the Prospectus, as the case may be, will not include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein not misleading in the light of the
circumstances existing at the time it is delivered to a purchaser or (iii)&nbsp;amend the Registration Statement or amend or supplement the General Disclosure Package or the Prospectus, as the case may be, in order to comply with the requirements of
the 1933 Act or the 1933 Act Regulations, the Company will promptly (A)&nbsp;give the Representatives notice of such event, (B)&nbsp;prepare any amendment or supplement as may be necessary to correct such statement or omission or to make the
Registration Statement, the General Disclosure Package or the Prospectus comply with such requirements and, a reasonable amount of time prior to any proposed filing or use, furnish the Representatives with copies of any such amendment or supplement
and (C)&nbsp;file with the Commission any such amendment or supplement; provided that the Company shall not file or use any such amendment or supplement to which the Representatives or counsel for the Underwriters shall object. The Company will
furnish to the Underwriters such number of copies of such amendment or supplement as the Underwriters may reasonably request. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)
<I>Delivery of Registration Statements</I>. The Company has furnished or will deliver to the Representatives and counsel for the Underwriters, without charge, signed copies of the Registration Statement as originally filed and each amendment thereto
(including exhibits filed therewith) and signed copies of all consents and certificates of experts, and will also deliver to the Representatives, without charge, a conformed copy of the Registration Statement as originally filed and each amendment
thereto (without exhibits) for each of the Underwriters. The copies of the Registration Statement and each amendment thereto furnished to the Underwriters will be identical to the electronically transmitted copies thereof filed with the Commission
pursuant to EDGAR, except to the extent permitted by Regulation <FONT STYLE="white-space:nowrap">S-T.</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Delivery of
Prospectuses</I>. The Company has delivered to each Underwriter, without charge, as many copies of each preliminary prospectus as such Underwriter reasonably requested, and the Company hereby consents to the use of such copies for purposes permitted
by the 1933 Act. The Company will furnish to each Underwriter, without charge, during the period when a prospectus relating to the Securities is (or, but for the exception afforded by Rule 172, would be) required to be delivered under the 1933 Act,
such number of copies of the Prospectus (as amended or supplemented) as such Underwriter may reasonably request. The Prospectus and any amendments or supplements thereto furnished to the Underwriters will be identical to the electronically
transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation <FONT STYLE="white-space:nowrap">S-T.</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Blue Sky Qualifications</I>. The Company will use its reasonable best efforts, in cooperation with the Underwriters, to qualify the
Securities for offering and sale under the applicable securities laws of such states and other jurisdictions (domestic or foreign) as the Representatives may designate and to maintain such qualifications in effect so long as required to complete the
distribution of the Securities; provided, however, that the Company shall not be obligated to file any general consent to service of process or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not
so qualified or to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise so subject. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Rule 158</I>. The Company will timely file such reports pursuant to the 1934 Act as are necessary in order to make generally available
to its securityholders as soon as practicable an earnings statement for the purposes of, and to provide to the Underwriters the benefits contemplated by, the last paragraph of Section&nbsp;11(a) of the 1933 Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Use of Proceeds</I>. The Company will use the net proceeds received by it from the sale of
the Securities in the manner specified in the Registration Statement, the General Disclosure Package and the Prospectus under &#147;Use of Proceeds.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Listing</I>. The Company will use its reasonable best efforts to effect and maintain the listing of the Common Stock (including the
Option Securities and the Conversion Shares) on the Nasdaq Global Select Market. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Restriction on Sale of Securities</I>. During a
period of 90 days from the date of the Prospectus, the Company will not, without the prior written consent of the Representatives, (i)&nbsp;directly or indirectly, offer, pledge, sell, contract to sell, sell any option or contract to purchase,
purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise transfer or dispose of any shares of Preferred Stock, Common Stock or any securities convertible into or exercisable or exchangeable for Preferred
Stock, Common Stock or file or confidentially submit any registration statement under the 1933 Act with respect to any of the foregoing or (ii)&nbsp;enter into any swap or any other agreement or any transaction that transfers, in whole or in part,
directly or indirectly, the economic consequence of ownership of the Preferred Stock or Common Stock, whether any such swap or transaction described in clause (i)&nbsp;or (ii) above is to be settled by delivery of Preferred Stock, Common Stock or
other securities, in cash or otherwise. The foregoing sentence shall not apply to (A)&nbsp;the Securities to be sold hereunder and the conversion of the Preferred Stock in the Conversion Shares, (B)&nbsp;any shares of Common Stock issued by the
Company upon the exercise of an option or warrant or the conversion of a security outstanding on the date hereof and referred to in the Registration Statement, the General Disclosure Package and the Prospectus, (C)&nbsp;any shares of Common Stock
issued or options to purchase Common Stock granted pursuant to existing employee benefit plans of the Company referred to in the Registration Statement, the General Disclosure Package and the Prospectus, (D)&nbsp;any shares of Common Stock issued
pursuant to any <FONT STYLE="white-space:nowrap">non-employee</FONT> director stock plan or dividend reinvestment plan referred to in the Registration Statement, the General Disclosure Package and the Prospectus, (E)&nbsp;the filing by the Company
of a registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> or any successor form thereto with respect to the registration of securities to be offered under any employee benefit or equity incentive plans of the Company referred
to in the Registration Statement, the General Disclosure Package and the Prospectus, or (F)&nbsp;shares of Common Stock or other securities issued in connection with a transaction that includes a commercial relationship (including strategic
alliances, commercial lending relationships, joint ventures and strategic acquisitions), provided that (x)&nbsp;the aggregate number of shares issued pursuant to this clause (F)&nbsp;shall not exceed 10.0% of the total number of outstanding shares
of Common Stock immediately following the issuance and sale of the Securities at the Closing Time pursuant hereto and (y)&nbsp;the recipient of any such shares of Common Stock or securities issued pursuant to this clause (F)&nbsp;during the <FONT
STYLE="white-space:nowrap">90-day</FONT> restricted period described above shall enter into an agreement substantially in the form of Exhibit B hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) If the Representatives, in their sole discretion, agree to release or waive the restrictions set forth in a
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreement described in Section&nbsp;5(k) hereof for an officer or director of the Company and provides the Company with notice of the impending release or waiver at least three business days before the
effective date of the release or waiver, the Company agrees to announce the impending release or waiver by a press release substantially in the form of Exhibit C hereto through a major news service at least two business days before the effective
date of the release or waiver. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>Reporting Requirements</I>. The Company, during the period when a Prospectus relating to the
Securities is (or, but for the exception afforded by Rule 172, would be) required to be delivered under the 1933 Act, will file all documents required to be filed with the Commission pursuant to the 1934 Act within the time periods required by the
1934 Act and 1934 Act Regulations. Additionally, the Company shall report the use of proceeds from the issuance of the Securities as may be required under Rule 463 under the 1933 Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I>Issuer Free Writing Prospectuses</I>. The Company agrees that, unless it obtains the prior
written consent of the Representatives, it will not make any offer relating to the Securities that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute a &#147;free writing prospectus,&#148; or a portion thereof,
required to be filed by the Company with the Commission or retained by the Company under Rule 433; provided that the Representatives will be deemed to have consented to the Issuer Free Writing Prospectuses listed on Schedule <FONT
STYLE="white-space:nowrap">B-2</FONT> hereto and any &#147;road show that is a written communication&#148; within the meaning of Rule 433(d)(8)(i) that has been reviewed by the Representatives. The Company represents that it has treated or agrees
that it will treat each such free writing prospectus consented to, or deemed consented to, by the Representatives as an &#147;issuer free writing prospectus,&#148; as defined in Rule 433, and that it has complied and will comply with the applicable
requirements of Rule 433 with respect thereto, including timely filing with the Commission where required, legending and record keeping. If at any time following issuance of an Issuer Free Writing Prospectus there occurred or occurs an event or
development as a result of which such Issuer Free Writing Prospectus conflicted or would conflict with the information contained in the Registration Statement, any preliminary prospectus or the Prospectus or included or would include an untrue
statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify
the Representatives and will promptly amend or supplement, at its own expense, such Issuer Free Writing Prospectus to eliminate or correct such conflict, untrue statement or omission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <U><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Materials</U>. If at any time
following the distribution of any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication there occurred or occurs an event or development as a result of which such Written <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make
the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Representatives and will promptly amend or supplement, at its own expense, such Written <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication to eliminate or correct such untrue statement or omission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <U>Emerging Growth Company Status</U>. The Company will promptly notify the Representatives if the Company ceases to be an Emerging Growth
Company at any time prior to the later of (i)&nbsp;completion of the distribution of the Securities within the meaning of the 1933 Act and (ii)&nbsp;completion of the <FONT STYLE="white-space:nowrap">90-day</FONT> restricted period referred to in
Section&nbsp;3(i). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) The Company will reserve and keep available at all times a sufficient number of shares of Common Stock for the
purpose of enabling the Company to issue the Conversion Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4. <U>Payment of Expenses</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Expenses</I>. The Company will pay or cause to be paid all expenses incident to the performance of its obligations under this Agreement,
including (i)&nbsp;the preparation, printing and filing of the Registration Statement (including financial statements and exhibits) as originally filed and each amendment thereto, (ii)&nbsp;the preparation, printing and delivery to the Underwriters
of copies of each preliminary prospectus, each Issuer Free Writing Prospectus and the Prospectus and any amendments or supplements thereto and the reasonable costs associated with electronic delivery of any of the foregoing by the Underwriters to
investors, in each case in connection with the offer and sale of the Securities, (iii)&nbsp;the preparation, issuance and delivery of the certificates or security entitlements for the Securities to the Underwriters, including any stock or other
transfer taxes and any stamp or other duties payable upon the sale, issuance or delivery of the Securities to the Underwriters, (iv)&nbsp;the fees and disbursements of the Company&#146;s counsel, accountants and other advisors, (v)&nbsp;the
qualification of the Securities under securities laws in accordance with the provisions of Section&nbsp;3(e) hereof, including filing fees and the reasonable fees and disbursements of counsel for the Underwriters in connection therewith and in
connection with the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
preparation of the Blue Sky Survey and any supplement thereto, (vi)&nbsp;the fees and expenses of any transfer agent or registrar for the Securities, (vii)&nbsp;the costs and expenses of the
Company relating to investor presentations on any &#147;road show&#148; undertaken in connection with the marketing of the Securities, including without limitation, expenses associated with the production of road show slides and graphics, fees and
expenses of any consultants engaged with the Company&#146;s prior written consent in connection with the road show presentations, travel and lodging expenses of the representatives and officers of the Company and any such consultants (which, for the
avoidance of doubt, does not include the Underwriters or their representatives for purposes of this Section&nbsp;4(a)(vii)), and 50% of the cost of aircraft and other transportation chartered in connection with the road show, (viii)&nbsp;the filing
fees incident to, and the reasonable fees and disbursements of counsel to the Underwriters in connection with, the review by FINRA of the terms of the sale of the Securities, (ix)&nbsp;the fees and expenses incurred in connection with the listing of
the Securities on the Nasdaq Global Select Market and (x)&nbsp;the costs and expenses (including, without limitation, any damages or other amounts payable in connection with legal or contractual liability) associated with the reforming of any
contracts for sale of the Securities made by the Underwriters caused by a breach of the representation contained in the third sentence of Section&nbsp;1(a)(ii); provided, that the amount payable by the Company in respect of fees and expenses of
counsel for the Underwriters pursuant to the foregoing clauses (v)&nbsp;and (viii) shall not exceed $25,000 in the aggregate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
<I>Termination of Agreement</I>. If this Agreement is terminated by the Representatives in accordance with the provisions of Section&nbsp;5, Section&nbsp;9(a)(i) or (iii)&nbsp;or Section&nbsp;10 hereof, the Company shall reimburse the Underwriters
for their reasonable and documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses actually incurred, including the reasonable and documented fees and disbursements of counsel for the
Underwriters. For the avoidance of doubt, in the case of termination by the Underwriters in accordance with the provisions of Section&nbsp;10, the Company shall have no obligations to reimburse any defaulting Underwriter pursuant to this
Section&nbsp;4(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5. <U>Conditions of Underwriters&#146; Obligations</U>. The obligations of the several Underwriters hereunder
are subject to the accuracy of the representations and warranties of the Company contained herein or in certificates of any officer of the Company or any of its subsidiaries delivered pursuant to the provisions hereof, to the performance by the
Company of its covenants and other obligations hereunder, and to the following further conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Effectiveness of Registration
Statement; Rule 430A Information</I>. The Registration Statement, including any Rule 462(b) Registration Statement, has become effective and, at the Closing Time, no stop order suspending the effectiveness of the Registration Statement or any
post-effective amendment thereto has been issued under the 1933 Act, no order preventing or suspending the use of any preliminary prospectus or the Prospectus has been issued and no proceedings for any of those purposes have been instituted or are
pending or, to the Company&#146;s knowledge, contemplated by the Commission; and the Company has complied with each request (if any) from the Commission for additional information. A prospectus containing the Rule 430A Information shall have been
filed with the Commission in the manner and within the time frame required by Rule 424(b) without reliance on Rule 424(b)(8) or a post-effective amendment providing such information shall have been filed with, and declared effective by, the
Commission in accordance with the requirements of Rule 430A. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Opinion of Counsel for Company</I>. At the Closing Time, the
Representatives shall have received the opinion, dated the Closing Time, of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel for the Company, in form and substance reasonably satisfactory to counsel for the Underwriters, together with
signed or reproduced copies of such letter for each of the other Underwriters to the effect set forth in Exhibit <FONT STYLE="white-space:nowrap">A-1</FONT> hereto and to such further effect as counsel to the Underwriters may reasonably request.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Opinion of IP Counsel for Company</I>. At the Closing Time, the Representatives shall have
received the opinion, dated the Closing Time, of Cantor Colburn LLP, special intellectual property counsel for the Company, in form and substance reasonably satisfactory to counsel for the Underwriters, together with signed or reproduced copies of
such letter for each of the other Underwriters to the effect set forth in Exhibit <FONT STYLE="white-space:nowrap">A-2</FONT> hereto and to such further effect as counsel to the Underwriters may reasonably request. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Opinion of Counsel for Underwriters</I>. At the Closing Time, the Representatives shall have received the favorable opinion, dated the
Closing Time, of Latham&nbsp;&amp; Watkins LLP, counsel for the Underwriters, in a form and substance satisfactory to the Representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Officers&#146; Certificate</I>. At the Closing Time, there shall not have been, since the date hereof or since the respective dates as
of which information is given in the Registration Statement, the General Disclosure Package or the Prospectus, any Material Adverse Effect, and the Representatives shall have received a certificate of the Chief Executive Officer or the President of
the Company and of the chief financial or chief accounting officer of the Company, dated the Closing Time, to the effect that (i)&nbsp;there has been no such Material Adverse Effect, (ii)&nbsp;the representations and warranties of the Company in
this Agreement are true and correct with the same force and effect as though expressly made at and as of the Closing Time, (iii)&nbsp;the Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied
at or prior to the Closing Time, and (iv)&nbsp;no stop order suspending the effectiveness of the Registration Statement under the 1933 Act has been issued, no order preventing or suspending the use of any preliminary prospectus or the Prospectus has
been issued and no proceedings for any of those purposes have been instituted or are pending or, to the Company&#146;s knowledge, contemplated by the Commission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Chief Financial Officer&#146;s Certificate. </I>At the Closing Time, the Representatives shall have received on and as of the date of
this Agreement and on and as of the Closing Date, a certificate of the Chief Financial Officer of the Company, reasonably satisfactory to the Representatives, as to the accuracy of certain data contained in the Registration Statement, the General
Disclosure Package and the Prospectus; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Accountant&#146;s Comfort Letter</I>. At the time of the execution of this Agreement, the
Representatives shall have received from PricewaterhouseCoopers LLP a letter, dated such date, in form and substance reasonably satisfactory to the Representatives, together with signed or reproduced copies of such letter for each of the other
Underwriters containing statements and information of the type ordinarily included in accountants&#146; &#147;comfort letters&#148; to underwriters with respect to the financial statements and certain financial information contained in the
Registration Statement, the General Disclosure Package and the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Bring-down Comfort Letter</I>. At the Closing Time, the
Representatives shall have received from PricewaterhouseCoopers LLP a letter, dated as of the Closing Time, to the effect that they reaffirm the statements made in the letter furnished pursuant to subsection (g)&nbsp;of this Section, except that the
specified date referred to shall be a date not more than three business days prior to the Closing Time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Approval of Listing</I>. At
the Closing Time, the Securities shall have been approved for listing on the Nasdaq Global Select Market, subject only to official notice of issuance. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>No Objection</I>. FINRA has confirmed that it has not raised any objection with respect to the fairness and reasonableness of the
underwriting terms and arrangements relating to the offering of the Securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreements</I>. At the date of this
Agreement, the Representatives shall have received an agreement substantially in the form of Exhibit&nbsp;B hereto signed by the persons listed on Schedule C hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I>Conditions to Purchase of Option Securities</I>. In the event that the Underwriters exercise their option provided in Section&nbsp;2(b)
hereof to purchase all or any portion of the Option Securities, the representations and warranties of the Company contained herein and the statements in any certificates furnished by the Company and any of its subsidiaries hereunder shall be true
and correct as of each Date of Delivery and, at the relevant Date of Delivery, the Representatives shall have received: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Officers&#146; Certificate</U>. A certificate, dated such Date of Delivery, of the President or a Vice President of the
Company and of the chief financial or chief accounting officer of the Company confirming that the certificate delivered at the Closing Time pursuant to Section&nbsp;5(e) hereof remains true and correct as of such Date of Delivery. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <U>Chief Financial Officer&#146;s Certificate</U>. A certificate, dated such Date of Delivery, of the Chief Financial
Officer of the Company confirming that the certificate delivered at the Closing Time pursuant to Section&nbsp;5(f) hereof remains true and correct as of such Date of Delivery </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <U>Opinions of Counsel for Company</U>. If requested by the Representatives, the opinion of Mintz, Levin, Cohn, Ferris,
Glovsky and Popeo, P.C., counsel for the Company, together with the opinion of Cantor Colburn LLP, special intellectual property counsel for the Company, each in form and substance reasonably satisfactory to counsel for the Underwriters, dated such
Date of Delivery, relating to the Option Securities to be purchased on such Date of Delivery and otherwise to the same effect as the opinion required by Sections&nbsp;5(b) and 5(c) hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) <U>Opinion of Counsel for Underwriters</U>. If requested by the Representatives, the favorable opinion of
Latham&nbsp;&amp; Watkins LLP, counsel for the Underwriters, dated such Date of Delivery, relating to the Option Securities to be purchased on such Date of Delivery and otherwise to the same effect as the opinion required by Section&nbsp;5(d)
hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <U>Bring-down Comfort Letter</U>. If requested by the Representatives, a letter from PricewaterhouseCoopers
LLP, in form and substance reasonably satisfactory to the Representatives and dated such Date of Delivery, substantially in the same form and substance as the letter furnished to the Representatives pursuant to Section&nbsp;5(g) hereof, except that
the &#147;specified date&#148; in the letter furnished pursuant to this paragraph shall be a date not more than three business days prior to such Date of Delivery. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>Certificate of Designation</I><U STYLE="border-bottom:1pt double; padding-bottom:1pt">. Prior to the Closing Date, the Company shall
have filed with the Secretary of State of the State of Delaware the</U> Certificate of Designation of Preferences, Rights and Limitations of the Preferred Stock, substantially in the form attached hereto as <U>Exhibit
D</U><U STYLE="border-bottom:1pt double; padding-bottom:1pt">.</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <I>Additional Documents</I>. At the Closing Time and at each Date
of Delivery (if any) counsel for the Underwriters shall have been furnished with such customary documents and opinions as they may reasonably require for the purpose of enabling them to pass upon the issuance and sale of the Securities as herein
contemplated, or in order to evidence the accuracy of any of the representations or warranties, or the fulfillment of any of the conditions, herein contained; and all customary proceedings taken by the Company in connection with the issuance and
sale of the Securities as herein contemplated shall be reasonably satisfactory in form and substance to the Representatives and counsel for the Underwriters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <I>Termination of Agreement</I>. If any condition specified in this Section shall not have
been fulfilled when and as required to be fulfilled, this Agreement, or, in the case of any condition to the purchase of Option Securities on a Date of Delivery which is after the Closing Time, the obligations of the several Underwriters to purchase
the relevant Option Securities, may be terminated by the Representatives by notice to the Company at any time at or prior to Closing Time or such Date of Delivery, as the case may be, and such termination shall be without liability of any party to
any other party except as provided in Section&nbsp;4 and except that Sections 1, 6, 7, 8, 14, 15 and 16 shall survive any such termination and remain in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 6. <U>Indemnification</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Indemnification of Underwriters</I>. The Company agrees to indemnify and hold harmless each Underwriter, its affiliates (as such term is
defined in Rule 501(b) under the 1933 Act (each, an &#147;Affiliate&#148;)), its selling agents and each person, if any, who controls any Underwriter within the meaning of Section&nbsp;15 of the 1933 Act or Section&nbsp;20 of the 1934 Act as
follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) against any and all loss, liability, claim, damage and expense whatsoever, as incurred, arising out of any
untrue statement or alleged untrue statement of a material fact contained in the Registration Statement (or any amendment thereto), including the Rule 430A Information, or the omission or alleged omission therefrom of a material fact required to be
stated therein or necessary to make the statements therein not misleading or arising out of any untrue statement or alleged untrue statement of a material fact included (A)&nbsp;in any preliminary prospectus, any Issuer Free Writing Prospectus, any
Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, the General Disclosure Package or the Prospectus (or any amendment or supplement thereto), or (B)&nbsp;in any materials or
information provided to investors by, or with the approval of, the Company in connection with the marketing of the offering of the Securities (&#147;Marketing Materials&#148;), including any roadshow or investor presentations made to investors by
the Company (whether in person or electronically), or the omission or alleged omission in any preliminary prospectus, Issuer Free Writing Prospectus, any Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, Prospectus or in any Marketing Materials of a material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) against any and all loss, liability, claim, damage and
expense whatsoever, as incurred, to the extent of the aggregate amount paid in settlement of any litigation, or any investigation or proceeding by any Governmental Entity, commenced or threatened, or of any claim whatsoever based upon any such
untrue statement or omission, or any such alleged untrue statement or omission; provided that (subject to Section&nbsp;6(d) below) any such settlement is effected with the written consent of the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) against any and all expense whatsoever, as incurred (including the fees and disbursements of counsel chosen by the
Representatives), reasonably incurred in investigating, preparing or defending against any litigation, or any investigation or proceeding by any Governmental Entity, commenced or threatened, or any claim whatsoever based upon any such untrue
statement or omission, or any such alleged untrue statement or omission, to the extent that any such expense is not paid under (i)&nbsp;or (ii) above; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided, however, that this indemnity agreement shall not apply to any loss, liability, claim, damage or expense to the extent arising out of any untrue
statement or omission or alleged untrue statement or omission made in the Registration Statement (or any amendment thereto), including the Rule 430A Information, the General Disclosure Package or the Prospectus (or any amendment or supplement
thereto) in reliance upon and in conformity with the Underwriter Information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Indemnification of Company, Directors and Officers</I>. Each Underwriter severally agrees
to indemnify and hold harmless the Company, its directors, each of its officers who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of Section&nbsp;15 of the 1933 Act or Section&nbsp;20 of the
1934 Act, against any and all loss, liability, claim, damage and expense described in the indemnity contained in subsection (a)&nbsp;of this Section, as incurred, but only with respect to untrue statements or omissions, or alleged untrue statements
or omissions, made in the Registration Statement (or any amendment thereto), including the Rule 430A Information, the General Disclosure Package or the Prospectus (or any amendment or supplement thereto) in reliance upon and in conformity with the
Underwriter Information. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Actions against Parties; Notification</I>. Each indemnified party shall give notice as promptly as
reasonably practicable to each indemnifying party of any action commenced against it in respect of which indemnity may be sought hereunder, but failure to so notify an indemnifying party shall not relieve such indemnifying party from any liability
hereunder to the extent it is not materially prejudiced as a result thereof and in any event shall not relieve it from any liability which it may have otherwise than on account of this indemnity agreement. In the case of parties indemnified pursuant
to Section&nbsp;6(a) above, counsel to the indemnified parties shall be selected by the Representatives, and, in the case of parties indemnified pursuant to Section&nbsp;6(b) above, counsel to the indemnified parties shall be selected by the
Company. An indemnifying party may participate at its own expense in the defense of any such action; provided, however, that counsel to the indemnifying party shall not (except with the consent of the indemnified party) also be counsel to the
indemnified party. In no event shall the indemnifying parties be liable for fees and expenses of more than one counsel (in addition to any local counsel) separate from their own counsel for all indemnified parties in connection with any one action
or separate but similar or related actions in the same jurisdiction arising out of the same general allegations or circumstances. No indemnifying party shall, without the prior written consent of the indemnified parties, settle or compromise or
consent to the entry of any judgment with respect to any litigation, or any investigation or proceeding by any Governmental Entity, commenced or threatened, or any claim whatsoever in respect of which indemnification or contribution could be sought
under this Section&nbsp;6 or Section&nbsp;7 hereof (whether or not the indemnified parties are actual or potential parties thereto), unless such settlement, compromise or consent (i)&nbsp;includes an unconditional release of each indemnified party
from all liability arising out of such litigation, investigation, proceeding or claim and (ii)&nbsp;does not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Settlement without Consent if Failure to Reimburse</I>. If at any time an indemnified party shall have requested an indemnifying party
to reimburse the indemnified party for fees and expenses of counsel, such indemnifying party agrees that it shall be liable for any settlement of the nature contemplated by Section&nbsp;6(a)(ii) effected without its written consent if (i)&nbsp;such
settlement is entered into more than 45 days after receipt by such indemnifying party of the aforesaid request, (ii)&nbsp;such indemnifying party shall have received notice of the terms of such settlement at least 30 days prior to such settlement
being entered into and (iii)&nbsp;such indemnifying party shall not have reimbursed such indemnified party in accordance with such request prior to the date of such settlement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7. <U>Contribution</U>. If the indemnification provided for in Section&nbsp;6 hereof is for any reason unavailable to or insufficient
to hold harmless an indemnified party in respect of any losses, liabilities, claims, damages or expenses referred to therein, then each indemnifying party shall contribute to the aggregate amount of such losses, liabilities, claims, damages and
expenses incurred by such indemnified party, as incurred, (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Underwriters, on the other hand, from the offering of the
Securities pursuant to this Agreement or (ii)&nbsp;if the allocation provided by clause (i)&nbsp;is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i)&nbsp;above
but also the relative fault of the Company, on the one hand, and of the Underwriters, on the other hand, in connection with the statements or omissions, which resulted in such losses, liabilities, claims, damages or expenses, as well as any other
relevant equitable considerations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The relative benefits received by the Company, on the one hand, and the Underwriters, on the
other hand, in connection with the offering of the Securities pursuant to this Agreement shall be deemed to be in the same respective proportions as the total net proceeds from the offering of the Securities pursuant to this Agreement (before
deducting expenses) received by the Company, on the one hand, and the total underwriting discount received by the Underwriters, on the other hand, in each case as set forth on the cover of the Prospectus, bear to the aggregate public offering price
of the Securities as set forth on the cover of the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The relative fault of the Company, on the one hand, and the Underwriters,
on the other hand, shall be determined by reference to, among other things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the
Company or by the Underwriters and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to this Section&nbsp;7 were determined
by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take account of the equitable considerations referred to above in this Section&nbsp;7. The aggregate
amount of losses, liabilities, claims, damages and expenses incurred by an indemnified party and referred to above in this Section&nbsp;7 shall be deemed to include any documented legal or other expenses reasonably incurred by such indemnified party
in investigating, preparing or defending against any litigation, or any investigation or proceeding by any Governmental Entity, commenced or threatened, or any claim whatsoever based upon any such untrue or alleged untrue statement or omission or
alleged omission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the provisions of this Section&nbsp;7, no Underwriter shall be required to contribute any amount in
excess of the underwriting commissions received by such Underwriter in connection with the Securities underwritten by it and distributed to the public. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the 1933 Act) shall be entitled to contribution
from any person who was not guilty of such fraudulent misrepresentation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Section&nbsp;7, each person, if any, who
controls an Underwriter within the meaning of Section&nbsp;15 of the 1933 Act or Section&nbsp;20 of the 1934 Act and each Underwriter&#146;s Affiliates and selling agents shall have the same rights to contribution as such Underwriter, and each
director of the Company, each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of Section&nbsp;15 of the 1933 Act or Section&nbsp;20 of the 1934 Act shall have the
same rights to contribution as the Company. The Underwriters&#146; respective obligations to contribute pursuant to this Section&nbsp;7 are several in proportion to the number of Initial Securities set forth opposite their respective names in
Schedule A hereto and not joint. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 8. <U>Representations, Warranties and Agreements to Survive</U>. All representations, warranties
and agreements contained in this Agreement or in certificates of officers of the Company or any of its subsidiaries submitted pursuant hereto, shall remain operative and in full force and effect regardless of (i)&nbsp;any investigation made by or on
behalf of any Underwriter or its Affiliates or selling agents, any person controlling any Underwriter, its officers or directors or any person controlling the Company and (ii)&nbsp;delivery of and payment for the Securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 9. <U>Termination of Agreement</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Termination</I>. The Representatives may terminate this Agreement, by notice to the Company, at any time at or prior to the Closing Time
(i)&nbsp;if there has been, in the judgment of the Representatives, since the time of execution of this Agreement or since the respective dates as of which information is given in the Registration Statement, the General Disclosure Package or the
Prospectus, any Material Adverse Effect, or (ii)&nbsp;if there has occurred any material adverse change in the financial markets in the United States or the international financial markets, any outbreak of hostilities or escalation thereof or other
calamity or crisis or any change or development involving a prospective change in national or international political, financial or economic conditions, in each case the effect of which is such as to make it, in the judgment of the Representatives,
impracticable or inadvisable to proceed with the completion of the offering or to enforce contracts for the sale of the Securities, or (iii)&nbsp;if trading in any securities of the Company has been suspended or materially limited by the Commission
or the Nasdaq Global Select Market, or (iv)&nbsp;if trading generally on the NYSE MKT or the New York Stock Exchange or in the Nasdaq Global Select Market has been suspended or materially limited, or minimum or maximum prices for trading have been
fixed, or maximum ranges for prices have been required, by any of said exchanges or by order of the Commission, FINRA or any other Governmental Entity, or (v)&nbsp;a material disruption has occurred in commercial banking or securities settlement or
clearance services in the United States or with respect to Clearstream or Euroclear systems in Europe, or (vi)&nbsp;if a banking moratorium has been declared by either Federal or New York authorities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Liabilities</I>. If this Agreement is terminated pursuant to this Section, such termination shall be without liability of any party to
any other party except as provided in Section&nbsp;4 hereof, and provided further that Sections 1, 6, 7, 8, 14, 15 and 16 shall survive such termination and remain in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 10. <U>Default by One or More of the Underwriters</U>. If one or more of the Underwriters shall fail at the Closing Time or a Date of
Delivery to purchase the Securities which it or they are obligated to purchase under this Agreement (the &#147;Defaulted Securities&#148;), the Representatives shall have the right, within 24&nbsp;hours thereafter, to make arrangements for one or
more of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters, or any other underwriters, to purchase all, but not less than all, of the Defaulted Securities in such amounts as may be agreed upon and upon the terms herein set
forth; if, however, the Representatives shall not have completed such arrangements within such <FONT STYLE="white-space:nowrap">24-hour</FONT> period, then: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) if the number of Defaulted Securities does not exceed 10% of the number of Securities to be purchased on such date, each of
the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters shall be obligated, severally and not jointly, to purchase the full amount thereof in the proportions that their respective underwriting obligations hereunder bear to the
underwriting obligations of all <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters, or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) if the number
of Defaulted Securities exceeds 10% of the number of Securities to be purchased on such date, this Agreement or, with respect to any Date of Delivery which occurs after the Closing Time, the obligation of the Underwriters to purchase, and the
Company to sell, the Option Securities to be purchased and sold on such Date of Delivery shall terminate without liability on the part of any <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No action taken pursuant to this Section shall relieve any defaulting Underwriter from liability in respect of its default. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of any such default which does not result in a termination of this Agreement or, in
the case of a Date of Delivery which is after the Closing Time, which does not result in a termination of the obligation of the Underwriters to purchase and the Company to sell the relevant Option Securities, as the case may be, either the
(i)&nbsp;Representatives or (ii)&nbsp;the Company shall have the right to postpone Closing Time or the relevant Date of Delivery, as the case may be, for a period not exceeding seven days in order to effect any required changes in the Registration
Statement, the General Disclosure Package or the Prospectus or in any other documents or arrangements. As used herein, the term &#147;Underwriter&#148; includes any person substituted for an Underwriter under this Section&nbsp;10. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 11. <U>Notices</U>. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if
mailed or transmitted by any standard form of telecommunication. Notices to the Underwriters shall be directed to the Representatives c/o Cowen at 599 Lexington Avenue, New York, New York 10029, and c/o Stifel at 787 7th Avenue, 11th Floor, New
York, New York 10019 and to the Company at Spero Therapeutics, Inc., 675 Massachusetts Avenue, 14th Floor, Cambridge, Massachusetts 02139, attention of Ankit Mahadevia, M.D., President and Chief Executive Officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 12. <U>No Advisory or Fiduciary Relationship</U>. The Company acknowledges and agrees that (a)&nbsp;the purchase and sale of the
Securities pursuant to this Agreement, including the determination of the public offering price of the Securities and any related discounts and commissions, is an <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> commercial transaction
between the Company, on the one hand, and the several Underwriters, on the other hand, (b)&nbsp;in connection with the offering of the Securities and the process leading thereto, each Underwriter is and has been acting solely as a principal and is
not the agent or fiduciary of the Company, any of its subsidiaries or their respective stockholders, creditors, employees or any other party, (c)&nbsp;no Underwriter has assumed or will assume an advisory or fiduciary responsibility in favor of the
Company with respect to the offering of the Securities or the process leading thereto (irrespective of whether such Underwriter has advised or is currently advising the Company or any of its subsidiaries on other matters) and no Underwriter has any
obligation to the Company with respect to the offering of the Securities except the obligations expressly set forth in this Agreement, (d)&nbsp;the Underwriters and their respective affiliates may be engaged in a broad range of transactions that
involve interests that differ from those of the Company and (e)&nbsp;the Underwriters have not provided any legal, accounting, regulatory or tax advice with respect to the offering of the Securities and the Company has consulted its own respective
legal, accounting, regulatory and tax advisors to the extent it deemed appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 13. <U>Parties</U>. This Agreement shall each
inure to the benefit of and be binding upon the Underwriters and the Company and their respective successors. Nothing expressed or mentioned in this Agreement is intended or shall be construed to give any person, firm or corporation, other than the
Underwriters and the Company and their respective successors and the controlling persons and officers and directors referred to in Sections&nbsp;6 and 7 and their heirs and legal representatives, any legal or equitable right, remedy or claim under
or in respect of this Agreement or any provision herein contained. This Agreement and all conditions and provisions hereof are intended to be for the sole and exclusive benefit of the Underwriters and the Company and their respective successors, and
said controlling persons and officers and directors and their heirs and legal representatives, and for the benefit of no other person, firm or corporation. No purchaser of Securities from any Underwriter shall be deemed to be a successor by reason
merely of such purchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 14. <U>Trial by Jury</U>. The Company (on its behalf and, to the extent permitted by applicable law, on
behalf of its stockholders and affiliates) and each of the Underwriters hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this
Agreement or the transactions contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 15. <U>GOVERNING LAW</U>. THIS AGREEMENT AND ANY CLAIM, CONTROVERSY OR DISPUTE
ARISING UNDER OR RELATED TO THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF, THE STATE OF NEW YORK WITHOUT REGARD TO ITS CHOICE OF LAW PROVISIONS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 16. <U>Consent to Jurisdiction</U>. Any legal suit, action or proceeding arising out of
or based upon this Agreement or the transactions contemplated hereby shall&nbsp;be instituted in (i)&nbsp;the federal courts of the United States of America located in the City and County of New York, Borough of Manhattan or&nbsp;(ii) the courts of
the State of New York located in the City and County of New York, Borough of Manhattan (collectively, the &#147;Specified Courts&#148;), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to
the enforcement of a judgment of any such court, as to which such jurisdiction is <FONT STYLE="white-space:nowrap">non-exclusive)</FONT> of such courts in any such suit, action or proceeding. Service of any process, summons, notice or document by
mail to such party&#146;s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of any
suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been brought in an
inconvenient forum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 17. <U>TIME</U>. TIME SHALL BE OF THE ESSENCE OF THIS AGREEMENT. EXCEPT AS OTHERWISE SET FORTH HEREIN,
SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 18. <U>Counterparts</U>. This Agreement may be executed in any number of
counterparts, each of which shall be deemed to be an original, but all such counterparts shall together constitute one and the same Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 19. <U>Effect of Headings</U>. The Section headings herein are for convenience only and shall not affect the construction hereof. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding of our agreement, please sign and
return to the Company a counterpart hereof, whereupon this instrument, along with all counterparts, will become a binding agreement among the Underwriters and the Company in accordance with its terms. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">SPERO THERAPEUTICS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONFIRMED AND ACCEPTED,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">as of the date first above written:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">COWEN AND COMPANY, LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Authorized Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">STIFEL, NICOLAUS&nbsp;&amp; COMPANY, INCORPORATED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Authorized Signatory</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For themselves and as Representatives of the other Underwriters named in Schedule A hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SCHEDULE A </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The public offering price per share for the Common Stock shall be $[&#149;]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The public offering price per share for the Preferred Stock shall be $[&#149;]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The public offering price per share for the Option Securities shall be $[&#149;]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purchase price per share for the Securities to be paid by the several Underwriters shall be $[&#149;], being an amount equal to the public offering price
set forth above less $[&#149;] per share, subject to adjustment in accordance with Section&nbsp;2(b) for dividends or distributions declared by the Company and payable on the Initial Securities but not payable on the Option Securities. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:68.80pt; display:inline; font-size:8pt; font-family:Times New Roman; ">Name of Underwriter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000">Number of<BR>shares of<BR>Common&nbsp;Stock</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000">Number of <BR>shares of <BR>Preferred&nbsp;Stock</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cowen and Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stifel, Nicolaus&nbsp;&amp; Company, Incorporated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cantor Fitzgerald&nbsp;&amp;Co.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oppenheimer&nbsp;&amp; Co. Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">H.C. Wainwright&nbsp;&amp; Co., LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Sch A-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SCHEDULE <FONT STYLE="white-space:nowrap">B-1</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Pricing Terms </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The Company is selling [&#149;] shares of Common Stock and [&#149;] shares of Preferred Stock. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">The Company has granted an option to the Underwriters, severally and not jointly, to purchase up to an additional [&#149;] shares of Common Stock. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">The public offering price per share for the Common Stock shall be $ [&#149;]. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The public offering price per share for the Preferred Stock shall be $[&#149;]. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The public offering price per share for the Option Securities shall be $[&#149;]. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SCHEDULE <FONT
STYLE="white-space:nowrap">B-2</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Free Writing Prospectuses </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">None. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Sch B - 1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SCHEDULE C </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>List of Persons and Entities Subject to <FONT STYLE="white-space:nowrap">Lock-up</FONT> </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directors: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ankit Mahadevia, MD </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Casper Breum </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Milind Deshpande, Ph.D. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jean-Fran&ccedil;ois Formela, MD </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">David Southwell </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Frank Thomas </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patrick Vink, MD </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Officers: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ankit Mahadevia, MD </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Joel Sendek </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cristina Larkin </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">David Melnick, MD </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thomas Parr, Ph.D. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Others: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Atlas Venture Fund IX, L.P. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Atlas Venture Fund X, L.P. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lundbeckfond Invest A/S </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Sch C - 1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SCHEDULE D </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications </U></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Investor Presentation of Spero Therapeutics, Inc., dated June&nbsp;26, 2018. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Sch D - 1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXHIBIT <FONT STYLE="white-space:nowrap">A-1</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>FORM OF OPINION OF COMPANY&#146;S COUNSEL </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>TO BE DELIVERED PURSUANT TO SECTION 5(b) </U></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXHIBIT <FONT STYLE="white-space:nowrap">A-2</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>FORM OF OPINION OF COMPANY&#146;S INTELLECTUAL PROPERTY COUNSEL </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>TO BE DELIVERED PURSUANT TO SECTION 5(c) </U></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXHIBIT B </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[&#149;], 2018 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cowen and Company, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stifel, Nicolaus&nbsp;&amp; Company, Incorporated </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">as Representatives of the several </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Underwriters to be named in the </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">within-mentioned</FONT> Underwriting Agreement </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Cowen and Company, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">599 Lexington Avenue, 27<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Stifel, Nicolaus&nbsp;&amp; Company,
Incorporated </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">237 Park Ave, 8th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York
10017 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"><U>Proposed Public Offering by Spero Therapeutics, Inc.</U> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned, a stockholder, optionholder, officer and/or director of Spero Therapeutics, Inc., a Delaware corporation (the
&#147;Company&#148;), understands that Cowen and Company, LLC (&#147;Cowen&#148;), Stifel, Nicolaus&nbsp;&amp; Company, Incorporated (together with Cowen, the &#147;Representatives&#148;) Cantor Fitzgerald&nbsp;&amp; Co., Opppenheimer&nbsp;&amp; Co.
Inc. and H.C. Wainwright&nbsp;&amp; Co., LLC propose to enter into an Underwriting Agreement (the &#147;Underwriting Agreement&#148;) with the Company providing for the public offering (the &#147;Offering&#148;) of shares of the Company&#146;s
common stock, par value $0.001 per share (the &#147;Common Stock&#148;). In recognition of the benefit that the Offering will confer upon the undersigned as a stockholder, optionholder, officer and/or director of the Company, and for other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned agrees with each underwriter to be named in the Underwriting Agreement that, during the period beginning on the date hereof and ending on the date
that is 90 days from the date of the Underwriting Agreement (the <FONT STYLE="white-space:nowrap">&#147;Lock-Up</FONT> Period&#148;), the undersigned will not, without the prior written consent of the Representatives, (i)&nbsp;directly or
indirectly, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise transfer or dispose of any shares of the Company&#146;s
Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock, whether now owned or hereafter acquired by the undersigned or with respect to which the undersigned has or hereafter acquires the power of disposition
(collectively, the <FONT STYLE="white-space:nowrap">&#147;Lock-Up</FONT> Securities&#148;), or exercise any right with respect to the registration of any of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, or the filing of any
registration statement in connection therewith, under the Securities Act of 1933, as amended, or (ii)&nbsp;enter into any swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic
consequence of ownership of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, whether any such swap or transaction is to be settled by delivery of Common Stock or other securities, in cash or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the undersigned is an officer or director of the Company, (1)&nbsp;the Representatives agree that, at least three business days before the
effective date of any release or waiver of the foregoing restrictions in connection with a transfer of shares of the Common Stock, the Representatives will notify the Company of the impending release or waiver, and (2)&nbsp;the Company has agreed in
the Underwriting Agreement to </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
announce the impending release or waiver by press release through a major news service at least two business days before the effective date of the release or waiver. Any release or waiver granted
by the Representatives hereunder to any such officer or director shall only be effective two business days after the publication date of such press release. The provisions of this paragraph will not apply if (i)&nbsp;the release or waiver is
effected solely to permit a transfer not for consideration and (ii)&nbsp;the transferee has agreed in writing to be bound by the same terms described in this letter to the extent and for the duration that such terms remain in effect at the time of
the transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, and subject to the conditions below, the undersigned may without the prior written consent
of the Representatives, </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a.)</TD>
<TD ALIGN="left" VALIGN="top">transfer the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, provided that (1)&nbsp;the Representatives receive a signed <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement for the balance of the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period from each donee, trustee, distributee, or transferee, as the case may be, (2)&nbsp;any such transfer shall not involve a disposition for value, (3)&nbsp;in the case of clauses (i.) through (v.) below,
such transfers are not required to be reported during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period with the Securities and Exchange Commission on Form 4 in accordance with Section&nbsp;16 of the Securities Exchange Act of 1934, as
amended (the &#147;Exchange Act&#148;), and (4)&nbsp;the undersigned does not otherwise voluntarily effect any public filing or report regarding such transfers during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period: </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i.)</TD>
<TD ALIGN="left" VALIGN="top">as a <I>bona fide</I> gift or gifts; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii.)</TD>
<TD ALIGN="left" VALIGN="top">to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned (for purposes of this <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, &#147;immediate family&#148;
shall mean any relationship by blood, marriage or adoption, not more remote than first cousin); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii.)</TD>
<TD ALIGN="left" VALIGN="top">as a distribution to limited partners, members, stockholders or other equity holders of the undersigned; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv.)</TD>
<TD ALIGN="left" VALIGN="top">to the undersigned&#146;s affiliates or to any investment fund or other entity that, directly or indirectly, controls, is controlled by, or is under common control with, the undersigned; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v.)</TD>
<TD ALIGN="left" VALIGN="top">by will or intestate succession upon the death of the undersigned; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi.)</TD>
<TD ALIGN="left" VALIGN="top">pursuant to a court or regulatory agency order, a qualified domestic order or in connection with a divorce settlement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b.)</TD>
<TD ALIGN="left" VALIGN="top">exercise any rights to purchase, exchange or convert any stock options granted pursuant to the Company&#146;s equity incentive plans existing as of the date of the Underwriting Agreement or warrants or any other
securities existing as of the date of the Underwriting Agreement, which securities are convertible into or exchangeable or exercisable for Common Stock, provided that (1)&nbsp;any filing under Section&nbsp;16 of the Exchange Act made during the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period shall clearly indicate in the footnotes thereto that (A)&nbsp;the filing relates to the circumstances described above and (B)&nbsp;the underlying shares of Common Stock continue to be subject to the
restrictions on transfer set forth in this lock- up agreement and (2)&nbsp;the undersigned does not otherwise voluntarily effect any other public filings or report regarding such exercise during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Period; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c.)</TD>
<TD ALIGN="left" VALIGN="top">sell <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities to the Company in connection with the termination of the undersigned&#146;s employment or other service with the Company, provided that, (1)&nbsp;any
filing under Section&nbsp;16 of the Exchange Act made during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period shall clearly indicate in the footnotes thereto that (A)&nbsp;the filing relates to the circumstances described above and
(B)&nbsp;no <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities were sold by the reporting person other than such transfers to the Company as described above and (2)&nbsp;the undersigned does not otherwise voluntarily effect any other public
filings or report regarding such transfers during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d.)</TD>
<TD ALIGN="left" VALIGN="top">transfer the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities upon the completion of a <I>bona fide</I> third-party tender offer, merger, consolidation or other similar transaction made to all holders of the
Company&#146;s securities involving a change of control of the Company; provided that, in the event that such tender offer, merger, consolidation or other such transaction is not completed, such securities held by the undersigned shall remain
subject to the restrictions on transfer set forth in this <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement (for purposes hereof, &#147;change of control&#148; shall mean the transfer (whether by tender offer, merger, consolidation or other
similar transaction), in one transaction or a series of related transactions, to a person or group of affiliated persons, of shares of capital stock if, after such transfer, such person or group of affiliated persons would hold more than 50% of the
outstanding voting securities of the Company (or the surviving entity)). </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything herein to the contrary,
nothing herein shall prevent the undersigned from (a)&nbsp;establishing a <FONT STYLE="white-space:nowrap">10b5-l</FONT> trading plan that complies with Rule <FONT STYLE="white-space:nowrap">10b5-l</FONT> under the Exchange Act <FONT
STYLE="white-space:nowrap">(&#147;10b5-l</FONT> Trading Plan&#148;) or from amending an existing <FONT STYLE="white-space:nowrap">10b5-l</FONT> Trading Plan so long as there are no sales of Lock- Up Securities under such plan during the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period; and provided that, the establishment of a <FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plan or the amendment of a <FONT STYLE="white-space:nowrap">10b5-l</FONT> Trading Plan, in either
case, providing for sales of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities shall only be permitted if (i)&nbsp;the establishment or amendment of such plan is not required to be reported in any public report or filing with the Securities
and Exchange Commission, or otherwise during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, and (ii)&nbsp;the undersigned does not otherwise voluntarily effect any public filing or report regarding the establishment or amendment of such
plan during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period or (b)&nbsp;effect transactions pursuant to a <FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plan in existence on the date hereof, provided that such <FONT
STYLE="white-space:nowrap">10b5-1</FONT> Trading Plan shall not be amended during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period and that if any such transaction is reported in any public report or filing under Section&nbsp;16 of the
Exchange Act, such report or filing shall include a note that the transaction was pursuant to such a trading plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, during
the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, the undersigned may sell shares of Common Stock of the Company purchased by the undersigned in the Offering from the Underwriters or on the open market following the Offering if and only if
(i)&nbsp;such sales are not required to be reported in any public report or filing with the Securities and Exchange Commission, or otherwise during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period and (ii)&nbsp;the undersigned does not
otherwise voluntarily effect any public filing or report regarding such sales during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned also agrees and consents to the entry of stop transfer instructions with the Company&#146;s transfer agent and registrar
against the transfer of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities except in compliance with the foregoing restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, the Representatives waive any prohibition on the transfer
of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities held by any record or beneficial holder of the shares of capital stock of the Company, the Representatives shall be deemed to have also waived for each Major Holder (as defined below), on
the same terms, the prohibitions set forth in the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement that would otherwise have applied to such Major Holder with respect to the same percentage of such Major Holder&#146;s <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Securities as the relative percentage of aggregate <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities held by such party receiving the waiver which are subject to such waiver. The
provisions of this paragraph will not apply: (1)&nbsp;unless and until the Representatives have first waived more than 1.0% of the Company&#146;s total outstanding shares of Common Stock (determined as of the date of such waiver and assuming
conversion, exercise and exchange of all securities convertible into or exercisable or exchangeable for Common Stock) from such prohibitions, (2) (a) if the waiver is effected solely to permit a transfer not involving a disposition for value and
(b)&nbsp;the transferee has agreed in writing to be bound by the same terms described in this <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement to the extent and for the duration that such terms remain in effect at the time of the transfer,
or (3)&nbsp;if the waiver is granted to a holder of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities in connection with a <FONT STYLE="white-space:nowrap">follow-on</FONT> public offering of the Company&#146;s securities pursuant to a
registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> that is filed with the Securities and Exchange Commission, provided that such waiver shall only apply with respect to such holder&#146;s participation in such <FONT
STYLE="white-space:nowrap">follow-on</FONT> public sale. In the event that, as a result of this paragraph, any <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities held by the undersigned are released from the restrictions imposed by this <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreement, the Representatives shall use commercially reasonable efforts to notify the Company within two business days of the effective date of such release, and the Company, in turn, in consultation with
the Representatives, shall use commercially reasonable efforts to notify the Major Holders within one business day thereafter that the same percentage of aggregate <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities held by such Major Holders
has been released; provided that the failure to give such notice to the Company or the Major Holders shall not give rise to any claim or liability against the Company or the Underwriters, including the Representatives. Notwithstanding any other
provisions of this <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, if the Representatives, in their reasonable judgment, after consultation with the Company, determine that a record or beneficial owner of any <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Securities should be granted an early release from a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement due to circumstances of an emergency or hardship, then the Major Holders shall not have any
right to be granted an early release pursuant to the terms of this paragraph. For purposes of this <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, each of the following persons is a &#147;Major Holder&#148;: each record or beneficial
owner, as of the date hereof, of more than 5% of the outstanding shares of capital stock of the Company on an <FONT STYLE="white-space:nowrap">as-</FONT> converted to Common Stock basis (for purposes of determining record or beneficial ownership of
a stockholder, all shares of capital stock held by investment funds affiliated with such stockholder shall be aggregated). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
undersigned understands that, if (1)&nbsp;the execution of the Underwriting Agreement in connection with the Offering shall not have occurred on or before August&nbsp;15, 2018, (2) the Company files an application to withdraw the registration
statement relating to the Offering, (3)&nbsp;the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of the Common Stock to be sold thereunder or
(4)&nbsp;the Representatives, on behalf of the underwriters, advise the Company, or the Company advises the Representatives, in writing, prior to the execution of the Underwriting Agreement, that they have determined not to proceed with the
Offering, the undersigned shall be released from all obligations under this agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page Follows] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="77%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print&nbsp;Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXHIBIT C </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>FORM OF PRESS RELEASE </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>TO BE ISSUED PURSUANT TO SECTION 3(j) </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Spero Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Date] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Spero Therapeutics, Inc. (the &#147;Company&#148;) announced today that Cowen and Stifel, the lead book-running managers in the Company&#146;s recent public
sale of [&#149;] shares of common stock and [&#149;] shares of Series A Convertible Preferred Stock (the &#147;Preferred Stock&#148;), is [waiving] [releasing] a <FONT STYLE="white-space:nowrap">lock-up</FONT> restriction with respect to
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] shares of the Company&#146;s common stock held by [certain officers or directors] [an officer or director] of the Company. The [waiver] [release] will take effect on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 20&nbsp;&nbsp;&nbsp;&nbsp;, and the shares may be sold on or after such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>This press release is not an offer for sale of the securities in the United States or in any other jurisdiction where such offer is prohibited, and such
securities may not be offered or sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended. </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXHIBIT D </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>FORM OF CERTIFICATE OF DESIGNATION </U></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.3
<SEQUENCE>3
<FILENAME>d521849dex33.htm
<DESCRIPTION>EX-3.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPERO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF DESIGNATION OF PREFERENCES, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RIGHTS AND LIMITATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SERIES A CONVERTIBLE
PREFERRED STOCK </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PURSUANT TO SECTION 151 OF THE </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">DELAWARE GENERAL CORPORATION LAW </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
undersigned, Ankit Mahadevia, does hereby certify that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. &nbsp;&nbsp;&nbsp;&nbsp;He is the President and Chief Executive Officer of
Spero Therapeutics, Inc., a Delaware corporation (the &#147;<B><U>Corporation</U></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. &nbsp;&nbsp;&nbsp;&nbsp;The Corporation
is authorized to issue 10,000,000 shares of preferred stock, none of which have been designated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. &nbsp;&nbsp;&nbsp;&nbsp;The following
resolutions were duly adopted by the board of directors of the Corporation (the &#147;<B><U>Board of Directors</U></B>&#148;) in accordance with the provisions of Section&nbsp;103 of the Delaware General Corporation Law (the
&#147;<B><U>DGCL</U></B>&#148;) does hereby certify that, in accordance with Section&nbsp;151 of the DGCL, the following resolution was duly adopted by the Board of Directors of the Corporation or by a duly authorized committee thereof, on July
[&#149;], 2018: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Amended and Restated Certificate of Incorporation of the Corporation, as amended (the
&#147;<B><U>Certificate of Incorporation</U></B>&#148;), provides for a class of its authorized stock known as preferred stock, consisting of 10,000,000 shares, $0.001 par value per share, issuable from time to time in one or more series; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Board of Directors is authorized to fix the dividend rights, dividend rate, voting rights, conversion rights, rights and terms of
redemption and liquidation preferences of any wholly unissued series of preferred stock and the number of shares constituting any series and the designation thereof, of any of them; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, it is the desire of the Board of Directors, pursuant to its authority as aforesaid, to fix the rights, preferences, restrictions and
other matters relating to a series of the preferred stock, which shall consist of, up to [___] shares of the preferred stock which the Corporation has the authority to issue, as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, BE IT RESOLVED, that the Board of Directors does hereby provide for the issuance of a series of preferred stock for cash or
exchange of other securities, rights or property and does hereby fix and determine the rights, preferences, restrictions and other matters relating to such series of preferred stock as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>RESOLVED</B>, pursuant to authority expressly set forth in the Amended and Restated Certificate of Incorporation of the Corporation, as
amended (the &#147;<B><U>Certificate of Incorporation</U></B>&#148;), the issuance of a series of Preferred Stock designated as the Series A Convertible Preferred Stock, par value $.001 per share, of the Corporation is hereby authorized and the
designation, number of shares, powers, preferences, rights, qualifications, limitations and restrictions thereof (in addition to any provisions set forth in the Certificate of Incorporation that are applicable to the Preferred Stock of all classes
and series) are hereby fixed, and the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock is hereby approved as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SERIES A CONVERTIBLE PREFERRED STOCK </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;1</U>. <U>Definitions</U>. For the purposes hereof, the following terms shall have the following meanings: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Affiliate</U></B>&#148; means any person or entity that, directly or indirectly through one or more intermediaries, controls or is
controlled by or is under common control with a person or entity, as such terms are used in and construed under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Rule 144 under the Securities Act. With respect to a Holder, any investment fund or managed account that is managed on a discretionary basis by the same investment manager as such Holder will be
deemed to be an Affiliate of such Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Alternate Consideration</U></B>&#148; shall have the meaning set forth in
Section&nbsp;7(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Beneficial Ownership Limitation</U></B>&#148; shall have the meaning set forth in Section&nbsp;6(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Business Day</U></B>&#148; means any day except Saturday, Sunday, any day which shall be a federal legal holiday in the United
States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U><FONT STYLE="white-space:nowrap">Buy-In</FONT></U></B>&#148; shall have the meaning set forth in Section&nbsp;6(d)(iii). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Closing Sale Price</U></B>&#148; means, for any security as of any date, the last closing trade price for such security prior to
4:00 p.m., New York City time, on the principal securities exchange or trading market where such security is listed or traded, as reported by Bloomberg, L.P. (or an equivalent, reliable reporting service mutually acceptable to and hereafter
designated by Holders of a majority of the then-outstanding Series A Preferred Stock and the Corporation), or if the foregoing do not apply, the last trade price of such security in the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market on the electronic bulletin board for such security as reported by Bloomberg, L.P., or, if no last trade price is reported for such security by
Bloomberg, L.P., the average of the bid prices of any market makers for such security as reported on the OTC Pink Market by OTC Markets Group, Inc. If the Closing Sale Price cannot be calculated for a security on a particular date on any of the
foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as determined in good faith by the Board of Directors of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Commission</U></B>&#148; means the U.S. Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Common Stock</U></B>&#148; means the Corporation&#146;s common stock, par value $.001 per share, and stock of any other class of
securities into which such securities may hereafter be reclassified or changed into. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Conversion Date</U></B>&#148; shall have
the meaning set forth in Section&nbsp;6(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Conversion Price</U></B>&#148; shall mean $[&#149;], as adjusted pursuant to
paragraph 7 hereof.<SUP STYLE="font-size:85%; vertical-align:top">1</SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Conversion Ratio</U></B>&#148; shall have the
meaning set forth in Section&nbsp;6(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Conversion Shares</U></B>&#148; means, collectively, the shares of Common Stock
issuable upon conversion of the shares of Series A Preferred Stock in accordance with the terms hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Daily Failure
Amount</U></B>&#148; means the product of (x) .005 multiplied by (y)&nbsp;the Closing Sale Price of the Common Stock on the applicable Share Delivery Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>DGCL</U></B>&#148; shall mean the Delaware General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Distributions</U></B>&#148; shall have the meaning set forth in Section&nbsp;5(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>DTC</U></B>&#148; shall have the meaning set forth in Section&nbsp;6(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>DWAC Delivery</U></B>&#148; shall have the meaning set forth in Section&nbsp;6(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Exchange Act</U></B>&#148; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated
thereunder. </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Note: conversion price will equal the investment price. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Fundamental Transaction</U></B>&#148; shall have the meaning set forth in
Section&nbsp;7(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Holder</U></B>&#148; means any holder of Series A Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Issuance Date</U></B>&#148; means July [&#149;], 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Junior Securities</U></B>&#148; shall have the meaning set forth in Section&nbsp;5(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Notice of Conversion</U></B>&#148; shall have the meaning set forth in Section&nbsp;6(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Parity Securities</U></B>&#148; shall have the meaning set forth in Section&nbsp;5(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Person</U></B>&#148; means any individual or corporation, partnership, trust, incorporated or unincorporated association, joint
venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Securities Act</U></B>&#148; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Senior Securities</U></B>&#148; shall have the meaning set forth in Section&nbsp;5(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Series A Preferred Stock</U></B>&#148; shall have the meaning set forth in Section&nbsp;2(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Series A Preferred Stock Register</U></B>&#148; shall have the meaning set forth in Section&nbsp;2(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Share Delivery Date</U></B>&#148; shall have the meaning set forth in Section&nbsp;6(d)(i). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Stated Value</U></B>&#148; shall mean $1,000 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Trading Day</U></B>&#148; means a day on which the Common Stock is traded for any period on the principal securities exchange or
if the Common Stock is not traded on a principal securities exchange, on a day that the Common Stock is traded on another securities market on which the Common Stock is then being traded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;2</U>. <U>Designation, Amount and Par Value; Assignment</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) &nbsp;&nbsp;&nbsp;&nbsp;The series of preferred stock designated by this Certificate of Designation shall be designated as the
Corporation&#146;s Series A Convertible Preferred Stock (the &#147;<B><U>Series A Preferred Stock</U></B>&#148;) and the number of shares so designated shall be [&#149;]. Each share of Series A Preferred Stock shall have a par value of $.001 per
share. The Series A Preferred Stock may be issued in certificated form or in book-entry form. To the extent that any shares of Series A Preferred Stock are issued in book-entry form, references herein to &#147;certificates&#148; shall instead refer
to the book-entry notation relating to such shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) &nbsp;&nbsp;&nbsp;&nbsp;The Corporation shall register shares of the Series A
Preferred Stock, upon records to be maintained by the Corporation for that purpose (the &#147;<B><U>Series A Preferred Stock Register</U></B>&#148;), in the name of the Holders thereof from time to time. The Corporation may deem and treat the
registered Holder of shares of Series A Preferred Stock as the absolute owner thereof for the purpose of any conversion thereof and for all other purposes. The Corporation shall register the transfer of any shares of Series A Preferred Stock in the
Series A Preferred Stock Register, upon surrender of the certificates evidencing such shares to be transferred, duly endorsed by the Holder thereof, to the Corporation at its address specified herein. Upon any such registration or transfer, a new
certificate evidencing the shares of Series A Preferred Stock so transferred shall be issued to the transferee and a new certificate evidencing the remaining portion of the shares not so transferred, if any, shall be issued to the transferring
Holder, in each case, within three Business Days. The provisions of this Certificate of Designation are intended to be for the benefit of all Holders from time to time and shall be enforceable by any such Holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;3</U>. &nbsp;&nbsp;&nbsp;&nbsp;<U>Dividends</U>. Holders shall not be entitled to receive any dividends in
respect of the Series A Preferred </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Stock unless and until specifically declared by the Board of Directors of the Corporation to be payable to the Holders of the Series A Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;4</U>. &nbsp;&nbsp;&nbsp;&nbsp;<U>Voting Rights</U>. Except as otherwise provided herein or in the Certificate
of Incorporation, or as otherwise required by the DGCL, the Series A Preferred Stock shall have no voting rights. However, as long as any shares of Series A Preferred Stock are outstanding, the Corporation shall not, without the affirmative vote of
the Holders of a majority of the then outstanding shares of the Series A Preferred Stock, (i)&nbsp;alter or change the powers, preferences or special rights given to the shares of Series A Preferred Stock so as to affect them adversely,
(ii)&nbsp;issue further shares of Series A Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Series A Preferred Stock, or (iii)&nbsp;enter into any agreement with respect to any of the foregoing.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;5</U>. <U>Rank; Liquidation</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) &nbsp;&nbsp;&nbsp;&nbsp;The Series A Preferred Stock shall rank: (i)&nbsp;senior to all of the Common Stock; (ii)&nbsp;senior to any class
or series of capital stock of the Corporation hereafter created specifically ranking by its terms junior to any Series A Preferred Stock (&#147;<B><U>Junior Securities</U></B>&#148;); (iii) on parity with all shares of the Corporation&#146;s Series
A Convertible Preferred Stock; (iv)&nbsp;on parity with any class or series of capital stock of the Corporation hereafter created specifically ranking by its terms on parity with the Series A Preferred Stock (together with the Corporation&#146;s
Series A Convertible Preferred Stock, the &#147;<B><U>Parity Securities</U></B>&#148;); and (v)&nbsp;junior to any class or series of capital stock of the Corporation hereafter created specifically ranking by its terms senior to any Series A
Preferred Stock (&#147;<B><U>Senior Securities</U></B>&#148;), in each case, as to distributions of assets upon liquidation, dissolution or winding up of the Corporation, whether voluntarily or involuntarily (all such distributions being referred to
collectively as &#147;<B><U>Distributions</U></B>&#148;) and/or as to the right to receive dividends. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) &nbsp;&nbsp;&nbsp;&nbsp;Subject
to the prior and superior rights of the holders of any Senior Securities of the Corporation, upon liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary, each holder of shares of Series A Preferred Stock shall be
entitled to receive, in preference to any distributions of any of the assets or surplus funds of the Corporation to the holders of the Common Stock and Junior Securities and <I>pari passu</I> with any distribution to the holders of Parity
Securities, an amount equal to $.001 per share of Series A Preferred Stock, plus an additional amount equal to any dividends declared but unpaid on such shares, before any payments shall be made or any assets distributed to holders of any class of
Common Stock or Junior Securities. If, upon any such liquidation, dissolution or winding up of the Corporation, the assets of the Corporation shall be insufficient to pay the holders of shares of the Series A Preferred Stock the amount required
under the preceding sentence, then all remaining assets of the Corporation shall be distributed ratably to holders of the shares of the Series A Preferred Stock and Parity Securities. After such preferential payment, each holder of shares of Series
A Preferred Stock shall be entitled to participate <I>pari passu </I>with the holders of Common Stock (on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, without regard to the Beneficial Ownership Limitation) and holders of Parity
Securities in the remaining distribution of the net assets of the Corporation available for distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;6</U>. <U>Conversion</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) &nbsp;&nbsp;&nbsp;&nbsp;<U>Conversions at Option of Holder</U>. Each share of Series A Preferred Stock shall be convertible, at any time
and from time to time from and after the Issuance Date, at the option of the Holder thereof, into a number of shares of Common Stock equal to the Conversion Ratio. Holders shall effect conversions by providing the Corporation with the form of
conversion notice attached hereto as <B><U>Annex A</U></B> (a &#147;<B><U>Notice of Conversion</U></B>&#148;), duly completed and executed. Other than a conversion following a Fundamental Transaction or following a notice provided for under
Section&nbsp;7(d)(ii) hereof, the Notice of Conversion must specify at least a number of shares of Series A Preferred Stock to be converted equal to the lesser of (x) 100 shares (such number subject to appropriate adjustment following the occurrence
of an event specified in Section&nbsp;7(a) hereof) and (y)&nbsp;the number of shares of Series A Preferred Stock then held by the Holder. Provided the Corporation&#146;s transfer agent is participating in the Depository Trust Company
(&#147;<B><U>DTC</U></B>&#148;) Fast Automated Securities Transfer program, the Notice of Conversion may specify, at the Holder&#146;s election, whether the applicable Conversion Shares shall be credited to the account of the Holder&#146;s prime
broker with DTC through its Deposit Withdrawal Agent Commission system (a &#147;<B><U>DWAC Delivery</U></B>&#148;). The &#147;<B><U>Conversion Date</U></B>&#148;, or the date on which a conversion shall be deemed effective, shall be defined as the
Trading Day that the Notice of Conversion, completed and executed, is sent by facsimile to, and received during regular business hours by, the Corporation; provided that the original certificate(s) (if applicable) representing such shares of Series
A </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion, are received by the Corporation within two (2)&nbsp;Trading Days thereafter. In all other cases, the
Conversion Date shall be defined as the Trading Day on which the original share certificates (if applicable) of Series A Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion, are received by the Corporation. The
calculations set forth in the Notice of Conversion shall control in the absence of manifest or mathematical error. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
&nbsp;&nbsp;&nbsp;&nbsp;<U>Conversion Ratio</U>. The &#147;<B><U>Conversion Ratio</U></B>&#148; for each share of Series A Preferred Stock shall be equal to the Stated Value divided by the Conversion Price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) &nbsp;&nbsp;&nbsp;&nbsp;<U>Beneficial Ownership Limitation</U>. Notwithstanding anything herein to the contrary, the Corporation shall not
effect any conversion of the Series A Preferred Stock, and a Holder shall not have the right to convert any portion of the Series A Preferred Stock, to the extent that, after giving effect to an attempted conversion set forth on an applicable Notice
of Conversion, such Holder (together with such Holder&#146;s Affiliates, and any other Person whose beneficial ownership of Common Stock would be aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) or Section&nbsp;16 of the Exchange
Act and the applicable regulations of the Commission, including any &#147;group&#148; of which the Holder is a member (the foregoing, &#147;<B><U>Attribution Parties</U></B>&#148;)) would beneficially own a number of shares of Common Stock in excess
of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by such Holder and its Attribution Parties shall include the number of shares of Common Stock
issuable upon conversion of the Series A Preferred Stock subject to the Notice of Conversion with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which are issuable upon (A)&nbsp;conversion
of the remaining, unconverted Series A Preferred Stock beneficially owned by such Holder or any of its Attribution Parties, and (B)&nbsp;exercise or conversion of the unexercised or unconverted portion of any other securities of the Corporation
(including any warrants) beneficially owned by such Holder or any of its Attribution Parties that are subject to a limitation on conversion or exercise similar to the limitation contained herein. For purposes of this Section&nbsp;6(c), beneficial
ownership shall be calculated in accordance with Section&nbsp;13(d) of the Exchange Act and the applicable regulations of the Commission. In addition, for purposes hereof, &#147;group&#148; has the meaning set forth in Section&nbsp;13(d) of the
Exchange Act and the applicable regulations of the Commission. For purposes of this Section&nbsp;6(c), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as stated
in the most recent of the following: (A)&nbsp;the Corporation&#146;s most recent periodic or annual filing with the Commission, as the case may be, (B)&nbsp;a more recent public announcement by the Corporation that is filed with the Commission, or
(C)&nbsp;a more recent notice by the Corporation or the Corporation&#146;s transfer agent to the Holder setting forth the number of shares of Common Stock then outstanding. Upon the written request of a Holder (which may be by email), the
Corporation shall, within three (3)&nbsp;Trading Days thereof, confirm in writing to such Holder (which may be via email) the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be
determined after giving effect to any actual conversion or exercise of securities of the Corporation, including shares of Series A Preferred Stock, by such Holder or its Attribution Parties since the date as of which such number of outstanding
shares of Common Stock was last publicly reported or confirmed to the Holder. The &#147;<B><U>Beneficial Ownership Limitation</U></B>&#148; shall initially be 9.99% of the number of shares of the Common Stock outstanding immediately after giving
effect to the issuance of shares of Common Stock pursuant to such Notice of Conversion (to the extent permitted pursuant to this Section&nbsp;6(c)). The Corporation shall be entitled to rely on representations made to it by the Holder in any Notice
of Conversion regarding its Beneficial Ownership Limitation. Notwithstanding the foregoing, by written notice to the Corporation, which will not be effective until the sixty-first (61<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>) day after
such notice is delivered to the Corporation, the Holder may reset the Beneficial Ownership Limitation percentage to a higher or lower percentage, not to exceed 9.99% of the number of shares of the Common Stock outstanding immediately after giving
effect to the issuance of shares of Common Stock pursuant to such Notice of Conversion. Upon such a change by a Holder of the Beneficial Ownership Limitation, the Beneficial Ownership Limitation may not be further amended by such Holder without
first providing the minimum notice required by this Section&nbsp;6(c). Notwithstanding the foregoing, at any time following notice of a Fundamental Transaction, the Holder may waive and/or change the Beneficial Ownership Limitation effective
immediately upon written notice to the Corporation and may reinstitute the Beneficial Ownership Limitation at any time thereafter effective immediately upon written notice to the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) &nbsp;&nbsp;&nbsp;&nbsp;<U>Mechanics of Conversion</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) &nbsp;&nbsp;&nbsp;&nbsp; <U>Delivery of Certificate or Electronic Issuance Upon Conversion</U>. Not later than three
Trading Days </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
after the applicable Conversion Date, or if the Holder requests the issuance of physical certificate(s), two (2)&nbsp;Trading Days after receipt by the Corporation of the original certificate(s)
representing such shares of Series A Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion (the &#147;<B><U>Share Delivery Date</U></B>&#148;), the Corporation shall (a)&nbsp;deliver, or cause to be delivered, to
the converting Holder a physical certificate or certificates representing the number of Conversion Shares being acquired upon the conversion of shares of Series A Preferred Stock, or (b)&nbsp;in the case of a DWAC Delivery (if so requested by the
Holder), electronically transfer such Conversion Shares by crediting the account of the Holder&#146;s prime broker with DTC through its DWAC system. If in the case of any Notice of Conversion such certificate or certificates are not delivered to or
as directed by or, in the case of a DWAC Delivery, such shares are not electronically delivered to or as directed by, the applicable Holder by the Share Delivery Date, the applicable Holder shall be entitled to elect to rescind such Notice of
Conversion by written notice to the Corporation at any time on or before its receipt of such certificate or certificates for Conversion Shares or electronic receipt of such shares, as applicable, in which event the Corporation shall promptly return
to such Holder any original Series A Preferred Stock certificate delivered to the Corporation and such Holder shall promptly return to the Corporation any Common Stock certificates or otherwise direct the return of any shares of Common Stock
delivered to the Holder through the DWAC system, representing the shares of Series A Preferred Stock unsuccessfully tendered for conversion to the Corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) &nbsp;&nbsp;&nbsp;&nbsp;<U>Obligation Absolute</U>. Subject to Section&nbsp;6(c) hereof and subject to Holder&#146;s right
to rescind a Notice of Conversion pursuant to Section&nbsp;6(d)(i) above, the Corporation&#146;s obligation to issue and deliver the Conversion Shares upon conversion of Series A Preferred Stock in accordance with the terms hereof are absolute and
unconditional, irrespective of any action or inaction by a Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff,
counterclaim, recoupment, limitation or termination, or any breach or alleged breach by such Holder or any other Person of any obligation to the Corporation or any violation or alleged violation of law by such Holder or any other Person, and
irrespective of any other circumstance which might otherwise limit such obligation of the Corporation to such Holder in connection with the issuance of such Conversion Shares. Subject to Section&nbsp;6(c) hereof and subject to Holder&#146;s right to
rescind a Notice of Conversion pursuant to Section&nbsp;6(d)(i) above, in the event a Holder shall elect to convert any or all of its Series A Preferred Stock, the Corporation may not refuse conversion based on any claim that such Holder or anyone
associated or affiliated with such Holder has been engaged in any violation of law, agreement or for any other reason, unless an injunction from a court, on notice to Holder, restraining and/or enjoining conversion of all or part of the Series A
Preferred Stock of such Holder shall have been sought and obtained by the Corporation, and the Corporation posts a surety bond for the benefit of such Holder in the amount of 150% of the value of the Conversion Shares into which would be converted
the Series A Preferred Stock which is subject to such injunction, which bond shall remain in effect until the completion of arbitration/litigation of the underlying dispute and the proceeds of which shall be payable to such Holder to the extent it
obtains judgment. In the absence of such injunction, the Corporation shall, subject to Section&nbsp;6(c) hereof and subject to Holder&#146;s right to rescind a Notice of Conversion pursuant to Section&nbsp;6(d)(i) above, issue Conversion Shares upon
a properly noticed conversion. If the Corporation fails to deliver to a Holder such certificate or certificates, or electronically deliver (or cause its transfer agent to electronically deliver) such shares in the case of a DWAC Delivery, pursuant
to Section&nbsp;6(d)(i) on or prior to the fifth (5th) Trading Day after the Share Delivery Date applicable to such conversion (other than a failure caused by incorrect or incomplete information provided by Holder to the Corporation), then, unless
the Holder has rescinded the applicable Notice of Conversion pursuant to Section&nbsp;6(d)(i) above, the Corporation shall pay (as liquidated damages and not as a penalty) to such Holder an amount payable, at the Corporation&#146;s option, either
(a)&nbsp;in cash or (b)&nbsp;to the extent that it would not cause the Holder or its Attribution Parties to exceed the Beneficial Ownership Limitation, in shares of Common Stock that are valued for these purposes at the Closing Sale Price on the
date of such calculation, in each case equal to the product of (x)&nbsp;the number of Conversion Shares required to have been issued by the Corporation on such Share Delivery Date, (y)&nbsp;an amount equal to the Daily Failure Amount and
(z)&nbsp;the number of Trading Days actually lapsed after such fifth (5th) Trading Day after the Share Delivery Date during which such certificates have not been delivered, or, in the case of a DWAC Delivery, such shares have not been electronically
delivered; provided, however, the Holder shall only receive up to such amount of shares of Common Stock such that Holder and its Attribution Parties and any other persons or entities whose beneficial ownership of Common Stock would be aggregated
with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act (including shares held by any &#147;group&#148; of which the Holder is a member, but excluding shares beneficially owned by virtue of the ownership of securities or rights
to acquire securities that have limitations on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the right to convert, exercise or purchase similar to the limitation set forth herein) shall not collectively beneficially own greater than the Beneficial Ownership Limitation. Nothing herein
shall limit a Holder&#146;s right to pursue actual damages for the Corporation&#146;s failure to deliver Conversion Shares within the period specified herein and such Holder shall have the right to pursue all remedies available to it hereunder, at
law or in equity including, without limitation, a decree of specific performance and/or injunctive relief; provided that Holder shall not receive duplicate damages for the Corporation&#146;s failure to deliver Conversion Shares within the period
specified herein. The exercise of any such rights shall not prohibit a Holder from seeking to enforce damages pursuant to any other Section hereof or under applicable law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) &nbsp;&nbsp;&nbsp;&nbsp;<U>Compensation for <FONT STYLE="white-space:nowrap">Buy-In</FONT> on Failure to Timely Deliver
Certificates Upon Conversion</U>. If the Corporation fails to deliver to a Holder the applicable certificate or certificates or to effect a DWAC Delivery, as applicable, by the Share Delivery Date pursuant to Section&nbsp;6(d)(i) (other than a
failure caused by incorrect or incomplete information provided by Holder to the Corporation), and if after such Share Delivery Date such Holder is required by its brokerage firm to purchase (in an open market transaction or otherwise), or the
Holder&#146;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by such Holder of the Conversion Shares which such Holder was entitled to receive upon the conversion relating to such Share Delivery Date
(a &#147;<B><U><FONT STYLE="white-space:nowrap">Buy-In</FONT></U></B>&#148;), then the Corporation shall (A)&nbsp;pay in cash to such Holder (in addition to any other remedies available to or elected by such Holder) the amount by which (x)&nbsp;such
Holder&#146;s total purchase price (including any brokerage commissions) for the shares of Common Stock so purchased exceeds (y)&nbsp;the product of (1)&nbsp;the aggregate number of shares of Common Stock that such Holder was entitled to receive
from the conversion at issue multiplied by (2)&nbsp;the actual sale price at which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions) and (B)&nbsp;at the option of such Holder, either reissue
(if surrendered) the shares of Series A Preferred Stock equal to the number of shares of Series A Preferred Stock submitted for conversion or deliver to such Holder the number of shares of Common Stock that would have been issued if the Corporation
had timely complied with its delivery requirements under Section&nbsp;6(d)(i). For example, if a Holder purchases shares of Common Stock having a total purchase price of $11,000 to cover a <FONT STYLE="white-space:nowrap">Buy-In</FONT> with respect
to an attempted conversion of shares of Series A Preferred Stock with respect to which the actual sale price (including any brokerage commissions) giving rise to such purchase obligation was a total of $10,000 under clause (A)&nbsp;of the
immediately preceding sentence, the Corporation shall be required to pay such Holder $1,000. The Holder shall provide the Corporation written notice, within three (3)&nbsp;Trading Days after the occurrence of a
<FONT STYLE="white-space:nowrap">Buy-In,</FONT> indicating the amounts payable to such Holder in respect of such <FONT STYLE="white-space:nowrap">Buy-In</FONT> together with applicable confirmations and other evidence reasonably requested by the
Corporation. Nothing herein shall limit a Holder&#146;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the
Corporation&#146;s failure to timely deliver certificates representing shares of Common Stock upon conversion of the shares of Series A Preferred Stock as required pursuant to the terms hereof; provided, however, that the Holder shall not be
entitled to both (i)&nbsp;require the reissuance of the shares of Series A Preferred Stock submitted for conversion for which such conversion was not timely honored and (ii)&nbsp;receive the number of shares of Common Stock that would have been
issued if the Corporation had timely complied with its delivery requirements under Section&nbsp;6(d)(i). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)
&nbsp;&nbsp;&nbsp;&nbsp;<U>Reservation of Shares Issuable Upon Conversion</U>. The Corporation covenants that it will at all times reserve and keep available out of its authorized and unissued shares of Common Stock for the sole purpose of issuance
upon conversion of the Series A Preferred Stock, free from preemptive rights or any other actual contingent purchase rights of Persons other than the Holders of the Series A Preferred Stock, not less than such aggregate number of shares of the
Common Stock as shall be issuable (taking into account the adjustments of Section&nbsp;7) upon the conversion of all outstanding shares of Series A Preferred Stock. The Corporation covenants that all shares of Common Stock that shall be so issuable
shall, upon issue, be duly authorized, validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) &nbsp;&nbsp;&nbsp;&nbsp;<U>Fractional Shares</U>. No fractional shares or scrip representing fractional shares of Common
Stock shall be issued upon the conversion of the Series A Preferred Stock. As to any fraction of a share which a Holder would otherwise be entitled to receive upon such conversion, the Corporation shall pay a cash adjustment in respect of such final
fraction in an amount equal to such fraction multiplied by the Conversion Price. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) &nbsp;&nbsp;&nbsp;&nbsp;<U>Transfer
Taxes</U>. The issuance of certificates for shares of the Common Stock upon conversion of the Series A Preferred Stock shall be made without charge to any Holder for any documentary stamp or similar taxes
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
that may be payable in respect of the issue or delivery of such certificates, provided that the Corporation shall not be required to pay any tax that may be payable in respect of any transfer
involved in the issuance and delivery of any such certificate upon conversion in a name other than that of the registered Holder(s) of such shares of Series A Preferred Stock and the Corporation shall not be required to issue or deliver such
certificates unless or until the Person or Persons requesting the issuance thereof shall have paid to the Corporation the amount of such tax or shall have established to the satisfaction of the Corporation that such tax has been paid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) &nbsp;&nbsp;&nbsp;&nbsp;<U>Status as Stockholder</U>. Upon each Conversion Date: (i)&nbsp;the shares of Series A Preferred Stock being
converted shall be deemed converted into shares of Common Stock; and (ii)&nbsp;the Holder&#146;s rights as a holder of such converted shares of Series A Preferred Stock shall cease and terminate, excepting only the right to receive certificates for
such shares of Common Stock and to any remedies provided herein or otherwise available at law or in equity to such Holder because of a failure by the Corporation to comply with the terms of this Certificate of Designation. In all cases, the holder
shall retain all of its rights and remedies for the Corporation&#146;s failure to convert Series A Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;7</U>. &nbsp;&nbsp;&nbsp;&nbsp;<U>Certain Adjustments</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) &nbsp;&nbsp;&nbsp;&nbsp;<U>Stock Dividends and Stock Splits</U>. If the Corporation, at any time while this Series A Preferred Stock is
outstanding: (A)&nbsp;pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Corporation upon conversion
of this Series A Preferred Stock) with respect to the then outstanding shares of Common Stock; (B)&nbsp;subdivides outstanding shares of Common Stock into a larger number of shares; or (C)&nbsp;combines (including by way of a reverse stock split)
outstanding shares of Common Stock into a smaller number of shares, then the Conversion Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding any treasury shares of the Corporation)
outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event (excluding any treasury shares of the Corporation). Any adjustment made pursuant to this
Section&nbsp;7(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a
subdivision or combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) &nbsp;&nbsp;&nbsp;&nbsp;<U>Fundamental Transaction</U>. If, at any time while this Series A Preferred
Stock is outstanding, (A)&nbsp;the Corporation effects any merger or consolidation of the Corporation with or into another Person or any stock sale to, or other business combination (including, without limitation, a reorganization, recapitalization,
<FONT STYLE="white-space:nowrap">spin-off,</FONT> share exchange or scheme of arrangement) with or into another Person (other than such a transaction in which the Corporation is the surviving or continuing entity and its Common Stock is not
exchanged for or converted into other securities, cash or property), (B) the Corporation effects any sale of all or substantially all of its assets in one transaction or a series of related transactions, (C)&nbsp;any tender offer or exchange offer
(whether by the Corporation or another Person) is completed pursuant to which more than 50% of the Common Stock not held by the Corporation or such Person is exchanged for or converted into other securities, cash or property, or (D)&nbsp;the
Corporation effects any reclassification of the Common Stock or any compulsory share exchange pursuant (other than as a result of a dividend, subdivision or combination covered by Section&nbsp;7(a) above) to which the Common Stock is effectively
converted into or exchanged for other securities, cash or property (in any such case, a &#147;<B><U>Fundamental Transaction</U></B>&#148;), then, upon any subsequent conversion of this Series A Preferred Stock the Holders shall have the right to
receive, in lieu of the right to receive Conversion Shares, for each Conversion Share that would have been issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction, the same kind and amount of securities,
cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of one share of Common Stock (the &#147;<B><U>Alternate
Consideration</U></B>&#148;). For purposes of any such subsequent conversion, the determination of the Conversion Ratio shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable
in respect of one share of Common Stock in such Fundamental Transaction, and the Corporation shall adjust the Conversion Ratio in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If
holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holders shall be given the same choice as to the Alternate Consideration it receives upon any conversion of
this Series A Preferred Stock following such Fundamental Transaction. To the extent necessary to effectuate the foregoing provisions, any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
successor to the Corporation or surviving entity in such Fundamental Transaction shall file a new Certificate of Designation with the same terms and conditions and issue to the Holders new
preferred stock consistent with the foregoing provisions and evidencing the Holders&#146; right to convert such preferred stock into Alternate Consideration. The terms of any agreement to which the Corporation is a party and pursuant to which a
Fundamental Transaction is effected shall include terms requiring any such successor or surviving entity to comply with the provisions of this Section&nbsp;7(b) and insuring that this Series A Preferred Stock (or any such replacement security) will
be similarly adjusted upon any subsequent transaction analogous to a Fundamental Transaction. The Corporation shall cause to be delivered to each Holder, at its last address as it shall appear upon the stock books of the Corporation, written notice
of any Fundamental Transaction at least 20 calendar days prior to the date on which such Fundamental Transaction is expected to become effective or close. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) &nbsp;&nbsp;&nbsp;&nbsp;<U>Calculations</U>. All calculations under this Section&nbsp;7 shall be made to the nearest cent or the nearest
1/100th of a share, as the case may be. For purposes of this Section&nbsp;7, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding any treasury
shares of the Corporation) issued and outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) &nbsp;&nbsp;&nbsp;&nbsp;<U>Notice to the Holders</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) &nbsp;&nbsp;&nbsp;&nbsp; <U>Adjustment to Conversion Price</U>. Whenever the Conversion Price is adjusted pursuant to any
provision of this Section&nbsp;7, the Corporation shall promptly deliver to each Holder a notice setting forth the Conversion Ratio after such adjustment and setting forth a brief statement of the facts requiring such adjustment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) &nbsp;&nbsp;&nbsp;&nbsp;<U>Other Notices</U>. If (A)&nbsp;the Corporation shall declare a dividend (or any other
distribution in whatever form) on the Common Stock, (B)&nbsp;the Corporation shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C)&nbsp;the Corporation shall authorize the granting to all holders of the
Common Stock of rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D)&nbsp;the approval of any stockholders of the Corporation shall be required in connection with any reclassification of the
Common Stock, any consolidation or merger to which the Corporation is a party, any sale or transfer of all or substantially all of the assets of the Corporation, or any compulsory share exchange whereby the Common Stock is converted into other
securities, cash or property, or (E)&nbsp;the Corporation shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Corporation, then, in each case, the Corporation shall cause to be filed at each
office or agency maintained for the purpose of conversion of this Series A Preferred Stock, and shall cause to be delivered to each Holder at its last address as it shall appear upon the stock books of the Corporation, at least 20 calendar days
prior to the applicable record or effective date hereinafter specified, a notice stating (x)&nbsp;the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be
taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y)&nbsp;the date on which such reclassification, consolidation, merger,
sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or
other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange, provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the
corporate action required to be specified in such notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;8</U>. <U>Miscellaneous</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) &nbsp;&nbsp;&nbsp;&nbsp;<U>Redemption</U>. The Series A Preferred Stock is not redeemable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>. Any and all notices or other communications or deliveries to be provided by the Holders hereunder
including, without limitation, any Notice of Conversion, shall be in writing and delivered personally, sent electronically (with confirmation of receipt), or sent by a nationally recognized overnight courier service, addressed to the Corporation, at
675 Massachusetts Ave., 14<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor, Cambridge, MA 02139, Attention President and CEO, or such other address as the Corporation may specify for such purposes by notice to the Holders delivered in
accordance with this Section. Any and all notices or other communications or deliveries to be provided by the Corporation hereunder shall be in writing and delivered personally, by facsimile, email, or sent by a nationally recognized overnight
courier service addressed to each Holder at the facsimile number, email address or mailing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
address of such Holder appearing on the books of the Corporation, or if no such facsimile number, email address, or mailing address appears on the books of the Corporation, at the principal place
of business of such Holder. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of: (i)&nbsp;the date of transmission, if such notice or communication is delivered via facsimile or email
prior to 5:30 p.m. (New York City time) on any date, (ii)&nbsp;the date immediately following the date of transmission, if such notice or communication is delivered via facsimile or email between 5:30 p.m. and 11:59 p.m. (New York City time) on any
date, (iii)&nbsp;the second Business Day following the date of mailing, if sent by nationally recognized overnight courier service, or (iv)&nbsp;upon actual receipt by the party to whom such notice is required to be given. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) &nbsp;&nbsp;&nbsp;&nbsp;<U>Lost or Mutilated Series A Preferred Stock Certificate</U>. If a Holder&#146;s Series A Preferred Stock
certificate shall be mutilated, lost, stolen or destroyed, the Corporation shall execute and deliver, in exchange and substitution for and upon cancellation of a mutilated certificate, or in lieu of or in substitution for a lost, stolen or destroyed
certificate, a new certificate for the shares of Series A Preferred Stock so mutilated, lost, stolen or destroyed, but only upon receipt of evidence of such loss, theft or destruction of such certificate, and of the ownership thereof, reasonably
satisfactory to the Corporation and, in each case, customary and reasonable indemnity, if requested. Applicants for a new certificate under such circumstances shall also comply with such other reasonable regulations and procedures and pay such other
reasonable third-party costs as the Corporation may prescribe. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) &nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver</U>. Any waiver by the Corporation
or a Holder of a breach of any provision of this Certificate of Designation shall not operate as or be construed to be a waiver of any other breach of such provision or of any breach of any other provision of this Certificate of Designation or a
waiver by any other Holders. The failure of the Corporation or a Holder to insist upon strict adherence to any term of this Certificate of Designation on one or more occasions shall not be considered a waiver or deprive that party (or any other
Holder) of the right thereafter to insist upon strict adherence to that term or any other term of this Certificate of Designation. Any waiver by the Corporation or a Holder must be in writing. Notwithstanding any provision in this Certificate of
Designation to the contrary, any provision contained herein and any right of the Holders of Series A Preferred Stock granted hereunder may be waived as to all shares of Series A Preferred Stock (and the Holders thereof) upon the written consent of
the Holders of not less than a majority of the shares of Series A Preferred Stock then outstanding, unless a higher percentage is required by the DGCL, in which case the written consent of the Holders of not less than such higher percentage shall be
required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) &nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>. If any provision of this Certificate of Designation is invalid, illegal or
unenforceable, the balance of this Certificate of Designation shall remain in effect, and if any provision is inapplicable to any Person or circumstance, it shall nevertheless remain applicable to all other Persons and circumstances. If it shall be
found that any interest or other amount deemed interest due hereunder violates the applicable law governing usury, the applicable rate of interest due hereunder shall automatically be lowered to equal the maximum rate of interest permitted under
applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) &nbsp;&nbsp;&nbsp;&nbsp;<U>Next Business Day</U>. Whenever any payment or other obligation hereunder shall be due on
a day other than a Business Day, such payment shall be made on the next succeeding Business Day. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)
&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings</U>. The headings contained herein are for convenience only, do not constitute a part of this Certificate of Designation and shall not be deemed to limit or affect any of the provisions hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) &nbsp;&nbsp;&nbsp;&nbsp;<U>Status of Converted Series A Preferred Stock</U>. If any shares of Series A Preferred Stock shall be converted
or reacquired by the Corporation, such shares shall resume the status of authorized but unissued shares of preferred stock and shall no longer be designated as Series A Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">******************** </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>,
the undersigned has executed this Certificate of Designation this [____] day of July, 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ankit Mahadevia,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">President and Chief
Executive Officer</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEX A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NOTICE OF CONVERSION </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(TO BE
EXECUTED BY THE REGISTERED HOLDER </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">IN ORDER TO CONVERT SHARES OF SERIES A PREFERRED STOCK) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned Holder hereby irrevocably elects to convert the number of shares of Series A Preferred Stock indicated below, represented by stock certificate
No(s)._____________ (the &#147;<B><U>Preferred Stock Certificates</U></B>&#148;), into shares of common stock, par value $.001 per share (the &#147;<B><U>Common Stock</U></B>&#148;), of Spero Therapeutics, Inc., a Delaware corporation (the
&#147;<B><U>Corporation</U></B>&#148;), as of the date written below. If securities are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto. Capitalized terms
utilized but not defined herein shall have the meaning ascribed to such terms in that certain Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (the &#147;<B><U>Certificate of
Designation</U></B>&#148;) filed by the Corporation with the Secretary of State of the State of Delaware on July [&#149;], 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date hereof,
the number of shares of Common Stock beneficially owned by the undersigned Holder (together with such Holder&#146;s Affiliates, and any other Person whose beneficial ownership of Common Stock would be aggregated with the Holder&#146;s for purposes
of Section&nbsp;13(d) or Section&nbsp;16 of the Exchange Act and the applicable regulations of the Commission, including any &#147;group&#148; of which the Holder is a member (the foregoing, &#147;<B><U>Attribution Parties</U></B>&#148;)), including
the number of shares of Common Stock issuable upon conversion of the Series A Preferred Stock subject to this Notice of Conversion, but excluding the number of shares of Common Stock which are issuable upon (A)&nbsp;conversion of the remaining,
unconverted Series A Preferred Stock beneficially owned by such Holder or any of its Attribution Parties, and (B)&nbsp;exercise or conversion of the unexercised or unconverted portion of any other securities of the Corporation (including any
warrants) beneficially owned by such Holder or any of its Attribution Parties that are subject to a limitation on conversion or exercise similar to the limitation contained in Section&nbsp;6(c) of the Certificate of Designation, is <B>[__]</B>%. For
purposes hereof, beneficial ownership shall be calculated in accordance with Section&nbsp;13(d) of the Exchange Act and the applicable regulations of the Commission. In addition, for purposes hereof, &#147;group&#148; has the meaning set forth in
Section&nbsp;13(d) of the Exchange Act and the applicable regulations of the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Conversion calculations: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date to Effect Conversion:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of shares of Series A Preferred Stock owned prior to Conversion:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of shares of Series A Preferred Stock to be Converted:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of shares of Common Stock to be Issued:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Address for delivery of physical certificates:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>or</U></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">for DWAC Delivery:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DWAC Instructions:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Broker no:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Account no:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">HOLDER</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">Name:</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">Title:</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">Date:</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;</B></P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>d521849dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g521849dsp47.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">One Financial Center</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Boston, MA 02111</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">617-542-6000</FONT></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">617-542-2241</FONT></FONT> fax</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">www.mintz.com</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July 11, 2018 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Spero Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">675 Massachusetts Avenue, 14<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cambridge, MA 02139 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acted as legal
counsel to Spero Therapeutics, Inc., a Delaware corporation (the &#147;Company&#148;), in connection with the preparation and filing with the Securities and Exchange Commission (the &#147;Commission&#148;) of a Registration Statement <FONT
STYLE="white-space:nowrap">(No.&nbsp;333-226093)</FONT> on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> (as amended, the &#147;Registration Statement&#148;), pursuant to which the Company is registering the offering for sale under the
Securities Act of 1933, as amended (the &#147;Securities Act&#148;), of an aggregate of 3,250,000 shares of the Company&#146;s common stock, par value $0.001 per share (the &#147;Common Stock&#148;), including 487,500 shares of Common Stock subject
to the underwriters&#146; option to purchase additional shares of Common Stock, and an aggregate of 2,166 shares of the Company&#146;s Series A Convertible Preferred Stock (the &#147;Preferred Stock,&#148; and together with the Common Stock, the
&#147;Shares&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Shares are to be sold by the Company pursuant to an underwriting agreement (the &#147;Underwriting
Agreement&#148;) to be entered into by and among the Company and Cowen and Company, LLC and Stifel, Nicolaus&nbsp;&amp; Company, Incorporated as representatives of the several underwriters to be named therein. The form of the Underwriting Agreement
has been filed as Exhibit 1.1 to the Registration Statement. This opinion is being rendered in connection with the filing of the Registration Statement with the Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this opinion, we have examined the Company&#146;s Amended and Restated Certificate of Incorporation and Amended and
Restated Bylaws, each as currently in effect, and the form of the Underwriting Agreement; such other records of the corporate proceedings of the Company and certificates of the Company&#146;s officers as we have deemed relevant; and the Registration
Statement and the exhibits thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our examination, we have assumed the genuineness of all signatures, the legal capacity of natural
persons, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified or photostatic copies and the authenticity of the originals of such copies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our opinion is limited to the General Corporation Law of the State of Delaware and we express no opinion with respect to the laws of any other
jurisdiction. No opinion is expressed herein with respect to the qualification of the Shares under the securities or blue sky laws of any state or any foreign jurisdiction. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B<SMALL>OSTON</SMALL> | L<SMALL>ONDON</SMALL> | L<SMALL>OS</SMALL> A<SMALL>NGELES</SMALL> | N<SMALL>EW</SMALL> Y<SMALL>ORK</SMALL> |
S<SMALL>AN</SMALL> D<SMALL>IEGO</SMALL> | S<SMALL>AN</SMALL> F<SMALL>RANCISCO</SMALL> | S<SMALL>TAMFORD</SMALL> | W<SMALL>ASHINGTON</SMALL> </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Spero Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July 11, 2018 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 2 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please note that we are opining only as
to the matters expressly set forth herein, and no opinion should be inferred as to any other matters. This opinion is based upon currently existing statutes, rules, regulations and judicial decisions, and we disclaim any obligation to advise you of
any change in any of these sources of law or subsequent legal or factual developments which might affect any matters or opinions set forth herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon the foregoing, we are of the opinion that the Shares, when issued and sold in accordance with the form of the Underwriting
Agreement most recently filed as an exhibit to the Registration Statement and the prospectus that forms a part of the Registration Statement, will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We understand that you wish to file this opinion with the Commission as an exhibit to the Registration Statement in accordance with the
requirements of Item 601(b)(5)&nbsp;of <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-K</FONT> promulgated under the Securities Act and to reference the firm&#146;s name under the caption &#147;Legal Matters&#148; in the prospectus which forms
part of the Registration Statement, and we hereby consent thereto. In giving this consent, we do not admit that we are within the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the rules and regulations
of the Commission promulgated thereunder. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Mintz, Levin, Cohn, Ferris,</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Glovsky and
Popeo, P.C.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Mintz, Levin, Cohn, Ferris,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Glovsky and Popeo, P.C.</TD></TR>
</TABLE></DIV> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>d521849dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the use in this Amendment No. 1 to the Registration Statement on Form S-1 of Spero Therapeutics, Inc. of our report dated April 2, 2018
relating to the financial statements of Spero Therapeutics, Inc., which appears in this Registration Statement. We also consent to the reference to us under the heading &#147;Experts&#148; in such Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ PricewaterhouseCoopers LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July 11, 2018 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g521849dsp47.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g521849dsp47.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MP  +"  D -H! 1$ _\0 'P   04! 0$! 0$           $" P0%!@<("0H+
M_\0 M1   @$# P($ P4%! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$(
M(T*QP152T? D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%56
M5UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI
MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W
M^/GZ_]H " $!   _ /=-3OCIMA)="SNKO9C]S:H'D;GL"1FN>\)_$/1?&.H7
MMAIR7D5U9#,T5U#Y;+S@C&>H(P:ZRLSQ#KUCX9T*ZUC46=;2V4%]@RQR0  .
MYR16=X6\9VGBZ(7&GZ;JD5FR%H[JYMQ'')@XPISD]^V.#724444@(/0YI:,C
MUHHHKA_$GQ2T?PE="#6=-UBW#.R12FU!CEV]2K!N>Q]>:Z?1M5.L61N?[.OK
M$;L".]B$;D8!SC)XY[^E:-%%%%%%%%%%%?-L5S-X(\<P^/=[MINI:S?6.H #
MA%\XX/Y#=]8SZU](HZR(KHP96&58'((]:\;^,UU+X@L]4T:VD9+'1+,7^H.G
M\4S<0Q'\"SG\*Z[X=6L&I_"/0K:=7,,EFJL$D9#P>S*01R.QKD/A;IWVWQMX
MO2]O]3NHM'U 0V,<U_,RQ+ODZC=AONCKFJ7C6+7?!GQ!M[[PG+J%S:6>G_;[
MW3IKR26-H_,V/@,3V(/MC(Z5ZYX:\2:=XLT*WU?2YO,MYARI^]&W=&'8C_Z_
M0UP\_A>V'Q=M+!;O5!IDFE27CVHU&?89EE5<_?SC#].G%:^C_#JWA6[NM6O;
M^74+VYEN9Q:ZA/#"A=B0J*C+P!@9(R<5Q_@+2UUKQSXVT[4-1UB:TTR[6*TC
M_M6X7RU+2#&0^3]T=<]*Z'5/AQ>KJ.HRZ-J<XAOM+>Q OKR6<V[22)O=-Q)_
MU8;OU ]:V8/ &AZ?8JLM]K+)"F7EEUBX7@#DG#@#\ !7G_@[3)O&_CBZU>PO
M]7M_!^G2"*"-]0G?[=*O5CN8G;SDCTP.YKVZO&/VA>=.\-9_Z"!_D*]GK!\9
M:=#J'A;4!*]Q&T%O)-$\$[Q,CJAP<J1GZ'BN"^%&AP^)?A[8ZIJU_K%Q>2R2
MAY/[5N5R%<@<*X'05MQ?#PO_ &W:C6]2;3[H))I\HU&9IK28!U?YMW*YVG!)
M[@UD_!&[DDT[6=/U26ZDU_3KQH+QKBYDE++D[3AB0.0XX Z5O?%!6G\.VUC:
M-.NKW]VEKI[0SR1%)&/S.=A&55 S'.1Q2ZQX.L-/\!7\"76IO<6UI),MVU_-
MYIE6,_.3O]1G'3VK#^$.E0ZW\.(-1U2YU"[N[XRI/++?S$E5E( 'S?+]T<C!
MZ^M<KI_B+6/ASXWU>XO)[Z_\''43I\DD\[3O:,%5U/S$G $F/< ]P*]RD2SU
MG2\"3SK.ZC!#PRE=ZGD%64@_B#7!> -!C@\4^)I)KW4;G^SM1-O9I<7TLBQ1
MF-6Q@M@_?QDYZ5Z117E/AWP[#XV^"=SI\FW?>W%Y-"Y'W)?M$A1OS S[$U2^
M&GQ#6Q^&VI6^M[_[0\- P/"WWY%SMB4?[6[]W^ ]:O:_H=QHWP/\0R:B0VKZ
MA$UYJ#^LSLI*CV484>RUT/PE??\ "OP^<8_T<C\G85S7PD_Y'?XC_P#86_\
M9YJZ<D?\+G53W\/'C_MX'^-<9XATG4/A+XBE\6>'(&G\-7;C^U=-CZ0DG_6(
M.PY_#IT/'3Z=J]CK_P 3=(U33;A9[.X\/3M'(O\ UWBR#Z$=".QKOJ\E^%O_
M "4WXD?]?Z?^ARUZU7E'Q$UB]\7>(8?AQX>F*M,!)K%VG(MX.,I]3D9'NH[G
M'I.C:19:!H]KI6G0B*TMHPD:_P!3ZDG))[DU>KQC]H7_ )!WAK_L('^0KV>L
MSQ'_ ,BOJW_7E-_Z :\J^$&BZ_>?#2QFT_Q7/I\+23!(%L890A\QL\L,G)YZ
M]Z]%\!Z7?:+X-LM/U,?Z;$\WFMD'>3*[;^/[V=WXUPFO'_A!/C?INN#Y-+\2
M1_8[L_PK,,!6/I_ <_[]=9IP_P"$B^(=]JI^:QT)#I]IZ&Y< SN/]T;$_P"^
MZW/%'_(HZU_UX3_^BVKD/@;_ ,DETG_?G_\ 1KU;\,Z=9ZN_CK3[^!+BTN-:
MDCEC<9##R(?U]^QKD=)U*]^#7B)/#VM327'@^^D)TZ_?G[(Q.2C^@]?^^A_$
M!VO@DAO$/C1E(*MJRD$="#;Q<UV=97B"]U2RTUFTC27U*Z?*K&)TB"G'#,6(
MXSZ9-<K\+-/\0>'?#-KX>UG1'M_LPD;[8MS%(C[G+8P&W _,>V.*S;GX7+-\
M:(_$P0#2FB%U,FX8:Z4X4;?3H^?53ZUO_$BVUO5?"U[HFC:,U[)?PF,SFXCC
M2'D=0QR3CT%9WP[@\3>&/!<&B:GX:E,UA&_ER0W<++/F0D*,L-IPQZ\?+UY
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611111111111111111111111117__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g521849g14h50.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g521849g14h50.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1\:4&AO=&]S:&]P(#,N,  X0DE-! 0
M     &<< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (4E(Q,3<U-S(< @4
M/DUI8W)O<V]F="!7;W)D("T@4U!23R M(%,M,2!F;W(@1F]L;&]W+4]N7V1R
M869T($UA>2 R,#$X7RYD;V-X #A"24T$)0      $+7?A%,A=ZR+H1B';CO,
M[B0X0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T    !0
M  !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M    #W!R
M:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M  ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U
M '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN
M4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2
M<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O
M;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B
M;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U
M8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M          !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M              !2<VQT56YT1B-0>&Q 6             IV96-T;W)$871A
M8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&
M(U)L=                %1O<"!5;G1&(U)L=                %-C;"!5
M;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC
M<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M    #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M     #A"24T#[0      $ /      0 " \     !  (X0DE-!"8       X
M            /X   #A"24T#\@      "@  ________   X0DE-! T
M  0   !X.$))3009       $    'CA"24T#\P      "0           0 X
M0DE-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF9@ &
M       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4
M   ! "T    &       !.$))30/X      !P  #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@  #A"24T$"       $     $   )    "0      X0DE-!!X       0
M    .$))300:      ,U    !@             !=0   ?           0
M                       !              'P   !=0
M       !                         !     !        ;G5L;     (
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M        3&5F=&QO;F<          $)T;VUL;VYG   !=0    !29VAT;&]N
M9P   ?     &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M$@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R
M:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
M5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,
M   !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M          !"=&]M;&]N9P   74     4F=H=&QO;F<   'P     W5R;%1%
M6%0    !        ;G5L;%1%6%0    !        37-G951%6%0    !
M   &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!
M"&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M    #T53;&EC
M94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L
M:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M
M$453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M       *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M        "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M        .$))3001       ! 0 X0DE-!!0       0    #.$))300,
M !1N     0   *    !X   !X   X0   !12 !@  ?_8_^T #$%D;V)E7T--
M  +_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48
M$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+
M"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,
M# P,# P,# P,# P,# P,# S_P  1" !X * # 2(  A$! Q$!_]T !  *_\0!
M/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M03K.OIR;"ZS&O#WL:*BT'7F;7.+2UC;?[*E]ES"P[\AS9#N_$[1RT,^@S?\
M^?DK/8J;Z2H.QKK7>I3:T'8T!X<7'0&6;OW+-^_U%(XN6)/V@DGL3 (D^V6M
M]FYOIL]1J-GLINIE1?BYGID').H=O<26QH\2W9]#_!_G).IR'$6MR1Z/T]VX
MQ.[?]+Z/IUL_S_\ ")6>RF\0FU0,6G)K=^FL]0;0-3)W NDC1GBK"2D;@?%
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M?TRMUCK \ASG%XT$!Q!:7\?N[&?];3MZ<QN\AYW6M<QSM/SXW%K?HM]W^O\
M-JQ0ZUU+#> VTM'J-;J [\YH1$N$=E--O3FBJJMUCG"EV]ATT/YH_J,_]6?I
M/>E3TYE;V6EY=8R(/ ,-](>SZ/T%;)#023 &I)5:CJ.%D/>RFYKG5F'#CC]V
M?IM]OTF('@! -6?E'DI'^RV["SU7$!NQDP=K?;]$'\_:S;O4V=/J8XN#G;G
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MJ_G'3!_/_P"-_P"%4>D7V7]2S?TKGTXSFXC 7%P+JZZ[LE[I_/\ 5R/1W_\
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M(%;0_>?=N_3;ME.WZ;T_VR[^3]Q_\DA6=1O#S777ZE@;O B&>#6OM+O9N0)
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M&%71:;&66ND$;7O<]HD@^W?NV_104Q=3D22#7'J-($#^;_/;]'Z:E0VP;_4
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ME)5\GSCBOZ+3OJ__V3A"24T$(0      50    $!    #P!! &0 ;P!B &4
M( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O
M ', : !O '  ( !# %, -@    $ .$))300B      %&34T *@    @ " $2
M  ,    !  $   $:  4    !    ;@$;  4    !    =@$H  ,    !  (
M  $Q  (    >    ?@$R  (    4    G $[  (    )    L(=I  0    !
M    O    .@ #J8    G$  .I@   "<0061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD ,C Q.#HP-3HR-" P.3HT-#HU,0!24C$Q-S4W,@       Z !
M  ,    !__\  * "  0    !   !\* #  0    !   !=0         & 0,
M P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@  P    $  @
M @$ !     $   %& @( !     $              $@    !    2     $X
M0DE- _T       @          /_A 4A-30 J    "  ( 1(  P    $
M 1H !0    $   !N 1L !0    $   !V 2@  P    $  @   3$  @   !X
M  !^ 3(  @   !0   "< 3L  @    D   "PAVD !     $   "\    Z
M \     !   #P     %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R
M,#$X.C U.C(T(# Y.C0T.C4Q %)2,3$W-3<R       #H $  P    '__P
MH ( !     $   'PH , !     $   %U          8! P #     0 &   !
M&@ %     0   38!&P %     0   3X!*  #     0 "   " 0 $     0
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M*C^4]>4(.H_JG^O^S3,?RGW_ $A%.O[OZ_\ =JN<[A[X0>9]W]?^[3.>'O\
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MN//@9[DL\;VJQA[&:.0N%N@Y:P\\J<;?NGBJ1[! O(M?C\AUQWK<JX@861&
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M2R0D@AB&&5FWAFX186'(1F44I*7U^4GRDJ:)ZBVGWBC[)(X"04HZ>3ZI!!Y
MXNI:4BI#=>4&O4UX_#KW1>TVDI3UMHY"$)\W@%2^DA0Y6H<KZE>_U'U5[WVB
M#IE0H L&(<&UZO\ .)BXM-,I!:;0 .0$A"0E(62I12$@=/4KNKC@*)Y/)/.B
M4(%0![OE2$8BRVL*ZH["@M/"@0.%)( *5 J[I*>!TD<< #C@<:$(=R$/Q >%
MXR='/<M-$CCN>">WIW*^>VH*)1J0E_*$5:989Z4I:;1Z%(2A("%$D^X!V'=1
M[I_KU5(3*5E2$I"ZLD-KPZW0<[XT78[39*PVAM3?4M"5I:2E8;(Y4%*'2TVT
MA*>@*^RA*0/LC5)N'ED]YE0%)%/"FU SM0-:E]6BPYT\V#@Z4KU6,,21!LVT
M2*^1!F1?,YCR(S[4QJ04?RH;?0I:$+:<1T@H(Z%)'!!2.)1]W5;NU*'])((N
M.#?1J-$.6N=W"@'K2D=3R6%H1YC:01PKA92I25CXE1Y]\=_>['DD^NKJERE%
MU!)(K4 L1N<%B+4B(UU(;'F*4D=3WFH*B4ELM)]TJ7W[GRTI2>?T0!Z#1:$9
M#0,4!!+"J6]D[TU-#2]+B)<_,;W^-_K&&(_!FH0_!=BRVO,6TIUEUM;:'&7.
M%I"D$]#Z%I)=3]H.!74.1JLM4HL4Y<R4]WF #Y1^%V<)>K6UB#QWGUU]=80V
M?[58EN7'J5WJ+*)/H)$J50WF/VT_'L@IU3651I?U7=TST2U@-3(JE1I*8LA@
MR(JE,O=394D\^.P,K'("5%BFQ2WTX4@PW<F)!!]?=Z-%N";78MMXS/\ J5B8
M_-M93<ZZOKRQFY#D5S(97UQ#:7]Z_*LIQB$CV/VF4[[, GR0CUUS[/V9*P 4
MK,22:J4:DN[GB37B:VO/ :[R2>OB:W9G%3Y9Y*F4)*DIZE=* YR@<IZE)'"B
M@_+W0>Z>W;7J'* 5L+.[#R+Q#;QPC0;EPW7Y$)B1"$F,EM4B*7&5/LI<=*65
M/1FUEYAM]KI\A:T(#B0GCMQJJ5(F#+0_F&]KO\:[P8JHA(T?0>5VW:<(P2IU
M?$=9;FR(D5Z8\U%A"5(80]+F=GV(,,/*#DJ2VTA3A0WUJ'YQ:0>ZM0N;AD>%
M2T#*<K$:C<];Z,X>M8NSA)+U8N>(#EN/PWQKNWN/LR!7/V]6Q-;4DJC&=#0^
MC@GR_-96Z2QYO93".@)Y/2D#T'.<3@@PS2F<M[)%";D>;#W")RD'=8MFZ%.K
MQL2[2KJV&Y4^375L8+;91(FOQ8R.M:.@(\Q3J&RX$>YP@ =(Z![O3PF3Y$J2
MF>G*D+F"6%  &I( \/ 4#V%HA]"H#6JF XE_EYZQFAV%?/3YD*1&EL^6"'HK
MS+S)2?1/G1PZ"A(4>$J/"0>/75D8B6K$*PX8]W+2NU X%69@>=?=$4(<$'S'
M7[CRYE[=T5!6N6MU:U-/7M'^^+:QF0:^ RI'4D(D39*1&9#9Y3^>'F) (5WY
M Y\9-PLM,F8L2TJ6H,62]A0ECO 8@\KQ85>M.)O<CWUC8QZ^I,DKHEO06U3>
M5TI@I:M::RCV=:XX!U+\F5$48[P42HI>9 0L*#B$!*@-=LJ;(FR\TM2"AG(2
MS!ZD$,/A%=]=?K&U,EPV2VPZ]"CF:[Y$-F2ZVCVN:62^(S:%\%UX-M+=" DD
M<*X[>M^\E@!B *90*:4 T%(4L2-U3\-_(/K%7+*N:<<2_/BAQ,=<Y:'7TM%$
M!E02[-4R5A2&6GD)1[0K\V.E)!]W6*\3):X;VCHP!]H;Z_%X:D$@$:.-[;[<
M8TJZ[H[5QR/76=9.?;*TN1H=A#EEH-\H6KI2\'$='<+\L$<<CDZPPJ\+B3,R
MB6LIF*!#)4R@2%$48%Q5OF8G-6B^3*<D@6H3T]2T6R<CH84T09EU71)R^D-M
MN3&$/MMK*E N(=<2ORW"2&BK[/*>#J5;3P<N<,.I:0LJ9J  O]2^Y_::%&]I
M-="6K5OT??'=9\A02I3;*NIM*0X$H45( )2/,!(*/>44])*??)'VB3VD(;,6
M((?-0EB-">%M&B" ^_COO]3ZF.';9!34Q2[9V-?7M2GFV$.3YC$-#KK#JFRT
MSYSC:UN)4/T0$$GD+ /.N&=CY<DI"B +5+.78T<$EZU]Y>)9DN2 !6IK7Y;M
M(Z,68Q+0S)9=;<8E)"X[J5L/1W0A///M+*EI(6 2/>5U>G)(UVRYB)J$J200
MI(4/,/U>(#&KN.%?T]\-?FVS.(;AW$'(Y[F14N2P(9K&LDPO*[[$[E59[3[6
M:F39X],KI3]<9/$A4%]Y453X\\MESE0\W'[+E8PA3)"@?: &;==BWJW"CQ(8
M%Z@Z$4IZ\;><*W#,#Q_ J6/C^.5Z8E:V[*DRG%K$F9+L)2R9,^PD.<OSY\M9
M4Y,G2%.RI:UEU]Q:U**ML-@I>'EHEC*G*A*3[-2$@.S-]:Z7DD:/PM;BWTX$
MG1;(CH Y4$E92A*EI2E)4$<E// ]$J*E)'H"3P!R>>P2T"P#4LPM:P%M(K&N
MM#82IKRT%M(*.CH!3Y8]T-]/IT< #I]. !\!J%(18L.!8^X]4X0C5CRXDDO>
MS.QGG8SKC#@8=:=5%E=+JE-.]"U&.\I!:4M"NE8"U!8'*AJJ52T43[LH%G-'
M%V>HU$6U9]PUZHY]^^-6))@R&%383L>5%+3RX\J,\AR.\N*7&G6^6CT\-.-^
M2XGWO?:2D]T )QE2Y:IBUBN8J4"-034/=JBEBP8,T":,_ BW+YOQ:.VAIH@=
M33:@VLJ;6M*5*ZB"DKZE GS"GW5.<]2@2"2>>>LA+ $!A9].45<]>?U/K%Y8
M9402TVHC[)*02.5(<[$^G*T(7V_20A7JD$5[I%P.3-K6E(1A4V$$=DE27%.]
M75Y0;1W2.I0'?ALE')[A//Z/8V&4:CW/Y^D+MKN_2.5,DUL9*3-?BP6I4F-7
M1'%.-)1(D2D_WFQ'</3U/!\N&.A/"QYJNGIZCJJS+2DE64 ZTJ3Q\_?QB06]
MWNT>[1UTLQU\<I2>RO<4$$<+YZT\<<<*ZB%#T5R>H$$\DE"A^$EMPJ]_7C>(
MC(EI//5Y;(Y]>$#J]5'CJ'KP3^]2N./C<@*#4(W;OUA%BH[25)<Z$]:>0E72
M I(5T%02KU 5Y;?(' /0CG[*>,2@)+@#5B&?=\&>$)J7D./197U7(LZEB9UH
M2F$_.9COK*7"4!2 $N1RESDQ^ 2\KA0)4>5<QVE@Y<Q4M<Q*9@)2H,'<$@OH
M*V>KUO6!0]R="Q/F&KR-;4;2%!^;<X4$M$@>ZM2070DE*NY/?D\!2N?BGD]P
MG72%2)P!9*G 4*.:U'']>,*CF*<8Q+2UT*00V YTH2@KX5TM'OY:#Z))!(2"
M!\>#J5=TA+,D,&#  TL*-YCU#1+E_KO\XY,"[J+6PN:N)/BRI]'(CPKR*R^3
M*K)5C!C6D!A]/_9.NU$J+/Z3ZM.I<]X$<5ES9,V@RJ*:&@N1S.G3Q-1Y-]:T
MU-O?"A0TA:6W%-]*RV.R@.I 6$J4WR03QU =0Y[E()Y(UH9:3<? _$16+_*9
M2.Z4<?YP3QV[_$?#X?+X<:D!** L&H-PX 0C*._<>AU>$&D(-(1;TI_53^X:
M0C35]I7\X_QU@;GF?C"-8^I_$_QUL+#D/A"-!8Y4KG]97\3KDF^V>M3"-!\#
MI5V'VOE]YUQS0'MH?@H_&L63]/B!\*<HX\I "N4I '<$  #U/KQ^[6*T@I%*
MLUMXO% 0::_JT5IP!<PN !W7Z ?Y)[48>7EQLFGYJTT0?K%$W2^X^KGZ0MW/
MY1S^>K_6.O?C2,@]!^ _AJ&&X>D(SA!(24<D'CK'(]1^T<CUX_;WU%% C<X^
MAA'GIOK-V^1XCZVLW"QB5F4&;LM=IK\>A4$W)Y<F:YFE7'0J-70T*8BR VZI
MEF:X&WT(=*2\D*6#^?[40%[36E4L*3E60EAE<%P3[(<CS]Y-)F3,,P=Y8%B6
M+DBKAO>:BC1@VYR+=#"\?VXVBHHR:S*\UL-T\OHXV?2;&QE8!LW29/'>I*VX
M8;?$^5?U\/*\1HH%9,EOO4R7S6EU,: @:VP.*G8?+(*B[J2ER2$(31(:C$%\
MH8L&"19\ J<E(ECVEYRG,?91H]+FK5#) # &-'=C<_>63M[O5B"K:CH=S-MY
M>%3(^08\F_;I[O'+UZ+/@2&F'WD2JR>7C(J[4,25MOI:>C!;K) $;4VE/$I8
M$Q0*&!R%0S F[IL1F2]J$4)#&BU3PA:7\:,KJ2_B2?*A!(W.*$T8K?<C?O*=
MK(6VN)7F6X;#RG-F+J5)S"U@7+6,4U/2U\5Q+S%3!*I<N7+DO,--=;G0P7E)
M*N.E2K':F(1A<,.^+]S+=>9;-D0'! !)<%Z'=1R(T5.*$I!*<R@Y4Q*11K97
MJ03[.YA0LFQXH-PIF"R[/&H.+Y)DL/>S =JXDY3F05.*Y+3YC>TE.Y=0ES.)
M;%C6-W,IR4PWUQER8/EH6M*$J3?#;6GJ#F8LD*"7*E,006-30N"-*%S8108D
ME+)"2L+2AZY5.E1=RQ2Y <4N+5$+Y6]V8[=6>YM3NL[2W",+VBE[R0+#&C)@
MON44!R;$OZJ?&7Q';57RZ]+D2>WR\F&^IQ7!*N/0_B[9D+JMBH$&KOE+UL^\
MILX81T +;Q!1.7-0ZT!!;BY<6:@8UZS5OXEHN(WV5VJMNY$XX+8Y!6XI7-Y
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M^!U^@^U\A\]9S$AG8.]V'&+)U_I,8'T(Z%^ZG]+]$?(_=KAF .:"ZM."HE5
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M)K4  UO4#76%[Q<$(2GI"$A/ZH2 G]P'&K0BTM-*]6VS\>Z$GTXX]1\.E/\
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MV'8==080D66,YM'W$PW<#%\X8?X9?8;I;'"':N5&BOMN2VY;3J5G@]3KYQ#
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M5-6<!M,KAH0=-XY]F+G<>9MZM]ZNCI>FPHN72GJEG%II@O.L/-LRW;!WJCN
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M1.@N4IFXB^NQ=L%37FI3]HMY^&5*]A<;( TZ;3S@U>._EN>D)BI\*F&5,9^
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MJ*ET%(\?:&Q-DXXA6)PTB9,]I)5)ES"X#OXT$BI)&E*$M I2M@L)6Q!'>#,
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MK!Q[RE?I*)*E?I*)/)*CZDD]SSZGOJSEF<MNT](9CO/J8ITIZ5(Z1TJ/4I/
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M? ?R:/@YYH^'P=_.#Y.>_P#:[Z0B_H1SSTIY*NHGI')5P$]7/'/5TI">?7@
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MY?@S*S+"*!2G\04 V9ZN3<GU[E($I)+)31RP J7>HY,]F/.)*[5@?DDGL/\
MK&2?AZ^<YW^_\?CH$A( 84 %FM^T4!< Z$/ZPXL<#SD=A^E\/\U6I8;AZ19S
M9RT95_;5_.5_$ZF(CGRWFX[+CBWS%;;:D/O/];<8,M(0XZIU(F)<05EQ/2J0
ME/E!*DJ Z3TZ0I\.NO41Y8>&U=WD?BLW2RDV6454.^R'+\D3C>5YGMI;3J_R
MZM5!2OQAB>43\LOL.DQI,W(,3Q*?CF".88W=R!+GW$U4U^0?@/+0^E=U:V@/
MKQ^C>5M(]:&>GR6ND<)\IOI Z!PGH' _-@-]A^H C]4 <:0C+I"#2$1FW?\
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M$_A 8G5J1Z%8MX'[/?+&Z?.O'KN)FN\>176.LW,_9:.9&"[,;<SY\%M"*AK
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MNN:MZRUL:G&I4C)ZV2[&:CX[:81+9BW*)D164I1%KW41DHC73COZ^G"/0AM
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MX[&JEH_B.TDB1A)A0TV4A17,64+HM"LH5+EJ&HE@*R+(C"1+3,)$T)6 "MU
M+)) 8#,[W=@!1[,(]%VT]"4#GWDN>?U>A]I4SY"Y'W/+9Y:4Y]LM'RRKH[:_
M/):YZ*S)DQ4TA/>J4I14M20 <Y)=517,7)>.@2T(]E"4_P!*0/@(J   D
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MKI"#4D$7I0'R.L(-1"-%%A6.VIH6[6I?O4QA/-!%L8IR1$-:0XB8]4/6R'1
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M88SONF$$E4U,K(<2$'#EE%0[T)8$+(2ZD$F*?=CWX.8Y20<N;1_9?-NLYLX
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M#\=Q4=]*7V%+;)9>2'6RE8"M(1U$,LMH2VVTVAM X0VAM*4('(5PE"0$I'4
MK@ #D ^HTA#<Y]AM=G5!(QRSE2ZV.J=4SX]G7B''LJ^11WC%Y$-=[7&E1FU!
MRM0//\KJ5Y:%*!4$D(0T,[PMX-9(Q^3*L\G3=X[(Q2<F_:?HHUS.EXU;.W?F
M3)D."RM:KZ8^ZU:AM2&984I"T*:X3HWSKSW0ZX_2)-(9;$<,/-)4RIH-*8<0
MT4>6!TEM3:$A@@^A2VA+7 ]P=/ %%+"% V.\%B.1O3Z5@SAM].,>%OCG^B;\
M&'B1\2F-^(/=?/,BP6SJ(V+5N98+CBJU-#N!68ZF^LJ9%DV&5NTC/LK%DJUD
M-I2FPB445B45HB-!O[O8_;K'[)V6O""7(GH2)^7$35J"Y0F@L)@91F!"ZH+O
M4AQE$<.(V?+GS$+*B@I-4T#G2EC3A0 [WB6'B(^CT\!&8;*9]BV6[ ;*;;T&
M0TL>L>W!P;;+;[&LMH'Y=C!:JK2@R.)C+=A$MW;AZ+"C+B.L*<COJB(Z6GO+
M/A[*[7[=P&T96-DXO&3A+F]X):L1/,J<D@CQR^\"5YPK,D*! ("CFUW7AY9D
ME  HD"P#-N+,"&''0&T1S^C_ /HI_ )LK@671*&FP7Q83KC)&)-QG6\6!XKE
MT^ W]61#7U%4W?4LYN+6O1RB<TJM#,&2X\93+:>L%7L]J>W_ &@VZJ4O/,P2
M914CNI$V=*[PJ4',S*H9BEDI2&85I8#+"89$L$EENIPHIJP#,E]*5=@Y=J&&
MTO\ Z(#P"5WC9Q+Q.UV6OX$]$S=BT8V*QI%#5[:IS_$"Y6LJ?AP("?R:IC):
M>>F5?3#KIMB/-<;4]R=7_P#M$VD=B2]DSNZ,P)3)&(4L][X4E(S!JK0625%0
MSEE$N6.*]FH.(,X$C,LK(:GBJ=:!1%@"Q=FK'N%90L'IXS4NVB8U7Q77FH(>
MGQ*R.EZ1,46V"N:XTE+2UJY+*D+ZGCPD*)XY^&F*&<SUU6[E9JJI>Y<T-;[X
M]%(RVI7=J.APY"./B%EMGGE>Y<XFQCMK7HE)A..HJ6&G8TI4"/8.!Z.]'2DH
M>K)$2?&/04EN4AQO@K.@98"V?-XG.KL:\:N:ZQ-S\KFL<:7FNQK%[$QPY!MT
M[?R;Q_&4T4:;CLBY;OFE..R*Z76QGO.C28RJR9'?CO):=C+\UE:4*\Q!,-P]
M!"CLX]=W+J^XQN9CD>V> 18$O*JB- 3:VS=%7QXF%6=Y)ESGUN=;GL-#06ED
MS"CA"E.6BFF:AAH>:JR<8*'E&&X>G1@_7[7XGG'8QR3MMF-;*ML5:Q>YK8<Z
M97/V$*!!DQA(BH2N2VTXACI?6R2I*%-=0('*3QQIE&X5X0T)T'#=[_J=]X1^
M*[B[,YMD!Q[&XC$RV;C6<X19&!W%3$6S7/J@S NSM,<AUBFF9#:O9)<::_$G
M(_OB+(?96AU9AN'I",&XN:[7[8+I8^35#;KV3/NQZ]-=CD>R_.(ET=7'1(->
MVR89L[7):*H@*8<4EN39PIDLB,W/?0( T'H*<_J>6Z'OW&^[TX>HJ[+'')FW
MN48C59O JJIN@M:5C($/3J./ E,P2RV\KVJ&MKKB/)2PXF3&6KJ9<+K2BM7/
M)D[AZ?I#K];QJ4=UM9E-Y-HJ)O'9UA6M(ES&&JR.VAZNZ0PJ1$66 "(TF?':
MDK'JZTGD]0"@8;AZ"%.NNN+07F1;28U>UV,7[V(5=Y;15R8L&57QP7FHR.IU
MSVMN+[-!"0"1[2I'G]@DJYY)AN'I"%&6L$%(QD2H>(LTC\)JP:MIT2JKX:H+
M[27VIOM+T<Q_9W&5I=;<*>E25)*?7G3*-P](==>3PGL1R#9_.'YT;$+/ \K?
MJ%QF;-% Y0VZ(8LXXEPG77X48(Y=8(6U]KW3R/7NRC</00O')O<UV3QR_AXU
M>7NW-3D$V970&<?G.4C-TN3?R7(]4E,,R6E_GW&RAKJC\CCCA"CQHR=P]! W
M^@\OC7U\G/B1XD-GRH$:-#C+47@S":98C]3GO%:41@&5%7//6CD*YY"B#SK$
MT):E3\8V #"@L-.$;\;^7;_$_P"J=!<<Q\8*]D^7Q$=G6\8P:0@TA!I"*%*5
M=E *'?L0#Z@I/K\TD@_,$CT.D(H4I/JE)_$ _/\ M/[S\SI"&GW;3+7MWFC=
M3B\K+)S<!Q<;'ZN<JKDRYHD1W(Z6I<<M+2MHDVSRDJZUELQ5+)5TZ@)2ERE(
M25$J)2 "234EKDFI)N:P>F]G#;BS\-XUJQJQB/\ X58DRM9W$C6/G9%8QIU"
ME&8(AJQR/DL>PK94\18>/@,IKI--83%5,ZV2TEZU4\QYSCOU.CRA -5 *.A(
M!.E"2^[]-8C]GJ/37J[B,VZ^W8N,GRRY@[(1,SGQZAYZKRV9F==76"YEA3SZ
MZ8UB]>XWT(?JS7PXDU$QQM2693C$4J:5TJOG7D$O,KNPQ$O,<@*0 &2[!A:E
M-&#")^?7Z0YV^6,/Y1A556U^/V5W.9RFE3$%5E5EB[U4W*C3:RSFR\CI)+%G
M&;C5\^R2MYA84ZJ5&\Q7O$*C,H/E4H.&+&I'$5<4#@TU>D*ZG4:^5WZ%&C4V
M,9?::SBN>V_=V^=K;:KJG*=4MJ;2RGZZ@KFI4O'%( $NKD/MK?@V$I"9LUA3
M4J2 \XX=0*5M70]5JYYB(;0CR(ZORW\@SUJYLLQNB[(IZ^^EY!(WHQZCL\MN
MK&ZD8I59X]9Q[:RPK$_;)3T6NR6RBRUHLZ.I@L4]O$2ZNR>DR5@FV=99UK+,
M$^(L !I6@L&;DP=XRAP6%+%K<11^GJ6B5V58!BV<1*>/EU9'M(E18ILH\20A
MX17I'LWD/"1&7UK4RXZ2LMR5+6H]W27.5&A -P"V\/%OHQX]4](S8=@N,8'0
M(Q?&:B-35/MEM.9K&5.)C-RKF=(L;/V9">&X["I<IXQ6P!THZ.G@CG0I20Q
M4-R@"#S!<'S?S@  "  'T##T-_G"#A^'_ *NWQ?(:B-80K7$;>PN&GX<YZ"B
M]F3BX"YE2&%-?E&]"0M3<)^U]I>BI_DE(!&I    #    6#;MPW#2'/KW]5Y
M1AW?V+PW>6!&:R)J3'LZMQ<JJNX2_:GH7$H!3<B"]_>MRV\TVMMV%9)>9KEN
M+]D".$DNO+]8,[U]-_Z-\F,.C6XU45&+PL2A,>S4M?1HQJ*AD!*VX0A(AI2V
MIM('4VRCI)0 "KW@#STZ0AF=LO#QAVTN1S,IQZ3</S':%5,IB7)=?B&*)-(\
MOR(SK8;;*V,;QV/$Z"?)D-V4AM16^ZHH4W=4-+#36.5O7@%_E-WCK6/8Q8S'
MFHLUV=D$7):NHAL1HH2RQ6VU?<4-C#LW)S<N0J"IY+Z(+D-A;2P8[:D.GZZW
MTH70^$*2157$G84U4K$[*+<*PUAAW"G;Q$RU9M%IC^3$?R"$B*S*+'3Y+[D-
MAB*MIM3;$9F,4LMO7KKY 0ZZZJ\-[L)A-S19S>W&0;=1L"D6>+1(<6NQNR7(
MPQ,-NVEN.SH]*GRJVDMKM*6Y5FB#'96XL]#A<\L:==;NN#QP;KSN_G6&Y\3^
M$0+[<#$;4;=65G>M6.%6,.]BQ)MG5YG!QBRO<P7@:VDK,>EO'KBIJZ^)E;C:
M)2*O*%04/B-$4TEU\;]/Y1)KUYCX7\@QB4^[]'79+MS<TUKB3^55EK]31;"A
MK'W*^Q^J7;.I8L;"#*0M#L*PHH\F1/;<:4V^IF*$H) Y2.M?G5^C:^D1Y4W<
M/3RW:PS'@WKVJ_;N[3&J S"GY39Y&W<QH,:O:MORGEO6TJJ4RRAM7M&'OR33
MR9+O+DQR(7E$]1)1(^-?7KYQ,MOGH1U*ZU=">I7'3U'@<JZ>W3R>_'';GC2$
M7Z0AEK+?/:REW=HMB;7.JN!NSE=/-R7','?7(%O:T446RO:F5>6JO0E9J+I]
MALR&Y;L.O"O* :'#KJGN?EK#7KA]?K:&DD^.WPL,5HNSO#1RJC\NL@VU:EU5
M=DUFN5F^*Q*VPR2GBQ:NCGN2$4U;;09SL]LO5K[3P6S(<94E>D''O:X](W\B
M\:_AEQ:?B55?;P4T*1G&.0\KQV7$JLGN*Q['K.S%)7W=O<U-%,HL:C.673">
MCY%84ST:<M3$N.P^A;:$'Z\^N0O#C;J;Y[7[)8[7YANIF#>+4%S9,U-4\IJW
MM3/L)C!L&8M:Q0UUA)GR"RQ*>"6/.CMQ&U+2XN.D$J4X]:7T<M^HTKH*[W\M
M.3\Z66V(YSB^>XI3YOB>1P;[$<AK&KBFR&"]Y<&94%MEQRQ\QY$?R&D@NE7M
M#;3C7'2XVA:2E*'[U^G7&-T9+1*AR+07]=]7QWFHS\Y%E&7 9?0KVL10^F5Y
M*Y#K3K;2R#RM   4D\:==?K#C]>=/TB]V\IFY+E:[>0VYZ7F(9@)M(_UCY]F
MUU1&0S[5YJ9;JD+?BM\!9C$+0.GG2$7O9#2(0@KO*MI$KSO8BJR80N4VPLQI
M"8OY_J?6S,;6TIYLJX6/+!X/<_TA",Q3=7$,S%N]472645.6W&'246ZC3ONV
MM!(>@V":YB6\@S&?K1MV"T\RE27EM<)Y[:==?M!^#=>G7E"Z3?5P>EQE6=>F
M16L^TVT<R&E2*UE:>IIV6TE\J82M/!/4D)'/P&D(U5Y#3D1E(NZU#MBS&77M
M.V#"38B9(+4!ZO93(*GV9KP7'84A/6YT@<$CG1]-8GH6ZW>^%.C@I3QSQTCC
MJ"@KC@?:"_?!^87[P/VN_.D1%VD(-(1C+32N26VR3SSRA)YY"P>>1WY#C@//
MP6L>BE<H1=T(]>A/Z/Z(_045H^'Z"B5)_5421P3SI"#I3P!TIX'8#@< #T '
MPXU4I2JZ4GF ?C"(!>)/",RL\SEY+!H7Y-%544!ZO<KEUZL>R*1#D6WU_2;U
M/25"S9V_%-96-;"<J4R)S,:YRR"VP(R8B'(,M"J*EH4-'2"*-2H]. $-7>K?
M'>=QY1+'-J:=;XJ_755?C4^S]IIYL"%DBIYH$V%;81K"%,4F$I-C*<KIL2--
MK2TZA+<B/&DL*9<:;6+I\/L>%@R<IRL!8.G32E/*!)( =Q9N&O(/5OB82&U-
M/?X_9;@,7D7;:&^;/'F(WY!UEO2Q_(A8U71(L6U8L'9#,;V*.VB-7(B+ #"&
MVW>$IZ=64M:SXU*47?Q$JJ6)-=]"3K 4MR] S>@9H9[-L%RVBR'/,SJL-VQ>
MC97;X]C\MF?60Z?(;*D]K3)G74O(X30%U,,HF2Y3*:4XF47$><I:>K6)E2R<
MQERU$$D$I22]W#AZ[Z%_6!).^POIN'D-(=_?2PQ2OV[EVN;X=!SNGCVF,K9I
M+*H4]6NW2[6.FCLK)F4U)71U]3;NL3I]C9(D1H=<B0IQ/1U<Z$ @@AQJ"''G
M"W7J/1[/NCF["Y'19-59C+J:F%2-Q<O:KI5?6-LS*!IRLQ?&Z&M507$&/#@9
M#CRJ:!'A1;6&PW#?92TJ,RRR6VFPI8  ,  &8  !AHS4:C,U(!MV^_'XWXOJ
M8?9C':!M3,E-'5(E-ROK),A5?$5+19+;=0Y8*DEDO*L5ID2$NSBLR7//?ZW5
M>:YU(1L2*:LER(DJ3"C/R8#KST!]YAIQZ"Z^E2'W(3BT*7%6ZA:D.*84A2T*
M4E1*21I".5CV+XQBD9^NQ>DK*.(_/F63D.FK8==#^L9SBES)GLT1EB.9<E1)
MDR2@O/?]HXKX.OWWPCDU6W^)T5]:9)3T<"LNK:&B!-?CMM1H\F(ASK/4Q'0A
M 4\YRZXA0*2X?,^USRZZTZYNU_;J_'7RBW*MO\&SD0F\SQ;&LG;J52S ^OJZ
M):&";)ER)+,5<^-(,=4N*XN/+6R4&2PXIMY3C:E)TA&TG'*VEQ)>+XY3TD&I
MB4LFFJ<?\A#6.H82RMF/!?0Q&2F-"(6I"HS* VE*U@)Y/=#D.B?/R$,-M'M9
MF>"Y78W5U&P5BMN<<<"142<GFVM3E$J0S)EU5=)O)#\2+BC[+;4A^%7MQJR1
M81VI?LO6ALI#W:[PS6/&NM_<K73U]XX$<8MW=VYW'S.^LF,4CX(SCEO0L5%T
MK(JE^WDWZ4E,GE3J?S3,B,D>R1)JD^9&:Z4,="$@"-?U^4(=GZFMV=KV,?I:
M:B@W+. LTL'&YC2)=#&MX]-&CUM2^U)"V54T)QAR&_&<;4V[#6SU)*3TZG?O
M8L?(^[?!BW+?S%:N>7'E#*^'/#+O%;[<Z0YAJ\,Q[*+IJPBU\\16E5TJF6[3
M5-;01(B&V&,-K\2BX>JKAI2VPS/?OG0TB1+EEQUU[_2 /[:TZ&ZC%[0@=_:*
MWE;M[=RXV+4J+1_)H%YAEW%,2NGV[^'4L:3'H\R+*4/W$!FRD3%U$"Q7(8AO
MI#D5ML@'2QY=7A?SZ;?Y>L3C5SYB@KUZSU?'OU=^_P >^LU@-;7ZQ=)-:GV3
M&1C_ *0W_/5_JKUSI)[U(<MG-'X&"C1/$5]T=G79%(-(0:0@TA!I"#2$-SN5
M%RN9A.4Q,%MH./Y8Y!=;HK6RB&;!ASBXF8\Z^TKE"D2(B%M-K[>R2UMOIZ5(
M!TAU3ARABO#;(R*_A9YDEB[8-U<JYK:#'*[))<V\RFK>J*=2K7Z^OIS[TZVJ
M9UM>3)=/62Y$B-6^U.^SM(6ZM8=<8@?MTY^45W-PG>:^S&X317$9>.V2L/3C
M$=RQB0:;'T55B',A1EF-2XSRLQ^LD-D5CBRXF.0TIGRPE/#H5]:>D""3<-J&
M%>O=#L[I5.;V^*/-;?VC-)DJ95<HSUA$60]4IGQU6M9"M7V%HJI4Z(RS'2\]
MRZVMMKSE+4RDA$]="C1RMFJ'-Z&CN!F+T9,ZUNYMA3,RIZ;FWBU;KB_9(V17
MS+81=V,6 &8CEF>6Y;C)>9 ;<0G2#?K\H6;VW."2,I:S4XO4/9&VXU)%RJ.D
M/-OQF&H[,WK2W[U@W&8991*<"I#;;;;0<Z4)Z4(7Z VIM'0$ELH0$@) 24<#
MH 3P $\>B> !\ -(1=T([^ZGWN"KW1[W!Y'/;OP>XY]#Z:0BO [=AV].WI^'
MRTA%I;;//+:#R$@\I2>0CGI![=PGD](^')XXY.D(KTI]WW4^[W3V'NGYI^7[
M-(1:6622HM-E2OM$H3RKNH]SQR>ZE'O\5*/Q.D(J6VR>2V@G@#DI23P M('I
MZ!+BT@>@"UCT4>4(KT(Y!Z4\I)*3TCD%1Y40>.Q4>Y(]3W.D(H&VQZ(0..GC
MA([=)*D_#]$J)3\B21W)TA%$LM)45I:;2L\<J2A(4>"X1RH#D\%UTCD]BXX?
M5:N4(X5U5&SKKF U(=@/6T&RA(EQ'5QY;#\RM1":G1Y#*FW&9D="1[/(0XEU
MGGW%#@Z0TMUQZ\H3V"X-2X%4RZJE?L'*N3/ES6X\Z2[),5Z;(7(?9B)<441X
MI<65!II*$>@(X2GA#KKKR$.".>!U>O YX].>._'[=(172$>7GBW\(.[F[V[\
MW>;:G,ZC!\\QS;_"Z7:K*7TJ5+QC+*S,;Z/D:Y ; >1&N<(S&[CLR6"'&EGH
MZNDG0=:6K\:_"L07ZWGR]_K2[;87X(=W=B<HQ/(MFF-O+V!ANZV;WM527]K;
M5+4K"\OV3P;;-P3C#;2TJRAY!C4BQG$A2Y]:&FUJ6WT(2B6.ZW3>ZV\-""M/
MHU]T':BMC0]S:9V17;25E=9T<*98TFW>:9>O>R?NKE6+Y?BZ&BFXVE]AFM5M
M(^TEN8Q9LL.F,VWR (_?K478^<1=VHPM;?ZCEQ(X3JWZ\/63;^YKX?I=IDMY
MA.(;</Y9E.5?D#D=QAF:C*++%AC%'!H[VDF19]55M,7MHU(?B3$2G(<=3;JC
MYI!=:'Z^HUMI$M8U;DW7+F[Q3)=B<XG>$W*-AL!_(W:BV;K;7%<)CXS(N7\?
MA89#R%3U)#F6#+L.?%MLKQIEDY')@I/5-G37%*<\Q14K;H\Z0O4CAY<J^>^D
M0%O?HV=X,DCU;,N?M_CF*Y!NKFU_F&U&&Y#F59CM'B]YC6'X]BC%=="7%F/W
M= G';N:VXVTI#&0Y>BY8XE1B^$0'\NOUTT\H>RS\$^Z5._&SK!'<%L]QHOBA
M7NDRYE-EEKD*3M;CV.6.'[;XB\\J4IYU-#$<8L+1ET>7/>;$MUH/'G3KX==&
M'+WDZ=?N*1$69X5MTZC=;:?9:97'<F4RWL-+R7<=ZKS]^!MU44^0YCEVZ\O'
ML@CV+5>6<VO)D1F4Q8H7)FT;,"+;B0(R$MK'C](AJ#7E:UN3/?U=HD#_ /H[
M]SKR$T[E]_26&11O[F!I[A5SDC,W'9]AOAD>XN]&001%LFXKUXFDLZ^JQZ>E
M*76*>,W4M.,P&T,!$A];[Z<R!?E\XY1\!&]TV)F;]S/PBPR.9C^XF-3[NBS'
M/L;R;=N3G.=0<OKLYS>TK+&._5JQ&E@LT&+4L:0Y&AQ;&RJHZ&(,Q]EQ45:]
MMW6_YTA=P_ MQ]8Z=#X -Y6MR-N).976U.2XWBN2;&Y#:9+2_E-CV4551ME@
M3D+),#P;&:\QZ.CK<NSEM[,VYL1<%Q+CWF2 9:EDFX4]QK5_@6^,-;UX-NT=
MN=15JTM[2L@I::!*"0V@$MH\M!(2 2AOJ7Y:"?LHZU] X3U*XY*)C)I"#2$&
MD(-(0:0B"7B-Q*^EY]CLF#?240\WET6&U;Q>D)7MQ;&]CJL,OQR)!/-C>VL>
M0Q&DS;/I->Q25T>,^F/714,MW/KA[_2'76ONB3^Y&,V>8X/>8C4Y+,QBVL8K
M3;-[7J6R]&]FEQ9+H<3%4'F8]FS$DQ)*HBFW&8\I[H3TJ*5-]-]^O7G:'FYU
M\^O47A'[1[<W&WD')DSK.(&KVZ3<T^.U"WY5+A[;=(W3(A4<R<P)]PW-5 1,
MD0YJPQ%DR''64AQ168#ZG]/TW?.$(G+MB,HO=PI.60<W,6+/NJFS1:2HSLV\
MQ"#CZ?*.)XQ":4*%['[Q+(7;-VL=Q]M[F0X'922LSU7Z0\_AIIU6)4AB+,C_
M )YB+(:E, .I4&Y3+[3S/EK2I:TE,AEQE9;*E I=9401TJ(TA%L2MKH#+4>#
M A0H[*7D,L1(K$=EI,A8<?2TTRVA#:7W ''@E(#BP%K"E#G2'RMPC=    '
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M;%8?%))E3$JT# .30L=0=UG%(=%LDMH)X)*$DE))3R4@GI)Y)'/H22>/77O
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MM/F)(6H=TD#E"+&9;1);2^E9:X\Q"7@MR&'6GG&U3U>U25)2\.%,*60  ..
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MW/P_Z1K+,>BKZQ9SO/K!]>W_ /\ 6*[_ /YM._\ SC3,>BKZP<[SZF#Z]O\
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M0EBD!:E$LIU)2$E6=2B3E\*P,,7*7C929.=2C+0F674I1*D@)+N0[#-F)<T
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MU6(>L5Q*PJ1_*/C2D!1310( >HK=W%3=N/G]3;>;E;C;LV&XT2^NJ_;FSOE
M6+DR;4JMZ!D.-(KX,:*\T\U6RD%#J4E*65)6E:D]1''\FX/LAVV[2]I<7VB1
MV@VC)V/)QCS, K$XH8>8\TJ4$R>\[D@@,X02;%TD"/G587'+FA29V(91?^T6
MGPDTH%/44+4#N*WF+7[3[;U]4NE8Q&CDQ/S/MJ[.,Q8R9RXJ0EOVN3*:>=L'
M4D'AZ4XZZXKEQ2NHDZ_HN7V/[+3Y6'F8S8.S<5B>[E*F3I\J6J:9I"5+6<R#
MD65NI031)M2/73@I!EH3-E)6H)3G[Q*5%2@&45YDDJ4]235WWPO84.)71F8=
M=&9@PF$A$:'%;0S'CM!(2EMIIM*$) 0 CW4CD <C7T.'PF&PDD8?"X>5A\.D
M )DRDI$L)  2" E(4P #D$FI)),;RI,F2 )4J7+8 >!"44']($;) 4VEI0Y:
M3P4MGNVDCT*4'W1Q\.!VUUYE90G,K*  $N<H H !8 "@%A&MK4BG Y)X'*D]
M)/'<I_5)]2G[CVT2M2/84I/])*?@1$DDW)/,O%A;20 1V2 E*>!PE*1PE*1Q
MPE*0 $@=@  .VM53LX'>([P@ .LYC9G\0-XMG+ %B PJYL&&ND"D(/J ?L^J
M>2>.PY^!].!R.WPUI]]69?<904FB4DNE.H9)H#:HH]=[0)@EU+#6]/(=:;H@
M[XG_ *13PI>$7.,-V[WTS&[K,KRV,Y8M0Z'&)UXBAQUUQIIF]O7G%J988>5-
MDJ:<B@/H$-OR^DMMA/V79GLKV@[082>,-ADRI7\SNIY(E9P/9:: 6*FY DNS
MJCGG;2E?V8\)LH@,7!()<,[TOO!:@AD]S_$-O_XK]N,XP#P:;0Y/CU-EV*6>
M/1O%#O%<(VCQ*N8L5.2A9[>T$QMW),F<O&BD8]?MJC.+KY,=P.H#A3KU-A=F
MMC=C-LRL5VGQYQ@1B%3)V#6L8T!967EJ0HJ2<JRZA[ *6S*0'5YTR9B)KIE+
M6'!\>92/#J1>K%Q0EJ-8"(OT?7@.^DAV3Q+<"+FWBE<V9C6N2PYE?CXI*'>[
MZX6RE3-C/FR,S9G.8=[9**I2DTI9-N^HN3U.*6HZ^J[>]L>R&(5A#L[9.'[N
M5X):Y"!A$KDY4I2\N4$H5F0G-<Y*A+%RJDM./0/[:<'MXU*L#6IH38N'UUCQ
MU^FRW(W@V&\3^!X%N+XO+O>K/1MM62ZFHK,99VPD8K]99 ^AD9%C&+.PL5:B
M7\<2_-FL1DSYU-&;:>+D?I2-]C]N>RFSMB]RC9<B5B9JYTP^$8F:5E"4IF*G
M3$J6@)8 (H$%*C+=U%5EHVA-*5&?.+)2/:4EFN&!\2G<NU:/N'T\_1P^!^O\
M(&U$BRR]JCL_$KO4U49%O9DF.-1V6:L&.W-I=K]NFV6FXT#:_;[&'HD#'&HZ
MFHWM$9$R/&:>6-?C.U=K3MI8J;B.]GF7,FS)J4*FK(R35J4GPE1% 0U/2ICT
MI" E""WC*1F4P<J*1F<@5>N8O4QZ>X,EM67XT VV&_;EI0V&TI0AMQ"W%-I;
MXZ4-J7[RFP.DJ[D$CG7BY$*5G,M&8K)?*'%":$A[UC8^+VJ\#7XO$QD?83_-
M3_ :VA%VD(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(PEX D=)[$C]VL22Y
MJ;G6$:;AYY([<J)_?R= 36IMOXB$<M2CR>Y]3\3\]8K)>YMOXF+$ES4W.L:3
MZE=)[G[7S/SUS35J#,I0H;$C17&"2YK6U_ZDQSGU*#*R%*!#JAR"0>.LCCD?
M#[M<IJQ-RY)U)<U,4.G/Y&,=0XX;B&"M9!6YR"HD'\POX$ZIA5*^^X<9E,<[
MARQ\"[B*OXAS/^40Y&OHHO!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#
M2$&D(-(0:0@TA#,[T8U$R; <H!BT;MYC4";EN)R[YOKJZ'-:*!82\4R*>IX%
MHQ*V:8\F7T]VHZ9(! *M(1'?P30,*DX%E.XF.UN)Q<RS^[@7NYSF&5SU94VF
M45U(S&<2Q62(\>+&6N6Y82)#U>@QW79,EUIPAXK4AU;KW7^,[$ A" 04D)2"
M"HK(/ [%9)*R/0J))4>Y)YTA%VD(-(1&;=__ !D8_P! :_B=0J\ODKXF(%SS
M^0AKQZ#\!_#6$3% !R>/CW/]?;^/_'IT8>2DDS"6"3;3>Y.[A:G-YX^G,-]8
MTI\Z'6M/RI\V-#A1FVBJ3)>3'90XZ!PA:E%*2$D\<\]N.3P!KR]L;:1@4&8I
M00A%'!*7"=:,[MQ)>Q<-!( )5^YOY\O-Q#&W<I[>&]?P^GG#^Y[CSL29FV2P
MED(OY[:D^1C546R \W$=0(\Q])4A:4J4KNHJ/YKC<9M'MIM"1A]G3"=GX50^
M\E"E92$$)5W@!91HWC!=52"PCRY<TJQ2D(4K*9AS!R ^8Z#<"=*ZT"8?EB(U
M7H;B1(S4*-%:]E9C,% :B,-CH3&:Z E/E-A(2 @!"N >._.OTS ;/_AR9,C#
MI'W4HE":920F6%!*02PIX2XJ'#/'L]XE('A31M - *%O+EJX$9_W?/\ WZ[Y
MBB)DS(M13G6RLQ\0S%B3JXKYQF59B5?F.;UK%2>>Y[D]R3\=91$&D(-(15#?
M6 V XLK>,=QMI: XE+C:I@F>T/* 89CM'\_TD!"$E)]T:ZL-AA.6$L[^(T&K
M, 6)JQ#"ZG%#2)6,@!-BG-^GEO,1#WG\:>S>U52RQCM]"WGW4O+E>&X-LUM/
M;4V19IF^:R2I+-,IAAN1%QN) 6#/L+B:6HL2H;="W3+2$J^MPG9=2RF:4=VA
M*!,7,G@"6$Y7) 4?9;,[@90');*#Y6(G&OB-U )222:T:K?E-!H=8A+=_17U
M/BVR6LW]\<]Y/O-X)\RK?3MQM=:/5FV6WV'5SYM:';:1=LK:DV\=+3J49%G2
M0;=^T;D1/.6Q(4%?03/M#QO9_9XV'L?#-]USB;."5I[U4PA.=B0<@*7EI/L
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MOB8@7//Y"&O'H/P'\-81,4)XY'IR"?V]_P"/KKH<(0N66!G8*8H-O[QPJWM
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M^T;N: >X#X?6$[]9ICL24MH6IQ;P06^24);*N.L#N$]0[G@=^>>-9&:P I0
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MH#OQWX_#U[\<GT_ ZXIJZEM2:<+V!O\ "FL7L  QU\^?52]:0C9LP-J<4M7
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MMOCJFQ'EH05*)0E"203WZ0!Z_+M\/7Y?/I&*2D!R"R0FQW,^YG>G*L:F8D
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MP#-PRB<JB=V<#,D4%0;^AY]H2E8R0)*%*2<F4$$@'*SI.6P.\N7 W&(0[,^
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M,FJF1\:WHS#%SMW>_5S3;+^.VSV![;X[DT(26DJ6P^U<S:V4[Q)L3.0I3J_
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M;VJ: >0HX-*"M+$QG&VN,K2A)DV2G@XA@.)LH9:,WI\Y$9UMDA96[&4%E "
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M5P\X#RH]N%*' _VZ_K[#.A4\KFK4#,64I6HJ"05$A* 20 D4 #48,&C[,U
M %J[Z#@^OSBWSNH](ZN.W*@KT^\>G;\3Z?NUB-HJ5B#)1AUJ2%%)6U&!9]17
M0CAQB0FCWX:6U?R-Q[JW%U([>TK'';@%)].WKQKI5+E.I1QBD9B24&9)&0J+
MY,JI:B,KY:DD,Q+QF5W9!W6?XEO-HM,IL?\ :@\?$GN?O/ ///K\1I]ZPLOP
M]^E1%"76IVUHDIJWX0$[FB')T/N'N>+DNGU2H+ZNX'4.>..?C_5Z??Q\+RIT
MAB58F6K,2H S4ND*J$L4@AG 8AQSBX +:>3GW=7T%,X*B$GS"D\#E/(XYX]#
M^'W?MY&LYDLE06G%K2FX"64E0-O98$6JUK,[P<!PVOSUU]&XO&7E7')5R/4=
M^_'W\?O[@'X?+70$DI'C472"#4.X!=J7NU(S"B[-OK7?%GF'E1)[#[S]_I\.
M_P#QZ:J5=W[1>S$GW_6-DLPH]W<"C-KN$8R5$D^]W[_'5A,! -:A]/K%2FIJ
MGUBWJ_SOZ]3G''W?6*Q>%+^!7Q\."=,XX^[ZQ;+Q3ZP<N?-?[U:9QQ]WUAE_
MO)]8P%QSD^^OU/Z2OG^.N=4U3EC1RU]_.*Q3S'/\HO\ I*_MU'>KW_'ZPC,'
MR  5=^!Z]6MQ-2P<U8/:[5UBN7BKUBOGG];_ %M3WJ-_P^L,O]Y7K!RH]_>[
M]_C\=3W@X^[ZQH$T'B3YFOG!YH'8^H['U]1^S4=ZG?\ #ZQ.0[QUY17SQ\S^
M\_V:=ZC?\/K#(>'O^D9@5$ CJX(!^/Q[ZN% U<>HBAI2#@_(_N.CC>/40C">
MKD_:]3\]5SCC[OK%LO%/K&,NGD<E7*#RGO\ 9(Z@"GOV("E $<$!2OF=<ZIJ
MG+&CEK[^<5C6"P@*0CE""1RE/"4GI;2RGE(('NM(0TGMV;2E ]U( CO5[_C]
M80W6[DN' VSS.=*BY%-99I52'8N(M"1?/I1+0EKV **5]3,P)>LG00[#A(=$
M50"4D@LH6)X)3- 83$OWB4Z,H$* !XTH PB:-3@?-V)-.-@;/K=A?"E)FO-[
MDLY%+CR\C1.QY^TDXT_.FX59M6J,CRR-)HI=I_?4S*$&TLZC+E24A+:Z>IBM
M.+CU\-#6DV<K$A/>J5,"$I"<Y*V"11*<Q+!(#!+ "C6, 2-23^U*N?>=T<#<
M'%:;^Z7D66-8=O9=Y$WG>$'Z\Q:R@1<4CMO/;?0VF(R7\@ARGX$!5%,B2&Q$
M4A$#(,J9" U<V:)4KF)EH2P2#E2#E  LSE@Y)-M2U32L D%P2]P4T(;]+VWP
M^N^L=^=AT'ZL<RQF\&51(..R,+DPJRP>LKBLL:CIERYY=BIJD,V+SCJ@0T;*
MMB2>LNQV5HI)6DJS,,Q+!8 <&FHL#;PTH]@3%E%2@SF[7)\A6M:W(K2YCB;"
M/44>/G%+C]-EN.1J&\K84BCR=H1I,&_>J@W?MQWWBY42O;)PD39TVK9;A6<M
M2YZ H/!9@J"5+;PNLYLK *45%R:"Y)/B%;TBN4'\-V-DN^MKE_-M\--!J=NX
M.X-6U3[CY9E^3QL^<KJF1;V)AP<88C>US\GPO$KR/C-/A^11YS72JWQB=)LI
ML>0R2[.FRFO:U\"L@7F266E1*5!@I*G<Y5&UW:CL]7)B,J2:@.*.U&TT]=:^
MLE\OQF#EHKH<VZR&BB0K1FS_ /HW?VN/R;..W'4U[%)LJ27'DOP''2EQ3#CR
MVW.RE=2N5B5X@K&5<Q:P&HM:E @ @7)#;GI5C=XH0,UPFKT<."Q9W&N\ES&+
M",9BX+1F@@V-[8QGK2]N7)N16TK)+!$BRG2KB5$=L[1^3-EP8"9HB59DNGRH
M;$=ML)"0!GGHS>$Z$!AEN*N" 'YBS 4D'*&=3G,:U;4A^18:'E#84^R5?2W^
M-Y!69IEL5Z!E<[(\MCKF2957FTR<AU<!5ZEUYQ5385[;B6F[2$E,BR(YFNK\
MXC5DK "641E:U PJ!0TIP+BK#6X*0 Y)H _E<DAP26-]=SOU-X=M7]SZF$FO
MS;+,'MJU+RX\C'+K(X578H6^1)C751C5E7-/NM +;BNO!:V#V;/3H9E2Q;D7
M>INP+&NYJ;KB4L/@U=YL]CPIJ8<*FID4N(UV)>V391@8W^3B[2?(FRYDY/L*
M("Y<MRQ?D6#SRNA3RS-D/R5.%7GN..E2C(F@  J8U&HT8[N8&G.D9G^I0W/:
MNG!N+,[\2P>S7AIJ]ILTF95%R!RRD.UDZF;C.4\&*TARPBXU%]F3+:BAZ13"
MLHH%HIA:ULO91=91<N!5E;63SUDS+%Z/1V]:_AJP)&H>( 53QN?-GH=S,QOY
M;XYGB1K;6YM4C'JS<&R4WBAN[V-38] MJ*?65LBZA,L,/6F88Z$9BIBPG3J^
M97-7-LR[78Z]'JD.P(+;5S/12@<AW:I/F"Y%WJ'8-0Q?, U+C<"_&O#5GM:'
MJRNP0=G;#VR/DA+^$5(7&#\Q&2RENQ(Z17/J4U#F1+,]9CW+RX\1YR0'_:66
MU^8TD9R2"X27J+&HT%*%M#N(N\25  >5'W\/>?0W$,+X>S81,RG)GXYGV%4C
M>)-1<;Q?)KEBPQR,(,RB@SY]5*4[*>A2)DEYAVGKU!EN/4&7&80W'4Z@\)4D
MS%G*EB5$DL-6N4^8IOK6 F(>Q!9P[ .#>AY%O*$/OD\W#W:HIC5_N)72:RUJ
M[.^P_P#*S)X6-9+C]0X+!*L/C4TINJ_+2]F2RA>/J914V%$VENP:*FT-I@E%
M\J0?Z0U+-07:C!@X:D0J8D*J"S\*B[N=&J&X!ZDQ)O> PY>!Y%&D/90Q 6BE
MKW9N'6MA3913IGW58)-O!M:]^//*:^&Y"=E>2\%F*JS:62V^^E:8J6Q\"':A
M8#<02P>E+-?G&<P@NP+:59G-2*UIEII4F\,;X2K-;V%Y0T_:7U]._+>1>FYL
M[.TM6IM?DSCEKC\-OZX>?5!^JJN4Q'R*OA=$9FV;D)4CD#7&J<@ L!=O9?0G
MT&H!NSFD40HL:DD%-U%G.9G+FE5 [Z-J8E7[6GX+*A\%=2E]0^"NLJ)5R._4
M22KU/<ZQ.(ZS*_TQ;O2*926U8_6*^V']97_^W]NJ_>3^9/\ B5](=Z?RGT/U
MC55*]Y7O_I'_ +3CX_+GMJAG/5S7=G_TQB5.2?%4G\3>YHIY[AX(6?N]Y1[?
M#@\ZCOS^:W]X_.HAG-M//WUK 'E\*]Y1)/KU$\=^_P >W&I5,40#F59_:.[H
MZ.&NXB4J+*J1Q=OGP\-_2.>_,0CR_,=4CS/-0D]1Y)'("CW'Q[@GT]/7OKG4
MN]3<DU^;W O[]1 :$DEPJMR.J^L<M4YP,H\N;TO(X:"EI*E.)3[HZU$DJY Z
MN3R#R2>YUF9@#6<4/H'+<0+UNSZQ0%0KF.FOGI\XT)<^6(SJF%2'7D%2W2PI
M+ 4._4D*2H$MDGW>>>4@GCUUS+FD L31V#LWO'6HB74;/R'O]]?ANC00A=E5
M-JZ7F5\)6EHOJ'2>$GI]U73[OV>P'V?AR-<<Q)6"02"JM#O^=7YDWB;IY:/O
MI;>=3Q-S0<@.NK\^L<9=3(;25EYXMJ:+2>1PVI9XZN!SSR%'JY]!SKAF!0=+
MJ!8N="'^7KYQF"'REWU)JXM^_P!1#<3X7#TAWVEIMD.NI0E:E@I(6H!2N"$A
MT<<J4 #SSP>.=?.8B4L+F$+*?$JRB_M$UKQ;C1J,W(I+%1S);,JA=[D %@:^
M;:VCE2(4IV.R4S67&@MT.CJ>+C@2H\=^23Z=N_VOPUY4[#XF992B,Q_$2^ZY
M#7\W&K"(8 !6=+.014$ZE];:U:G.$])KFCY17)EPP$I<4A_H2A]'"2.GH)=6
MVKX%P=13QU J[ZXSA)CL5*#49W"M'9P=-:VU$4+4+J#L1F8 B]#<N&8JJQ<W
MC50&I3A17-S(2@I33TA#8:*/(44MN1U^ZM#3_2%(X/O)4">_;5?NRE$A.87J
MY%C0AC1QYL8@*!+H!27J0PH &8@!G(L-QXPJZ"K7,9EOV$65*9AME:GW&)0E
MB2C@N D/A3[(<!4"$]*@>I(([:]+9TY4OOQ,!5W<LU8DA20H$AR7YBATM'2B
M7G0ZDDA*?$K*226KJ')J]2/,N4),SY5;>5<5;:9G3*=>89,!A#D1MA?NJ<#J
M5+:0D  I4KJ3TD$DCOX*NTR9.T$HGG,E$Q0 6Y]DD/5Z!ANI46CC5-[M02 "
M024^!((8E^-=.0H[1M[K>)A-U0PJFE BW,>4VTW):;Y98:AE+4V4\IOCI;D!
M"U,D'A25H*==/:W[1!-PN#P^ G)E+2)4H]RONRR4Y5Y@@@&M6+M5R]HQ6V92
MY.4 =\"&4*L115*Y23PI>M(3\K,HV44M=-0Q($1]+:G)4M+?ES7VD)*GDI=)
MY#BPIQLGDA*N>W.N+%[5DXW8B)BO[5DYYA]HJ"1F(40]W)<[HYDX@SRE24J"
M%7*ZYU)H5:CB!QKJ(CCF>4/_ %A++BGD,A^06$\-/LK075]"D-\E Y'21V'N
MGC[M?C^U]JS994TU:0"JA4HC*"6H;^A\@"H<&+GGO57 "CH"+FH#$5O06< U
M:%5X5KYR9XC]LF2YREZTN>4@=/\ ^S5ZO@H!Z4]QR4 < C@=@->S]C^UAB?M
M/[+R,ZE9\1CV=1/L[)V@IFL/9LP MI$;+F9MJX4$U4J81?\ X*S8. 2&I1H]
MJGY ;DR.KL Z\?C[W"U\'CX_>?C\-?W2E:I<V<9A.0SIF70,5J:O7+6/T-5$
MC*0^0&_ @NW%FX^D>4OTNV]F_>T/AQQ.VV3M\VPFDOMV\,Q/>G=+;3$)^:9U
MMKM99/N.7.38S50WG)%7.93Y<9W('&EQ(@//E!!0@?I/V?838VTMH+3C)<F<
M1)5]WD+6B5+G8@@.F84B<5.:$F62"<Q02 !Y6*GS988%0&9BH%5-0P<;SJ,S
M,#0@>6&>>*"-B'T??BOS'PU?2@;^>(*]QFRVI><O,\G5]?NQL'5SLBC1KR;/
MOT8PS8R6K5YV3!<CQ_-B*2Q[.@O,H2#]VGL_/&W,'A\;V4V7AT+3/" F:DX7
M$%$O,2H4#H0@S_YTI*LH5[/C$<OW@E"U(FJ75! ).<9B6<"[DA)"2237=#4I
M\7V[>"Y=/Q'PO^/S>KQFXME'A.WXS#>N9EK_ -?S_#]E>,;?)NL7N\?S2I@U
M!HK!5^N1'B<+:G1Q&0A:@[RG7U4CLWLJ>B4K:W939&R#(VY@9.#5(Q"#_$Y*
ML4B4J7-DISA4N:@E"Y(8#^U2[%B<0H/W:S-:4M2\Q<)4E#I((L%*!2'!<Z5!
MAU?H[M\\?WGF["2KSZ5+QC9EX@L@QNVR"X\/EO836MNKO(L?I[*_G8C)L9N+
M2WG(0;@27DRTV[H<B1TPA(=01U>3VMP$G9^(Q*978WL_A< HRI.'Q4LR530A
M:4A4_NT(EE*Y;DESF4Q6RJ!5Y6(*@@JFKSD J0^5(4 ^5^-J!A8[Q#':3QQ;
MYN[/;9[C8-](UXAMU_''<;WS,2_YFD^'9YSA65TKVY5A6LUGU4YCZ+"KB/[=
MQFLBDW,R;*.,R%JAN%MQHH/MX_LYA1)Q8Q'8K8F&V.-FHF)VU)5*3,ESTRDJ
MF524J2RRP4H(.1IBBH%E6^\,E)3,F+F$AY1.:^F1LVK9G9QQ$>M&^GC W/S_
M #3(;S(-SLZV(VXQ#(F\$Q["MOLHE8OD%QE,>MCNY2_E.00TQ)=A[):,RG::
MHC^QN0((\BPCN@.MJ_/L%V1D(PZ'$N>M:$K!RH6 E39 GVPP20,R'2L@JH\7
M3.43F\27:CZLZJN->+V:/5+PR;Y6V:R<>Q6URIS/H^5[7O[GX%EDF#6U]Q9X
MQ2WU-A=TW=LU,:)5S$KN;6OFT62-1VG+R")<YM"42B-?GW:#9OW*9/2E("I<
MZ9*4D.0E3"8$I- V1:20 R7(S$".^4MV!L4NX.^E16C@ZV:EP)EB5R 0X5@C
MD*'4@*'P4$\>Z#Z]/PYX^&OFDS&2EU$>$4J&IN%!$J22HG,:D_'G%//3_P <
M_P!FI[P?F/OB,I_,??\ 6+O:>.W+G[#V_9W'\-4*RY\:_?\ ZHN(/:?O<_?_
M /W:C,?SK]_^J$8#(3R?>5ZGY_/\=5[TCCQ)#GGXHME/05](IYZ?UE?UZ=\=
MP]1_JAE/05](QE_N>W]7^_5Q-5O^/UBL9@Z.![H]!\/]^I[[?G?@#$9'KF/^
M(1E$G@ <K' XX![#\/>]-5SDUSKKS_U1-J17VA/ZH/WD'D_CV]?GJV;^]ZI+
M^=8N/ZR.#&#VA/ZJ?W'^S3,/S#_"?K"GYSZ&+Q,4.P) '8 %7;4]X?S^Y7UB
M&3^;W&,HD@@$N'D@?I_VJU/>'>?4?-3Q.8"F4'COXVC$99Y/?GN>_*N^H[P_
MG]Q^1:(9)KF;@QIPC07(Y6H]:NZE?I?>?OUSJF*<^(7/YM\,J-S\?#\Z^L:[
MDGCL%'GGYG^O@_\ 'KH)AU4?)V^O5!>(( H/D3[J<K\82&>3\LB89E$K!F:Z
M=EK-0N311[EZ1'K)-DR$M*5-+:N"B!7)<,.$?[ULY:$>V(*G%*U;O=')H+V+
M<S^'2@?7<9RG**EF_6M]W!W<VHS'AMOL@REK.[R:U)E4GUKC--5V5U5U^&7,
MNQJ8#\B^CW.+4<5JJJ(45VX0U6S(;9>MF$-&:IPJ))"BQ-AX;>$ M2Q%&JX8
M/Q<0;STW.7U\WUN&TKR,]NM])>XC=9"K94G#QEN!S:4ML08%#98@P7D90YDF
M4-);OJ#*8MJXVY65M:I$>4ZJE@NI]BM+H:SQ,U645)!;E2E;:D&X9Z*8L,3G
M!+.P(%F-QJ+/8UI44)$.CN3,SN+BDIO:]BJEY*7X22R^E+\CZE8?<?F.5$&2
M#"L9S8=?=KX$T>S)D/$!*"XKG+#3W.4*4:M0GF&>X?3?:E8DDFQ<\'-*<P:E
M[EGWNVML\<Z-;D=KFM=:Q9-GE#=C42+EV+6918X]%:5$@2,KI8'%9B\MF'Y
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M_/\ '5>_ HYI2Y^D4*PYJ!PRGZP>U'_*.?O5_;J/O*?S?]Q^D,Z=_N,91-X
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M2)(&K\P#%O\ <PB_^6)7_J[?_P 34?[-2_\ G)O_ ):?]<3W0X>@@_N81?\
MRO*_]7;_ /B:?[-2_P#G)O\ Y:?]<5[@?F/H($[81T\\74SO_P#8-CC_ /%U
M8=G$#_YR<>&0?ZXGN$[VY !^)WQM(V[90 /K>0H  >]&0?3Y_GO]FKCL^@?_
M #<[_"/]45^[IW^X1?\ W/6/_*C_ /ZNC_XVK_P&7_S4W_"GZP^[HW^X1C.W
M,<DGZWE=SSV81\?_ $NG\!E_\S-_PI^L1]V&\?X1]8Q';5GD_P"&YP^X-)X'
MW#\[\-4/9]'_ #D[_"/]47$EOQJ\HR#;B/P/\+RC]Y81R?O/YWXZ?[/H_P"<
MG?X1_JB.X'YC%#MM&/K:R3^,=L__ -34?[.R_P#FINOX$ZW_ !:ZP[@?F/H(
MP':^&HDFVD_^K-=ON'YSY=OPT_V=E_\ -S?\"?\ 5#N!^8^@@_N81?\ RQ*_
M]7;_ /B:H>S4LDG[Y-K_ .&G_7#N!^8^@BY.V;"3_P!<RN!\#';XX_\ ON.W
MX:C_ &9E_P#.3?\ RT_ZXGN1O]PZZY11>V$51Y^MGQ\3Q$:[D_,^;S^\Z?[,
MR_\ G)O_ ):?]<3W7]XCD&C YM5$<'!N90'''NQFD^OQY\WG_9]WKJ#V8E&^
M,F_^6GT]K]=7>'=?WCU3K75XP+VCB*' O)B?=Z>T9K[^Y_.CE7W_ -6LU]E9
M2QE^^S10AQ+2]0U\T1W(U42Q>H?RY1KG9R(?6_FG\8K7_P ;6'^QLAW^_P"(
M/.6@W_ZHCN!^8QIO;(PGB3^4,U )YX$)GU[_ /VX^>L5]B)"_P#ZCB$AR?#*
M0+M_?X?&,U80*=UFO =>=XTE[!5RR2<DL 2>3Q"8[_\ XW]NN9?V?X=8;^*8
MH7J)4MZ_]?1B@P27),Q2GL" 0.5=8YKGARKW%J5^5ULD*43TB&QTCGT _OCM
MQ^'[M<ROLVPRE/\ Q?&Z4[J6Q8O7QU?IXC[@*_S55)/LBC[JQ9_S;JSN?RKL
M^Y)_Z#'[<_\ I_35A]F^#UVIBCP,F4WGXHK_  \?\9?H/K%%^&VL6GI_*NS'
MS(@1^_X_WQJ3]G&$(8;3Q(Y2)7^J)^X#_C3&TZ?Z1K.>&6K601EMFCCX)KHW
M?[S_ 'QWUR+^R["++_QC%BKMW$L[_P#Q!O@<"#_OE<@ WQZ%-[U3X9Z]'V<Q
MM/P^KHI']<C4I^S##)_^M8QK =Q+##=_::<H?<!_QE>:4GWQL)\-]>/7++%7
MXUL7_P"/_P ?'G6B?LTPP?\ ^^,83QDRR/0K,/N (_M3Y);_ -46GPW0/T<M
MG)^\5,+J^/J?/[_MU"OLSPZO_K.+'$2)0/J%@^^'W ?\4\\@^I$7(\-\%''.
M8VZN/A[&P$_'MQ[3P!W[ =AP /35I?V:X5!<[7QB_P"J3+_UF).!_P#&6.0X
M-OMPC,?#E4J*5*R6>HI*CRJOC$GJ^9+Y]/AK17V;8)1?^)8@'A(E?ZO2L/N(
M_P"*KC2_.NFFZ+/^;C7?#*[$?_X]C_\ .=8G[,<&7_\ O7%>4B4_KG^D0-G@
M?[U1YC]8QJ\-M8H$?E58@G](5T?G]_M.J_\ V88/_P#JV+?_ / E?#/\[>L/
MX>G_ (G_ &#Z_&-57ACK%#@YA:<<\_\ 5\?U^?\ TG53]E^$-ML8L?\ ]O*O
M_P"9[HK_  Y/_%5_A'UC KPNUJE*)S.VX4$@)^KHO">..XYDD$GCN2.?O[:R
M/V584DG^.8WE]WE,.3S.O2'\.%?YZF9F*00&\_VHS:X5>%:H423F5MU$D@_5
M\7MR>>!_?';CT]?35#]DV#4[[:QM7_\ EY5'W?S#%?X8D_[Z9Z#TOI'+D>$*
MDD!07FMN2I15U&KB*()))]9/<=_GKD5]CF 4Y_CF.!))?[M)U_\ S-(J=DH-
MY\W707-2>N$<\>#.C!)&=W0)' XJX?N]N 4_WUVXUBK[%L"K_P"OX[__ %9/
M'_Q>,!LF4'_FK.M4II:VZS<HYR_!%0+4I2L_O"5**B34PB2I1Y)),ODDGN2>
MY.N5?V%[.63F[0[0())8X600'-@#,C+^"2_^8FUOX4UBYGP1X\P>IO/+I)^/
M^"((YY]?22/7]_W]@=0C["MERZHV]C@3?_W3#U/E,'SXO ;%EI+C$3/\*?K'
M6C^#VJC@A&?7/!__ '3# X]../:SKIE?8I@)2BH;?QY>K?=I*6/E,][.=8U_
MA2&8SYGH.NO..A_S3*[R%,?EY<<J*?S@JH84$IXX0/[YXZ>.W'RUV'[(<-E*
M1VAV@-Q^[2"0 U'SO[Q%ALM _P!],JSEA5O..>]X/*I[KYS^['6LJ/%5$/J>
M>!S+X_J]/0#7&K[%<$LE1[0[0S&I/W:34FY($T#T:!V8G_CS =[#Z]<HY_\
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D')#&BC&F$V%+PF)E8E.)FK,I2R$%*0E6="D,2*L IPVX1__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g521849g25i47.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g521849g25i47.jpg
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MF3!!XIFM>V2]\,<,<=)<XYB]W/)<W&(W;S2D%V65HE)"A1E'%HC0!5 "HB@
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M,,(O,26:1VMKJ=(T$#B.:RMKB&TEN]39&-N/G4+"W;Z(IV8 1DU*+L<?'#I
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MOQ,JZ4<M#N/*VTWNO86:F[??$_U0Q #)@; @97%-1P9SLW8\Y#I3V-1.8@B
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MH)H3!+.;EXY(9HY(YE-P3,!,KZ'[9-.0RHUO&Y):,YLP<L"ZL&"Z RLI#*=
MTG21F-QSS-1HWT:.F3X:'Q][Q]3:AX-&24*!L0!^319-U#31!0P;B,K4C$H$
M+3V,'#*[HT; 3I21BC!I^2+DFCHB3(.7,L>/XK$\TB7K%[B59Y&D2"73/&NB
M.:$2QN+:6- $22W$3I&J(I"HH%IM(2%7BL@BE %UKFI.95M)&M2=Y#Z@222,
MR29-AP#@"4=6BB&DU&P%><1K9.;-J</M5,9Q#X7'M=QN1(/V\C3(MGHJ&14
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M9G%>0C_2-YR,<V'\]R,=Y'=.\U;U):>"V_='\S'W>7^CW>[61$\7>-0$L./
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M.1/:(,RS#/( G*O+).DY:PV8;5B$MAW)^/Y:=;QMQ+CSD1''X-6T_-&8UJE
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M-%'>2K!#;SRW3S2/=QPMB&75#E];LT>(/"S%B0D,6DJ1G5&L(B"%+1J69E5
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M07)_BQQ)V**X_H;?F,"D&'( :TQG,4#J[O,:6DNVH%!=6O'9N<OPD+C60R,
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MZ5U,X&AX7&=;B1Z^NH@JR%Z[A9@?(8= AS7,/D@RAD3/B11R-1=LFF$!&!K
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MB>^O'GMYPZ2+<- V=NL4,=_7*[S8ZT!=BSD0Q N269@Y"=LK%W)!SSU$>MR
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MTFZQ/$[HJR6>'6:,'N+AP>5(84FN9H();XXWE=8XU+NYTJJ\I/VWDG<!F20
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MVXP:RNIFGE$ID?3J*R:1VJA1NRY@*CW5>:1])6]_I-!/=M7.?<0X%?:NV?\
ME;;7ZU5!V/8=^#-\:?-3JO-(^DK>_P!)H)[MJ?<0X%?:NV?^5MM?K53L>P[\
M&;XT^:G5>:1])6]_I-!/=M3[B' K[5VS_P K;:_6JG8]AWX,WQI\U.J\TCZ2
MM[_2:">[:GW$.!7VKMG_ )6VU^M5.Q[#OP9OC3YJ=5YI'TE;W^DT$]VU/N(<
M"OM7;/\ RMMK]:J=CV'?@S?&GS4ZKS2/I*WO])H)[MJ?<0X%?:NV?^5MM?K5
M3L>P[\&;XT^:OQET76C\[7QSV3OB^&5KXY6QE4(2O?&]NQE:RJ&N4ED[WMV;
M641435PO_A)YX9VME:Y.!/@7C=)%X+MG=4;*ZZ\2VPF34I##7%-M/)#*N8[:
M.6-XW&:NC*2"['L._!F^-/FJR\7XKZLA8 7%XNF<# 0S:S0<.:/!_<T4^WR5
M44445%*+NG;I=15V^?.E5WK]ZNX>O7"[MPLMGZB\S.0=,:!4CBCCBC2&&&&&
M-8H+>""()#;V]O"B0V]O"B0V\$<<,*)$BJ-ND,<:*B#0B *JKD  />Z3RD[S
MF36>^#]"_P!H27Y:-_)ZMUGQ>7SU=H'C\GFI\'Z%_M"2_+1OY/36?%Y?/30/
M'Y/-3X/T+_:$E^6C?R>FL^+R^>F@>/R>:GP?H7^T)+\M&_D]-9\7E\]- \?D
M\U/@_0O]H27Y:-_)Z:SXO+YZ:!X_)YJ?!^A?[0DORT;^3TUGQ>7STT#Q^3S4
M^#]"_P!H27Y:-_)Z:SXO+YZ:!X_)YJE</U='H237*B71==PX8JC\\'[AFLC9
M!5PU<Y98XMV#7.RME&B=L<KJ7QMA?.U\+WOCEC0L3N.55"@;QG6R*MJZE*5R
MC9Q/AF5);)=SZ;S%S*3&QMI1!NI*@KL;F.(.N6$ZF 2(P@$WCI(5)';7>.$I
M7@(H\UDLFV(T'F%\@)G7Z*848JO^')[W1S<W-4,VS$^$T&QG>E9B)V6H$U8\
MU._O&6,QUI$P0\R?<:FUB%?Q]$K+88Z$#C[[:\'R/2.7)!-<W(#Y SB9EJZC
MQX)95=_+N]WW-^_//DR]W++/E&?SO,.&FR9I)DH\QW>QE)G7!AD6;0V2PUJ7
M-1/;&<)Y$EAUQ#28/91#0@LUN2&2QSM@H/A>M0*HM-DYVCG#[$6Y]5#GEO\
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MT7R)X][BC^I];_!A%AWFRB,2D)"#-(MIPE"8G-#>N)E+#<C-C,3Z) ;X$80
M\$$GB\1'2:<L%@IJ$"CL1<D3 E3?RY\G-G[GVYN0Y'=6-RY:Z"E0L4!E7&MI
M)MDQI]M2.QK6"0;3QM:/A1WD[N\6'OC\A9M0<?ET6V9$LBZ[-LBD1<A9<)L/
M(*B!+8RI[GB\_P"_]U>36O-;C\PCD' .N-9+7B6P9R(PC\?AL6UH9AJV-]S[
M!B\2FF3V/%F3'OP9,==/Y'DCD,3D21C.QF(,S^+=4HFJN1WG//ES._W^7?\
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MO#FQ8A6CWD2@GUA WDD^MRW@Y$;ZZV1$R2D,6CIXQ'G\2+& PXD2C!19NX(
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MPEG)EQ:@.; 6S!3+>,CS>6H"ZYL;.>PPJ=;<578I+)C*1PUS))')'85E(XH
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M)W=W?7HQ,%\&R3/ H1P9H/;$D6N+YSBV1(V_19^DA96R2;VUK?H=88V7M_\
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MO77%#"+8XE?FW6(PK;]67'$K"5E0Q"+C- B*3SJ8PN@K-*N64C@TUOD%UMI
MR U'(#?N SRR[9MW_B/.:P]8%6TI2E*4I2E*4I2E*4I2E*5XW[]H,:+/GRUD
M&R%L>WS[7-3/+-3/%)%%%%+%1=RZ<KJ)MVC1NFJY=N54FS9)5=5-/+:X'@>+
M[2XOA^ X#A]SBN,8K<I:6%A:)QD]Q/)F0J@D*B(H:6::5D@MX$DGGDCAC=UJ
M 6(50220  ,R2=P  WDD[@!RU<+0&@':#L=L_9XZZ!Q"]GD'A#RV"F$-P4PO
MBF?/IXY*(.9RY04RLBC;)5M$6RN;-GFJ75?/J_4K@<X&\(X(\(9G>VQ7;?%+
M818_C\0XR"S@DTM)L_L_(RADPU& &(8@ DV-3H"1'A\5O W985A(M@MQ< -<
M$9JNXB$'R&3+E;D7UJ]UC=*O8:WM*4I2E*4I2E*4K>O'S^>9/^C#W_>H6K'Y
M/?\ X&KTY?>_B*N'452TI2N=DPY!<S!$R.!(AQO&3 .-G$['BR"S"9QU@?CX
M8X'8PT&SD3ZZZ#202",.3<T(; )@V>JVK@4S@0TH2.%+DV*JY#+EWY?Q^WC[
MNX4C&_.63%K.Y7L?40ME$0?'>=; "$QX64AV+[9T%DNP/!<8=1J1I,YQ%T)C
M!QT8/*IFLC-D723@:U7%KO!JAY3(9\O=\7)SYYY5\FN\N6CR7QX2(T:)Q;RG
MP0&([ *:OV"!:(-76VBT>9SA^+=2?OMB# :U0>R9[KN4'0DIP)O&;IN9;C3B
M39)3(<_-^[,^8?NK!WWGSV!P^'N7&CXI+CQ9H"8FU[1"<QZP,P/U?$ST@<F!
M(R02D@JVF>TS937 1R+'HBX&W"O)N;<26.).L6*F[Q^?EY\O\?%6>DN[N9L3
M%R^5K:CBQ$5'@$EE60EZ/?B45F[1:&,@(%B>4E"2(90<R.R24RX^<P,M7Z$.
M),AC"--GR3P8IN\GEW^+W.[NS[M>I[RCW<ZTS"=J0?7PF=M"CS<N9@HRADW$
M"BP37FW$89%2[,.\-KF-?L9AK%"4[@3(RMV;9=I$$X&SR6/S6-N\5,AGER<@
M]SG\6[WOWU&1?*+E.4.9!6>HF;Q)J+@I<H4MJ3:C!4=#9E,9X(*[0O'W<ER(
MNLX2(B@RZ6C&SC/9FP\2V<ICI(6&1L,I5<AEGGW>?FRW<G+X^2OOY9>84;>)
MS)]Q]#X-I?#I"1*0>+0&1$I,UV&&UKBI%+2:9B)"_2+8E9VVC6NTLG 0:U'1
MAXH97,("(L7*#E6_;]_)]N6O3+]K<Y<'T;\$ZR8LF*[+;A$UX"B3E_;%NWU-
M@5U;&LK$S1A=I+%]GJI!<Y9C92,9MK.4RL+NUPN0;*;OM_V^WDJ9::WCRNE<
MTU\(VGHX;"X[)24J:R5T) SIPZC2;"#-I QP)EC>8V/BVH.8X$M?.CJ:QU#8
M[S()(X *3CCTP^CZJ[M_O<WO\_\ AW=_+?"E4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E5MY"<78'R1RAZLQ.S2/NH3XP8"'D-?@6:RJ$F\"7*-GR<
M@C<E:K)9*1X8JADBV;N$<TE+66NFLIA?3[0[-[,[7X.VS^UV 6>T6#G$K+%T
MLKN\QJP$6)8?;8C9VMTEQ@6*X1=DI;8M?Q&&2>2W<3!VA,D<3IA7MA!?K&L^
MO*-BRZ&T[V&1SW'/=5;^K#TQZ3=Y?/.L_=57!?<&X#O:MP;\Y>$;Z[5K^QW#
MOZ_XT?,IU8>F/2;O+YYUG[JJ?<&X#O:MP;\Y>$;Z[4['<._K_C1\RG5AZ8])
MN\OGG6?NJI]P;@.]JW!OSEX1OKM3L=P[^O\ C1\RG5AZ8])N\OGG6?NJI]P;
M@.]JW!OSEX1OKM3L=P[^O^-'S*=6'ICTF[R^>=9^ZJGW!N [VK<&_.7A&^NU
M.QW#OZ_XT?,IU8>F/2;O+YYUG[JJ?<&X#O:MP;\Y>$;Z[4['<._K_C1\RG5A
MZ8])N\OGG6?NJI]P;@.]JW!OSEX1OKM3L=P[^O\ C1\RG5AZ8])N\OGG6?NJ
MI]P;@.]JW!OSEX1OKM3L=P[^O^-'S*=6'ICTF[R^>=9^ZJGW!N [VK<&_.7A
M&^NU.QW#OZ_XT?,IU8>F/2;O+YYUG[JJ?<&X#O:MP;\Y>$;Z[4['<._K_C1\
MRG5AZ8])N\OGG6?NJI]P;@.]JW!OSEX1OKM3L=P[^O\ C1\RG5AZ8])N\OGG
M6?NJI]P;@.]JW!OSEX1OKM3L=P[^O^-'S*=6'ICTF[R^>=9^ZJGW!N [VK<&
M_.7A&^NU.QW#OZ_XT?,IU8>F/2;O+YYUG[JJ?<&X#O:MP;\Y>$;Z[4['<._K
M_C1\RIC ^CLT+"),PECLCL&=D@U\UP*,U-@%AH,EGCW/PTQ81F*Q=%8PBA=1
M!D])V(9#<%UU!N+1PLHO?J-EN#[@_P!AKB[O=B]C<*V;O[ZVZBNL0MKS:#$[
MU[(MKDM(;C:'&L9:R@G8*;I;#J5KM8XX[IIHHU09-K@]E:2<;&CLX&2F1]6G
M/E*@ 9'+=GOW<E65\B&O_P!GOOG1Y]^NOUMS^0>:MEH7F\I\]/(AK_\ 9[[Y
MT>??IK;G\@\U-"\WE/GIY$-?_L]]\Z//OTUMS^0>:FA>;RGST\B&O_V>^^='
MGWZ:VY_(/-30O-Y3YZ>1#7_[/??.CS[]-;<_D'FIH7F\I\]/(AK_ /9[[YT>
M??IK;G\@\U-"\WE/GIY$-?\ [/??.CS[]-;<_D'FIH7F\I\]2*,:ZB\1?K$@
MC5R@[79J,5,UGB[C&[=59NXSQM@KE?&V5U&R5[96MV;6M>W^+*]4+$\IJH4#
MD%3JJ56E*55&#J<JGFZ2R<U2#B-+LGTT=LUDD(DX(F+IRF2#H,*$YCBKTPTC
M:^O\X3("[LZQ;R?RB(3=C;-O#W$::(*577$1TBA@J,-NR^$=S%,5W^ !OEJG
M( 4/C=.3IRY%FD6SU^]7C<AWL:CX",71(>$$=1A1!"2J@=BMWTG457=]OL.3
M]_BK:4%=<YW;"5NYT.AX@HQC6Y%HT(:91-ZQ,3K$%KC#5#1$DS)772@.4C<;
M068^%FXN5Y"6<;;S-ZBY;K.#ZF[/Q;O>'G]S=7D>)<Z;&Q %H^"9A\Y.,&F)
MO<=KS#!/7+C:\G;2&2-AV9')\GMEGK/&%O(P-\6WVN\62DI='6Y.6V$1S%3=
M]NYN]_N_N[E8K8C?G::#0%N)8@&!6T0:.Y+A"3($>)<3#* '\#[";OSAT3(A
M;7QW5C:<,3UDZ-,^X^,"TF+H)) 7R"@R_P >85%&3'I!'HK5,;(MLA*L3>09
MM/I*W-Z\71F[)>"SM&2/7;O&1+R5>P"190-4A9HVCCLS)DG>35$[$,B"JZJ?
M;[?XUMK5[WFV]V-%TMMAH2&@3V$/%)4ZB;F/O&HB5V?3-A@U8)NGKB2+%%$6
M&O3PIW9(C%T!YF9"C#9P4Q"* U5W=SQ;OW]SWOMOUI#&_2""X=#8B0;CLC$)
MB(2QV:2!] CSO94B%ZXF1# :L\PD3AZC@7V T@$<FQIR% N\V[^3NHHY;MLF
MDH8*;O\ #H_QR]ZO#%AW2'6=R$L468-';LND919FG4">L\[BM%-5EX@ '"9(
M_$"8&?Y B["AQ5RW0V!AKDNX<&2 V2+N)"R4[7=R^/I\V[W:L7Q-G.XY["):
M3W2 D0 \/F[84&3DL+O!G#\;Y-]=E9$\#B5.YO'40;[-*[ #0HF79L9 O%!(
MAO)$G)]H2)OU#]OMD*M+2J4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2J!)Z(Y8BY2\3C>\6@F$&]J&9B:4R,X$3J4(DF]9E,CT/%#S.KBUTCBF
ML2T2CP*4J2RS2+X1M:$!HVW'NDYVFJN[R<WB]WG\^7<KY3#0?+2^UM^["UIO
MEM'1\YR#)ZPCDC.$I$ C[5CHV51==$E&B$(?LXUBTW&^CDN%)18D]078(&C!
M_ L]<XQARIF,N3[9^[OW>YXNZ3ZMD:@YFRS5$7A\=W6 C<U4UW.8Y,I6,//P
MG<).<>M< !D6[;:V)&S=Q\6N3C@\JB^@I>+&W3:?YWFAADV'HJ;L_%]O&/W^
M+QU&'&B><X,R'3@G(.,(PY4_-9)(Q4M>.3AIL^D^T"TA',8^9OK;_G8\&UTX
M;Q5(*5040\+O7A9KDT?C!1BRF[W]WN<F^ME[%UMRW7P"MM;;4!YIL->:^ O'
MLKDMPV9"8L#QI3:1TTQ Z@*N2^,PCKJ/)@7P(_!'D8*@'&(IH-9G".:J@R[O
MC_P\OV-:G*:'YY&X!8*:Y!1PA))'&4A4S2'GL8P)8&<XU,Q#@A%#8K22IE,1
MX3+QHN2$8CPI,VJ*SP'R.(I-L4"2F[/]W=[O=&8^W<[M8-+0G2#B50#L+NW7
M2Y08&@04H\)2DVB%(LXVTD2Q1 3$F.FL6@&Z[UU%Q[ETZ*R'.48A71YXWCR)
M%W$7"G:^/^/[\O)XM_+6_>,^L.5&NC;EIN[;('84&8:]A,:C;9N2*FI-G) 4
M3A8HZ<D!8S% [Q^X(R(9-3.950HY(%\9.VL70OD,'(C%#EW/MR^[XO\ &KET
MJE*4I2E0]78$)14415E 9-5+/--1/)ZE;+!3#*^.>&5KW_1ECE:]KV_\+V[%
M5R/,>@U3,<XZ17Z>42#>=83Y<E]M,CS'H-,QSCI%/*)!O.L)\N2^VF1YCT&F
M8YQTBGE$@WG6$^7)?;3(\QZ#3,<XZ13RB0;SK"?+DOMID>8]!IF.<=(IY1(-
MYUA/ER7VTR/,>@TS'..D4\HD&\ZPGRY+[:9'F/0:9CG'2*>42#>=83Y<E]M,
MCS'H-,QSCI%/*)!O.L)\N2^VF1YCT&F8YQTBGE$@WG6$^7)?;3(\QZ#3,<XZ
M13RB0;SK"?+DOMID>8]!IF.<=(IY1(-YUA/ER7VTR/,>@TS'..D4\HD&\ZPG
MRY+[:9'F/0:9CG'2*>42#>=83Y<E]M,CS'H-,QSCI%/*)!O.L)\N2^VF1YCT
M&F8YQTBGE$@WG6$^7)?;3(\QZ#3,<XZ13RB0;SK"?+DOMID>8]!IF.<=(IY1
M(-YUA/ER7VTR/,>@TS'..D4\HD&\ZPGRY+[:9'F/0:9CG'2*>42#>=83Y<E]
MM,CS'H-,QSCI%/*)!O.L)\N2^VF1YCT&F8YQTBGE$@WG6$^7)?;3(\QZ#3,<
MXZ13RB0;SK"?+DOMID>8]!IF.<=(IY1(-YUA/ER7VTR/,>@TS'..D4\HD&\Z
MPGRY+[:9'F/0:9CG'2*>42#>=83Y<E]M,CS'H-,QSCI%/*)!O.L)\N2^VF1Y
MCT&F8YQTBGE$@WG6$^7)?;3(\QZ#3,<XZ13RB0;SK"?+DOMID>8]!IF.<=(I
MY1(-YUA/ER7VTR/,>@TS'..D4\HD&\ZPGRY+[:9'F/0:9CG'2*>42#>=83Y<
ME]M,CS'H-,QSCI%/*)!O.L)\N2^VF1YCT&F8YQTBGE$@WG6$^7)?;3(\QZ#3
M,<XZ13RB0;SK"?+DOMID>8]!IF.<=(IY1(-YUA/ER7VTR/,>@TS'..D4\HD&
M\ZPGRY+[:9'F/0:9CG'2*>42#>=83Y<E]M,CS'H-,QSCI%9$7+8R;<W9"3@T
MB[LGFMWNU<IJJ]RPOC;-3M,;]GM<;YXVO?\ \.VM3(CE!IF.?/W*D54JM*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E<-^:&W)AJ..@%(,\C0&0;*WU -/(3>9#U
MS$6UXWV#*%ACJ8EPZ!4#8LHT22N, C7)P2Q>R@L#0?.[M,U6SC?X-90WMQ.+
MA99([6QN[TP0,$FN3;1ZQ CE)- 8G7(XC=EA20JN>1&!<2-&BZ-(9Y(X]; E
M4#MD6(!&>0W*"0"Q7,Y;CS-FG-CE($FM]0@S8*7%X1L?D3"Y%LS66B<]B93L
M9JG6>@]CA7K+7RVW8HR"%0*VW#$.V+8?,7S1$W'<5A[)GFY6&L>G@P+"9+?J
MUXY($N+;#)XK2[Q#J;J=KRZQ&VD#7(LIFD24623VNJ!6XN7MRP4.V$UU.).*
M5E8J\R,Z0E]7%QP.,DXU<BIE*/VWKEW 9Y"1 NDNE;S<'#2*&LM<-XKM'5V@
MB>_% K8^XR'[%Y1Q(R_UHC!BKQ;O88!C\A'1&TB9G\W+W(+M>-YHO7*S%996
M*79:%;'&YH^JC-:7F(IAX<QC5:X3-&MT;A5&;/)&\_%-'I7C+.4%1JR%PO6,
MELIT:9(X3+I#')YU/%Z"3VJA@N8;,Y2+W15X>-F_C.V^-F&R3Y*+K;"2;[=<
M/Q0;N2*+3"$SZ;1L(HN&[_=/6Z>0X&)[\R55QLX<+9JX72LX3PQT&*8='9XI
MU+&LHMB;,*[YDGC[>"60!](4]M(^G(;@,M^1-94,IDAUDKKR?,#D[5F W9Y\
M@&=<XX'SYY1;/UR00N[UYK+;6O\ @V8Y73-)WKTE+8]*[^#XO-=?OXPBM+X_
MDTB\[@LG08D'&#TDI&)P'E@2R9#P%>RO3W.SN$VETITW-W97./QX/ 1<I#+#
MV\T%RLI$,N<UO<0ED!51+;R0R=KQF[#2[G>,^L21+4SMFA*MN5T*C6.U=6R.
M\Z75A_1K/SKF_P FM/3'7<,DQ[6\X5VQQ;BLBB15IKM_%+(\D]W/=GY:8"N6
M&$U/67B:%]=J1XFTL\1=G7[M!9NY&+ND6=H[? ,*O8+F>*.Z@ZCQ>:*9&NEE
MSPK#UM.KW#=3IE,1<\:K9$1JI!5P":JUU/&R*QC;C+="IT%?O\IEXL$:SVOW
MO2=XS)&\$U-IOS"Y(NM+\ Y) L6=I[R<TF:V%-$(QIDIMITYDPO4T-FS,?'(
M6SG41<#@STZ==MG[UQ(%L10W-)917+O?)7+'M\%PL7VT45QJZGPJ_2V@,M\E
MDHB:\G@9I9VMY@SB.,%5$8UON WY5<US-Q5FR9:[B+6VF,R=MQ2ODJZUR&H[
M\SN'=J'(\V^7PS=P^+3.+@0#$;N/B3I^=0MIJYT:B 0_NW3FGIELD(INMIL_
M!R)E@:4SN2#X /M!I()+N6L8%D2MT"K@DWG. X*U@TT$LDK/8XS>V\[78CGD
MCL+Z^@M9.H3:$/"\-M$;EN/B= TLB)]["&P75SQNEE50);:-UXLE5,L43R R
MB3<P9R$[0@G2"=Y(Q;_I"N04&U'KS>Q4AJ'9;;?&@]S;<#:HC\9+@WVABNO!
M LT*3ELC;RXR3E</C>13**;9=/P<9)LI0Q[H'<"45E1+>Y=F\.N+RYP]%O;4
MX?B-C9/>22I*N()<LZ,88C#&D,TP03V:K+*IA;)P^YZ=63+$LIXM^-ADE5%4
M@PZ "-9U'4JYZ9-RD,-V7)4CV!S)Y"0 J?U&)V5%=H;%8;3XY T)-%>/KZS_
M #B>ZQ.RUGR\9AWE6\6YVQ=/8(BZA!%K,P;[O!4BW.).\<!IA]';8)AMS''>
MO:S6ELUGB<G%38DI7CK%[0*)9A9\=;LJW)6X5H'74$,1';HM[W$J$QAUD</"
M,UA.>F4.<PO&9,"4S7M@<L\\]QJ$3+I0MH0#5FCSIQ.$JS!;:6ZR>Z6SV&2$
M 7OQ_P! [I<:GDJ.<(;R"39Z[V](&RRI5(<YDDIC[ C"Y2V;NW+95'!KD0;)
MVES>7\<?'\1U)8)8LL\<B=<<1L!>1'CS'%U391L A8112LL\1(# DQM?.D<1
M;1J+RF7-64\3#+Q3=IJ;1(>7(LP!5AOY*^VS.DBWI%]B[A@,=2UV^\"\DM<1
MK6Y7($]>(N=&NWY0-LH@\N@<P1+& YQ37(YL;;YM6C:VTP2O>+SO92U[;79?
M#Y;:RN9>J5UX7<RW2<8JE<0"J]JJYQ9I&\?5+&,ZF/4<G;+F*J][*'E0:#IG
M1%.1/WHDAR=^1R.@ [A]\'+7=FO/ZVE*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4K=.AOY\Y?ZD(?\ ^K.K'Y/?_@:O
M3E][^(JS9+9&NPSYP,+SV%BB33.R;L>2E(-B^:J988J6P<-'3Y)='.Z>>&=L
M5$\;WPRQRM;L96O>:.POI462*RNY8VWJ\=M,Z,,\LU94*G>"-QY1E5QDC4Y&
M1 1R@LH(]XFO#Y7-4^D[7OTTC?YE5_6S$O8^^_)+CT=4XZ+OL?PU\]/*YJGT
MG:]^FD;_ #*G6S$O8^^_)+CT=..B[['\-?/3RN:I])VO?II&_P RIULQ+V/O
MOR2X]'3CHN^Q_#7ST\KFJ?2=KWZ:1O\ ,J=;,2]C[[\DN/1TXZ+OL?PU\]/*
MYJGTG:]^FD;_ #*G6S$O8^^_)+CT=..B[['\-?/3RN:I])VO?II&_P RIULQ
M+V/OOR2X]'3CHN^Q_#7ST\KFJ?2=KWZ:1O\ ,J=;,2]C[[\DN/1TXZ+OL?PU
M\]/*YJGTG:]^FD;_ #*G6S$O8^^_)+CT=..B[['\-?/3RN:I])VO?II&_P R
MIULQ+V/OOR2X]'3CHN^Q_#7ST\KFJ?2=KWZ:1O\ ,J=;,2]C[[\DN/1TXZ+O
ML?PU\]2$#+HI*>^O%B3QZ1]X]P[^\ FAI?O/OKNW>W?7@]RX[W[X[W<=P[MV
MG=>X+=S[;N6?:P36MS;:>J+>>#7GHXZ*2+7IRU:=:KJTZESRSRS&?**N5T?/
M2RMERZ6!RSY,\CW<JD-05=7,784*!SA&5Q691(3+XJ==$&9J-R8"S/Q\RRR>
MYJ7:DPY5J['$&N6:::G<'3=9*^>&&?:]G'&]LR&:6"1)K>62&:,ZHY87:.1#
MEEJ21"&4Y$[U(.1K&958%74,IW%6 (/B(.X^_4(C>E]:0YA'!41U/!XL,A[(
MV-B0Z.P4"$8Q<=)LF^<D81YJ-%MD K.0YLVF9QL-P;(ELVK?(A@XR13OC++>
MWD[2O-=W,KSM&\S2SRNTSQ9\4TI9B9&CU-Q9;,IF=.69JU8XU"A410H(4*H
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MM+#Q#=_(TGBN62KI,PX>8.%<LE%L<\\LLKRR7]]-'##->74L5MD;>*2XF>.
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MCG^ K]VE*=YO/BCG^ K]VE*=YO/BCG^ K]VE*=YO/BCG^ K]VE*=YO/BCG^
MK]VE*=YO/BCG^ K]VE*=YO/BCG^ K]VE*=YO/BCG^ K]VE*=YO/BCG^ K]VE
M*=YO/BCG^ K]VE*W-HENX2G&62J"R>/@4A;MLTL\,>S=5GV+=G+&UNS?_P#B
MK'Y/?_@:O3E][^(JY-15+2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I6D-W\B]2<
M=QL:([3.'F*DS-.X_$0$.U]L7:LTDQ0<%(R,JD"@.J8I-9L4:A8^)(FCI)F
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MO9;J>U@P:.&[GQ&X>$8(ZR1&"VEL3!=08]:7%G.UZL=U$DO$L\C0)-+UONM
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M*4I2E*4I2E*4I2E*4I7(;I1_\_\ 'K_56YO_ '6HJ^<_Y6'^IB'_ -S-DO\
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M4I2E*4I2E*4I2E*4I2E*4KBWSF_[W3H/O_/=(U_\:XC788+_ /*NVG^SL_\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g521849g32e47.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g521849g32e47.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1Q,4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $@< 5H  QLE1QP"   "  0< E  !W!H86YL;VX< @4 *$UI8W)O<V]F
M="!7;W)D("T@4W!E<F\@+2!3+3$@4FED97)S+F1O8W@X0DE-!"4      !!5
MM#$W1&:QXNFEW<$^X0OT.$))300Z      #E    $     $       MP<FEN
M=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M    0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M
M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\
M;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N
M=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT
M   0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O
M;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B
M;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P
M  ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0&+
M   *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=0
M0P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M  H  0         ".$))30/U      !( "]F9@ ! &QF9@ &       ! "]F
M9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "T    &
M       !.$))30/X      !P  #_____________________________ ^@
M    _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@  #A"24T$
M"       $     $   )    "0      X0DE-!!X       0     .$))300:
M      ,U    !@              [    ;8          0
M           !              &V    [                      !
M                     !     !        ;G5L;     (    &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG    [     !29VAT;&]N9P   ;8    &
M<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC
M94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T
M   ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T
M   *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   .P     4F=H=&QO;F<   &V     W5R;%1%6%0    !
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M3001       ! 0 X0DE-!!0       0    #.$))300,     !'9     0
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M;\JFJEUE0KMESGY (/J4$V,9Z?K.][+*F?S:*UV Q@B !'$#Q3,IIK,L8UI
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M :>6AH&W;[4F='Z=79ZK:SNEI&Y[W06M=4TMW..W]&]S%<''@G35K1;T7I3
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MDI^JDE\JI)*?JI)?*J22G__9 #A"24T$(0      50    $!    #P!! &0
M;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H
M &\ = !O ', : !O '  ( !# %, -@    $ .$))300B      %"34T *@
M  @ " $2  ,    !  $   $:  4    !    ;@$;  4    !    =@$H  ,
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M   " 0 $     0   4(" @ $     0              2     $   !(
M 3A"24T#_0      "           _^$!1$U- "H    (  @!$@ #     0
M   !&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "
M'@   'X!,@ "    %    )P!.P "    "    +"':0 $     0   +@   #D
M   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I
M #(P,3@Z,#8Z,C@@,3$Z-#4Z-#4 <&AA;FQO;@   Z !  ,    !__\  * "
M  0    !   !MJ #  0    !    [          & 0,  P    $ !@   1H
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M 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ EP$8 P$1  (1 0,1 ?_$ !X  0
M!@,!               #!0<("0H! @0&_\0 1!    8! P($ P0(! 4"!P
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M_+7HJ5SHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB\_G\B8"@ ] \#SS\AX'V_\
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M+,)/$4W1:!'UEK$,2S!*E&-YN+C$YU1*JHS+E-!55<5)0 (,EYG @-W-/*1
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M(_0Y"#PYQQD$'CG#B2>>HR2>G/RX78C5!,H%33*0"ATEZ0 ."^_2' =B\]^
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MMG+= %(](KD5$Q4!(-W]^^%\\N.7AP'0-!W<YP",C& ,],>S>,'L'[@]_?\
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MY.H-(I8^X(6QI*'E62REVD')5,7G,P7JS\$6D<RX>#8T3&=).8P $I:7#\)
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M-C6&>(U.P'![BGD=GR)#L>S[G+;WB*YPN+G8 J(^(0<[=SBUKVMYQU>&^N2
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M(ZQF3V3>,%#)&:^F1*5>R<G6 !SP " _Q#V^8"'\/^W;1%R4O2' CU#R(\B
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M '7T%R6#M[FU;<"KZ/&68:O+V$BZB#ZF3 .JE>(YVD80492%-M#.&GDG" \
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8FB)HB:(FB)HB:(FB)HB:(FB)HB:(O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g521849g40c11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g521849g40c11.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1T"4&AO=&]S:&]P(#,N,  X0DE-! 0
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M<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M"7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T
M<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !2
M9W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O
M;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M      !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M    4G-L=%5N=$8C4'AL0%@            *=F5C=&]R1&%T86)O;VP!
M %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M          !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F-
M60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1"
M;W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P
M4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE-
M ^T      ! #P     $  @/      0 ".$))300F       .
M #^    X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         ".$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             !
M.P   =L          0                         !              ';
M   !.P                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   !.P    !29VAT;&]N9P   =L    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   3L     4F=H=&QO
M;F<   ';     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    #.$))300,     !)T     0   *    !J   !X   QL   !)8 !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !J * # 2(
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MJGOJG8][/<W(_<]3_2?Z*D%+&OI^KH<&F.G61N;4[_M/2WV_:GU[?I?X'?\
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ME.XP)7&.^OF)>UKK>EFSN-SV.B?ZS52QXIY+X1=;L\\D85Q&KV>R#VDP""?
M%27$8WUUP\2EC:^FD.K8&%X<QI<&CO#?SH78X>1]IQ*,D-V"^ME@:3)&]H?M
MG^3*.3#/'K(4#MLB&2,MC=)DE%SV,&Y[@T>),!,VZEQVML:XG@ @E1KV:RNH
M]<Q\=]N*'/KR& 18*][02 _Z.]F_VE:JX[KW_*^1_8_ZAB2FW5]8+Q?-N3NH
M:6D!N/#G#_"M=^G]G\A;73^IXW4 \T!X],@.WB.1*XM=#]4_H97]9GY"DI__
MTNQQ'U_9?K'4-HL;;>^QC X-&^O:WW/96QUK_2]2W9_Z,8@4FL4_5TO /^3K
M(DTC7[/3/]+#OS-W\Q[_ /3?JGKJWE;>E=.ZJ_-<**<ZRUU.ZUUC&FRH[MSK
M0UN-79;799_H*]ZJTO\ 2J^KVYS6$].L$/=6R8HI?#?M++=VW;[O3]/8S]+;
M^KLNJ24RQCCQ6 Q@,TQ#\ _]H+=O\U5_HQM]GYGZ3'_R3ZU2)A.J_:6&&!H/
MJZ[78Y_[0T?]PVL=]';_ #G_ %K]2^R*&-DM<VL"RDZT\7X9YP;;?\'BM_=W
MMV_3I_6:?3Z=ZF*B8=P?U+#;N8[]*?H64OYPJ':_9:J?WOS_ /!_I:_U6S&I
MJ26E_C7_ /$7D_\ &T?^?&+PM>Z?XU__ !%Y/_&T?^?&+PM)#M?4O_Q6](_\
M-U?E7M_US_\ $MU3_P +O7B'U+_\5O2/_#=7Y5[?]<__ !+=4_\ "[TZ'SQ\
MPB6Q?&5%_P!$J2B_Z!6HTP_0+N#\%X_5_-L^ _(O8'<'X%>/U?S;/@/R*OR.
MV3_!_P"Z7\UO#_"_[E=WT3\"O5>C_P#)&#_X7J_ZAJ\J=]$_ KU7H_\ R1@_
M^%ZO^H:CSWRQ\RCE?FEY,+>L8#'NJ>\AS"6N&QQU'/YJ'7UGIS00ZPZN<?H.
MX)G]U8F;_3<C_C7_ )4)-CRL" ;EJ!U89<[E$B*CH2-I?]\]=CY%634+JC+'
M3!((X.TZ%<GU[_E?(_L?]0Q=%T3_ )-I_M_]6]<[U[_E?(_L?]0Q5) "<@.A
M(;^.1E",CO*(/VM!=#]4_H97]9GY"N>70_5/Z&5_69^0H%<__]/TGJ[&NZ9E
M%P!+*;7-)'!V/;N;_9<L&BXTT_5XBWTMW3K!_.,KW1139'Z9EOJ;=GJ_HOYO
MT_6L_05V5OW^J_\ )>9_Q%O_ %#E@46&NGZO$6&O=TZP:/-<Q12Z/;7?ZNV/
M4_X/^?\ \'Z%J4SQLXN%?ZT7 FG_ +4XSOI8-M_YM#=V_;Z__"?TRK]2_5["
M8>0;>I88]8V 6G0VU6Q.#19_VGJKV[O4]3W.]^_UV?H+J:ZQ8V82*_UEY!-/
M_:MSN<"V[Z7V5N[?_/\ _"O_ %[]'_1+2X=[K>I88]5U@%IT-IMB<&BSO13M
M^GZGT_TGJ?:/\/Z-*2TO\:__ (B\G_C:/_/C%X6O=/\ &O\ ^(O)_P"-H_\
M/C%X6DAVOJ7_ .*WI'_ANK\J]O\ KG_XENJ?^%W_ ,%XA]2__%;TC_PW5^5>
MW_7/_P 2W5/_  N_^"=#YX^81+8OC*B_Z!4E%_T2M1IA^@7<'X+Q^K^;9\!^
M1>P.X/P7C]7\VSX#\BK\CMD_P?\ NE_-;P_PO^Y7?]$_ KU7H_\ R3A?^%ZO
M^H:O*G?1/P*]5Z/_ ,D8/_A>K_J&H\]\L?,HY7YI>3SN;_3<C_C7_E0D7-_I
MN1_QK_RH2EA\H\@Y\_GEYEZ3HG_)M/\ ;_ZMZYWKW_*^1_8_ZABZ+HG_ ";3
M_;_ZMZYWKW_*^1_8_P"H8L[)_.3_ +TOS=C#_-8_[L?R:"Z'ZI_0ROZS/R%<
M\NA^J?T,K^LS\A32O?_4]&ZU3U&_"-'3O2]2W<RSURX-]-S'L=K7+MV]U:QJ
M>D_6BIF$V,+]0QSC5EE^17N!;74ZRWTZ?W:MS*_\';^E_P "NG5+J&>ZH/Q\
M,,OZCL#Z\5SH):21OLC^:J_1V,]9_P"C]7]&DIP6-^L;<YN"QM%EK&-ML)S<
MHAC16[$I]3?7NM]9I>^ST_\ M3Z6;?\ I/15AO3_ *U-OJO:,-QI<7!MF3DV
M S4,4#])2=GL9ZCO])=ZMO\ .6K2Z5TNS%G(S;1E]0L&VW*#/3EN[U&U^FT[
M=M3G;:W_ $_36DDIY+ZR="^M/UBZ1;TK(.!CLM<Q_JUON>1L<+/H.J9]+;^\
MN%RO\475,:VBD]0QG6Y+PQC UX.W3U;)?M;^B9[]GT[/\&O7\G,HQW5U.>T7
MWRVBHGW/<.0QC=SW;)WV[?YJK]+_ #:H=*Z;ENM'4NKEEF>2YU#6M .-78UC
M;,)MS#^L,_1[M[FI*>#Z1_BFZYTKJF+U)F;BW/Q+6W-J<+&AQ:?H%X:_9_F+
MK^JX'ULZITW)Z?:WI]3<JLUFQMEQ+9_.VFENY=(J^?FT8&)9E7D^G6!,0-2=
MK!N>65LW.=_.6OKIK_PME=:0-&QT4^89O^+?K>'B795F9A;:6%T.<ZL$CZ+/
M5NV55^H[V;[/8C'_ !6]=>WVYF&6G@Q;Q]R[.OI>1U;*HZCU5M1HJ%PQ\%])
M+A7<&M:[(==[FY/I[F9%.ST/_/BW&M:QH8T!K6B&M&@ '8*7[QE_>_"*SVH?
MN_FY!=];R?YGIT?\;?\ ^D%RA^HO7Z:BY^3@M96V7/<;0  /I.<6+T"^YE%+
M[K#%=32]Y )AK1N<=K=SG+"%.1]9'TY%P97TBJUMM6-;5NLN+-WZ5]F[TJZM
M_IV8MF,ZWU:?YS^<_1-AEG"^ U>Z98XSKB%T\SB_4KZP9>+5D-NP6MOK:\ /
M>^-PW;?5J:ZJS;_I*W;'KJ<:KZW8V-5C,KZ<YM+&UAQLODA@#)_F/);=---%
M3::*VU5,$,K8 UK0/S6L;[6IWO:QI>\AK6@ESB8  U))1GEG.A*5TJ..$?E%
M6\M=T7ZT6VOM+>G@V.+B/4OY.O\ HE6Q.F_6++J=;3^SBUMCZ]+K'ZUO=5NW
M4L>WW[?4]/\ G*_YNW](M+*MR/K*V["P7MJZ8)KRLBVHV>L9;^AQVN+:O1TN
MIR-[OM%=O^#K_P -N8N'BX=7HXM+**YG;6T-!/[SH^D_^6D,^0:<3&>6PDDF
M&_C)QL6GZW8M#:&5].<UDZFR_N2[_0_RE1S.A_6C+RGY+QT]KK(EH?<> &?Z
M(?NKK5B974\CJ&0_IO1K&LL: <G-<PV5UL(<-E$>RS+]U3V>K^@LJ_F_5].W
MTF$DDD[G5E    T T#@4]%^L-V1D8[#T_?C.:UT76./O:+/=6QCK*?\ KW\Y
M_.+5Z9T[ZU=/WAK.GO;:YI>?4N! &GM_1+7Z1TC#Z5B,HQJJV/#&MMLK8&%Y
M:/I.C=^<Y^QF_P#1*\@E_]7TCJF9DXM(&)0Z_(NFNGVEU;;"":W9/I^^NG=]
M*SZ'_"5H?2>E?8P[(R7_ &C/O]U^0[4C=#WX^.YWZ1F&RSW4TN=[%HI)*4J^
M;E?9,=U_I67!I:"REI>^"0PN;6S<]^S=O=L;O5A,DIR^F=,R3<>I=5+;<]_\
MW4WW58X]S=N+ZFYS+;*G-9EV,_GMBU4DDE-3JG4L7I>#;G9;BVFENYT:N)X:
MQC?SK'N]K%F=/Z9FYM]'5.LP,FL6BG'K=NK;7:&M:T^VO=[/4W_3];>SUOYJ
MKT]3J?\ 0K/YG@?TG^9Y'\]_)5EO"2E 0AY&13C4/R,AXJIJ:766.,!K1RXH
MJ#E_T>SZ'T7?SO\ -_1/\[_P7^D_D)*<+%IROK'LSLN:.GMNKOP*FN+;'"O=
M^DR UK?3>^P[O;;^C]+]#_A++^B: T  0!H $+$_HM/T/H-_FOYO@?S/_!?Z
M+^0C)*6<YK6ESB&M DDZ  +GADYGUC).#99A],:]OZ9U8G(8#N<^DV;VV8]W
MM9[Z_H>MZ_J>MLKU^K?\EY?\U_,V?S_\S]!W](_X'_2(/U=_Y"P?YK^89_,?
MS?'YO_?_ /A$E-ZNJNI@KJ8VNMHAK&@  >36J:222G$ZV[KN1EX_3^F!V-0^
M+<KJ/M.Q@/\ ,X[7;]V0[;_A&;-C_P#C%JXV-3C5BNIH:!J=K6MDG5SW-K:Q
MF][O>[VHJ=)2DDDDE/\ _]DX0DE-!"$      %4    ! 0    \ 00!D &\
M8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O
M '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !1DU- "H    (
M  @!$@ #     0 !   !&@ %     0   &X!&P %     0   '8!*  #
M 0 "   !,0 "    '@   'X!,@ "    %    )P!.P "    "0   +"':0 $
M     0   +P   #H  ZF    )Q  #J8    G$$%D;V)E(%!H;W1O<VAO<"!#
M4S8@*%=I;F1O=W,I #(P,3@Z,#4Z,C0@,34Z-3DZ,#  4E(Q,3<U-S(
M  .@ 0 #     ?__  "@ @ $     0   =N@ P $     0   3L
M!@$#  ,    !  8   $:  4    !   !-@$;  4    !   !/@$H  ,    !
M  (   (!  0    !   !1@("  0    !              !(     0   $@
M   !.$))30/]       (          #_X0%(34T *@    @ " $2  ,    !
M      $:  4    !    ;@$;  4    !    =@$H  ,    !  (   $Q  (
M   >    ?@$R  (    4    G $[  (    )    L(=I  0    !    O
M .@   /      0   \     !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W
M<RD ,C Q.#HP-3HR-" Q-3HU.3HP, !24C$Q-S4W,@       Z !  ,    !
M__\  * "  0    !   !VZ #  0    !   !.P         & 0,  P    $
M!@   1H !0    $   $V 1L !0    $   $^ 2@  P    $  @   @$ !
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M5V1GB)>FP\3_Q  = 0$  @(# 0$              0(#! 4'" 8)_\0 8Q$
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MIQT].[W<ZM,R,XD.-+ZKL"<F&Q;,JZ_'F&IX=N3TCS>7A[Y]4<8MO'F[\/\
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MA<H?#H(L$HQOU_CE6.1H]3_?P&R?B=^,M_7YI!_A#3'D\D)V[D29V(IN&OX
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MJ)"GY!3 ?L$  0$!V$0'G,<J8"8P D0AA RBBI.4=BF :/M,%A:6I .!N*)
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MI7(^JNKMMV8%)_Y352/U8\!\.G^12WB?YYM<P/BM^O\ \US(?" X"?L&S/\
M\XT=H"R*\,3CCUO$6R#<T%5.,74V5MQ+?)4,Z"RXK(@UZ5C>C 9REB1L@Q@Q
ME45ZE5^H5I;@6OJT*=&WKE71#I$C&^0Y7\@+3DI=["\.O[KV+Q;.L@'W4W3Q
M>&R?:$DNM;7'YH%,$5J26@\YL/E2_;%Y==Q=K.QP,#W.\?XTD.=A;A#!2OG!
MQ!@R/-(.?>GJ%%4CF."0F3V()D3"9(ZA0Y5A()MC 4JP*)@!@W 2#Y1O1UJU
MQ<2"!0"HUEK3ZI)'4OLW>2V=?J^GV*;(83  CZ0 >SX=_P"C5P:D;H]JAID
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MS20=W1U@0;\..>F9U=!R.Y?.*XZX@GQ7<LBAZT*J$]@4YEMO]SA#_83I1.!
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M%-,RA ZMGBI^#4,43I[G33,/(8H&$A>8!Y2[001FBV-42[=)VB/X0Y0 =NP
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MJG7OU/(]2'7WWSZO_ 2.O"SK>\<WO'UB]4G?KO\ =>GC)_CEZG^\WCK]=?\
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M\_X+-!V^?\=J@[_GB8=4_P#T\73_ +VN/3L(GU1M8+-_E@VEKR;;_P 3:/\
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M)-Z9-Q2ML$VMZQ/0DQ0O,J(&9+KO-RL@W+'<) D2Q*\<=/M2G7QG[.(6:RT
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MXI# QK8$(&CAB@TQBP+$#*ZK L0W8D''ADEA#H%)?!VAA(G#6\UFG4<92&F
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MJO,G\M3]4&L?WFUZNY2WX>Q](_J6B^<7QV_=7LM/Y;"OW;8:U[(\%/R$V/\
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MC:]:N_B=W+HYN;NGO*:JKIHB:(N?XA_B#4C,=([54^<WK[%7;%7VSF-O]_\
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M+\S(POKMQFKWS!T*Y5WM!N9)MAKXZR_"\]S!67&D>-KC(+],S5'&;$W,.5K
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MNQQXMSP;3:#A@TF_6V>>8B.@U.GGWE>(Y1[3M&@DVMI88@:@>+NEW8V  ")
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M<UV'"'AI$B1Y.( 4<2'34RO7[H3]\/\ E$?]+JRLO'O%4@")2GZ+E,1?GYC
M)P3*0#*BF*?2\H@F!A\L +OL._8.K-LW/<PM+AAM&5:0*DTF>@FD9+':NNS;
M.U^R'0/%6KF1$DM8214BF4Q/KA:VAR)%%0" J8IE##ZY P$$@B@<AN99$0.1
M1!3F$ -N42@8I!+Y?NRY6;K&RL&&U-H76;20\DE@#09!#* AX,FA(H(E?E=?
MKI=[&\[:-A:VAL[.]/#2Q]DUMHPOM&L#HQ!Y!LW @.:!)DDFG!52&  $3>2
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MG6<^;JYT47((D#T ;GW#R_6B @'X$%=M]_XW+V /+S;#ME4+7/SN*(952ES
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M)=R2Y+/C'R=V&^KB/&;*N%H9=A#H\98.SPB=2<Y47^I<,3/^'+Q1?\HB'_\
MNWZG_*#RY/\ [6\H/^*7L=EHJ?T-Y)?]V.3_ /P?9_\ R%8+G9ZGMM,%&P])
MC1D%Q0IA-,&<T!P=/P]8]@D'JNQG?@.OK4F$"Q_!%I.S#,D;78>5^O4*^/&\
M-RZ-RT*RM?;2Z?Y0>7/_ 'MY0?\ %+W_ ,U4?R/Y)-@#DOR?DSGL?9](C3Q
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M)_W?]/Z4\I?]?[8_XC>_^:G]#.2'_=;D]_P;9_\ ^.HZ'J<J(T3\X\33C%5
M^CNC,%E&Y0](%%&!D# !^SG#F'?E+MML.]3REY0.>RTM-L;2MG6>+!XZ^WBT
MPXX#HQ6AC% Q01,"9A79R2Y,6))N_)W85BYPPN-GLJXV9(D$3AL!,$4F8ZU^
MUH> I9K30I6RQ\7+CAMZVH'4/3V]O9Z4=EH$!6.*BO14=##R5,7G4,=0=D@'
MG.<V^YNSB;Q;VU[MW7B\6C[:V>9<^T<YQ.ZKB304%:+FKG=+M<;JRY72ZW6Z
MW:SQ&SL[M8LL&M+W%SB&V36-DN,DX:YF223-K<"4%A 1XR''B2V#;9#B&F2
M>W?<P%B+M'X1UB<9,PT:>2("S@0([5#+P("%-S#QDN/(IL!@ JO$.%4@"8AB
M@84U(A,0PDYN8H'*8O, <Q3%W*,*53AQ>IQ(F=%RJ+XY>*!QFW'>JKD[LN]\
MS2:MTN525%)-% BM3604L<Q44T]B]H&V$>8Q@ H%L'$?3QSHOS_]33P/_P 9
M)QA/\K]D_P#8)J<9YO;[T2I]33P0@!1)Q(N,.?F X /C?,L4R*  &3%=0D!F
M%! =C%.KT2@$W X[ 40-!M" X^3(Z>-VOLDB!)=!%#E&9]N?54TW38!_ 6.$
M.)B.-(Y?<83Q.28*EG-2?0R!JA$F30SUX#]302N$,C$QD^JKG>*3,&T$>M14
MH5%X1O V:G7MR2QM3:@DQ(R@&.TDP<R.N!)$VWVL BM#(UD"2/N8-<CEJ8(5
M_P"AZFF@A01 _$CXPI1 H"(!F R?/OL(")H$[!]/* "7E$AR**$.4PSXPR1
M@1!Z2>?F4-JT$Q)GV:QNZSD=RFOZF@@7_C)>,-_E@,C_ + ],9YO;[U*]FP^
MIPHD:MSI[VV.*!QG&[>J3I.Y;O8\TFI:[C3E62416(E544%(G*59-02G\YM@
M#E,4!.!H+B?HXYD51AX$20B)AXQG'>Y_)%,W\(5L""A4A2,L@D$0@@FJH03
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M@FABE 2#@:"\DN)H:0<\P9[AEK4Y7;(TY$2=&4QQ#F,;<PEW\HPB >24N_*
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MMN-VUHJ+E1M]E;MEHJ:QVRWH '2((4J(I*"O4$J:<IA5*KK/<<0)@N<8=T"
M.^D0/N:*K/-!K6<X.1/OZZ:K]O3H$IP,FF E(4I"D* [)D(7FZ---(O*DD1,
M@E3*":9/P9"%,)N0HA* R7<T#MXG753.BLFB)HBAJ'Y!+V;@.^_O]FWF_/HB
MA+5 (E ^W,3E$X@0ICJ&*7;G A"AN8P%$3[>?8H@!1'<2E DD@P!H>)[%3*6
MY=CV#XZ>$M2\\6_'T;Q[8ZIS/)W.&H/2VNRV2D IU%UP':J5K:K8*.V6FCIZ
MNZ7.YU%';K71W"XU-+0U.%]HX. &6M/96!.<=AUS-8TMFI/9ZM,JZY4K&O7G
M)Q*&3(#SN,=+'AF\8_VZC8#P93R;E2YY$G59KO..4Y*:^>T:6%NVB[,:7L(&
M156N0($RP9C9J+A?[FTCR+8*QQ5=QNMCA24999"T,.!SI$3O.8WCHRW+&^T=
M9!YLRWK!(U$4C6@BHSC('-QBSB_$^/C"9]H94:-IC7ZQ,"PL@1MEYN[_ +HS
MVFA>+Z^J:%&S*;ZME#)-VA6.G8\G,6*69?::S6-EMRXH69LM1IV5&E;-IRAC
M;(OPUQQ,Q]R2 ?)#1(K6LU.JQ!QM?.TT&0+LXF=PB@TFHI=6C3IH!L3<?)*4
M3&Y14,4G,!.=3E Z@D*($ ZACG$I0$QC'$YS23-59K0W*>M1]0K)HB:(FB+@
M3 7SB ?'\'O>_P#DT1>>M6'2%$ 3$XJJ\FQ$SGY2E(=4YCF P)HD*FD?=9<Z
M:0&$B9#*U*M-2U!-W'''0L3&8_$UC..K"]V=!TO8S7"7HXE=GQ!-CCEAVU5R
MB#$!:1&I=+LVI'R>M37O%B<%IC6].9"QP\=Q$OS<;MG>SYH*6^.R@KK;=&RI
MKO)+FM<*$U(G4@4-<Y[C$K98UN%[@:@4!@[R)_!R#AZLVDFA'#.B;'3**DDR
M>[K =L;BBM8T(VO<3ORI=+D,R5FZ9H3FW8F?+1=K3M4;2XTH4>-ZLDR833E5
MVQ>0V!$$NV>-*%KP8JRKHR*S;;9ML&V3[,NQ5<)CR'2#B:1#AN_!(=4$@$<<
MZU?:VEHUP:&B!+<4G0R30]64="SQT],BES<FYQ 0V.<W.?L#E#<X^4;8H% !
M,(B  &VL>(N)!B&F!%(&[OWDDR5F:T-RGK4YJ59-$31$T1-$4A6F4*9$""4H
M&!4!,9,3E*;=+DW-TJ0;F'\&1+<#*J*$$#D*F<#BYK1B>8:(U DDP!)WGF*H
MYKG%H WSS95^B"==%;[-N4D$P#71M:)@E5AQQ=I?=Z<=17;G>Y;)9JI^OVI)
M4J4;3L"=QN-,56XU*M"%*2JJC4EG1NE5:[747=&XW2V4-RT[2U>[&T69>;."
MZQ;/CGBTQ-8;,R6@2UQ=+3+08(@K9L+-F)H))DQ0B@.[GK%0<Q23Y.O'8<@F
MMQ(<A(VB^?XVC,EZ=KGI#45DCMSRPW;C%U:S:AUN)R8L9&.^W6=1YPUQ$L3G
M1%-^GJ#Y08]*QK6]+19GY&-MND1L^4;4^9CW[K<@VRMK1SB_S8>T@6;B2:-G
M%YK7#'NW ^0,=]M&W=UWP'$YQ=.(9"+/(- ))FDF3(%*N6S&PV"SF3;+K:&<
MU[0TZ:ZN&_.B^GLEFLMC.YGDZK@O>W<^;VE:*.EI[LZ79?:VNO#EOMQI1K+_
M 'U>ONM6%26M[LK:-LQ8B&DP275KG!SWY91%(,R!@+S;F2,.>5(&0B9F-)D'
M,2()J#3TJ5-N5(!*4"E(0G,()IIE\E--)(-DDB)$*5,A4B$W(4O.)S!S:B9<
M[FCO-?6L@&$0%,ZE2FB)HB:(FB)HB:(H"ZBA  $@+S& X\YBG4!,"$$W-T*?
M*=<=^4H(D4(H;?<H[%,() SUR1>94K&J"\I1*8G/T0B0A5@37'=,I#E265.*
MR2FU0J!BE1IZ8%!7$3%*H7%;,<YGDF#!&L\QC6"-_/HKL<T.KI%1$=!FHI.F
MZH$SA"RSA?(^2<OH:R.Q3IZ*\I]7[/;<<9!1?=X'J;''%SH9;K!FRQ92V]P.
MIB2YD3C)*$:7F@I+-'\/O:YWEER$P%[W8K&TI$K&+(S4Q[)8+*TO/CZA_BHF
M''R?&DR"(S()+IW#"&R(VFYSV7<V1@,\9B EH\OQ( &$D9-AH;!)KY6*'7_X
M^8+8Q0?;&M5M:$VK3/9K4[=-:GZ[KDXIGD>P+V%NW>P6&VM28)EKGA*=$T67
M9'0YFQ'U@3OMHL;0;EZOEI:K9;5HO-;;ZCD+9X+W%OFDN@$S +B0#$5'72F)
MV:TV,=#<570)($-D "0,Q2 <I(D %7JD3*03"7F\KEW 3&, <H<H; (B #MY
MQ]<8?7".P;8%L@0(7?12FB)HB:(FB+SZU8R1Z8I3)ATIE 'G,4!*0A04.H!1
M5(8Y2E*)#@0I@3Z0JZIB(HJ<U'M) BA_"/FB8H8U.E1D45B6?+2<<_XLSO#L
M56:.92?5.+#*X8@<BD?W==W-XCH:+N<<:'))%IOS%8,BRA'M-?F]%;AD&RJM
M]O.>^M=XW*NL-+3%O5IQ U@@C% PB/& $U,D0&_[,\X(A6:["9&8R&4].=#K
M[)TMNQ<P ;\FLPCCSFCV]S+<J"D&/HX9&23N1DJ^DQ\9[Q>5\A=I98,)F27(
MF(.1\TL [GO+ALV0J-@=#S4*ZBV^]NN]/YO.A^/':LXL6D6,-:X5P"&5@^3K
MBG,]!;O46KO'8<9DLF()^Z SF<XC.L>O,#14%-0$Z.F3*0H$(D&Q$BB5),RA
MTT2]&FGRH)&65%%$ !) %#E0(F0>74$DYGGS.O3U+&U@;$33H[@!ZH]2G=0K
MIHB:(FB)HBDZRK"EZ,1Y?PINC(!S)I@98QB F0%%ED2<Q@YP!,!,J<?*(7E3
M4T16!9<9U6'%N3L?8W<,:OQVTDUW5U4]S=C<8\MNVS-JQMNQEN%7:FZVXIBR
M5WC,$UW\55+FTX+8=@6OB\;-64I5=3K93&8=RKZYGD"=S6U>>< 1('W1^Y%8
M*RV;9:^3A(B'&C9$G"22()($9Y*P2$L FO/DDOO(AUR9<9ZA[)NVVAT7F4JB
MZW6V77)V'[C3WR^PNSY=C;N%G+8\Y%81/9>T7#'G(#'9*%W=96I<'!878QFM
M*-FN-YJ&1)8\AU"VU80<,2(8Z",1J'@@Q(@UE:[W5'D^3-;($U(/G@@U!/E#
M$3Y.F:S16Z%H@3DZNFNEBZ.J2::]HHL6OF"F9+9IY3N,?#<D;S3,VO?9+9X6
M+M9"^4"%R*W:N[JVL+K;**XGIE*NF27";,FR;@L_(9E@;YF<FF1Q&2<YD[U%
MICM2'/\ +(R<:Q&0&++"=!E2@R%6T:<B/:!C'-RE+SGY.;E)ORE$Q2%$2EYC
M& !W\HYS^N.<35(DR<^"L@H -W:<SU]P4;;M$??V_FU*J!!)WKG1631$T12-
M<KT12FW .PPB(E4/L&Y"@()(E.LH(G.0NQ2 4 ,/,H4W1D4(J.S9,%D@>'96
MFUW69Q7YN0W'CRDN_6=D6U*\.^]V9E-VZ7V[VQMVBNKK5;*EP5U+;JFDMEOJ
M7!3(EKE*'OE7T*%0HHC&(3$U5PPD$QI(KGWU@Q2L&M*X6).H!XK=5%R*:4H1
ME>(4N,8O:3\47A(C59[E;=))=,@XX.SNQ:G^&[H^(ZD=VQO?[/>W1$CA*\I>
M@R1[+8'.R'NQFP\CC;[7#K,$XZB9C*L4W>X'H 4,>6@C/S<YTW&9STSZ-<HD
M8X.X\MMJM&VOJ,8QE5\-9_4,W5;T<D:6,MN1R-JK;9RN^=XP8%V)?6E!+L?;
MELQ9 <-/#B#7MBLA7*_NFH15=5VOUVN5FG#!&E./>*JCABF=:F*<=>BO,0IT
MZ<# F)Q PAZXYC 4"E A"D+ZPA2E  V(4.;;F.)CB8PR229/%9/M)^I0&ALQ
M-=ZCZA631$T1-$31%Y]<L*/1#Y/*/-S[@;?;G2* $, <@J',<J::1C%.J<X<
MFX$.&L;W%N&(K,SN$9>M78T.F>T<^>=-YB@ZEB3GW.]L.F29OP_IB3[CN>V7
M^-H%I,XFW:8<OS+B^>IV9!71&2%:S;ZZ+_*37LKB&]61CM*3'9$-IC1UR2J[
MXVM,CM-V62R.&OR-,@'>H>,)B-QWTZL]XI6F62@8+<-9J0?:;!52.U+-353%
MJW>#(BBS.9R/.,XE<4B4CT;V1-3#KR<M:C)%RQURL3OC?EIR8M3)4OEFQ1-U
M!>;O8JR^W:T-2_6 Y@EIK(J.N-(YIFE""(S,->1C:,C .\&NH-<R-W3 *R=Q
M7$460BRK/',,QVR(HCQOC7C86'&S1;K#95D-<[E67>Z'LS1:=LL[=M W2\5]
MPO%Q[VVRD"ONM?6W*K!6MJZA92220 =,ECP"9WF37LX]JJ*0@$W -^WW_P#Y
M!J@$$G>KKOJR)HB:(FB*3JUUT!1,F1(41,H%2JJ90O<Z8)&.58I4R*"J)3E
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M4UAS,8UJ9 Y0NE%I1%8&)<FG;6^XZ)[8[5ELQV,06N#7,Q--0,6,D@P1(AI
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M:(FB+H<W+MYNW?S_  ;:JYQ;$:RD$Y"5)U-6=$"\G0F.?F*F150R8**%#GY
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MXYLIU+)GE/)<Z3$P:09.493,;ZU-0+H*>C1I^D$G2',KR"H950ZHG$G,!3F
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MHG<-)IE&$S U),KC;)KZDN-3)TYRVD34DXMY,0  KG:-(B(&(3L WE"4"D*
M"&VY@Y"$\I0QC&/ON FW$ +N.^);,T C+6M:S6L>H!3NBA-$31$T1-$7FW*I
M4I2)'(5,P&,)/+.4ASJ&$A$J= RATT@7J!,)$>F521,J!$U%4@4Z0E'AQC#U
MYY&.*J1!,<=A]@)TBJU6N-5F/>'>Z)"@1K6EL+46(*:TP21%$NLB=)PB?("U
M4#"9SF0O&2..L*0&Y::CQ-9-;(C>N;(FZ8,FHA8)I[C]RUM7$LEVZ)Z9QV'
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M,B1"B1,I$R@0A$T3*HI$(0H 4I$TDR$*4H   &^VXB([MH9#/1GU@$^TK1L
M ;2!'FCJ&(#V+V-8UL)HB:(FB)HB:(FB)HL;R1$&,^Y0C@&^^W;Y/;Z?3_0&
MBK)@5.9UW1[^("&\Q?B_HUCM-.ON5F$F9,Y=ZY3]/Y/VZ6>O5WK(HFLB)HB:
..(FB)HB:(FB)HB:(O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g521849g41w64.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g521849g41w64.jpg
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M 0$! 0$!_\  $0@!' '> P$1  (1 0,1 ?_$ !\  0 " P # 0$!
M   ("08'"@,$!0(+ ?_$ $80  $$ P$  00! 0,*! ,$"P4#! 8' 0((  D1
M$A,4%18*%R$9(B,D,399>978&"4RM3-!428G*$(I-#4X0V)QD9BVT__$ !P!
M 0 " P$! 0             ! @,%!@<$"/_$ $81  $# P(#! @#!@0% P4!
M  $  @,$!1$2(08Q01,B46$4<8&1H;'1\",RP0<5%D)3X3-2<O$D0U9BE1<E
M5R8T1)/3LO_:  P# 0 "$0,1 #\ [^/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$
M3Q$\1/$4 _D]Z.N'D+B2\.FZ1_NU=S&F8^QEF05J1&42V,R0;N=$AW@C"<2L
M.N2@=]OH4_9;%OY$H@ENW_ J(7PO^9 K, <X ]=ME#"DNOOD%OGC'GGHR"2O
MCHG=-SU"^OU/F_/.MXH/I+7,-ET/"6<P@DU;=6E-DI)'1\YC283)2*$4Y!)#
M(@7J.:-GCAXP*2&@N&^Q(SD<]\;8ZX]GGR.:US\AL@Z0[5[&Y!KJX:,H>=\R
MR0!"*U@5IPTI,9S=YG:-[&)A.MQN+-KI5_  QA1( VC,!^^4-6#?27&I.V9R
M(2&:$+<!I.3JW\/9R._7[RHE]_?)K\B?#_/_ !;8)Z#\R";7OZ\)-15N0"75
MK:L@#Q(\UF\L9!I9 3X:\(.X)Q%Q%A@=P(:F!"[J0-'+>1IGF[<GH/;%+6!V
MK&=AGGY<N7Q^"E%6_P B-^_Y5*T/C"L>+U;+7;&BTKC@%]U?$)I'AL44<Q\6
M32#6_6!RR)NKLTP^)X:MRH>R0&Q';>/--6;):5:N 906C0'9YG&#\\_V]JP[
MXD?D.ZQ[JN[NB"7:ASP#B7'=R?W.#\576%DQ^13QYM(+-!_U(\+2V]9T,C[9
M'$"9NOX9  75<?R;E#^6:_JI++D>T-#2,]X ^KRY;_!7L^*BYUJM^17O^V_D
MF[OX'"E>.0#3DZJ"5E0R?F*'N=ZK,W2B-;/ 0"5,D.K1[8"UU1L'#0P?&[/L
MZJ#=B#4-JFM^AH60M 8UV_>R,;=,]<+>?Q9_-#3?=7-D9LV]CM/<PVX6M\U1
MC&OY5:L; ,[/FHD5!R[9W3[*9E!<@D:)9*PHZ,_IQIH;,#9 IN*RZ(ZN1SMX
M4/9I.!OMGERY\_<K+!'7W*4@@*UJ@.E*).UHA-MJTWGH:UH.5B6UC8W033@*
M!Y@;<#7,T<[.FF646;.%3C_1ZR49,5TWC;94JX(Y@^*R5QT7S^TJ9Y?3J[ZD
M;T@.07</[?6L2))5HR2;$,B'/[<WW+8C;=1 OC(A9%4CHLD6_P#+-T\/O]!X
MF#G&#GPZJI.@/E=)V9\F73_,IVR.5SO'%/\ *@_IB&=%0IP]")[#R1JJ6:R,
MPL@G<$MK-]'XVUG!UD9-L!$9UW)BFZR^@?#9\-5*Q;AH.^2<8^]]]E:$GV-R
M(L.K<PEU1S@J)N0DX#5 43O"LMQUJEV<A4B3L56[W63Y;3DDUE22L9<,8PJ4
M=(2%-0*JEJ2TV;8*N#OL=N>W+UK(IQTMSM6<L90.Q;UJ*"34@H"2:1276+$H
M](-U)4]6&Q75025+-7K?,I)MUQD9_912Q(":*HX/EZ]3W0P3!YX./%>R8Z)H
M*/6(UJ(]==5!K3>O0(QM792?1=C,U"DJ0=NHJ*_IQR43*Z%92U8$',9&*-='
MTA;#WZX=N]28NMT2C'7I]_4>]:\D'<W%,4S+=9+U[S$#4@,E%0R=(D[XJYHX
MA<N..2;,/&)8V6E.J\</DG(0TFS$&$V;]?(4QMHAG06_V;E.#X'QY+-?_$YS
MCF=?W8XOFG\V-F2(PW6#8L>(YE:LQ7;-WVD01!8+?R2\JU8.V9%:.(M]S+<<
M\:$'#))FZ074)@^!\5O+Q0GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)
MXB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(
MJB?G;,"V?Q4]> G+]JD=F<!'QF'A,K:;&95(G,NCCM(''!>F=GYLKEDT>/\
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M5KD)(V$A-$)5^#=$,Q-,02[U8&.P0W16*.2N6/XAJ+M1#*J^J22E@TGZJI<
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MC.E:.-\L)XI("-9[.KQ3M5Q.5HN1?DDQF@AM#G7\02$Q7=)..IJ.-6J@X?\
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M<[D\CU^F-N6WQ*ZOV?QW1^S6[4MTMTM?W3S8BB@\W /9RK7U1$4'">JZ;H=
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M6T$:H\\A-5Y$;&G/<=WFZ)=3;7J]@$/JJ"Q&M:^ L8Q"()'1,4BD?&IY39"
M01DBP',D?NSLHIE)NAI^5PONHY=+94<N557"JBFW"U=545U345E7*Z>IJII)
MYYGG+I)97%[W'H,N)P   ,    +IH((:6"*GIXVQ0P1MBBC;^5C& -:T==@-
MR<DG<DDDK,/?.LR>(GB)XB>(O0_E1F"F G\BQ_F=F&Q7 G]M#^2R,U<:M-B.
M&/Y/V?T=76^K;+O\7X,.-L(_D_)G[?$6@^C^K:.Y2B2,KN68MPVY-79G%(B,
M1W-3V=E\[:)HA87$66=BIQ\LX6;MMEDTT1;!5TWW+D1S93"^) )Y*"0/O<^I
M4T=0P[Y4._([&\"*7B--<O&9"+,%.?YY8"$6M:R(Q'S @TPQ;Q-L.=NXRUD>
MS?.6T.$;,7@!9!3>0MBCMH&?J6&D>)/CT!\O%5[Q\AX;@D>!VV_NLZN2J_D^
MMBP.;;.'\U\UUO,^9YUJ?B1J(W6[SN0@Y0;J$FM6OFCD#HW3BTN"I-1[C]?[
M%AJ;;'Z&$\+KXW@$#(W(/D/JI()QC QRW/NY!7R([[J(I**H[-U-TT]U$-]D
M]]T-]M<;;H[[I;;I;[)[9SIMLGONGMG7.=-MM<XSFJLN>WH3JVC^)OF3+V;>
M1],C#;-XLB4))2J/"BDT-<X*A;+=/T<3L%'&!8U'8'8*SL:Y1*-&J[M4Z^';
M+B\#%=B>?6;38KEQ+^SR.CMD6BIHN(ZBH9!*^.FCO EHVM/HLLSHXYJJC:UX
M+'. $37X?K 8N#K[I1V?BUU36O#H:BSQ0.EC:Z9] 6U)<!.R-KWQP3ES2' 9
MUN:2S2=:SJ$7#$OD1^2_F"^^6AA\Y07&U>WXRLWHEY%3\2BEG26Y(HUB,:J"
M(K208&,2?,,?).)F05V'Y&CU5W*B.[?9T/<FOEJ;?4<(\&WJUWQ\,5UXAJ[6
MZBM#9XJB>BAMT[IYKA.(7R1P>D-(IF#7K>  00U[8\T-7'?N(K;6VQLCZ&T0
M5S:FO,3XHJF2KB$4=)$9&L=)V+AVSN[I;DD$9:7WN>\P7;)XB>(GB)XB>(GB
M)XB>(GB*)-L=V<F4;-B%<VK<P.(342V'.R0!T'E;]RS;EF2)$=NLL' $6>NS
MIBX0=:)X<Y5U263V4TT^_'UD-)Y!07 <S\"J9^S?F*BH+IGFK6@)@M+:C@QC
M>1V6L+;%!K2?J'T'<?+1G#0TU&+K?TW$W3YR'<.6WZ>98>9./QJ* T%<7#-C
MG;H/OX*A<,C&^/OY9WP<*T_3Y2^!]]=-L=%QS7[\:YQC>,V!IMK]V,9^F^-H
MEC[<X^OTVQM]/MS]?K_L]72[P^2MJ;X_-3U8/FA-BS),%TW3 @U;OF3I+.<I
M.6CM'1=LNGG.,9RFLBIHIIG.,9SKMC_#'JJRK^^0&X>I.=:.Z+Z)J Y2;*%4
M/S?*;/'QFPZUF4X/3BQ8PVEII^*<F(];U=-8M$VH45&T$\Z!9 3)OS1);5V.
M1$)MR!6: 2T'.[@/8=O!>Z$,=OYT&3:6W-R?&Z3VJAC9<AG3ZBI^.*1Y_D3J
M1,QX@P?].ZB&D>%#ME),XL!T63209-5P;F,I;8_J+4HVZ Y]>?T4"'O??;F.
M5E^NFV]!"JML[K7G>H^95971]CA3TTYXM2W(I4!2^)F"7OY%<'O-W4G7GE3A
M/V&.S:"# Y&2:D%9>E@"5@T9QN3I<3C', G YYY*?O+O3EAVET7UASS,]JZG
M@[G/2GG@F\*B$&8[#3S^U 4B,%JND4>,3.Q$Q5E5RD"&D3F!4V)H/P$RC9!^
M"B3AP@R(%4C !\>A^8\CT]14O&EE1!]9T@I]L16WGL7@<.LHT)RP>Z(-HA/)
M!.8O&2.A/=# UPL^,UQ+6RC!!TH]9Z#TG#M!%!\R47*%%7L>6]5UI$I_;U26
MKSS654U+4Y^<R5I:% V/>LWEYR.LSYHB/ )0_HFA1T?;;#& 86!8[(S O))
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M1!!%/7_9HDDGKJFGIC_Y:Z:XQC_Y8]S))<2YQ+B=R2223XDG<K=      #8
M; >H+S>A2GB)XB>(GB)XB>(GB)XB>(L7E(C=X(,N@X*,%I7H'?XC^DG3_"*<
M&$VB^PAJ7(MAQ,@S$J/\HZ/G#-B^<MFNZRS9FY6UU1W*, \P%REV#\#/95G3
M8]8,LMVAG<FDADA("CM"73YNFH5*$%RCURDCBG-M4/RO7*JNJ:?T32QG1)+7
M1)-/37)K;C&_A][JFAQ\/'JKY. ^<+=YXH=C3]_+U9,B$0,O](/((8N5-J?T
MB1WP1T$'%9)#HTZP[$%UR6HY5#]Q'^'<,1^N&N@Q+5:KB"<A6:W'/&<J?'JJ
MRBCW-1\TZ8Y#Z'YX@#Z+B9/=U4S*KV)R8/RK " TF85V#<''?\*$/D'NPM)W
ML[1&(LT,/U$\-]R#'7;*^I2TX(/@0?<5'GJ_EGH7HJD>?^?FSZK6E2L7L74Z
MX@ZM@3>-N[GAT&&C]A=.1N="ZO//!=>3B1LD'%H.G,6'G#D18;PIAEFTD)<@
MF0'&_7IY'QZ;CIYK&NN^7^L.K:\#U5N"YBKVN(K9/-,["PIO.YQ*6!1*E;B
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MY[F"N8]S#47"L:PM>;?"6L,3<M[:30YI9JIYEQ-\ XDK6\/4P'HM)(RINU<
MUQIG-#A%24Q<',]+D#G!Y(/9LU-(=B6-;/X*^$/EW@ZU=[PC\FL"V+08,2HN
M'&Y^H!;C8.S--%AI1X!# !3#7>0$!#IX'=&2+QYKH,>NVXY@.V=.55OBXI_:
M5>^*:$6R6&DH*%SHWU$5*)2^I=&X/8V6261_X+)&MD;&QK>^UI>]^EH'TV3@
MZVV2J],CDGJJEK7-B?.8PV$/&EQ8R-C?Q'-+F%[G$:7$-:W))N:]YVNM3Q$\
M1/$7SWY84+W')$R3 >H7()B12;YVW:[DRJK=R[2&L-5U-,NWZK5D\<IM&^%'
M&Z#5PKJGG1%3.I%7AV%U1/F<T#<=<CH,)-UG9(S]TD;<::NXGSA73C\:1"V;
M$5U2<MT'Z+9QIO#HXZ257)/UV#M=B^U= @<ID#J>7S^^JJ3T'/Y??12#Y1Y7
M@/)E9Z0:(KOY')3I!>4VC9TCWV=S2U+ )YV7.3"4DEE7#I99VZ56_CF"CMRD
M*9;:M]5G3I1Z_>B<G]/!2!@?KXJ3GH4IXBI@^7MR,@)C@[HNT@[F1\O\^=5#
M)/?XQ-@H991_23 EXK6EG& 22:ZA077\R?:*J(MVKU\HZ--&+)DZ7?X2V]%X
M :^JCXHM%#(V&]W:QOAM3R\1NE[&9L]911RD@,DJZ=I )<UH$;G.<T-RN1XK
M+8'66OJ6&2VT%S9+7-#=89VC#'3U+V;ZFP2NY %Q+PUH)=A:2^2OJ#FSL>!<
M_<Y\G6=!+^Z=GG15*32GG-2&&,T(4TG#9:PD,KM>4F06SM. L8]$FY5B41,.
MAIK1N45=9&[M!A!=GL^#;)>.':J[7>_455:K+2VBY4UP%?&ZF9<34T[X8*""
M.72:M\T[F.C,;7Q98!K#GL#OCXAN5NNT%#06RHAKKC-<*.:D-*\3.I.QE;))
M52/9D0".+4UP>6OP_5ITM<6]!GO)UW2>(GB)XB>(GB)XB>(GB)XB>(GB)XBB
M]9W:_)=,3!_7]J]"5=!)L*08.2<7D4H9,C(]$HS1(#MWK+.VRK7+U@X;OF^B
MV-%%6CANYUURBNEOO.">0*@N V)54_4?R6R4G=L#F_(Q5&V>8^3V8.U.P93"
M7>2(<Y'K,.*5HRB3'*6F,ER</CK^0S_1HGG<>F^9(EGBR68@XU]( Y'F>73[
MS^BJ7<B/RCG[?I^H5BR?R7<"J:Z;Z]94MC"FNNVN%)<U2VQC?&,X^_1773=/
M;&,_YVJFNFVF?KC?&N<9QB-)\#[E.IOC\U-EB^9DV3,D.=MWX\@U;OF+YFLF
MY:/&;M+1=J[:N$MMTEV[A!319!9+?9-5+?7?3;;7;&<PK*!G=UY=)\W4]?\
MT!6;2G=ZZH+G>1VYN-GT:ELFD5AS:-(RPJ2A;%S&[%A3>%!&@,*"W4D;X7*E
MG+V1;:-!:F@IUIN5F@$@'.20/>O;CDF[G*/@I(Q).5P53D:T%V,_MMU6M@);
M!GKQ@F[>P=[7SKH5NJG@<V5_FUK!6F[<+J+06:+ $7N?R)E&WGZO[X_3S\E!
MG;Y%.L'7-Q+J0&#HM_4,SZWHGG_G"5%JRLF.OK@JNS[:C=,&^@5X>K=!%W'X
MN_D\FW.50-7/[OIG#([J?)Z@6TR#;C"MI&<==))WS@@$XY#PP?/U*?7._3$Y
MGW1_4G+=B@XF0DW-0ZF9#M:=;Z%V$,EHNZ0LF+C8Z7B9PE(R$!L"+ZQ99P5C
MVTSER!*/'(Y(F[X?J0V')%4C8'QSMZL?53>\4)XB>(GB)XB>(GB)XBKZ^1V5
MTHKSZ?JFR+ZHBF9=-S57O*]3O1G$)G$BLI%V_"',._K&J),39;3*LW4S:AQ<
M\>:Z)M(S'7!23J$Q*H'4DS*1G.0"?5M\?'[P>2JF^.N-W&V[#ID/TKWCPY93
M:N8'TF_YCYNX2=L2$/V6GIX*8LDK,R.6P\P&9Q0*:11AD"4:/@:0]/1V%+IJ
MQ0HD2*[B,;-<.62[R&!T'K]:Z7O%C7C55202466431113W5555WU32223USN
MHHHIOG&NB>FN,[;[[9QKKKC.<YQC&<^(H'!OD5H*14[<73@/,C=\H4F*GA$[
MTBLT'-:^G2M<*NV$I:4X/W);S.QVS(^P>QAI)6L:&0Z2R%#(V$2*5K:K_@*V
MDY ZGIU]JR;F?MRM^E)Q.:K8@)+7]JP"OZ<MDO!)?N%6(.:TO>((3" R<8^
ME"@Y]ELFH[C$S'I+Y4C$P%NV.JQ0$^C<C/E!&/5G&?,<Q]]%2E_:.O\ ?SXA
M/^8!"_\ WF#>+)%S=_H/S"Z?/%B3Q$\1<R7S\=A:A6L.Y5B1#51;58;/K020
M5S]%%]\;*0J+O/QYQMC5!IEU+2#177.F5'$.=Z9QMKGZ9&#K[EC>>0]JG_\
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M,)+_ #X14K-KB1W1>S]<(17C#EDR@T&0RRB006T9K)N&>1;EL4V2:JML9-1
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M\ZJQQLX9B9J@JJFHT<[I+E=@'YM301R!SX;'W\O,<BHV_$U4%15SU@.7YO\
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M[YA7*^A63Q$\10@^0OJ/')W,LMFP,2G*[8F[T;4-"0#]9,@YGUTV-NJ#A0%
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MDF6"LP$G;!(WP<?(\U3K\0\ZX"EW?$>UI7KWMKY ;>Q5EXDHU,NB]9^RAW.
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M'E9OG.U5.KE* 89*(8@?5U359O'#*I]IX_;:)ZK+,64@&+;ZI(%VFRY1W=+
M[_,[/JV'+F-_+H56K\DB'R_I7;\9F?DK><WN85GMNL\5EK1^NFI364?U;#/Y
MG)W[6K?_ %#(G\.&OUSM_K'W?X8_V^+*SL^]HSG2>?AM_9=[_B^9/$3Q$\15
MZ?(3UU).=H-$:QHT2A-^P.DS:U:\V0#Z)+X3/N$M<';.DR*FJB32"U@-<?U
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M[\^2@\O7M[_IS4NJ,J"*4!3]<4O"4?Q1FMXD(BPY39/1)<AL/;ZX?FGVJ?\
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MQC(XV#46ND?U_#?#\7#]&^ 2^D5$[Q)43:=#7%HTLCC9EV(XP78))<YSG..
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MM>,:9:ES@#EDC(W+XY.(JBX/=3\-T1N#@XL?<JC7!:H'#()[0@253FD=Z.$
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M\8\0U%CCM]!P]1TG#L-^LE#>[F+?"8;@:BX]LZ2CEJ<]K%!#H_"AA['0UY:
MV,]FIX;L\-T=5U=WJIKK);+G56RC]-E[2E[&D$894LA_*^275WY)#('%H=N\
M:U,\_P!,-25+NZ+C7]G+^06M8J7(!WTED$$'V<C8TM1!K9>LP\FL&3\LRB3$
MP.2VK0TH'R^29:DQS!5NFW02W;J^0ESB=1)).Y)ZG?<^)W.Y7H A8!I#V >
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MEMG6W'CT]ZV5_E_.SO\ @+?(!_T"UO\ MI\4=F/ZC/>/JG^7\[._X"WR ?\
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MYU''@? ^)\OJMO\ &/:%%=X47&[[H229*QTOML,D<;)ZHLIG7,S9(I*'(%/
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MKS$X%-GHC W%E38)!VL\G Z.J-C#F'Q!4W@Z:9,7PIR729)@FYH(X*I%F12
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M8!"Q'0MK(2:9R./+GQH,%I*0-2"9@2=H5U7!63ATSBD:BXR/#2+QL,57%M6
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..1/$3Q$\1/$3Q$\1?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g521849g48n25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g521849g48n25.jpg
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M='6RM;;1&C=14E57=G>4L[C3U-4D)C1A-39"0U9B<7F1I['!PL/P_\0 '0$
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M<X4G[%B#GV9'KU-#\JW^SZ'_ +UL[_+U\XJ+Y&/RWM\>W/Y+]HC??\E_=_\
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M4DTV:JVT=7+SR+4QAOFL[\OH#"X'?&3(*&VTU12QRR=3G8OGE? ]%V4=L'U
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M5<HTKSQAN>&0"/7N5"880077F=O]$, %!]A;!./8%/D1JMQIA4IB][>ZNT^
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M888/QCVCV$9!]6FNX):\:('$NU^S>!WK1]AK/^7L;'9'(=)G4L@6:)AUBIB
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M1)%,B9"E"BI999Y9)YY))IIG:66:5VDEED=BSR22.2[N[$LSL2S,2223HJ
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M5@"KHP*LI ((((R-38$$ @Y! ((\B#W!'QZB4YVFF[O<G22T0%0C_<LP8HE
MR[BB-03[I*RR59B9,ELI,:!0%9V^LE)=3JD3$(=QY&Q14$)B>-JHLA:/!W=J
M;2WC33U<G3M5SB-JN<C'$=-'4RQ&EK),^BB4]8L EE;M'3RSX.6 9A<J?Q%,
MP7O)&>I&/6Q4'F4>TLN<#V@:A Y9F?XG?_ .)=3[)?(S&N_FC,TVR/HUEFR
MJ=K:Z]5$T3GQK82I"5[+P*$"Q3I-^JS/J[DL=-*_9V4=-NJ78"#<O$6QR[%O
METW13T,EQV-O2%K?O2UT^ U+451(%QIRV4BG:>0UE#4OZ,=>]13/) M9 =#:
M*4544<#-R5=*>>FD;Z(+] WK*@#D=?,I@C)4ZM7XP&KY?/7,GWO%QJ9G&EQZ
M5=LU6LYO<IC'$^0'9I%G!OBJ&AIF ?.73]U5[[ HBTM4&LW>(.454W$='X]O
M^RMNIN6EO[TM#>:RB@:*P7\H[LM"SS.K002L5H*T"HD2LB:)*RGD9H7=HUB9
MC"PP32)4R0+XF)>0%_2:+S)Y,^C@EB5D498$=^V!5>YN8S'+)YKN%^8;C.G1
MLK'98H]YE5Z\<!B8*6RO$T"7Q;;TI7VY,H TDX>X46V2RR?CDI>8<3S_ ,GN
M!C/AU_PL$7$7AA>-AW&KDB>V5M%$*@?-9XK7+717.D,?4/=HYZ2MI8@<QQ0K
M!'CI@)H/7YHJ^.K100Z.<>0,@0HV<>T,K'UDY/GHR=!^6-D_)=>K>]>Q6<\O
M6',VY24+E'*D;C/,^0L"?-_'-MAT)S'K9I+8O?0$U.RT)&.HATK5)"1CZA7X
MT&%5@X8BU?2F'=8<4N)5VM5VM&RMB;:VA+M+:MQJ;/=OECM\5TN!6$/35%;:
M%K8:RWAHZU9#4"IIWJ;E$99O&0R3E!U@HZA^E5.Y=JE@]0!+)"5B9<H4,>.9
MER"R-A>7T5P1DRKX+Q9>-=(.'9HTG+.8;)-SZT+6;!E?-D]D.ST/'RLD[308
MVZQV"1FJ]$I0K,6:[$:+7(A>4A'S>%G$)&?KTK9+%GK<.]+_ %=#8ZVBX9VV
MVW2OJULU19+ MCM-OL]HIIG6CN5?7T%#SI3-!R51M,?NC'1U#RI3S0ATIH7$
M?B*>.,K1R22R2=-0\X/0@#$*99/2"JJX8)$A['E/IJ69PN8%L]$Z>Z?YRSP_
M?(-)FL4N2CJ W5.0%)7)=E2- T&-01'JHX*-D?L7LB"!%5&L*RE)$Z?IV2YR
MV7L7;<N[-UV6R(C-#4UD<E<P!Q%;J<]>ND)'93X='2/F(#3/%&#S.-/:N<4]
M/+*3W52$^%V[(/OB"?8 3Y#4-?R8C#$I4-2\RYNF&ZR"V<LO$CH1=<#B:6J^
M+(E2+2ER+'^*J9[A9KO%&'J8P.8AR)AZF^%M_)'7>.JW1:+-$P86:U&28+_B
MJFYRB0Q$>HBDIJ.7V<LJX\M#K+&5IY)3_C9,#X508S]\S#[6K+O&=]&=1&<T
MCFU8IY<U4C(1HPCLH;#VY)L]J>)4Y86",973.A2=W*^2+1)TY@($Q$7;6!;%
M;GD[++)F0CT21K&:E8NT^&O"ZY[_ *F29WDMM@I2R55T,74,M0%RM)0QL46>
M?+(T[<PCIHCS2$R/#%*/KJ]*-0,<\S>]3/8#Z9SZAZ@/,GR[ D9K4+G,:*;;
MUV(.TR[6\-9)<MT"3&*,RSD72IUE*F*4%F=>GIA=C6+PV.J"AF"]<DW$FLS*
M1>3A(9R91BCQW5PCWKM:HE#6JHN]O5B8KI:(9:R!XO4]1!$KU-$P&!(*B-8@
M^5BFF7#MZI[C2U &)%C?UQR$*<_Z))PWP8.<=R!Y:D[;6JKO8\)9G9(%W%BG
MY@DFTQ'+QXI=.[R@\2<';BGT^/?Y.WI\>O3BN6IJE)#$]/.LH/*8VBD60'V%
M"H;/P8SI[S C((Q[<C'W?+4 O/ YENM6/]1,OZX4C)E.R9G'-, ./TJC2)V-
MM):7 RCUJ%IL%W?PSAXPKJB$$F\:0T,^<ISTC+2$<X;QIHA"2D&=X\&N'FX:
M[=5JW!6VZKMUFL\_CC55D$E,:R>)&\+3T<<RI)4!IRC33(I@CBCD5I.L8XW%
M7.MA2GDA5U>65>3E4\W*#[XL1V';( )R21VQG5!?C<&HKKI#H8NF\+<C"UXP
MLS59A9JGRT\EM;-'."&(O%V1[KU9I:?B5BF # I%2[]Y'GZ@41,V$>TO7H'S
M\:Y0W?C137&G97IJKB';FIY%.5EITOU/%!*"/5+%&DG[;4PZ9BM;(>S+1/S#
MV,86+#[1)&N;QQ] ]0_71SY!/W*/63^&YP_V@LI\?/\ XX?HG;D^QLW] VO4
MPM7SA!^Z_CI-3&\5/HAI<+2TN%I:I]?*M_L^A_[UL[_+U\XU;\C'Y;V^/;G\
ME^U'[[_DO[O_ ,G5;C0:1CX?>O2R6EGS.+BHO;37*1DY.1=(,H^.CV68::Y>
MOGSUR=)LT9M&R2CATZ<*)H-T$SJJG(F0Q@T'OB.2796[XHD>263:^X(XXXU+
MR22/::M41$4%G=V(554$L2  2=!Z4@55,2< 5$))/8 "1<DG73J^N(U__P >
M>'?RFTK_ )WQ\Y?<"^_YENW\'5G_ $=33K1?58_OU_KTOKB-?_\ 'GAW\IM*
M_P"=\+W OO\ F6[?P=6?]'2ZT7U6/[]?Z]+ZXC7_ /QYX=_*;2O^=\+W OO^
M9;M_!U9_T=+K1?58_OU_KTT^[DG&S6AVWDO#R#&6B934C/[^-E(UV@_CI%B[
MP[;5VKUB]:J*MG;1R@<BS=RW54162.51,YB& 1*;-CDAWOM2*6-XI8]U6))(
MY%9)(W2[4JLCHP#*RL"&5@"""" =<ZD@TM00<@T\I!'<$&-L$'7*YX^EVH/K
MHV\@3[E/K;_&>;OS]9,XP#QQ_1-W#^IV;^@[=J7VKYQA^.7\:^GLYL6F".\6
MEN2\814>D[R?54/JFX97[""Y#(E19O5FL&@H;IXR76%<S-*4%0X-T#SR$BJ4
MQX]$2A^&&[SLS=]ON4KE;;4GW.NZY/+X"J= TQ'K-',L-8,#F80-&,"0ZZU]
M-XJF= /37TX_LUSV_;#*_;SZM<RM=!9LLLV<HJMW#=51!=!=,Z2R"R1Q3516
M24 ITE4CE,11,Y2G(<HE, " AQ]%00P#*0RL 58$$$$9!!'8@CN".Q&H7J^E
M\G3WB^K_ *OO=9KO,>JRAK"BQC( 7B_>^G\)RBJB5/<)>00.O\Q'Q'%(=$0)
MX8R"3I!%E#.)$1'$G'W9GN'N1-QT<7+;=R%Y)^0>A!>8P#5J<>]\:G+6J6.9
M)S6\H"QC4IM%3U8#"Q].# 'PQ'WOWIRI]@Y<]SJ>3*E3GKA2Y%C3YEO6KW&'
M0L% L3Q!9S'Q%QAC"ZAC3+9L=)X\K,J<%:_<HUBX:/)BG3$_#MWC11^#A.DK
M9504E7&]7"U1129@KJ=&"R2TDOHS=%FRB5,0Q/22.KI%5Q03,CB/E)1U+*>4
MX8=T)\@P\L^OE/DP&"5) (SG5-/>CEW67,-PN6\'+T@[#C[8?%EV]?M=J%6I
M$S#,6"\VQJWO#V]XG3B!9N[% 6ARD>WUMQ6TR)7&/<HVS'I7Z<G(5>M:VV7O
MZGM-+2;-WY-!7V&Y4?)MC==3&'M-[LT@Z245T,W.M//3*125"U!)I)%:EN!0
MQQU53'JJD,C-54@9)HVS/3J<212#OS1\N"0WOACWP]),Y*J57+_^4=5A=I&8
MCYA4/(4R[0QB0)L]URN.EX6579J>D5^J?1(AH:;JLZDLD)9&4J<7)Q#IZ=8R
M];JK=LHHK&=\_(_U >2Z[$FCJZ.7,_N)45"K-$KCG'N;72MT:F$@YCBJI(Y5
M0#%35,P [4EX':.K!5AVZH'8D=O30#*GVE01GZ%1K;?E#^2]>]CN7UBC*F'L
MK8VRB-6V.J247,T6W0%G.A&VK'^14)F(=)Q3URYC%UG$;#O'K%\DV>-UH<J+
MENFHF<A6W 6W7[;^^[I;+M;+C;?$[?JC+#6TD],&DIJ^WF&53*BK(H625$="
MR,LV58@@GU=WAFI(Y(Y$?EF7!1@W9E?(.#V\AGUC&#J57E)9L+<>5MJCD[),
M_%P3:!QC(4N4L-CDF<1'-HC$=RL^*HI_)RDBLW:(E4AZ6P67>.ER^4YS+*J"
M<YC#67%*S^$XE;GMUO@DF:>XQUD5/3QO+(TMUI*:YRQQ11AF.)JQPJ(O8 !0
M  -/J"7GH8'<@80J22 ,1LT8))^!1DG7OE.97BW)MJLF.=1I.OYB=4AJXD\Q
M[#OG9H_4_7>KLT57,E9[YE-1Q'15XED&"2SZOT3'\JY^<AFS@DM<:5#LY6Q1
MG./AY<[;2T]PW5'/:5K'6*TV!%$FZ+_4N0L=-0VP+)+11&0A*BMKHE\/S*8J
M.ME>*GE_36([%*?EDY>\DQ.*>(#OEI.P8X\E0G/K90"15_W\VLRASI]OL1:3
MZH.)>=PG3+$+:(M4FQ48-;M/,VPQ]TV(O#!FU8HPU/K4$>2"JL#,6;U.-?21
MFS)M-7-I6([2&Q]L6WA!M2Z[QW.L4-XJZ?FEIHW#M1P.W4H[!1.[.9JNHFZ?
MB7ZCH9$C#.T-&U3($JYWN51'30$F)6[,1CF(&&F;RPH&>48'8GL"W*+J6O6#
MJ3K3A#%^!L=-C-Z=BRGQ-3B3K%3([DCL4>^3GI+Q 5(\Q8Y=9_/S*R92D7E9
M)XL0A2J 4,@7Z\UFXKS<KW7L&J[G5RU4H&>2,.<1P1Y[B*GB"00@DD11H"21
MG4DAB6&)(D]ZBA1[3CS)^$G)/PG3R<"==-4)^;QR>MR<;9BR9LO67U\VUQC?
M9Z1MDU>$6ZEARS2@=&$Y8N^U6';%7<0<"Q33CXNS4^*+58Z"C4$GT12VB#&-
M-MSA7Q7VE<;3;MNU*46UKE0P1TL-&6$%KK.48ZM#53-A9YW)DDIJN4U4DTC%
M)JQB\FHM<+=4)(\REJA'8L6\Y%SZF4>8 [!E'* .X48&J[)R&3,8ARF(<AA(
M<AP$IB&*(@8IBB "4Q1 0$! ! 0$!#KQ?@.>X[@]P1Z]"-?SPM+7H:-'3]TV
M8L6SAZ]>+HM6;-HBHY=.G3A0J2#9LW1*=5===4Y4T44B&444,4A"F,( /EF5
M%9W941%+.[$*JJHRS,QP%50"220 !D]M(#/8=R>P ]>K2O)XY&&3+9D"E;/[
MFTM[0<9T^1C[70,,6MD=I<LC3\>LF]A)2\5QV0KFL4>->IHOSP4\BA-VM9LD
MT>Q#:LN#N)?-G%CC1;J6AK-M[1JTKKC5QR4M==Z5^:DM\$@*31T50AY:FMD0
ML@G@+0TH8NDK5*A8CEOMCLZSU*E$4ADC;LSD=P6'F$'L."WLY?.U9O\ ?:(;
MK_@D;(?F<N7&9=C?GVV?^RG;_P#2U)HY5_.M3^MYOQ;:Y6W'TOU!]='/D$_<
MH]9/X;G#_:"RGQ\_^.'Z)VY/L;-_0-KU,+5\X0?NOXZ34QO%3Z(:7"TM+A:6
MJ?7RK?[/H?\ O6SO\O7SC5OR,?EO;X]N?R7[4?OO^2_N_P#R=5!.-5ZC^EPM
M+2X6EI<+2UT@:;]P9C?_ '4SO_93<\?/VJ_1MD_VG+_ZG74P3\RQ^L3^(.N;
M]Q] M0_71MY GW*?6W^,\W?GZR9Q@'CC^B;N']3LW]!V[4OM7SC#\<OXU]3)
M\5+HCKGE<_;2KZUC=*6R/5(GT.)=GBRN3ZUZ9'QQ\1?0=HERK5TNT"ID,G/2
M#2X-D$B)MFL9=&,:U*)8U7LWEP/WA\LVT(K?52\]TVYTK;4<QS)+0\A]S*D^
M9.8$:D9B2SRT<DC?X09B5UINA4EU&(Y\NN/(-]&OW2&^)@/5H#>7CM].Z.;:
M8KS[&G>+UR)E?F[DZ#9F$3V7%UE418W&*!#N(1R\:M 2L,"DL8$"6>#@W*O4
MC<0&;;\VI!O/:]SL<@05$L?B+=,_E3W.G#/22\V"51F+4\Y YC33SJ.[::TE
M0::H249Y0>5P/HHV]\/A^F'^D ==0RM62"N-<@+=5I5G.UFU0L58Z[-QRH.(
M^8@IQBA)Q$HQ7+]%9G(1[IN[;*E^"B*Q#A\!X^;M13STE1/2U,3P5---+3U$
M,@Y9(9X7:.6)U]3QR*R,/401J; A@&4Y# $$>1!&01\8T!6X^CDQFFQPNPFM
MF47^M6YE!B#1%1R_#-RNZY?*VFJ+PF,,X58R#IA>:"Y=@"C,\C'2CZKO3%DX
M]G)(HJPSV<;2WI%9Z>:P[AMJ;BVC72]6JM,S%*BAJ".0W*S5(99**N5.S".2
M)*E,QN\3,)D:5%*9")H7,-2@PL@\G'GR2KW#IGV@\I[@'RU7<V^R?A5W8!J_
M.IY9ENQAE190(MCN=J$=-M Y!<$3%!O-D?J2<="SZA6:9')XNR6/(4S%HK$3
M5IM?53)'IWUM6VWA8/$\'^(M+<K8HZC[1W4"TU OOFA*".2: %R5$E/3V^&0
M@D5E0"9")J'C)Y;E1-')Y"II_)_8<YP>WJ9G(^E7RU'5-:P\CV?.:2IO,XSA
MCM@H/D3K>1-4\A7VPMR#](&ZTS2JK6()98H?0%5)$J0F#N#Z/$]AW)QE@'3K
M.'-GN$@[&HM^YZ"A@8]_2$-955,P![=B<_\ !F8+8>ZULJ#Z5X'9ONJH'\0U
MB7<QR;,*QT>@XN6Z6_#JNBJK6Z [.RUSP,HH955RJE**NE'N38=%TY644$U;
M:@)O4.CN2&54 3=EBXMWAW*TNT-D)48%17)S[@O:@ *IB50EMF*J /RP_;E4
M*0!C2S;H@,M4U6.X3M#%]O.7&3]+\/VW0K3;F-<W.,@<!ZU80KNN&E,!*)@V
MI>.8-[C+6VOF;NDQ4F\A795L>5R_<FZR+=](M$?G'++2R03C&H1[M1T]X&U+
M; X623WS<5YJ-P;PGC/-67"9+CN&<,IQ!040816FC*LR1L?#Q"(]!ZN10J:]
MKXRX 10QK#3 ^]0<D(QZW;SD;V^9SWY1YZMP\MKEBX5Y<N-W,143_/C,%P:-
M"Y0S'*QZ3.6L)VXE73KU=8@JZ&KTA@ZZKLX-%VZ=/W14Y&=D)-V@Q]#EGB%Q
M&O&_[@LM4/!6FD9_<VTQ2%XJ<-Z)GJ'POB:R1?1>8HJHN8X(XT9^<]1T4=&F
M%]*1O?R$8)_T0/H5'LSW/<D]L26\5YI[I<+2TN%I:%?,&CFG6?GKF6S'K+A2
M_3SPQC.K/-X]KGSN7$W[;R6YFQ:V80,/TA+[KVB;H80[@ 0DUIWGNRQ(L5IW
M%>*&!/>TT-?4>$'Q4CNU-_\ B\NWEKA)34\IS)#&Y^F*+S??8YOX]"PIR3.5
MNHZ]8;46G KW"?L3N&4TFO41Z]/0I7PC+MZ_L$]/V 'P H!\.)*.,7$H+R#=
M57CRR:2V%OOS1%_M\V?7YZX>YM#^EU^^?^UHK\*:4:C:YNDY'"&N.'\;S:1#
M)DL]>H\&G;_$8HD,B>X.FKJT*HB43 **DL=/Z1Q[>IS",8O&\-T[@4QWG<%V
MN$).335%;,:3(.<BD5EI@V0.XB![#OV&G$=-3P]XX8T/TRH.;[['-_'HH.(W
MKMK 6JK5V\U>R4JWPS"Q5*X0$Q5K17Y5 KJ+G:[8(YQ$S<-)-C_0<,).-=N6
M3Q _T5FZZB9O@8>.]+4U%%4T]923/3U5)/%4TT\3<LD%1!(LL,T;#NKQR(KH
MP\F4'7XRJZLK %6!5@?(J1@@_ 0<:!S]2GY<'WE^ ?Q$C?ZN)G^2;Q ^NZ^?
MOV33;P5'^EH?P:_U:+_%>)L:X.HL+C'$-)K^.\?5PTF>"J%68)QD%%&F99].
MRIF3)'];1%_,23^2<]OV1V[75'Z1QXBESNEPO-;-<KK63U]?4=/KU=2YDFEZ
M,201<[GN>2&..-?8B*/5IPB)&H2-51%SA5& ,DDX ]I)/QG3A\,->M+A:6EP
MM+0^YUU2UOV;&KFV"PO0,O#20F@J0WF!;3?S?"Q^TC.A%^H ?3>ZC!0WK>S[
M-[:T[OL1>#MEW/N#;GB?<*[UUJ\9T?%>"G:'K^'ZO0ZG+[[I=>;DSY=1O;KE
M+!#-R]6-).7/+SJ&QG&<9\LX&?B&A_\ U*?EP?>7X!_$2-_JX._DF\0/KNOG
M[]DUR\%1_I:'\&O]6E^I3\N#[R_ /XB1O]7"_)-X@?7=?/W[)I>"H_TM#^#7
M^K2_4I^7!]Y?@'\1(W^KA?DF\0/KNOG[]DTO!4?Z6A_!K_5I?J4_+@^\OP#^
M(D;_ %<+\DWB!]=U\_?LFEX*C_2T/X-?ZM&$VQ3CAIBTF$FU+@$,2)T4V,B8
M]38)EJY<?F@C5DU0",^PA!C7S&B!9?8_0B*'[7B)M<[@UR-X:LG-T-;[HFO+
MGQ/C^OXGQ?4\^MU_FO/Y\_?3CD3DZ?*O3Y>3DQZ/)C'+CRQCMCV:#W]2GY<'
MWE^ ?Q$C?ZN)9^2;Q ^NZ^?OV33?P5'^EH?P:_U:+[%6)<:8-HL-C+$%)KV.
M\?UX\DI"5"JL$HN#BU)F4>S<J=FR1_6T3/Y>1?2+D2_9'3I94?I''B*7.Z7&
M\ULUQNM9/7UU0(Q-55+F2:00Q)#$'<]SR11I&OL50/5KND:1J$C5409PJC &
M3DX ]I).G$X8:]Z93-^M^!ME(.'K6?,34?+4%7Y8TY!QEW@FDVVB9<[-=@H_
M8 Y()VRZK-PJW6%(Y2JIB7R%,*:0D,6;<%[V]-+46.Z5MKGGBZ,TE',T+2Q!
MU<(_*<, ZAAD9!S@C)SSDABF 66-) #D!U#8/ED9^#0S&Y4_+CZ?1TOP (_]
M]%C@_P#QXD7Y)O$#Z[KY^_9-<?!4?Z6A_!K_ %:,RCT6M8NIM>Q]CFKPU4I5
M1C$(:L5B) [2)@XAKW UC8YOT.#9DU*;QMFQ!!%NB!442D2(0A8?6UM7<JNH
MKZ^HDJJRJD::IJ9CS2S2M[Z21OHG8]V8]V/<Y))TX550!$4*BC 4=@/@ ]0U
MFEE[$'7P,(X_]SO>J%_^B _L_P#\'#77Z<^H?Q__ #_Y_%IMF86>R1+^ F:1
M2+-!RB!VLE"V)T$A$2+8_03-G\<\AGK-V@<0#N27153,( (E'H'':&:6GE2>
MGFF@FB;FCFA9HI8V'T22(ZNC?"I!UY(+ AE4@]B#W!^,'L1Z\>SX=1N9 Y4^
MHF09%:3F-!M7TW2ZIE5C5::LN-$5%#F$QU!8XZAZ\R YQ$3'$$.IC")C=PF$
M>)U1<4N(% BQP;MO#(!@>+ECN# =^W/7I4OY>7I''8>78-'H*5CDTT6?]'*=
M\#U*5^Y__ISV,>5]J1B]^WE:YHAJ^A(M5"K-GEB5D\E.&BQ!ZIN&A\B0M@%N
MX2, '2<(>-=(X =-0AP 0Y7#B9OVYHT55NR\]-LADI:CP"LI[%6% *7F4CS4
MY4@X(\QK]2AID.5IH<C&.8<YSY]N<MCX/8<=\:D:B2VN.9M(YO6JS%L&+=)J
MT81KTZ#)FU0(5-%LT;I1Z"*"""903212(1,A"E*0H%  X@[NTCM)([R2.Q9W
M<EG=F.69F9B68GN2223W.G8R.P  \@ ?+'VO+V#_ .#9$5IL0#SLV)!_=[':
MAO\ ](<>->M9 AG A]--(!_[CF$/Y/\ ]N%I=_7_ "Y_X#7V^E_<#_XC_5PM
M+0BVC#VT$K9)^3KNU?S;@)"9DGL)7OJ45>3]CBG3Q9:/B/<7+HKA_P"W-3I-
M/6+E*JY\7F4 #G$.*7N^R>+%9=+C5VSB][EVZIKJJ>@MORGVFJ]SZ.69WIZ/
MQ,LHDJ/#1,D/6D >7DYV ).@\M%=7ED:.[=*-G9DC\)$W30L2J<Q.6Y1@9/<
MXSH;]>$ML\_8Y0R"AM&I5DUIF4B/:E<7T^8.48PR)17]81.- 06\O4$_3!X^
MW]N?K\*PX:)QCXC;8CW)'Q:>TK)6U=%X-]IV6M8&D9 9.NJTH(?GSR](<N/?
M-H;;A=[A3"H%UZ0+NG(:6%_>X&<X7S]F/MZ(S8JS9-PUJG-SC6]J2>2:VA4F
MKB])0<2S/(NGUPA8Y^\"#7;OXIKZI@\6;"B"*I4@,*B0E4 IRV;Q-NNZ]C\(
M*^X0[A:JW1:X[-#+N!+?10-535%ZH*:IG%!)'44D75IYWB*!'"@EE(?!!*Y2
MU5%:9)!/S5,0A!G"(.8M-&K-R$,HRK$8P<>K1.U!ZZDJG5Y%ZJ*[U_781Z[7
M$I""LZ=1K9=PJ)$RD3**BJASB5,A2%Z]"E*4  +8LT\M59[34SOU)ZFVT,\T
MA"KSRS4L4DC\J!57F=BV%4*,X  [:*1$M%$S'):-"3[25!)^[H9\S9(NM7V-
MUHI$%.JQ]7O;FYIVR)*SCETY<D6R9*L 4<N6:[UKZ=150P"Q<M1/W=%1.
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M*:&M^&R)%*4IJ1%K"!0  %1SY7"QOA_Y1UE3F,/[(F$1'X]>#G!Y%CX8;(5
M #8*-SCZ:4-(Y^,N[$_"==[2 +;18^H(>WM/<_=))/PZ>R8KE>L/H0GX*&G
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M]0VK77<'YDU/QP?[Q%HF:%_XC4O_ "3KG\SL^+5V]^8%C_U/;/\ <H-%(/\
M 0_J4?\ ,&@YV%^VWTZ_AF0OYNCN*2XD_HR\$OU?<W^ZTN@MQ_-BS?'4?S5U
M^<Q(Q2X0K)C"!2ERW33&,80 I2@QL(B(B/P  #XB(_  ^(\?GR2Q V%:B2 !
MO*QDD]@ (+EDD^H#7YN3YQB_7D/\R71B?5!H7_IO4/QEAO\ C>+L^63;O^?[
M+_"E#_U]&O$4_P!7A_"I_:UEXJPP$[YP@YR'F1:^(7(14FRD?3^;R>'S^D76
M\/E\2OB\G;Y/&IV]>PW1[1W*W7#J> KZ*NZ/)U?!U4%3TNIS<G4Z,C\G/R/R
M<V.;D;&>4X]I)')GIR(^,9Y&5L9SC."<9P<9\\'02:I?V_\ =?\ SDUK_7WK
MBB.$/Z(W';]E%J_EON@=I_-&]_KF+^6?6*VICW^$\I8ZVRK+591A'.FM$S P
M9E'K)U*44*V8R*Y"]I5%FX&%BDJN82^YMZH3IV(&X9<7::HV)NW;/&*U0NU/
M2RP[?WK3P*<U=FJV$4%5(HP'DB'Y75Y#CQ45H7WL9UXNRM0U5-=X@>56%/6*
MOT<+G"L1VR1[T$_1B'U+IY-I\O,Z/KG9KA79!-T[ND.RKM'>,E.\7[RZMA29
MR$8<GQ45;0JKZ=:"4#"?T)>A1Z].)OQ<WI!M_AE=;U;*A9IKY106VP34[%O$
M3WV+D@J:5E[LT5$\]?"0#S= 8!SC3VZUBP6V6:-LF=%C@93[XSC"LI]H0M(O
MV.F-Q7KOMICBA5VIU3/-,JD.R9F=E@#XVAY5>.>RRRDK)-W,H\9K.I!=)^\<
M)F<K*FZE(0B0)H)I)$@.T>&G&+;&W;99[/Q#L=GHH(.L+<=JT-7)33UCM5U4
M<M7-$\M3(E1-(K3.QR% 0+&J(K&DMUVIJ>*&*X0Q(JYZ?A4<JSDNP+MW8AF(
MR?XA@:TZ)B<HZ][8T&W98NL1=&^P+)YCZ:L$- (5MH27CD8=O64WT>T319"^
M%XG!L6ST2)JG8+2(=3^!7O"4='NWAMQAV[>=X7VBOL7$>";;5=<J*W16N%:Z
ME2C2U+44T(2#Q!F6AIXI\*S4[U([]-N;@J55NN]/-5SI.MQ5J>21(Q$H= @B
MYE7T>;/356."5+^PZ=787[;?3K^&9"_FZ.XEW$G]&7@E^K[F_P!UI=.[C^;%
MF^.H_FKH\N-"Z/Z7"TM1Y:?V6N0=LVJ1F[!"0ZR^P=O512E)5A'J+)A)29!4
M2([71,H0# )1.0!*!@Z"/7X<9KX+72V6^\<7TK[C043R<2;VT:5=93TS.HJJ
MH%D6:1"R@]B0" >WGJ.V>6*.:[!Y(T)N,Y =U4D<[=\$CMHX"W^B',4A+K4C
MG.8"E*6R0QC&,8>A2E*#T1,8PB    (B(] XOL;CV\Q"K?;,S,0%472A)))P
M  )\DD]@!W)T<\13_5X?PJ?VM";O9 SA\>47(L%&K3 X?R=6[_,QS<HF6/ 1
MPKE>N2%(!CB5HY%@=T<"B1LP.[>K&(@T4,%/?) VZX-MO;^YK?2R5IV5NNU[
MCK:6(%G:W4ID%1*H&21#+X=I3CECIS-.Y5(F.A-^CD\-!4QJ7\'515#J/7&N
M>8^OR/+GU!2S'L-$=5<U8IN57;7&#OU64@EV9'B[AW.1K!6+**8**MYEN[=)
M+1+MJ B5TV?%141,41$!()3FLZT;ZVA>[3%>Z#<5H>W/"LTDLM?2T[4@*AFC
MKHYI4>CFB\I8IPC(1W&,$DHJVEGB$T<\1C(R275>7MDAP2"C#UAL$:$;$$PV
MS;N-D#,=1!1[C>A8];XTCK.5-0C&Q6!9\V?N C5%"E*Y;(%5ECF62$X>F+%.
MS%*C*MC&IG9=;%OSC;N/>UFYI]L;=VU%M6ENH5A3W.Y25$=3+X5F $L40>L)
MD0M\R%'+@)5Q'0>C<5UZJ*R'TJ:GIA2K*/>R2%@QY<CN!E^XSV"'R<:D*XTE
MJ1: SEZ_VI\B_P"?.\_S14^,]_(W_G/W-_M W#_NEHT V[\Z5/Z_G_F0Z<[=
M;[5[+?\ %$-_2J!XE/';]";>7ZRHOZ7M^G5[_,JL^P3\;'K,,:HZO6I<93&(
MD!_:=?8R!CQ4,!$RR,ICUNT8&4.;X%3*\51%0PB  0!'J'[/#ZGM$NX.#M+8
MX.7Q%WX<4MNIBQ"J*FKVW'!3EB>P43.A8G P#DC7M(C/:$@7WTMN2-<^7,],
M%7/P9(S\&FKTRS'4'>)*]C*PS#&KY'QHF]J=DJ5A=(Q$NC[5(.DVSILT?G05
M=-P:&;HO!1*8S%^FNV<E3#TZB\1X';ULTVS+;M6Y5M/:=S[56>S72S7*6.BK
M8S25$RQ2Q0U#1O-'T.FDQC#&"H22*4+\S:1K9:V$TD=+(ZQ5-*##+#(0CCD8
M@$!L$C& Q&>5L@^K.?ONQ[U_F'&^&<'.*U<IV4F?6Y-E"D6G8BG4MD=$9(YG
ML7(M6B$V*)G!DDUW*Q&SE-BQ<M_4RK4G!'</$Z>HWKM?8^P9+7>[A5UWB-UU
M85[A162Q0%/%$STE3##'7LAD*+)*XBE6"GDB,M9"NO=1<F:LIJ*@,4TCOS53
M]Y$AA7'-Z2,%#XSV).&Y5(RXT\%_SSB_%]MJE.OEB+6Y"XM7SJ)D9)JX;UY(
MC%5)$224^H0L;'J.%5#%2\ZX)I>/N?*,RN&(NIKN+B%M/:=XM%DW#<Q:ZF]Q
M3RT=3512Q6U1 Z1\M3<644M,TC.0G4D"H$S.T*R0&5Y47"EI)HH:B7I-,&9&
M8$1@*0/2DQRKDGMD]OHL97.Q3N4<90,"YL$]>J>S@$FJBRSY>>BU6JZ'C$1(
MW*FX5,_46+]!%JU(NNZ.8J*"2JARD,3N&[-K6ZWRW*X;@LL%N2)I'J)+A2-"
M\?+DB,+(QJ&<>BD4*R22LP2-'9@IZR5=+'&9)*B%8\9YC(A!&/5@GFSZ@,D^
MH'0FZ",'(4/)]D8QSF'HMRR_:I['D8X1,V*G7#%:M4W#5O\ M$VOZPE&%\8]
MOGB7!0#M(4QJ=^1UIY/E>W7=*>FEHMOWS>MXN.VJ65#$%M;=&%)88_)(OF:T
MHY>W/1R 9 !(C;X/AZJ55*035LTE.I&!T\* 5'L[<G;UH1ZM'EQH31_2X6EH
M.M%V[=K@=HDV01;I!:K&8$T$B(I]QE&O4>Q,I2]1_='IU']WBD^ ,44/#V!(
MHXXD]U[F>2-%1<EXLGE4 9/K.-!;" +>H  '5E\NWK&MBW-01<ZZ7I%PBDNB
M=Q4^])9,BJ9NVXP)B]Q#@8INTP 8.H#T, "'Q ."G&^..7AEN))8TD0O9LI(
MJNIQ?+:1E6!!P0".W8]]=+V ;;4 C(S#V/?_ !\>G_II0+4*J4H 4I:W!E*4
MH  % (MJ   !\   ^  'P .+$L@ LMH   %KH  .P %)%@ >H#1*'_!1?J:?
MS1H7,VMVZNR^KJRB"*BR#F["@J=(AU4>Y@R WB4,43)]P '=V"'7I\>*GWW%
M$_%/A-(\<;/'+?\ INR*SIFGI\\C$$KGU\I&?7H37 &Z6HX&0:C!QW'H+K'[
MZMFSK"#))TW0<IA?($X)N$DUB 8(R? #=BA3%[@ 1 !Z=0 1^/Q'AM\D-%%-
ML*%)HHY4^6"W-RR(KKD4MP /*P(R 3@XSW.O&X0#0KD _EB/S&?H)-0U^RPW
M^"8S_0&O^ZXQ#X"A_25)^]H?[&H5R)]*OWH_JU)CRZ&3)FKE_P!(T:M?(G0O
M)Z9NDAW]AKEV]_B(7N[>XW;W=>G<;ITZCQJ?Y&:G@@?>G1@AAYEV[S=*-(^;
M!OF.;D49QDXSY9.//4HVT #68 ':G\@!ZYM/GKDV;HYIVQ410124<7NOG742
M2(F=8X*6_H94Q2@90P=QNACB80[C?'XCQ/\ AC%&F^>,+I&B-)N&W&1E15:0
MA[U@N0 6(R<%LD9.B%M %==\ #,\6<#S_P -YZ>?8)HT?80RLV>M6[QN:BV-
M4R#I%-PB*K:.7<MU!26*<@J(.$DG")Q+W)+))JD$IR%,$YXCPPU&PMWQ3Q1S
MQ';]S8QS1K(A:*EDEC8HX92T<B)(AQE'577#*"'MQ :@JPP!'AY#@@$9"D@X
M/L(!'L(!T :R"#_#^D;)\BD\9!E B8-'29'#4$V5S]$S(#=8#I 1HS.=HV*!
M.B#4QD$@(D82#G62..HV3P'@GC2> ;L11#,JR1!8+V8(%$;AD A@)AB &(XB
M8TPA(T P&HK$&',/&*,'N,"8J!@]NR]A[!V';4KG&OM2S06;RMFZN-:.Y401
M4<,LL5I9FX.D0ZS18(BQF!5LJ8HG05 Q"&!1(Q#@8A!Z]2ATHOC]%$^UK!*T
M<;2P;QM4D$C(IDAD%%="'B<@M&X*J0R$'*@YR!H'?@/"P' RM9$5/K4\DO<'
MS![>K7LS:W;J[+ZNK*((J+(.;L*"ITB'51[F#(#>)0Q1,GW  =W8(=>GQX<;
M[BB?BGPFD>.-GCEO_3=D5G3-/3YY&()7/KY2,^O7JN -TM1P,@U&#CN/071C
M\79HUI<+2U78R]#Q*F6<H**1<<<Y\B74YSG9-C'.<UEDS&,8QDA$QC"(B8PB
M(B(B(CUX^:.]*&B;>.[&:DI69MRWUF9J>(LS&Z51))*9))[DGN3W.JVK57QE
M7Z*_/,_J'U5]:C PT.$Y#"$3&@(2T<("#%J @(/$>@@/B^ AP&MU!0^Z%#^4
MJ3Y\I?\ )X?JZ?Z&N,:)U(_17WZ_0CZ8?!JRF<A%2'34(51-0IB*)G*!R'(<
M!*8ARF 2F*8HB4Q3 (" B @(#Q]1F564JP#*P*LK %64C!!![$$=B#V(['5G
MD9['N#V(/KU7?V8K-;A=EGT+#U^$B8<9TA!B8R*8,(P2'7^F7T#5NDU[3=1[
MB^+H;J/4!Z\?-GBE:;50\3ZBBHK9;Z.B]T,>$I:*FIZ7!<9'AXHTBP<G(Y,'
M/?5<W2*)+H42.-$Z@]!455]]]* !_%J>W'4)"UZCU:,@(B+@XU.$CEDXZ'CV
MD8Q36<M$EW*I&C))!N51PNH=9<Y4P,JJ<ZB@F.81'Z%[:H*&VV&TTENHJ2WT
MJ4%*Z4U%30TM.KRPI)*RPP)'&K22,TDC!07=F=B6).K ID2.")(T6-1&I"HH
M502 2<* .Y))[=SWUNO!S7;0<:2MF[7&]Z(V01;D-F"WJ&(@D1(IE#1E; QS
M%3*4!.8"@ F$.H@ =1^ <4EP'BCBVO?UBC2,'>EZ8B-%0%C2VS+$* "QP,D]
MSCOH+8P!35& !^79_(8^ABUO^V"*2^O62T5TDUDCQD4!TE2%43. 6.&$ ,0X
M"4P ( (=0'X@ _LAQ(^+Z))PWW2DB+(C4E+S(ZAU;%RHB,JP(." >X\P#IQ=
MP#;JH$9'(O8]_P#&)IRL4D*GB[&Q"%*0A*#3B$(0 *4A2UZ. I2E   I2@
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%UU^Z_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g521849g51q40.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g521849g51q40.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1S64&AO=&]S:&]P(#,N,  X0DE-! 0
M     $@< 5H  QLE1QP"   "  0< E  !W!H86YL;VX< @4 *$UI8W)O<V]F
M="!7;W)D("T@4W!E<F\@+2!3+3$@4FED97)S+F1O8W@X0DE-!"4      !!5
MM#$W1&:QXNFEW<$^X0OT.$))300Z      #E    $     $       MP<FEN
M=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M    0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M
M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\
M;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N
M=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT
M   0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O
M;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B
M;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P
M  ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0&+
M   *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=0
M0P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M  H  0         ".$))30/U      !( "]F9@ ! &QF9@ &       ! "]F
M9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "T    &
M       !.$))30/X      !P  #_____________________________ ^@
M    _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@  #A"24T$
M"       $     $   )    "0      X0DE-!!X       0     .$))300:
M      ,U    !@             !!0   >8          0
M           !              'F   !!0                     !
M                     !     !        ;G5L;     (    &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   !!0    !29VAT;&]N9P   >8    &
M<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC
M94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T
M   ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T
M   *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   04     4F=H=&QO;F<   'F     W5R;%1%6%0    !
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M3001       ! 0 X0DE-!!0       0    #.$))300,     !)D     0
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MRZK65F]Q97HQV_U;F;?2K:WZ3][/Y"2F'U6U^K/2#_W1QO\ SU6M19?U7_\
M$STC_P (XW_GJM:B2E*CUNC'OZ/FU9#/4J=19O:.=&N<"S_A&N&ZMW^D5Y5.
MK$MZ7F%N[<*+2-FCIV.^A_*1&X\U.;]7<M]-&/TG)+B^O&KMP[GC6['#6-]S
MO^Y6(Y[*<K_K&3_VH].O=6..G/SNBX0#CC9N/75;C7_2=5<UFV71_.U6-<ZG
M(J_PU%EE:M]+ZA]NH+K*S1DTN-67CG4UVM <YF[\^M[7,NHM_P -CV56IT];
MD._J\_WO\) [.?:/K2;[#4Y@I]1WI;O3GT]WZ+?[7?G;/_0+UO\ M;Z2)Z_U
MF];T;*J-KJK7-OK!@6 ?J];_ %+7;?=]-^RS_OZV4DQ+4Z6.H-Q WJ3FOR@Y
MVY[(VD$S7]$-^BSV*VDDDI22222E))))*4DDDDI22222G__2[?H;;!UWK1?6
M6L-E7HV?FEL6;PQNK6_IO5]3T['^I9_.>AD>K2KGUAPZ\SHN=4YGJ/.->VO2
M7!SZK*?T?\MS+',5'ZOLQF=9ZS51BB@465L]46O?O#O4R7,;3;_1JV77W6>G
M4VNG?=^C]3Z:%U')^LM'2L[(R:,:UF/]KL?0]H<RW&;7:_'K,6?G/9LLW5_I
M*KJ_^&24Z/U6T^K'2!_W1QO_ #U6M187U8ZA0/JYT6O9=-F+14V*+BT.;56'
M%[_2V5U?N7V?H+/\'8M!O5L5PK(9D#U;#2S=C7M]P_?WTM]*K_NQ;^K_ /"I
M*;JK=2<&=/R7E[J@VJP^JP2YD-=^D8W\Y[/I-0V]6PW!I N]UWV831</TGGN
MJ]M/_=G^C?\ "H.=UC";@Y+_ %K<?8Y^.;A1:2RP-<[U&L]/](RO;O\ 6_F/
M^%24W,)V[$I<'&S=6P[W"'.EH][Q^\Y9G7*[^GBSKV"W=?CU$9=!,-NH9NLU
M_P"[&)N?;CN_<]?'_P -OJ/1UOIU>*UUE[G^FYE#[#58"ZQS9;[=G^$^EO9^
MB_EJ'4^JX#\'.I;>UCV3C/<]K]K++ YC-VQNYW_6TZ!J0[=?[JCLRP?K#TK)
MKK#LRAN0]K2ZESO3=+A/MIR/2OV_];6GYK*LS^D#"LHZC;2_[&*Z\P/:75M>
MX;6Z6M=]-5;L3ZJXSLIS;&=/=B;?M1QKGXPK]3^:-K<=]5?Z3^6Q$\%G<?\
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M^?4DE/T1=A?6)V;D.9U!S*FMJ#V-K,.8&,]=V-NK=75DV6LOV>DZW9ZOZ3_
MK:P&Y#<'';DNWY#:F"YXD;GAH]1WNVN]SU\NI)*?JI)?*J22GZJ27RJDDI^J
MDE\JI)*?JI)?*J22GZJ27RJDDI__V3A"24T$(0      50    $!    #P!!
M &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "
M4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300B      %"34T
M*@    @ " $2  ,    !  $   $:  4    !    ;@$;  4    !    =@$H
M  ,    !  (   $Q  (    >    ?@$R  (    4    G $[  (    (
ML(=I  0    !    N    .0 %N-@   G$  6XV   "<0061O8F4@4&AO=&]S
M:&]P($-3-B H5VEN9&]W<RD ,C Q.#HP-CHR." Q,3HT.3HP- !P:&%N;&]N
M   #H $  P    '__P  H ( !     $   'FH , !     $   $%
M  8! P #     0 &   !&@ %     0   3(!&P %     0   3H!*  #
M 0 "   " 0 $     0   4(" @ $     0              2     $   !(
M     3A"24T#_0      "           _^$!1$U- "H    (  @!$@ #
M 0     !&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "
M    '@   'X!,@ "    %    )P!.P "    "    +"':0 $     0   +@
M  #D   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O
M=W,I #(P,3@Z,#8Z,C@@,3$Z-#DZ,#0 <&AA;FQO;@   Z !  ,    !__\
M * "  0    !   !YJ #  0    !   !!0         & 0,  P    $ !@
M 1H !0    $   $R 1L !0    $   $Z 2@  P    $  @   @$ !     $
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ IP$W P$1  (1 0,1 ?_$ !X
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M#[CR <?WXY_/ #S_  T!M^>'/ E,'YYX_ #VX$0,'?@3 /3SR "(AH#3U''
M"3N//8#!SP E#J^KHY*'4'4(<B41XX'WT!NG.)0 0*8XCSP!1+]BB;_4)??C
M@/XB'8 Y$ -2&Z@Y_P"G(#Q^.>.W(AP/'\?<0[Z VB+=9A "\  <\B8OX*(
M(%$>##U#V[A]/("//8#?#O\ _'?0%)C=/';D!Y[]_<..W8!]^_\ ;VXY$ *
M4Y$  O\ /OSP/;\<@/'/(B ]@X'V, Z U.H!/U=@[=^0]Q'CL'WX]Q_ ?G0
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M0#0#0#0#0#0#0#0#0#0#0#0'FI\4.795??=B.NI35 Q_7K+C.!N,H>7REA7
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MW[]^>??CVT!NZ : : : : : : : : : : : : : : : : : : : : : : :
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M6&;U*EN]KK!B]R+.K6N)?4^JL?VS6AY9+;7XJP2D>1I'+&A19,WIQ SD 8#
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M]?J2NQ_:1)JI @=YMUQ&J9 H]14Q"DPQ0 3<%ZA$"\\])>/;CWY@$P- - -
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M,YSF+R(B/<WW'C0$Q= - - - - - 1,S)A=>^9\VFY-3M<3!H8.M>5IIQ7)
M%3R-P&\XOEJ:FQ@^'")#KPZKP)AZ55-P86:1CE(D!>H2X6%PGU2Z/Y^H)6H]
M/0/ <<F$1_F/?[>X]/ "/Y#4))=$EY\< +E*<G28.0Y >?QQ]7V[]^./ZZB<
M8R6)8:S%X?3W9)K]FDU\4ASY=2%.\S;?+YJJ<!=\82J5,W$83E39"PA>@*8@
M(6*.:G.[IEA.EPH]I-[;$/ 66.5*N@9!PD_!LLX9) ;K/!OB2CH6H7>GZI0E
M=>&]?HQM=;MX\KV3:@KNDGG9>V22K6U6.)YC[--*654ZM9SN*%*ZMU&-_8[J
MMO.26YN*<O92>5FE4?NRA)J+W<X(T[7O$?O6X')D7ATVW>5@+A!L),^6U)#)
M582=8]DJG(Q59N:,A4G+<EA C:R2*)Z\V5(5>P0#II--A!)42ZZ7Q;^'5CX8
MT>X\0S\3?FM/G6C/2:5'3+A_GK>ZI3N;.,+N-7V$Y*WIR]O/A4ZRG2E%RBBO
MT_7[G4+RG8NP4:M.BOS52%2$8PG&6R;]EA/.]X45+]+B\XPWED1<^84O2=-0
M! !Z@,(&X'@?T\#Q[]N1Y[@&OEKDT]N$VN)8FNOGA++^_P <^G2I2PI=822<
M7AI-/SYSGR\_N<LH@(FX'D0XY 1YZ1X]N_M_V/WT@T\X<GA\Y><<9_DDKUF!
MH!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H#S?;W,L[?\F7S<7><DU5J
MWNFU_,F*]N3W#K'<[8,777=)B.5EZ/=I>)L6*H=CTY!C'L[;UUL2TAV@^8WI
MRWEF+V9CV,P[9J!WWW\ST9QP%!FW!-$6Z?IVXD;F3!(Z!!1)T(G(7L4R1.E,
MQ> X,4P  %Z0 #G: Q$^-QC]KD'8/EMJYV^/-PI:]"6&TDC&>26N-/V=*Q%*
MM9B93<.G4M$_-3:J"KUJTY!1VO, Y "LU 1$2 2[V$%Z-E>TX@M?1&+MWQ-R
MUZQ7%#_<J#'RQ<=1NH>!*/'(_?D>0T!+O0#0#0#0#0#0$4\Q86D+]GO:?E!K
M;8V#8X-M&5)N2K;PC@7]Q2O&,).E-V<4*2Z+<BL*Z>?&W@+%<E].@8Y4BG3!
M0 )3HF$Q.HP<"(\B4> $O)2CP(![#^0'D>1_IH#<$.>/P \B'Y[#V'^O?^FH
M:SWQ]0;"Q#=!Q*8>Q#"! *41$>!'@HB B41]@$...VL=NW<\R:PWM23?'IYM
M_#/+P0\]5U7*7D\>3]4^A@2RSL?G;5XJSC)>,\_6_"EDM."%<FJR-3@X.1=H
MRD!(0.,W$6JWD5OALQ!RS9VVDI!M+,'2WJ4^2J@8B"J7W71/&].V_"E:=JWA
MZVUFVM==_P!+A1OKBHE*WKTZNHQK.I3W5*=>E-3I4Y4ZL7LPMJ]Y2XZYT??X
MF<[:\KV-2K;_ )BI["*VMQEME%QFU&2FTGM:VO'3TENVI'B?XY<K*PF8]N&X
MN&2Z_+C,@8_G\/VHH$$/+;_&J2\GZRZX .D5E(5B;K$3&Y#@1Y.5]^%FH+;5
MT77_  ]<.6)UM.N[?5K;=S[_ +&YA1NE_P#7VLO3G)8JV\16^91N;*\IK_VX
M3<J-79A-*HDW"-3JFHIQ\_/CZ!-X6[+'S=9;.'A_Y)]$VY%:P8!R)0,S1ZJ"
M?T"Z0KHR-7N*1#CP<K4T0LY(4>.E00$=3_X1\*:A.,-#\?:>YRCGV&O:=?Z/
M.,NJA^8]E7LWQQEUH^]GA<&/^K:G0DXWVCU%%O,*EG4C<1V^>^+<91DN.(Y6
M/-8Y^C$>*IL]%XTA\A6^W8-L+M4&Y8/..,[]C10J_8#)!,3\ C6U!((_49*:
M.''?N''.FO\ A=XSC"5:PLK+7;>*4O:Z'JEA?Y@_ZE2C<0K\9SCV3;PTDV;X
M^(M-X5:=:VEG#5>VKQ2?HYQA*&?+]77CJ3'H^;<3Y.9?$,<9(HMY9@FFL*U6
ML\1."1%3]"BB4<\<+) ;V#S$R<^_WX#D-0T;6-*GLU#2M0M9YQLKVTZ+SZ*5
M51@\>>),L:%[:W23H7-O*,LI.5103^'O;?O\OG<U-R53N!DQ#["4W(&#M]0&
M[!QWU5RDH]?W;27W9Z4V^<Q:_P"E[G]<9*BJ\F$/IZ?L(=_^_P"8?Q[:C>FL
MQYZI8Y65\5E??X/#,L<)^OKP_P!NOUP:"N'5T@'(AW$>#"''\! /_O4YEY8R
MNN=WVX^Q&5\?HO\ LC> P#P( /?M[#_UY !_Z:R73D)Y\FOF5:$C0#0#0#0#
M0#0#0#0#0#0#0#0#0#0&$;Q"-WE/VM[L,"H.MF])S#=+3!>MJ^7).LR"^1/C
M/Q2681]"Q5.Q6,K@HM9VJC!!PZ1DK+6T(]6RUPB0>F>OI%B!FL8*BX;)+F(H
MF95,B@D4XZR"<H'$AN#'$#$$W28HF-TF 2@8P!R(&%S;SN@W(.][^XBAYBEK
MBUQ8QD[A6X2"E\9/6E2QQ8QRS4J-@!G6;7&UIJ^M#3+-,FI2W3CM[8)M!H=F
M9V+V#8-1\L#&?XEN_O?!M6\/_.;G)55Q]FJ,R)N5W/[3+1<+.RLF+IV#KTH2
M1C\;RF.Z7%Q[V.DJBV@D)X6DG*V&0<O$VL:95])'<N3IRN7Z?<CZ]_V[P>AS
MP_Y!22V0[2))RAZ55SMVQ(<Z)1 2I\TJ&*'/L80$ */(AV .X^VH))@>:3^/
MW_TFX[#P/?C@./N B _PT!KYA!]C /\ +O\ ?@0[>X@/(" <B @(>^@* 72$
M> -W[_8?MQSR'N7I$P%,!@ 0,/ ASH"H%2#]^_MQVYY >!#@!'N'N(?8! =
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M;Y&)1;UWE7.]\R3)U\B3>0;%>4U_:)!ZO5I(Q9!111[%F2657;LECB8[5,=
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M1GE'MBN%FMLA;88X-6U=N"RUFF9UY#*6&,9).#0[1RWCB]*C])FW*]\@M?\
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MXV\K&QTFVQ/X=Q6\BP:OT06RCF_S@2=H).$@533I(%3/Y:I>HA#K%*;J_>B
MET!'W=5O"\8?:7B)UF/(&&MA4C6VERH-+4;5G(N:'TJ>2R';H2F1"I&SZJL&
M_I6\G.MEGJOJQ.DT27,5$QR@40)(C:?&\ QBABKPZAX__:&<Q[#SP/\ Z)*(
M<\<\<#P ]/6<0,.@(V[C-X?C#;:FV(7-VPYL)?%S+G"AX(K00&1<S/3-;5D%
MR^;1#R5(ZJK,6\.U-&KF?.&YG;HI52>4U.<!+IW_ )^P)(_-?C=FY$N*?#K
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ML/W^_O\ D= <9>.9.D%&SEJBX;K$\M9!=,JJ*J?  !%4S@8BI  H<%4 Q0$
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M5&P6TEWV)\07;!%NNYXVNEDJ_=!M+J5R9"T6DV^SN4'Y5'L^LR:M*ZBI'H,
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IOS]OS]_YZ$FN@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g521849g65v09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g521849g65v09.jpg
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M 0$! 0$! 0$!_\  $0@!30(1 P$1  (1 0,1 ?_$ !\  0 " @(# 0$
M       &" 4'! D" PH!"__$ &80  $$ @(   8*"0D5!@8 !P4" P0& 0<
M"!$2$Q05& D65UB4E9?3U=<7.%155I.6U-89(393=G>UM]$:(B,D)C$W96AT
M=7B2F*2EI[*VTM@H*35!D;@*)5%98::T,B<T.4-Q_\0 'P$!   ' 0$! 0
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MF[84OA3]X\87@+ L0)TL'$VR.1H<DQ\6R;::K(M^C&*[?67L-Q!<P_P9)8<
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MZB!XK6G^E/8Y.P>HY]K7BGODA\L#JFC5;QK#5%D&Z=JF@P*R+?/.)*0HJCQ
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M;E995P&XRYSS;]KLZ7QM<-F"2!1;'/9OTMJ3$7<.HTZQLWT5Q;>;@6QRV(;
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M%-I8W"9%VGW8G$;U,A)3N!QW#1-HXS'BIKBK9[3&2>C6N)P82 G6>WNC1M"
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MJ[QL60($DV"C0B2;<HE,LS%>]/2 )N-6H1AX?)L,H5/B (T]^,ZTF'%UN/\
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MQ(,#&'F\BZKC"VG9K#;B,Y2 PK&%(5E.<XSC/Z_ZV<9Y*U<IBNMIKM;W _\
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M> AJ&R28\;;XGIL.\4A2TE(5_;CZ&LG,J=+T?:J*+DG9_)[>[W*G3W10.X1
M$6"16 N->KI>K4U#I@OPGYUR['C^S[Z \QYAR;4YL2]B!@1P[$>G$R5/C-1I
M*T6(=7;* CF'DAY_GDY];W?\:AG^3VDR]SORS1=12?8V2SF*U7L[!+$J="UU
M8-5&7BM&#.V2+17M=ZZU-7QE6SZ,>ACK*W2:;.?(WU;[9&);9^"@H/@#(<J\
M.&8Y(FN.2(J<J9Y9(F[+DW=/GZ66ZF?NHOIIGW:L3O7K+>-M3+S-'V50IBXZ
M#V)H-(.75):F8 K:.1K1ZT9.,2G)3Y,2D=&FB1F!C,24Y'6.ERXZ)WI*#%2%
M?VX\BIRIT_3J";M]6J]$E?O80^!2?F^1UP\D/W2=VE/1)7[V$/@4GYOC7#R0
M_=)W:4]$E?O80^!2?F^-</)#]TG=I3T25^]A#X%)^;XUP\D/W2=VE/1)7[V$
M/@4GYOC7#R0_=)W:4]$E?O80^!2?F^-</)#]TG=I3T25^]A#X%)^;XUP\D/W
M2=VE/1)7[V$/@4GYOC7#R0_=)W:4]$E?O80^!2?F^-</)#]TG=I3T25^]A#X
M%)^;XUP\D/W2=VE/1)7[V$/@4GYOC7#R0_=)W:4]$E?O80^!2?F^-</)#]TG
M=I3T25^]A#X%)^;XUP\D/W2=VE/1)7[V$/@4GYOC7#R0_=)W:4]$E?O80^!2
M?F^-</)#]TG=I3T25^]A#X%)^;XUP\D/W2=VE/1)7[V$/@4GYOC7#R0_=)W:
M4]$E?O80^!2?F^-</)#]TG=I3T25^]A#X%)^;XUP\D/W2=VE?-;[*?I;<=O[
MA6HW4]3;,M 5ZCZNCLEZ[0[2;%NOQ*(%CRV&YXT5)B+>BR&UL2&TNY6R\A;3
MB4K3E..*XPA3'K]+<9B276R!C(VF'7 7)H47(@!17)=RY+N7=7E3X*C"&+;O
MIEOLZTX7Q%=(3EML -S+=9+E-BF3=IC X(2(T9UHB;-% T$U4211)$5,JZZ?
M5O[$>X+NCY+;Q]!<UCBVX^4)O:K_ .;KYUZ'F/\ J'QA[&;U\"J#HZ<]@/(C
M8LC2&YY$8=9"-K:SG4-T1,;+SK'+L:%PYN ^7(3+;DZ6,DMH0XJ>'D/P7W$H
M?D9=O-A<\W"2VS4(X[<5?U/(4%:".$==<-GD9*@"Z*KDC;HB8IF(Y;>Y:M(R
MO3Y+.CW&+#\ZP0,-N(ECOIQ7+9#L46PD$N(MN%N6Z;<*+<(YFH#"NC#,QD%-
MEA&IQZM_8CW!=T?);>/H+EGQ;<?*$WM5_P#-UJ'0\Q_U#XP]C-Z^!5:_36A]
MXP>M/<<5-TUM:&4. =&MA1LK7=OCSS#@_;XN;/;%PW@Z)!!<&&A<N8F(V\J-
M%2J0]A#2<KQEH4"<-LO(%"EH1MP4 5C/(1ZLP2+510S+5'>N2+DF]=U=3PA@
MC&C&CC2]%>PABAF3-@X)&''=L%V;?EE'Q9&>?2,R<1''U991774:$U;;13/(
M4SJJ'JW]B/<%W1\EMX^@N8GBVX^4)O:K_P";KEG0\Q_U#XP]C-Z^!5JQ/1_L
M#YJ>@JU%O?S,V,G@<(1J.UI>@ YSUCG>:,/*KSF')<<E8</LSGFU>-&$#HCL
M9Q2R,F=DE2YZS!I:96NRX#V:QY2HX\"1PUB353(2;8U5!%3>ZX2*GB!#HR]$
M7A-FF#HNQ)PJTW"%>5,K%B56YEWAM6*'PEYH8H*W&?@6-67(;3@ZLBYSY+;X
M",&/#Y,7I5V%:,"#<K3>Z),X<8)6"1(;TU;XLJ43)QID%]IB6D.X["#*@2F8
MKPO'G"I.!\-UZ9E_SIR5*3=Q5IUD;7-$#:!A!5F20"V! :$H*VB&]K@I([NU
M=H:"")JZM"1&T@N6JZ6B-HTQA'AS[7 LK+!VK$4B-'M\!^++9<>C%;@;EW49
MD=V2U<5V",%.EMMQD9X.$?.$>G6[B ^Q#\Z&WRQBS"2H<@\FA;)DJ;CF&'&9
M+D2-/%RX,=Y'E,K84B+A+6<8;PCR.5-JHML79LV#XODEP=UIT!X X.9-*BBA
M$#(FHKEDJ:V_EY414P\"TZ5(,ZQ34P+B%Y</W.VW2$RN")D<3?M;S;L=N2_"
MM4:8^T6S0'A.0I.(JFI;5!-,+GIEV4_H<I.JMWH,-'W;0DAC3-LRQ@W)$D*[
M(>\P4%SC,3VNS_1T>(J2K++T5B>Z_(>R^EZKLI^\5M$Q6E82,K>QDY[$70?%
M-=&T\5MPVA%J[T(@1!3)4RR0,:^.1BT3XK.U.65K#I05M>)$>XHCW.%?6&N&
MC;T7A/'L+A[\E(Z(ZW(>AMLL-(R37JI/1[=]$G><!]';N\T:'/C8L5>IK>V^
MMF4X->><+3V:^A\R]&>&)]$+DI1D4Q.)QFO*-2DX9C+2[3 U7;=,UE<1PB2-
M)5,Q1Q$1H%!190D<7:H.>T(&R7)0WU,6EI4QE#V%TT?XKX2[.9N$F2-@Q$XT
M+L=N>RT%MANQ3:M33[5P+C,(Y&ER>AV^0[J.1E5W<];ZY]A&K$ ==T1N5MIL
MT*<<<<U?=T-MMHG,*6M:U \)0A"<94I2LXPG&,YSG&,<LVK;<$=;58$U$1P%
M55BO[O%)^\K2[;H^QZ%P@$6",7B(S8I$18:O*"(H^"J1*L)$1$1,U5=R)O6M
M]]RM";T.=L^R1D)I;;)@.4W;LJ>,*BM<W @-(P95L*/1IL"=$#/19D22RM#K
M$F.ZXR\VI*VUJ2K&<WUYM\\[M<S"%+,#G2B$QC/$)"3QJA"2 J**IO14545-
MZ5O&E[ V-INE/2)+AX.Q3+B2<9XB?C2HV'[L_'D,.W22;3S#S40VW6G 5#;<
M;(@,50A545%JEY;IQV((V#T\QIW>,%64P9&8B=1V^0UDL)A&X0DCY1X#Y3"(
MV#CC\B%^NW+?'CO XPSB>R0I-LW$&-B5KEFGBQ0^#R179.FR;K>0ADNMLLA+
ME%''-RKJ*&,MEKQ_ LG$SVC+%,P4*8RDDK%B)AQ+9<Y=GEW*#J-0]37?*S@T
MQ+W.1FIT_,'G5A.PL'*Z/]B'FC+3.I=X-8)+))A9=T[<'_1D4U9W[<783A B
M/F6Y)+/-ML/O93YJ/B1H^&G9&9,R35%+B*LJMIEKL]FI9,24VALQQBM$JJT6
MJ@M"JJ*?/&1%F@ZHCEXZX_:=M3CNBO%3G  @++1NSXA9XPDVG#S.&+8\JE;7
MDC Q;&C<>9:$N$3I+[ZN-L)'BQY .Z=;_B&#IA_1FXE.'H>8,M@5I^Z@FWT+
M>=?=F$'H CSH@6\9Y;,<FMYJ1%BY4VU_1G7Y#U%QBYFTPT-NG(C!ZXDXQ(>4
M51$1!;0VM5MK=K$VB*)%O7<@BF$G6G2-)M=FM;. ,:"%FE),C/W&S7V\FR8-
M-LMQ834VV\'A6S5:%U^W@RXQ)D9&YXTVRPUY$.G6_P!R*-;#Z4WJ(F"#+AP?
M,>UGL$YY.8^&(U^1AUHN,D+<96+*S$M,I?:;9E^1E>*OQ'6GX Q<T)Q7;;*=
M!UI&7 2(\SF NMOCDK30Y+M&PS7)54<QW9HHPA6G2.W(GG=-'6)KG%NEJ"T3
MHK.%+E9]I$9NL"]L;-RV6ED6W1N-MB$XZ3+CCL9'8^L&LVZSA,=(NP#7HIB-
MJ#>S$ 7#JHW$7[$EM<<>@44JV;J3/G*Z_P"%MT>20XN:_EIS).,^Y'6AA26W
MT5LKFNT(K5*(W#DN:W!Y2(AS6]C*750$S0V\D <TV9(A(I;Q7+JFD9SC)U_1
MAB5Z9<)6))ZR.(L2-MM3<8VURT8F=V Q?%MS;>0!$91QO@$AH'Q-X5<9.35+
MJ/V"JD&;#9T9N1W$\I)+.-1=0W0:-B/2F8S3S(L:R&=;@175QLSI#6'G?+$Y
MA";E2<RO)-V\J-<I)@:VZ<.HV+2*4>0XX0BI*BN.*VBF2(6H*Y)DV !OU<UU
M[$V'M(>))D24[@#&;7 K='MK;DBQWZ?/DM1W9#K;MQGNV]LYDAL9"0V'%::V
M-OBPHB"21MH=O=9:$WI$ZR=W14O2VV8I0_K;3<4$-D:YN#,\U*@]C]7%)L83
M#<#)D$7X8R)+(RF8;;SD>#%D2W4HCLN.)I2;;<%P[B-I($U7'8UN1MM(KZFX
MHWB"9( :FL:B D9(*+D(J2[D5:]3_P!!<@3L"^#%M-\QO"EX-LH88Q0R=WQ5
M&>P]:P=>POB!IIHKA=PAQ!<==<;;;!7D(W# !12(46@OJQ=E/>];Q^2:^_0'
M.9<1WKS'NGK?+_,U^OSHN:*?/.T>^S3#?QE6PM7:9[$:ZN8ZW3.KF\K(D;')
MM,B\Z[V"'0MTD-E"\O.2VJI-<REF/,?4EI+2?'=\FI2\)0I"[R#;;Q#DA(*Q
M71[40T0.!S&T53 @S4DCDNY"5<LN7+?TEUG%^.]%^*+#*LC&E_1[:EENQ#<E
M^&C#,XD"+*:EHV+)WF..;CC#:*:FNJ&LB#F2$./B:<[8C09*LC>O>W6 ))<W
M+L:5H0N2)(:FIPVM"#\VBN&F5I:0A"'8DV+EI:<NQDL+5GD@VZ_@T; 6>X(T
M:EFA6EPS1"W*B/%%5U-V2(HF.7*F2U<O8YT+RKA%N\O2;@ERY1!CZCK.DB%$
MB$<=5(2*V1\1#;S%34E('H[R&*H#JN"B5NVL#^QE?&:X%2>H.]#;>L6++,JY
M A5MH.F*_:[) K$%5AJDR34)<>O1@SM:P>  \P2<41;"T^Q0Y#4J.);&Y1@;
MRRW";7#MU<X"+Y,.&Q.5UF0^+([:.2QR1D6MCM66M5P6Y#A/"2$C:!S^[2=%
MMRF8IFLZ;]'EO+%KEJ8O$6->,(A!N5FM4B[R$MEY8:O;+MS=GA=N+;E<$D1'
MIUEA1K6^T;+DTI=97^LO9!;SRVNN^\VFENN+::7JJ^O+;;4O.4-K>]KK?E5(
M3G"5.>(CQ\XRKQ$^'P8P:V2]*JJEGNB(JJJ(L"6N2<V>Q3/T>G76F]+6BL6P
M$]*&CPS$!0S'&.&P$B1$0B0.-"U$)<U0=8M5%RS7+.I#2NL_8]BY5)]_K_NU
MEEFS 77GG=4WMMIIILK$6XXXXL#A"&T(QE2UJSA*4XRI6<8QG/*L:R7E)$=5
MM%T1$>:556!+1$1'!S55V58R_:6=%CEBO3;>DO1^;AVFX@ !C+#A&9E#>$1$
M1N2D1$2H@BB*JJJ(B9UO3NGUW[ '>X':0T$T9N(R&+]@MODA185K*ZD!A,=-
MOIZ3#GCY\0(]%FPI<=QM^+*C.N,/LN(=:<6A259RV)[/=W<1WUUJUW%QMR[W
M VW&X,DP,"E.J)@8M*)"2*BB0JJ*BYHN5<\T"Z3]&MNT(:(;?<-(>!H,^%HU
MP3%F0IF+;!%EQ)4?#EN:?C28S]P!YB0RZ)-NLN@#C9B0&(DBI59?5B[*>]ZW
MC\DU]^@.8/B.]>8]T];Y?YFNL]%S13YYVCWV:8;^,J>K%V4][UO'Y)K[] <<
M1WKS'NGK?+_,TZ+FBGSSM'OLTPW\94]6+LI[WK>/R37WZ XXCO7F/=/6^7^9
MIT7-%/GG:/?9IAOXRJT=(,=V*,]6HX[K#?)=8JHI 49526B+X4B-P53QQJ>U
M@V9$E+5AHI81(ZPRA^3JPT8I$84(%C(K$>*SG8KF)XBL"%CEDQ'!&VXYVJ48
MH.N#IIM7&SD9./M@\0;56D<%-FV H(IR#$$+0#B$+L[*TN8<9NUXF%/EWB+I
M&PY#>*0D:5 C'Q?!FQ+,IP[9-E6UB2EN&>[$><2;,ENN.NG5U763LHI2E>KS
MO#'C*RKP)U+?4IQX<^'P)3@!X,)Q_6QC'ZV,?K8Y@ELEZ7?Q/=/2M\O\S77D
MTMZ*41$Z)VCY<D1,UQKAQ57+=FJK<LU7G5>6OSU8NRGO>MX_)-??H#CB.]>8
M]T];Y?YFH]%S13YYVCWV:8;^,J>K%V4][UO'Y)K[] <<1WKS'NGK?+_,TZ+F
MBGSSM'OLTPW\95,==]:>QL;8%%DR= ;LCQX]QK#[[[^JKVTRPRT;@N.O/.N
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M-QGX,BTV?&$N5BNT'A?%+IVO$LAV^VXG6L+X@=:<*#=#E1B<;<;!QLU:4@,
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MX\Q$A0844NU&B1(K#:&8\:.TVRRTA#;:$H3C&,MB>ZW1K$=^;:N4]MMN[W$
M;;F2  !&6Z@B BX@B*)N1$1$1-R)7.] >CO1_/T'Z()L[ N#IDV7HSP1)ERY
M>&+)(E2I#^'+<X](D2'H)NO//.$3CKKADXX9*1DI*JU6/UB.P'NY[B^4VZ_3
M?,'QS>/-6Y=O2OSM=:Z&&C7SO,#>Q*P?%]/6([ >[GN+Y3;K]-\<<WCS5N7;
MTK\[3H8:-?.\P-[$K!\7T]8CL![N>XOE-NOTWQQS>/-6Y=O2OSM.AAHU\[S
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MR3\N>>^F?Y%[&?=K:FW.GP7<$JV%#_I))FSZ^L>LX\QQ8.1'K%<NH=^L7"2
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M151:T*V:'=+MHN$6Y0L, ,F(ZCK>UN^&GFCW*)M/,G=E!UAYLC9>:-%%QHS
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M ]$VSKGZJGX9?>1B3(MDJ; VI7A%X#.>M$!9+*HI*#;[3+C+4Z>$G%/^Q?\
M9)YDNPG6)AA!AQ:G?([)UIG,1A\Q,L$J&/\ +VIY,6++,SY,Y]&$K=SG+$5M
MUN##A18]1(%]0FB6&T2M(F6;D;Q1"T# FYJR!4S%H!!%5<N4E13(R+),X+TW
M-.VQTL'VMXK4 (UM9V'424\U:XMDCRIVQOK12)$:U0V(;)*0MHB/2#;.9*E2
M'L]']C@[0MD)Q.7JV67E3H"A2\%;]K"3'9%N.YD/CV8R+4RQF/)?SY5_SA#[
MB\);9PXF,TTRBB5IO2M@V,,&A ]HFS>CB1.(FJ)D2R%76%-PZJHB9JN6LJJN
M&?T7:83@P[?%PE%MD>'-&Y"MMN]ACONW%MI&&9KL@KZZ\C\=E-FRK)L@*D;R
M@4AQQXO5/]C8[*S(<:'&U!Z#Q"(9*PI%?O.L!,B*07 E"GY+68]KPUEV0+G3
M![JG67,^;R%91E#S;#K0+5?!,B*-MM<-F8OOQW1-M#%U!76?SR%P -$14\4.
M_,5)%J0]&NFR+*D2I&'N-^%P4MLMB]WRQ7)B3"";'N34=U'[YM4;8N,.+.;%
MMT$V[ ZZ&T;S3F-5[&)V/RX/RC5))A@:R*C,0V-E:\;BJB5^8T1KD-U&+CES
M,>O$6DSA6$.MK:?4ZE]R0PZXRJKQ??LCSB-J1JZ2F3D12UWQ4)!IF]EK/MKJ
M.YHJ**)JH)(BU?C@;3@@34/"T!UZ>Y<GWI3TW"YR!E7N*Y OLILENZ-H_>X+
MA0[DIMF#C(MJT#+S;;HY\%['5VE -3D1=6RI+Y,@LH2FS;_K-V3-G+BQ(/EW
M?(VQB.WE,*!#C81'CL-J2QAUQ*Y#C[SM!ZSWE]04H8BC8(VV /1D$ 0B/53-
M]27Q9D7BB5=^29"@HF%O&B;2[>G(92,)1H[-OA#;H$2)=\/MQXD,9,F9L6]K
M>WGS0I<V4^I/OO&A/*V! P#+3=HM<=+.S SKCW*K4[6OD#5TU[J,=687MQH#
MGI*8'[!ZTL1%GSEFU.1(?FX<9.F>4(/Q6GO(>;L+=E.LL.2R+#=CL&((XQ,W
MI$>WBR&WC)KDW=H3QIK*\@CDVV99D0HN629DJ(OIU^A 62YZ&_!:6O%^DB-X
M7,.M8;Q+&<N.VCWC5?DX;OL9@."6%VZ3EUWY#0:PQE =?6,A 2(:-_J>7<+W
M(?\ ]_U?^FW.<^$[$?F=_6X'PJOU=?-.:#NK?_EK%_Q!6Q-8=1^_VG;3#N.O
M=?R0)J(^+><4W?=5O1"+(@Z)LL. 5A/71<<@.2;!B9ZXCZ%-J?@QW,>*MM"D
MWD'#V+K:^,F'$)ET2;5527 431IUM\!<%9*B8(ZTV>J29*H"O*B5J^+M-7@:
M\<V=^Q8GQ*U<8#S<L!0L.8Q;?BG-MTVU/R8<ANPBY&E+ N$R,+S:H2-R'!7,
M2)%P:.E/?5H>1$,4RQQQ!=V8^4$1=M4"*)(.D?\ ^_7+&1[\W!?S,_K2<.1U
M8>3C"5XRG&,8I)AC%B ;:1GA;<4E-L;A#%LU/Y_6;&6@+K=/,=]9 M/G@<#D
MQ9KE]M3LZ$##<.<]@O$KTV,$7]C"S,=PV<EO8<K2BZB@N:BJ*JK6RP77'O?7
MA%=!0-"4M8RO5Z96,QIEEUQ+0<$R[:(OZ6SWEMDJQ+<B7@"(M$5R+B%X)T%$
M20F0'=D#'KUJRXK9;9:"TQM1EDF,B>A%M6RDMS$1W.;XI1E--OBJ:OBAU516
ME)M=4N&E+P.ESG72XR=)%^27=+FQ=MLQ:L4L%;YK-EG8;4[=L\*IL0>P]<IU
MH>%[A&<>03[:MSP:EMZ<+]!^Z1XL3.%]5+FE3)":5)S7+[JM+DL@1DNS)LIQ
M+5S;:2N1)>==4EM"&\*7G"$)3X,8QSF$L3.N&ZY 4G'#)PR67 S(S)2(ERDH
MF:DJKN3*MYA>"0T"VZ%$M\+&(QX4"+'A1& PWC%18BQ6@8CLBIV$C46V@ $4
MB(E04UE5<UK)T[V/OMY#MU6F2=2>3CQ+&$DR'/;[K%?DV6"<5UU?B-W12U>*
MVE2O%0E2U>#P)3G.<8Y/'PAB(9#!%;LA%YHE7A<%<D0Q55W2<^3FJUOG@E]"
M3]EO##6-=9UZUW!IL?"YBT=9QR(\ #K%84%,R5$S)4%.551-];J[@]%NU%R[
M7]EK;6]6^D:]9][[7/@R'MWUS#\^$E[P;GCY?FD^W19T;SB(^T[Y"9&CR6O'
M\1]EIQ*D8RF(\*WZ3B"]R&(&NR_=9[K1\*A#K-N27" M4Y D.8JBY$*$G(J(
MM:#H/\$/H>L6AK139;KB_@MSM&CO!UMN$;POXH?X/-A8?@1Y+.VC61Z.[LGF
MS#:,.N-'EK-N&"H2UR_4\NX7N0__ +_J_P#3;F%\)V(_,[^MP/A5=2^:<T'=
M6_\ RUB_X@I^IY=PO<A__?\ 5_Z;<>$[$?F=_6X'PJGS3F@[JW_Y:Q?\04_4
M\NX7N0__ +_J_P#3;CPG8C\SOZW ^%4^:<T'=6__ "UB_P"(*WE4]!^R54B<
M)F5FKS1,4(PQ''5^#==/0:G'0PAM.5IJD"U10"9<IQEJ63(H'H(EB"/2)27,
MG*7(5E(]HQM%)LF&#;%I$0&1E6X8Z9(F_@XR!9UB5$(S0-=P_%N$1JI5SV\Z
M2/ I7^/-9NUWCS'K@XX[*N4BP8YD7ETG%)=5;S(LSUR5ED#-F)%*2L6%&7@L
M-EB.@MIH]7L>G<1:E+5J+PJ4K*E9S?\ 5_ARI6?#G.?ZM?\ SSGP\Q:X/Q(N
M];=O7_\ EP/A5=!3P3>@T404QMDB(B(B8:Q?N1-R)] .DE>/ZGEW"]R'_P#?
M]7_IMQX3L1^9W];@?"JC\TYH.ZM_^6L7_$%/U/+N%[D/_P"_ZO\ TVX\)V(_
M,[^MP/A5/FG-!W5O_P M8O\ B"I;0?8_>W0^]TJ?,U+Y&)!MM<F2G?;YK)SR
M4>,8AO/N>3:N:W%^(VA2O$;0M:O!X$)4K.,9N(F$<0A+BF5OR$)#)$O"X*Y"
M+@JJY))55R1.1$5>:L)B7P2VA.3AR_QF,:Z[TBR75AD/"YBT==UV"^VV.L=A
M$!UC)$UB(13/,E1,UK[X>?65?G$JMEG_ &0F/[_D?[^>7P?.#_%'W$I6"Y-2
MJC;2[NZ'T:;("-T/;,UC"AV0E6H=SL>E]L2M<&G!5<IEEEF1^Q:W3SU-BUO+
M-WAB8QLZ9#19M@!V\/$R]*JY;#$JDB<N:=?)<N1%Y<LNGV<TZ511%7D]U,^Q
MR]Z<Z59NJVBNWBL5RZU T.LE2MX$/:*O8A$EN:)/5VP#XY8(:%S&<J:ECB@V
M7&G0I+2LMOQGVG49RE>,\FJ%9[BE:ANFT;^0VB9UWK6@5&R)H=$U^3M1RZ;)
M+T5*"ES&GI(00!&AM9;!?+,1XH2/).%YL@)'B-EF61#!Z=!)PXM,%^>3]^76
MZ:Y=*F[+K\W^-5KI/=2:6G]?1E\UW6:*_P!B-4P]TUTE'VPR9KE7H<"I$[O?
M)5O,&Z/2W1I2I '*>J /:'2&K7(L%ADCIL6NZWN=A@3(6:#GNUDS3?ULUYN1
M,O\ LBK4<N5>;O3\O8K 7KV0BL4Z?O41"HJK02U<;U]&U[Z)N0_(O=E9MFM!
MFUK3:*V80'DQ!S>NZ=[8SIR(SZ?C2P\&K2XI9N9>!XR"4N7=R<F_E3+->PF?
MM;]],N3T\^=,ER_[=>MO;;[<4C25CN<*\0)^057@4*-!E!UCG#!VWVP!MR[E
M:Y$AFB(,;AP/1-78-CD8+*(VDF635J] (698D27BJY<O)[O+N]++N;Z(BKR=
M_)W:Y;?;S6RR?HY0#83#35WL5(GE7Z["0-%.UC:T+1A.R$%)-*G)JJMNS'*5
M!GQH,J;.6-,6F.,71!4VU-,T[_1R]W=[?)OJ'?\ EK%3.[6EXH<6=8:NQ081
MU_&VM)D#:NMWT%KA=)JNQB=N-H?FQE1H%?IMO%ERT2+B:7<6B2+$#2IGS0=+
M9IR];/TJCDJ^YZ?-W^G4:W-W$G:ANEZK,_6,EP33ZU;; //32IR%,M::-J+.
M[#LH0-S2U5SVHRJV+M=-&6A-[D%$;-KDP%.IS(=MP\DJY=+=_AGW]>B)G[7I
M9KES]_/6]MY[)NFKJ]7#M/I57NRC-^U]0YD2RWXM0TP).R+W6: #(19(O7>P
M<D6(A:S,2RK#L<:XP.BNN1%SI*T1L%54Y$SY.GERKES+4$W^W[29U6C/>2<-
M>KTVS:E4*JIWM/<>M;Q^-9;;XX6#3;)M*H$MGS4VG4U.KQ6O1S6O1\LLU4[5
M9!0"M&S!<M:&)M2>"F(:W6_;*G3Z6>_>B<WH<N_=4<N7K)G[G=J<TGMLWL#7
M[EY"4:1$1/W_ %C4-0@2C*)*[74[00J)@5L1M:1\+T2LQJVS+NX^L3<+D1YK
M$6O$"34B0[(CM;W41.OGEO["YY4RWY=^>7)V=WMUC6.^FDK&.;DT";.LTU^9
M5FH[!$<9K\)Z!9I>D(K9%F<H026\VQ(WU5 [.$Q$PI-L#72L2B0R14+%+&-9
M/<]O+N]FF2\W?R^XG?FE9+5O;R#M0G4H8.@V)R"<TOL+9DTRA41L;.LVN)NI
M!-BHM+>G/P\FWAA[8Q2O%"QI-:B1R]>:Q$Q/'$'",,BYY;N5%7L9=WIY<E,M
MV?H>WGW*]8/O%JPI6JR5FUS8 JTV<70R437:@@\A:L(V.K2T&K.-.P3#@&2+
M)6#?NNZRP<P8:%(,R3;,V1"16+"X-:R;N7>F?9RR]M43FY=^2+3+T^__  6L
M1/[ZZAEB+[(IN"1HYK6C&+_;@1)J*,EB(M,KP&]WRH$H34Z8;&VT113*9D&;
M*#^T<D=S@# ML\G#)PHC63?SHF:IT^3/+T<E_P >7)E[?)U^_KU>7DU0IQ2G
M%*<4IQ2G%*<4IQ2G%*<4IQ2G%*^7'V7'[=:W?N!U+_%\"YPK&OTPS/XD?[R%
M>0_@N?JWX@^Q>'?Q/%KK-YJE?,]8&,8=?LQ@ J,A#0P)7B[4M+REKD9.3;+#
M<8<8RRA+/FN:_A:%I>>\MB5GPX:RWX%5R:1([3Z$JJX\^TH99(.Q".:$A9KG
MK;=45,DRU>GG69D6MMG#]KO0OF;EPNU\MCD96A$&4M$2P2@=!Y'2)WA"7M1(
M2::V2QTR5S:*HY[E"L-5P=(?:L]W/W/:"_CH$\S$'Z%7O^3M_P"&A76\%_4Q
MTS_6&!/[8Q:I]S#UR2G%*@EKNCE:GCX;0M!!MZ*HB3>7/S"7"&H- PJG(;&(
M,O!*;Y4UA]$-3L!M341Q*I:'7HZ'+V+$20!DKNS5"1MM-370W%9>>1#77'9A
MDSJJ:(:HIHNHJ(2IN6&\)A?X4V4Y<2@FW)2!;VAA)+&7<"M-WNPMRG5F1E@1
M-G:59*4+4PT=DMDD8FFGS#'$;_-B'28B*!:E,P9\@*Q+40(9D234:JB[DXRH
M6,KQ>8D>H,24AF7#](3G24;,/ C#3[4KD[<$28;=)Y14P%TAU U19*2Y$0MH
MX^T.TVS>\"U 1LM?:YBHU?0,%19-G@721>7(SDN$Q=GHR0H2,1[5(Q'<<*MN
MI<;A>[9%6:EU@(;L:4L*&W;W^%+<U<9<C5+JL<Q9:X$/XC>9Y+C8DYR'Y;SC
M,-Y]I*WH:WO)1UJ<BO96PYAV/%D(<;4B1%C/I<8;M9+/!WWF-;7V3A@AY:NN
M@JJ":)F29$F1)D1"J+F)$.1+K.(K0M@OMWLO".%I;+A)AA+V6P26TRZ0M2@:
MVCPBW(:0'FU;?D,D!B;$B0R0/'GN4:PM9VK_ +)J[_AT1_"$?E1G]=:_E _Z
MDJ^MGT2M_P!?1/PANK#]W_MQ>T/[_&T?^,"W,A>_HS=?LA+^_G6_:9_JN:2_
MMXQ-^-Y55;YBZYG7YG.$XRK/];&,YS_Y_K8QX<\5%$551$Y55$3/=O7=R]*M
M4#-F/$ 3Y58!N/+<Q1G1,%)=3\>7'V)*@0:XLA/]%-*'/-3)WB&6(\(IB"RR
MI^&\3\HVWG)N6\0>1M'U(4X8CI[)$(2@"9OH ;5=HBB'C)$;>NJY&C>2K72;
MAH^:A7EJVA>G'XS:XP;N<Q;6++\9_ L>;,OHPH2W)P9[3D6'KVIYZ9;EF.NH
MS*:M^S<-.6#V#**G!(>4"1 048LK>9B)\Z0TR7JI=\,3',O2 (\9/0[(A3I$
M',4JHPZ/CX(20,.)EYV/(]!%MEUT'MILRCKJZ@"JM26A>;<5$>-T,A,!/6:1
MI'"V8OD>2%;7C!$>VV>YW6/>#F%;WK :12A0V77;7B2V,W6WSG66+S-N$(FX
M\N$S+63;AM3<Y]8,>\RI2--O[-YCZY]3BE6BU5]JIWS_ 'K](_\ N=U+RI*^
MEK$WUK;/QU KV7_0,O\ SLV?[5,6?V4Q%77;SE=?M)IQ2MU:LTX[M:!);#V*
M/!LZKSK>DB@<P<[D?+7L8_[6HI,@>3+3Z-9@DGHO@CL"RCDF/Y\\\Y S&BH(
MY.!;5G@J-O(#_"H48&B!=0N&/; 7#=UO$()JGB4;-53655#(4/0<8XZ#!LEH
MIUK<D6A,/8JO\RX,2@X4R.%[8MV>B1K<K*\+<D16WO'7)<,6G>#@V,G:O%%C
M>SZ&C7UC9%1)\LR'("XID$?D-5A#!T9(?EPU3QSM.NE_KTJ$V1@$!RG8=GEN
MLS8,R#/CP"$25#9HSXB0WD;$R=;-L76GE1A$= E(=<%C29;)"A@89B^2H0$!
MB!B0IE<(XC+$UK.8_&9@3HTQZ!<;:T=W)RW2VFV7TC2@OEAPU<VGRBR8TI ?
MM++9QY#$B,[)C/,ON:YY95M-2JB_LWIW[JJ]_"\/E>+^R8_\NU]\&L/B'Z 7
MS[#W/\"?K?\ WH^W3[:?XQ^Z?XP[#S,8J^F;$'V9N7X6[7-? \_4%T+_ .ZW
M ?\ 9FV55;F KL5.*4XI5L]7]0-A[*(@'XSR4T>QUTF=&7FOBB%FCR9$)<46
MR%;K_@#GF22K41A YOI**.99A1SME&.&@P1UV1L,'#DV:;*BOZE?9-T);+9O
MBJBHMHULLFW4<X08M$AB"(*.O@KK32DO%\7Z;\,84BW)MULEQ!:[I$MTO#UR
MF1K2ZTU(1Z6=P*Y9SK<<5+/%?N#'!7I3CDAVW6J6,"=< !JIJDJ2K*58RE2<
MY2I*L9PI*L9\&<9QG]?&<9_6SC/Z^,_K9YKU=G14)$(5145$5%1<T5%WHJ*F
MY45-Z*G+7YQ4:<4J;:T_LCT#]VU5_AV!RZ@_LV']=1_OH5K^+/I5Q-]K]Y_%
MTFOZ57/M:ORGU6RS_LA,?W_(_P!_/+X/G!_BC[B4K!<FI70'[)K3J!IW<M"N
M-(D4SKM;MQB-EW6Z=AKMW#[&]2J?9K9K]-#BB=5Q++K T]K"-LJ]A#98N)F;
M.JY0=.&TTFU!"V!Y!)N)2-$145,DSSS)24>;=FG3Z:9HO(NZIQWY]/F350EW
MY\^_).MS\J5W'=9[A#V%UPZ_WX<JXK'W?2>J[=!7L28R1V N'8Z*",1EW@C&
MB0(Q"WK9F(599T:##CS#.9LAB+':<0TBHBYHB\Z(N_EY.G4JIDJIS*J5N[D:
MA7%LNH-;'[I6-EE1-33?!-5 "X5AF0YJ321P]J?(%Q9;\.&XT1BB91DS, MD
M,R\ YA@M+%)@R24UU^D*Y:WB57Q9;TU>=><D7IKV:5'H&AM1"W:^^."4"%(J
M@ZEB*S)CBIK<D *UW#L ^CC1$A(K#P^#6!]LM,$3%BN-LQX5D/Q?$4P8(-R)
ML_WA;N3YSI?^ZE<8UUZTM8RY&P'JQK4P<+1K-#(ER(!Z41E1KH%J-=MK*YCP
M93Z46(#0:6(,8;6CSX?60\5_QVH;2<,_WA?T.GR_MNLG8I6N-R]/-5[N++.V
M2XD0Q=SVLJ5-K4J.WE#U3![7K@F='C6"E6&%$,-B-R6]A!^'&8/07F:]-$$Q
MLT! D(+O_:%TN10Z6?[[K^Y3O[^Q6PG^NNEI<FM39@"AS)M0,F+%7IDR 5E2
MH1RP6YG8!HHY(?'+=GRR5^BP[U)<(JE^-<X ZTXPDZ.@SX[/]X7]#GS\ESIG
M2M=N=(^LBBH$DS3:!#C5_P!-98 Q!TQJO$'#<.LBU*,#,AE)(,# 52$5D.,<
M=2'@U5#M7P.< ^0'QW_XR_H=/=Y+F3+T-W)4<U[_ $^ZM;!N_7G56PLV=ZR*
M!2"%PJA"BGBS;AGTD]33;<2-9*Y">D#9#8>!:1T&**L;@AF#-*P(\1#\ORXX
M;(AE7/E MZ9<H\GW50J0P=14:& ;K3T\,7%-7"5?TM''C9=S%PE7V1L[!M+D
MP>YEE^#>)&3@=B/AF&%<8A1!4:'!@Q(S,<U\@79#WU._\GN5#Y'5W0<V%9QD
M^J:](B[F0N!6S"2< N2$E2&PH%M%WJ2Z+G09 ]E=O'WNY1;&F+&8;+M60MB<
MA[,I>>0SZ6S7+?Y#I\O[;IYKG3.L^3T9K<@*2'CNUP%$3>J9L?.:ZQ.$NJM=
M%+UDJ$G94P&RA*'&:D&!$66T(3-KC;X96417U8Q'-?(%TE_:=+_W=:E8,7U@
MZ_A%2EAZ/JD8N:V*:E*@UIR-EYD'?[%M0.RK+05/@9';'MMENL5E/BMMV$S.
M(X3Y=WQL0SRY&U_H<^?DN=57T:9]_M>Y62J77G2]#.R++3:[KVMG9(=RONDA
M(F=$?]"/H!HE"FL(%^28A355H$_/88;;1/EC(TV;A^6E3ZF?[PNR/6_?=9*5
MK,QTFZ]F,3&7(@2"/E5?1]):%C53HL,94.O^U2>XJ'7!+F03L^ )S;RB_2\5
MF;XKPN&,AC<BG1\:4B'_ +"Z2?M.05S3]MSTS_+[>Y:E4OJGHMT(7KPT34ZT
M)L%='5 ]#JZ"P6*9JL!D4.=!DX489YA+:*UP/#J!4D[%4=DU-/H1HLQ&:B^;
MQS7DU"_H>^YMU,UY:WKZ'A_A"&_]"OT9R.LOD"[(>^I3T/#_  A#?^A7Z,XU
ME\@79#WU*>AX?X0AO_0K]&<:R^0+LA[ZE/0\/\(0W_H5^C.-9?(%V0]]2GH>
M'^$(;_T*_1G&LOD"[(>^I3T/#_"$-_Z%?HSC67R!=D/?4IZ'A_A"&_\ 0K]&
M<:R^0+LA[ZE/0\/\(0W_ *%?HSC67R!=D/?4IZ'A_A"&_P#0K]&<:R^0+LA[
MZE/0\/\ "$-_Z%?HSC67R!=D/?4IZ'A_A"&_]"OT9QK+Y NR'OJ4]#P_PA#?
M^A7Z,XUE\@79#WU*^>#V3+1E(NG;&S'C/9_0^N)S]+UI&75KJWN!1^,W#I(>
M,S,?S5=3V8/YL1;;3,A>2+.O^;.M^=L19'CL(X[BR"P_?)3CES@Q2(6<V7TF
M*Z.30HBEL8CS?BDWIDXNY=^2UYC^"9P79KUI<O<^;I(P3AM]RWV,"M5['%:W
M!E&K5& 7'5M6&+G"U'Q1'6MG,<+9DFT%L\P2@/JPZS]^UU;_ !/8/ZB.:WQ9
M%\W+7]S<?@%<!Z&N&_/FT9_<8\^1%<1'5/5#<V021W3ZL)G2X\6))E89[">5
M>BP7)3L..M6=$_KM1G9TUQE'@PEMR7)6G&%/N95,MOCJ MK?;9J"1$(ZMQR0
MC04,D_4'*2 "*O3013D%,KD\!65R(Q /39HV*'&?DRH\=0QWLVI$P(S<IX$\
M)&YR0W#B-O'GF81HXEFC+:#R_5AUG[]KJW^)[!_41R7BR+YN6O[FX_ *MNAK
MAOSYM&?W&//D15H-1]?*! ZZ]MQ#';7KN5B'@>EVIU@'M;M]#U5([:XV?'>L
M&)NG(9/+1A]&!8WT,.+N8GN(\^;A0_&EIRD.WQAMUW!+O;C0VX6LX*3M1K5E
MB2*YK0Q-==?$CLQ-=;YY!',JZ7A3 5B8T?:5HC>E3 $IF?#P<+\]@<9<$M:1
M\41WVSGH]A)J2HS#3@T?@<>46W(=N++6;J5?]6'6?OVNK?XGL']1',7Q9%\W
M+7]S<?@%<TZ&N&_/FT9_<8\^1%/5AUG[]KJW^)[!_41QQ9%\W+7]S<?@%.AK
MAOSYM&?W&//D16((]0M,EY(^83[C]3YTH4[EX>_(B=@7'(J\OQ)?]#5G1'ZZ
M/.X$"9AM?C-XF0(,O"/.(<9QJJW"::%P&\06T!=3)P12Y(A)JD._]0>1,PSY
M=0S'/5,D7*0,(0;9'G1+?IVT>Q(UR;V4YE@L>@$@-C)C>+1,$;BX+-FQ5<'5
M<6+,EQE+82GVW,;GI9HCRKDC';WJ:B0[$:A+?;C=A6G_ "#*(;;7BO-Z+2XV
M^AH>/9Q+;4F5EF!!9R]EJ''2W4X.F2#X8K<J(2GDJ7%4UEUU7-%MZHJ9N.+J
MKF.;AJB9D2K?<1KLVV5T_:/R9:DN2P9<\/3C.V=.4XYK-'@8FS9)V=-=X,8E
M&1V;+<1I#DODYGX/5/4XR''@#^Z/56'"B-)8C18\7L"TRRTC'@2AM"=#XQC&
M/Z^?_/.<Y4K.59SG- [?'<(C<OUM,R7,B)+DJJJ]-56!6&F8!LUPE/S9VF[1
MQ*ERG">D2'_#\XZZX:YD9F6"555Z2=)$1!1$1$2N5ZL.L_?M=6_Q/8/ZB.2\
M61?-RU_<W'X!5MT-<-^?-HS^XQY\B*S%>ZRZU9/@W4=U.K\A31@8XEAEGL!Y
M9]2)K"DLM>4T6VWY1S.,(1Y1Q"/&5CQUI3X58G:MD5'&U2]VM<C!<D&XYKXI
M-R9P,M]7EOT;X<"?!--,>C5Q1F1B1L QWKFHO J .M@H1UB5,AUB%,U3-43?
M6\.W/7C7Q_M)V&-S^W77.J32VY-AD9=9L#6\,G0$B7:"3[H@OD+IDN(R1'K6
MJ-,R,*D8.7VU^;39+/B.JOKO;HQW6XF5XMS1'-DDK3B3]=M2>-5 ]G",-857
M5+5,AS3<JUN>E; %@GZ3,?37]*^CZUO2L78@D.VV>&-.&P7';G),XDO@>$)<
M7A#!*K;O!I,AG7%=F\X&1+7?U8=9^_:ZM_B>P?U$<QW%D7S<M?W-Q^ 5H'0U
MPWY\VC/[C'GR(IZL.L_?M=6_Q/8/ZB..+(OFY:_N;C\ IT-<-^?-HS^XQY\B
M*BC/2C0D>([!8[<]2&HCWC^.PW![ I;_ )[$+"/$QC1&,M>;)&CTP?)91Z/1
M!B(@^;ICM81<JQK$AKB.WJ2<A+QEG^WSS_4&_6VCBGGGM%,E/64ESV1RRN/2
M6I;O@@L!N26=74>-S'Q'N66IZRK@A=IP@I\XIFTUN'%,DE,VY/N*7+@]-](C
M94:;![A=3HLF%&S$B.-1>P>/-F5(PVO+",Z)RVT^\WC#3\I",2I#7]#>><1G
M*>2G%!P2 \0VXA(M8D7C'Q2YYIG^H,U1%WH/SHKO1$6K:7AEB?'D1)FGK1](
MCRWTDRFW%QXO"'4-7 1XTP0AN--.+M&8YDL=ESQ;30'OJ0>K#K/W[75O\3V#
M^HCE#BR+YN6O[FX_ *PG0UPWY\VC/[C'GR(IZL.L_?M=6_Q/8/ZB..+(OFY:
M_N;C\ IT-<-^?-HS^XQY\B*L/KCKQKZ'UQ[E"&>W?7(A$L.O=1Q"%AAM;P]#
M5%J!V#UJ68GV/$K3,8IF&5E0F0(_T&--2<%R,+,V/#&^=$8T\FV1BL&(&N.[
M6(NQ[>A/DEQ1EA NT)Q">R@*YDX0HT&S;<7:&.L@AK&/JE^A 6Z/H_\ !:6N
M_6"[V[2S.##>)61PKH\2<-_=![#=]9.0VN-8>#[-L8X.E(?U[N#NQ8=V3;KN
MS:<HUZJ6K/?W]2_Q'9'_ *>^<YX@@]56'O\ C7Q-7ZNNC)C#]SKIH]4T6?WE
MT]5+5GO[^I?XCLC_ -/?'$$'JJP]_P :^)J=&3&'[G731ZIHL_O+J:5W2P*I
M"282L^R)]708TQ,&$2+(U'8V,Z_/"R6Y@B:F8CKOB;'E"YC3<J _&D,N1)*<
M/L*0[X59N6;:W';-IC&-A:!P@,T#CE%4VU0FRUN)=9";)$(%1442WCDN^L#=
M,>W"]38EPNW@8-+UPEP6)<6*Y*+1>Z#<:>T3$YA6"TG<'<9EL&3,EMUHP>:7
M9N(09)6-M&@*C=2N35J]D(ZKFR>8[$1$F8CL?G#$2-A6&(D5AOKRW'AQ6LK<
M6B-%998PZZ\]Y/RKSJUR/VB/)<VK^+[ Z>J@ZQ<=;A'D$42S(@BG,*(F:JN6
M:JM75GTE7NP0TM]F\#-IAM\3:N/DTP6BWQQ]U45Q]YP])I.OO'JB).O&;B@
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M9>2AQ"DXXQB^WW"3?93L>#,?:(&$%UF,\ZV630HN1@!"N2[ER7<NZO+/P4F
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MK>Z=L+\M+)])<M>,;AY>F=LO>_K8?"3@SJ1PQZP6KX)4HI&V=IN72H-N;+V
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MHB::'OQ2+HJ4/A8D):K]=]%7?%E\\?\ \JX9UI*N$\?'>'MH3CR2!==0]OK
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M+G&U+D)=K1'C,R2&ZRXW!%AC;)$]N'9XK93!F3)<UZ1& X]JGH'&3JPXV8K
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MEU^ UB?"#@/S[,&^QO2-\D*>KWU^]_3I7Y+^S/U,\<7V_P W87:EU^ T\(.
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M\<\9:?-Y155-H=57E(6W,^DP\%6]V_21<L,QP$L-FF-X=&5+:,+W)EX49O\
M;!D%K3M>S6V_2+N<9UPY-L;2.5U*1'A34>SM0NL\A92HTW-A-M*&UQR+#PZ.
M4L;8Y^2^"U=6N&[F1'DQD1(Z61Q?"RC[D8E,:5B(G$>-0E1 ;CM.,@:KM'T(
MLG/'& V6R?R)-4A)3+-QK)H4)L%37S(L-BC"4*#8+;/M$26XX,^^A(E*W/$9
M]BAI:^++X 2FT9?CR#E/J[.MBC;F0?@17 X2JOR,8U?3S1&T)\I%(OPH-[S'
MK^(R67Q9BO'5#J2,4MI7GCKU\#H>,L-2\J=DICJD"O)P5X1RHL%E0CKXH!,X
M6;ZEF+C3[.TF.;TU$&"[JLDH[AULG<S2K]S!=F=A8>) D06)<O!J/WO;DZS<
M+9?+,,_%UP07!X*TU@VZ&U:GG(R"U')]&+EKRP4ZP0W9%@78A@MPBV9K[IJ'
M#@'QS UB1:TD$4QA]$)I3#T25"KA*P&$G$"O-I\06,5(=F>=!R31*NY;V48<
M<1M67T:,G&'%<(8NS662:RYH0E(;8:V"NZP&XYD(ZKK:MYF?@*R#8KA< @G:
MKTU:94J;9I[T]YC#A0CQ6ZR4MT7FI,:7?8%DM96<KEPB'*N$]&&HG![K =M]
MC.8&N$U:+57VJG?/]Z_2/_N=U+RI*^EK$WUK;/QU KV7_0,O_.S9_M4Q9_93
M$5==O.5U^TFG%*L]HK4%<V96CLNP0;$*CP-C:D $-AL2<IK-6J]NM#8.TRB$
M=P4J$U(%#Y2"[Q(@8Q%B1VV,.06FUN2'\Y:K<S.9=)X7FQ"9;VCF(7C$=B0^
MC3Y&*MZJ*V!(XIFYJB*)F*(JJO(](F-[IA*ZVYFV2+7,=DX7QK<HV&'&D6[7
MB[V2SG<+.S%=&8D@VIDEDH+<6-!5Y]TW-609"#3<)WQ285$N[8P<,; 0R ,<
M79K3[1Z&?KJ'WID)(ZVB[)-(%!EB?3 P6=:S*Q#GBR8LV.ABX)6.+A6UUBC$
ME( -HR)M XC*HZ+S**I"@2&WB-QMY=3:*FMJD!@Z MBXC8Y_1SB"1B/#YRY4
MLKD]&N,F$=U;.W/VVZ*VVP^LJRR[5'C0Y=L;62L(31G;1ID29;Y+\R1"<F2-
M+\QE;[4JHO[-Z=^ZJO?PO#Y7B_LF/_+M??!K#XA^@%\^P]S_  )^M_\ >C[=
M/MI_C'[I_C#L/,QBKZ9L0?9FY?A;M<U\#S]070O_ +K<!_V9ME56Y@*[%3BE
M.*5=S4G7S4]EMM7C6#90"4T;J[\R=K^=<:A5K(+/D&(,87B1:D'2E2D"HN9\
M\_D<T2BW_+E8>KUGHE2:,#SCNSV^SV]^3'%Z:TJ.L*1Q"DQF'FWC0!#.1M7(
MY-CKF]J(8R\V%9?B1T<!U?G_ !II,QG:K+=W;;A2Y,G;[NVQ'Q+&L5\O%JF6
MV,Y(=F*U9RMT.]M3'N#1[;PDXCV&T"[-W.T8BO1P9-O"DJDY2I2<^+G*593G
M*5)6GPXSX,^*M&5(4G_Z*2K*58_73G.,XSS6*[^BYHBIGDJ(J9HHKOW[Q)$5
M%YT5$5.141:\>*C3BE3;6G]D>@?NVJO\.P.74']FP_KJ/]]"M?Q9]*N)OM?O
M/XNDU_2JY]K5^4^M"V#VO>FRGG/IGR_GCWE?(>8^1\?QL^-Y/RG\_P"+X?ZW
MC?K_ /UY=#M=4<MGEJIEGK9Y9;LZ5A_ZF/[??ZOY-X[_  ?]*E/ZF/[??ZOX
M\=_@_P"E2G]3']OO]7\>._P?]*E/ZF/[??ZOX\=_@_Z5*S!GVO>4'^7],^'T
M.+\GY+S'P>0\U1Y+Q_'_ /\ ;XG@\IXO\YXW_P#+^MR4=IORU/GBSSUN7/?Z
M7-2L/_4Q_;[_ %?R;QW^#_I4K'QQ%#B$")>*-GQBI=$)LL2CQ [,XF@:V\T.
M20EMMI?F)@M2'VH>)"W/-FW7&V?$0K../'?X/^E2LA_4Q_;[_5_'CO\ !_TJ
M5@R=8UF:G#RAFOK+$A+3C L@2% 9TT:RZ7 6!QJ!)E,.O1&UGJI5S:DL+;QD
MM7 1'P>>"8#S#QW^#_I4K.?U,?V^_P!7\>._P?\ 2I3^IC^WW^K^/'?X/^E2
ML?D10U%FSRAL_)MH>\(:,9B!\E&Q4B2Q,?&HG^3\Z3 >EQH\IR)AWS=<AAIY
M3>7$)5AX[_!_TJ5D/ZF/[??ZOX\=_@_Z5*?U,?V^_P!7\>._P?\ 2I48"4K5
M%:<ANUZK^A'1X5NNPG10H% <B@6ICI%L.PN,RVIL<DA(?G>:)SAG,Q]Z2I&7
MG%K4\=_@_P"E2LNX)H;I6(==&SW#< >0$P3#D0.LI#%%I(R84&Q9ZF\RH\ E
M+"AY4^(TZB/,D"AKTAMQR#&4T\=_@_Z5*R']3']OO]7\>._P?]*E/ZF/[??Z
MOX\=_@_Z5*?U,?V^_P!7\>._P?\ 2I3^IC^WW^K^/'?X/^E2G]3']OO]7\>.
M_P '_2I3^IC^WW^K^/'?X/\ I4I_4Q_;[_5_'CO\'_2I3^IC^WW^K^/'?X/^
ME2G]3']OO]7\>._P?]*E/ZF/[??ZOX\=_@_Z5*?U,?V^_P!7\>._P?\ 2I3^
MIC^WW^K^/'?X/^E2G]3']OO]7\>._P '_2I3^IC^WW^K^/'?X/\ I4KYW_9,
MO5(];&S?92]8SVW^TO6GG7M ^QG[6_,?:2']%^;^V+_YIYUYCY'S_P I_0?.
M_*^;_P!!\7G'\6<4\>2N%\8[?59U^#<&V66R'5U=KXOYW+//IYY;J\Q_!,]"
MOHN7KPT]$#CGBZQ[?B#PN<6;/BN/P?8\8_JK7V.IMM?Q.TUM3Q.54!_[ G]V
M!_L7YK?^0/\ 7']2K@/^@G_:U_R=3_L"?W8'^Q?C_('^N/ZE3_03_M:_Y.I_
MV!/[L#_8OQ_D#_7']2I_H)_VM?\ )U6@U'ZE_JZ]M_0_K0>UOT'I?VX>D_L4
M^G/(?97&^@_:UYK_ $AY;TOY+TKZ4_G/1OE/-/Z9\7F4A\2\77?4XTV6SA;;
M6X)M,N%CJ;/+Q/S_ ,_K?M>3?73,*=![H?:5N!]$KB[@>#N-^$^%?ANIX:(_
M N+=EXQK<+U>%<*W<'UMEXYE57_^P)_=@?[%^8O_ "!_KC^I5S/_ $$_[6O^
M3J?]@3^[ _V+\?Y _P!<?U*G^@G_ &M?\G4_[ G]V!_L7X_R!_KC^I4_T$_[
M6O\ DZO4RQ[']'1EN.SV[8;4Z^^I#+>E&D9>DO.29+V4HPE.79$AUU]]S./'
M=><<=<RI:U*S%5L)+F2WE5R1,U6&JY"B"*;^D(H@HG(B(B)N2JCKV@]\D-YW
M2\\:-M-(;IX1<)&H[0,,-(1JJHVRPVVRT"+JMM-@V"" BB>W_L"?W8'^Q?D/
M\@?ZX_J54_\ 03_M:_Y.I_V!/[L#_8OQ_D#_ %Q_4J?Z"?\ :U_R=68KOJ%>
MV %YMZW?G'I@9Y#R_P!AKR/EO/6/)>6\G_/^2\?Q?*>)_/\ B>'Q?U_!RHUQ
M!M6\N.,]H&6? LL]9,LZO+?T#>'P=ET6-IPR-L]?PH:FOM@U-?5\5JZV6MJ[
M\L\M];P[<^I1ZTG8;VX^M)[;/LR;#]LGM9^Q-[7O37MH)>DO0GI3_P"9>B_.
M_*^8^?\ ]-^;^3\O_1/&Y>W?B3C6X[;C7:\-D[79\$V>TVQZ^IK>*U-;/5UM
M^66>^MSTK=!KHF8^XWZ)O&GANQ!QCQ;X5>+^&<9R>$<"X5^J."[76V.W\=V>
MKK^*SJN__8$_NP/]B_,=_D#_ %Q_4JT#_03_ +6O^3J?]@3^[ _V+\?Y _UQ
M_4J?Z"?]K7_)U>IQCV/YY;#CK/;MU<9W+\9;C>E%KCOJ9>C*>84K&<M.YCR'
MV,N-Y2O++[S6<^(XM*HHMA1%1%O*(29$B+#1"3-"R7G36$2R7=FB+RHE5 >T
M'M"\#;NEYL)#:,OB!X1 7VD=:?1IX15$<;1]EEY -"%'6FG$37;%4]O_ &!/
M[L#_ &+\A_D#_7']2JG_ *"?]K7_ "=3_L"?W8'^Q?C_ "!_KC^I4_T$_P"U
MK_DZG_8$_NP/]B_'^0/]<?U*G^@G_:U_R=5AM<>I1ZN/<KT9ZTGM:^Q[J/VZ
M^?\ V)O3OHWU@]:>A_:MYO\ TAY][8_1?I/TM_0/0OG_ )K_ $]YORI(X@X@
MQ!K\<<'X/;^$:O MMJ\;0MGL<_$:VVV>OK[MGKZOBLJ]4OT(#B3YK2U]!GC7
MPX>%O$NRZ)W!/"UP;PMWWA6T\*O^5-OP7A&PU?&]OL=IXWKU1O\ [NW^[2_V
M&\YS_F;_ .IO^%5^KK_Q/_[!?_D*G_=V_P!VE_L-X_S-_P#4W_"J?^)__8+_
M /(5/^[M_NTO]AO'^9O_ *F_X53_ ,3_ /L%_P#D*G_=V_W:7^PWC_,W_P!3
M?\*I_P")_P#V"_\ R%3_ +NW^[2_V&\?YF_^IO\ A5/_ !/_ .P7_P"0JD=.
M_4]O;=5O,O7+\\]L83S3SK["/FWG/I.+Y#SCR7]%\AY7Q/*^3_HGD_&\3^>\
M'*T?PG\(8U?#+K;9K5UN*]76UQRSRWY9\N6_+DK%WSYIKB6\;?H$[#BNX;;8
M]$#:[+@CVTV6OXC::F>IK^)ULM;=G6ZNX/J)>M?V6]N?K;>V[[.^U_;1[6/L
M.^USVP>W@WZ7] ^E?_F?H?S_ ,OZ-](?T[YGY'SK^C>/S*8C\*GA@O?"?##P
MCC6?M]AQ;L=MPES:;+:>.;/7SU-?Q6KEK;ZT'0?\T5T&M%/$/05XDZ'>#N*.
M-_#SQKQ;X7X' N,N!_J3AW!MGPK@OZGV^OL?&]6JY?\ =V_W:7^PWF%_S-_]
M3?\ "JZE_P")_P#V"_\ R%3_ +NW^[2_V&\?YF_^IO\ A5/_ !/_ .P7_P"0
MJ?\ =V_W:7^PWC_,W_U-_P *I_XG_P#8+_\ (5/^[M_NTO\ 8;Q_F;_ZF_X5
M3_Q/_P"P7_Y"I_W=O]VE_L-X_P S?_4W_"J?^)__ &"__(5/^[M_NTO]AO'^
M9O\ ZF_X53_Q/_[!?_D*G_=V_P!VE_L-X_S-_P#4W_"J?^)__8+_ /(52V@_
MJ?'M[I7H_P!<GS_VVUSS'SS["7F?GGIB'YMYWY#^C>;>6\3R_D?Z+Y+QO)_S
M_@Y<1/"APN+J>&37X0SJ:W%>KK;0=76RWZN>6>6_+DWUA,2_-,^%R_\ "N@5
MP;B2Z\(V'A_V^PX"_M=CM/&]KL];9Z_B-?+6\3G7WP\^LJ_.)5;+/^R$Q_?\
MC_?SR^#YP?XH^XE*P7)J4XI3BE.*51'M8![&2-KNRM,YV"1:/ZGI06.^HS9
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M]8=H3:KTNUGAMW!CT)Y^QQ[E*%^.IS8F=V9O#M_P^4&<U<0A/28]F9L(709
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M.PF)KHN CR*99!:DU&O6F.=6^_9@HV0*F23::XQ&6Z-:](OCW\G,^75"Y5"
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M!:]("[/(U1U_%7JP]Z V''P\5NY_2RSR3L)GGNSSR]J.[?R>WU_;]/+KU.R
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M3T(G9-<;IBWRQO56')4Y(%VM;I<1/:*@\J+K=+GZW)EZ'27->GR^E3=T\_\
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MB6]3W<2!<?"[,DML2L,OP;+'<&/(N82%C;>V,LVUF2&S:3!*#*C7!IK+JBD
M/"AS%2).)<E;L9E+.')4A+TE"Y;B$)7*PU*EL-R%.-L2Y3*$2',?,-MR5(<:
MRV9NF8:HZHHA+GD*:HKJHJJ@YB)*.2D(DJBG/L73+=<<3WZ?:4;2W3;I+E1!
M9C\&8!N0Z3NSCLJU'(8S9$01U<C1GG&1;<>BQG3-AN4<MJUVL[5_V35W_#HC
M^$(_*C/ZZU_*!_U)5];/HE;_ *^B?A#=6'[O_;B]H?W^-H_\8%N9"]_1FZ_9
M"7]_.M^TS_5<TE_;QB;\;RJJWS%US.OS/ASC.,9\&?!GP9\'A\&?!^MGP?\
MGX,_^7%13+-,TS3-,T1<LTZ:9]+-.G5?@U;N\.KRQLD28\XE8I"R<99\;(=*
M20,D&J^OLS%'%>3]O,%!"+!2Z]#Q*>9DR#F SA#RCN<>D0SD X+C.J'#$;)&
M'!1L7A>X"*@C._@1JV1JB'JHH"SMD;R3MMTOV$)6(HUP8N5KV$=<7! ?"RSF
M&[='O,>\!@QEZ*-G1#\)\LH,F83;,I8[3T=BSK= @ZC?*I5:O@FTL2BT9QT0
MMZ?YIF?.B3L5VK/M%'Q==CO-EWIF3X^<Z-BS'&H4P-+%I=RHS*DP1B&99;\)
MR,H-$B.H((>H!!PB2*MHY(5%90=@X".$**8.@YDB-")N*MMBV_X-N6'7HULD
M-MW(6H7"4A0Y4-;[B-EVW,W&^O-';&HJ66;#;GR(@.2XETC7!6]6TQF9EP)W
M?',+7&J<4JT6JOM5.^?[U^D?_<[J7E25]+6)OK6V?CJ!7LO^@9?^=FS_ &J8
ML_LIB*NNWG*Z_:33BE6>T59=7AJT=A[0GUEX3G8VI+ ]5I%5(D+98JY7;0W)
MN\ 38X-6ELPXTZM/2HB!)2V!X$R3Y1>8V'E-R',Y:GX+;#HSC85OAEO=5A6#
M.0\RR^A2@;?".2 )LJ0[,Y#8$6_5SR6N1Z1+3B^?=;<_A"-=FYJ87QK;6[PU
M>8L:RVNZW2SDUA^3-M<B\,N/NQ[L#+ZS8EEG26&M44=4$)H83O@W5+#>&RU5
M.)L&)(,?@\0AMDVJ]Z>;>F(7&J;9RMU$VU7XPE(AIN*2KPWS G@F/%-* 11#
MB[6ZN1WI2.1W=MFT&U,4-&=JBDFK'1UF.ZC(M[-$$V0U#UP;39"VJY_1S;[S
M;,/G#O-O6V;*XRN+8SYQ#N?%I P0NWHK?=;W;SN3LU9I$]$N<KA,3@DF88W)
MZ: Z7YC:WVI51?V;T[]U5>_A>'RO%_9,?^7:^^#6'Q#] +Y]A[G^!/UO_O1]
MNGVT_P 8_=/\8=AYF,5?3-B#[,W+\+=KFO@>?J"Z%_\ =;@/^S-LJJW,!78J
M<4IQ2M^ SU<'=?[H%?MM;FV>Q6,<W H1&NFO28,<.G@2$BY!+"Q49(A^R%E1
M\@FD3+>*0&J$6V1<PRLVTCF(&6:=8"T2FR?8-]YX$"*;+NT9 #:,I+3R1R;5
MYS+9(A26T;CC('5<-\$#F]QMMTE:2[!<&[+=8]HM=KE')Q'%ND#@EPE2HURB
MM6*?;'+VU-;M4)'4N)DQ9)A3KV]97D?AQ[/*<D:#YB:Z13BE.*5-M:?V1Z!^
M[:J_P[ Y=0?V;#^NH_WT*U_%GTJXF^U^\_BZ37]*KGVM7Y3ZK99_V0F/[_D?
M[^>7P?.#_%'W$I6"Y-2NAGV4VLR9]\UG7;&<D[6.&96U]EZ]I#'4;L+LVP:T
MUB'":6I=UC"MO=+MFZLWC2*K'M)-HG8Y^8][>LLB_B19\,X&I@#RU,^EGUU3
MQ)+DB(F>\5143/EY>7K5.'37+<F2+XH43-57+<2*B^UR+SUW =<H(<7U[T0-
MKP8)7  _3>L802O5D7;P=<!"8U)",C@X +L& *OH@*-B(9ABQEW%CK? @LL1
M;+ B&FIL=N=.1/03K>[O[-2+RKT^OSUN;D:5,B8Z-)P+==,#H:\A!./(24SL
MNXQB(C&%9S'AOM^!7]?'@<\/_P!<8Y3%536\2J^++>FKS]<D6E8OT/"_"(/_
M )!7Z-Y-K+Y NR'OJ4]#POPB#_Y!7Z-XUE\@79#WU*>AX7X1!_\ (*_1O&LO
MD"[(>^I3T/"_"(/_ )!7Z-XUE\@79#WU*>AX7X1!_P#(*_1O&LOD"[(>^I3T
M/"_"(/\ Y!7Z-XUE\@79#WU*>AX7X1!_\@K]&\:R^0+LA[ZE/0\+\(@_^05^
MC>-9?(%V0]]2GH>%^$0?_(*_1O&LOD"[(>^I3T/"_"(/_D%?HWC67R!=D/?4
MIZ'A?A$'_P @K]&\:R^0+LA[ZE/0\+\(@_\ D%?HWC67R!=D/?4IZ'A?A$'_
M ,@K]&\:R^0+LA[ZE/0\+\(@_P#D%?HWC67R!=D/?4IZ'A?A$'_R"OT;QK+Y
M NR'OJ4]#POPB#_Y!7Z-XUE\@79#WU*>AX7X1!_\@K]&\:R^0+LA[ZE/0\+\
M(@_^05^C>-9?(%V0]]2GH>%^$0?_ ""OT;QK+Y NR'OJ4]#POPB#_P"05^C>
M-9?(%V0]]2GH>%^$0?\ R"OT;QK+Y NR'OJ4]#POPB#_ .05^C>-9?(%V0]]
M2GH>%^$0?_(*_1O&LOD"[(>^I3T/"_"(/_D%?HWC67R!=D/?4IZ'A?A$'_R"
MOT;QK+Y NR'OJ5\\'LF6CJ'<^V-F.F^T.C-;D'J9K6,NK7.)N%T[&;ATD/&9
MF/+JFJK*&S&(M-IF0\,EG7\1G6\2V8TC#C"..8MA1WKY*<<N<**1 QFR^,U7
M!R:%$4E8B/-^*1,TR<7<N_):\Q_!,X,L=YTN7N?.TDX,PW(<M]C K3>6<6'/
M9%JU1@%QPK5AFY0M1\41UK9RW"U"':"V>8)0'U9-6>_<ZQ? .POU%\UOBV)Y
MMVS[BY_%]<!Z&^&//GT;]KX^^15/5DU9[]SK%\ ["_47QQ;$\V[9]Q<_B^G0
MWPQY\^C?M?'WR*IZLFK/?N=8O@'87ZB^.+8GFW;/N+G\7TZ&^&//GT;]KX^^
M156@U'U^UU ZZ]MA$?MOU]*PSP/2[9"P0(>[L"*HD=M<;.C/'DS=/Q":VS$A
M"18[ 4<7<Q.<1F>B%#\>6G*0X$8;;=Q2[V\Q,(2$X(3]1K5EB2*XA0A-4-?$
MCLQ/Q7SVJ/BJZ7A3 >'F-'VE:(WI5P'*9G0L'#(GL,8S2):TCXICOM'.1[";
M4DAF.(D:/P./*)'R17Q99S=2K_JR:L]^YUB^ =A?J+YB^+8GFW;/N+G\7US3
MH;X8\^?1OVOC[Y%4]635GOW.L7P#L+]1?'%L3S;MGW%S^+Z=#?#'GSZ-^U\?
M?(JGJR:L]^YUB^ =A?J+XXMB>;=L^XN?Q?3H;X8\^?1OVOC[Y%4]635GOW.L
M7P#L+]1?'%L3S;MGW%S^+Z=#?#'GSZ-^U\??(JGJR:L]^YUB^ =A?J+XXMB>
M;=L^XN?Q?3H;X8\^?1OVOC[Y%4]635GOW.L7P#L+]1?'%L3S;MGW%S^+Z=#?
M#'GSZ-^U\??(JLQ7NM&KF; #=1W7ZS2%M&!CB6&8/8'RKZD36%)9:\KHYMOR
MCF<80CRCC:/&5CQUI3X58G:ML5'&U2]VQ50PR1 N6_Q2;M]O1-_77*KNWZ.<
M,A/A&.F31RX0RXQ(V$?'FL:B\"H ZV"Q'6)4U4UE1,U3-43?6\.W/7K7!_M)
MV&-D.WG7FJ3BVY-AD)E9/PMY+-@),NT$GGA!9073A<0H@/<6J-+4,*$(.7VU
MYBS)#/B.JOKO;XQW6XF5XM[1'-DD33@7!3;4GC50-6X1AK"JZI:AD.:;E5*W
M32M@'#L[29CZ9(TL8!M;\K%U_D/6V<QC4IL!QVYR3.)*6'A&7$60P2JVZL:3
M(94Q79O.!D2UW]635GOW.L7P#L+]1?,=Q;$\V[9]Q<_B^M Z&^&//GT;]KX^
M^15/5DU9[]SK%\ ["_47QQ;$\V[9]Q<_B^G0WPQY\^C?M?'WR*IZLFK/?N=8
MO@'87ZB^.+8GFW;/N+G\7TZ&^&//GT;]KX^^15/5DU9[]SK%\ ["_47QQ;$\
MV[9]Q<_B^G0WPQY\^C?M?'WR*IZLFK/?N=8O@'87ZB^.+8GFW;/N+G\7TZ&^
M&//GT;]KX^^15/5DU9[]SK%\ ["_47QQ;$\V[9]Q<_B^G0WPQY\^C?M?'WR*
MJPVN>O6N(?7'N4(9[>]>",.PZ]U'$)6&'"WE@14&8'8/6I6.0L*).FXY5<0K
M+AL@8& 0TS)26(PU38\,9B60C5)%MBE8,0-+>[8(.Q[>AOD%QV3"#=H3@DZB
M0-HHN$*-#LFW%1PQUD$-8T]4OT("W1L >"TM=^P[>+?I:N#>&\2LCA7  SF+
M\Z#V&[XR<AL\;0\(6;8Q@=.2]K787=BPZC3;CJMMG1KU5M2^_P >J?Q=V4_Z
M?><ZXAMW598?4[W\45^KGHQXU_<YZ8^VM%?]Y-/56U+[_'JG\7=E/^GWCB&W
M=5EA]3O?Q13HQXU_<YZ8^VM%?]Y-/56U+[_'JG\7=E/^GWCB&W=5EA]3O?Q1
M3HQXU_<YZ8^VM%?]Y-/56U+[_'JG\7=E/^GWCB&W=5EA]3O?Q13HQXU_<YZ8
M^VM%?]Y-/56U+[_'JG\7=E/^GWCB&W=5EA]3O?Q13HQXU_<YZ8^VM%?]Y-2.
MG=7-41[=5GV^]/5F6XQ8PCS<2./['XD2EMDXJTQV,OZ"98P\\I.&VLO/-->.
MI/E'$(\*L5H]BMZ2&%3%5B)4>:5!1N](I*ACDB9VE$S7D3-43G6L7?-+^,W+
M+=VS\#QI@8!RUW "><DZ+E;9$XCHDZXC>D8W%!M%4R0 ,]5%U1(LD7=7<'K;
MK$_VO[+'2/=#K54IYC>^UR<VK6"!V 6=KDJ=>#<F0#,K":/,!E%!;KBH4Y0H
ML3'*DLN9ASY<?+;Z\IB.RP'L07MT\366.;EUGF3#S=W5UDBDNJK3BM6MQM3!
M5U2V;AAK(NJ9)DJZ%H0TJXNMFAK13;HN@;2M>HT'1W@V)'O%MDZ-AMUT9CX?
MM[3=P@C/Q_"G)$E@*/QTF0XDI&G 1^,R[K-C7+U5M2^_QZI_%W93_I]YA>(;
M=U66'U.]_%%=1Z,>-?W.>F/MK17_ 'DT]5;4OO\ 'JG\7=E/^GWCB&W=5EA]
M3O?Q13HQXU_<YZ8^VM%?]Y-/56U+[_'JG\7=E/\ I]XXAMW598?4[W\44Z,>
M-?W.>F/MK17_ 'DT]5;4OO\ 'JG\7=E/^GWCB&W=5EA]3O?Q13HQXU_<YZ8^
MVM%?]Y-/56U+[_'JG\7=E/\ I]XXAMW598?4[W\44Z,>-?W.>F/MK17_ 'DT
M]5;4OO\ 'JG\7=E/^GWCB&W=5EA]3O?Q13HQXU_<YZ8^VM%?]Y-/56U+[_'J
MG\7=E/\ I]XXAMW598?4[W\44Z,>-?W.>F/MK17_ 'DU+J!U=U1%O=)DM=Y^
MK<YV/;JV^W"BC^QN)4QQHS"<1%C9E:$C1L2)"DX:9S(D,,8<6GRKS3?C+3<1
M+%;QEQ23%5B-1D,J@"W>=8E1P504UK2@YER)FJ)FN]43?6$Q+I>QF]AR_LGX
M'G2_&!VR75LY#TG1>K+ G!?$GG4:TBNNJVTBJ9[-MQS5%=0#+(5^^#GUE7YQ
M:K99_P!D)C^_Y'^_GE\'S@_Q1]Q*5@N34KHS]F"E!H-PZXD[0YJ;60<'7MS&
MP?8[;EZ[0:P'56[Q7-=1Q>J*QM'K-?J)+UC;-D!I1TO LU[]M0>?$I<T2(J1
MN;F9">IN=+D3+-=95),N3=F*IEFF?/R<BU./3RS7DW(B+GR[\ESSR]#T:[7>
MLUH1=^M_7ZYMCKD(;MVDM569 G8ILA9=@C$':*!*)'WJQED-E;!<(>)6(]E.
M$VT$"QIN:0F(3(D.)Q.F]$7K)R\O)TZE7E7DY5Y.3EZ76YJW?R-0K5EYV^71
ML2;KVD:TL%\GU"D4@I:RT4[4Z^'$3;8.,/UX(VL^8B3R,]48)Y^:<BP,Q18\
MP#=C/%94B?"&4P7YY.8B]M5W<_M4R[^_OW+6A*5W,K]EF:3&'M?6JDSM_:XB
M[=H2RY*M3!"=<Q@4FS7.Q6(W *.0@"=>AI-*79V)N<)7/V33H 9\HK-@> S(
M2+E^^3-.NF6=1RK%W'OKJFFR=YP'P-M,DM)G=<"VX0+%=G?9,&;'I$+8+-EU
MY*R=;ADQ%6JR+0;MF)[X^:-"T\D78C2X9($HDUDW];+T\TSW=_2YLJ9=/T5[
M%;8V#V=UGJFPW0;L*60!@Z4 JI6981X.S6UV63/@]J7$H$CUNG@#Q[QZI0=4
ME;N<))B.06 4S#[JF,09*LQ543E]Q>_I;Z99\G?R=/T^_.C7:W1CQ-H2FT'T
MRG;F;H/E7M:;1CC(]DKE['ZO,XG&I%,:##@,38Q-BD8N$^?&J$JSL% \,[(F
MA3+4!K)[>7(O*BY<W/T^2F2^Y[?)7%G=O>O0\<(+/7N6\--5>%>(DT=1MAEV
M(U+G5BOW1%M-+%5.;[6ZU"JMI!'#1RP^BQE?@3LN'90[,2:F,UDRSSW99YY+
MR<N?H;Z9+W]^_P#+4&USW4HNR[@-IX>ODHDN;;P%:FN2C=;F/U^);Z[N@M5I
M-F'A")656[)+,:.LU9.4(_Z,L]8GEJZZ4C8\^?8B0ULUR[^GW.1<E2F7^'+O
M]"I1N/M74=*6FS5VU 2B(U7T\6W&^:?*5T-%/B0K=MD%PE+C'"D"5;C-:AU%
M<Z[,B4N>T^!9Z41*I]&GG9@XI(F>?23/I;^7<F:\N[?S;LUIEG[G?W]):C^.
MZ^K99JYB ,0I:&Z^[.&5,O79H$H&V9:($C3 E54J1".44P@M)L^_=:UB'DLJ
M#%?*$26?+HC!ISS;63T>QDO)N1<^7>G+E3)>_P!/N+67V7VK Z[N#5156UE5
MR-IU33+!:5::]6!B+_8M2W#=LP9,DV%Z''8CC*(!KKL5YF1+EF35R@BX\".@
M?(F/154143G7+I<N2K^3VTIEN]OTL\O=K5MS]D)US0PT\W8:B;A(%7Z^T@F#
MDV>A#K<,7KX02-S\E*P6LD">+LEA%C?2E*II#,8I:PY0"7%ON0BJ%LM9$[*I
MTN7+/VTWIUM_)1$55R]/O]RK% ]\!3I"BL-!",0=?-I[PTT.GRWXV'V+UI,Y
ML@;,CK@Q\OX<$V0;J'8)P<1\[:>AQQPJ),@^=%EX'L^3KJJ>FF?<6H9?D7L_
M]ZA>S^V5+U+=[+3[:&(#6*Q6*I:I!PD7K@1HP,M%M%5-\E5QIDI"(V,!4)!:
M,[>3XQIZ)5GG84(DVVLE!=>*N7M>VN7M=/FS2E8D1W/UF?GDX8,>7,,Y.0*Y
M2B@R4#GBMCE7=SPM'FTU.9$*/(>B5"S6"E$[1-E^;L#:]<Q1#PNYC$VH<-9.
M_D7?EW]94IW_ ):F1KM+J>HVB_5R^'H]+:HUF%U3)4JV2?B%R,X9I";)>:<@
M#),,?!A$.P^K@F')\]N5(EDC,_,2.#KA4HS'-$SSW9?X=U*9=_9[E15'<[4*
M[/Z*:F3YM<4P?Q'M(<-:#CQ F.=ZT1P </4A5;E6BP3+G([.5#->57QY5B9#
MB8(,.2(I%*X4%)$_PS7FZ2<O*G)4<NGW]/N+60"]O-7R@^G"UAB6^KM;FU3/
MVZ(ER:?:"("MUP63UZ'G-7&P00RH]9D,SME5_#SYR..@C(S<V18)03'F")[6
M3=R[TSY.3DY>;E]VH9<O6[_3KD2^YG6Z LYY[L-^+$KTXJ)(&9%'V(U6WC8@
M0W87Z\&M"ZEBNV2RSZ^ZV?KU;KI0J=M8-:2]8'EQV?.>1S3L>C4<E7O]*IGK
M#?-)V]8#(NCR?2X:!3*E=1MD0F9$9+0[);=G4>>+=$E8 TN(-U6S:K/#3XXA
M%0_#>D0F7TL2\28K!%S[_13LHJ+FE0K2UC[AJJ9XA7K%JLB%EQM[#>O\&:6O
M]#&AB-N):1F;^9FY)RR;34(6JC-#HT?$A'G\NRE60[$/*&'IF&?I;\NERY9\
M_I>CUM]1R]S/V\J]8SO3K4K-8#QZM=L6!7:"Q]8IH)4<%F<-FUR[0J(]M61X
MII3;NK91L_3H31>*I\HP6MPP#*$-%HQ2/"AK)_2U?3[G=Y]U,O<1>STO1K9A
M#M+J>MV*W +P>CT[%>O46C"")%!*7$L\IU_18"60CNP!CT87%';![ T>B2\$
M92,LS53SCZV*\/)D!\<T3E[^1/=5$IER>AG[O<J(L=T]/R+2V&8E$R &9!?D
MA[$! VVQSCLMX5H0U7Q@.E!*Q-MYR5916_J\6'J"#"3+00;*,R'$P%R71S-.
M_P!+NTR7L?X]Q:W[JB_1-K:MUKM& /DB8&R:!3K]"%S%^4EC8EQKHZQ1A\I?
MDF/'DPV2*([Z_(,^,ZVK/DF_#XF(HN:(O/OJ"[E5.:I_Q2G%*^7'V7'[=:W?
MN!U+_%\"YPK&OTPS/XD?[R%>0_@N?JWX@^Q>'?Q/%KK-YJE?,].*4XI5P=(?
M:L]W/W/:"_CH$\S$'Z%7O^3M_P"&A76\%_4QTS_6&!/[8Q:I]S#UR2G%*<4I
MQ2G%*<4K.U?]DU=_PZ(_A"/RHS^NM?R@?]25?6SZ)6_Z^B?A#=6'[O\ VXO:
M']_C:/\ Q@6YD+W]&;K]D)?W\ZW[3/\ 5<TE_;QB;\;RJJWS%US.G%*<4IQ2
MG%*<4JT6JOM5.^?[U^D?_<[J7E25]+6)OK6V?CJ!7LO^@9?^=FS_ &J8L_LI
MB*NNWG*Z_:33BE.*4XI3BE2JB_LWIW[JJ]_"\/E>+^R8_P#+M??!K#XA^@%\
M^P]S_ GZW_WH^W3[:?XQ^Z?XP[#S,8J^F;$'V9N7X6[7-? \_4%T+_[K<!_V
M9ME56Y@*[%3BE.*4XI3BE.*4XI4VUI_9'H'[MJK_  [ Y=0?V;#^NH_WT*U_
M%GTJXF^U^\_BZ37]*KGVM7Y3ZK99_P!D)C^_Y'^_GE\'S@_Q1]Q*5@N34KHM
M]E?V 9J_8;J#68VPS-/$6BA]AI;P9GO20Z0C+&?"%=*H!N!['"ASPEMOXR,4
M+I! =E17*&1"3[(,;6Q898]SE,UR5-^6XN4U!,TU>RO,B[N6IQRR+TM^KK9<
MO83K\^72SKN)TT[.?U!JIXF\:DDGM;49TA(LEI 7BQ2)SE8%KEO'[K5$-U:X
M&G7\N.%;36D( 6"<I\L&0D=+C8Q.G(F?,G+R^GENJ1>_O7?6R>1I6N+/4=2D
M=S0K*@LY$VX'U_0LFA8/8]J .3ZSE%LS3Y-VH(&SCJ]:X+4E-UQ7)MPKI?,=
M48ND:\VF$O#-,,O%<^L73Z6:Y;NS3I=:H)!T?U\%JJ9*(!!-+U57:)5ZG.=M
M)>2JG5JC"+95JB*C291U[,2$X#N=MKY9,E><W,<5E#;6L\PS':8GR3L99>ER
M4K7-XUQU (N7G8]SJH^7."6*Q:WMDEN+?7C<>U;/K>K=:SZP(JP3*B[YRXU4
M'J\!5V*H%>G3A)&*_3U>2N)>2:AD/+Z*=/IHB<GH(F7M<M-_)W]_+6JNR>L>
MN6YI.;;:MSF:"MZZT(,I\6J8+;'; HNN-JSA,Y7])02PBT#Z#NZ5972!"8@2
M(<J=.GFX,B %,"2141>5>GNR7IHB_D7/TL^E4R*J>W[>79Y/=]%-P6ND]4*X
M /;#N$N*,K^B+/:#-SL<BXW8:(@6<U=P^];&BY0Q)F(*O6'=AF!=OAUHP/L0
M8399ZP]>#CY*Y(=)4'E7I==?1W\^_?DM0W^Y[6Y*]*NC'7S$T&J&&ML.NBPQ
MX%-J;>SMG2 ]A"&@E/K#%;,.R[D^0D4455Z:/KD;6Z9:=?2PKSH\E6I<9MAM
MMJIR=+DY5ZR;^Q3->SUDZ_=Y>7KU.+3UDH=C4N5#-7^MFI!TG8I=M'WFQFKG
MDC*U[L/7H1 RT72?:"0 ;26=F6*U4<($7!"5>Y>0.BAT=UXHV1CEW^DJ?EW4
MS]#L5)K]H#5FT2$4C?PQRS9@B"0:$,GWW8**U$9+URQT\F1C5*+:8]78LTVK
M6ZR@'K@T'3;%"C$R%@UAE:4I*B+R[_\ %%3W%5*AGW]_N<E<HMHG4YVPCK67
MI\::?$[+C[@@SW2)I.6]B1*6/U_%/NQFR2(<MN/61 9ED)+COUYLP$"6I G%
MJ###45DGMY^GR4S7\GI5A+#UWU[:K<3MQM5IQ+G6JM7^(S7KI;:.\'V!7J'8
MM6NVV 9HINMGURCNN#S5/,BYI24"E#! ]ST8F9AV2MDGY>54WY9=+K>E4<^Y
MZ51^P]0]"VR24G6:N6TZ1-JEMERQ/;VXY9@B*FBC@.3599AV_*)O41P79['$
MQKY4O-(;2=+.-5]#T^2XX5$7_NO7]K>N[DIFO8]#O].O$CU5UT^\K($SL:FQ
M7+-L>\^:5W8EN4D5>MI1K;!M5NIBCI8TG7!5^#L;9*(V->M5F/#G7249ALQR
MX:O3!;).OTUY5Y5]SE7D[E,U[^M[OIU-KEH35VPK+"MEU#&K&4%O#Y0B*1O-
M]76@I 9(AR8A<'2T6=NG!3F%06F)!T4"B&)L%\B-FSI \L4BS&29YU#OY*]Z
M]$ZG<M%5NBZ?&5:*3;;Q>:P741-9>&6?9$-V#=I_DO27FLV.=:=0^X)(,2PT
M,C"%%AP^&4#BID-DF[K9KV>7W:5$+=U9TYL(E;9NP*XNWQ+==5[!D"B)$E"B
M#[/+TW"T.6D1'0DL5+D#RFO!T&.L23?GP(5@BQ;6/:BV(:%(BVJB^FN?IY9>
MYW\E1S5._KY^[WY5^.=3M +C1XK-$=')AQQ,8=)"V^\@2(E *)I2"&=#%@MF
M@% TP;%Z[:;9ASQ4R'.9Q2VE)D86;LBC#)._/K=Q*9KW^GW5KE6'K/JLU1!=
M#A"B 6!6=17[2=0DLV"RD%!*)L:O"J[8A1&(2-28MU8D,5^O3?$NZ+ KTF$@
M$D.MD$*E*:J9(G,F2>AEEWYU#/N]BH,*Z1Z%A+--DPI^PBI[-8A@P)*YW&."
MIT:I:II>H@LVM!Q1X>*'7*'6J7'5"V5'@M;$&.%",479X<!349N&JG>O)EEE
MZ:9;EY4YZCFO>G7S]WI<E;("Z$K%=O0R\AK%>X+PD14P#(7%M+3QI,)3H>W6
M18NT3#+Y2P6F"LCN>Q6"3',F9+;AT#2"'BX75XF'(Y=_H9]VF??V.Y62LVAM
M86V8\2*B#<4J_L:/ME9BM7N_4LRC8$;6*---GXYBG6<"3BX7K-&*G)$Q93(.
M9#4Y*EC7R;SLU;)/R]/FR]RF:_DZ7/G[M82/U@T/$L[]TCZ\'MVF3-A$'3?I
M.P*F^=P-PF-^L+;4LNI##:MMGB-OEQV$-QI[OH\//9DUX.'$P62<N7?GG[N^
MF:]_H9>XE8RT=5-,WR;:9-]KCUMCV6YV.\,P994J)9 $[EIT=I*VQ!+U<G!I
M2AAZJPY)1^*1?G9AW(A[<1KD.Q!JR1"%%%Y?1]K+OZ^_FIFJ<G?OS]WN5[)/
M4[0,A;+S5%>$RXGHK(TC6[A>JL5"J"!M7UT6Y7RU;LPHE7G8H'3.MPV'@DJ
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MX>4_*O7_ .EG'A*Q1YDN^KQ/A%/FV? I^??@SU:X? *?J='<_P!P\I^5>O\
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MK?,77,Z_,YPG&59_K8QG.?\ S_6QCPYXJ*(JJB)RJJ(F>[>N[EZ5:H&;,>(
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MJ=FVVXA&27#DG;XPO,NBXPC\4F)3^N>6=;14JHO[-Z=^ZJO?PO#Y7B_LF/\
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MAH&EO2/(@W_#T6R7NVN0<$N2)]Z)^YV2ZVU@P8OL;#L%6@?GM&ZI7 3%H7%
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MBOJ>XZ(/^J/Z_P#_ $J?-WKYUB>S=?DC3^: G?>FM_+HKZGN.B#_ *H_K_\
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M_P!IL#\=L5PSP1?T!P]]EW_P,ZI?[/S^Q/K+^Z+:/\&TCGJ5I _6K7_*2_\
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M,Q6DE0SD>169K(*(IW]_2J1V;J5K"X:Z&ZSL,VVD ;);:IJQ3EE!J#-YF;Q
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g521849g78m75.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g521849g78m75.jpg
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M)"4G,C,T5EF1U.9'5,+3U=9RF*&QP=?P_\0 '@$!  $$ P$!
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MQG.,C%@ !CS@.,YP (A9^ .<X _? ' ' ' ' ' ' ' ' /P(TL(P%", $PW
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MP81#C@4^%?G H>U?XWEQ P)*%8$4H:]52G6NM=EV&\BZ5AK7&[97>;'<B2'
M' ' ' ' ' ' ' ,&V<*%8LBAL20F2&2$4LDV(28SB2X:27+$27Y<127!PL'B
M19;^]A)A%C)^%F B-SY/"D(I*M(J4I15KQZNE=A&*E8:UK5TIA6FOFYS.7(D
MAP!P!P!P!P!P!P!P#7&QAU]C8G6T$@3RPR?#0W/[O#VD:/$53E!BK/F7>UH#
MQ86#,-:_+!8?(!$$*WQLK>P&2,XDJZ,6RZOGI[R+II0[;Z>37[C8[D20X X
MX X X X X X X!\>KL. -\K001?.8>BG#H$H;9#5<F94TK<0'I7-<0)!'3EH
M'=6$Y"RO*PH2=&9@Q*TN:@&<DH%0R@.<9Z3%5+:=U)]@K.S;]0IW!/":*+Q5
M![S*@VLJ[*ZA;-XJ9H+AID9&7DHW+WC)LN*%ZD)-/R'"L($(QRI3ZE*C=6[[
MJ+CO]Q?)Z:..SIQ=/_'Y^S2753';CYB8'_5PL$<:+%\;YS=K@H. . . . .
M1K;*]7_IRZ@6N[4=L9LFV5O:;$VLCN[1,^NK@DIR)OD3<2[,QYCI#:]D3&/*
MUN4$J@DE.9B@D!@,*"B1Y[O%:?P;YB2A;54KC >/2'NCCG\VY[/_ +&]B_\
M^H?_ /?GY2O'Y']PT(EBN8EY@,YBEH06&65!'<N00BPHI'IQ#GXE.M1DO<6E
M;0D?8^[%)'),C<4I;BTKTBP"9>C2K2 G8*5)B#PC*#4B[KGBCY:R_>#ZRJ[V
M&>(RU(O>0U8G14ARFPH=H9ZI>1.+7'?,)5(LOIQX4QJ4*,259X9!HL*0) +
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M?9HYMDGRK599L<B;%*BF6:U2(HY-IL\;@<4F?)CBE3I;AF2XHH(DWY_)G&'
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MNN/JKGS63A4[K)GT"Q>C&>]OY/+YN=B^N.=/K;&0Y\ZX-Y1P#W\4_2F-_O\
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M(884O,5WWN9!)961R[<W822HGRQ(NR+&U39$[3)C4JER(&H H";+EY:D@\H
MTYJ<PG #"S18'G(>T(IO*^<EEGV)Q9RY8G0S;9(EQ016VU0PN%QIM1)VB-1)
MI4::HTW4M6?@[X"LY,C9VR[/P$<&>2;1D_-;+&4)%KDYK9NS9L$Z399D,N*4
MX,B6:.5,EQQPS8)L,S2AB@5$G1JXG/?4WOXH#SEENT:>/)VSZFK=(D=#FJS
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ME2Y,QQUEK1T6IR26/4O:<6?;(9$>@X(HGHIU32QJ:&_WU[K7_FKWC_:>!?\
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MVX<(< < [$<!_02%?PE'/L='SS^M7RFT>'F^LB/IH.LA[V'F1];RP2' ' '
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M^D?=YF]KL_?J-EWU!=!L#V4]_FO?K6<2!DE.$5N>RD*;R%AC#."\QEI]>F2
M\D&4:<4918*<6K"T0,J%1H\)LY,*$$6V*K1W77<FSWGYVWBN7EZ8E*+K>_*6
MW]^[:?\ P6K_ )UEG'VWM/>R/42SSXX>/SH9P>!R-]B9/(G>8,Z?' ,N:_\
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MC9R2&I)@DP2B<%.ITZW4K2FK9N1/0KB<5<%PG-?&8^M<AB*&-P5LS<I7#&G
M660,2LY,-0(1)91190LF9R6 LL(,X" .,"V>7EB9!/()&)G:A2$MO$TEOV6]
M)EY U#/\T-L Z9)\\%O$IQA0)$$_"81^/&R7DS^5P#VO .:YZ3#K_>BKJ3[!
M7JFIRSE%*HX511*RVB8/)3:W2G!KJ%QK)2B: ;A1XDS$@4)V/(!N <X=CBF_
M./-&!*R.5)BAT5#55J[B^3TT,=G3BZ?^,_!G&DNJF,XS_B[*)@?!QXNNB[Y\
M_+SL@CZBZ@Q)Z2'TOU!+M-6,PK5>UL@=JZCJ6635%G,7VN#XC!'EL8F25S5"
MQG)9Q)T9=@EHQJ3\$%B*"I)$X>Q1\</.B;\<=/9%Y0RHL;"\0M>B*3&5+ 6>
M1CIS$M?6T2E+JL)3JP?FP&JV<#%G9Q8X*C!U^0H<U2!6WC1@=$0M^=/;=Y;_
M 'GGE1\]D/:3BHR;"LPM>P1].KJ>"-$A<*=)D[Q20U, U>+4:PYQ.:-LW"8P
MS8Z8+3"%D!\!V.;U[&..(W"M0KTOOQOQQ5;O/OA Z_$3$U]*ZZPBKR"L8($&
ME88E3-[0B:V"C2'68:?KQU#J&\)J&KA186MLH.8Q2.?2M?(DZAKLZ+,43+8S
MT32DBM2"Y*?5P\O+=%>[W??Y//87TW^*'JM]&^COPQB_!;>+XWSE"[TN;Y2>
MF_H35K^..QO!R9'6/OGS(JT<%X< < [$KR&O!0#2GV[.EA2T,MJ,4#Q&<),I
M39MBO5WJTN4>: ,08X)/E9YO*+NKO,>6P$6$F5N<2AKU5*=:ZUV78;S&Q4K#
M7&MW3R%+7TH/Y1^,?1@K'[ZVIS:K@6[D)WCJV^S6$PUO^4?L0^\KF<[<.$.
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MW;/R@E0GJ+?*FV]\UM?_ '.A7-=,].[O*/T*Q^R68]L?@Q_,^S'^N.<OVWG
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MNB[Y\Y!1U$D(G+TD?I>(0L#U*!*-6+6!AACTE,A[TY=D6VO'X2"2%/,>,:C
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MI\@+#D&!<A[',_8])D.4H0WGEBLYK['L.Q)OI9$86QX&?,>NL-QM9GN,/7I
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M,CF*%N6ZP/J'"^I=ZH^,^+7^C6]15 A6+A]16L3 (TJA4( :]DF!#"G)&<(
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M)!*I:0VC3)S3L9*+-- ,S'<QGEG_ &)DK_@I7EC_ .\QBX(^#)M+^9N3;_\
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MY S1]A</(*B6QKPE:_(1IM\!$(HX19WF#,J!X-P$ E%$XJ-ZE3D-T^"(X X
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M^]@+AMD5P0^&O[A%+$@2JJ*]@\^//>7%V8=>ZADT1BE@UC5,+CK@P0,CVL(
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MP!P!P!P!P!P!P!P"/#J6[$[-ZMT&TW/JU36+^D$)GB9WMJLTR42]X/HPF"V
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MIP<TC(@<I?(F>--ZUY<,CP@:4BQZ6(DZES6Y+,PD0$F#5*<@'@DH>0B[ I7
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M?)@**M;8D$0TMA.6^/-H_.&-B 1ABYQ>7]P?) \"+=7A3=L-A."@X X X X
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M#$RRRR[3?C(K%H$NLR[9.EG5G/$"@BB3*H)#'N5$,S'EV8X<=-)8)DPN0G.
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M3RPC(DY,DBS(*:;:OHUA1T\SQ7)<O,6)HO7,+A[].)<PQIE;)A9[LSO]CR5
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M4E2H%+@%.2%<H0H3EBA$C/5X!@\U*C/<7 ]*G,,$2G.7+#"0 &J/$,#RN .
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MMTI74C9G@H. . . . . . . . . . . . . . . . . . . . . . . . .
M. . . . . . . . . . 8#J;6"BJ.E%@3*KJ\98K(K*?U\@D2]*$X\20UU*:
M<NS-%RU9IY</BCHZM!4F<(E&0M<=52I8YR$QMRYKC3^ VWB9\X X X!_@@A$
M'(18P((L9"((L8R$0<X[,XSC/P9QG'P9QGX,X^#/ ,#4KK%1FO!TN44]7K-#
M39J^+GQV&CP>I,2@7GA5BC; <N-4GQR#(5^5+@QP1E-11&.J5Z[# SMJ<_P
M"K;>)GK@H. . . . . . . . . . . . . . . . . . . . . . . . . .
% . ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g521849g81r65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g521849g81r65.jpg
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M,[JQPF[I5\'JEH*<FN4,ZIOL2'$J-39R3/D6)3.J829N=4K>J"H4E'*4P2L
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M/55I*J*NI*6M@+C!5T\-5"7-+7&*HC;+&7-.[7%CQEIW!V65YQ%R%"SM+O\
MYJX!BD:FO2TG>(K'):>])69:TQ]9(!GJF(#4-8E^40"VK&J,T\(](TR8E0H5
M;^/LLOVD&"UW-ML=3<Z.YW!E10TM):6TSJN:MJ.YWJS,VGC@C:R26HFD,$F(
MH6.D.,AI&2.MK+G#1U5!1&&JJ*FXNG%/'2P][@4XB,SYGES&0QL$S"9)'-8,
MX)S@&#O,/V@3QU=9V5%Z?K&76*GL>9S!+#XQ')17S@R#=CW20:865R3K3%1J
M,2%?HY(Y'E!.$XM2)0(3BA($G.]L6FR55X@N4M-/0LDME)6W":DJ*GN:F:BH
M62333TC'1\%0>YC,O<QR&=C=Y(V $C/=ZZFM$]!%(*FHBKY*"FCJZ>F>ZGAK
M:YL(\DJ2XA\)@J974KIW,\GF?&7P2R->S-VN=.N6F$3")A%7;W]Y+>?.!>:I
MUT#*'QDLARCJIOCD3K"'2YA%)9K.GM08E9X[H\LUQ^XD)7P%KG(7M2WK/N9C
M:W-4G;75R+1M"XK-:7$ +FYXU^UG.UF]%1&M^J>>H#6U1V)*6Z*H+%KJ32)2
MY5HH?5Y3>T/$U0R42I')XXF5*$X)&Y- HPK:6W:I[2M3J))IG4%E=#AI(.2-
M^7OPNRZ/SN$2P]0EBLRBLF4I"@GJD\?D+0\GIB!#T6$Y04W+%)A)0C-Z $PP
M(0;'O0=;]WTPL"R8XXM.2:>;O82B"S#C-A ,P6BRP[&/>BRPC,'O00[WH  B
M&+?T"'8MZUA%7Y67>!ELU%&[\B%)R!SIVPZ0G][5Q.$,VB3DA6,T'3-+DG@-
M@)D CU->VM)6=6]+D4:T"3,3*LBKY'9/+&:2)#FHDK$8.#M@X(ZC]0M+R?RT
M0R"TS![AFU%V''T-L\>37MNH&W4AACH5/:IK.!0RSK$BH7%N<3CXU:D9@T\8
M'H+!(VE!$7H1JE SSQ6L2*"BR!N3@'[P;[SC]^I;I7^1"MH&Z6$Q7E"Y=4SI
M7G)3YVRJ4;5,$U8)!0\55%-TK6L#E'G'[RU,(TZ+&IN715\8F0QR/>VP<77R
M$D+H8V%&/#??'IR>6WI7O2;O6*0"=M5-V-!G:*W=-$]'+*P@)3\V/"*<)+\E
M[_!H]O\ *E.G3I6=7 'V*R ^WDVV]R!'&-&E<X<IL(UW:T*HF/=O\,9_/;XX
M6: [0KQ%570EB21G?&I\Y@FLLK2TZ];]IGM_,L&.1A@FK0Q0U0$2!-(4<_B$
MOALGACLM+8@:9),D42Y+$U+7(T;*3'+T[@^C]\_2I'5I-DME5S +&0H5#8BG
M\)BLV1MJLPLY4WI94Q('U.A4FDZT4:H2%+P$'&%:T6,PL0@:]N]84+0/0<_Z
MS)--A_(=-U;+Y:F*(,>[#Z,L*4UI4$=,5$Z4IVQJ1P:#SV?V(^Z2C(/7D-35
M&HHVE+4Y INJ?4KK'T!2.'[Q/J R?B0%@]$6'WVR.Z1C[+I3G@;4\KDC<V6=
MR-9-BS)I8W!P/ D0$3NM;6K^'RQJ9%"PPA&.61)_G!38>K)6R-B8(ND>90UE
M)X?ND^W ]V#^_2MV=7.,9:.9K]<I>N8VU@24_8@U:Z1J4"1I3FCB;J2B$>I<
MAEI"C1K3$Y238QZ&-48263ZG#!K90WF/6%R\\LA>3.9?LV-J)WM%JC:7LZX(
MW>KOIT3?D] I]+J[FK)62B=J-'_)QHU.M_**/)U;X)&%&[2MI;!&%JY WD+"
MR'G*.IW'I'%T\=OAE5_T34O0-4<_&2&\VN2LU=V[X&/)#6O.K1(T2\@PZQ+
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M3IDY!0= +)((*" HHHL.M! 66$( !UK0=:UKTS9VM:QH:UH:UH :UH : .0
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MRJHQV9<]/3QW):Z7A$;31V,RYM9W1^7.-M11Q4@F#<G2,*)P<UZ=\.=#(XU
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MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%S]>66
MU?T#(7IKLGBKO^Q'OFU14;O ;$Y1<#(JJO8BSCY 0^5O#G)M?=#DR:MMA,E,
MJVN:DCQ#STJU6UN;.V.JH$O+(S(Y.:,YV=TQC?D>?3Q6.^'&L:L@-Z6RMBG#
MWD%YJE#M4R1*=8?=,UD<EW(&!OF#6:;#*W3N"US;0Z"XKDSY)CA*4ZU-\JR
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MB;)*-X3%D8W[V6#P#CCVXP<CY^I?.\-#8P1F>VQ%Z>ICRI\^TVFA#:Y/5?\
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M33)(C5+1=C%N*NAU6MBN5Q2TF0F*EL+0_G*&AV4(S=K70M060@8>=C@,+<#
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MOU7+/]UV)1MH:7BP^L.K:EYEAAL@)7*V"*%3A>J62R>O+6VN+*O?$T9C+2N
M@8T;XRFN4A=&0HYR2MX5QH"D#.?0,GX?JH/U/YZ^(4%;%*NN[?BM V\S6;<U
M1R6+D1>RY"Q.[[2T\6PQRE$8-CT:EIK>PR1'IED*1G>G,]T91NYK*:N>@MNG
MI>5N!V?-&1@'V$9"IO\ %=Y6_'Y0/;'F+M&WNCF&%P/I3I^.3RD)"KA]EN)$
M]B2*0W>L5/")(R0IS<6LHI-*6 W:>0(VE:+3B7H"80BE(28'S/YE9'L<61@
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M5X:^T%>'K8]@_OJ17W:UZ[WNM+ST#T^G[#-U?\,6_K_NZ%O?[?I]-^A.[?\
MA/P7G^D#^'O\:L2_=O>'],<)W;_PE/T@?P]_C5B7[M[P_ICA.[?^$I^D#^'O
M\:L2_=O>'],<)W;_ ,)7@#[05X>AZ]0]J176M;WK]>M+S+WZZ_Y3*O#O>O\
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MV6S^OZ?JV"SN?&?%G4UAU?Q.,2V:F_'^9^++9&R-"%XD9GS/^8][PL6"^/\
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=,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g521849g86o64.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g521849g86o64.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2%H4&AO=&]S:&]P(#,N,  X0DE-! 0
M     !<< 5H  QLE1QP!6@ #&R5'' (   (    X0DE-!"4      !#'71?E
M=+5N]=N^.93 Z7E<.$))300Z      $-    $     $       MP<FEN=$]U
M='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%
M6%0    5 &$ >@ P #$ -0 Q "T > !E '( ;P!X "T ,0 X "  1P!/ $\
M1       #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M    #@             _@   .$))300-       $    'CA"24T$&0
M!    !XX0DE- _,       D           $ .$))300*       !   X0DE-
M)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M   ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    !
M "T    &       !.$))30/X      !P  #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M #A"24T$"       $     $   )    "0      X0DE-!!X       0
M.$))300:      ,U    !@             #$@  !>@          0
M                   !              7H   #$@
M   !                         !     !        ;G5L;     (    &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG   #$@    !29VAT;&]N9P
M!>@    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@
M  =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I
M;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP
M965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   Q(     4F=H=&QO;F<   7H     W5R;%1%6%0
M   !        ;G5L;%1%6%0    !        37-G951%6%0    !       &
M86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E
M;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO
M<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L:6-E
M5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453
M;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M   *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M    "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
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M# P,# P,# P,# P,# S_P  1" !3 * # 2(  A$! Q$!_]T !  *_\0!/P
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MV55L #&AH #1 [#Z(3@;%C6UM5NTF=>Z-8]E;,NMS[7!E;0=23MV[?ZV]O\
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M1D5_IG/86UO;KO/Z$XS/M#VN][V^IZ>RS^9WHYIO?_.76O\ (V. _P UA8U
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MVC\ST_T?\\N2&5C,L=9DV5LM::'7LL#VO;8ZMV'ETNIL8VQ[Z7>G=?L_F?\
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M300A      !5     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@
M;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V
M     0 X0DE-!"(      2Y-30 J    "  ' 1(  P    $  0   1H !0
M  $   !B 1L !0    $   !J 2@  P    $  @   3$  @   !X   !R 3(
M @   !0   "0AVD !     $   "D    T  U[M8  "<0 #7NU@  )Q!!9&]B
M92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$W.C$P.C$Y(#$S.C T.C4Q
M   #H $  P    '__P  H ( !     $   7HH , !     $   ,2
M  8! P #     0 &   !&@ %     0   1X!&P %     0   28!*  #
M 0 "   " 0 $     0   2X" @ $     0              2     $   !(
M     3A"24T#_0      "      !    _^$!,$U- "H    (  <!$@ #
M 0     !&@ %     0   &(!&P %     0   &H!*  #     0 "   !,0 "
M    '@   '(!,@ "    %    )"':0 $     0   *0   #0   #P     $
M  /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3<Z,3 Z
M,3D@,3,Z,#0Z-3$   .@ 0 #     ?__  "@ @ $     0  !>B@ P $
M 0   Q(         !@$#  ,    !  8   $:  4    !   !'@$;  4    !
M   !)@$H  ,    !  (   (!  0    !   !+@("  0    !
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M7VK0"1C54MX')20\B+#@"&JN2$WOD%+B2+6\R.VL/M7;5UEH:]94T;*:M=A
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M0GWHBR&A#HLR7E4EZ.IY:UY^6\G:;?<5K<.5LYA\G#/+L-XJ"8S/20UAX6;
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MF32U<%*W@3$G0X=Q_P"7/*E-@KD0NJA#9P,I$60I,25="K,F?"G,0GY-F(I
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MT,GZ0V7?VT'%/.HM^XS=- 9D92IV!5]'0X>HI(EKPYRG$'.SJQM&S0T_VO\
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M2Z.L8_M+GK^\>(.(^<C$?/TUF*O5F]H/H*?[+/H?9SS(S/R@IG5\:M;*M>
MRUTJR@+?5S4=,P/9*N8''P):(O.<(E#3 J1+'SHZLXSA+T60ZWG.,XPKOC/6
M'K,TX.FFCIIHZ::I9OZS[8-&::8T#@A91-&MJ@^S6H)*8,K^<PMD:9D'T.O-
M&*_FT/5FEM[$][C!)A:)&+CC51,Q)A'XC6I+35:Z9MWVD-]H=3,0M:@A#]T
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M[Z::T''*&Y62=N=LC3*8O5D\7$]TOB?@+!Z?_,,ES_W(CYZO!E..S4%'?B9
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MI54^0-BK78EC&*<@WI<1EK]%_ S8V/S^Q-IYG9N<30KHPU"KN!M5R9;B\JD
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MIC16T:RRYZ=\8;)["K5,#9RKY8\1)/;/]OPX]>M0[?>T4?OYZD7_ ,&6V?\
M^.MNMDK:NX7<=&*LQS[V>6F/MEIAQIIDN:!%ISR!'&/><W.?[$XH;T$'%93G
M'=*UKC[J,&V\=\]EH4 \U&._[/*OU,ZA_BELY,3(7;5CY)H6HF>._;SP1'XZ
MV2MA[C;/!5JZ?FVVB8^Y1-G\-42OGMB+-6:F6V($X^TN=3P9DX%GPK#O0B&L
MV(U=-R!1BT^4&T_:1R!$=B#,)BQK+TV<>A986J4&?6F,OF5G])7;2M[CLU.
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M!*1CM)<3TQ/SGTUSHX[\Q>/^H@FT=@;"-6^CU7<6_M@':\]*H5H=I5:#LE5
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MQ&C-?8QLTM/##Q3,^,5DC=F>3-=$LR4E)%52VLFUCU=NT[.#L7JK'KNTSF&
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M+EQD*UZJ^R5CS9X_5ME=)H$H5QYCC<T$^:0L:;.G3V2O09<K(N*NBR3'_16
MR(D)XCI8@3)L3U3/ 0H>!ZIB!+46<::5%L%PY#:J&A+]L"ZS0\RSMZR7K)6"
M@>! ^$B?IK%)[*V10Q$*/"*SB(DQ%,N6/WN48%/59%V+Q3+.MISF6S7W+CLN
MT)!3:Z5QU,4LBF"F&M+VQ#A)10<0H@.S!_M(]K'RC6G44:_F';6/4P@20@J
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MW<*W7Q9U7]#A,5O66(6Y+]>EE)<(<+V! F-8H%/K(B4'DV"U%*EYY V4F64
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M)BS;.O!T72^0#>2"*D&L9?!;8%Y*;,I&)D$U8B!%UBV%JW.#V^*Y9CY 76[
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M+L&^1-:V2"X/+DV!-CIU7 HJ5K!DJBV_"!3)]K'!/B4AX,ZXY.L.EC;Z]O\
MB%Y>+?EAJO9:37L^7#?*)Z3J9!-ATF!6%!8990//EN/RQ.6F40TYO@_$O,9C
MPN7GLDO;Q9RFD77*S'M0%U$.E^.L*K*CBJ^WC_9+C.@G5UFZ8!*PGV=.6/(Y
M2<G>,\%"-6U<EK[4>SFJKLZS6+9L^JB=PIU:LD+5)US#B5J]V*1[M:H@<Z5<
MMWPF&&N]:E5R$7N$:#*L.,#'XFU@-\9;'UK6-9D7JO5\1:*+%6JMMIB_.9"U
MU;D+%:)MXQZ.J.@F.!33%<&4GK^(U3+>'V.WC9PF613A:WY7')91L6JPJ\R!
M@#=:H^T@\1KY"FSH43JS:YN6DV$H5:^[J3R4BZCN%>IN\(&G]7V^Q%-NR 6O
M),MC6FQJ'+%BZT'6C/O%<OARK/Q[3/&1* Y?45\RW4;FR-DOQ:^W*P,!CLIA
M[&Z<66-BWN1BHQJZQN3R^JV;,Y2%.)ZFM"QQ4%GLI2VW599I=0C8;&M[9WOM
M>WA,)N:<K*=NVP"X%Z:ET@04P/LT6Q56;%,TEYT%%ORP0T ?/,+ I?)T2-V^
M0TEN/0-+G[CXZ<;!QL;/+KM**L D6=J%3%5P=0'#JI9RQW37:@#@"XJ.# H@
M,0FG:"3MF++%OE?$V=OMREA6X\-,KHYW<[U\/O"526BEN07E:K "JPE"]MB8
MA<K2H+5>"GI95"5Y&>W'B,50JY\0L9;#XI(.:S#>S706JRFL^E8!AW$ X9K^
M6X20QS#KN AB1>/F."D2B'(B[VWE?HL)70HG55,B:=+Q=X)(,6E%R&D#%DN5
M8"5"M$O*AQ6<V@(++7==LE#RD\$AZN [16VQ=CG>5<7E5UQV-E1=B)L9NQ:8
MX*WMLD]=>HA/G"MZ%>0$*)E=PN9!!9-@!Y;!)NNM;[P]C#,WGMN:NX*B<:EL
M 5V<9)(8;I,$RZG:;-D#@E6*[*Z92Y,I:</6Q:F_K$C.Y:F>0>PH=D%<<"=&
MK%/T/LVB*:K^RYVQ#U*G&]@P9@$O8!<05"UA(%;-(A%N3:GFQW-HH:'$85*7
M6FU&MI&VLUAK>/VYDJ[7(IYRY<IW\5/0ZNS(4,:N;BW/4T.DPJTV(&:\-1:K
M',-&8("T-;Q3PFX]MV]R;>MU*=G]5CYU'/ 1\OJ6[J6T#15M5SDTM%W4X;!*
M=7>DQ60G$CCUGLV-RY7OS3?)>ZP:I#TU$K<*& U*R[51VV9AMXB<K^PK$6(/
M&;5590"?7VQ0:HTVV0DC[!72ES)'"D>P5FMTK,+P\RNV=QH_5_G910G7<M@L
ML4V*QUY353YY5&K*7&2[E5H0?DM2N98N0LRM4;Q'CAB=V[4M6K5E>V,BB+])
MD+]EO+;EL<2&G%3V]# ]CFM;Q]L)-,M!UDZ\-DJ<NL1YQ]VK0;UL'>/'?DM;
M"FTM;:>I-6;U4 E2F08@I&N\RY-$L;/AUMP4-V@8KRZS"'AI5J'28L88ZW+F
MP"=PD&K63W>7\,+",^%O"1-B3_5^1L)OBNW%0+++2V(#J#AD>94DDL8/F N1
M6,R2R8V([:_2!K9+;MNONQ\4VU[&7Q%7(8EC<<>3;230L)N%*3$J[85D!6Y%
M8Q2;1EW2(.6A$;:#Y*:8HG+#8FN]B&X6R];56@9L6D:=L6Q(L@G4=G(EY8NZ
ME*;%/O2W_,.09 B"*D.29?T)BC+&)J&00ZWGXD_<YGPSJ-RU/]2,3BLJVA6O
M6JU=@AY,5G>SM9621<I3;\P (5"*@*I,# PV1F'[6\?+B<)F?Z7#8SNWZV7M
MXC%Y*ZN6^U3=I^V*J7+<#TV;&-&NQ@%9,[#%Y )*3]G$PBO5?.[CGQYYX6XM
M"GU,9#M^M;#@3 EN*P#'V2>; M&"H <G.0HLY<14&+!/E8T=DO:X5)"QI+\N
M( ;0UL-S;3VSD,EB\1;R-#';FN8Z7O.'+K6;P4G(\GGZ0=;CZWS/:7/76[<C
M5GHTFPO$S>F(Q.YMR4,/E\UL''YM56F/L]B]1Q+\E5NE;\O@6>555Y=&)XD:
MM-]WOPS(<,;Q?;D+>NS.8.SJ!AIO7M?X8;KKVP3T9*6 LT[,P,,4X;+D82EA
M\B(B-6\A#0ZZJ0%&32+K[41FR15S/F#],*WM,,7L/:=:W2R>^*3KS@35-=G)
MU,(^@U)KM"HC<M5V][-[*EG=S$--8_0*9^C?T, WEDMP>(V\[./OXG8F8#%J
MKQ;2ZM0O9Y-Z638H V !A5*,N5<LIB!_:H49%*Q!<X<A.3I7CQJCAKL/7BI5
ML-PK=5HQ6LU T/\ I!+K#_"W68(J0P.5(2N>/!69T*V395EK$4BB.UXE$FXT
M&1R+P*SF"V?EZ+MZHMHQ#-NAB;XB@B96L,=!AY]<H@RA+:_+%C'FCT]0@<AT
M3]%>-6V=X[RVW>J^';J);EIYA>7Q\6;'D*M*0/EO0BT(FM+K"+!BAC.E)3/E
MFQ0LEH<N]F<X.0.X>1>L=DZQUR646UV9+F,-6I@F'6248K1NK3H+#K;.2$67
MF&=E279TL<F(C,6)#99FHG2I0_ZLW5^D1X<X1>"Q^WZS-PXBM<FSDRD#HJ&L
M5.S4A53VM8&RP!69:76H$Q"H7U_M))?R/L?]$_QDW):W5G]Y9*OL_<=S%C0V
M^M;E9=OMD9&AD3L9*:+22JD88\:H0BRVSS88XE#%<5V$[9^T>;'(/;5$,"*G
M.H)BBGF3X^65C(,-O%&H\B(J-,B-O*CK$NHE.*?DMEFB,C+<=,;X5Y*UOQ/=
MOZ5>!56Q2MF8;RZE.ZF[=C,BD8M H&#-%=>H]O2!RR#FR3H,26'2OF)G4UV%
M^A!N9^0SU_Q0W4-G)9#%6L5BBVN=CJQS;#5'.5.[D:J9:\ 3"AI34)$J:X6M
M."B(4-C:DYU;_NU8CW6>Y6&JT7'F1Y>KOR$.LEQDAJ8-)MRY3*6668DYEF?\
M-S E>\28T=N;,EP4R84F$[O_ $MLAF,=21MW'U=M15MUKSC6Z,@^P^HT7I3P
MVLE(UI:(DQ<J83.D1E@A)070-@?H+X#;F7RE_>.=R.^FWL??Q-8+5:<16I4\
MB@JMMXS7MNL-OE6,U*LA90"881@F6]!K?FM_9Y\Q^9VU#]2N%^^D--U1>1@,
MQ*6VF)B6\P( 6*/+)(PX^J1(C8*H6TU%S"&>\MLRU0%2HT5UB2'XP;I\1MJX
M^<B=*I2N03;-;'5BKC:96LL4!6)8UQE$&GS(6) KS.DI64@$C@X7]'/P^\)-
MYY&_AUY7(Y:KRBC>SM^+QXU-NLN7A0!=>LH"8ETIFPT'6?)(UBX!:Z&>T73O
M'H1K#5U'U^AY;^*G7X8CS>^/VBF,*RM6/NRM:NWW?5CY=1O72IGF>=<*_:5C
M.9E3Y;2K-PR@';'?2>N!!2[4^"/"GJO/I8 C9$U>??XMI?A@*P+>.$+/$"EX
MARJ6H^Y'.#@I,@R$(1Q^IR.Q<?O9B*UJH+;(<IJV8MA18DFSST ]K5H*3D>8
M4V&1,C)"':9UDKWJW9E9]R+;$UX&7V$+IOR'FK3ZLFM62U\"'7$&Q<!Q!0)'
M'5$:BO4?M/YC4V;5.1NF356LE:E-";:8UZR^2^!E/=FI2Y!W7)B4JPC1<AM:
ME"I-*LNU4%T)2] 6ZSYJV.5;O\ -P;>M-33;#VA L]AR$!6MRL^ZR39 CHVP
M*(GI<!I4720C,E$CJ;;-\;]M;LH*OI:#*AF:)O4"-Z >KB')LUF@J]2<N9CK
MKO4=A<$!$$"8E/3S5.X]/;L@/D-6[!K-R]R2C),:/G89L0)2\]DLV*JD$P[)
M7)*LYQX8QT4/D*2I"L->%2<YXGDL-E,.^493'V:+?=%A) )^O,K9QY;1[?O+
M,QGOW[3KK5/*4<BOS:-Q-I7O)3(*1G^Z8?O@7R,1GY:E](Y'SSV^KM\_S]GV
M]:[67UQS\8^[_G^&LB8;6/GV^WY>OW?CCU^SY^GKUYS]7X_+W>_X1\_KXCSK
M^7Y_/\/GK+B,TGYX_I^?K]?L_#I]<_GT_P )[<<:IDIGY?G\_P#/OJ%=QQ4.
ME-*-)QZKW'!Q^[&O]B*_^'K.I_U>1[\?Z 7;MV_TJKWX]9UCN9,.I%\+7/IS
M_P"[6(^O4G(#?:GM^[\Y^?WX_#K ^TN)^7?^'/U?/X\ZV$NF??'O_/'^7?CO
MW]=A(A..W?MV_'O^?XY]/3MTXCW1^/KW^OB>?G/IV^6J/.GXSZ_?]7;^/'WZ
MSI%M8^>,?PS^'KZ=OSW^S/3B/A^'Q_#W>O\ +U\\W_>^_P#SUF2/:Q\\8S^<
M>O?^/IZ=>]_A$?;^/^7&J).?J_C_  _EK,F*SC^[^[T_G\_J^WI'?_#_ ![S
M[OS\'7/R_/X_=K)AAO'R3CO^?ECY??CI]O\ +\_+GG7G47QU]^!./DG'\._V
M_+.>GY_CZ>[\/K]=>=4S[YU^]L?+MCUQZ_9GOZ9QG'V9Q^./M^][_G\?\OA\
M/=SW]?7S7GCV_P <= 638V]/A)6U:\K-:L\NL@]9UTRU&KF2@IMW-H-8:(1)
MY8'!GV&3(8!U:OE!]6' !8Q,(5&A$)(U')=^[PR&"W12K8K!8D[@(J7+V8MU
M667VK%L5VE1%>7#09 5B6+VOJ.>^RRP;&D< P?IOPZS?B-8VQB\=^OLDS;&1
M"[C4)JQ3KY"ACJCWXR:U?-JISG4Q+E.E$(RB?8ZRJM>M"DP:9MMPSYA:U%T>
MXA]X;<UK2"NN+(BICG["?J=*7:*Y\%%$*^1&UAMX;'1,CHD20,J!6Q+ UR0*
M9D#1\%L@V+B=FPP9;=>*Q^2J8BXZS:%D6UTJUJRL+2CD6D)]+3A;1);H\UAD
M/68$PX#KGBWBGM?&^&FZ#PAY144GXRAF,?[<^LJRJG>\Y<5['3Y(&U%BK86)
M+4OS*\(9*X)DQJ>[#[1[BR%_9"+'<KM+RE2FH]2UK>%QG\)3XD>2?L(6O51:
M7<>C;GQ_#2L^F7,?/J7T_#7>5SB1Q$UAG^U;L5D3'NYE1-EW$1Z_L^>([:Y+
M8WGMROVG("XO[M=+W<_\8K\O_P ^JQW#VN]9'Y+8I^B+;);"J:02G[&N-<J
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M,NM]^V.^%>3C[?3[NM[B\TYDWX$I'IQSC[<\]0MK\>_OQ'U?'6#D<?6Z:'5
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M+_'6ST342-J<()&MJ)7\U>QM;0UO;CMJ9$W6=K>?8036Z:]=X42ZF"]QO-8
M"62XZQ.$!!<9 JSXNVQ&ACZS]W ;T/ [@N8G-TGY]63O4;8,MV3F_0R%^G3&
M5DVT+#:*XE--H-\IB_98+I NM&N<^('@W_2+%XRSL;*U-E6<3CWXKV*M1@<-
M>Q:K5FR 2FD2)JN6Y]NR#U!8&Q-MH-$N1>++UEN>R^ST&;7"<FLTGX_R5D!-
MAA-J5U98S1+G7<4X.,'5&N6ZP5ZMRU%:5*BEWR%1DBQCX]%@;LD>(Y%LN)S\
MFH/P7B'FVY&W;' Y3$9#H5B[5U8E-*NFNH"2<^2#(AZK)/2L2A#6$7)PZ#/E
MF8K;N\"]LJP"L8[=N(SN-:R[G\=B7DL<W9N7'6$VU*BTVN4UG4TU+%D@FZBL
M "(E6)*8JXD:AXO<H)7*/>6VS%OCJ+6L,%US3*U:SU'!OH$TD$7QL0K*JL\&
M9-%[%&L\<1&2HF]7U@  :8F/.E9AR!].Z\-&YMTU<EBJ.-S.-J$K"W;*G,:N
MP=5*GL8;*K8 ["IN35*9DI!=9<=7I"_?#/<A;(\/\EB=PY7,[6S>4*WNK&XZ
MU655?23D+#Z592$WJYL"I8'%CD8@! 6.NNGI[E+8GX]\>N6,:V<@YW"RP%@&
ML=3VJ$A=N,;%R!J3Y<L+04,4Z?7"%6V,(V59@L20+E_2BQT(D08%'V8LZWX.
M0\.R>4>)?A%L^_NE&&!-!7MU9!#[7-P;%"XP9(Z:\A64VX2A5*+ PYIB,/@#
MDYCB>V>#GC;O%VP+VY,LK(7BQ&1NH%^.#'"&8QE8A ,BS'V+-6DNQ[2-NBR*
MRU"QE.6+!<'/#L7[3[8PDU7:QORC:X^ENH]D*(V%X7=F->$7W(-2L(>-G%?/
M9LPLJ&(M6<:5S= MDA,K0I^%]!Q9.-,$0?GC='Z/N1VYE+^,K736PZHSY5I<
MV5^S-:EX7*]RJ ^=7(5&(P=99"42#2!@,&/HS9GCO@=ZX*AGJPB=8KC$$4$-
M2PJ]7%B78^U3L&?DVP-@%,+L.6U9K?7\Q#5,.R /G1S)W9FSQ^//%2M%<U 7
M"-V NU9YNQA 464\U0EXO,,R>/=?BSB;3+S\(- M1<N]#:R2Q$4.RF3G6X7P
M%]N<E+\Z1FX_+$5)K4%DR>_EKL7+#1,^)B9X5S$2,E$1,3.[SGC"C$U7VIQ9
MPNNJ7-F/:;[ 3',>:RO3KP8!R)\23(@NDH"9(9B(RU1LSVD7,.UWNI:MOH2@
M&-70<3-K"W:_3=<5VH.ON2$CZ]F78Z;N^Z$+$78BODQ*:X;E"7 ;+1F1:(D0
MK7LFIRKP'P&'O>P9NA>6T+":QLR-FPP?->,&J5QC(0IX&O@X8$DF0F)@^9&)
MA2_&]V>Q497;=^ED4LJV+:UX]:5'"JIRJP-C]92;:CEN&5$AH#8%D%'E< 4C
M'NF-$;:Y/;]N?'[D)R!V)08E%K6;5?9\S:%MV0"LD4S(?@U>'K,%:Y\.F8]^
MD#S2K,3L&O\ &*LZ(ABL5 K&M8:P1>D,\%JNVF]8[<QEE KJ/KV,?72QUM-H
MV#!*L6Z['I.O*B]IAJRE1DF(@UN!NN:XSQ[H;N42D9^[CKXV,A3NU,P9@O'6
MJ"D,Z7)J6P387;&P!4C18$7K"SR0.KM1"/K'B?I*E<T O'G9%QDRM)D*Q:;P
MHY68PJDW^SR*W,%#<4@\;I4"OPH<$DLW](%6.JP:N<]T!.AFELN25EG.CY'P
MI;6KT+N'\UZ[=%KEXR] PU5I#*T&HW500+$&IS&! *28DKI(BB>9Y9A?T@*M
MK)9C"[C]EI-QF2K)/-XLB]DL4;:KLJ:%>ZRV2+:[%52&>:YZV!8EBP @D85]
M@T;BEI[FEI.HR,RK#Q\NMI,L6[6USMYFS#C$L+4K+8*RS.,6LP4.9 DYPE,>
MP5')-0.S)BCX\N#D8Y8A]BDESPNJ/QF%LJKAB\S<-]$ZT&9U7V?8;=M-B%62
M9,,5[(<>2LA6V#$C"967F0:AX_W:.Y=S8VS>9G-KX^O6RRLA*E!?H4XRV-QK
MZA6*:T":+!9()]I<)/0:Y6MG#AE*ER=O/'>C<I-%;%T#JJOQ'JYL,98[!0M:
M5%$D:9IU3A3[#+(62KU*#EDO%U;%&2-K")LN"ZY57J2LJR]$@?$42=S>VAAL
M5MG%MW6VC6OHOU:*LF0+0PQO3-4P<Q8CUKKJ8V^N3F8K'5AT$(0WF+8_Q/W%
MGO$',5O#I.5R6'LX7(Y6]@DM=<4LL2 9!+:R&D<*L7;2:^(8*9$[J\C-;RVM
M*M J/(_E(8YT[<U*+XQ5V+LW;-:O=,VL-;K[HV'$%#]?%XIV<2G'R"FA%=A3
M1T*6!:+FY0\5,(E85>S-5,-QH[]^\O:NQ-H^QV\BC)!8N474ZZ')M6FB-Q+&
MNK##.($*_G=39,%=!0J6<M$2PL;>W]XO>):<CAL'<PC<;C\JG)Y"[4N8_'UC
M/%6:Z*=]LHB9-]TJT!6A;GP8>U0B8K$Q3EVN2Y4>T*L8S2SFI-LZO@)/P0^R
M=I;$II>LB-=CA,N,LV0$E3T*,'M%H$1LID5L-7)AEPJ94(<>5!KCLX_ U=_=
M^QMK[8R%?;+RMW\Q4.*56:=I,*]IB5^UOEZ5"((GJ8'3)$UJQ%<=/+!D&/\
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M'M-. ?[/VXC%@WX7(Z9'DPMVT+;!1>->S9*6JY07*(L3J.AR26S)YK7]&@Q
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M1QU;;V'W!D*E3)6_:*LW7L$3BH*";,V'=I2J;BJJTN<0+@B<,'$&?.CV5O\
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MXG%E;ER?5W$E$J/*E<^DA)@X^/[Y&4Q'7I>XP5VVE+=R1V7)GR!5;+;.*5
M)FIBQ^PG7I*P2B=W-/,J::D$[$9M)8=#(3H[))F@U.CC2LB8^,5(S:W<]"Z&
MU\6,+99K8==^[8 B*!=D4UA715!<RM-2K20XUB<JG)7,BY(K!L#JK&@9-OV)
MZA6RR25"4<3())D2XN..HFL:8#,CU0A2 *2D>=5JH%ZUV3WO8-W\@-J&JL"!
MV M T29M54N-6U(<"RPA:/'O(W:!.N1*$8@I VPUK_7[,.R1Q)]U=FM@AJQ%
M[[#FM;7*N96VA5HX/&-.E9KH9N')A7<?E.%Z"&D1$,0D;-JG6R5BR?5UR6/Q
MZW+71E+-(G+8B<_[%>R])>4(V1C,<VRE;; B#.MB(*1]H-*6M5Y*I(UB+WFN
M99)B^K,3L6FML3>8FRM06L=IJ^4&%58I9\W%F[7K^O(+X P,LT_5C$1:Q]<:
MG)M%H(5ABU2=CMPC37GT9-H8?J[=-'%Y?/;4/!8U==EC"WG96UCQ::[C7DJR
MNP8J*O"&V!K144(>U2R!KDH (Y$"TF>W[MW:N4QUO-S<JX_-@NI4SDJKLQ2Q
M,URB7M"T5M%<VD9>T%3]G"&0UK 5U,A</8V-6(J^=M3#Z=FA-GZQJ L9J<VL
MZ[?).O*L4MUKK\TCL@684"I]IM4&YMOF0T>A7<0%>%B!R#AO$1THN_@=MY+<
ME =HE;.B_'6K>7K"VH9TW6\C4H+\EUD+$2(K"E$"Q=9D+-[YB&@43.GWKXFT
M-F5D;IB@G*XFR8TK4UKX*RJ:]6PX3L)I-K>6PNIA2-=UJO+8 ()B"YB&:$D4
MO;.GXW,X#N"Z:SW1>QIB8&JU8^BD(-KFJS7@[46IV(00"'QMVM8V#3ZS!O!&
MW.V00JSARGT1@5X(\W$=WVV]E9*VY&W<[5L/PYK58EJ7FHZ-\/:_,!'3$AU5
M66[BCAPN V2<D,C  N&;X\8J%/ 6-Q;7S=6MDZ]ED(HV::+*<C0F%'798ED0
M\0OH!%A4UVUV EBX@N1DV1]I/;V@N2&C;7MKDB&I]VY QK%9JQ"-N8\%;UN/
MHQ<O6!J-<5Z=/(MT=X]#8=MI<HP^Y:9A.SS(LD])##@$ =N<)X:9#&Y12DLK
M9+$#;OULBNW71878)%UB@ZT-AJU3"%(-@AP7F?2YF("1AFX?'O#9K:]AMH\C
M@,Z_&XO(8L<??N5#J^UXRO89(/02#L#%IED%-9$C*8"($>60=Z.!&Z;[N7@7
MR53<S!RUBM8VG<FLM<7:S3IA>P6G7PW7=<L@M1<\0<>G6.56B=H,4UL[-D2R
M,R#7H;)J<1.Q"I"5RCQ$P^-P.\<IC<5P%-15&@B#DXJLLU46&UH(I*9%;&%T
M1,S(+(5S,R,S/=_!#=&;WCX:[?SVX))N1L3D:Y6R5"2R%>CD[=.K=)8B(PQR
M$!#B$1%K@8X1&&0,=H.H/KK&CIIHZ::.FFCIIHZ::.FFCIIHZ::YV<Y@S7(T
M:6X:!$U<8?L%$C;3/[&MTXPU%U1#BG",'7ANN P!($4M=R/62MV1L<-=L(6N
M0PU=/.6EXM#G0ZM89;M"UDL3D59VB!$JFY56R/LOMB[ 718!56HDU=2FK Y,
MQ:MB9@&*,'0LHC>X;U0%QBS97]NMU;-NLNQ:]D$0I2J2=YT+:0R+&J$!A10S
MDQ+Z$'KD-.VENO%$W%P[^B=@W;OR%KN3'IEQUR%F/0K+KNS&WZC9CUP19#LH
M32#&M0!%3PV7>-@R8VR784/W<M(L2S [$^O[81@MV;;S5DZXXG).#*K166-&
M5W* J=[$==KS"LJ]?\D -;?) '/A"UQ7%4<UVAXGHW7CMU8]U&U2RFV&#3N2
M$ORE:S5M^T0FW2L5ZP->Q"4.]IKFCS$R*"8QD61/29R$WIJZ/P)O^OK$X)-7
M:GU"BZ5-4O:X03%- =AW,3]%Z]9Y ^P9FAWHJT1+'9*]:@4XJ,E.UTO##%7C
M8B?"BZW&8)I^(]><]3#%4#R-C<+%W#1[,>,4]MQ:UM$SK60L$(4HA;# F&0G
MQ LZ9C1W/AL[MJQ:P&15E 2/ZJ<2A:MU:Z( IJ[=9ZU6*CE"4/D'J64KZ&!!
M 823BY'Z-T3:.,>JK9'>CUZWU@3HO4E<V3IDS!'Q"86P["I]-)A4LA,2Z9;@
MZ))^PRPJ2@HGD"0GDY8*0.<)%DS<?9F8RM?=61C W;./IW0S^0:A,)A1(H4,
MEDJWF(LI?7&4^4(P?D^8 2:P((*8UA;WV)M#>6*HKW;A*F8*B5551[&VJ]I!
M6G5D/%%W'V:=R%.GI(T18\EA !FLY 9AYW;V>#M1KTU/#3;D_4K\L-,?L%)O
MR#.R -ZM[,'RH=DQ9BECCGZ:<,)8@B3CD5)FKH@01;@2K@W8,OXKE;7\5<YB
M+EB<OY6;KY"X-JRVZ)3;J-,4I:^K*I ?+!"PXIQ *GRA%)U^HY* [U_1WVCN
M.EC4;?LW-ELQ5']6J7AA!E&W2%UBR*;E:P4L.S[19>?M_M'M!R]DVHL\+\NG
MVJ#/)K1NEJ+#U3'<WU3N1)-1\#[N4K%(N VY7PD DNB#M;L5B8@2A15ZZUZP
MCB(VT'9=<C&306U/11U,5:3'3*^X<:K-9U.[<7YUW"VKET<CC$#-9:1BP=FN
M:GV?/'R+%*XNNWJ9[8$+B%I-BE'S?<OA#O?%XC%TO#+. _$WL=3QN0QN=NQ7
MO'95 J#(*<FK%5BGH<F7UN$LKF!$)6H-AJ=X[?UNX5Z>M6C>5NJFZ19;8>N.
MQ73+T,8=JMQ:NQXE96'!5_A9D "!BM#B$"IV,2T5D/U^6";BL9E5OZ/%"./A
M';%W?DHS[,FK&Y&K=O3-/)6$U++*[;CFTV#$MZ'1-4U**$DR4D$JX@87):#<
M@>+7AK@AV6G;ES<&+R&+Q8+R>W:-O)U R XVLC)H.$UO/K'.27:L 5E->+0.
M&P/)DX0BWCU*X<8T#L!G:NK ]>W!;;G;;?89%O#. [='KUE+3#>NH[0PK&C3
MV*S.UY.K!@$Q&CMPB3960==946+E'G,NIM)&Y,^>Y<5D%LJ1D;U:\E80J9]D
MM,17%ZI$"CF@NL8>8,2T"%OTB89%A9'Q'?X?;.7L+=6$LTLQ&%QEZ@5PC:0_
MK*BF[=*NV3.)\O+NR"F>2<PAJCJ]A0( P.,._P#1O'75^V0UVH2*_2=C[(L9
MC3MJME;FQP]KIX@."K,L=2[44BH&'8E0M("P5UP8.(R,55N"P%5'@#8XUCKP
M-L;'M[HR,U,KCJ+\)D()E*+"ZP1)U*;+)K@C &"-N;*V>7)Q7;!(*%P !%J/
M$?Q2Q?A_A?UKMO.Y:KNC$'%3+%1LW6DM63R:<>FQ*P<U+3Q@TG5_.%17JQ+M
MKEY->V9(T)<N0?'^D;1VK XR[*>T=R3OK)S7T^L5%^PR)1-0P74%2)M2$Q9M
MP 0;:^/%)K)::#9!VI,?XD$FR\$HSTVAF7\.,KNG( ^P,'CI0ZK<16<^G;.O
M5$;SDNK@V?V0I6##,148JEJ6,ZB+61CMN^/.!\/\0>-P]BR.:C)#=Q#+2*V6
MQ->U>8[&IM5+C:_ M\][Q!9,?6E_E64HZ(&'=4=5<Z-)Z_VYS%BT2M0*MM(=
M")V#51"UCZWL:K4FEPRTX)?IP\K*@5UUBP1[$28F5E\Y N(> $ 29 J9,-SQ
M%5L?](.ULKO"<?\ J6WD*LACL9B[*5I6X[M9UR3DJMME:5)<=J%"9M!H^1$F
MKI/E>QQW@=XJXW8M9U+<6*Q6>N9#,97.8BX^Q-==7)5\8FND,C05>6RW6#'$
MURUI.N?MA"NUU(_;R#K?@YR4^@EZY3/;_H^N-L6Y)B+;-;E13U@I RBZ\F'8
M[;)*Z!?',@7465^DSI!T+ M50?&X'P($J0XA^P2M1>\6K [J\NOMZO:QS:V-
MHT\?;;"KG6PILUK4/4-E2C;%V!.OY;A@87'F"SJYD>*_1D:.S1K7-[6L?NEF
M2OY3(97&5IMXH@<FO4/'>R664+%E:(HP:KDMJ,EK7=5<U>7 _ND. 7Z5.,13
MDH3VOL8?RLV?53MIUZ3K4YFO56-76FBSU#I!:MV-B=&,@[TZP#LYFQ2F*Y8X
M;$P3 #O@H8XF@YA9_P 2=P8[?LJ*S2J4<>Q&'NUJZ/;Z:$RQ+,E,R?0RS:J.
MEJ_.3-:3FL(B B9B4GP'Z-^QAV.>'R)Y7*Y*[<+,'GQL3B<F5J$G7K!66HK"
M*],J\S_HUJ+P]5ACB9)BF5;NI^)/''8?"/:ER%4NX[:Y.&JP5=>L]^./@=@U
M';M8JDJ6/J6OB-2E5MNNUY!2P>^*$N377;E[V,$[1>*I"0PE?P<YN#<-;Q%Q
M3<[GIKTDVD#7O8R3J50P-JWT.,4JZCZ'BF9MR<V.ORA)9N2JJ6IAMWPB\/,5
MLC([=H;;3DJV0/VK(AG.,A?N92LDHK-;;,52MM46F%/V4:PUX<XA!3K%HCL+
MQEH'%RQ<.MCUK26L@#-KVA2)==V&K<(DE<RY'9P8',9!OVMK8V;#(570-N><
M. 0L2/' @IJR2HH079$'(C$;W467I[S0_=%Q^5K)O5;"7!9&P+<1%H72JH:I
M%2CFO,]0K@!(SAP=:FJ:R9[6VSM?!;=;B=JX7'X>HY;A?636Z(=;)7E2RZ3H
M8^Y,\0'7:8X_+'R2*(7("[N$N[]6:NX\R@:]=U+CG)U>OZ/;3\N!4JP),GJX
M=.:VS<#)\'E@><,&CU*,")<V<^X0E&H#K4#,P5+"3)^'OK#^R9LK=:Z&0HYD
M@O4'+\T.E=RM4OJJRIXB:X57R%0D1/:$-6!=#P<I>ZP9UZ] :ZJBJ$4H-;$K
M6I21E3&K8T83PKZ;$MEA1$<G!E'T2$BKQP=Y(S2<S=^T+"4_V;*-:VHE&UO7
MO?[!=WRD;7]:IH^/'HHR'(LQ W>*_K6L64:B"+DH0E^S0EK;:J!U^)F[K7CD
M8;9^$H'[1=3C2L9&QT\1UV;-FZ "43S"ZMB]D43)=,&FNJX,RBPLYLXRY#GY
M:\3D^SC:FN$*8+.@TBI!K. ZI\\H57GRXF60QDHX\P>-.'B?NNV:YQL*F;6J
M5V"<I-][SN6S0VBIX]B+93DFX?"F!]:J9Z7/:HI&#3Q S$FR3%6IKZ)@6%E+
M,V/3E&'LC?\ 4.Q8P,XZE8_4E#;]'$T,B8!*+L8\'6+5PC2;A69PTG-2PA=$
M1/"YCIYU&WMT82TS+5 RE=F61>)U[&3#47:Y7'!6KKBK:57:Q9-@4J>L"1)3
M'+8F9X7!6R-O\?MQWNC;AI,1.ZN3>X8WZ.B0Z\I,ZOAN?"Q-7IE"MMK=K(8O
M38U3I "59)Y"+4CHP].8L \).G6\U7 1UF<#D\E@]M7<:BJS!X_'#CR;4:UC
M!O-.UD+]NVIU>NSJN6&,"MT0T.A=2M)@TE"6GJ^(VW:VX\MMO)%>QVX.J;B*
MN056!=ZM!(JK"C8JVK:3]F"1;96TDN!<V+0K8A+V PN1*=P:!Y1T>\[%O.KM
MA3+GBI:+I-B 5ZRU:LZ6-7RS(!PKW)K<V\6N3?V,MVHS"-CVSM.>(N9",^]#
M8#+\X7NJ&VLCD-@^3B3@$,RZ7Y4+%0J]]PN-%=0"7G6%M6NPJJ:E0*)3^T89
MM%C(&,Y7Q9QN!WU&!SE14'8Q]D\1D*.0&U2\VLAMMJKH'6K,K2587S[0!/AA
M#"84!=!%(MU+0N$'*VB\A*EN"T;F8V,:H&JMQC[*.U^$=LM(.3U 6B(Q-#IE
M0Q\?HLHO%L8S!1LPX:'UN-5I#S&7H1<;E_T7R-[PVR"WC9I3M\K6612N&NPC
MI#I9=.NWR0?7<Q"S,06V:I$;8*M#;'GAIK7BZG$^*.W<$NSC\UB=UV*F(]II
MH.O=I7+<^50/Z+V)L59LM6E\-7#P7(M"QTHE#?1OUPC7TKJJ_)+A;QRY9(!N
M[KHCQHS6F)$,!:Z]9K11K>-'3'FY$P/BR4TP#*3@<E]M,AP$4?GB$R^\YJ$W
M.\,G&VQ&>S. >=G#9&UCG,#RVE69(PT(YF!:N>5M@9F9#S +H*>H>)[ZC>YM
MG[7WE451W1@\?FZJ&2ZN%U,&==LQ$$==XR#ZY&,0+)2P/,&(%G4,1&N=.V/9
M>;#U+AU[V>-@HE%KUBAPTWK5>X;3L%\<1M$2(R+7L43L?W+8MH=-E@D,0(.U
MTZ,D"7D QI 03#.8GP"?0=J^*%G$,N_TAI'N0+=KVX;#K,+O(MRI2"D6L4X3
MKDE" %'2L4^7$KGIF0UQW?\ X"UL\C%CL;,+V(>-H3B3HU*,MQ-O'^TV+@05
M=%BJQ-P+-RTX[?4\K4NF'A)P+8H!0MA7WV5.UM^4+EGFHN6[?PBJWZL;AK\8
MU/H=LH\(%#K\ZA#K,;#BG636N;^]:%RA1""&D3!]T!V!@8RR9PS'F>.RN"\3
MLFVUE+*<#?QUM+,;5?>Z5LQJTK%2P<R$J:Y=KVIS5@*YXL#( 4"P]<TRF!W3
MX 8!-#!T+N\L3FJ-J,[E*F+(W)SSK#I<YU2M%MU>F^A./JUVM8T>JB0FT"-2
M];?#B!ICD+,Y1;PMFQ[]6(Q.V5$3KVGT2X&J..FSZ92)<R#L<H5JTP4?>,SH
M.T3H$>P.,QA#U=2AT@T8<D#\"-GNF@[/;@Q]G$U:66Q--88&[;KV6E%I*O9K
MS0<ZH\(;*WO$07)%"I3U_O']#6^&F>7L_9V?1G<IE]J9_.M=NJEC;E558Z?G
MLM8VL2*N1JL-8VDX\;#&0(^?#EAQ *Y;EX\C^0>X-\[<NT>G5_D/KKCB-$4L
M;>MG;%12I$2;E1&Z0*4Y,'4B\D;]8JT]81=BG&"@6%YD9C6Y J=*VVKLSI>A
MW3BJ& =.S\-;+&*S%A5WS#FQ8]B?:J*3;QTL$2>4!7378DS;,C4RUZNPR!I
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MK6[V&18Q:]B"BPU8]ZR$;!(GGKB =8LEDL#-4M)4R!A6Z2U9&AN2*8$@=O\
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M][O QS9J(FTR&''"5EZ<?OE'H/SB/4O^[[YXNE7J^#J8$)5JR)@ :Y6Q(X$
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M9"- S Z4C+<F 4$DF), A"D-YRA^++CNL.HSE*T*QZ=--5;G<;K;1%YE\?\
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MI#8M;DW+PY4U0Z_.^E>P9?S]!] JR"]Q(KSV5V;@@Y*_3./#GMU42TIC]JT
MF/[Q1U3Q\!GZ7_=B?EKR#<W^K4P_G E(\_[W[L?5/&DV/<]W;!5Y>L-*& PI
M]+3C-[WK-<U6"7&=SEIYT;0VX%@W'*+#U=GO@5PH.MH!-M&6V;9#\U,A..=^
MLOLL2<7Q_<#[RCJGZNC_ (M9 4++>):8J'X<]1>_W#/3'_?^SG3H$<5AUC>C
ME>0UPE;U(-+8D-TR4(14M%C9;&4KP["U%')&T6A.'V8A"*K<-IVM*"&(C12K
M2:^[V;3KGW7OY&2Z%SV\M?(C,? N\R7U%,Q\(C6R130CB1'J./\ 6'P11/\
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M*XG'($)Q[I">J)^V)XG5J;!!V8) 7O@XF/?Z<%'/_+M[M2(DZGZUX[_N[?\
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D+W;:!TJ0[(?93BL9EKFN"I:RC35[>FFCIIHZ::.FFCIIK__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g521849g92g41.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g521849g92g41.jpg
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M$0'_Q  ?  $  @,  P$! 0          " D&!PH#! 4+ @'_Q !.$   !@,
M 0," @0*!@<$"P " P0%!@<  0@)$1(3%"$5%@H7(C$8&B,D)S)!5YC4)CA"
M>)&V&24H,U%A@31Q@M8I1U156&)RE=7A\/_$ !X! 0 " @,! 0$
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MLAU75:M*LB/G<.\SPV5RN!V%:U;RE8'X7%O?8,)ZC1:ML9WV-.!04Z>0M[@
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M;.!I3BAPVU#PCUQ>>'^JGVZ2^V-MM=6OM-3+5T!%TM5%>*;P*B:FI)),4E?
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M)0-%E%%@#Z:" L 0A '6M:"'6M:^VLV.QC8V-C8T,8QK6,:T8:UK0 UH V
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MVO-AKQ>JS^=X/V-0=@W!$=T?2\LJ&U.NKAN4%H!Z.?F.8,<!MR>;?AG#JH5
M.R)QD4<:#3#/P4-DHDCNL*"DT\MI9NU196)! W.0 ,8&/KS^"\'-7&-A4STC
M9,XE#G%WJD*R1VHW<4Q%J7+1OL1;NG+#!=E_II4C7-J9K9!,LS:XY7=4_A;@
M\?A5:-RY&(]K3.IS.60G..N>^?,;#"UY&.+NFHS;,7[I%-XRZ=F2N::8K[KP
M<LD(:)<^27US0(D/-\'5FL6CDCQ1#<B0V7 ;*/BS>XSBW!V*&2$M$3M,])&2
M<PQR]L;>?-YGX].NPQU(WMZPJIA$PB814V^9A33<8JFD+.E]N]&4S?%;6L\O
M7+TDY/@Z>T[N<IFIK68$6&Q-E8N)!C#+(6=5)<J<I]^8UL?8VUE; FN,B2IE
M!C6\E9G7& 0>H)P/CY['RW[#JO)XC$%-F(NDY='[ZOCHGH^<2NHI#TG/NB8L
MW0.<&)W6H6%_I%&P0J.D B#-7)=>OPQ1A3&%SXWN+D*2:*>E2-(A3I".[;
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MN]M= WJ^=L;!G.#8.002F))3)RBR$Z<HL@@DH.@%$DE T6446 .M! 66 (0
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M1,(F$3")A$PB81,(F$5=]$_TB=_=H6:;KZAOJ>'TES5$UVOVB_<!J<[8L-"
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MC9^_ZZN*J&OMF;[V#[Z& G4490"T((BP;4!-'Z_'H(\-UC_:1I^SCVOE74%
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M[$4C;)FHNR=.O3R=A-DDX@4E;Y.@B$925:IET:1(HV]1%^'+1$OB@YZ:@&H
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MWQH_TRV#W;W(I_G*/H_I=WJRI'$/[:17SSR 2KHR#N+4,?J,M#*+#;[>F6P
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M?SODQL:VF  CUNK)6B<8;&96FCT7.L1M/B4F=7E:RF*FQ^:!NAGTA2'X'3<
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MN;*K2%[X@:A9:[H:^TUMN@=4&L=>:4&@J*J*XP^);:C]?21<AA?RS1Q@X?\
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MX8/J6MXQN';F<V%UF5#L"0R,QTB*LB"#NTDK1C0LJ=Q<70M.&/U\\1IE,/\
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MJ8HL@@L!0 AUVD<<<,<<44;(HHF-CBBC:UD<<;&AK(XV- :QC&@-:UH#6M
M  6 5M;67*LJ[C<:NIK[A7U,];75U;/+55E;654KYZFKJZF=\D]34U,\CYIY
MYGOEFE>^21[GN)/T,NOF4<K"Y!Y<MB5.$YLR@JKG4Q=2T1+E)I/#F=W>5Q3:
MB(;D!:E>K3&'F@1H$J=(G",>]%)R2RP^@0:UG2UFG+#<*A]776BWU=3(&A\\
M]-%)*\,:&,#GN:2>5C6M;OL  MHZ9XV<7=&6>FT]I3B1K'3UCHWU$E+:;1?:
MZBH*=]5/)55+H::&5L;#/42RSREK1SRR/><N<2MPP:"0VLXJT0:OHPRPV',!
M2@EDC4=0)VMF:RE:Q2XJ2T*!* LA. ]<L5*S0E@UH:A0:9OU$,6]]E2TE-0T
M\=+1P14U-""(H(6-CBC#G.>X,8T -R]SG' W))ZE8/J#45]U9>*W4&I;M7WV
M^7)\4E?=KI4RUE?6/A@BIHG5%3,YTDKHZ>"&%A<X\L<;&#9H"RS/H73)A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(JFO+
M,IY*=:]I: =31NV5XG^Q)?.JWGU'2!7"K*HE52-0SRT["O!KG:!V:%D;;877
M+ _IW(!.W;;L:]-Z/;&KT'ZYL*S203C'3H=\Y(&-]OK6E_!C-*&D5/6X@JZC
M+SIBP7)^K6X[-=>C[/+NRW+GC-XUVAE-(W"_V@%28-S3R>OD 2$D7VB: Q Y
MO6I3&\2Y>N7KBE^<C=I&X'*, 8.^V!W)\\J\W"HJS>QO(RAY;Z!Y4YV9J:GU
MB2'HB]J4JN43S;0]QZI:KC]RR.21QD7+;!.9EC'([&<#HG('!AK-I/VX&LC$
M[O4@<8\CTRZ?"L&Y!.1L#\3CW?BM%WKY<7.GNF;)K=NYZ!*^<N>[FYFY_P"C
M+],L].RR*&V+U*F;U4350ZKMP]Q!,8E!0OD93S]Q53./NH%CX80QM"\+2::M
M(&[9SN0X@8[-SWSMT.-OI6NOT@UX:%''U.-I#JVGN)/=G)^CD!*Y*8M*V5.5
M>C=&)0&B/!LO>]:,]P->S>_07IA2SJ[^1WW*^O"HHY]>W\U<L<NW[T2\:)-(
MI^JIE-T*$_U]CS(6IF4BBL=!K6P[$HDLF&T,"0'N!\BIR)![P^[W:*0,D#S(
M'UK6_CJH%UYDXGYVJ"3[.-G[5 $DIM98J]-K'&XK)6K;(MQP6&^T(U!ZFQ97
M)1:.-U\@B=$AWH&@! $I<<N)[9V^'0?8L1Z\O20O;B=QKSVV-LSZ%MN+.**2
MJ%^SC8=1%6OR4;4]V;92E)O8TYPT"XPF&QK0M.#ZZ')#_@.3B0('O#]1W::5
MYTS9XV55YN-.]LY?DTUIH)F^'+75SF[M/(\BF@^?-(6G!:6,E])<$^'MLH*5
MG'3B95U5BX9:*O%+/:HJ?D9?.(NK[=,VMM^DM*Q3#EEC%13M??;M@TUNI(YX
M_$9*VIJ;?#:H/!31]1V35UI([IM9YD%8SB$S]*C4H8@D9G9YA;\V2(A,H3E-
M)JU,V+EK:$HTDMP,5$I31  L&<'1^\9MO">TVZNH*]MSN$LU!54M8UKFTS8I
M):6:.8-($1<V-[F8(#RX-. XG=;SUM_NAW$+6NE=7:0GT'HV@MNK=/W_ $W-
M/%/>YZZBH;];JNV22QROK8Z>:KIZ>J+V/=3,ADF8'.@:PF,7EYM9?GPF$3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3"+GZ\J+%>G3<I<: ?/$1</4M-5Q(&U^KV^*T[9K+GMPD
M^Y96Y318#.F;#E*&9MT:<VZ6RRKIG'WH\]ME3>B4. "0E'-*E*7(W WYP#Y%
MI./(]",]P5+3QB0B51Q)T/*9QP?,>'I/84\ASLI:II?D-OI1-6B.P=%#8PUQ
MA=#1;10>!UC'6%NC,5A>PEI4!"Q2>A!OYU(Q%5W8<W-CW$8R2>^_7\^5J.%5
M05[EY=F_3XN.MPE\BK)_!W[JH#J*7?FE2[IOQ>$5.5,0/S'&_P )9WCZB5+]
MR)'MH3.?X6T&Z)4_6/"+VE?*\O=_@1^*D'&?>"%7=T7XI>@[5Z6O4V'6#3"#
MD7KCHGDCI&]TTDW-2[QB3YS"F8R7B%5LUMC&LA4@:K341&-K3)'(Y,PJH>8:
M[%$L3Z66F^J*P<,#(W <!Y'FSU[]^RAWYR/&QQ33\6B':5=4L&.],63WISXL
MFEEZL.UG;;TIG]B'.$M,_)[Y.7.!-_XLL(*.V!JBR$"'V_&VA1E"$#968YQ!
M:3L&.VV\C]*ZO\+B53_DK_IFL;A#AM/_ #E%T3TJUVU;C>+]M&KY[X^)1W?,
MVUV+!ZC @E-DHZ?AX1CUHH\;Z:FT+1@M#*@]OSTW_/V*S>CCY# ^)V'X_@I#
M=2=,26$O<?YZYZ:&^>]5V@A.419A5B$9&:MB6C-)7.X[64$!-_"8>PB'O\+0
M&@^NEKR EG:DRH0C@YC%^OD]+-#9K/&RKO\ 7L+H(G9,%!3YY7W*X%N?#IHC
M_=L.'U,@$48<<A;ZX0\*+5?[?<^)G$RNJ=.<'=(U#(KQ<8 &W;5]Z+/&I=#:
M-BD+!6WRXM:/6ZAA]7LM Y]=6RPM$9.P^8N9XUS?$71*!X<)Y:$\<_S7<MP2
M,(3);9TV4!&)4Z.)NQ&[0,C>(XY'%HRF-$W1]KW\)/SKE+BX+OLL5C@LE/(T
M2/JZ^K?ZQ<[E/O4U]4?G2/._)$S);3P-/)#'L,O<][\9XM<5[KQ3O5',ZBIM
M.Z1TY2?(VA=$6LEMETE8(B!%1TK,-%3<*D,CGO%VE8*JYU8\23PZ>*EIJ>2^
M=XM4IA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$P
MB81,(F$3")A$PB81,(F$3")A$PB811?LSKZDJ]AO3K^WRQJL.8<EUY*[$MRG
MX.[-;G:S.AC,$'829N,AYJM.Y)#Y.Q;2;CCBO)3,KB<M*^-QV E4(DI )Q[S
M@$]/K^]1]\?/D-;.[!7 VE0&(PYZJ#=>JW%?670-8=.5J]-EEIY:>R)4%HU0
M9N/IILR"A;G^=8(L(+=HPF<XLX&GK$4C0G84N;RX]_8@@_4>WE\"K(L*J815
M'71Y:X13G34MI(ZCK#E%55#:7/=(]!=(-<@AR*(U%:/3R9.KJUG%#G!Q*EDQ
M8R"'-BW.I&PEZ!$#7<I,8WN2L "#RN&9 .=R"0/,-Z_<<!:7_2$O]3*F/]^O
MDO\ YX681G5W\CON4Q/*SVXZ>/7AJX^G(W&$$PFL8+C<:@+$\Z5;CYLSG$C;
M8NS.,D^A.2K#&%A$XG/SBA2JT*EX+;=,J9Q;3W(M>F*&-YG!O3*X6.)?.IWI
M,?(C6UGVHHK_ *!LVV(L/C^N$LKBS' V.L4=T6''5K KC1==,[(5HA'8R6)K
M92I?4,@D,EB+6?'!/J,[\-<VWY*\U@HJHVYL+ZX02>J-J'.; :CE/A>*6@NY
M.;&0,9Z<S0>891I6GTO)J.Q1ZRJ+K2Z3==:+](ZBRQ0SW>.T>.WUY]!%4.;"
M:H4Y?X1?S!A/.(9W-$+_ -!+EOF)NY]8Y ^2.0J;,O>T%Y,DNVY7DD 7J;23
MX_:4WMQ7MT%B@\:+%MLA\51:);VEM+#L)&E)QPM]78;$RSQ32S3.KKM7O$]T
MN4H_6U4^-F,'_!4D /ATU.S#(XQ\WF)6;\7N+55Q*N%MM]KMD6D^'>D:=]JT
M#H6@>XT%@M7-E]35.R3<=0W5P%7?+S4&2IK:MQ!D,4<;1*K._6GDPB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$7.AU_&>E;^\B46KE]YE=M5I%+*KN+5I>==47:,2L>.
M4_)(A&7>R;OCOD2@5PQE!54A@TJ=)DC)H9V@[HV34$-;65Y89("7)7(I^?R5
M<8#>ISC/48SDC!;C?;O[_<K?>5J1N&@$$S@,[MB)W!71*QG<*JD@:KCE96Z1
MI1IW*E2"X5-?Z9ZTG[H66GBYC+.(Q H ZNNQO8)0S+%9*)U5E4D'MCZ21[L9
MW&VW4J66%"81<Y_2_C-ZLL?I;I&*P9NJY;RMVGT]QITM8]I/,]<&BP:?(YH3
MQL-A01!70(JOU.7.Q%<+95D*>D<D9VQ@"M5H7\L0?:N3ER!X ;UYFAP]QSG&
M^<C&?(_0I"=!>!?BKIJR9Y9]IS+J=<[V%.G"Q79A;.@9"BA;7)7!Q-=-'1F+
M&MZMM8DS<J.'MH(2!]S:7[0IC >W6\*!(1T#0<8S@9^M1@Z3_1Q.8Y=1]AL-
M9S[JJ4V&K90CA;+9?3DG>H2JD*9:D4H1OK<\-ZEO.3IME#4$B4$BT4I*)-!Z
M& #O77W3Y1%OJODD0FY>%_9!4_W!EYACQ=Q[/+GNLPT [1IUEI\<0S<8]%&O
M:-1R61@^566\Q2![J'V7_KQ)X9;ECAC.6D9"HP\=7Z-U<\JZ3DRKJV$V17U-
M5)<TSAFGIMEYM>RN3-\98URR&V36+T6QA62%F52S\"$VRI@$E0'$D+3TP0C+
M#LKK&R:G=665KZ:VQT3J7Q+Z]DCW3,K#3S#P*)KG$&G%1X1\1W.\L)',,$NS
M^JIN!$&F>*$M'?-;5NJH;]ZIPFI:FBI8;;5Z:;>+<[Y5U3+%3-<R\2V;Y0C-
M)"::EBJ.5_@O=)$(>D#^+U<5_P![W<G^+&=?Y;,C6D.<_P +/Z0G\7JXK_O>
M[D_Q8SK_ "V$YS_"S^D* ]#^#F-R;NGNZM+5D?=[%RS6;=S8=RM.#;\L9E23
ME9+ZU4/%T%I)D<4)',]QR:@);3RT99>X^,7X>H]Y@M;PK%XY6X:S.^?9'NQ^
M*GQ_%ZN*_P"][N3_ !8SK_+85><_PL_I"?Q>KBO^][N3_%C.O\MA.<_PL_I"
M@.G\',;'Y.5]-'2/N\/$)7$@+'2V7^ORQ@H1]-[NM''!0K5A_%^'C5:K,Q2]
M?E#1/U>B@;=_D^$'MPK<XY,X9S<W3E'S<?#S4^/XO5Q7_>]W)_BQG7^6PJ\Y
M_A9_2$_B]7%?][W<G^+&=?Y;"<Y_A9_2% >Z/!S&X]WMQ;6%:R/N]YY1L.)]
M!KNE9V5?EC.R2&R"*PD+C4213-2B@HHD)_DV]HB4JLLP3X+7T9&PC^^%(>.4
M^RS(QCV1[\_@I\?Q>KBO^][N3_%C.O\ +84<Y_A9_2$_B]7%?][W<G^+&=?Y
M;"<Y_A9_2% ?L_P<QNO;)XC:.;)'W?,878_4,9A?3CBFORQI8"%4:L0*#7N3
MJG!*467$"$RH!)8I&KT8G3[%[! WL6L*P>"'9#,XV]D=?J4^/XO5Q7_>]W)_
MBQG7^6PJ\Y_A9_2$_B]7%?\ >]W)_BQG7^6PG.?X6?TA0'\CO@YC=2<_,TIX
MUD?=]B6VHN2IX^XL"*_+&GIQ-</DF+1S]XVR("BCB2FIDV-28[;'\38'7U!H
M1!UZ84M>"3EK.AQ[(ZXV^U3X_B]7%?\ >]W)_BQG7^6PHYS_  L_I"?Q>KBO
M^][N3_%C.O\ +83G/\+/Z0H@]\^">LJOX_O6?<G3'NR>=$QF*)%U61%)T38<
MU4OC\.0LJ10E*BR(DI4\B SJ')1],28$0=$[/]?:5O6REK]QEK,9W]D=.ZD+
M6'Z/YRF]5I7CQ.+1[G;)J[0:).4P;3.I9ZW&-\H7,#>JD"$;>8GV8@&D=C59
M D9F]C2[+V0+>Q WA07^368_D'^"SG^+U<5_WO=R?XL9U_EL)SG^%G](6I[Y
M\ W-,8HVYY+5-E=T/MHQZI[%?*V9">GY\]&O,^:8@\+X<U%,Y*<)SL8X2).W
M) -A0@F+Q':2@WH1NMX4A^X]EG](6MN*? [3MB\GT%.>F)QW7#+]E%;,#O;,
M55='V%$5##-%1(A.S:=&59)BED&09H.MMYPQ&$>OH+>_7"%^YPUF,G'LCIG9
M2A_B]7%?][W<G^+&=?Y;"CG/\+/Z0G\7JXK_ +WNY/\ %C.O\MA.<_PL_I"@
M/XTO!S&[AY,B4Z[6D?=];W^OEME(9!%%U^6-7RA)'V>=OK9"E8HPO*-4I0N4
M53-:X"H8]A< GZ6EZ" X.M![^JESP#LUA&W[H\AG[<J?'\7JXK_O>[D_Q8SK
M_+84<Y_A9_2$_B]7%?\ >]W)_BQG7^6PG.?X6?TA0'X4\',;LM?V45U/(^[X
M.EK[MN\:XYP&KORQH;J8\QQHYC#5TU3#6%&:EB5\+4NFRI>D^-(\?!O9)8?A
MWZE9SQ[/*UGS1GV1\[NK D/Z/KQ@WKD:\BW>WQG(52=82 _JZ<&DB-3' .+"
M<4)-[32A#!K1A8OL,&]AW]MX5><_PL_I"O0PJ)A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3"*"W6'>E<<NSJG:72Q25W/T%>+VCU#:4KD32&2H:Y0.99
M5@W+-'A_6ML9@M:0!E)=G);(Y6ZM3<Z+VTQK3*R$J5^>6 I#2<GL//N>P'F3
MV"F'$9K#K 8TTG@<MC,VC2PP\I'(8B_-<D8U1J4T1"DM,[,RI:@/,3G!$2>
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MT1IR-P;7%"H(5HEB4TPA2G-+-*&( M;V55]W"*(_</9-;\$\[R3IBVV*9/\
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M.:;(C(98XCA\JE*5.X0"*2@"]*^ =VD]O<@$NQ4I' 2OC9W+D$?.:<'8'KG
MV!QD8]_1;H\77%MC47UY9EKPOE";\"\LE\Y,])*Z%G%\LUS+[INF.6"0N9+W
M*11F7SEHC_Y>KAL.BRIU5O9*R0+Y,J.;DBD@+JZ+"AQ!&,AQSG(&-B.G;O[L
M>_L+[)2Z.3)&)&],S(HDSNT,+NZ-4<2'@3*Y Y-[>H5H61*I- ,I.H=5112
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MH.OY=XW7OF9@:IC642:YH1015:FW(;I*ODC2@A)C*MC[R8/\VEQ\R0G$[/9
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1,(F$3")A$PB81,(F$3"+_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
